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Abstract 
In Chapter 1, the literature relating to rabies virus and the rabies like lyssaviruses is reviewed.  
In Chapter 2 data are presented from 1170 diagnostic submissions for ABLV testing by 
fluorescent antibody test (Centocor FAT). All 27 non-bat submissions were ABLV-negative. Of 
1143 bat accessions 74 (16%) were ABLV-positive, including 69 of 974 (7.1%) flying foxes 
(Pteropus spp.), 5 of 7 (71.4%) Saccolaimus flaviventris (Yellow-bellied sheathtail bats), none of 
151 other microchiropteran bats, and none of 11 unidentified bats. Statistical analysis of data from 
868 wild Black, Grey-headed, Little Red and Spectacled flying foxes (Pteropus alecto, P. 
poliocephalus, P. scapulatus, and P. conspicillatus) indicated that three factors; species, health 
status and age were associated with significant (p< 0.001) differences in the proportion of ABLV-
positive bats. Other factors including sex, whether the bat bit a person or animal, region, year, and 
season submitted, were not associated with ABLV. Case data for 74 ABLV-positive bats, including 
the circumstances in which they were found and clinical signs, is presented. 
In Chapter 3, the aetiological diagnosis was investigated for 100 consecutive flying fox 
submissions with neurological signs. ABLV (32%), spinal and head injuries (29%), and neuro-
angiostrongylosis (18%) accounted for most neurological syndromes in flying foxes. No evidence 
of lead poisoning was found in unwell (n=16) or healthy flying foxes (n=50). No diagnosis was 
reached for 16 cases, all of which were negative for ABLV by TaqMan® PCR. 
The molecular diversity of ABLV was examined in Chapter 4 by sequencing 36 bases of the 
leader sequence, the entire N gene, and start of the P gene of 28 isolates from pteropid bats and 
3 isolates from Yellow-bellied sheathtail (YBST) bats. Phylogenetic analysis indicated all ABLV 
isolates clustered together as a discrete group within the Lyssavirus genera closely related to 
rabies virus and European bat lyssavirus-2 isolates. The ABLV lineage consisted of two variants; 
one (ybst-ABLV) consisted of isolates only from YBST bats, the other (pteropid-ABLV) was 
common to Black, Grey-headed and Little Red flying foxes. No associations were found between 
the sequences and either the geographical location or year found, or individual flying fox species.  
In Chapter 5, 15 inocula prepared from the brains or salivary glands of naturally-infected bats 
were evaluated by intracerebral (IC) and footpad (FP) inoculation of Quackenbush mice in order 
to select and characterize a highly virulent inoculum for further use in bats (Inoculum 5).  
In Chapter 6, nine Grey-headed flying foxes were inoculated with 105.2 to 105.5 MICED50 of 
Inoculum 5 divided into four sites, left footpad, pectoral muscle, temporal muscle and muzzle. 
Another bat was inoculated with half this dose divided into the footpad and pectoral muscle only. 
Seven of 10 bats developed clinical disease of 1 to 4 days duration between PI-days 10 and 19 
and were shown to be ABL-positive by FAT, HAM immunoperoxidase staining, virus isolation in 
 v
mice, and TaqMan PCR. Five of the seven bats displayed overt aggression, one died during a 
seizure, and one showed intractable agitation, pacing, tremors, and ataxia. Viral antigen was 
demonstrated throughout the central and peripheral nervous systems and in the epithelial cells of 
the submandibular salivary glands (n=4). All affected bats had mild to moderate non-suppurative 
meningoencephalitis and severe ganglioneuritis. No ABLV was detected in three bats that 
remained well until the end of the experiment on day 82. One survivor developed a strong but 
transient antibody response. 
In Chapter 7, the relative virulence of inocula prepared from the brains and salivary glands of 
experimentally infected flying foxes was evaluated in mice by IC and FP inoculation and TaqMan 
assay. The effects in mice were correlated to the TaqMan CT value and indicated a crude 
association between virulence and CT value that has potential application in the selection of 
inocula.  
In Chapter 8, 36 Black and Grey-headed flying foxes were vaccinated with one (day 0) or two  
(+ day 28) doses of Nobivac rabies vaccine and co-vaccinated with keyhole limpet haemocyanin 
(KLH). All bats responded to the Nobivac vaccine with a rabies-RFFIT titer > 0.5 IU/mL that is 
nominally indicative of protective immunity. Plasma from bats with rabies titres >2 IU/mL had 
cross-neutralising  ABLV titres >1:154. A specifically developed ELISA detected a strong but 
transient response to KLH.  
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Introduction 
Australia was considered free of rabies virus and the rabies-like viruses of the genus Lyssavirus, 
family Rhabdoviridae, until the recognition in 1996 of Australian bat lyssavirus (ABLV) as the 
cause of rabies-like disease in a Black flying-fox (Pteropus alecto) and a wildlife carer (Allworth et 
al. 1996; Fraser et al. 1996). Initial characterisation of the isolates from the flying fox and human 
indicated that ABLV was very closely related to rabies virus and European bat lyssavirus-2, which 
are present in insectivorous Microchiropteran bats of the Americas and Europe. No endemic 
lyssavirus had previously been isolated in Australia, although other Rhabdoviruses of the genera 
Ephemerovirus including Ephemerovirus (Bovine ephemeral fever), Adelaide River virus, 
Berrimah virus, and Kimberley virus are present (ICTV 2000). 
The presence of a virus closely related to rabies virus had important implications for human and 
animal health and threatened Australia’s WHO rabies-free status. This allows Australia to enjoy 
considerable economic and trade advantages and is pivotal to Australia’s live animal import 
restrictions (AQIS). Dog-variant (urban rabies) is associated with the deaths of over 30,000 
humans each year, particularly in India, South-east Asia, South America, and Africa. Bat-variant 
rabies is associated with human deaths and the loss of thousands of cattle in South America, and 
with occasional human deaths in North America (World Health Organization 1992). Large flying 
fox colonies are present in Australian capital cities including Brisbane, Sydney, and Melbourne, 
from which they disperse nightly to feed on urban and native fruit, blossom and leaves (Hall and 
Richards 2000). The diagnosis of fatal ABL infection in a volunteer bat carer less than 4 months 
after the first recognition of ABL in bats, the urban distribution of thousands of bats, the large 
number of volunteer wildlife carers rehabilitating sick, injured, and orphaned native animals 
including bats, and the strong similarities between ABLV and rabies virus, suggested that there 
was potential for large numbers of people to be infected with ABLV. 
To effectively manage human exposure to ABLV and defend Australia’s rabies-free status 
required information about the epidemiology, natural history, and molecular diversity of ABLV. The 
geographical and host species ranges of ABLV were unknown, as were the modes of 
transmission, susceptibility, clinical course, and serological responses in bats. The susceptibility 
of domestic and other native animals to ABLV and the risk infection of these secondary hosts 
posed to humans were also unknown.  
Pending specific information about ABLV, and given the close similarity between ABLV and rabies 
virus, it was presumed that protocols for the management of rabies were appropriate. Initial 
responses of the relevant authorities included pre-and post-exposure rabies vaccination of 
persons known or likely to be exposed to bats and or ABLV (McCall et al. 2000; NHMRC 1997; 
Thompson 1999; Torvaldsen and Watson 1998). This included wildlife volunteers, veterinarians, 
researchers, staff involved in the care of captive bat colonies, and members of the public bitten or 
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scratched by bats. The death of the wildlife carer received considerable media attention and there 
was rapid pubic awareness that bats posed a threat of fatal disease and should not be handled. 
Testing and surveillance programs were set up at Australia’s WHO rabies reference laboratory 
(The CSIRO Australian Animal Health Laboratory, Geelong, Victoria) and were incorporated into 
the pre-existing Hendra virus (previously equine morbillivirus) research program investigating bats 
as the natural Hendra virus reservoir at the Animal Research Institute (ARI), Yeerongpilly, 
Queensland.  
The presence of a lyssavirus in Australia had substantial cultural implications with respect to 
attitudes towards wildlife. It required responses from government and non-government 
organisations involved in human and veterinary health. A clearer understanding of the natural 
history of ABLV was required if these responses where to be appropriate and effective. Given the 
importance of ABLV to Queensland, and as surveillance of bats was being undertaken for Hendra 
virus, it was decided that concurrent research into ABLV should be undertaken. Funding was 
allocated for the targeted epidemiological surveys, diagnostic investigations, molecular 
characterisation, experimental infections, and vaccination trial described in this thesis that 
characterize ABLV. 
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Literature Review 
1 Literature Review 
1.1 Lyssaviruses 
Lyssaviruses, which make up the genus Lyssavirus, are a group of related, unsegmented, 
negative sense, single-strand, ribonucleic acid (-ssRNA) viruses within the family Rhabdoviridae. 
The genus includes rabies virus (the type virus) and the rabies-like viruses; Lagos bat virus, 
Mokola virus, Duvenhage virus, European bat lyssaviruses 1 and 2 (EBL-1, EBL-2) and Australian 
bat lyssavirus (ABLV) (Amengual et al. 1997; Fraser et al. 1996; Shope et al. 1970; Tignor et al. 
1977). All lyssaviruses can cause rabies or rabies-like diseases with severe, generally fatal, 
encephalitis. Lyssaviruses are generally maintained in bat (Order Chiroptera) or carnivore (Order 
Carnivora) principle host species, with spill-over and endpoint infection of individuals of other 
species including man and livestock. 
Lyssaviruses are bullet-shaped with a helical nucleocapsid consisting of the ribonucleic acid 
(RNA) genome, nucleoprotein (N), phosphoprotein (P, formerly M1 or NS) and polymerase protein 
(L, large). The nucleocapsid is surrounded by an envelope derived from a host-cell lipoprotein 
membrane and is studded with viral glycoprotein (G) trimers (Cox et al. 1977; Dietzschold et al. 
1978; Gaudin et al. 1992). A structural membrane protein (M, previously M2) supports the viral 
envelope.  
The organization of the rabies virus, Lagos bat virus, Mokola virus, and Australian bat lyssavirus 
(ABLV) RNA genomes is similar and is presumably the same for all lyssaviruses. It comprises ~12 
kilobases (Kb) of nucleotides in a gene order of 3'-N-P-M-G-L-5' (Bourhy et al. 1993a; Mebatsion 
et al. 1993; Warrilow et al. 2002). With a large (423 base), non-protein coding region (intergene or 
pseudogene, Ψ) occurring between the G and L genes of the genome (Tordo et al. 1993). 
1.1.1 Classification of the lyssaviruses 
The lyssaviruses were originally classified into serotypes defined by serum cross-neutralization 
studies (which reflect similarities in neutralising glycoprotein antigens), biochemical, and 
histopathological comparisons. These were: 
♦ Serotype 1 Rabies virus  
♦ Serotype 2 Lagos bat virus  
♦ Serotype 3 Mokola virus – least closely related to serotype 1 Rabies virus 
♦ Serotype 4 Duvenhage virus – most closely related to serotype 1 Rabies virus. 
Since a major component of vaccine efficacy is based on antibody responses to neutralizing 
epitopes on the glycoprotein, a consequence of the variation in neutralizing glycoprotein antigens, 
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as reflected by the different serotypes, is that vaccination against rabies virus provides poor or 
negligible protection against Lagos bat and Mokola viruses (Fekadu et al. 1988b).  
A new classification of seven genotypes has been adopted as a result the development of 
antigenic (Wiktor et al. 1980) and molecular methods (Bourhy et al. 1993a; Sacramento et al. 
1991; Tordo et al. 1993) to characterize lyssaviruses, and the recognition of two rabies-like 
viruses in European bats and the rabies-like virus of Australian bats. Genotypes 1-4 correspond to 
the original serotypes 1 to 4 with genotypes 5, 6 and 7 corresponding to European bat lyssavirus-
1 (EBL-1), European bat lyssavirus-2 (EBL-2) and Australian bat lyssavirus (ABLV) respectively 
(Bourhy et al. 1993a; Gould et al. 1998; Tordo et al. 1993). The seven genotypes super-segregate 
in to two main phylogroups; phylogroup I includes genotypes 1, 4, 5, 6, and 7, phylogroup II 
consists of genotypes 2 and 3 (Badrane et al. 2001). The viruses that make up the 7 genotypes 
have been formally recognised as distinct virus species by the International Committee on 
Taxonomy of Viruses (ICTV 2000).  
The relationship of the lyssaviruses to their serotype, genotype, and phylogroup classification is 
shown in Table 1-1. 
Table 1-1 Comparison of the serotype, genotype, and phylogroup classifications for the 
lyssaviruses  
Serotype Lyssaviruses Genotype  Phylogroup 
1 
1 
Rabies virus 
Australian bat lyssavirus (ABLV) 
1 
7 
I 
I  
2 Lagos bat virus 2 II 
3 Mokola virus 3 II 
4 
   4 * 
   5 * 
Duvenhage virus 
European bat lyssavirus-1 (EBL-1) 
European bat lyssavirus-2 (EBL-2) 
4 
5 
6 
I 
I 
I 
* EBL-1 and EBL-2 are not generally described in terms of serotype. Early antigenic studies identified 
EBL-1 as serotype 4 and a 5th serotype was proposed for EBL-2 but not subsequently adopted 
(King et al. 1990).  
 
For the purposes of this thesis the term rabies will only be used in reference to serotype 1/ 
genotype 1 rabies virus or the disease rabies that is caused specifically by rabies virus variants. 
1.2 Rabies virus 
Rabies appears to have been recognized as early as ~2300 BC in the pre-Mosaic Eshnunna 
Code of Babylon which contains a reference to humans being killed by mad/vicious dogs. The 
term rabies is derived from the Sanskrit rabhas, meaning ‘to do violence’, and lyssa (Greek) 
means ‘frenzy’ or ‘madness’, both terms referring to the disturbing effects of the disease on the 
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behaviour of affected animals (Wilkinson 2002). While it had long been recognized that the 
disease developed as a result of a bite from an infected animal, it was not until Pasteur in 1885 
developed a crude but effective vaccine from the nervous tissue of inoculated rabbits that the 
potential for clinical disease could be managed. Negri’s 1903 identification of “endocellular Negri 
bodies” and recognition of their diagnostic value formed the basis of rabies diagnosis until the 
development of immunofluorescent techniques (Tierkel 1973). 
In all species clinical rabies is almost invariably fatal and poses a considerable public health 
problem with over 30,000 human deaths and 4 million post-exposure treatments reported each 
year (World Health Organization 1992). More than 99% of human deaths are the result of dog 
bites in the developing world, and the cost of pre- and post-exposure vaccination is a burden 
worldwide. Where dog rabies has been controlled with dog quarantine and vaccination programs, 
as in Europe and the United States, wildlife poses the greatest threat of rabies to humans. 
There are a number of terms used to describe different ‘types’ of rabies virus and disease. These 
terms as used in this thesis are defined below and their relationships are illustrated in Figure 1-1. 
♦ Fixed rabies virus – rabies virus isolates that have been stabilized or ‘fixed’ by multiple 
passages by intracerebral inoculation in laboratory animals or in cell culture. Passaging alters 
the pathogenicity of the virus isolate, typically enhancing its neurotropism. As a result, fixed 
rabies virus strains have certain characteristics that usually include a shorter incubation 
period, more consistent clinical signs, less Negri body formation, and more rapid death 
following intracerebral inoculation, but attenuated pathogenicity by other routes. Attenuated 
fixed rabies viruses can be effective as live vaccines. The mechanism by which an isolate 
becomes ‘fixed’ is not understood. 
♦ Street rabies virus – rabies virus isolates from naturally occurring cases of rabies that are not 
‘fixed’. These isolates may be adapted for cell culture or have undergone limited passage in 
laboratory animals. The point at which the pathogenicity of a rabies virus isolate from a 
naturally-infected animal, which is subsequently passaged in vivo or in vitro in the laboratory, 
becomes partially ‘fixed’ is indistinct. This ambiguity complicates the interpretation of some 
experimental reports. 
♦ Classical rabies virus – serotype 1/genotype 1 rabies. This term differentiates ‘true’ rabies 
virus from the rabies-like viruses.  
♦ Dog rabies– rabies in dogs, also referred to as urban rabies as the high concentration of dogs 
and people in endemic urban environments results in high case numbers in unvaccinated 
dogs, humans and other domestic animals. 
♦ Sylvatic rabies – rabies in wildlife, including bats and terrestrial animals such as raccoons, 
foxes and skunks, but not including rabies in domestic animals, notably dogs. 
♦ Terrestrial rabies – rabies in terrestrial mammals, including carnivores such as dogs, 
raccoons, foxes, and skunks but not including non-terrestrial animals such as bats. While 
birds can be infected with rabies, this is exceedingly rare, so that in practice the term 
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terrestrial rabies differentiates between rabies in terrestrial animals and in bats. The 
distinction is of epidemiological significance from a human health perspective.  
♦ Bat rabies – rabies in bats. A form of sylvatic rabies distinct from rabies in terrestrial animals.  
 
Figure 1-1 Terms used to describe rabies virus 
     
        Classical rabies virus 
  
Fixed rabies virus        Street rabies virus 
                (maintained in laboratories)          (isolated from natural cases) 
 
 
Bats  Terrestrial wildlife Urban/Dogs (and other domestic 
                                                                                                animals) 
          Sylvatic rabies  Terrestrial rabies 
 
1.2.1 Terrestrial Rabies 
1.2.1.1 Antigenic and molecular typing of rabies virus: recognition of variants 
Prior to the development of monoclonal antibodies, all rabies viruses were considered 
antigenically indistinguishable due to the inability of (polyclonal) anti-rabies serum to differentiate 
strains. When plaque reduction neutralization tests were developed, some minor antigenic 
differences were detected (Wiktor and Koprowski 1980). Considerable antigenic differences 
among street and fixed rabies virus isolates were recognized when monoclonal antibody panels 
were used (Fekadu et al. 1988b; Smith et al. 1984a; Smith et al. 1984b; Smith et al. 1986; Smith 
1989; Wiktor and Koprowski 1978). A number of studies have been done to type isolates of rabies 
virus and other lyssaviruses using one or other of the following panels of monoclonal anti-
nucleoprotein or anti-glycoprotein antibodies.  
♦ ERA series: produced using the Evelyn-Rokitnicki-Abelseth (ERA) vaccine strain at CDC, 
Atlanta USA (Smith et al. 1984a),  
♦ Wistar series: prepared from ERA, CVS, and Kelev rabies virus and Mokola virus isolates at 
the Wistar Institute, Philadelphia, USA (Wiktor and Koprowski 1978; Wiktor et al. 1980),  
♦ CVL series: prepared from Mokola, Duvenhage, EBL-1 (Danish bat), EBL-2 (Finland man), 
and Lagos bat virus isolates at the Central Veterinary Laboratory, Weybridge, UK (King et al. 
1990).  
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In particular, the ERA and Wistar series have been used to type American rabies virus isolates. 
Reactivity to panels of these monoclonals indicates antigenic relatedness to the isolates used for 
antibody production, and implies relatedness between virus isolates with similar profiles. The 
reactivity of isolates across the United States indicated that: 
♦ There are antigenic differences between isolates of rabies virus from different 
geographic/outbreak areas, such that in the United States there are multiple endemic patterns 
of antigenically and geographically discrete rabies virus variants (Smith et al. 1984b; Smith 
1989; Smith et al. 1995). 
♦ The antigenic profile of isolates from a given area is stable over time (8-18 years) (Smith et al. 
1984b; Smith 1989). 
♦ The majority of isolates with the same antigenic profile are derived from a single species in 
each region that is primarily responsible for the maintenance of each rabies virus variant (for 
example raccoons along the Mid-Atlantic coast, red foxes in New York state, and skunks in 
central USA) with ‘incidental’ spill over to other local species (Smith 1989). 
♦ Two or more independent cycles involving different rabies virus variants maintained in 
different principle host species occur in some areas,for example bats, grey foxes, and skunks 
in Texas. (Smith 1989). 
♦ During multiple laboratory passages, some fixed rabies virus strains developed unique 
antigenic profiles (Wiktor and Koprowski 1978). However, the antigenic profile of street 
isolates was preserved through limited passage in cell culture and laboratory animals (Smith 
1989). 
♦ Antigenic typing may be used to determine the likely source of new outbreaks, human 
infection, or isolated cases of rabies in non-endemic areas (Smith et al. 1984b; Smith 1988, 
1989; Smith et al. 1995). 
The geographical and species compartmentalization of rabies virus variants has also been 
demonstrated using polymerase chain reaction (PCR), nucleotide and amino acid sequencing 
techniques, and phylogenetic mapping (Smith et al. 1995; Tordo et al. 1993). 
1.2.1.2 Antigenic variation and epidemiological observations of terrestrial rabies 
Within given endemic areas characterized by a single antigenic strain of rabies virus, the majority 
of cases occur in one species, even when more than one apparently suitable host population is 
available (Parker and Wilsnack 1966; Smith et al. 1984b; Smith 1989). The principal species for 
each area/rabies variant include (Smith 1989; Tordo et al. 1993):  
♦ Arctic foxes (Alopex lagopus), Grey foxes (Urocyon cinereoargenteus), Red foxes (Vulpes 
vulpes), coyotes (Canis lantrans), striped skunks (Mephitis mephitis), and raccoons (Procyon 
loctor) in the United States and Canada (Smith et al. 1995). 
♦ Dogs and wolves (Canis spp.) in Africa, the Middle East, Latin America, and Asia. 
♦ Red foxes, raccoon dogs (Nyctereutes procyonoides) and wolves in Europe. 
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♦ Yellow mongoose (Cynictis penicillata), dogs, Bat-eared fox (Otocyon megalotis), jackals 
(Canis mesomelas), and Kudu (Tragelaphus strepsiceros) in Africa (Nel et al. 1993).  
There is evidence to suggest that strains of rabies virus have specifically adapted to the unique 
biological and social characteristics of their principal host (Parker and Wilsnack 1966). It is 
presumed that the virus is maintained in the principal species with opportunistic, dead-end 
infection of individuals of other species, notably humans. The mechanism of interaction between 
variants and the biological and social characteristics of their preferred host, and how that 
interaction limits transmission among incidental species are unknown.  
A possible exception involves African Kudu (an antelope). Rabies in herbivores is rare and 
secondary or tertiary transmission by herbivores is even rarer. However, an apparent rabies 
endemic exists among Kudu which is thought to have originated from the local jackal strain of 
rabies virus (Barnard and Hassel 1981; Rupprecht et al. 1987). The ability of this jackal-variant to 
persist in the Kudu has been attributed to relatively high viral excretion in Kudu saliva, 
contamination of food and water sources with saliva, lesions in the Kudu’s oral cavity due to 
browsing on thorny acacia trees, and high herd densities (Barnard and Hassel 1981; Hubschle 
1988; Smith 1989). 
1.2.2 Rabies in bats  
1.2.2.1 Bats 
Bats (Class Mammalia, Order Chiroptera) are the only mammals capable of true, self-sustained 
flight and there are approximately 900 species of bat worldwide (Hall and Richards 1979; 
Richards 1998). All bats are nocturnal. They are classified into two suborders: 
• Megachiroptera (megabats) consisting of a single family, Pteropodidae. All megabats are fruit, 
blossom or nectar feeders. Most megabats do not echolocate but navigate by sight and sound 
and have relatively large eyes. Bats of the genus Rousettus navigate with the aid of audible 
clicks produced in the mouth (not the larynx).  
• Microchiroptera (microbats) consisting of many families. All microbats echolocate with 
laryngeal sonar. While not blind their eyes are usually very small. Most microbats are 
insectivorous, others eat fruit or are carnivorous, and three species of true vampire bats feed 
on blood from living animals. 
1.2.2.2 Bat rabies virus 
Vampire bats, frugivorous and insectivorous microbats have been demonstrated to be capable of 
transmitting rabies virus (Humphrey et al. 1960; Miller and Nathanson 1977). In North America the 
epidemiology of bat rabies appears to be independent of terrestrial rabies (Constantine 1967; 
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Smith 1989; Tordo et al. 1993). Unlike terrestrial rabies, rabies in bats is not confined to particular 
geographic areas. Rates of rabies virus infection in surveys of clinically normal bats in the United 
States were 0-3%, while the positive proportion of rabies-suspect bats submitted for rabies 
diagnosis was of the order of 10-12% (Constantine 1967). Although not initially evident (Smith et 
al. 1984b), antigenically and phylogenetically discrete variants of rabies virus appear to circulate 
in principal bat hosts (Smith 1989 ; Smith et al. 1995), and are distinct from the well-characterized 
terrestrial variants (Smith et al. 1984b; Smith 1989). Relative to rabies viruses endemic in 
terrestrial animals, there is greater variation in the antigenic and molecular profiles of bat rabies 
virus isolates, and their relationship to particular bat species is more complex (Tordo et al. 1993). 
Rabies virus has been reported in most but not all (30/39) bat species in the United States and 
Canada (Constantine 1979), but is most commonly reported in one or two species of bat in a 
given area. Principal bat species (all Microchiroptera) include (Smith et al. 1995): 
♦ Vampire bat (Desmodus rotundus) Central America 
♦ Big brown bat (Eptesicus fucus) USA and Central America 
♦ Mexican freetail bat (Tadarida brasiliensis mexicana) USA and Central America 
♦ Red bat (Lasiurus borealis) USA 
♦ Hoary bat (Lasiurus cinereus) USA 
♦ Yellow bat (Lasiurus intermedius) USA 
♦ Silver-haired bat (Lasionycteris noctivagans) USA 
Rabies virus is rarely identified in Myotis spp, which are equally prevalent in affected areas. It is 
likely that principal bat hosts incidentally infect these and other species of bat. While bats do infect 
humans with rabies, and it is suspected that bats infect occasional terrestrial animals (Charlton et 
al. 1982; Rupprecht et al. 1987; Smith 1988), bats are not believed to play an important role in 
establishing or maintaining terrestrial endemics (Smith 1989).  
There is a unique situation in Central America where blood-feeding vampire bats transmit rabies 
virus to large numbers of apparently ‘incidental’ cattle hosts (>10,000 cases in cattle per year) 
(Tordo et al. 1993). However there is no evidence for maintenance of vampire rabies in cattle by 
cow-cow transmission. Nor has it been suggested that cattle play a role as intermediate hosts in 
the maintenance of rabies among vampire bats.  
“Rabies virus” has been reported in megachiroptera (fruit bats) in Thailand (Smith et al. 1967), 
and India (Pal et al. 1980), however no antigenic or molecular characterisation of these isolates 
has been done. Without this it remains unclear whether these are truly isolates of genotype 1 
rabies virus or another rabies-like virus. 
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1.3 The rabies-like viruses 
As a result of the recognition of rabies virus in bats in the Americas, surveys of African bats were 
conducted (Swanepoel and King 1992). Three rabies-related lyssaviruses, Lagos bat virus 
(serotype/genotype 2), Mokola virus (serotype/genotype 3) and Duvenhage virus 
(serotype/genotype 4) have been isolated in sub-Saharan Africa. There are only a few isolates of 
each virus, and cases in domestic animals or humans are rare. This suggests that these viruses 
circulate unnoticed in wildlife hosts with sporadic spill-over into other mammals.  
European bat lyssavirus-1 (genotype 5), and European bat lyssavirus-2 (genotype 6) have been 
isolated in Western Europe, including countries that are considered free of classical (genotype 1) 
rabies. 
Three other rhabdoviruses, Kotonkon, Obodhiang, and Rochambeau, which are more distantly 
related to rabies and the rabies-like viruses, were isolated during surveys of insects (Shope 
1982). The Kotonkon virus and Obodhiang virus, previously considered lyssaviruses, are now 
listed as unassigned viruses as serological and molecular analysis has linked them with viruses of 
the genus Ephemerovirus. The assignment of Rochambeau virus as a lyssavirus remains to be 
confirmed (ICTV In press). These viruses are not considered further.  
1.3.1 Lagos bat virus  
Lagos bat virus was first isolated in 1956 from pool of six brains from Straw-coloured fruit-bats 
(Eidolon helvum, Megachiroptera) at Lagos Island, Nigeria (Boulger and Porterfield 1958). 
Encephalitis but no Negri bodies were seen in the brains of intracerebrally infected mice. The 
isolate was shown to be a bullet-shaped rhabdovirus morphologically indistinguishable from 
rabies virus that could be differentiated from rabies virus on the basis of complement fixation and 
mouse neutralization tests, leading to its serotype 2 classification (Shope et al. 1970). Subsequent 
antigenic typing and molecular analysis supported the distinction of Lagos bat virus from other 
lyssaviruses (Bourhy et al. 1993a; Fekadu et al. 1988b; Flamand et al. 1980; King et al. 1990; 
King 1993). 
Lagos bat virus has been isolated from two other species of bat (a Dwarf Epauletted fruit-bat, 
Micropterus (sic, Micropteropus ?) pusillus, Central African Republic, and a Nycteris gambiensis, 
an insectivorous bat, Senegal) during virological surveys, and from Common Epauletted Fruit-bats 
(Epomophorus wahlbergi, South Africa) showing abnormal signs or found dead (Swanepoel et al. 
1993). It has also been diagnosed as the cause of paralytic rabies-like disease in cats from South 
Africa and Zimbabwe (King and Crick 1988; Swanepoel and King 1992) and a dog in Ethiopia 
(Mebatsion et al. 1993). Routine diagnostic tests do not differentiate between rabies virus and the 
rabies-related viruses. The cat cases were recognized because the fluorescence with anti-rabies 
conjugate was uncharacteristically weak, the cats had been vaccinated against rabies, and the 
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absence of aggression was considered atypical of rabies. The dog case was recognized by 
concurrent use of a monoclonal antibody panel. Antigenic typing, neutralization tests and 
molecular analysis differentiated the dog isolate from rabies virus and other rabies-related viruses 
(Mebatsion et al. 1993). Details of the differentiation of the cat isolates do not appear to have 
been published. 
While laboratory vaccination trials suggest that some rabies vaccines confer protection against 
Lagos bat virus (Fekadu et al. 1988b; Mebatsion et al. 1993), the cases in rabies-vaccinated cats 
clearly demonstrate that those particular rabies vaccines in those individuals did not confer cross-
protection against Lagos bat virus. This raises veterinary and public health concerns. The distant 
antigenic relationship between the glycoproteins of rabies virus and Lagos bat viruses was also 
illustrated by the failure of many anti-rabies-glycoprotein monoclonal antibodies to cross-react 
with Lagos bat isolates (Fekadu et al. 1988b). Molecular techniques have further demonstrated 
this relatively distant relationship (Bourhy et al. 1993a). 
Infection with Lagos bat virus appears to be rare but may be underestimated if bats are not being 
submitted for testing, and because routine tests do not differentiate infection by Lagos bat virus 
from other lyssavirus infections. Lagos bat virus is the only lyssavirus that has not been isolated 
from humans. 
1.3.2 Mokola virus  
Mokola virus was first isolated from three shrews (Crocidura sp.) in Mokola, Nigeria in 1968 
(Kemp et al. 1972; Shope et al. 1970). The morphology and mode of replication of Mokola virus 
as seen with electronmicroscopy was indistinguishable from that of rabies virus and Lagos bat 
virus. Complement fixation and mouse neutralization tests demonstrated that Mokola was related 
to but distinctly different from rabies virus and Lagos bat virus, hence its serotype 3 classification. 
Antigenic typing of Mokola with monoclonal antibodies subsequently supported this distant 
relationship (Flamand et al. 1980; King 1993; Wiktor et al. 1980; Wiktor et al. 1984). Analysis of 
the derived nucleoprotein sequence confirmed that, of the lyssaviruses, Mokola was the most 
distantly-related to rabies virus (Bourhy et al. 1993a).  
There have been two cases of Mokola virus infection reported in Nigerian children. Mokola virus 
was isolated from the cerebrospinal fluid (CSF) of the first which presented with fever and 
convulsions and made a full recovery (Kemp et al. 1972). However, for unspecified reasons, this 
isolate is no longer regarded as valid (Swanepoel and King 1992). A further isolate was recovered 
from the brain of the second child who died from poliomyelitis-like encephalitis (Familusi et al. 
1972). The absence of an acute excitement phase appears to have lead to the unjustified 
conclusion that the human case of Mokola virus infection did not show symptoms of ‘classical 
rabies’.  
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Mokola virus was the cause of fatal rabies-like disease in six cats and a dog in Zimbabwe (Foggin 
1982, 1983; Wiktor et al. 1984) and a cat in Ethiopia (Mebatsion et al. 1993). The diagnoses were 
confirmed by mouse neutralisation tests, antigenic typing with monoclonal antibodies, and 
molecular analysis. Mokola virus is the only lyssavirus not to have been isolated from bats.  
Poor cross-neutralization in mouse serum neutralization tests and mouse vaccination trials 
suggested neither rabies vaccine nor antiserum would be protective (Fekadu et al. 1988b; 
Mebatsion et al. 1993; Shope et al. 1970; Wiktor et al. 1984). Moreover the Mokola-infected dog 
had been vaccinated with a potent inactivated rabies vaccine (Rabisin; Institut Merieux) six 
months previously (Foggin 1982). These observations are consistent with the low homology 
between antigenic sites in the glycoproteins of rabies and Mokola viruses demonstrated using 
molecular and antigenic techniques (Bourhy et al. 1993a; Wiktor et al. 1984). However, DNA-
based immunization using a chimeric construct of the glycoproteins of Pasteur virus (genotype 1 
rabies) and Mokola virus in a plasmid (with in vivo transcription and translation) produced virus-
neutralizing antibodies against rabies, Lagos bat and Mokola viruses. This technology may 
produce an effective pan-lyssavirus vaccine. 
There have been few other isolations of Mokola virus, including one from a myomorph rodent, 
Lophuromys sikapusi (Swanepoel et al. 1993). It is assumed the cats and dog were infected by 
shrews and/or rodents during an epizootic in these wild animals. It would appear that Mokola virus 
is a poorly recognized or rare cause of disease. 
1.3.3 Duvenhage virus 
In 1970, a further rabies-related virus was isolated from a man (after whom the virus was named) 
in South Africa who died from a furious form of rabies-like encephalitis approximately five weeks 
after being bitten on the lip by an insectivorous bat (Meredith et al. 1971). While the fluorescent 
antibody test (FAT) with anti-rabies antibodies was negative, Negri bodies were present in the 
brain of the patient and the brains of mice inoculated with material from the patients brain 
(Meredith et al. 1971). As had been the case for the other rabies-related viruses, it was shown 
that Duvenhage virus was related to, yet distinctly different from the other lyssaviruses and it was 
subsequently designated as serotype 4 (King 1993; Tignor et al. 1977). It has since been isolated 
from two insectivorous bats (Miniopterus schreibersii and Nycteris thebaica) but appears to be 
rare (Swanepoel and King 1992; Swanepoel et al. 1993). 
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1.3.4 European bat lyssaviruses (EBL-1 and EBL-2) 
Between 1954 and 1984 there were rare reports of ‘rabies’ in insectivorous European bats (King 
and Crick 1988; King et al. 1990; Schneider and Cox 1994). Isolation in 1984 of ‘bat rabies’ from 
insectivorous bats in Denmark and a man bitten by a bat in Finland (Lumio et al. 1986; Mollgaard 
1985) eventually led to the recognition of two discrete endemics of rabies-like viruses in European 
bats that are independent of the prevailing rabies endemic in European foxes. 
The most common, EBL-1 is found principally in insectivorous European house bats (Eptesicus 
serotinus), with occasional cases in other insectivorous bats in northern and western coastal 
Europe. The other, EBL-2 is found only in the insectivorous Myotis daubentonii and M. 
dasycneme (Amengual et al. 1997; Bourhy et al. 1992).  
Initially the virus in these bats was presumed to be bat rabies (i.e. serotype 1 rabies) like that 
recognised in insectivorous American bats (Lumio et al. 1986). Then early German and Danish 
isolates were shown to have such a close serological and antigenic relationship with Duvenhage 
virus that they were considered variants of serotype 4 Duvenhage virus (Fekadu et al. 1988b; 
Schneider and Cox 1994). It was at one stage proposed that the two European bat lyssaviruses 
be grouped together into a separate 5th serotype (King et al. 1990). However, subsequent 
antigenic and molecular characterisation of EBL-1 and EBL-2, Duvenhage, and the other 
lyssaviruses has shown that EBL-1 and EBL-2 are closely related yet discrete viruses that form 
two distinct genotypes within the lyssavirus genus, with EBL-1 being more closely related to 
Duvenhage virus than EBL-2, which is most closely related to rabies (Amengual et al. 1997; 
Bourhy et al. 1992; Bourhy et al. 1993a, b; Bourhy et al. 1995; King 1993; Kissi et al. 1995; Roine 
et al. 1988; Tordo et al. 1993).  
The debate regarding classification was resolved by referring to the original lyssavirus serotypes 1 
to 4 as genotypes 1 to 4, EBL-1 is referred to as genotype 5, and  EBL-2 is referred to as 
genotype 6 (Amengual et al. 1997; Bourhy et al. 1993a; Bourhy et al. 1995; Kissi et al. 1995; 
Tordo et al. 1993). EBL-1 and EBL-2 were recognised as distinct species in the lyssavirus genus 
by the International Committee on Taxonomy of Viruses (ICTV 1995).  
From the original molecular data Bourhy et al. (1993a) derived a definition of a (lyssavirus) 
genotype as a group of isolates which have a minimum nucleoprotein (N) amino acid similarity of 
97.1% (maximum intra-genotype diversity of 2.9%) and have a maximum similarity of 93.3% with 
isolates in other genotypes (minimum inter-genotype difference of 6.7%, observed between 
Duvenhage virus and EBL-1). However, a subsequent investigation of the intrinsic molecular 
diversity of the nucleoprotein (N) among isolates of genotype 1 rabies, showed that there was as 
little as 92.2% amino acid homology among rabies virus isolates (maximum intra-genotype 
diversity of 7.8%) (Kissi et al. 1995). This indicates there is a greater N protein heterogeneity 
(7.8> 6.7%) within genotype 1 than between the two most closely related genotypes Duvenhage 
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and EBL-1, which suggests that Duvenhage and EBL-1 could be considered a single 
genotype/serotype as originally proposed. This appears to be acknowledged in the following: 
“Some of the lineages, containing only one or two isolates each, may not 
warrant consideration as distinct groups. However, the robustness of the 
bootstrap resampling and their phylogenetic distance to other clusters 
obtained by two independent phylogenetic methods, establishing them as 
distinct entities, should be emphasized (Kissi et al. 1995).” 
The low level of N protein amino acid similarity between strains of EBL-2 and strains of rabies 
(similarity = 86-87%) is of the same order as that between Lagos bat and Mokola virus (87.1%), 
Duvenhage and Lagos bat viruses (85.8%), and rabies and Duvenhage viruses (87-88%). 
Differentiation of EBL-2 (genotype 6) from rabies virus (genotype 1) is as justified as the 
undisputed differentiation of rabies, Lagos bat, Mokola and Duvenhage viruses from each other. 
The EBLs appear to be widespread in European bat populations, suggesting that they have been 
present and undetected for a considerable time (Amengual et al. 1997). The United Kingdom 
appeared to be free of bat rabies and European bat lyssavirus until a M. daubentonii at Newhaven 
was diagnosed with EBL-2 (Amengual et al. 1997; Anonymous 1996b; Whitby et al. 1996). This 
species of bat is not common in the United Kingdom and it has been suggested that this individual 
had ‘blown in’ from Europe. 
Human infection with European bat lyssavirus is rare with only four reported cases. There have 
been two human cases of bat associated rabies-like disease in Russia (Selimov et al. 1989). In 
1977, a 15 year old girl in Voroshilovograd developed hydrophobia and died 35 days after being 
bitten on the finger by a bat (Selimov et al. 1986). The virus of this case was isolated but does not 
appear to have been characterized further. In 1985 an 11 year old girl in Belgorod became ill 21 
days after being bitten on the lip by a bat that flew away, and died 6 days later (Selimov et al. 
1986). This isolate (Yuli virus) was characterized as EBL-1 (Amengual et al. 1997; Bourhy et al. 
1992; Selimov et al. 1989).  
European bat lyssavirus-2 was isolated in 1985 from a bat biologist in Finland who died of a 
rabies-like disease. He had a history of being bitten by bats on three occasions, the most recent 
occurring 51 days before he became ill involving a M. daubentonii that behaved oddly (Haltia et al. 
1989; Lumio et al. 1986; Roine et al. 1988). EBL-2 was also isolated from a 55-year old male 
wildlife artist trained, licensed, and employed as a bat handler in Scotland that died in November 
2002 after a 19 day rabies-like illness (Fooks et al. 2003; Nathwani et al. 2003). He had a 12 to 14 
year history of handling bats and multiple bat bites, the last had occurred 40 days prior to clinical 
signs and involved a bat suspected but not confirmed to have also been a M. daubentonii.  
There are discrepancies in the literature as to whether rabies vaccines protect against challenge 
with EBLs. Humans do occasionally get bitten by EBL-positive bats, but as yet there have been 
no cases of EBL in those who have received pre- or post-exposure rabies vaccination. 
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Transmission of European bat lyssaviruses to terrestrial animals appears to be rare. Without EBL-
specific antigenic or molecular testing, infection of terrestrial animals would be diagnosed as 
genotype 1 rabies. A review of 501 French rabies cases found no evidence of EBL in other 
animals (Bourhy et al. 1992). There have since been four reported cases of EBL-1 virus in sheep 
and in a stone marten (Ronsholt 2002; World Health Organization 1998). 
No European bats have been shown to have serotype 1 rabies virus, however an isolate from a 
Vespertilo murinus from Western Siberia (Asia, isolate Omsk 1150, ~1988) had an antigenic 
profile very similar to that of rabies virus from foxes from European USSR and Kazakhstan. The 
Omsk 1150 profile using the Wistar and CVL antibody panels was quite unlike that of the Yuli 
(EBL-1) isolate (King et al. 1990; Kuzmin and Botvinkin 1996). More definitive molecular 
phylogenetic typing of the Omsk 1150 isolate does not appear to have been published. This 
antigenic profile suggests that either genotype 1 rabies virus, genotype 7 ABLV, or a new 
genotype virus is present in insectivorous bats in Siberia. 
1.3.5 Tentative lyssavirus species from Asian and Eastern 
European bats 
The number of recognised lyssavirus genotypes / virus species may soon be expanded as a 
result of recent isolations of bat lyssaviruses from Central Asia and Eastern Europe. New 
genotypes have been proposed for each of four lyssavirus isolates from bats. They are: 
♦ Aravan virus isolated from a Lesser Mouse-eared bat (Myotis blythi) from Aravan district, 
Kyrghyzstan in 1991, GenBank AY262023 (Arai et al. 2003; Kuzmin et al. 2003).  
♦ Khujand virus isolated from a Whiskered bat (Myotis mystacinus) from Khujand, northern 
Tajikistan in 2001, GenBank AY262024 (Kuzmin et al. 2003). 
♦ Irkut virus isolated from a Greater tube-nosed bat (Murina leucogaster) from Irkut, Eastern 
Siberia in 2002, GenBank AY333112 (Botvinkin et al. 2003), and  
♦ West Caucasian bat virus isolated from a Common bent-winged bat (Miniopterus schreibersi) 
from the Western Caucasus Mountains in 2002, GenBank AY333113 (Botvinkin et al. 2003). 
Phylogenetic analysis of the entire N gene sequence indicated that Khujand virus is most closely 
related to EBL-2 but separated by a distance longer than the distance between Duvenhage virus 
and EBL-1 (Botvinkin et al. 2003; Kuzmin et al. 2003). The position of Aravan virus changed 
depending on the phylogenetic method and whether nucleotide or amino acid sequence data was 
used, but it appears to be most closely related to EBL-1, EBL-2, and Duvenhage (Arai et al. 2003; 
Kuzmin et al. 2003). Phylogenetic analysis of limited N gene sequences (400 bases) of the Irkut 
and West Caucasian bat virus isolates placed Irkut virus closest to Duvenhage virus, and West 
Caucasian bat virus closest to Lagos bat and Mokola viruses with weak bootstrap support 
(Botvinkin et al. 2003). All four bat viruses have been listed as tentative virus species by the 
International Committee on Taxonomy of Viruses (ICTV In press). 
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1.4 Australian bat lyssavirus 
1.4.1 Bats of Australia  
Australia has 13 Megachiropteran and 63 Microchiropteran bat species (Hall and Richards 1979; 
Richards 1998). A cladogram summarising the structure and relationships within the Order 
Chiroptera in Australia is shown in Figure 1-2.  
Australian megabats include flying foxes (Pteropus spp and Dobsonia sp.), tube-nosed fruit-bats 
(Nyctimene spp) and blossom-bats (Syconycteris sp and Macroglossus sp.). While the flying 
foxes are also called fruit-bats, for clarity and the purposes of this thesis, they will be referred to 
by their more specific common name of flying foxes. Flying foxes of the family Pteropodidae are 
referred to as pteropid bats.  
Figure 1-2 Bats of Australia 
Adapted from Hall and Richards (2000) 
Pteropus  (7 species of flying fox) 
including   P. alecto 
   P. poliocephalus 
    P. scapulatus 
    P. conspicillatus 
 
Dobsonia (1 species of flying fox) 
    D. magna 
 
 Megachiroptera  Pteropodidae  Nyctimene (3 Species) 
       (Megabats)     Tube-nosed fruit bats 
 
        Syconycteris (1 species) 
        Blossom bat 
   
Macroglossus (1 species) 
Blossom bat 
 
 
Chiroptera   
(Bats)     Emballonuridae  2 genera, 8 species 
     Sheathtail bats incl. Saccolaimus flaviventris 
 
     Megadermatidae  1 genus, 1 species 
     Ghost bat 
 
     Rhinolophidae  1 genus, 3 species 
     Horseshoe bats 
 
   Microchiroptera  Hipposideridae  2 genera, 6 species 
       (Microbats)  Leaf nosed bats  
   
     Vespertilionidae  11 genera, 34 species 
     Evening bats 
     Molossidae  3 genera, 11 species 
     Free-tail bats 
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1.4.1.1 Flying foxes 
The Black flying fox (P. alecto), Grey-headed flying fox (P. poliocephalus), Little Red flying fox (P. 
scapulatus), and the Spectacled flying fox (P. conspicillatus) inhabit the northern and eastern 
coasts of Australia. They are large, social bats (adults weigh 310 to 1,000 g), which roost in trees 
during the day. Camps can contain hundreds to hundreds of thousands of bats. Their nocturnal 
feeding on blossoms and fruit is important for the dispersal of seeds and pollen, and plays an 
important role in forest regeneration. Unfortunately, consumption of cultivated fruit crops when 
native food sources are scarce, and the noise, smell, and damage to trees associated with large 
camps have brought them into conflict with humans.  
The distribution of these flying foxes is shown in Figure 1-3. 
Figure 1-3 Distribution of the four common species of Australian flying fox 
Adapted from Hall and Richards (2000) 
 
 
 
 
 
 
 
 
        Key 
    Black flying fox  
    Grey-headed flying fox 
    Spectacled flying fox 
    Little Red flying fox   
 
Three other species of Pteropus and Dobsonia magna (Bare-backed flying fox, previously D. 
moluccense) are not considered further in this study as they are uncommon or absent from 
mainland Australia. P. macrotis epularis  (Large-eared flying fox) and P. banakrisi (Torresian flying 
fox) are confined to the Torres Strait Islands, P. brunneus (Dusky flying fox) has not been 
reported since a single specimen was collected at Percy Island in 1874, and D. magna is only 
found north of Cooktown to Cape York (Hall and Richards 2000). 
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1.4.1.2 Microbats 
Australia has over 63 species of microbats weighting 2.7 to 165 g that are broadly classified on 
the basis of tail morphology into three groups; freetail-bats, enclosed-tail-bats and sheathtail-bats. 
All are insectivorous and the largest, the Ghost bat (Macroderma gigas) is also carnivorous.  
Particularly relevant is the Yellow-bellied sheathtail bat (YBST bat, Saccolaimus flaviventris, 
previously Taphozous flaviventris), a solitary, rarely encountered, and relatively large microbat (30 
to 60 g) that feeds on insects and roosts in tree hollows of coastal and inland Australia. The 
contrasting colours of its jet-black dorsal fur and pale (white to yellow) belly fur readily differentiate 
it from other Australian bats. The general public has more frequent contact with other species of 
microbats that roost in colonies in houses, other buildings and/or caves.  
1.4.2 Recognition of a lyssavirus in Australia 
In 1996 flying foxes were the focus of research by virologists looking for the natural host of 
Hendra virus (previously equine morbillivirus). A five-month old female Black flying fox (P. alecto) 
found under a tree, unable to fly, at Ballina, New South Wales in May 1996, was found to have a 
severe nonsuppurative encephalitis (Fraser et al. 1996; Speare et al. 1997). While tests for 
Hendra virus were negative, immunoperoxidase staining of paraffin-embedded tissues with an 
anti-rabies virus monoclonal antibody (Clone HAM) was positive. Plasma from this flying fox was 
negative for rabies virus neutralizing antibodies. Virus was isolated from a weanling mouse 
inoculated with a homogenate of the flying fox kidney (Ballina isolate). The mouse developed hind 
limb paraplegia, had nonsuppurative encephalitis, and was positive for rabies virus antigens using 
the fluorescent antibody test (FAT) and immunoperoxidase staining (Fraser et al. 1996). 
Sequence analysis of polymerase chain reaction (PCR) products (size not specified) amplified by 
nested primers for lyssavirus nucleoprotein from tissue culture virus (presumably mouse derived) 
and formalin-fixed brain (presumably the Ballina flying fox) showed that they were identical. 
Electron-microscopic examination of second passage mouse brains revealed classic bullet-
shaped rhabdoviruses. In an island continent proud of its rabies-free status, such a discovery had 
profound implications. 
Retrospective examination of archival bat tissues identified a further two infected Black flying 
foxes which died in January and March 1995 (Fraser et al. 1996; Speare et al. 1997). The scarcity 
of appropriate material from flying foxes prior to 1995 limits investigations into how long the virus 
has been present in Australia. 
In a flurry of bat testing, it was soon revealed that the new lyssavirus was present in all four 
common Pteropus species (Black, Grey-headed, Little Red and Spectacled flying foxes) and the 
insectivorous Yellow-bellied sheathtail bat (S. flaviventris). Cases were identified in New South 
Wales, Queensland, Victoria and the Northern Territory, a range broadly correlating to the 
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distribution of flying foxes (Hooper et al. 1997b). Unwell bats in Western Australia are yet to be 
tested. It appears that Australian bat lyssavirus is endemic in bat populations and there is little to 
suggest it is a new arrival.  
Initially called pteropid lyssavirus (Fraser et al. 1996) it was renamed Australian bat lyssavirus 
when it was isolated from the non-pteropid Yellow-bellied sheathtail bat (Hooper et al. 1997b). 
The original name was also inappropriate as other lyssaviruses, reported as “rabies virus”, had 
previously been isolated from a flying fox in India (Pal et al. 1980) and dog-faced fruit bats 
(Cynopterus brachyotis) in Thailand (Smith et al. 1967). Differentiation of these Asian viruses as 
genotype 1 rabies rather than ABLV requires antigenic and/or molecular phylogenetic analysis. 
The relationship of the Indian, Thai and Australian isolates is unclear due to the limited 
characterization of the Indian and Thai isolates. Interestingly, although the Indian bat was 
reported to be a Pteropus poliocephalus, this species is not present in India and it is likely to 
actually be a Pteropus giganteus (Les Hall pers. comm.).  
The range of some Australian bats, including P. alecto (Black flying fox), P. scapulatus (Little Red 
flying fox) and Dobsonia magna (Bare-backed flying fox), extends north into Papua New Guinea. 
The current name, Australian bat lyssavirus (ABLV), has been criticized because this host 
distribution means it is likely that ABLV will be identified in Asia (St George 1997). In any case, 
there is a precedent for naming viruses after the place from which they were first recognized 
/characterized and the name Australian bat lyssavirus accurately reflects what is known of the 
current isolates. 
1.4.3 Classification of Australian bat lyssavirus 
1.4.3.1 Electron-microscopy and Serotyping1 
The electron-microscopic appearance of the Ballina isolate was typical of the family 
Rhabdoviridae (Gould et al. 1998; Hooper et al. 1997b). Positive staining with the anti-rabies 
monoclonal HAM (Feiden et al. 1988), the pan-lyssavirus monoclonal W502-2 (Wiktor et al. 1980) 
and fluorescein-labelled Centocor  antibodies indicated that the Ballina isolate was antigenically 
related to the lyssaviruses (Fraser et al. 1996).  
In a modified rapid fluorescent focus inhibition test (RFFIT), isolates of Australian bat lyssavirus 
(ABLV) were neutralized by ERA-rabies antiserum. The neutralising titres of anti-CVS-11 rabies 
serum and anti-ABLV serum against ABLV were similar (Fraser et al. 1996). Commercial human 
and animal rabies vaccines conferred complete protection to mice challenged with Australian bat 
1 For the purposes of this thesis, the term serotyping will be restricted to the classification of viruses using 
polyclonal serum. A form of antigenic typing, seroyping is done principally, but not exclusively, by using 
serum neutralisation tests which differentiate between viruses on the basis of the presence or absence of 
common neutralising antigens. All the neutralizing antigens of the lyssaviruses are present on the 
glycoprotein.  
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lyssavirus, but none to those challenged with Mokola virus (Hooper et al. 1997b). These results 
suggest high antigenic, immunogenic and functional homology between the neutralizing G protein 
antigens of the fixed rabies virus and ABLV isolates. Using the old classification system, these 
results indicate that Australian bat lyssavirus is a serotype 1 lyssavirus. All previous serotype 1 
lyssaviruses were called rabies virus.  
1.4.3.2 Antigenic typing of Australian bat lyssavirus 
Antigenic typing with a panel of anti-nucleocapsid (N) protein monoclonal antibodies showed that 
Australian bat lyssavirus was most closely related to ‘classical’ (genotype 1) rabies virus but was 
unique from previously described lyssavirus isolates (Fraser et al. 1996; Gould et al. 1998; 
Hooper et al. 1997b). While the antigenic profiles of ABLV isolates are indeed unique, analysis of 
the profiles indicates that the differences in comparison to rabies isolates are slight.  
♦ The W502-2-positive, W422-5-negative profile of Australian bat lyssavirus is common to all 
tested strains of rabies virus (Charlton et al. 1982; Flamand et al. 1980; Smith 1989; Wiktor et 
al. 1980; Wiktor and Koprowski 1980; Wiktor et al. 1984). The negative reaction to W422-5 
only differentiates Australian bat lyssavirus from Lagos, Mokola, and Duvenhage lyssaviruses 
(Wiktor et al. 1980).   
♦ The reactivity of the monoclonal antibody HAM (Feiden et al. 1988) has not been extensively 
evaluated and is of limited use for virus characterization.  
♦ Four isolates of Australian bat lyssavirus were shown to have variable (negative, weak, or 
positive) reactivity to monoclonal antibodies 3-1 and 24-10 (Hooper et al. 1997b). 
Consequently, these antibodies are not useful in differentiating ABLV from other serotype 1 
(rabies) virus isolates.  
♦ The Ballina isolate profile described by Gould et al. (1998) and Hooper et al. (1997b) includes 
positive reactions to 17 antibodies, and a negative reaction to 3-1 (synonym 62-3-1) that are 
common to 178 isolates of raccoon variant rabies virus (Smith 1989).  
♦ The sole consistent antigenic difference between Australian bat lyssavirus (ABLV) and all 
other serotype 1 strains of rabies virus is the negative reaction with the monoclonal antibody 
62-15-2 (apparent synonym C15-2) (Fraser et al. 1996; Gould et al. 1998; Hooper et al. 
1997b). This antibody produced positive reactions to five strains of rabies virus when 
originally cloned (Smith et al. 1984a). However, its reactivity against larger numbers of rabies 
virus isolates has not been clearly included in subsequent papers (Fekadu et al. 1988b; Smith 
et al. 1984b; Smith et al. 1986; Smith 1989), possibly because its pan-rabies reactivity 
precluded its use for differentiation of rabies virus variants. It may have been one of six pan-
rabies monoclonal antibodies used by Smith et al. (1984b) that were not specifically identified. 
It may be the pan-rabies antibody referred to as MAB-N 4 in Smith (1989), and may have 
been mislabelled as pan rabies antibody 15-3 in Fekadu et al. (1988b). Without clarifying the 
reactivity of other rabies virus strains to monoclonal antibody 62-15-2, the significance of the 
negative reaction to 62-15-2 by ABLV is unclear. The 62-15-2-negative profile of Australian 
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bat lyssavirus is consistent across five isolates from pteropid bats (Ballina/96-591, 95-2, 96-
390, 96-0963, 96-648), two isolates from YBST bats (97-0747, 96-1293), and the human 
isolate of YBST-variant ABLV (96-1256) (Gould et al. 2002; Hooper et al. 1997b). 
If is assumed that the 62-15-2-negative profile of Australian bat lyssavirus is characteristic of all 
ABLV isolates, then this unique antigenic profile differentiates Australian bat lyssavirus from all 
previously characterized variants of rabies. By definition, each antigenic variant of rabies virus has 
a unique antigenic profile. The antigenic homology of Australian bat lyssavirus to the ERA vaccine 
strain of rabies virus used to produce the 62-x-x ERA series of monoclonal antibodies is extremely 
close. If the ABLV reactivity to 62-3-1 is discounted due to its variability, only one of 19 ERA-strain 
epitopes (that for monoclonal antibody 62-15-2) is apparently absent on isolates of Australian bat 
lyssavirus. This single epitope difference is less than the two to seven differences demonstrated 
among 11 other rabies virus variants (Smith 1989), which suggests that Australian bat lyssavirus 
is even more closely related to ERA-rabies virus than are many other rabies virus variants. An 
absence of at least 10 ERA epitopes has been demonstrated for all other rabies-related viruses 
(Lagos bat, Mokola, Duvenhage, EBL-1 and EBL-2) (Fekadu et al. 1988b). As such this antigenic 
data suggests Australian bat lyssavirus is a unique variant of genotype 1 rabies virus and does 
not suggest it is a new lyssavirus genotype. 
However, further ABLV antigenic data recently published by Gould et al. (2002) is inconsistent 
with that previously published by his laboratory colleagues. The antigenic profiles of five isolates 
in Gould et al. (2002), suggest ABLV is more distinct with between five and 11 negative results 
per isolate using the same panel. However, whereas Hooper et al. (1997b) reported positive 
responses by isolate 95-2 to nine monoclonal antibodies (3-1, 52-2, 64-4, 71-2, 97-3, 97-11, 141-
1, and 146-3) and a weak response to antibody 24-10, their reactivity with isolate 95-2 is reported 
as negative in Gould et al. (2002). As the antigenic results for the same isolate are inconsistent, it 
is difficult to interpret the panel results for the other isolates.  
1.4.3.3 Molecular analysis of Australian bat lyssavirus 
Initial phylogenetic analysis of nucleotide and amino acid sequences of PCR product (size and 
sequence not indicated) derived from the nucleocapsid (N) protein gene showed that the Ballina 
isolate of ABLV was most closely related to European bat lyssavirus-1 (EBL-1) and street stains 
of classical rabies virus (Fraser et al. 1996). However the analysis was not shown and neither the 
method nor program used was clearly indicated.  
The amino acid sequences of this limited and relatively conserved section portion of the N protein 
(amino acids 298 to 426 inclusive, that is 28% of N) showed 92 to 93% similarity with that of two 
isolates of EBL-1, French street fox rabies, and Pasteur vaccine rabies virus. Subsequent 
determination of the complete N protein sequence, including the more variable amino and carboxy 
termini, allowed recalculation of the similarity between the Ballina isolate and the other 
lyssaviruses. The similarity to Pasteur virus remained 92%, the similarity to other genotype 
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isolates (Lagos, Duvenhage, EBL-1 and EBL-2) using the same GenBank accessions used 
previously differed by 0 to 3%, ranging from most different (Lagos bat virus) 82%, to most similar 
(EBL-1) 90% (Gould et al. 2002). 
Further sequencing of the Ballina isolate permitted analysis of the deduced nucleoprotein (N), 
phosphoprotein (P or M1), matrix protein (M or M2) and glycoprotein (G) amino acid sequences,  
confirming the significantly closer relationship of the Ballina isolate to rabies viruses compared to 
the other lyssaviruses (Gould et al. 1998; Hooper et al. 1997b). Phylogenetic analysis of N protein 
sequences indicated that ABLV formed a separate clade on the taxonomic tree relative to other 
rabies viruses but was closely related to rabies virus variants (Gould et al. 1998; Hooper et al. 
1997b).  
Analysis of nucleoprotein (N) gene sequences from 16 flying foxes showed low nucleotide 
sequence variation (0.5-2%) and no amino acid substitutions (Hooper et al. 1997b). Details of the 
isolates and the size of the 16 compared sequences (whole or partial N gene) were not indicated, 
but it is likely to be the same partial, highly conserved, N sequence region (nucleotides 443 to 
892) as that published later for a larger number of isolates (Gould et al. 2002). In this conserved 
region at least, the 16 ABLV isolates were reported as having sufficiently high amino acid 
homology (100 ≥ 97.1%), and were sufficiently different from isolates of other lyssavirus 
genotypes (7 to 8 ≥ 6.7%) to satisfy Bourhy’s original definition of a genotype. Use of this 
definition justifies classification of ABLV as a new lyssavirus genotype (genotype 7 within serotype 
1) rather than as a new variant of genotype 1 rabies. However, the 92% homology between the 
deduced amino acid sequence for the N proteins of ABLV and isolates of genotype 1 rabies 
(Hooper et al. 1997b), is no less than that within genotype 1 (92.2%) (Kissi et al. 1995). It is also 
considerably higher than that between undisputedly distinct genotypes (< 89%) suggesting again 
that ABLV is simply a new variant of bat rabies virus (Bourhy et al. 1993a; Gould et al. 1998; Kissi 
et al. 1995). As acknowledged in Gould et al. (1998), the degree of difference and justifiability for 
separate genotype classification between Australian bat lyssavirus and its closest relative rabies 
virus, is only similar to that between EBL-1 and its closest relative Duvenhage virus.  
Hooper et al. (1997b) indicated that the sequences for the nucleocapsid (N) and glycoprotein (G) 
proteins of two isolates from Yellow-bellied sheathtail bats differed from those from pteropid bats, 
but remained within the single 7th genotype. A more detailed report of phylogenetic analysis of 
partial N gene sequences (nucleotides 443 to 892) of isolates from three YBST bats and at least 
29 flying foxes showed that the ABLV isolates separated into two clades, one comprised of 
isolates from flying foxes (pteropid-variant ABLV), the other of isolates from YBST bats (YBST 
variant ABLV), with no other temporal or geographic distinctions (Gould et al. 2002). More 
comprehensive sequencing of one isolate from a YBST bat (AF081020) allowed comparison of 
the entire YBST variant N coding sequence with that of the Ballina isolate, indicating an 85% 
similarly at the nucleotide level and 96% similarly at the amino acid level (Gould et al. 2002). The 
origins of this YBST sequence were erroneously published in Figure 3 of that paper as being from 
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case 96-1256. While 96-1256 is actually YBST variant ABLV from the brain of a human case (see 
below), the published sequence AF081020 is derived from case 96-1293, a YBST bat found on 
the ground at Murphy’s Creek, Queensland in November 1996, being the first recognised case of 
ABLV in a YBST bat (Allen Gould, AAHL pers. comm.) It has been suggested that genetic 
divergence between the viruses from flying foxes and the Yellow-bellied sheathtail bats indicates 
that Australian bat lyssavirus has been circulating in these populations for sufficient time to allow 
specific adaptation to each suborder of bat (Gleeson 1997).  
ABLV has been formally recognised as a discrete virus species by the International Committee on 
Taxonomy of Viruses (ICTV 2000).  
1.4.4 Two human cases of Australian bat lyssavirus infection 
1.4.4.1 Rockhampton 1996 
In October 1996, a woman wildlife carer in Rockhampton became ill and died from a ‘paralytic’ 
rabies-like progressive central nervous system disease (Allworth et al. 1996; Samaratunga et al. 
1998). As a wildlife carer she had had close contact with a number of marsupials, cockatoos, 
dogs and cats. For the 2 to 4 weeks prior to her illness she had been caring for a number of flying 
foxes from which she had sustained scratches, but there was no history of a flying fox bite. While 
the first detailed report attributed the source of the infection to flying foxes (fruit bats) 
(Samaratunga et al. 1998), the virus was later sequenced and shown to be the variant identified 
only in Yellow-bellied sheathtail bats (S. flaviventris) (Gould et al. 2002). The patient was bitten 
severely on the left hand by a sick insectivorous bat either 4½ (Hanna et al. 2000) or 6 weeks 
(Speare et al. 1997) before her illness. The bat was aggressive and agitated and because of the 
bite and intractable behaviour, it was released onto a tree in a nearby park. The bite wound was 
painful and the woman sought medical attention shortly after the incident (Helen Luckoff ONARR, 
recollections of interview with patient’s husband).  
The woman re-presented with pain and numbness of her left arm. For 2 to 3 days she had non-
specific signs of fever, headaches, dizziness and vomiting. Despite symptomatic treatment she 
developed diplopia, difficulty in swallowing, bulbar palsy, muscle palsies, progressive limb paresis 
and was eventually areflexic and unresponsive with electroencephalographic signs of diffuse 
encephalitis (Allworth et al. 1996; Samaratunga et al. 1998). The woman died after an illness of 
approximately 20 days despite the administration of rabies immunoglobulin in the late stage of her 
disease. At post-mortem examination she was found to have meningoencephalomyelitis with 
neuronal eosinophilic inclusion bodies and chronic sialadenitis with eosinophilic cytoplasmic 
inclusion in occasional salivary acinar cells, but no myocarditis (Samaratunga et al. 1998). 
Anti-lyssavirus group antibodies were identified in serum (collected before rabies-immunoglobulin 
treatment) and ABLV RNA was amplified from cerebrospinal fluid using ABLV-specific primers. 
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Acute phase serology for a number of other viruses, including Hendra virus was negative. It was 
an alarming coincidence that a person died from ABLV-infection barely 16 weeks after the virus 
was first recognized in bats in Australia.  
There was immediate concern for bat handlers/carers, veterinarians, and others who came into 
contact with bats. A task force of infectious disease experts drew up protocols for managing 
further lyssavirus exposure (Anonymous 1996a). State health authorities produced vaccination 
protocols for pre-and post-exposure situations (NHMRC 1997), and advice for veterinarians was 
published (NHMRC 1997). Not all who received appropriate vaccination developed or maintained 
adequate titres of anti-rabies antibodies (Crome et al. 1998). 
1.4.4.2 Mackay 1998 
A second human case of ABLV infection caused the death of a 37-year old woman from Mackay, 
Queensland in December 1998. She had presented with a 5 day history of fever, vomiting, 
anorexia, left shoulder pain, paraesthesia of the dorsum of her left hand, a sore throat and 
difficulty in swallowing (Hanna et al. 2000). When initially examined she was well oriented, but 
febrile, drooling saliva and unable to fully open her mouth or speak easily. Within 12 hours she 
was agitated, had dysphagia and dystonia with frequent and severe muscle spasms and required 
paralysation and ventilation. Unless controlled by muscle relaxants, she developed facial 
grimacing, rolling eye movements, and arching of the back. There were also marked fluctuations 
in body temperature and blood pressure. On day 14 of hospitalization, 19 days after the onset of 
her illness, she died following withdrawal of ventilator support.  
The diagnosis of ABLV infection was made following detection of ABLV RNA in saliva, brain, 
salivary glands, and adrenal glands by hemi-nested-PCR (Heaton et al. 1999), intense staining of 
fresh brain impression smears by fluorescent antibody staining, and virus isolation in cell culture 
from brain and spinal cord (Hanna et al. 2000). Serum and CSF were negative for antibodies to 
rabies and other encephalitic viruses. Subsequent sequencing of the isolate indicated it was of the 
variant characteristic of flying foxes (Warrilow et al. 2002).  
As in the first human case, there was extensive and severe encephalitis and some inclusion 
bodies in the hypothalamus. Unlike the first case, there was a diffuse pancarditis and no inclusion 
bodies in the parotid or submandibular salivary glands (Hanna et al. 2000).  
The only history of contact with bats had occurred 27 months before the onset of illness. At an 
evening barbecue in late August 1996, a flying fox had suddenly landed on the back of a young 
child and was removed by the patient who sustained a bite at the base of her fifth left finger. The 
patient had sought medical treatment 2 days after the attack and received tetanus toxoid and 
antibiotics. Unfortunately, ABLV had only first been recognized in bats in May 1996 and in August 
1996 the potential zoonotic risk of a rabies-like disease from bats was not appreciated. However, 
in early March 1997, some months after the death and media attention of the first human case, 
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she had represented requesting a blood test for the “bat virus”. She was advised that post-
exposure vaccination was available, but did not return to receive the vaccine that was ordered 
and sent to her doctor, apparently due a misunderstanding that she was required to travel 300 km 
to Townsville to receive it (Roberts and AAP 1998).  
It has been stated that had she received the vaccination in March 1997, 6 to 7 months after 
exposure, her fatal illness may not have been prevented due to the long interval between 
exposure and vaccination and because guidelines at the time would have led to her receiving 
rabies vaccine only and not rabies immunoglobulin (Hanna et al. 2000). Clinical rabies has been 
reported in humans where post-exposure vaccination was delayed or did not include rabies 
immunoglobulin (Wilde et al. 1989). However, where post-exposure vaccination for rabies has 
failed, this has been in cases where the incubation period was as short as 19 to 25 days and 
where the delay has resulted in the vaccination being initiated only 14 to 19 days before the onset 
of clinical signs (Wilde et al. 1989). It is likely that the problem with delayed vaccinations and not 
providing passive immunity with rabies immunoglobulin is not so much the elongated exposure to 
vaccination interval, but rather the reduction in the interval between vaccination and clinical onset, 
depriving the patient of sufficient time to respond to the vaccine before infection was irreversibly 
established. In this case, while the delay to the opportunity to be vaccinated was long (6-7 
months), the vaccination would still have been received 19 to 20 months prior to clinical onset, 
ample time for completion of the vaccination schedule, a typical antibody response and subclinical 
resolution of the at that time latent infection.  
There is also the possibility that the disease was not the result of exposure in August 1996, but of 
some other, more recent, less conspicuous bat/virus contact, that may have occurred after the 
request for vaccination in March 1997. Within 12 hours of being admitted the patient’s capacity to 
contribute to an accurate history was greatly diminished, and the details of the August exposure 
and history of absence of more recent exposure were provided only by the patient’s family. 
Certainly the aberrant behaviour of the flying fox landing on the child is highly suggestive that the 
bat was ABLV-positive, but it is not conclusive. The long incubation period the August 1996 
exposure would imply (27 months) is atypical of lyssaviruses. Only 1% to 6.8% of human rabies 
cases occur more than a year after the purported exposure (Hattwick 1974; Wang 1956; Wilde et 
al. 1989). However, histories suggesting similarly long incubation periods for human rabies 
infections have been reported (Grattan-Smith et al. 1992; Smith et al. 1991).  
It does seem remarkable that the only two recognized cases of ABLV in humans should both 
result from contacts with bats in August-September 1996, just 3 to 4 months after the virus was 
first recognized in bats. Also that the first should be the result of contact with a species of bat with 
which humans have comparably little contact (the YBST bat), and that the other should become ill 
after a remarkably long and uncharacteristic incubation period. It is particularly poignant that both 
patients had sought appropriate medical attention as a result of the bites, the second on two 
occasions, yet neither received potentially life saving vaccination in the pre-clinical period. It is 
  Literature Review 
 26
perhaps of great significance that both bats to which the infections are attributed, bit people while 
displaying overtly aggressive and uncharacteristic behaviour. 
1.4.5 History of human rabies in Australia 
Since the differences between Australian bat lyssavirus and rabies virus are very subtle, and 
standard diagnostic tests do not differentiate between them, an obvious question was whether or 
not Australians diagnosed with rabies prior to the recognition of ABLV had actually been infected 
with ABLV. 
There have been three recorded outbreaks/incidents of rabies in Australia. In 1866-7, four or five 
dogs, a pig, and a child bitten by one of the dogs were provisionally diagnosed with classical 
rabies in Tasmania on the basis of clinical and epidemiological observations (Pullar and McIntosh 
1954). Unfortunately, as there are no pathological samples from the outbreak, definitive diagnosis 
and differentiation from ABLV is not possible. However, while there are six species of microbats in 
Tasmania, the typical urban rabies presentation combined with the fact that there are no flying 
foxes or Yellow-bellied sheathtail bats in Tasmania (Hall and Richards 1979; Richards 1998) 
make it extremely unlikely this outbreak involved ABLV. As there were poor quarantine restrictions 
at the time, it is assumed a ship introduced a dog incubating the disease.  
In 1987 a boy in Queensland died of rabies nine months after returning from eight months 
travelling in countries in which rabies is endemic (Anonymous 1988; Faoagali et al. 1988). The 
diagnosis was based on; a dramatic rise in rabies virus antibody titre between days 1 and 19 of 
his illness, nonsuppurative meningoencephalitis with cytoplasmic eosinophilic inclusion bodies in 
neurons, and the demonstration by electron microscope of bullet-shaped viral particles in the 
brain. The virus does not appear to have been isolated. This level of virus characterization is 
consistent with both rabies virus and ABLV.  There are grounds to suspect this infection was due 
to ABLV: 
♦ The long (9-17 month) incubation period required for infection outside Australia is atypical of 
(but not inconsistent with) dog or sylvatic rabies. In Taiwan and Thailand, only 6.8% and 
6.45% of 707 and 235 human rabies cases respectively, occurred after an incubation period 
of more than a year (Wang 1956; Wilde et al. 1989). 
♦ Initial inquires uncovered no history of a bite during his travels. A recollection that the boy 
received a minor bite injury from a monkey was only revealed when relatives were re-
interviewed after the boy’s death and so could not be confirmed by the patient. 
♦ As ABLV had not then been recognized, it is likely that inquiries would have focused on 
animal contacts outside Australia rather than recent bat contact at home, and the significance 
of any reported bat exposure would not have been realized. 
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Differentiation would require determination of the antigenic profile (notably reactivity to 
monoclonal antibody 62-15-2), and/or molecular analysis using ABLV-specific primers and/or 
sequence analysis. Such a review of this case has not been published. 
The most obvious candidate for an earlier case of ABLV infection is a 10 year old Vietnamese girl 
who developed clinical rabies after living continuously in Australia for 5 years (Bek et al. 1992; 
Grattan-Smith et al. 1992; McColl et al. 1993). At the time, sequence analysis of polymerase 
chain reaction (PCR) products from the patient's brain indicated that the highest homology (92.5-
93%) was to isolates of dog rabies virus from Southeast Asia suggesting exposure prior to 
immigration to Australia. This is a similar degree of homology to that demonstrated between ABLV 
and Pasteur vaccine rabies virus (Fraser et al. 1996). However, the sequence data has been 
reviewed and does not suggest this was a case of ABLV (Ken McColl, AAHL pers. comm.). Other 
cases of apparently long incubation rabies in humans have been reported in patients that died 11 
months, 4 years or 6 years after leaving rabies endemic areas (Smith et al. 1991). Antigenic and 
sequence characterization of the rabies isolates of these cases strongly suggested that they had 
been exposed in Asia or Mexico prior to immigrating to the USA. 
There was also concern that human cases of ABLV had gone undiagnosed. A review of case 
records at the Gold Coast Hospital, Queensland from 1980-1996, identified 21 patients who died 
with encephalitis or meningitis. It was concluded that none had a clinical picture consistent with 
viral encephalitis (Gerrard 1997). However, it remains possible that some of these cases were 
infected with ABLV as there is no reference to brain sections being re-examined or to specific 
testing for lyssaviruses. It has been shown that typical histological lesions may be absent in 
ABLV-infected bats (Hooper et al. 1999a) and that evidence of an alternative aetiology may be 
present (Skerratt et al. 1998; Speare et al. 1997). Despite this, it is generally considered unlikely 
that there have been unrecognized human cases of ABLV infection. This suggests that either 
infection in bats is uncommon, or the virus is not readily transmitted to humans, or human 
infection is not usually fatal, and/or the virus is new in the bat and human populations (Gerrard 
1997).  
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1.5 The pathology of lyssavirus infection 
The pathology of lyssaviruses has largely been studied using rabies virus as the type virus for the 
genus.  
1.5.1 Gross pathology 
Despite the dramatic clinical course of lyssavirus-induced disease, there is a noticeable absence 
of gross lesions such that gross post-mortem examination rarely even suggests the diagnosis.  
Most infections occur as the result of a bite or scratch from an infected animal; however these 
traumatic lesions heal unremarkably during the incubation period. Approximately 50% of humans 
cases reported pain, burning, numbness, itching or tingling at the site exposure during the 
prodromal stage of the disease (Hemachudha 1994; Mrak and Young 1994), but no characteristic 
gross or histological lesion has been identified at these sites.  
Occasionally the meninges are congested. Cerebral oedema is rare in rabies (Fekadu et al. 
1982a). Reduced weight gain, failure to thrive, wasting, and lymphoid depletion have been 
reported in experimentally infected mice, rats, rabbits, cats and cows (Torres-Anjel et al. 1988) but 
are noticeably non-specific indicators of the aetiology. 
1.5.2 Histopathology 
The most consistent histopathological changes produced by lyssavirus infection occur in the 
central nervous system and ganglia and are similar in humans and animals. 
1.5.2.1 Negri bodies 
The pathognomic histological lesion in rabies is the presence of Negri bodies, which are 
characteristic eosinophilic cytoplasmic inclusions within neurons. Adelchi Negri’s recognition of 
these bodies in 1903 using Mann’s stain (based on eosin and methylene blue) demonstrated an 
interaction between the aetiological agent and neurons (Negri 1903). He noted that they were 
particularly prominent in the hippocampal neurons of Ammon’s horn and their detection at this site 
formed a basis for rabies diagnosis. Negri believed these inclusions were a specific parasite like 
the then recently recognised Plasmodium of malaria (Kristensson et al. 1996). The nature of Negri 
bodies was hotly disputed until electron microscopy showed that they contained granular or 
filamentous matrix of viral proteins (Miyamoto and Matsumoto 1965).  
It should be noted that Negri bodies are not the only eosinophilic cytoplasmic inclusions of 
neurons. Non-rabies inclusions have been observed in the neurons of a number of normal 
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animals including cats, sheep, elk (Feiden et al. 1988), in human senescence and degenerative 
diseases such as myotonic dystrophy, but are relatively rare. Specific identification of inclusions 
as Negri bodies requires the use of specific stains (such as Mann’s or Seller’s stains) with which 
Negri bodies appear as magenta-coloured inclusions containing basophilic ‘inner bodies’. Not all 
the aggregates of viral proteins in lyssavirus infection are large enough to be seen using routine 
histological stains, and only a proportion of those which are, have the characteristic ‘inner bodies’ 
of true Negri bodies. The relationship between Negri bodies and other eosinophilic inclusions in 
neurons is illustrated in Figure 1-4. 
Figure 1-4 Relationships of terms used to describe Negri bodies and other 
intracytoplasmic eosinophilic inclusions in neurons 
 
   Eosinophilic cytoplasmic neuronal inclusions  
  (visible using routine histological stains such as haematoxylin and eosin) 
 
Literature Review 
 
  
Non-specific inclusions     True Negri bodies 
(no basophilic ‘inner bodies’ with special stains)              (contain basophilic ‘inner bodies’) 
 
 
Non-viral inclusions      Non-specific lyssaviral inclusions 
         (contain lyssavirus proteins, differentiated from non-viral inclusions  
   using electron microscopy or immunohistochemical staining,  
                            referred to by some as ‘lyssa bodies’) 
 
Electron-microscopy suggests that the basophilic ‘inner bodies’ of Negri bodies consist of whole 
or partial virions and cellular organelles such as basophilic ribosomes ‘trapped’ within the 
eosinophilic aggregate of filamentous viral nucleocapsid proteins (Miyamoto and Matsumoto 
1965, 1967; Murphy et al. 1973a). Negri bodies have also been reported in cells of the adrenal 
medulla and the cornea (Houff et al. 1979). 
The role of Negri bodies in lyssavirus infections remains obscure. While evident in most 
(approximately 75%) of infections with ‘street’ rabies, they are rare in infection with ‘fixed’ rabies. 
Their characteristic appearance may be the result of the accumulation of aberrant, non-infectious 
viral proteins.  
Inclusion bodies were not observed in the original cases of Lagos bat virus (Boulger and 
Porterfield 1958), however typical viral inclusions too small to be see by light microscopy were 
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revealed by electron microscopy (Shope et al. 1970), and inclusions were seen in experimentally 
infected hamsters (Murphy et al. 1973b).  
In the report of the original isolation in mice of Mokola virus (from shrews), the awkward statement 
that “Inclusion bodies compatible with Negri bodies were not observed” leaves open the possibility 
that inclusions may have been present, which for unspecified reasons did not fulfil the criteria for 
Negri bodies (Shope et al. 1970). Inclusions which were “quite different in size and appearance 
from the Negri bodies of rabies” were seen in the fatal human case of Mokola virus (Familusi et al. 
1972). However, rabies Negri bodies are known to be very variable in size and shape, so this 
description is insufficient justification for the subsequent suggestion that inclusion body 
morphology could be used to differentiate between rabies virus and Mokola virus infections. No 
inclusions or Negri bodies were seen in the brains of shrews inoculated with Mokola virus (Kemp 
et al. 1973). Only “poorly defined, irregular material interspersed in the cytoplasm of degenerate 
neurons” and no Negri bodies were seen in the neurons of dogs inoculated with Lagos bat and 
Mokola virus (Percy et al. 1973). Negri bodies were seen with Seller’s stain in the central nervous 
system of monkeys inoculated with Mokola virus, and it is unclear from the text whether they were 
also present in monkeys inoculated with Lagos bat virus (Percy et al. 1973). 
Negri bodies were “clearly visible” using “special staining” in the human case of Duvenhage virus 
infection (Meredith et al. 1971). 
While many eosinophilic inclusion were seen in one of the first two bats reported with ABLV 
(Fraser et al. 1996), they were rare or absent in a further 19 naturally occurring cases (Hooper et 
al. 1999a).  
The presence or absence of non-specific intracytoplasmic inclusion bodies or Negri bodies in 
neurons can not be used to differentiate between infections with rabies virus and the other 
lyssaviruses. The importance of identifying and characterizing Negri bodies or other inclusions for 
the diagnosis of rabies virus and other lyssavirus infections has been entirely superseded by the 
use of monoclonal antibodies and molecular techniques. 
1.5.2.2 Other nervous system lesions 
Cytopathology and inflammatory lesions are generally more prominent in animals inoculated with 
fixed-rabies virus, Lagos bat and Mokola viruses, than those infected with street-rabies virus 
(Murphy 1977; Percy et al. 1973).  
The dominant lesion of lyssavirus infections is non-specific nonsuppurative viral encephalitis, 
meningitis, and/or ganglioneuritis. No one lesion is consistently present and the severity of 
inflammatory and/or degenerative lesions is highly variable. Indeed, death may occur when 
virtually no histological lesion is detectable. The range of lesions seen is similar in dogs, other 
principle host species, humans, and other dead end hosts. Generally ‘fixed’ strains of rabies virus 
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and passaged rabies-like viruses produce more severe inflammatory lesions with fewer (or no) 
Negri bodies than does ‘street’ rabies virus, however there is considerable individual variation 
(Murphy 1977; Percy et al. 1973; Smart and Charlton 1992; Tignor et al. 1977). When 
inflammatory lesions occur, they may be widespread (Fekadu et al. 1982a), but are usually most 
severe in the brainstem. In any one case none, any, or all of the following lesions may be present 
(Baer et al. 1982; Bundza and Charlton 1988; Charlton and Casey 1979a; Charlton 1984; 
Charlton et al. 1987b; Charlton 1988; Fekadu et al. 1982a; Mrak and Young 1994; Percy et al. 
1973). 
♦ Perivascular cuffing with mononuclear inflammatory cells, predominantly 
lymphocytes, plasma cells, and some macrophages  
♦ Focal gliosis 
♦ Nonsuppurative meningitis 
♦ Neuronal degeneration with increased eosinophilia, chromatolysis, nuclear pyknosis, 
or spongiform change and neuronal necrosis  
♦ Babes’ nodules – clusters of neuronophagic cells (microglia and macrophages) 
ingesting necrotic neurons, seen principally in the ganglia 
♦ Demyelination of spinal cord 
♦ Peripheral neuritis, with infiltration of lymphocytes and plasma cells, and Wallerian 
degeneration, for example of optic nerve. 
♦ Spongiform change, particularly of grey matter neuropil. 
Most neurons infected with street rabies (those containing antigen) are morphologically normal 
when examined by microscopy. Neuronal degeneration may be more common in some species 
(for example cattle and foxes), and is generally more common after prolonged clinical signs 
(Charlton 1988). Massive necrosis was reported in the brain of a man bitten by a bat who died 
after five weeks of vigorous medical therapy (Dolman and Charlton 1987). Such a prolonged 
clinical course and histological outcome is rare in animals.  
Early reports of ABLV lesions were consistent with those of rabies virus, and it was noted that 
infected bats may have mild or no histological signs of encephalitis (Fraser et al. 1996; Speare et 
al. 1997), and may indeed have evidence of other causes of neurological disease, notably lead 
poisoning (Skerratt et al. 1998; Speare et al. 1997). Clearly, neither the absence of encephalitis 
nor the presence of lesions that suggest an alternative diagnosis excludes a diagnosis of ABLV 
infection.  
A detailed report of the lesions associated with ABLV in 21 naturally infected bats demonstrated 
how very similar the distribution and severity of lesions are to those of rabies virus, including that 
there is considerable variation between individuals. Lesions included neuronal necrosis and 
neuronophagia, cytoplasmic vacuolation, eosinophilic inclusion bodies consistent with Negri 
bodies, gliosis, lymphocytic perivascular cuffs, and subarachnoid meningitis, which were most 
frequent and severe in the brain stem (Hooper et al. 1999a).  
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1.5.2.3 Beyond the nervous system 
Lyssavirus lesions outside the central nervous system are generally non-specific and have not 
been intensively investigated. Myocarditis has been reported in cases of human rabies (Araujo et 
al. 1971; Metze and Feiden 1991; Ross and Armentrout 1962). Mild to moderate sialoadenitis with 
infiltration of mononuclear cells and scattered foci of acinar cell necrosis has been reported in 
skunks and foxes experimentally infected with rabies virus (Balachandran and Charlton 1994). 
Adrenal medullitis with heavy accumulations of mononuclear cells has been recorded in humans, 
skunks and foxes (Almeida et al. 1986; Balachandran and Charlton 1994). Ocular pathology 
including lymphocyte and plasma cell infiltration of the ciliary body, choroid, and retinal nerve fibre 
layer and loss of ganglion cells was reported in the human case of EBL-2 infection (Haltia et al. 
1989). Similar ocular lesions were reported in a dog inoculated with Mokola virus and monkeys 
inoculated with Lagos bat or Mokola virus (Percy et al. 1973). The involvement of the adrenal 
gland and eye may reflect the close embryological and functional relationships of these organs to 
the central nervous system (Almeida et al. 1986). While viral antigen can be demonstrated in a 
wide range of other tissues including the cornea and skin, no histological lesions have been 
recorded in these tissues. 
No extensive examination of non-neural tissues of bats naturally infected with ABLV has been 
published. Lymphocytes were present in the aortic body of a Little Red flying fox, and in two of 
eight salivary glands (Hooper et al. 1999a). 
1.6 The pathogenesis of lyssavirus infection 
Most of the considerable body of work on the pathogenesis of lyssavirus infections has been done 
using strains of terrestrial rabies virus. However, there remain significant gaps in our 
understanding of host-lyssavirus interactions and the subsequent development of disease.  
Much of the work on lyssaviruses has used fixed strains of rabies virus or variants of street rabies 
virus in mice or other laboratory animals. The recognition of species-specific variants of 
lyssaviruses suggests that the natural pathogenesis of lyssaviruses involves unique interactions 
between the host species and virus variant that at this time are not understood. It had been 
presumed that the findings from rabies disease models involving laboratory animals and 
‘mismatched’ virus variants/host pairs applied to all susceptible species. However, differences in 
experimental design, host species, virus variant/strain, and route of inoculation have produced 
considerable differences in incidence, incubation period, duration, and form of clinical disease. 
Identification of subtle aspects of the pathogenesis and mechanisms for maintaining infection in 
particular ecological niches is likely to require modelling in natural hosts with appropriate street 
virus variants. The largest body of such work appeared to have been done at the Animal Diseases 
Research Institute in Canada with skunks (Mephitis mephitis) and inocula derived from naturally 
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infected skunk salivary glands by K. Charlton and co-workers (Balachandran and Charlton 1994; 
Charlton and Casey 1979a, 1981; Charlton et al. 1983, 1984a, 1987a; Charlton et al. 1987b; 
Charlton 1994; Charlton et al. 1996; Charlton et al. 1997; Smart and Charlton 1992). 
Unfortunately molecular studies of rabies isolates from naturally infected Canadian skunks have 
since shown Canadian skunk rabies is actually derived from Arctic fox variant rabies that is 
believed to have reached south-eastern Canada via Canadian Arctic foxes in the north and is very 
closely related to isolates from Arctic foxes in Greenland and Russia. While the variant has 
persisted in red foxes and skunks in the area, it is clearly not a skunk-specific variant. Indeed it is 
possible that only the Red fox, a close relative of the Arctic fox, is the new principal host for the 
Arctic fox variant rabies and that large numbers of skunks are only affected as ‘incidental’ dead 
end hosts, much as cattle are in areas with endemic vampire bat rabies. That skunks are frequent 
incidental rather than maintenance hosts in the eastern United States, where raccoon variant 
rabies virus is enzootic, is suggested by spatio-temporal analysis of rabies surveillance data 
(Guerra et al. 2003). 
Inoculation of rabies virus and rabies-like viruses (Lagos bat and Mokola viruses) in comparative 
studies with experimental animals produced remarkably similar results (Murphy et al. 1973a; 
Murphy et al. 1973b). The clinical signs, gross and histological lesions, and virus distribution in 
dogs and monkeys inoculated with Lagos bat or Mokola viruses were similar to those described 
for rabies encephalitis in these species (Percy et al. 1973; Tignor et al. 1973).  
There are few reports of experimental work with bat lyssaviruses in bats. Most of the work using 
bat variant rabies and bat host species was done using vampire bats in the 1930’s (Pawan 1936) 
or insectivorous bats around the 1960’s (Baer and Bales 1967; Constantine 1966a, b; Constantine 
and Woodall 1966; Constantine et al. 1968a; Constantine et al. 1968b; Stamm et al. 1956; Sulkin 
et al. 1960). Related studies used bat-variant rabies in non-bat species (Constantine 1966a, b, c; 
Constantine and Woodall 1966; Constantine et al. 1968a; Constantine et al. 1968b). These early 
studies suffer from the limited technologies available at the time (e.g. reliance on detection of 
Negri bodies or isolation in mice for positive diagnosis), and not having screened experimental 
animals for pre-existing infection or immunity. There have since been only occasional papers on 
bat-variant lyssaviruses using modern virological methods to revisit earlier findings (Kuzmin and 
Botvinkin 1996; Moreno and Baer 1980). A recent review of bat lyssavirus infections has been 
published (McColl et al. 2000). Legal protection of European bats restricts the study of European 
bat lyssaviruses (EBL-1 and EBL-2) in bats to those that are dead or dying of natural disease. 
There have been no investigations of Lagos bat or Duvenhage viruses in African bats despite 
them being the presumed natural hosts of these viruses. 
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1.6.1 Transmission 
1.6.1.1 Natural transmission 
Natural human and canine rabies virus infection is usually the result of a bite from a rabid animal 
with deposition of virus-laden saliva into tissues. Transmission is rarely observed among wildlife, 
but as the bites of rabid terrestrial animals and bats led to rabies in man, presumably bites are 
also the principal means of maintaining sylvatic rabies. In unvaccinated humans approximately 15 
to 50% of people bitten by rabid animals subsequently develop rabies. Multiple severe bites to the 
face or head may cause rabies in 50 to 80% of exposed persons (Hattwick 1974).  
In the United States, post-exposure vaccination is readily available to people who are aware that 
they may have been exposed to rabies. As a result, despite the occurrence of multiple terrestrial 
endemics, human rabies in the United States is now rare. It occurs principally in those who were 
unaware they had been exposed to rabies virus and hence had not requested post-exposure 
vaccination. From 1980 through 1997, 36 cases of human rabies were diagnosed in the United 
States and 21 (58%) were characterized on the basis of nucleotide sequencing and phylogenetic 
analysis as bat-variant rabies virus. Of the 21 people infected with bat-variant rabies, only one 
had a definite history of being bitten. In 10 cases the patients, their family, or friends could recall 
the patient having physical contact with a bat but could not recall any bite or wound, and in the 
remaining 10 cases there was no history of physical contact with a bat at all (CDC 1994, 1996a, b, 
1997a, b, 1998, 1999; Messenger et al. 2003). Clearly, the mode of transmission of rabies virus 
from bats to humans is frequently unapparent, suggesting exposure by means other than a bite. 
Oral transmission is generally considered to be rare; however as most natural hosts are 
carnivores, it is possible that ingestion is a significant means of transmission in nature. 
Rabies was reported in two people who had been in a bat caves, including Frio Cave, Texas who 
strongly denied being bitten by bats or other animals (Constantine 1962; Humphrey et al. 1960; 
Irons et al. 1957). Foxes, coyotes, and a ring-tailed cat developed rabies after experimental 
exposure to the atmosphere of the same bat cave (Constantine 1962), and virus was later 
isolated from the cave air (Winkler 1968). Rabies virus has been isolated from the kidneys, 
salivary glands, and nasal mucosa of naturally infected Mexican free-tail bats and it is assumed 
that virus liberated in urine, saliva and/or nasal mucous contaminates the atmosphere of densely 
populated caves (Constantine et al. 1968b; Constantine et al. 1972). There was an outbreak of 
rabies among a group of experimental animals (coyotes, foxes, and raccoons) that had not been 
intentionally exposed to rabies virus, but were individually caged in the same room as clinically 
well and rabid animals that had. Transmission was attributed to airborne dissemination of bat-
rabies virus (Winkler et al. 1972). Rabies virus infection occurred in laboratory workers exposed to 
viral aerosols when preparing homogenates of rabid goat brain, or when spraying suspensions of 
modified live SAD rabies virus (CDC 1977; Conomy et al. 1977; Winkler et al. 1973). These 
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human and animal cases provide good evidence of aerosol transmission via mucous membranes, 
which may be important in the maintenance of some sylvatic lyssavirus variants, particularly bat 
lyssaviruses among dense colonies of cave dwelling bats. 
Natural transplacental infection has been reported in a cow and a skunk on the basis of 
fluorescent antibody detection of rabies virus antigen in the foetal calf and a skunk embryo, and 
virus isolation from foetal calf tissues (Howard 1981; Martell et al. 1973). The clinically rabid, five-
months pregnant cow was submitted for rabies diagnosis 20 days after being bitten by a rabid 
dog. The skunk was submitted for rabies diagnosis although whether it was clinically rabid was 
not indicated. In neither case was the infected foetus/embryo viable. As such neither case 
represents transmission to a viable individual but simply indicates non-specific centrifugal spread 
to the uterus and its contents. Effective transplacental transmission would require demonstration 
of rabies virus, antigen, or disease in young removed from their mother immediately after birth. 
For such transmission to be anything other than incidental would require the young be capable of 
transmitting rabies virus to others. Virus or virus antigen has been demonstrated in the aborted 
foetus, intrauterine foetus, and newborns of experimentally infected bats (Constantine et al. 
1968a; Sims et al. 1963). However, the high dose of inoculated virus and the possibility of post-
parturient contamination of the aborted foetus may have affected the findings, and surveys of 
free-living pregnant bats and suckling bats less that 5 days of age failed to find evidence of 
prenatial infection (Constantine 1986). While evidently possible, the role of transplacental 
transmission in the maintenance of natural rabies virus endemics is unknown.  
There is no clear evidence of natural human-to-human transmission of rabies, despite rabies virus 
being excreted in human saliva. Up to two-thirds of rabies patients develop furious rabies with 
violent episodes of aggression, and many cases receive intensive care by multiple people until 
their death. Possible instances of human to human transmission have been reported but occurred 
where rabies is highly endemic and other sources of exposure could not be discounted (Fekadu et 
al. 1996). This failure of human rabies patients to transmit rabies is consistent with humans being 
dead-end, incidental rabies virus hosts. While hardly natural, human-to-human infection via 
surgical corneal transplants has been recorded (Baer et al. 1982; CDC 1981, 1999; Houff et al. 
1979). This is consistent with reports of rabies virus antigen, viral matrix and rabies virions in 
corneal epithelium, indeed corneal scrapings have been used for anti-mortem diagnosis of rabies 
(Balachandran and Charlton 1994; Schneider 1969). 
Human infections with Duvenhage virus, EBL-1, EBL-2, and Australian bat lyssavirus have 
occurred after recent bat bites. The mode of transmission in the single human case of Mokola 
virus infection is not known, however shrews, the presumptive natural host were plentiful in the 
house where the patient lived. It is assumed she was infected by a shrew bite; however there was 
no evidence of a wound at the time of her illness (Familusi et al. 1972). 
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1.6.1.2 Experimental transmission 
Numerous methods have been used to experimentally inoculate animals with rabies. These 
include: 
♦ Intracerebral inoculation (IC)– commonly used in mice for rabies diagnosis (mouse 
inoculation test) and determining virus titres expressed as 50% mouse inoculation lethal dose 
(LD50). This method produces the highest proportion of clinically affected animals after a 
minimal incubation period. It is an efficient model for virus recovery and amplification, but is 
somewhat contrived as it does not approximate natural transmission and bypasses the 
processes that occur before the virus reaches the brain. HEP-Flury and mutant strains of CVS 
and ERA rabies virus that have been selected using monoclonal antibodies, are non-
pathogenic or have attenuated pathogenicity by IC inoculation in adult mice, and the 
alterations in virulence are associated with substitutions of the glycoprotein amino acid 
residue arginine (R) 333 or lysine (K) 333 with other residues (Coulon et al. 1994; Dietzschold 
et al. 1983; Seif et al. 1985). Virulence by IC inoculation of at least one CVS mutant has been 
shown to host species specific, IC inoculated mice were unaffected, IC inoculated skunks 
died (Tolson et al. 1990). All lyssavirus variants, strains, and mutants are pathogenic by IC 
inoculation of suckling mice.  
♦ Bite inoculation – using lyssavirus infected animals to infect others by biting is rare, 
presumably due to logistical and ethical considerations, but it most closely replicates natural 
bite transmission, except that in some instances extraordinary numbers of bites per animal 
(>400) have been used (Constantine 1966a). The bites of experimentally infected vampire 
bats (Desmodus rotundus) (Pawan 1936), red bats (Lasiurus borealis) (Constantine and 
Woodall 1966), Mexican freetail bats (Tardardia brasiliensis mexicana) (Constantine 1966a), 
leaf-nosed bats (Macrotus waterhouseii) (Constantine et al. 1968a), and shrews (Kemp et al. 
1973) have been shown to transmit rabies (bats) or Mokola virus (shrews) to other species. 
Uninoculated wild-caught bats have also transmitted rabies by laboratory managed bites (Bell 
et al. 1969; Pawan 1936). 
♦ Intramuscular, subcutaneous, intraperitoneal, footpad inoculation, or application of 
saliva to scarified skin – forms of peripheral inoculation, which to varying degrees, mimic 
the exposure that occurs during natural bites. The incidence and incubation period following 
inoculation by these routes is more variable than after intracerebral inoculation, consistent 
with the variability observed after natural exposure. Some mutant strains of rabies virus (e.g. 
CVS-tsG1) and Mokola and Lagos bat virus isolates (phylogroup II), which are pathogenic for 
adult mice when injected IC, were not pathogenic when injected IM (Badrane et al. 2001; 
Coulon et al. 1994; Prehaud et al. 1989; Tidke et al. 1987). This difference in pathogenicity 
has been associated with substitutions of the glycoprotein amino acid residues leucine (L) 
132 for phenylalanine (F) (CVS-tsG1), and arginine (R) 333 for aspartic acid (D) (Mokola and 
Lagos bat viruses). It appears however, that adult mice inoculated intramuscularly with 
Mokola or Lagos bat virus, were only observed for a period as short as 17 days.  
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♦ Intravenous inoculation – one of the earliest methods used. Viraemia is not believed to be a 
feature of natural rabies virus infection and this relatively artificial approach is now rarely 
used. No studies have been done to determine whether exposure of the host’s blood to rabies 
virus when bitten by a rabid vampire bat plays a role in natural infections.  
♦ Oral and intranasal inoculation – models for transmission via mucous membranes. Mucosal 
infection has been demonstrated in a number animal species including bats, skunks, and 
mice (Baer and Bales 1967; Charlton and Casey 1979b, c; Correa-Giron et al. 1970; 
Hronovsky 1971; Soave 1966) and led to the development of oral vaccines for foxes (Barrat 
and Aubert 1993).   
Experimental infection and transmission studies of Mokola virus in shrews demonstrated that they 
could be infected by subcutaneous or intramuscular inoculation of relatively high doses (≥ 30,000 
mice intracerebral LD50) of infected mouse brain suspension (incubation period 10 to > 59 days) 
or by ingesting live, clinically ill, infected mice (incubation period 4 to 32 days). Adult mice could 
be infected by the bite of an infected shrew, with incubation periods ranging from 6 to 17 days 
(Kemp et al. 1973). 
1.6.2 Spread from the site of inoculation 
1.6.2.1 Passage via peripheral nerves 
The prevailing dogma is that rabies virus is transported from the site of exposure to the central 
nervous system via peripheral nerves by passive, retrograde axoplasmic flow. This mechanism is 
implicated by a number of experiments in which: 
♦ Neurectomy or amputation proximal to the site of inoculation (prior to or shortly after 
inoculation) prevents the development of clinical disease (Baer et al. 1965; Johnson 1965) 
♦ Virus or antigen is first detected in areas of the central nervous system containing the cell 
bodies innervating the inoculation site, for example ventral motor neurons or dorsal root 
ganglion cells in relevant sections of the spinal cord following limb inoculation (Baer et al. 
1965, 1968; Johnson 1965).  
♦ Virus ascended peripheral nerves at rates that exceeded their ability to undergo replication 
and cell-to cell transfer within nerve support tissue, suggesting passive transfer (Johnson 
1965) 
♦ Removal of the nerve fasciculus (preserving the perineural structures) conferred protection 
whereas removal of the perineural structures (preserving the nerve fasciculus) did not (Baer 
et al. 1965, 1968). 
♦ Application of vinblastine or colchicine, which impair axoplasmic flow, to sciatic nerves 0 to 36 
hours after footpad inoculation of mice or rats with fixed or street rabies virus reduced the 
incidence of rabies (Bijlenga and Heaney 1978; Tsiang 1979). 
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♦ Cytochalasin B, vinblastine, and colchicine blocked fixed rabies virus transport in cultured 
ganglion cells in vitro, indicating axonal transport is a function of microfilament and 
microtubule networks (Lycke and Tsiang 1987). 
 
It has been proposed that the P protein interacts with dynein to use the microtubule-associated 
motor protein complexes during retrograde axonal transport (Raux et al. 2000). Inoculations at 
various sites, early demonstration of viral antigen in motor neurons and sensory and autonomic 
ganglia, and the failure of selective neurectomy to prevent disease, indicate that peripheral motor, 
sensory, and autonomic nerves can be equally involved. 
While electron microscopy and immunofluorescence have detected virus/antigen in peripheral 
axons, it has not been detected early enough post-inoculation to specifically demonstrate primary 
centripetal transfer (Baer et al. 1965; Murphy et al. 1973a). Indeed the inability to demonstrate the 
virus in nerves prior to its demonstration in the ganglia and/or spinal cord has been referred to as 
an eclipse period. Presumably the amount of centripetal antigen is below the detectable threshold 
for immunological techniques or virus titration, and the concentration of recognizable viral 
particles is too low for them to have been observed by electron microscopy. Failure to definitively 
demonstrate antegrade axoplasmic transport is a weak link in the theory of rabies pathogenesis. 
Whether haematogenous transport is important in the pathogenesis of rabies has been a matter 
of contention. Intravenous inoculation can induce rabies. Viraemia has been recorded within 1 
hour of footpad inoculation in rats (Kitselman and Mital 1967), but was not detected after three 
hours in mice (Baer et al. 1965). Failure of prior/early neurectomy to confer protection suggests 
haematogenous spread can be important in some cases (Baer et al. 1968; Charlton and Casey 
1981; Kitselman and Mital 1967). It has been suggested that haematogenous spread is more 
significant in young animals and particularly susceptible species such as the hamster. Viraemia is 
not a feature of the clinical disease in humans. The current consensus is that haematogenous 
spread from the site of infection is minor compared to that via peripheral nerves. 
1.6.2.2 Direct uptake by axons versus prior replication at the inoculation site  
There has been considerable debate as to whether inoculated virus enters peripheral nerves 
directly, undergoes prior replication in non-neural tissues (namely muscle), or both.  
There is substantial evidence for direct entry of inoculated virus into nerves. Amputation at the 
ankle as early as 2-12 hours post-footpad-inoculation with fixed rabies virus may fail to protect 
mice (Baer et al. 1968; Johnson 1965). The minimum in vitro replication time has been estimated 
as 6-15 hours, so the rapid escape of virus from the site of inoculation appears to preclude 
replication at the site prior to nerve entry. Viral RNA was detected by PCR in the trigeminal 
ganglia 18 hours post-inoculation, and in the brain stem after 24 hours in mice inoculated in the 
masseter muscle with fixed rabies virus (Shankar et al. 1991). In this study viral RNA was 
detected in muscle 1 hour post-inoculation (the inoculum), but not again until 36 hours post-
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inoculation. Rapid transit of virus to the CNS had occurred in the absence of evidence of 
replication at the inoculation site, strongly suggesting direct entry of fixed rabies virus into the 
nervous system. 
Assessment of replication in non-neural tissues requires careful differentiation between tissue 
involvement before and after centrifugal distribution. This differentiation is difficult because in 
many animal models centrifugal distribution occurs early, prior to clinical disease. There is 
however good evidence that inoculated virus can be taken up and replicate in local myocytes 
(Shankar et al. 1991) and viral antigen has been demonstrated early at neuromuscular junctions 
(Charlton and Casey 1979a, 1981; Murphy et al. 1973a; Murphy et al. 1973b). The observation 
that replication in local muscle occurs prior to that in the distant nervous system (Charlton and 
Casey 1979a; Murphy et al. 1973a; Murphy et al. 1973b) does not prove that invasion of the 
nervous system occurs after myocyte amplification. Unfortunately, it has not been possible to 
differentiate neural uptake of progeny virus from direct uptake of inoculated virus, and so the role 
of muscle-progeny virus in invasion of the nervous system is unclear.  
It has been suggested that sequestration of virus in local muscle may be important in cases with 
long incubation periods (Charlton 1994; Murphy 1977). However, rabies virus antigen in 
denervated muscle had only been detected up to 28 days post-infection, far less time than that 
which would account for incubation periods of > six months (Charlton and Casey 1981). 
In skunks inoculated with a low dose of skunk origin (street) rabies virus to produce a long 
incubation model for rabies, positive immunoperoxidase staining and recovery of viral RNA by 
PCR from the inoculated muscle of clinically normal skunks demonstrated that viral genome and 
antigen could be sequestered at the injection site in skunks for up to 62 days, in the absence of 
evidence that the virus had entered the nervous system (Charlton et al. 1997). It is probable that 
both inoculation dose and type of virus (variant and fixed versus street) influence the extent of 
prior muscle replication versus direct entry into the nervous system. The prior intracerebral 
passage of fixed viruses may have selected for proficiency in entering nerve endings/cerebral 
neurons directly and high doses of virus in inocula may increase the likelihood of direct entry to 
the nervous system. If this is the case, direct entry of inoculated fixed rabies virus may be the 
norm in most short incubation animal models, while localisation and prior replication in local 
muscle may be more common following natural exposure to street viruses. 
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1.6.2.3 Cellular uptake of virus 
The precise mechanism by which transmitted rabies virus enters cells, in particular peripheral 
nerve processes, is unknown, but is presumed to involve attachment between cell surface 
receptors and functional regions of the rabies glycoprotein. The role of the glycoprotein in receptor 
recognition and membrane adhesion is suggested by the loss of virulence in adult mice by IC 
inoculation of escape mutants of rabies virus that have point mutations at glycoprotein amino acid 
positions 132 (virulent phenotype leucine, L132) and 333 (virulent phenotypes arginine R333 or 
lysine K333) (Coulon et al. 1994; Dietzschold et al. 1983; Seif et al. 1985). Interestingly, 
substitution in rabies virus strains of R333 or K333 with other residues confers a total loss of 
virulence in adult mice by IC and IM inoculation, whereas wild-type Mokola virus and Lagos bat 
virus, with a D333 (aspartic acid) phenotype, remain pathogenic in adult mice by IC inoculation 
but are avirulent by IM inoculation (Badrane et al. 2001). It appears that Mokola and Lagos bat 
viruses remain virulent by the IC route despite ‘substitution’ of the positively charged R333 
residues because they possess compensatory positively charged residues at positions 331 and 
334 that are not present in rabies virus.  
A number of cell surface molecules have been implicated in in vitro binding of rabies virus 
including nicotinic acetylcholine receptors, neural cell adhesion molecule, and low affinity nerve 
growth factor receptor (p75NTR), although which is significant in vivo remains unclear (Langevin 
and Tuffereau 2002; Lentz et al. 1983; Spriggs 1985; Thoulouze et al. 1998; Tuffereau et al. 1998; 
Tuffereau et al. 2001).  
Electron microscopy has shown that rabies virus enters cells by pinocytosis, internalizing the 
whole virion within a coated vesicle (Iwasaki et al. 1973; Lentz et al. 1983). The nucleocapsid of 
virions within coated vesicles is discharged into the cytosol as a result of fusion of the coated 
vesicle with a lysosome and the action of the lysosomal enzymes. Free nucleocapsids also enter 
cells by pinocytosis (Gosztonyi 1994). 
1.6.2.4 Transit in peripheral nerve fibres 
It is not known in what form the virus travels centripetally within nerves. Possibilities include whole 
virions, nucleocapsids, or negative, positive, single or double stranded RNA. As the long neural 
processes of peripheral motor, sensory, and autonomic nerves are axons that have very few 
ribosomes, viral replication en route is unlikely. In an in vitro model there was internalization of 
virus into the neurites of cultured dorsal root ganglion cells exposed to fixed rabies, and 
retrograde axoplasmic transport was recorded at a rate of 12 to 24 mm/day (Lycke and Tsiang 
1987). Fixed virus was shown to reach the lumbar cord within 24 to 48 hours in footpad-inoculated 
mice (Johnson 1965). The first opportunity for viral replication in the nervous system occurs at the 
perikaryon (cell body) at the source of the peripheral nerve process.  
Chapter 1 
 41
1.6.3 Pathogenesis of lyssaviruses in ganglia and the central 
nervous system 
Having ascended peripheral nerves, virus reaches the perikaryon of motor neurons in the spinal 
cord or brain stem, and sensory neurons in the dorsal root or cranial sensory ganglia, or 
autonomic ganglia. Early detection of viral antigen at these sites indicates they are the first central 
nervous system sites for antigen amplification by viral replication (Baer et al. 1965, 1968; Charlton 
and Casey 1979a). It is unclear whether all the inoculated virions replicate here, and only progeny 
virus subsequently ascends to the brain and adjacent neurons, or whether inoculated virus can 
continue to higher segments of the central nervous system directly via the central process of the 
primary neuron.  
1.6.3.1 Replication of lyssaviruses 
The replication of rhabdoviruses, particularly vesicular stomatitis virus (VSV) and rabies virus, has 
been well documented. The morphology and replication of rabies and the rabies-like viruses are 
essentially the same (Gosztonyi 1994). Replication is confined to the cytoplasm with neither virus 
nor viral antigen occurring in the nucleus. Briefly, viral negative sense ribonucleic acid  
(-RNA) is transcribed by the RNA dependent viral RNA polymerase (L protein) into five positive 
sense, polyadenylated monocistronic messenger ribonucleic acid (mRNA) species. Each mRNA 
species is translated by cellular ribosomes into its respective viral protein (nucleoprotein, 
phosphoprotein, membrane protein, glycoprotein, and polymerase protein). The polymerase (L) 
protein also transcribes a single full-length positive sense complimentary string (+ cRNA) from 
which multiple negative sense genomes are replicated.  
The assembly of replicated genomes with transcribed nucleoproteins (N), phosphoproteins (P) 
and polymerase (L) proteins forms viral nucleocapsids. Randomly oriented strands of viral 
proteins and/or nucleocapsid form cytoplasmic bodies of viral matrix, which when large enough 
are visible by light microscopy as eosinophilic inclusions or Negri bodies. Nascent virions are 
produced on cisternal or plasma membranes by synchronous coiling of nucleocapsids and 
incorporation of viral membrane (M) proteins and glycoproteins (G) into the host cell membranes 
as the nucleocapsid buds through it (Gosztonyi 1994; Murphy et al. 1973b). Virions budding 
through the cell plasma membrane are released directly into the extracellular space (Miyamoto 
and Matsumoto 1967). Virions formed on internal cisternal membranes are released when either 
the cell dies and disintegrates (not a feature of most street rabies virus infections), or the cisternal 
membrane fuses with the plasma membrane (Gosztonyi 1994). 
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1.6.3.2 Dissemination in the central nervous system 
Following initial replication there is rapid dissemination of rabies virus throughout neurons of the 
central nervous system (Baer et al. 1965; Jackson and Reimer 1989; Murphy et al. 1973b), and 
simultaneous centrifugal spread to non-nervous tissues via peripheral nerves. Rabies antigen can 
be detected in several groups of neurons during the incubation period indicating there is no 
specificity for particular neuron types (Charlton et al. 1996). There appears to be negligible 
involvement of the glia, ependyma, choroid plexus, meningeal or vascular cells (Jackson and 
Reimer 1989; Johnson 1965; Murphy et al. 1973b). However, rabies virus replication has been 
observed in astrocytes by electron microscopy (Fekadu et al. 1982a) and rabies virus 
nucleoprotein antigen has been detected in oligodendroglia (Feiden et al. 1988). In vitro studies 
have demonstrated that, compared to astrocytes and other non-neuronal cells, neurons have a 
much greater susceptibility to infection and a greater propensity to sustain fixed and street rabies 
virus growth (Tsiang et al. 1983).  
Trans-neuronal and trans-synaptic cell-to-cell transfer of whole virus particles has been observed 
by electron microscopy and is implied by the stepwise spread of the virus revealed by sequential 
tissue titration and immunofluorescence (Charlton and Casey 1979a; Iwasaki and Clark 1975; 
Iwasaki et al. 1975; Murphy et al. 1973b). Trans-synaptic passage of infective RNA, rather than 
complete virions, may be important in the rapid dissemination of lyssaviruses in the central 
nervous system (Gosztonyi 1994). An immunoperoxidase study of viral antigen distribution in pre-
clinical, hind-limb inoculated skunks indicated that virus entered the lumbar spinal cord, replicated 
at L2 and L3, spread locally via propriospinal neurons, and gained early access to the brain via 
long ascending and descending fibre tracts (Charlton et al. 1996). Unlike earlier hind-limb 
inoculation studies where there was sequential involvement of the lumbar, thoracic, cervical spinal 
cord and brain (Baer et al. 1965; Johnson 1965; Murphy et al. 1973b), this recent study suggested 
that rabies virus reached the brain early by bypassing the grey matter of proximal segments of the 
spinal cord. 
As neuronal degeneration is not a feature of early stages of the disease, release of virions from 
disrupted neurons is not considered important for dissemination. Virus isolation from the 
cerebrospinal fluid (CSF) is generally rare, usually occurs late in the disease, and there is minimal 
viral antigen in ependymal and pial cells, suggesting CSF is not an important vehicle for virus 
transport (Murphy et al. 1973a; Murphy et al. 1973b). Transit in the CSF may be important in 
some intracerebrally inoculated mice (Jackson and Reimer 1989).  
By the time clinical signs develop, the virus is generally widespread in neural and non-neural 
tissues. In laboratory animals it can take as little as 24 hours for rabies, Mokola and Lagos bat 
viruses to spread throughout the central nervous system (Murphy et al. 1973b). In skunks street 
virus took a minimum of 4 to 5 days for virus to widely disseminate from the lumbar cord and 
cause clinical disease (Charlton 1994). In humans the incubation period is usually 1 to 2 months 
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(Miller and Nathanson 1977), however far longer incubation periods have been reported (>> 
1year). How and where virus is sequestered during these long incubations is not known, but has 
important implications for post-exposure prophylaxis.  
1.6.3.3 Clinical disease 
The most detailed records of naturally occurring clinical rabies involve human patients because 
the source of exposure and entire clinical progression is often recalled or observed. After an 
incubation period typically of 1 to 2 months, but up to several years, non-specific prodromal 
symptoms occur for a period of 1 to 10 days, often with paraesthesia of the bitten area, followed 
by clinical signs specifically indicating CNS involvement (Hemachudha and Phuapradit 1997; 
Warrell 1976).  
As in animals, human rabies is described as manifesting as either the furious (encephalitic) or 
dumb (paralytic) form of the disease depending on whether hyperactivity or paralysis dominates 
the acute neurologic phase. The clinical signs of furious rabies are mainly indicative of cerebral 
dysfunction. The most characteristic sign of furious rabies in man is hydrophobia: terror, 
excitement, and spasms of the inspiratory muscles of the larynx and pharynx triggered by the 
sight of water, attempts to drink, and other stimuli. Similar signs can be triggered by a draught of 
air on the skin (aerophobia). Other typical signs of furious rabies include intermittent episodes of 
excitement, agitation, hallucinations, aggressive or maniacal behaviour, tachycardia, pyrexia, and 
hyperreflexia, and signs of autonomic dysfunction including hypersalivation, fixed dilated pupils, 
anisocoria, and piloerection. Usually paralysis, generalized areflexia and coma supervene after a 
few days and patients die within 7 days depending on the extent of medical support (Hemachudha 
1994; Hemachudha and Phuapradit 1997; Warrell 1976).  
Dumb or paralytic rabies is mainly indicative of spinal cord and peripheral nerve dysfunction and 
is characterised by ascending flaccid paralysis that often starts with the bitten limb and 
progresses to generalised paresis with sphincter involvement, loss of deep tendon reflexes, and 
sensory disturbances. Death usually occurs from respiratory and bulbar paralysis after a longer 
illness than furious rabies, particularly when respiratory function is supported by medical 
intervention. In some cases hydrophobia can develop late in the course of otherwise paralytic 
rabies (Hemachudha and Phuapradit 1997; Warrell 1976). 
Humans bitten by vampire bats infected with genotype 1 bat rabies virus more typically develop 
paralytic clinical signs without an acute excitement phase (Pawan 1936). However, the few cases 
of other bat lyssavirus infections in humans have often exhibited furious encephalitic signs. No 
human case of Lagos bat virus infection has been identified. A child infected with Mokola virus 
died of a poliomyelitis-like disease characterised by symmetrical paralysis and drowsiness 
(Familusi et al. 1972). The only case of human Duvenhage virus infection was highly agitated with 
spasms and aggression on presentation, responded to water with typical hydrophobia, and went 
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“berserk” despite repeated sedation (Meredith et al. 1971). One of two cases of bat-associated 
lyssavirus infection in Russia manifested “a typical clinical picture of hydrophobia”, the other, 
which was confirmed as EBL-1 (Yuli isolate), presented with flabbiness and sleepiness, and 
developed aero-hydrophobia with spasms of the face, chewing and deglutitory muscles and 
extremities (Selimov et al. 1986). The only human to become ill with EBL-2 died after presenting 
with an ascending paralysis radiating from his right arm and neck and developed hyperexcitability, 
overt delirium, hyperventilation, muscle spasms and convulsions (Haltia et al. 1989; Lumio et al. 
1986; Roine et al. 1988). The two women to die with ABLV infection also first presented with pain 
and/or numbness in the bitten limb. The first developed progressive weakness and depressed 
conscious state and was eventually areflexic and unresponsive. On one occasion she became 
extremely agitated then lapsed back into depressed consciousness (Allworth et al. 1996). The 
second developed increased agitation and frequent and severe muscle spasms that led to the 
induction of medical paralysis and ventilator support, ameliorating and obscuring the subsequent 
clinical course (Hanna et al. 2000).  
The clinical signs in animals are similar to those in man, and are also described as occurring as 
furious or dumb rabies. Furious rabies in animals is characterised by altered behaviour, unusual 
aggression, or tolerance of humans. Hydrophobia is not a feature of animal rabies. Rabid vampire 
bats in Brazil were observed flying during the day and shrieking and fighting with one another 
(Pawan 1936). Paralytic rabies is characterised by ascending paralysis. Rabid animals may also 
manifest with a change in voice, pica, and cranial nerve deficits (de Mattos et al. 2001). As for 
human rabies, after a short clinical period rabid animals become moribund and die. Because of 
the threat of transmission of rabies virus to humans and others, naturally infected animals 
suspected of being rabid are usually killed quickly rather than treated or observed.  
Rabies in experimentally infected mice is almost invariably paralytic, although mice that die 
without preceding signs of paralysis (e.g. dying after a period of sluggish inactivity a hunched 
back and/or weight loss) are described as having encephalitic rabies (Iwasaki et al. 1977; 
Sugamata et al. 1992). Clinical signs in skunks infected with street (arctic fox variant) rabies 
typically included hyper-responsiveness to external stimuli, biting attacks, and mild incoordination 
and paresis, while the clinical signs of CVS-infected skunks were instability and hind limb 
incoordination, dullness, and lack of response to external stimuli (no biting attacks) (Smart and 
Charlton 1992). However, in neither animals nor man are the clinical signs associated with 
infection with any one lyssavirus genotype, variant, isolate, or strain, sufficiently distinctive to 
allow differentiation of the type of lyssavirus involved.  
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1.6.3.4 The cellular basis of disease: a missing link 
Immunofluorescence and immunoperoxidase studies in experimental animals have documented 
regional variations in lyssavirus antigen distribution. For example, heavy rabies virus antigen 
loads occur in the hippocampus and cerebellar Purkinje cells, while neurons of the cerebellar 
molecular and granular layers are spared (Johnson 1965; Murphy et al. 1973b). In contrast, 
Mokola and Lagos bat viruses invaded all levels of the cerebellum including the white matter 
(Murphy et al. 1973b). 
Studies of human encephalitic (furious) and paralytic (dumb) rabies found that the distributions of 
neither antigen nor inflammatory lesions correlated with clinical observations (Hemachudha 
1994). In the human studies this may reflect the fact that the brains were examined at the ‘end-
stage’ of the disease, by which time any significant early regional variation is likely to have been 
obscured. Similarly, studies of naturally occurring disease in animals are typically done late in the 
clinical course of the disease (Feiden et al. 1988). However, even in studies where experimentally 
infected animals were examined at various stages of the disease, no simple association between 
antigen, inflammation, and forms of the disease was observed (Charlton et al. 1996; Smart and 
Charlton 1992; Sugamata et al. 1992).  
Using immunofluorescence, Johnson observed early selective involvement of the limbic system 
rather than the neocortex and later considered this correlated with the early onset of behavioural 
changes and relative sparing of motor functions (Johnson 1965; Murphy 1977). However, he 
made this often-paraphrased observation in mice inoculated with fixed rabies virus (CVS) that 
developed paralytic rather than furious rabies, and his findings have not always been supported 
by subsequent immunoperoxidase studies. Studies using fixed rabies virus (CVS-11) in mice and 
skunk street virus in skunks found viral antigen in the cerebral cortex before it was detected in the 
hippocampus (Charlton et al. 1996; Jackson and Reimer 1989). Pre-clinical involvement of the 
medial reticular formation (modulates sensory impulses) and relative sparing of small primary 
sensory neurons and dorsal horn neurons (involved in pain) were associated with the hyper-
responsiveness to external stimuli in skunks (Charlton et al. 1996).  
Differences were found between the early distribution of viral antigen in the brains of skunks that 
developed paralytic rabies after intranasal inoculation with fixed rabies (CVS) compared to those 
which developed furious rabies following intramuscular or intranasal skunk street virus inoculation 
(Smart and Charlton 1992). No conclusions were drawn as to the significance of involvement of 
any specific part/s of the brain with respect to clinical signs. It was concluded that virus 
variant/strain, not route of inoculation, was an important factor in the early distribution of rabies 
virus and clinical signs. However, clinical expression does not appear to be simply a function of 
the virus variant as a single dog transmitted furious (encephalitic) rabies to one human patient 
and paralytic rabies to another (Hemachudha et al. 1988), and molecular sequenceing of the N, G 
and P protein genes from furious and paralystic human rabies cases found only minor nucleotide 
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differences, none of which encoded amino acid changes in functionally important areas of the 
proteins (Hemachudha et al. 2003). Evidently virus and host factors, and characteristics of the 
exposure (dose, site) have impacts on disease expression.  
It should be noted that the amount of antigen/virus in the brain per se may not correlate with the 
degree of dysfunction. As viral antigen is widely disseminated prior to clinical signs (Hronovsky 
1971), clearly neither the simple presence of replicating virus, nor the involvement of a large 
proportion of the central nervous system is the trigger for clinical disease. Non-fatal mutants of 
fixed rabies virus strains ascend to the central nervous system, replicate, disseminate widely, 
reach titres of up to 104  to 10 5  MICLD50 (mouse intracerebral 50% lethal dose) and are 
subsequently cleared in immunocompetent adult mice either without causing clinical disease 
(HEP-Flury, CVS-ts2) or in association with persistent (7 months) hind limb paralysis (ERA/BHK) 
(Fischman and Strandberg 1973; Kaplan et al. 1975; Smith 1981). Two mice inoculated with dog 
rabies virus and immunosuppressed by repeated injections of cyclophosphamide remained 
clinically normal until killed 20 days after centrifugal spread was detected by the presence of 
antigen in corneal touch impressions (Smith et al. 1982). High titrations of virus were recovered 
from the brains of these mice and massive amounts of antigen were detected in their peripheral 
nervous systems. Clearly, following infection of a considerable proportion of the central and 
peripheral nervous systems, some other trigger or threshold must be met for dysfunction and 
clinical disease to occur. Perhaps it is the absence/delay of this trigger, rather than a delay in the 
progression of the virus to the central nervous system, that is important in long incubation rabies. 
If a threshold viral load is important in cellular dysfunction, it is likely that different populations of 
neurons vary in their sensitivity to virus accumulation. Large accumulations of virus in some 
groups of neurons may be less significant than smaller quantities of virus in other neurons. 
Electron microscopy has not revealed any morphological basis for neural dysfunction (Murphy et 
al. 1973b). Levels of inducible nitric oxide synthase messenger ribonucleic acid (mRNA), 
undetectable in the normal brain, were present in the brains of experimental animals infected with 
rabies virus, Borna disease virus, herpes simplex virus and experimental allergic encephalitis 
(Koprowski et al. 1993). This suggests that nitric oxide, derived from increased levels of inducible 
nitric oxide synthase, may be a toxic factor for cell damage in neurological diseases. However, the 
precise mechanism by which rabies virus causes cellular dysfunction is not known. This 
constitutes a considerable ‘missing-link’ in our understanding of rabies pathogenesis.  
1.6.4 Involvement of non-neural tissue 
Centrifugal spread of rabies virions and/or matrix is believed to occur by anterograde axoplasmic 
flow in potentially all nerves of the body. Viral antigen and virus has been detected in peripheral 
nerves at times and locations consistent with centrifugal spread (Baer et al. 1965; Hronovsky 
1971; Murphy et al. 1973a). Remarkably, despite electron microscopic demonstration of viral 
matrix in axons and virus budding from intra-axoplasmic and axonal plasma membranes, no 
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image of viral uptake by non-neuronal cells has been captured. The mechanism by which virus 
and/or viral matrix are transferred from peripheral nerves to non-neural cells is not known. It is 
significant that direct inoculation of the salivary gland did not result in continued infection of the 
salivary gland (Charlton et al. 1983). Sequential immunofluorescence showed that the inoculated 
virus was rapidly cleared from the site and the salivary glands remained negative until 
fluorescence was also detectable in the brain stem and salivary ganglia consistent with centripetal 
spread via nerves. Apparently, substantial involvement of non-neural tissues is dependent upon 
uptake from neural networks and implies prior involvement of the associated ganglia or central 
nervous system. Centrifugal dispersion of ABLV is strongly suggested by the isolation of ABLV 
from the kidney of an unwell naturally infected bat (Ballina isolate) (Fraser et al. 1996). 
The involvement of non-neural tissue is relatively unimportant in the progression of clinical 
disease within an individual. Its importance lies in ensuring that virus is excreted for transmission 
to other individuals. It is likely that virus-variant and host-species factors influence transmissibility 
by affecting the rate at which salivary gland (or other relevant organ such as nasal mucosa) 
involvement occurs, how readily virus infects salivary epithelium, and the titre at which virus is 
excreted in saliva. Notably fewer organs outside the CNS contained European bat lyssavirus-1 or 
Duvenhage virus in intracerebral- and footpad-inoculated mice compared to mice inoculated with 
bat-variant rabies (Fekadu et al. 1988a).  
Infection of salivary gland epithelium, particularly mucinous acinar cells, results in replication and 
directional virion budding across the apical plasma membrane into duct secretions and budding 
into secretory granules (Balachandran and Charlton 1994; Murphy et al. 1973b). Virus titres in 
salivary glands can be greater than in the brain (Parker and Wilsnack 1966). In skunks inoculated 
intramuscularly with skunk street virus, virus titres in submandibular salivary glands and the extent 
of immunofluorescence were inversely correlated to serum and tissue neutralizing antibody titres 
respectively (Charlton et al. 1987a). In dogs inoculated with dog street rabies, virus has been 
detected in saliva up to 7 days, and 13 days before clinical disease (Fekadu et al. 1982b). On rare 
occasions virus has been detected in the saliva of naturally infected, clinically normal dogs which 
either did not subsequently develop clinical rabies, or did so after many months (Fekadu 1972, 
1975). Virus has been detected in the saliva of experimentally infected bats up to 8 days 
(Desmodus rotundus) (Moreno and Baer 1980) and 12 days (Tadarida braziliensis mexicana) 
before the onset of clinical disease (Baer and Bales 1967). Three rabbits and three calves died of 
rabies as a result of bites they received from inoculated vampire bats, 14 and 43 to 83 days 
before the vampires were ill (Pawan 1936). Considerable involvement of neuroepithelium in the 
olfactory end organs and taste buds has been demonstrated in bats, hamsters, and skunks 
(Charlton et al. 1984b; Constantine et al. 1972; Murphy et al. 1973b). The contribution by these 
organs to viral load in oronasal secretions and aerosol contamination of the environment may be 
significant in transmission for some host species including bats.  
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The involvement of non-neural tissues following centrifugal spread is generally not associated 
with dysfunction of those organs. Hypersalivation is most likely the result of autonomic dysfunction 
regulating the gland, or an inability to swallow rather than a disorder of the epithelium itself. 
Rabies virus antigen has been detected in the skin, buccal cavity, cornea, pancreas, and other 
epithelia, with no dysfunction of the infected organs (Fekadu and Shaddock 1984; Smith et al. 
1972). Viral matrix, virions and anomalous viral products have been detected by electron 
microscopy in the salivary glands, adrenal gland, cornea, nasal mucosa and glands, indicating 
that active replication, rather than passive accumulation of virus, occurs in these tissues 
(Balachandran and Charlton 1994).  
Antigen is commonly present in the adrenal medulla and while adrenal function is undoubtedly 
altered during clinical rabies (Hemachudha 1994), it has not been suggested either that altered 
adrenal dysfunction is a direct result of adrenal infection or that adrenal dysfunction is important in 
the pathogenesis of rabies. 
The heart and pituitary gland may be exceptions to the rule that viral dissemination is not related 
to non-CNS organ failure. Viral antigen in myocardial cells, myocarditis, and atrial ganglioneuritis 
have been reported in the hearts of rabies patients and cardiovascular failure is often a feature of 
the final stages of the human disease (Hemachudha 1994; Metze and Feiden 1991). Further work 
is required to determine if this failure is the result of direct involvement of the myocardium and/or 
pacemaker mechanism or is simply secondary to the failure of cardiovascular regulation by the 
brain. Rabies antigen has been demonstrated in the pituitary gland associated with reduced 
staining for growth hormone, failure to thrive, and wasting, suggesting infection of the pituitary 
gland produces primary growth dysfunction (Torres-Anjel et al. 1988).  
There has been some interest in the possible role of brown fat in long incubation and latent 
rabies, particularly in the hibernating microbats of the United States (Baer and Bales 1967; 
Kuzmin and Botvinkin 1996; Moreno and Baer 1980; Sulkin et al. 1957; Sulkin et al. 1959). While 
centrifugal spread can certainly involve brown fat, it remains unclear how this may be involved in 
the pathogenesis or epidemiology of rabies. 
1.6.5 The role of the immune system 
While the effectiveness of pre- and post-exposure vaccination schedules demonstrates the 
potentially protective role of the immune system, it may also be involved in the pathogenesis of 
rabies and might modulate or trigger clinical disease.  
1.6.5.1 The immune system in defence 
In the 1880’s, Louis Pasteur demonstrated that subcutaneous injections of desiccated spinal 
cords from rabbits infected with fixed rabies virus protected dogs against natural virus infection. In 
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1885, he used the same approach to treat 9-year old Joseph Meister who had received multiple 
bites from a rabid dog (Dietzschold et al. 1996). Rabies vaccines have undergone a number of 
improvements, including use of avirulent vaccine rabies virus strains and growth in cell culture to 
reduce the incidence of rabies due to inadequate inactivation of pathogenic vaccine virus and 
neurological disease resulting from allergic reactions to the vaccine’s animal CNS tissue base.  
Current human protocols recommend either vaccination (e.g. with human diploid cell vaccine, 
HDCV), prior to potential exposure, or vaccination and treatment with rabies immunoglobulin 
within 48 hours of suspected exposure (CDC 1999; NHMRC 1997). Post-exposure treatment has 
also been shown to be effective in patients where treatment was delayed for as long as 3-14 days 
(Bahmanyar et al. 1976). Failures of post-exposure treatment have occurred where the incubation 
period was short, the post-exposure management was flawed, and/or patients were 
immunosuppressed (Wilde et al. 1989).  
The rabies glycoprotein is the only rabies virus antigen that induces neutralizing antibodies (Cox 
et al. 1977). The production of neutralizing IgG antibodies to rabies virus antigen has been shown 
to be T-cell dependant (Iwasaki et al. 1977; Miller et al. 1978) and vaccination with the G protein 
alone can confer protective immunity (Fekadu et al. 1992; Lodmell et al. 1991). The N protein also 
plays a significant role in inducing protective immunity, and alone can confer immunity to 
peripheral, but not IC challenge, against heterologous rabies or rabies-like viruses (Dietzschold et 
al. 1987b; Fekadu et al. 1992; Lodmell et al. 1991; Lodmell et al. 1993; Sumner et al. 1991). 
Naturally occurring fatal infection of hosts (including humans) does not lead to the development of 
neutralizing rabies antibodies until late in the disease, if at all, and active and/or passive 
immunization is not effective once clinical signs have developed (Hemachudha 1994). Animals 
inoculated with high doses of virulent rabies virus may develop serum neutralizing antibodies just 
prior to or early in the course of clinical disease, but the disease progresses rapidly and they die 
(Charlton et al. 1987a; Niezgoda et al. 1997). Most animals inoculated with low to moderate doses 
of virulent rabies virus develop antibodies late in the clinical disease, or not at all, similar to the 
situation in naturally infected cases (Charlton et al. 1987a). Homologous antibody given to mice 
before and/or after inoculation with street rabies or Lagos bat virus reduces or eliminates mortality 
(Sugamata et al. 1992; Tignor et al. 1974).  
The effectiveness of vaccination schedules is often attributed to virus neutralisation by an early, 
and adequate immune response prior to involvement of the CNS (in the pre-clinical period), 
particularly as transport of neutralising antibody to the CNS is limited by the blood-brain barrier. 
However, as animal models indicate that virus can reach local ganglia within 18 hours (Shankar et 
al. 1991) it is likely that in some cases virus has reached and replicated in the CNS prior to receipt 
of, or response to, post-exposure treatment.  
There is evidence that effective immunity can occur following CNS involvement. In strains of mice 
resistant to intraperitoneal inoculation with street rabies virus, virus titres were detected in the 
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spinal cord but dropped steadily after the appearance of prominent serum neutralizing antibody 
titres (Lodmell and Ewalt 1985). Intracerebral inoculation of adult mice with attenuated rabies 
virus (HEP-Flury, ERA/BHK, CVS-ts2) induces protective humoral and cell mediated responses 
capable of clearing infection from the CNS. In immunodeficient or immunosuppressed mice, these 
immune responses are absent or poor and inoculation is fatal (Fischman and Strandberg 1973; 
Kaplan et al. 1975; Miller et al. 1978; Smith 1981; Wiktor et al. 1977b). Mice lethally infected with 
street rabies failed to develop cytotoxic T cells and had suppressed immune responses to 
concurrent viral infection (Wiktor et al. 1977a).  
It would appear that the pathogenesis and virulence of natural (street) rabies infections is related 
to failure (avoidance and/or suppression) of the immune response, and that pre- and even post-
exposure vaccination circumvents this. The protective functions of the immune system are 
abrogated in immunodeficient or immunosuppressed individuals as indicated by increased 
mortality in mice inoculated with street or fixed rabies virus, or Lagos bat virus (Iwasaki et al. 
1977; Smith et al. 1982).  
Even when the immune response is insufficient for survival, a positive role of the immune system 
in the pathogenesis of rabies is indicated by: 
♦ More rapid onset and progression of clinical signs in cyclophosphamide immunosuppressed 
skunks infected with street virus (Charlton et al. 1984a).  
♦ Tissue neutralising antibodies are associated with less immunofluorescence and lower virus 
titres in salivary glands (Charlton et al. 1987a), and immunosuppression facilitates recovery of 
rabies virus from salivary glands (Charlton et al. 1984a) 
1.6.5.2 The role of immunological responses in the pathogenesis of rabies 
The role of the immune system as a contributing factor in clinical rabies has also been 
investigated but there is as yet no clear understanding of how immune responses influence 
pathogenesis.  
Histological evidence of mononuclear cell infiltration and neuronophagia indicates that there are 
cellular immune responses to rabies virus infection that could play a role in neuronal dysfunction. 
However the low level or absence of inflammatory lesions in many rabies cases suggests that 
these visible immune responses alone are not the mechanism by which clinical disease is 
produced.  
There is evidence to suggest that the immune system influences the incubation time, clinical 
expression and mortality following infection with lyssaviruses in numerous studies examining the 
responses of normal, immunosuppressed, or immunodeficient animals, generally mice. That the 
immune system can have negative effects on the host during lyssavirus infection is indicated by: 
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♦ Immunosuppression delayed the onset of clinical signs after footpad-inoculation of mice with 
street rabies viruses by 1 to 2 weeks, albeit with increased mortality from 27 to 100%. The 
onset of paralysis after limited immunosuppression corresponded with a return to immune 
responsiveness, and passive transfer of homologous immune serum led to early onset of 
paralysis and death. There was an absence of clinical disease in two mice in which T- and B-
cell responses were suppressed with cyclophosphamide for 40 days post-inoculation, despite 
detection of rabies virus antigen in corneal touch impressions on days 21, 27 and 36, and 
recovery of high titres of virulent virus from their brains and demonstration of “massive” 
amounts of viral antigen in their peripheral nervous systems when sacrificed on day 40 
(Smith et al. 1982).  
♦ Immunosuppression with cyclophosphamide or by thymectomy and sublethal irradiation 
delayed the onset of clinical signs in mice following IC inoculation with Lagos bat virus, and 
death was accelerated by immune serum transfer (Tignor et al. 1974). 
♦ An ‘early death’ phenomenon, where inadequately immunized animals die after a shorter 
incubation period than unvaccinated controls, occurs in primates and mice challenged with 
CVS rabies virus and may be involved in the deaths of some humans in whom post-exposure 
vaccination fails (Blancou et al. 1980; Sikes et al. 1971). ‘Early death’ has been shown to be 
dependant on B lymphocytes, neutralising antibody, and/or T-cells (Prabhakar and Nathanson 
1981; Smith et al. 1982; Sugamata et al. 1992; Tignor et al. 1974). The mechanism/s by 
which antibody and/or T-cells precipitate the early onset of rabies in these situations is not 
known.  
Evidence for immune involvement in the paralytic form of lyssavirus infections includes:  
♦ Encephalitic rather than paralytic clinical signs prior to death in immunosuppressed or 
immunodeficient mice inoculated with fixed or street rabies virus (Iwasaki et al. 1977; Smith 
1981; Sugamata et al. 1992). 
♦ Paralysis of street rabies virus-infected mice was shown to be dependant on T lymphocytes 
and associated with inflammation including perivascular accumulations of CD4+ (helper) and 
CD8+ (cytotoxic) T cells, and the presence of CD8+ T cells in brain parenchyma. It was 
suggested cytotoxic elimination of infected neurons induces paralysis (Sugamata et al. 1992). 
♦ Immunosuppression by cyclophosphamide or thymectomy and irradiation reduced the 
incidence of paralysis in mice inoculated with Lagos bat virus (Tignor et al. 1974). 
♦ Onset of paralysis was associated with the return to immunocompetence in mice that had 
been inoculated with dog or fox rabies virus variants after temporary immunosuppression with 
cyclophosphamide (Smith et al. 1982). 
♦ Lymphoproliferative responses to rabies antigen were detected in human patients with 
encephalitic rabies who died after a shorter clinical period, whereas patients with paralytic 
rabies showed no response to rabies antigen (Hemachudha et al. 1988). Patients with 
paralytic rabies tended to have diminished numbers of B lymphocytes compared to those with 
encephalitic rabies (Hemachudha et al. 1988; Sriwanthana et al. 1989).  
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There is also conflicting evidence that paralysis is independent of the immune system. Nude 
(athymic T-cell deficient) mice developed paralysis after inoculation with fixed (CVS) but not street 
rabies virus (Charlton 1994), and disease expression in immunocompromised skunks did not 
differ from that in competent skunks (Charlton et al. 1984a).  
It is apparent that there is a complex relationship between the influences of the immune system, 
the host species, virus variant/strain, dose, and route of inoculation that complicates interpretation 
of results using different methods. The role and mechanisms by which the immune system 
influences the pathogenesis of rabies, neural dysfunction, and the expression of clinical disease 
remain unclear.  
1.6.6 Evidence of recovery and subclinical infection  
Clinical rabies in mammals is generally considered fatal. There are however occasional reports of 
asymptomatic carrier animals and recovery from clinical disease. Reports of rabies-neutralizing 
serum in clinically normal animals and humans suggest subclinical resolution of viral infection 
and/or recovery from clinical disease.  
1.6.6.1 The carrier state  
There are reports indicating that on rare occasions apparently healthy animals, with no known 
previous or subsequent signs of rabies, excrete infective rabies virus in their saliva. True carrier 
animals need to be differentiated from those excreting virus in the immediate (generally <14 days) 
pre-clinical period. 
The earliest reports of a carrier state involved vampire bats (Desmodus rotundus) (Pawan 1936). 
Wild-caught bats that appeared healthy transmitted rabies to calves on which they were allowed 
to feed. Bats inoculated with passaged rabies virus of human origin (variant unknown) that did not 
develop clinical signs also transmitted rabies to calves. A bat that was “restless and fierce’” when 
caught in the wild remained fierce and excited for nine days, then became normal, and three-to-
six days after its apparent recovery transmitted fatal rabies to a calf on which it was allowed to 
feed. The bat survived for at least a further 2 ½ months. These findings suggest that clinically 
normal wild bats and those who recover from clinical disease can be carriers of rabies virus. 
Unfortunately, these early reports suffer from a reliance on clinical signs and the detection of 
Negri bodies for rabies diagnosis. No evidence of virus excreting ‘carriers’ was found in a more 
recent study of experimentally inoculated vampires using suckling mice, cell culture and 
fluorescent antibody tests for virus detection (Moreno and Baer 1980). In these bats virus was 
only isolated from salivary swabs up to 8 days before and during clinical disease. 
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Early studies in which dog-variant rabies virus was recovered from the brown fat but not the brain 
of apparently well, IM inoculated Mexican freetail bats suggested that brown fat may play an 
important role in the persistence of rabies virus in asymptomatic carriers and allow latent rabies 
infection to ‘over winter’ in bats while hibernating (Sims et al. 1963; Sulkin et al. 1957; Sulkin et al. 
1959). However no special role for brown fat was indicated in later studies in which virus was only 
recovered from the brown fat of unwell bats that also had virus in the brain, and where virus was 
not recovered any more frequently from bats kept in hibernation for 60 days post-inoculation (Baer 
and Bales 1967; Kuzmin and Botvinkin 1996; Moreno and Baer 1980). In the absence of data on 
the prevalence of lyssaviruses, using modern techniques, in the brown fat of clinically well wild 
animals, the role of brown fat in long incubations, hibernation, and carrier status remains unclear.  
Outbreaks of EBL-1 in a colony of captive bats (Egyptian flying fox, Rousettus aegyptiacus) 9 
days after transfer from a closed Dutch colony, and of clinical rabies in captive E. fuscus 3 to 4 
weeks after importation from the USA, suggest that persistent, subclinical lyssavirus infections in 
bats may be common, and that clinical outbreaks may occur following stress such as transport 
and relocation (Ronsholt et al. 1998; Wellenberg et al. 2002). That bats may survive subclinical 
infection either as asymptomatic ‘carriers’ or having cleared the infection is supported by the 
detection of neutralising antibodies (n=3) or nucleoprotein antigen (n=2), and by amplification of 
EBL-1 RNA (n=30) from 40 remaining, apparently healthy R. aegyptiacus in the source colony 
(Wellenberg et al. 2002). 
In India, a boy died of rabies 44 days after being bitten by a clinically normal dog. Rabies virus 
was isolated by mouse inoculation from the saliva of the dog on 13 occasions over four years, yet 
it remained asymptomatic, had no serum-neutralizing antibodies, and no virus was recovered 
from its brain when it died, although viral antigen was detected by fluorescent antibody test. The 
cause of the dogs death was not indicated (Nanavati 1973; Veeraraghavan et al. 1970). The 
death of the boy suggests the dog carried virulent rabies virus, yet in the absence of neutralizing 
antibody; unrecognized host factors either protected the dog from developing clinical rabies, or 
had enabled the dog to recover from clinical disease prior to biting the child. 
In Africa, atypical strains of rabies virus appear to circulate in dogs that can produce a chronic 
carrier state. In Ethiopia rabies virus was repeatedly isolated from the saliva of five of 1,083 
clinically normal dogs submitted for isolation after biting, scratching, or licking humans or as in the 
case of one bitch after four of her two-month old pups died of rabies. The bitch died of 
bronchopneumonia after nine months and a dog died of furious rabies 19 months after virus was 
first isolated from saliva. Three others remained asymptomatic for at least four years (>50, >62 
and >70 months) and had rabies-neutralizing antibodies, yet rabies virus was intermittently 
isolated from their saliva by mouse brain inoculation (Fekadu 1972, 1975).  
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In Nigeria, swabs of saliva were collected from 1500 dogs presenting for routine veterinary 
examination over 5 years. Of these, four were positive by fluorescent antibody test and mouse 
inoculation. The four cell-adapted isolates showed identical reactivity when typed by a panel of 
anti-nucleocapsid and anti-glycoprotein monoclonal antibodies, which was clearly distinct from the 
LEP-Flury strain used for vaccination and other street rabies variants in Nigeria (Aghomo and 
Rupprecht 1990).  
If involvement of the salivary glands in these dogs and bats was the result of centrifugal spread, 
then at least limited infection of the central nervous system must have occurred. The question that 
remains is why this had not resulted in fatal clinical rabies. The possibility that the asymptomatic 
shedding carrier state occurs after recovery from clinical disease is suggested by one dog 
inoculated with a rabies isolate from the saliva of a naturally asymptomatic carrier dog (Fekadu 
and Baer 1980; Fekadu et al. 1981; Fekadu et al. 1983). Virus was recovered from the saliva of 
this dog 42, 169, and 305 days after recovering from clinical signs consistent with rabies and 
developing high serum and CSF rabies neutralising antibody titres. Sixteen months after recovery 
the dog died following the stillbirth of two pups, at which time virus antigen was detected in the 
brain, spinal cord, and tonsils, and virus was isolated from the palatine tonsil. 
The prevalence of true carriers, the mechanisms that prevent them succumbing to clinical 
disease, and the significance of their role in the maintenance of rabies within bat and other 
species populations remain unclear. 
1.6.6.2 Recovery from clinical disease 
While approximately 60,000 clinical cases of human rabies are reported each year, there are only 
five well-documented reports of human survival of clinical rabies.  
♦ A 6-year old boy bitten by a Big Brown bat (E. fuscus) recovered completely within six months 
(Hattwick et al. 1972).  
♦ Recovery of a 45-year old woman bitten by her dog was ‘nearly complete’ after 13 months 
(Porras et al. 1976). 
♦ A 32-year old male rabies laboratory worker apparently exposed to aerosols of modified live 
(SAD strain) rabies showed ‘gradual improvement’ from a deep coma, no longer needing 
respiratory assistance but unable to respond to verbal commands or communicate with others 
(CDC 1977). 
♦ A 9-year old Mexican boy bitten by a rabid dog survived at least 2 years with severe 
neurological sequelae that included quadriplegia and amaurosis with the capacity to breath 
unassisted via a tracheostomy and injest food by mouth (Alvarez et al. 1994). 
♦ A six-year old Indian girl bitten by a street dog was comatose for 3 months then showed 
gradual improvement over a further 2 months to be able to respond to verbal commands and 
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feed orally. She remained alive after 18 months with little further improvement and persistent 
rigidity, tremors, and involuntary movements of the limbs (Madhusudana et al. 2002). 
The merit of these reports lies in the validity of the diagnoses of rabies infection. The bat and the 
boy’s dog were confirmed as rabies-positive by fluorescent antibody test and both the woman’s 
and girl’s dogs died 4 days after the bite with clinical signs suggestive of rabies but no laboratory 
confirmation was made. Antemortem diagnosis of rabies is notoriously difficult and definitive 
diagnosis requires virus isolation or the demonstration of viral antigen or viral RNA, none of which 
was demonstrated in these cases. However, brain biopsies are rarely taken and tests on nuchal 
skin biopsies (Smith et al. 1972), corneal scrapings, and saliva are not very sensitive (World 
Health Organization 1992). In all five cases, the diagnosis of rabies was made on the basis of 
each developing extraordinarily high serum (1: 63,000, 1:640,000, 1: 64,000, 1:34.800, and 
1:265,000) and CSF (1:3,200. 1: 160, 000, 1:16,225, 1:78,125, and 1:124,000) rabies antibody 
titres. All five had received rabies vaccination, in four cases as post-exposure treatment (duck 
embryo vaccine (bat boy), suckling mouse brain vaccine (woman), VERO vaccine in the 
preclinical period and HDCV when acutely ill (Mexican boy), or chick embryo cell vaccine in the 
preclinical period and HDCV when acutely ill (Indian girl)), and in one cases as pre-exposure 
vaccination (man - primary course 9 years earlier followed by yearly boosters inducing a rabies 
titre of 1:32, suggesting protective immunity, 4 months before exposure). However the serum and 
particularly the CSF titres are far in excess of those recorded in response to these vaccines either 
in patients that remain well, or in those who develop Guillain-Barré syndrome in response to 
vaccination.  
High rabies virus neutralising titres in CSF, are considered evidence of recovery from clinical 
rabies because in cases of fatal rabies and in vaccinated animals CSF titres are comparatively 
low (Arko et al. 1973; Bell et al. 1971; Bell et al. 1972; Fekadu and Baer 1980; Fekadu et al. 
1988a). The presence of high neutralising titres in the CNS is believed to reflect in situ antibody 
production rather than ‘leakage’ of serum antibodies across a damaged blood-brain barrier as 
lead nitrate induced encephalitis in vaccinated dogs with high rabies neutralizing serum titres did 
not produce high rabies neutralising titres in the CSF (Arko et al. 1973). Evidence of intrathecal 
production of rabies antibodies in the CSF was demonstated in the Mexican boy and Indian girl. 
The relationship between high CSF titres and recovery deserves further investigation.  
Since Pasteur there have been reports of recovery from clinical rabies in experimentally infected 
animals including bats (Pawan 1936), mice (Bell 1964; Iwasaki et al. 1977; Lodmell et al. 1969; 
Lodmell and Ewalt 1985; Mifune et al. 1980; Sugamata et al. 1992), dogs (Arko et al. 1973; Bell et 
al. 1972; Constantine 1966c; Fekadu and Baer 1980; Fekadu et al. 1988a; Fekadu et al. 1992), a 
ferret (Niezgoda et al. 1997), and a donkey (Ferris et al. 1968). A monkey intramuscularly 
inoculated with Largos bat virus developed persistent unilateral paresis on post-inoculation day 22 
but survived until killed on day 108 (Tignor et al. 1973). In these reports the extent to which the 
diagnosis of rabies virus infection was confirmed varied.  
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Reports of recovery from naturally occurring rabies, such as that reported in a wild caught 
vampire bat and four of six pigs bitten by a rabid skunk (Baer and Olson 1972; Pawan 1936), are 
much rarer. In no naturally occurring case of clinical recovery has the diagnosis been confirmed 
by recovery of virus or viral antigen. There is little in the literature to suggest that recovery from 
clinical rabies is common in nature. 
1.6.6.3 Serological evidence of lyssavirus infection in normal animals 
Rabies neutralizing serum has been reported in clinically normal domestic and wild animals and 
humans from rabies-endemic areas. Interpretation of anti-lyssavirus titres in clinically normal 
hosts is difficult. Of primary consideration is the validity of the results, false-positives are a feature 
of any biological test. Serum neutralizing tests such as the mouse neutralization and rapid 
fluorescence focus inhibition test (RFFIT) are not entirely specific for rabies neutralizing 
antibodies and there should be concern that positive reactions, particularly those of low titre (e.g. 
less than 1:10) are due to non-specific virus neutralizing substances in serum. Results could also 
reflect the presence of cross-reacting antibodies to other unrecognized antigens. Presuming the 
results do indicate the presence of rabies (or other lyssavirus) antibodies, the possibility of prior 
anti-rabies vaccination should be considered, particularly when interpreting data from humans and 
dogs. Where prior vaccination is unlikely, often too little is known of the history and subsequent 
progress of animals to allow meaningful interpretation of whether the presence of antibodies 
indicates recovery from prior clinical disease, subclinical resolution of infection, or impending 
disease (tested during an incubation or latent period). In none of the studies have ‘wild caught’ 
seropositive animals been challenged to assess the effectiveness of their apparent immunity. 
In most experimental studies, inoculated animals that fail to develop clinical rabies do not develop 
neutralising titres, although 11% of Mexican freetail bats that survived inoculation with bat rabies 
were seropositive 181 days later (Baer and Bales 1967). Studies of inoculated denervated skunks 
indicate that infection restricted to the inoculation site can induce serum neutralizing titres without 
disease (Charlton and Casey 1981). The development of neutralizing titres and subclinical 
resolution may occur in wild animals as a result of factors/mechanisms that produce ‘abortion’ of 
the infection at the inoculation site, peripheral or central nervous system.  
In humans, rabies neutralizing serum was reported in 15 of 226 (6%) students and staff at a 
veterinary college (Ruegsegger et al. 1961), three of 200 cave explorers (Doege and Northrop 
1974), and one of 26 Alaskan fox trappers (Follmann et al. 1994) who denied exposure or contact 
with rabies vaccines.  
Wildlife surveys have found prevalences of 2 to 29% of rabies neutralizing serum in apparently 
normal populations of grey and red foxes, skunks, opossums, mongooses, bobcats, raccoons, 
and vampire bats, (Carey and McLean 1978, 1983; Doege and Northrop 1974). Seroprevalences 
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of 18% (n=49) (Yasmuth et al. 1974), 30% (n=463) (Ogunkoya et al. 1990), and even 80% (n=10) 
(Mebatsion et al. 1992) have been reported in unvaccinated dogs.  
The most striking serological evidence of survival following rabies infection occurs in bats. 
Positive rabies antibody titres were detected 14-80% of apparently normal Mexican Free-tailed 
bats, yet <1% were positive for rabies antigen and/or virus (Constantine et al. 1968b; Steece and 
Altenbach 1989). Similarly, 2% of Little Brown bats (Myotis lucifugus) and 9% of Big Brown bats 
(E. fuscus) in New York State were seropositive for rabies, as were up to 33% of vampire bats 
(Ortega et al. 1987; Trimarchi and Debbie 1977). A four month survey of normal adult female 
Mexican free-tail bats at Lava Cave, New Mexico (n=750) found a constantly high IgG antibody 
prevalence of 63-73%, low (2%) prevalence of IgM antibodies and a low (<1%) prevalence of 
rabies antigen in brains (Steece and Altenbach 1989). The findings in 600 neonatal bats over a 
three-month period were more variable. Initially the proportion with neutralizing antibodies was 
high, the prevalence of IgM antibodies was low, and rabies antigen was not detected. As the 
summer progressed there was a drop in the proportion with neutralizing antibodies, which then 
steadily rose (reaching 50% by the time the survey was completed) in concert with a rise in the 
prevalence with IgM antibodies. The number of juveniles which were rabies antigen positive was 
low (2%) but notably higher than that among adults during that period. In combination these 
results suggest: prenatal transfer of rabies antibody, the levels of which fell rapidly in the post-
natal period; early exposure of young bats to rabies virus with the development of IgM and then 
IgG antibodies; and persistence of IgG antibodies and loss of IgM antibodies in adult bats. 
Prenatal transfer of rabies antibody followed by a decrease in the proportion of young bats with 
antibody being associated with clinical rabies had also been observed in the same bat species in 
Carlsbad Cave, New Mexico (Constantine et al. 1968b). What remains to be determined is 
whether or not the adult bats that had high antibody titres had recovered from clinical disease or 
had seroconverted during subclinical resolution of rabies infection. 
Interestingly, while Lagos bat virus was first isolated from fruit bats (Eidolon helvium), in a survey 
of shot fruit bats, none had detectable antibodies to Lagos bat, Duvenhage or Mokola viruses, 
while 5 of 50 (10%) had titres to CVS-11 rabies virus (Aghomo et al. 1990). There has been 
serological evidence of Mokola virus infection in cattle, goats, swine, birds, dogs, and fruit-bats 
(Eidolon helvium)(Kemp et al. 1972; Ogunkoya et al. 1990). Perhaps surprisingly if shrews are the 
natural host for Mokola virus, no neutralizing antibodies were detected in a serological survey of 
shrews (n=91) and only one of 13 experimentally infected shrews developed a neutralizing titre 
(which was low) (Kemp et al. 1972; Kemp et al. 1973). Using a mouse neutralization test, neither 
of the two human cases, nor humans in a serological survey (n=82) had Mokola neutralizing 
antibodies (Kemp et al. 1972). Using a modified rapid fluorescent focus inhibition tests (RFFIT), 
7.5% of 158 people were shown to have anti-Mokola antibodies, and 2.5% had antibodies to 
Lagos bat virus (Ogunkoya et al. 1990). An aaverage of 7.8% of 976 sera from microbats in Spain 
were positive for EBL-1 specific antibodies, with an average seroprevalence of 24% among M. 
myotis in two locations (Serra Cobo et al. 2002). Banding and recapture of the Spanish bats 
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demonstrated that four individuals survived at least 1 to 3 years following detection of positive 
EBL-1 titres.  
The presence of anti-rabies antibodies in humans who have no recollection of prior rabies 
vaccination, have no history of an illness suggestive of recovery from rabies, and who do not 
subsequently develop rabies suggests either test failure, cross reactivity with other antigens or 
prior subclinical resolution of infection from an unapparent exposure. If subclinical resolution 
occurs it suggests humans (and probably other animals) have an ‘all or nothing’ response to 
naturally occurring rabies infection. That is that following exposure to rabies, either the patient 
develops antibodies with subclinical resolution of the infection or the patient develops invariably 
fatal clinical disease, with or without late production of antibodies. The virtual absence in humans 
of a spectrum of response, which would include people surviving clinical disease with and without 
sequelae, is unusual in biological systems. The unlikeliness of an ‘all or nothing’ response, and 
the fact that many seropositive humans recall no history of likely exposure, such as bites from 
dogs or other hosts, rabid or not (Ogunkoya et al. 1990), suggests that the neutralizing activity 
detected in serum is not necessarily the result of exposure to lyssaviruses.  
1.7 Controlling rabies 
A moderate level of rabies virus control among vampire bats is achieved though the application of 
anticoagulants systemically to cattle and topically to individual vampire bats. Anticoagulant, 
ingested by bats when feeding on treated cattle or by mutual grooming of treated vampire bats 
back at the colony, is fatal to vampires (Setien et al. 1998). Attempts to control rabies by 
eliminating litter-bearing (carnivore) principal hosts have been universally unsuccessful, 
presumably because the fecundity of the hosts quickly restores the minimum population density 
required to maintain the disease. However, targeting the susceptibility of the principal host in a 
particular area has successfully eradicated or dramatically reduced rabies in some areas. 
Between 1889 and 1902, restrictions on the movement and importation of dogs, and the use of 
muzzles when at large, eliminated rabies from the United Kingdom. Between 1907 and 1917 
similar measures controlled small outbreaks of rabies in Canada (Pullar and McIntosh 1954; 
Tabel et al. 1974). Presumably, variants of dog rabies virus then present in the United Kingdom 
and Canada had not adapted to sustain themselves in the fox populations of those countries.  
With the development of killed and attenuated parenteral (intramuscular and subcutaneous) 
animal rabies vaccines, mass canine vaccination programs have virtually eliminated dog rabies 
from many developed countries. The effectiveness of parenteral vaccination programs in many 
developing countries has been poor because success is dependant on costly vaccination and 
effective concurrent control of domestic and stray animals that is difficult to achieve in many 
social, cultural, religious, political, and economic circumstances (de Mattos et al. 2001).  
A considerable limitation to control of sylvatic rabies is safe, effective, suitably targeted, and 
affordable vaccine delivery. While vaccination by injection is not practical for wildlife, vaccination 
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of red foxes with standard (e.g. SAD) or attenuated (e.g. SAD-B19) rabies virus strains by oral 
baiting has been effective in some European countries, the USA, and Canada (Barrat and Aubert 
1993; de Mattos et al. 2001; Wandeler et al. 1988) and has led to development of new oral 
vaccines with increased efficacy, safety and thermostability. Recent advances in animal vaccine 
technology include vaccinia virus-, raccoon poxvirus-, or adenovirus-vectored recombinant 
vaccines expressing the rabies virus G protein (Charlton et al. 1992; Fekadu et al. 1991; Lodmell 
et al. 1991; Pastoret and Brochier 1992) and live cloned cDNA rabies virus vaccines 
(Pulmanausahakul et al. 2001). These new vaccines have the potential to increase the number of 
host species, lyssavirus genotypes, circumstances, and environments in which rabies control 
programs can be effective. 
Elimination of rabies from areas such as the USA, where different variants are involved in multiple 
endemics, will require suitable control programs be directed towards rabies virus transmission in 
each principal wildlife species. While the development of thermostable oral vaccines and 
improvements in bait design may result in effective control of urban and sylvatic terrestrial rabies, 
no suitable method of vaccine delivery to insectivorous bats or flying foxes is known. 
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2 Naturally acquired Australian bat lyssavirus 
infection in bats 
Aims 
1. To estimate the prevalence of Australian bat lyssavirus in bats. 
2. To identify risk factors for ABLV infection of bats. 
3. To characterize the circumstances in which bats with Australian bat lyssavirus are found, as 
well as the clinical signs, clinical duration and outcome, serological response, and duration / 
extent of possible human exposure associated with naturally acquired infection in bats. 
2.1 Introduction 
Recognition and surveillance of ABLV occurred as a direct result of investigations in to the origins 
of the 1994 outbreaks of Hendra virus (previously equine morbillivirus) (Allworth et al. 1995; 
Hooper et al. 1997a; Hooper et al. 1997c; Murray et al. 1995a; Murray et al. 1995b; O'Sullivan et 
al. 1997; Rogers et al. 1996; Selvey et al. 1995; Ward et al. 1996; Westbury et al. 1995; Westbury 
et al. 1996). A five month-old Black flying fox (P. alecto) with hind limb paresis, submitted to AAHL 
for Hendra virus testing, was subsequently diagnosed with a lyssavirus infection (Fraser et al. 
1996). Prior to this it was believed that no lyssaviruses were endemic in Australia. Even more 
alarmingly, within 4 months a woman that had had contact with bats was confirmed as having 
died of ABLV encephalitis (Allworth et al. 1996; Samaratunga et al. 1998).  
The recognition that one or more lyssavirus/es was present in Australia, was capable of causing 
human fatalities, and threatened Australia’s WHO ‘rabies free’ status, through which Australia 
enjoyed political, economical, trade and quarantine advantages, meant it was urgent that research 
be done to characterize and quantify the prevalence, distribution, risk factors, and natural history 
of lyssavirus infection in Australia.  
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2.2 Materials and Methods 
2.2.1 Animal submission and classification  
Bats and other species submitted to the Queensland Department of Primary Industries (DPI) 
between June 1996 and March 2002 were tested as part of a surveillance program for the 
detection of Australian bat lyssavirus (ABLV). The bats included in this analysis are those 
submitted for ‘diagnostic ABLV-testing’ and includes retrospective (pre-mid-1997) and prospective 
data. This analysis excludes normal wild bats caught and tested as part of concurrent structured 
surveillance research by the DPI (H. Field pers. comm.) and bats in the vaccination and 
experimental infection trials described in Chapters 5 and 7.  
Most bats were submitted dead to the Animal Research Institute (ARI), Yeerongpilly or other 
regional laboratories of the Queensland Department of Primary Industries. Live flying foxes 
submitted to the ARI were killed by injection of barbiturate (Lethobarb, 325 mg/mL 
pentobarbitone sodium, Virbac) administered intravenously via the uropatagial vein or by 
intraperitoneal injection. Live microchiroptera were killed by inhalation of CO2. The submitter 
completed a standard Department of Primary Industries submission form (Specimen Advice 
Sheet: Form A, GEN-008) giving their details, details of the bat/s, and the history of their 
involvement with the bat and their observations. The quality of the information supplied by the 
submitters varied. Where possible the submitters of ABLV-positive bats and some ABLV-negative 
bats were later phoned for further details. 
In addition, results and details of some Queensland bats submitted to the Department of Health, 
(QHSS) during 1999 and 2000, including all ABLV-positive bats, were added to those submitted to 
the DPI (see Section 2.2.4 Evolution of laboratory submission and test protocols). As such this 
study includes all ABLV-positive bats from Queensland between 1996 to 2000 inclusive, but not 
ABLV-positive bats submitted to QHSS during 2001 and 2002.  
Where possible the following information was recorded: 
♦ Date of death and date submitted 
♦ Species of bat 
♦ Sex (male or female) 
♦ Age (juvenile or adult) 
♦ History of circumstances found 
♦ History of clinical signs observed 
♦ History of human or animal contact with bat 
♦ Location found (town and DPI region, see 
Map, Appendix 1) 
The original intent was to have combined the data of DPI and all QHSS submissions to construct 
and analyse a complete data set for bats submitted from Queensland. However, information not 
required by QHSS to perform and report the test, but necessary for this analysis, such as species 
of bat, sex, age, and histories, was not usually supplied by the referring physician, and issues of 
privacy and patient confidentiality precluded direct contact with QHSS submitters. Bats were 
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classified by the candidate on the basis of the history and clinical signs for two independent 
characteristics; 
 
♦ Health status: the clinical health versus disease status of the bat 
♦ Contact status: whether or not it had bitten or scratched any person (Contact Human) or 
other animal (Contact Animal) 
2.2.1.1 Health status 
Each bat was classified as one of the following: 
1. Normal bat.  A healthy bat with no indication of being unwell. This group included captive 
bats with no recent history of being unwell, bats shot as pests in orchards, and apparently 
healthy microbats found in homes.   
2. Sick, injured, or orphaned. All other bats which were not normal (sick, injured, or orphaned). 
These bats were further classified as:   
2a. CNS bat.  An ill bat with clinical signs suggesting the central nervous system was 
primarily involved. This included bats with signs of paresis, paralysis, cranial nerve deficits, 
and abnormal behaviour including uncharacteristic aggression or tolerance of humans. Most 
of the bats submitted were wild animals and many were submitted by wildlife carers who were 
experienced in the normal behaviour of wild-caught bats. Typical aggression and fear was not 
considered an indication of central nervous system disease. Depressed moribund bats were 
not classified in this group, as secondary nervous system depression can result from the end 
stage of many non-nervous system conditions.  
2b. Non-CNS bats. All bats that were neither normal nor showing signs of primary central 
nervous system disease. This included bats with injuries such as fractures, bats caught in 
fences, found dead, or bats that were non-specifically unwell. Maternally-dependant orphan 
bats, even if apparently in good health, were included in this classification as it was presumed 
that some disease or misadventure involving the dam or the orphan had led to it being taken 
into care, and that it had been subjected to at least some degree of stress, dehydration, and 
exposure.  
3. Unknown. Where the history provided by the submitter was not sufficient to determine 
whether the bat was normal or sick, injured, or orphaned the health status was recorded as 
unknown. 
All health classifications; Normal, CNS bat, Non-CNS bat, and Unknown are mutually exclusive. 
The relationship of the health categories is illustrated in Figure 2-1. 
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Figure 2-1 Health status categories 
 
                All bats 
 
      Normal        Sick, injured, or orphaned         Unknown 
       
     CNS bat       Non-CNS bat 
2.2.1.2 Contact status 
Each bat was classified as one of the following: 
1. None. No human or animal contact (as defined below) reported. 
2. Human only. Where a bat was reported as being known to have bitten or scratched one or 
more persons. Often this occurred when members of the general public attempted to rescue a 
sick, injured, or orphaned bat, such as when attempting to release a bat trapped on a barb-
wire fence, and when wildlife careers raised or rehabilitated sick, injured, or orphan bats. 
Direct contact alone did not warrant classification in this group as virtually all submitted bats 
had been handled by humans. Where there was the possibility of people having been bitten 
or scratched (e.g. bat found injured in school yard) but no bite or scratch was known to have 
occurred (e.g. children denied touching bat, claimed not to have been bitten or scratched and 
no consistent injuries were found), the bat was not classified in this group. Classification in 
this group was intended as a measure of aggressive/defensive behaviour by the bat rather 
than the appropriateness of post-exposure vaccination for the relevant humans.  
3. Animal contact. Where a bat was reported as having had contact with an animal such that it 
was known or suspected that the bat could have bitten or scratched the other animal. Dogs 
and cats occasionally attack bats. In some cases, members of the public heard or observed 
bats being attacked, found their pet with a live or dead bat, or found a dead bat in the pet’s 
bed. Unless it was clear that the bat was dead prior to the pet having contact with it (e.g. 
advanced putrefaction or evidence of having been dug up), it was presumed that that the bat 
could have bitten or scratched the other animal. Bats submitted with no history of being 
attacked but with injuries consistent with an animal attack, such as puncture wounds and 
multiple fractures, were also classified in this group. Classification in this group was intended 
as a measure of the potential of bats to expose other animals to ABLV. 
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4. Dual: Human and Animal Contact. The contact status classifications of None, Human 
Contact and Animal Contact were not mutually exclusive as a small number of bats had bitten 
or scratched one or more persons and had contact with one or more animals.  
The total number of bats which had scratched one or more persons was the sum of those that had 
bitten or scratched a person (Human only) and those that had bitten or scratched a person and 
had contact with an animal (Dual).  
The total number of bats which could have bitten or scratched an animal was the sum of those 
that had direct contact with an animal (Animal Only) and those that had bitten or scratched a 
person and had contact with an animal (Dual).  
The relationship of the contact categories is illustrated in Table 2-1 and Figure 2-2. 
Table 2-1 Contact status categories 
Contact Human Contact Animal Circumstances Contact Status 
No No No reported human bite or scratch or 
animal contact 
None 
Yes No Only human bites or scratches reported  Human only 
No Yes Only animal bites, scratches or direct 
contact with animals reported  
Animal only 
Yes Yes One or more persons were bitten or 
scratched and one or more animals had 
direct contact with the bat 
Dual: Human and 
Animal 
 
Figure 2-2 Contact status categories 
 
     All Bats 
 
 
      None  Human only        Dual:        Animal only 
       human and animal contact 
     
               Contact Human Yes    Contact Animal Yes 
 
Persons bitten or scratched by any bat were considered potentially exposed to Australian bat 
lyssavirus and referred to the local Public Health Unit of the State Health Authority for medical 
advice, and where appropriate, post-exposure rabies vaccination. Dogs, cats or other animals 
known or suspected to have been bitten or scratched by virtue of having contact with a live bat 
were also considered potentially exposed to ABLV. Neither pre- nor post-exposure vaccination for 
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lyssaviruses is available for animals in Australia, except as part of preparation for export, typically 
pets travelling abroad. Animals known or suspected of being in contact with an ABLV-positive bat 
were managed by the Department of Primary Industries on a case by case basis. Where possible 
the outcomes for these in-contact animals were determined.  
2.2.2 Sample collection 
Bats were refrigerated at 4 0C until examined1 within a Class II biosafety cabinet within the ARI 
Diagnostic Virology Laboratory. Prior to September 1998 this was a Physical Containment Level 2 
(PC2) laboratory (Australian New Zealand Standard AS/NZS/ 2243.3:1995, 2243.3/Amdt 1/1996, 
and 2243.3/Amdt 2/1998 in which ABLV is classified as a virus of Risk Group 3, 
http://www.standards.com.au). In 1998 the ARI laboratory was upgraded to PC Level 3.  
The brain was removed and halved longitudinally. One half of each brain was placed in a sterile 
container and stored fresh at 4 °C for use in the fluorescent antibody test, and subsequently 
stored at -70°C. The other half of the brain was fixed in 10% buffered neutral formalin for 
histological examination.  
The anatomy of the major salivary glands in Black flying foxes is shown in Figure 2-3. The gross 
anatomy of these glands is similar in the four common species of Australian flying fox. The gross, 
histological, and electronmicroscopic morphology of the salivary glands of Black and Grey-headed 
flying foxes were investigated in detail by another member of the research team (Geisel 1999). 
The parotid salivary gland from one side was removed and placed in a sterile container and 
initially stored at 4°C, then transferred to the -70°C freezer. The contra-lateral gland was fixed in 
10% buffered neutral formalin. The submandibular and sublingual salivary glands, which occur in 
close proximity near the clavicle, were removed as a single mass. These two glands from one 
side were placed together in a sterile container at 4°C and then -70°C, those from the other side 
fixed in 10% buffered neutral formalin. Other tissues were fixed in 10% buffered neutral formalin 
as considered appropriate.  
 
                                                          
1 most (>90%) bats were examined by a member of the ABLV research team, namely the candidate, Kim 
Halpin, Craig Smith or Natasha Smith. Occasionally when no member of the team was available, ARI 
diagnostic veterinary staff examined the bat, in which case only fresh brain for the FAT may have been 
collected. 
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Figure 2-3 Anatomy of the major salivary glands of flying foxes (Pteropus alecto)  
Superficial dissection of the right ventrolateral head and neck. The skin and superficial musculature are reflected dorsally. 
 
 
 
 
Sublingual salivary gland 
Pale triangular mucus gland that borders the 
sternocephalic and pectoral muscles. 
 
 
 
 
 
 
Parotid salivary gland     Submandibular salivary gland 
Large pale serous gland that lies immediately    Round, darker pink, mixed serous and mucous gland. A second larger lobe of this gland 
caudal to the auditory canal.     lies deep and dorsal to that shown.
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2.2.3 Fluorescent antibody test 
Centocor FITC (fluorescein isothiocyanate) anti-rabies monoclonal globulin was reconstituted with 
5.0 mL of sterile reagent grade water and then further diluted 1:20 in phosphate buffered saline 
containing 0.75% bovine saline and 0.01% Evan’s blue (dilution protocol provided by AAHL). 
Aliquots of working dilution reagent were prepared by staff of the Diagnostic Virology Laboratory 
of the Animal Research Institute and stored at -20°C.  
Fresh brain touch impressions or brain smears were made on acetone-cleaned glass slides, fixed 
in acetone at -20°C for a minimum of 1 hour, and then air-dried. The brains were sampled so as to 
include the hippocampus, medulla and brain stem, usually by making a touch impression of the 
cut surface following sagittal section of the brain. Sufficient working dilution of the Centocor 
reagent was applied to cover the impression smear, and the slide incubated within a humidity 
chamber at room temperature for a minimum of 30 minutes. Excess reagent was washed off with 
phosphate buffered saline, and the slide cover-slipped with glycerol in 10% phosphate buffered 
saline. Slides where then examined in a dark room with a florescent microscope using a 
wavelength of 450 µm. Cellular material was stained reddish by the Evan’s blue counterstain. 
Positive material produced a bright apple-green fluorescence. All positive results were presumed 
to indicate the presence of Australian bat lyssavirus as Australia is considered free of all other 
lyssaviruses detected by the Centocor reagent. Most (>90%) of the fluorescent antibody tests 
were performed by the technical staff of the Diagnostic Virology Laboratory. 
2.2.4 Evolution of laboratory submission patterns and 
protocols 
Prior to 1996, Australia was considered free of all lyssaviruses, and lyssavirus (rabies) testing was 
done on a national basis at the CSIRO Australian Animal Health Laboratory (AAHL), Geelong 
Victoria, the WHO reference laboratory for rabies in Australia. The number of submissions for 
rabies/lyssavirus exclusion in Australia was low at approximately 6-8 tests per year, the majority 
of which were for rabies exclusion following cat or dog deaths in quarantine with only one or two 
Australian animals tested each year (Ross Lunt AAHL pers. comm.).  
With the recognition of ABLV and the concurrent research sampling of bats for EMV/Hendra Virus 
and ABLV it was clear that state based testing in Queensland was required and Barry Rodwell of 
the Diagnostic Virology Laboratory of the Department of Primary Industries Animal Research 
Institute (ARI), received training at AAHL to perform the fluorescent antibody test at the then PC2 
ARI Virology Laboratory. Samples from bats which were known or suspected of having bitten or 
scratched a person or animal, had clinical signs suggesting ABLV, were ABLV-positive in the ARI-
FAT or where the result was inconclusive, were forwarded to AAHL for confirmation by duplicate 
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fluorescent antibody testing plus immunoperoxidase staining, virus isolation, and PCR 
amplification of viral RNA. 
Due to the medico-legal implications of the results, the ARI did not report the primary FAT results 
from bats that had bitten or scratched a person to health authorities. Only after the DPI results 
had been confirmed at AAHL were the results forwarded to the health authority to be considered 
in the management of potentially-exposed patients.  
However, the time required to submit samples to the ARI, for sampling and initial FAT screening, 
and then forward them to AAHL for confirmation, resulted in delays, typically of 3-6 days, between 
the potential exposure of the patient and the results being made known to the health authority. As 
a result, a large number of patients bitten by ABLV-negative bats that did not require post-
exposure vaccination were receiving expensive initial vaccination and immunoglobulin pending 
the results, and post-exposure treatment of some patients bitten by ABLV-positive bats was 
delayed by 4-10 days.  
During this period Greg Smith of the regional medical diagnostic laboratory (QHSS) in Brisbane 
developed a diagnostic real-time PCR (TaqMan) test for the pteropid (flying fox) and Yellow-
bellied sheathtail bat variants of ABLV (see Appendix 3) and received training in the FAT (from 
AAHL) and post-mortem sampling (from the candidate). Subsequently either whole bats or a 
sample from the brains of all bats that had bitten or scratched a person and some ABLV-positive 
or inconclusive samples were forwarded to the QHSS rather than AAHL for confirmation. Medico-
legal implications and NATA (National Association of Testing Authorities) protocols for sample 
handling meant that by January 1999 all bats which had bitten or scratched a person were sent 
directly to the QHSS and no longer tested at ARI. A time line illustrating the evolution of the 
submission and testing processes for ABLV in Queensland is shown in Figure 2-4. 
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Figure 2-4 Evolution of the submission and testing processes for ABLV testing in 
Queensland 
 
June 1996 Samples submitted to DPI forwarded to AAHL for primary 
testing  
 
~January 1997 Primary (FAT) testing at ARI, confirmation at AAHL of 
samples which were ABLV-positive, suspect, or from bats that 
had bitten or scratched humans or other animals  
 
 
~May 1998  Primary testing (FAT) at ARI, confirmation at QHSS of 
samples which were ABLV-positive, suspect, or from bats that 
had bitten or scratched humans or other animals 
 
 
        January 1999 
 
 
 
Primary testing at ARI    Primary testing at QHSS  
Not bats reported to have bitten or           Bats that had bitten or scratched a person 
scratched a person, mostly bats with           and some other bats. 
CNS disease that had had contact with  
other animals or were otherwise ill.  
Confirmation at QHSS when appropriate. 
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2.2.5 Opportunistic samples from ABLV-positive bats tested in 
collaboration with other institutions 
When available, serum/plasma usually supplied by the submitting veterinarian or occasionally 
collected at post-mortem, was submitted to AAHL for rabies-rapid-fluorescent-focus-inhibition 
tests (modified rabies (CVS)-RFFIT, see Appendix 2). 
Urine collected from a small number of bats at post-mortem and a sample of saliva supplied by a 
submitting wildlife carer were submitted to QHSS for detection of ABLV viral-RNA by TaqMan 
assay (see Appendix 3). 
2.2.6 Statistical methods 
Crude analysis 
Differences in proportions of ABLV-positives between major groupings, ignoring other factors, 
were tested for statistical significance using the chi-square test. 
Association with factors (wild flying foxes) 
For wild flying foxes, the relationships between proportion of ABLV-positives and factor categories 
were tested for statistical significance by fitting generalized linear models (McCullagh and Nelder 
1989; Tukey 1977). The models used the binomial distribution and logit link. For models with more 
than one factor, the association with each factor was tested after accounting for the associations 
with all the other terms in the model. 
Preliminary analyses showed highly significant associations with species, health status and age. 
Associations with other terms were therefore tested in models with these three terms already 
included. Factors considered were sex, contact status, region, year, season, and reproductive 
season and all possible interactions between species, health status and age. Generally the terms 
were tested one at a time, though the interactions were tested jointly and models with both year 
and climatic season, and year and reproductive season were also considered. 
For the significant factors, estimates for each of the categories were calculated from the fitted 
model and differences between categories tested for significance on a pair-wise basis. The 
estimates were back-transformed to the percentage scale for presentation. 
The statistical package GenStat 2000 was used for all analyses under the direction of Tony Swain 
(biometrician, ARI).  
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2.3 Results 
A total of 1,170 diagnostic submissions for lyssavirus testing were submitted from Queensland 
between June 1996 and 31 March 2002. Of these 27 were non-bat species, and 1,143 were bats. 
Zero of the 27 submissions of non-bat species and 74/1143 (6.5%) of bat submissions were 
ABLV-positive. Numbers of ABLV-positive / total tested for relevant categories of submissions are 
shown in Figure 2-5. 
Figure 2-5 Crude summary of proportions of ABLV-positive / tested diagnostic 
submissions  
Queensland, June 1996 to 31 March 2002. 
 
Total  74/1170 
 
 
Non-bat species  0/27                     Bats  74/1143 (6.5%) 
 
 
     Unidentified bats  Megachiroptera   Microchiroptera 
0/11      69/974  (7.1%)    5/158 (3.2%)   
     
 
Wild  Captive colony YBST bats  Other micros 
       68/893  (7.6%)            1/81 (1.2%)  5/7 (71.4%)                0/151  
 
 
YBST bat – Yellow-bellied sheathtail bat (Saccolaimus flaviventris)     
 
Wild Megachiroptera (n=68/893) 
P. alecto (Black)   37/474    (7.8%) 
P. poliocephalus (Grey)    8/175     (4.6%) 
P. scapulatus (Little Red)  21/124  (16.9%) 
P. conspicillatus (Spectacled)    1/95      (1.0%) 
Unidentified Pteropus sp.    1/17      (5.9%) 
Nyctimene spp. (Tube-nosed bat)   0/2      (0 %) 
Syconycteris spp. (Blossom bat)     0/6          (0 %) 
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2.3.1 Crude analysis 
The difference in percent ABLV-positive between the following pairs of categories, ignoring all 
other factors, was tested using a Chi-square test. 
 
Megachiroptera (n=69/974)  
Microchiroptera (n=5/158)   Not statistically significant  (p > 0.05) 
 
Wild megachiroptera (n=68/893) 
Colony megachiroptera (n=1/81)  Wild significantly higher  (p < 0.05) 
 
YBST bat  (n=5/7) 
Other micros (n=0/151)    YBST significantly higher  (p < 0.001) 
 
Megachiroptera (n=69/974) 
YBST bat  (n=5/7)    YBST significantly higher  (p < 0.001) 
 
Wild megachiroptera (n=68/893) 
YBST bat  (n=5/7)    YBST significantly higher  (p < 0.001) 
 
2.3.1.1 Non-bat species submissions 
Twenty seven non-bat-species submissions were tested for ABLV. The majority of these cases 
were examined by diagnositic pathologists of the ARI. These were: 
♦ 5 domestic dogs 
♦ 5 domestic cats 
♦ 2 domestic horses 
♦ 3 domestic ferrets 
♦ 7 wild possums 
♦ 3 wild foxes 
♦ 1 captive Tasmanian Devil 
♦ 1 captive Macaque monkey 
 
None of these animals were ABLV-positive. Two of the dogs and a fox were examined by the 
candidate. The remainder were examined by ARI diagnostic veterinary pathologists. Case details 
are provided in Appendix 4.  
Most (n=19) were submitted because they had clinical signs of central nervous system disease 
and were suspected of having ABLV. Five of these animals had also bitten or scratched one or 
more persons and required testing to determine whether post-exposure vaccination of these 
persons was indicated.  
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Two dogs from the same household were submitted because they had been in contact with a bat 
confirmed as ABLV-positive. These two dogs and a fox were examined by the candidate. 
The three unregistered ferrets seized by the Department of Natural Resources were tested 
because the origin/s of the ferrets was unclear and there was the possibility of them having been 
illegally imported from a rabies endemic country. 
The three submitted foxes had neither signs suggesting central nervous system disease nor 
histories of having bitten or scratched humans or other animals, but were sick (n=1), injured (n=1) 
or orphaned (n=1). These animals were presumably submitted because foxes are well recognized 
as hosts of rabies and it is believed that foxes might be a likely non-bat-species host of ABLV. 
2.3.1.2 Unidentified bats, other micros and unidentified Pteropus sp. 
Eleven submitted bats were identified only as “bats”, with no indication by the submitter or 
recipient lab as to species or even order of bat.  
Of the 158 submissions of microchiroptera only 5/7 Yellow-bellied sheathtail bats (Saccolaimus 
flaviventris) were ABLV-positive. The 151 other microchiropteran submissions were: 
♦ Chalinobus spp. n = 13 
♦ Miniopterus spp. n = 23 
♦ Momopterus spp. n = 18 
♦ Myotis spp.   n =   2 
♦ Nyctinomus sp. n =   1 
♦ Nyctophilus spp.  n = 23 
♦ Pipistrellus sp. n =   1 
♦ Rhinolophidae sp.   n =   1 
Scotophilus sp.  n =   1 
♦ Scotorepens spp.  n = 22 
♦ Taphozous spp.   n =   2 
♦ Vespadelus spp.  n =   2 
♦ Unidentified microchiropteran  n = 42 
 
Seventeen submitted wild bats were identified by the submitter/recipient laboratory only as “flying 
foxes”, with no indication as to the specific flying fox species.   
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2.3.2 Health status 
For each health category and relevant species categories, the numbers of ABLV-positive / total 
tested bats are shown in Figure 2-6. 
Note: in Figure 2-6, Figure 2-7, and Figure 2-8 the term ‘other megabat’ refers to unidentified Pteropus sp. 
and non-flying fox megachiroptera (Nyctimene spp. and Syconycteris sp). The term ‘other microbat’ refers 
to all microchiropterans not identified as Yellow-bellied sheathtail bats, as listed in Section 2.3.1.2, 
including unidentified microchiropterans. 
 
 
Figure 2-6 Crude summary of the number of ABLV-positive / total tested bats classified by 
health status and relevant species categories 
              All bats n= 74/1143 
 
 
      Normal n= 0/47                     Unknown n= 2/22 
P. alecto   n= 0/18   Sick, injured, or orphaned             P. alecto  n= 0/7 
P. poliocephalus  n= 0/15       n= 72/1074             P. poliocephalus n= 0/5 
P. scapulatus     n= 0/4                 P. scapulatus   n= 2/4  
P. conspicillatus  n= 0/2                 Other megabats n= 0/1 
Other microbats  n= 0/8                    Other microbats n= 0/3     
                   Unidentified bats n= 0/2  
 
  CNS disease n= 50/237   Non-CNS disease  n= 22/837 
  P. alecto   n= 31/106   P. alecto    n= 6/369 
P. poliocephalus  n= 7/37           P. poliocephalus  n= 2/166 
P. scapulatus     n= 10/26   P. scapulatus   n= 9/92 
P. conspicillatus  n= 1/62              P. conspicillatus  n= 0/35 
               YBST   n= 1/1                          YBST   n= 4/6 
Other megabat   n= 0/1    Other megabat   n= 1/24 
 Other microbat   n= 0/4    Other microbat   n= 0/136 
Unidentified bat   n= 0/9  
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2.3.3 Contact status 
For each contact category and relevant species categories, the numbers of ABLV-positive / total 
tested bats are shown in Figure 2-7. 
Figure 2-7 Crude summary of the number of ABLV-positive / total tested bats classified by 
contact status and relevant species categories 
 
All bats n= 74/1143 
 
 
None  n= 56/797        
P. alecto   n= 27/351 
P. poliocephalus  n= 8/176 
P. scapulatus     n= 17/83   
P. conspicillatus  n= 0/91 Human only       Dual: Human and     Animal only 
    YBST  n= 4/6    n= 9/191                animal n= 2/11          n= 7/144     
Other megabats  n= 0/10   
Other microbats  n= 0/75 
Unidentified bats n= 0/5 
 
 
     Contact Human Yes n= 11/202  Contact Animal Yes n= 9/155 
          P. alecto   n= 6/73      P. alecto       n= 6/83  
P. poliocephalus  n= 0/28      P. poliocephalus  n= 1/19 
    P. scapulatus   n= 2/33      P. scapulatus      n= 2/11 
   P. conspicillatus  n= 1/7       P. conspicillatus   n= 0/1 
    YBST   n= 1/1        Other megabat     n= 0/6 
   Other megabat   n= 1/10      Other microbat     n= 0/32 
Other microbat   n= 0/47      Unidentified bat    n= 0/3 
Unidentified bat   n= 0/3 
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South Qld Total 1/28 
   0/4 P. poliocephalus 
   0/14 P. scapulatus 
   0/1 Other megachiroptera
   1/1 YBST 
   0/8 Other microchiroptera
2.3.4 Geographical distribution of bat submissions 
Bats were accepted from throughout Queensland; however the vast majority (n=>1,090/1,143) 
were submitted from the coastal strip extending south from Cape Tribulation that corresponds to 
an area of high population density for humans and flying foxes. The largest number of bats was 
submitted from South-east Queensland (n=828), an area inhabited by Black, Grey and Little Red 
flying foxes and numerous species of microchiroptera. Southeast Queensland is highly urbanized 
and houses more than 70% of Queensland’s human population. The geographical distribution of 
bat submissions is illustrated in Figure 2-8. 
Figure 2-8 Geographical distribution of ABLV-positive / total bat submission (n=1,143) 
North Qld Total 7/193 
   2/38 P. alecto  
   0/1 P. poliocephalus 
   4/20 P. scapulatus 
   1/95 P. conspicillatus 
   0/11 Other megachiroptera 
   0/24 Other microchiroptera 
   0/4 Unidentified bats  
West Qld Total 1/12 
   1/1 P. alecto  
   0/8 P. scapulatus 
   0/2 Other microchiroptera 
   0/1 Unidentified bats 
Central Qld Total 9/81  
   6/44 P. alecto  
   1/1 P. poliocephalus 
   1/21 P. scapulatus 
   1/1 Other megachiroptera 
   0/1 YBST 
   0/11 Other microchiroptera  
   0/2 Unidentified bats 
Southeas
   28/417 
     8/217 
   16/63 
     0/4
     4/5 
     0/12 
     0/107 
     0/4 
    Mt. Isa  
Rockhampton  •
 Gladstone   • 
Hervey Bay   • 
Murphy’s Creek  •
BRISBANE 
• Gold Coast 
• 
 
 
 Townsville   •
t Qld Total 56/829 
P. alecto  
 P. poliocephalus 
P. scapulatus 
 P. conspicillatus 
YBST 
Other megachiroptera 
 Other microchiroptera 
Unidentified bats 
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2.3.5 Temporal distribution of bat submissions 
There was a noticeably higher rate of bat submission in the early years following the recognition 
of ABLV. This was a period when wildlife carers were highly motivated to submit bats for testing in 
order to contribute to an understanding of the disease, and of high to intense media interest. From 
1 January 1999, a proportion of bats from Queensland were being submitted directly to QHSS 
rather than the ARI. However, even when the submissions to both laboratories are combined (see 
Table 2-2, the number of bats submitted in 2000 and 2001 was noticeably less than in late 1996, 
1997 or 1998. 
The yearly pattern of bat submission is illustrated in Figure 2-9 and Table 2-2. 
Figure 2-9 Yearly pattern of ABLV-positive (n=74) and total (n=1,143) bat submissions 
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Table 2-2 Yearly pattern of ABLV-positive and total bat submissions 
 June-Dec 
1996 
1997 1998 1999 2000 2001 Jan-March 
2002 
Total 
ABLV-positive 6 24 23 5 10 
 
5 
(+3) 
1 
(+2) 
       74  
      (+5) 
Total 204 346 287 
(+15) 
144 
(+67) 
117 
(+62) 
41 
(+59) 
4 
(+21 ) 
1143
(+224) 
() numbers in brackets are additional bat submissions tested at QHSS, not tested at ARI and not otherwise 
included in this study. The total number of bat submissions in Queensland during this period was 79 
ABLV-positive of 1367 tested. 
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2.3.5.1 Monthly submissions  
The accumulated monthly numbers of ABLV-positive (n=74) and total (n=1143) bat submissions 
are shown in Figure 2-10 and Table 2-3.   
Figure 2-10 Accumulated monthly ABLV-positive (n=74) and total (n=1143) bat 
submissions 
(June 1996 to March 2002) 
0
50
100
150
200
Jan Feb March April May June July Aug Sept Oct Nov Dec
Month
N
um
be
rl 
te
st
ed
0
5
10
15
20
N
um
be
r A
B
L-
po
si
tiv
e
Total tested ( n=1,143)
ABL-positive (n=74)
Table 2-3 Accumulated monthly ABLV-positive (n=74) and total (n=1,143) bat submissions 
(June 1996 to March 2002) 
 Jan Feb March April May June July Aug Sept Oct Nov Dec 
ABLV-pos. 7 6 7 7 6 4 4 5 6 12 8 2 
Total 78 93 102 58 50 64 72 44 95 128 196 163 
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2.3.5.2 Reproductive seasons 
The reproductive seasons of bats vary. For flying foxes the year consists of three principal 
reproductive seasons, although occasional matings and births occur year round. 
♦ Establishing territories and mating. During this period testicle size and testosterone levels 
increase to their maximum, males establish and defend territories and mating occurs. This is 
a period of comparatively high intra-colony aggression. 
♦ “Off” season during which testicular size, testosterone levels and sperm production rapidly 
decrease, accessory sex glands become non-secretory, and most adult females are 
pregnant. 
♦ Giving birth and raising young.  Births occur after a pregnancy of approximately 6 months, 
followed by a lactation of about 6 weeks. For at least 4 weeks, pups cling to their dam, 
including during flight. As pups become too large they are left behind at night while the dam 
forages, and by February/March are usually weaned and fully independent. During this period 
males usually congregate together in areas of the camp separate from the dams and pups.  
Black, Grey-headed and Spectacled flying foxes generally establish territories and mate in 
January to April, are pregnant in May to August, and give birth and raise young during September 
to December. For the Little Red flying fox these reproductive seasons are offset by approximately 
6 months. 
The date of submission for all flying foxes that had been identified to species (n= 868) was 
translated into one of the three reproductive seasons as shown in Table 2-4. 
Table 2-4 Reproductive seasons of flying foxes 
Months of the year submitted 
Reproductive season 
Black, Grey-headed and 
Spectacled flying foxes Little Red flying fox 
Establishing territories and mating January to April August to November 
“Off” season May to August December to March 
Giving birth and raising young September to December April to July 
 
The total number of flying foxes and the number that were ABLV-positive for each reproductive 
season are shown in Figure 2-11 and Table 2-5.  
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Figure 2-11 Number of ABLV-positive (n=67) and total (n=868) wild Black, Grey-headed,  
Little Red, and Spectacled flying foxes submitted in each reproductive season 
(June 1996 to March 2002) 
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Table 2-5 Number of ABLV-positive (n=67) and total (n=868) wild Black, Grey-headed, 
Little Red, and Spectacled flying foxes submitted in each reproductive season 
(June 1996 to March 2001) 
 Establishing territories 
and mating 
“Off” season Giving birth and raising 
young 
ABLV-positive 26 20 21 
Total 238 198 432 
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2.4 Statistical analysis 
The following relates to all wild flying foxes that had been identified to species, i.e. Black, Grey-
headed, Little Red, and Spectacled flying foxes (n = 67/ 868). 
Other categories of bats were excluded because key genus and/or species data was unknown or 
the numbers of submissions within each species were too small for statistical analysis. Captive 
colony bats were excluded because it was presumed that the factors affecting exposure and 
susceptibility in captivity could be different from those affecting wild bats.  
Bats that were excluded were; unidentified bats (n =11), each genus of microchiropteran bat  
(n =1 to 23, and 42 unidentified), each species of captive colony megachiropterans (n = 4 to 48), 
unidentified wild Pteropus spp. (n=18), and non-flying fox wild megachiropterans (Nyctimene spp 
n=2 and Syconycteris sp n=6). 
2.4.1 Significant factors 
Three factors were associated with statistically significant differences in the proportion of ABLV-
positive bats, each after taking the other two factors into account (p = conditional probability). 
♦ Species   p < 0.001 
♦ Health status  p < 0.001 
♦ Age   p < 0.01 
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The ABLV-positive percent predictions (%predns), taking species, health and age into account 
and assuming the proportions in each category are the same as in the original data, are shown 
below. 
Species   %predns 
P. alecto     4.6 
P. poliocephalus    2.3 
P. scapulatus   11.4 
P. conspicillatus    0.2 
 
In terms of statistically different proportions of ABLV-positive wild flying fox per species (p=0.05): 
P. scapulatus > P. alecto ≈ P poliocephalus > P. conspicillatus 
Health   %predns 
Normal      0.03 
CNS disease   19.3 
Non-CNS disease    1.8 
Health unknown    3.9 
 
In terms of statistically different proportions of ABLV-positive wild flying foxes per health status 
(p=0.05):  
CNS > non-CNS 
The proportions of ABLV-positive wild flying foxes with normal or unknown health status were not 
significantly different from those with CNS or non-CNS disease health status. In the case of bats 
with a normal health status this was principally due to the small numbers and this group (n=9) and 
the associated large standard error. 
Age    %predns 
Juvenile   1.7 
Adult    4.9 
Age unknown   2.5 
 
In terms of statically different proportions of ABLV-positive wild flying foxes per age group 
(p=0.05): 
Adults > Juveniles 
The proportion of ABLV-positive wild flying foxes of unknown age was not significantly different 
from either adult or juvenile bats. 
  Natural ABLV infection in bats
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2.4.2 Insignificant factors 
Other factors, or combinations of factors listed below, when taken into account with species, 
health status, and age, were not associated with statistically significant differences in the 
proportion of ABLV-positive bats (conditional probability p > 0.05).  
For example; sex, when taken into account with species, health status, and age did not have a 
statistically significant effect, p = 0.54. 
  
♦ Sex  (p = 0.54) 
♦ Contact status (Contact Human Yes p = 0.89, Contact Animal Yes p = 0.92) 
♦ Region (North, West, Central, South and Southeast Qld, p = 0.67)  
♦ Region (Southeast Qld versus rest of Queensland, p = 0.44) 
♦ Year of submission (p= 0.053) 
♦ Season of submission (Summer, Autumn, Winter, Spring, p = 0.13) 
♦ Reproductive season of submission (p=0.15) 
♦ Year and Season (p=0.15 and p=0.39 respectively) 
♦ Year and Reproductive season (p=0.85 and p=0.27 respectively) 
 
2.4.3 Interactions 
There were no statistically significant interactions between the three separately significant factors 
of species, health and age (p = 0.714 to 0.996 for all possible interactions). 
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2.4.4 Fitted values for percent ABLV-positive for species, 
health status and age combinations 
Where the species, health status, and age of a wild flying fox are known, an estimate of the 
likelihood of that bat being ABLV-positive is given in Table 2-6, assuming the same submission 
pattern continues as occurred during this study.  
 
Table 2-6 Fitted values (percent ABLV-positive) and raw data (ABLV-positive/total tested) 
for wild flying fox species, health status, and age combinations 
       CNS disease Non-CNS disease 
Species Age 
Fitted %  Raw data Fitted %  Raw data 
P. alecto Juvenile 15.4 7/35 1.4 1/137 
 Adult  34.9 22/56 3.9 4/187 
 Unknown --- 2/11 --- 1/32 
P. poliocephalus Juvenile 8.2 0/9 0.7 1/52 
 Adult     20.8     6/24 1.9 1/73 
P. scapulatus Juvenile     32.7 1/3 3.5 0/15 
 Adult     58.8 8/16 9.7 6/43 
 Unknown --- 1/7 --- 3/33 
P. conspicillatus Juvenile 0.6 0/10 0.1 0/13 
 Adult 1.9 0/48 0.1 0/14 
 Unknown --- 1/2 --- 0/8 
 
All species and age combinations of wild flying foxes with a normal health status had a fitted value for 
percent ABLV-positive of < 0.2%. 
Juvenile    sexually immature, typically 0 to 3 years of age 
Adult    sexually mature, typically > 3 years of age 
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2.5 ABLV-positive case data 
Case details for each of the 74 cases of ABLV-positive bat are given in Appendix 5, including; 
species, month died, location found, sex, age, health and contact status, together with a summary 
of the history, post-mortem examination findings and other comments. Case histories were 
derived from the original submission forms, and where possible, phone conversations with the 
people involved. Subsequent references to individual cases are by ABLV case number, e.g. 
ABLV-1, ABLV-2, as indicated in Appendix 5.  
2.5.1 Circumstances in which ABLV-positive bats are found 
The circumstances in which 59/74 ABLV-positive bats were found were recorded, or recalled 
during follow-up phone discussions. 
♦ 38 were found on the ground, often under trees in places that included; backyards and 
gardens, grounds of wildlife parks, cleared bushland, a garden nursery, beside the road, in 
bamboo by a pond, school grounds, caravan parks and city footpaths. ABLV-1, 3, 5, 7, 8, 18, 
19, 23, 24, 26, 27, 29, 30, 33, 35, 38 –47, 50, 53, 54, 57, 61-65, 69-71, 74. 
♦ 16 were found in trees, away from camp during the day, often hanging inappropriately low 
(< 2 m) from the ground. Normal flying fox behaviour is to return to camp in the early hours of 
the morning and hang as high as their rank in the colony and the trees will allow, typically > 
10 m from the ground. ABLV-4, 6, 13, 28, 32, 48, 49, 51-53, 55, 58, 59, 60, 68, 72.  
 
Of the 16 ABLV-positive bats initially seen in trees during the day, ABLV-13 was later seen to 
fly into the path of an oncoming car, ABLV-48, 60, and 72 later fell from the tree, ABLV-49 
and ABLV-51 flew from the tree to land on or fly towards a person in what was described by 
the people as an unprovoked attack, and ABLV-52 and 53 uncharacteristically and repeatedly 
“ran” / came towards and away from the person who had climbed the tree to rescue them. 
♦ 3 were found on man-made structures, away from camp during the day, one hanging on 
the ropes of playground equipment (ABLV-10), one on the roof of a captive bat colony 
enclosure (ABLV-66), and one on the roof of a house (ABLV-67). 
♦ 1 was found in a canal (ABLV-17). 
♦ 1 captive colony flying fox became ill within its enclosure (ABLV-73), one month after a 
wild ABLV-positive flying fox (ABLV-66) had been removed from the roof of the colony’s 
enclosure. 
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None of at least 89 bats rescued from entrapment in barb wire or other fences were ABLV-
positive. 
2.5.2 Clinical signs of ABLV infection 
The clinical signs reported by submitters, most of whom were non-professional wildlife carers, are 
given in more detail in Appendix 5. In summary: 
♦ 38 clinical descriptions were dominated by paresis/paralysis, usually of the hind limbs 
or generalized paresis, and an inability to fly.  Often these bats were unable to hang 
properly, and either initially or eventually were recumbent and required support such as a 
sling. Some bats that could hang were unable to invert to urinate.  
♦ 14 clinical descriptions were dominated by overt aggression, ABLV-13, 25, 32, 49, 51, 
52, 53, 60, 64, 66, 67, 68, 70, 73. This aggression manifested as; flying out of trees in 
unprovoked attacks on people and a dog (ABLV-49, 51, 64), advancing towards and 
attempting to bite, rather than retreating from, rescuers during rescue e.g. from trees (ABLV-
52, 53, 64, 66), aggression towards cage-mate bats (ABLV-32 and 52), vocalizing and 
appearing “angry”, agitated, and unable to calm down when placed in a small covered cage in 
a separate dark room (ABLV-13, 25, 53, 68, 73), repeated aggressive rather than defensive 
attempts to bite rescuers/carers, even from within a cage (ABLV-60, 64, 66), attacking 
inanimate objects within a cage or the cage itself (ABLV-32, 60, 64, 67, 68, 70, 73), self 
mutilation including biting itself (ABLV-67, 70), and head butting a tree and fracturing teeth 
when biting cage and banging itself against a cage (ABLV-68) 
♦ 19 were either dead (n=1, ABLV-19), moribund (n=7, ABLV-17, 20, 23, 31, 39, 45, 48), or 
were submitted with inadequate or non-specific clinical descriptions (n=11; ABLV-1, 2, 
7, 15, 16, 21, 34, 41, 47, 56, and 61) 
♦ 3 had specific clinical signs or injuries suggesting non-lyssavirus disease. One Yellow-
bellied sheathtail bat (ABLV-5) aborted a foetus shortly after rescue, ABLV-11 was submitted 
with a one word history of “electrocution”, and ABLV-57 had clear and obvious linear burns to 
both feet and necrosis of the left thumb, consistent with having received an electric shock. 
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Figure 2-12 Clinical forms of ABLV-infection in bats 
 
      All ABLV-positive bats n=74 
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clinical descriptions or   Specific clinical descriptions 
non-specifically ‘sick’  
 n=19 
 
Overt Aggression     Paresis/paralysis and an   Other 
            n=14   unexplained inability to fly      n=3 
     n=38 
 
Other clinical signs included; 
♦ Abnormalities relating to the mouth/pharynx suggesting cranial nerve deficits (n=11). 
These were described as; hypersalivation, inability to swallow (n=3), inability to spit out fruit 
pulp, saliva pooling in mouth, choking, difficulty eating, poking tongue in and out, grinding 
teeth, tooth bitten through lip, having bit own tongue while drinking, excessive yawning (n=2), 
and abnormally harsh voice. 
♦ Clinical signs suggesting CNS or cranial nerve deficits (n=13). These were described as: 
“fitting”/ seizures, twitching, shaking and tremors, head tremors (n=2), twitching of head and 
ears with clamped teeth, eyes “wavering” (nystagmus n=1), reduced corneal, “sneeze” and 
gag reflexes, reduced blink reflexes, and reports of glazed eyes and dazed appearance. 
♦ Altered/ difficult respiration was reported in five cases. On one occasion (ABLV-72), the 
respiratory changes of a weak and deteriorating bat taken to a veterinarian were thought to 
indicate pneumonia, no lung lesions were found in the post-mortem examination. 
♦ Altered appetite Bats were recorded as not eating (n=4), being able to eat / lap juice (n=3), 
and also to be ravenous (n=2). 
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2.5.2.1 Clinical recognition of ABLV 
It is necessary for wildlife veterinarians to make some sort of assessment as to whether bats 
brought to them by carers are sufficiently likely to have ABLV that they should be killed and tested 
rather than treated. Unfortunately none of the circumstances or clinical signs described above is 
unique to ABLV (see Chapter 3 and Appendix 6 for clinical descriptions of bats with non-
lyssavirus CNS disease). Some ABLV-positive bats have more ‘typical’ or specific clinical signs 
suggesting involvement of the CNS and are more readily recognized as likely to have ABLV than 
others.  
The types of clinical signs seen in ABLV-positive bats, and an assessment of how readily ABLV-
positive bats with those clinical signs are recognized are given in Table 2-7. 
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Table 2-7 Clinical recognition of bats likely to be ABLV-positive 
Clinical signs of 
ABLV-positive bats 
Ease of 
recognition 
Comments 
Dead or moribund Difficult Indistinguishable from other end-stage bats.  
Poor or non-specific 
clinical description 
Difficult The number of bats in this category can be minimized if 
veterinarians make detailed and specific inquires as to the bats 
physical and neurological abilities.   
Overt aggression High index of 
suspicion 
Wild bats are generally not aggressive. Most bat bites and 
scratches are clearly defensive. Any suggestion by experienced 
wildlife carers that a bat is uncharacteristically aggressive or 
‘angry’ should be considered very seriously. These bats are 
particularly likely to attempt to bite or scratch people and pose a 
high risk of human infection. Both human lyssavirus deaths 
involved aggressive bats. 
Paresis, paralysis of 
hind-limbs 
High index of 
suspicion  
While there are other causes of paresis (see Chapter 3), virtually 
none have a good prognosis and all bats that have hind-limb 
paresis and / or are unable to hang should be submitted for 
ABLV testing.   
Generalized paresis High index of 
suspicion 
Bats found with unexplained generalized weakness, or with 
progressive weakness should be submitted for ABLV-testing. 
Abnormal function of 
mouth / larynx 
High index of 
suspicion 
These clinical signs are uncommon in ABLV-negative bats (data 
not shown). All bats with a history that includes difficulty 
swallowing, abnormal salivation or tongue movements, odd 
yawning etc. should be submitted for testing. 
“Fitting”, twitching and 
tremors 
High index of 
suspicion 
All bats showing evidence of CNS and / or cranial nerve 
involvement should be submitted for ABLV-testing. 
History or clinical signs 
suggest a specific,  
non-ABLV diagnosis 
Low index of 
suspicion 
Perhaps the most difficult ABLV-bat to recognize.  
Many of the  >90% of bats that are ABLV-negative have histories 
and clinical signs unlike those of most ABLV-bats, such as being 
caught in barb-wire fences, electrical burns, being found as 
orphans, etc, which suggest a specific, non-ABLV reason for 
rescue.  ABLV-bats ‘masquerading’ as one of the common 
ABLV-negative bats are likely to not be recognized. 
Weak bat with 
respiratory difficulties 
Difficult The presence or development of respiratory abnormalities in a 
bat with lyssavirus-like weakness should not reduce the 
otherwise high index of suspicion for ABLV.  
Yellow-bellied sheathtail 
bats 
High index of 
suspicion 
Due to the extraordinarily high prevalence of ABLV in this 
species (71%), and the difficulty associated with safely 
examining this small animal, all sick, injured, or orphaned YBST 
bats should be submitted for ABLV-testing. 
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2.5.3 Post-mortem findings in ABLV-positive bats 
At gross post-mortem examination, a dead ABLV-positive bat is usually unremarkable and so 
indistinguishable from bats dead of other causes.  
♦ No post-mortem examination comment was recorded for 27/74 bats. 
♦ 9 bats were recorded as having no visible lesions.  
♦ The nutritional condition of 20/74 ABLV-positive bats was recorded as poor/lean with little 
body fat, moderate to good with some but not large fat reserves in 10/74 bats, and one bat 
was considered fat.  
♦ 7 bats had post-mortem evidence of blunt trauma which was not previously detected. This 
included; subcutaneous bruising of the head and neck (n=6; ABLV-13, 28, 45, 51, 55, 74) 
including bruising over the eye, temporal muscle and underlying cranium, and over the frontal 
bone, fractures of a rib (ABLV-55) and the frontal process of the zygomatic arch (ABLV-74), 
bruising of the thorax and lung (n=1), and haemoperitoneum (ABLV-17). These injuries are 
presumed to be secondary to ABLV-infection, e.g. as a result of falling or crashing. ABLV-13 
was observed to have flown into a car.  
♦ 3 bats had small puncture wounds and associated soft tissue damage that could be 
related to bat, cat or small dog attacks. ABLV-48 had wing and pectoral muscle injuries 
and was thought by the carer to have a fractured wing, however no fracture was found. This 
bat was known to have fallen at least once from a tree. ABLV-52 was found with punctures, 
bruising and swelling of the right arm and was later found attacking another rescued bat, and 
so may have been involved in earlier bat fights. ABLV-55 had bruising to the frontal bone, a 
fractured rib and multiple punctures to the back, pectorals and abdomen with a history of 
being treated with 20 mL of subcutaneous fluids. It was presumed the head and rib injuries 
could be the result of a fall and the punctures the result of s/c fluid administration, however a 
bat, cat or small dog could have been involved. It should be noted that other ABLV-negative 
bats, submitted after known dog attacks, usually had far more significant injuries than those 
seen in these bats such as gross disruption/avulsion of limbs and body cavities. 
♦ 4 bats had distended bladders containing urine suggesting visceral paresis (ABLV-18, 
35, 37, 65). The bladders of most bats are empty at post-mortem (data not shown). Bladders 
continuing urine were most often associated with evidence of neurological dysfunction e.g. 
ABLV and spinal injuries, see Chapter 3. 
♦ 3 bats had food in their mouth/trachea suggesting dysphagia  
(ABLV-33, 35, 41) 
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♦ 2 bats had injuries suggesting an electric shock from over-head power lines. The 
patagium of ABLV-31, which had been submitted live and moribund, was contracted, 
suggestive but not conclusive for an electric shock. The soles of both feet of ABLV-57 had 
deep, linear burns and the left thumb was necrotic, almost certainly the result of contact with 
overhead power lines. There was no post-mortem comment recorded for a third bat submitted 
with a one word history of “electrocution”. Power lines are a common cause of flying fox 
morbidity and mortality, accounting for > 50% of > 1,000 bat rescues / year in southeast 
Queensland (Helen Luckoff, ONARR pers. comm.) 
♦ Six of 24 adult female bats were pregnant. “Very small numbers of fluorescent particles” (ARI) 
and “some (1-2) positive cells” (AAHL) were detected by FAT in the brain of the late-term 
foetus of ABLV-26. While the maternal brain was positive for lyssavirus by cell culture virus 
isolation, attempts at viral isolation from the foetal brain were negative (AAHL). The brains of 
the late and mid-term foetuses of ABLV-34 and 42 were FAT-negative.  The embryo/early 
foetus of ABLV-44 was too small for testing. The mid to late term foetuses of ABLV-3 and 10 
were not tested. 
♦ Miscellaneous findings include 3 bats with dehydration (ABLV-43, 54, 55), ABLV-49 with gun 
shot wounds, ABLV-68 with fractured teeth and gum injuries as a result of biting its cage and 
ABLV-71 with congested meninges. 
2.5.4 Incubation period, clinical duration and outcome, and the 
extent of human exposure to ABLV 
The incubation periods (36 to 57 days and 30 days) of only two naturally infected bats are known, 
as a result of apparently clinically normal bats developing clinical disease while in captivity.  
ABLV-32, a male orphan Black flying fox, was rescued as an orphan from low in a tree when 2-3 
weeks of age and appeared to grow and develop normally for the following 5 weeks. After 36 days 
in care (8-9 weeks of age), this pup became suddenly aggressive to his cage mate, and over the 
next 9 days progressively deteriorated with paresis, dysphagia and weight loss (see Appendix 5 
and Field et al. (1999)). As no in-contact bat or other animal had or has since been diagnosed 
with ABLV, and natural lyssavirus (rabies) infection in bats is not known with be the result of in 
utero infection (Constantine 1986), it is presumed that this pup was infected during the 2-3 weeks 
prior to his rescue. The incubation period in this case was therefore 36 to 57 days. 
ABLV-73, a mature aged female Grey-headed flying fox was a long term, indeed dominant 
resident of a captive colony. In October, an ABLV-infected wild bat (ABLV-66) was found 
behaving abnormally and aggressively on the colony’s cage roof/wall, which consisted of a single 
‘skin’ of wire netting. Thirty days later, colony resident ABLV-73 was observed to be behaving 
abnormally and aggressively, licking its vulva profusely. It deteriorated rapidly during the next 24 
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hours and was killed. It is presumed that ABLV-73 was infected when exposed to ABLV-66, and 
developed clinical disease after an incubation period of 30 days. Details of the public health 
management of these cases have been published (Warrilow et al. 2003). 
 
2.5.4.1 Clinical duration and outcome of ABLV infection 
Of 74 ABLV-positive bats, 27 died naturally, 36 were killed, and for 11 the circumstances of their 
death were not recorded. 
The observed clinical duration of those bats that died naturally, i.e. where the clinical duration had 
not been shortened by euthanasia is shown in Figure 2-13. This data includes ABLV-32, the 
orphan who developed clinical disease of 9 days duration after ~ 36 days in care, and ABLV-60 
who had been observed in a Cocos palm for 2 days prior to being taken in to care for 3 days.  
Figure 2-13 Observed clinical duration of ABLV-positive bats that died naturally (n=27) 
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2.5.4.2 Duration of human exposure to ABLV via clinically ill bats 
The number of days that each bat was cared for, prior to its death while infected with ABLV, is 
shown in Figure 2-14 and Table 2-8. During these periods, in-contact humans may have been 
exposed to ABLV. Ill bats are often cared for in wire domestic cat cages. The extent of exposure 
to the bats and ABLV during these periods varied but typically included: handling the bat without 
gloves, sometimes with the use of a towel e.g. to place bats in and out of cages, holding bats in 
lap or ‘hung’ on the carers chest clothing to hand feed fruit and juice, attending to wounds and 
discharges, and cleaning urine and faeces from cages. Minor scratches from the hind leg claws 
were very common. In one case (ABLV-55), a dedicated carer syringed over 150 mL of saliva 
from the mouth of an ABLV-positive bat that was unable to swallow (see Section 2.5.6). 
Figure 2-14 Number of days clinically ill ABLV-positive bats (n=74) were looked after by 
wildlife carers and/ or veterinarians (duration of possible human exposure) 
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Table 2-8 Number of days bats were in care while infected with ABLV (n=74) 
Number of days in care   
0 < 1 1 2 3 4 6 8 > 30 Unknown 
Number of 
ABLV bats  
 
2 
 
37 
 
13 
 
1 
 
5 
 
1 
 
2 
 
1 
 
2 
 
10 
 
0 Dead when rescued 
< 1  Indicates that the bat died or was killed on the same day as rescue, not surviving the night to the 
next morning. 
1 Indicates bat survived for 12 – 36 hours and died or was killed the day after rescue. 
> 30  Two captive bats (ABLV-32 and ABLV-73) were in care for ~ 36 and ~30 days respectively during 
which time they were incubating ABLV infection. ABLV-32 as a result of exposure prior to being 
rescued as an orphan, and ABLV-73 after exposure to ABLV-66, a wild ABLV-positive bat. 
Unknown  The dates of rescue and/or death were not recorded and so the interval while in care is unknown 
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2.5.5 Serology from ABLV-positive bats 
Plasma from 16 ABLV-positive bats was tested for anti-lyssavirus antibodies in the AAHL modified 
rabies (CVS)-RFFIT. Titres for each case are given in Table 2-9. 
Table 2-9 Rabies-RFFIT titres (IU/mL) of sera from 16 ABLV-positive bats. 
Data relating to positive titres are shown in bold. 
Case No. Flying fox 
species 
Observed clinical 
duration (days) 
Died or 
killed 
Titre (IU/mL)1 Interpretation 
ABLV-8 Black < 1 Not recorded 0  Negative 
ABLV-18 Black < 1 Killed 0  Negative 
ABLV-23 Black < 1 Killed 1.5 Positive 
ABLV-24 Black Not recorded Killed 0 Negative 
ABLV-27 Grey < 1 Killed 0  Negative 
ABLV-28 Grey < 1 Killed 0  Negative 
ABLV-30 Little Red    3 Not recorded Plasma toxic to  cells No result 
ABLV-33 Grey < 1 Killed 0.9 Positive 
ABLV-50 Little Red    4 Killed 0 Negative 
ABLV-54 Black < 1 Killed 0.2 Marginally 
positive 
ABLV-57 Black    1 Killed 0.2 Marginally 
positive 
ABLV-58 Black < 1 Killed 1.9 Positive 
ABLV-62 Grey < 1 Killed 0 Negative 
ABLV-65 Black    3 Died 0.91 Positive 
ABLV-68 Black < 1 Killed 0  Negative 
ABLV-72 Black    2 Killed 0  Negative 
 
1       A titre of zero (0) IU/mL in the AAHL modified rabies-RFFIT corresponds to a count of 20 of 20 high 
power fields containing fluorescent foci at a plasma dilution of 1:20. Very low titres of anti-rabies activity  
(< 0.2 IU/mL) may not be detected at this level. Titres of 0.2 IU/mL are estimates that correspond to 
counts between 10 and 20 of 20 fields containing fluorescent foci, i.e. where the level of antibody activity 
is marginally below that for accurate calculations, normally ≤ 10 of 20 positive fields. 
 
In addition, serum from one of two ABLV-negative Yellow-bellied sheathtail bats (DPI accession 
00-164484, adult non-pregnant female August 2000) was tested in the AHHL modified rabies-
RFFIT and was found to have a titre of 2.7 IU/mL (test result confirmed in retest). 
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2.5.6 Opportunistic urine and saliva samples 
A sample of urine from ABLV-65 collected by cystocentesis at post-mortem was positive for ABLV 
by TaqMan PCR (CT = 27.18). Similar urine samples from ABLV-63 and ABLV-67 were negative  
(CT = 50 and 45.4 respectively, where CT> 35 = negative). 
A sample of >150 mL of bat saliva submitted by a carer that had syringed excess saliva from the 
mouth of ABLV-55, which could not swallow, was negative for ABLV-RNA by TaqMan PCR.  
2.5.7 The trouble with bats and dogs 
Seven ABLV-positive bats were reported to have direct contact with dogs or captive bats such 
that the dogs or captive bats could have been exposed to ABLV. One other ABLV-positive bat had 
injuries suggesting involvement of a bat, cat or small dog, and a further ABLV-positive bat was 
found with similar injuries and was subsequently observed to fight another captive bat. Due to 
government regulations, pre- and post-exposure rabies/lyssavirus vaccinations are not available 
for Australian animals, even in the event of known potential exposure to ABLV. The outcome with 
respect to the potentially exposed dogs and bats is given in Table 2-10. 
Table 2-10 Outcomes for dogs and bats in-contact with ABLV-positive bats  
Case No Circumstances Outcome 
ABLV-4 Sept 1996 < 1 yo German shepherd, blood on dog’s 
nose suggested bat bite or scratch. 
March 2004, dog alive and well.  
ABLV-23 Female Labrador “sniffing around” moribund bat. Dog subsequently killed in road 
accident. Not submitted for testing. 
ABLV-29 Inadequate original history. During follow up call 
more than a year later, rescuer reported a “dog had 
been with bat”. Dog not identified. 
Dog not identified, outcome unknown. 
ABLV-46 Two adult poodles in yard with bat, at least one dog 
thought to have bitten bat. No evidence of injuries to 
bat at necropsy.  
Both dogs killed at owners request 8 
days later. Both dogs FAT-negative. 
ABLV-48 Puncture wound and soft tissue damage to bat 
forearm and other puncture wounds and 
haemorrhage to pectoral muscles suggest bat, cat or 
small dog attack. No reference to attack in 
submitter’s history. 
Suspect bat, cat or dog attack by 
unidentified animal, outcome unknown. 
ABLV-52 ABLV-52 rescued with bruising swelling and tooth 
marks on forearm. Later found attacking another 
injured bat in care. Presumed to have had previously 
been fighting other wild bats. 
Other captive bat recovered 
uneventfully from original injuries and 
remained well until released 56 days 
later. Long term outcome unknown. 
ABLV-64 Oct 2000 bat flew from tree on to back of  
3 yo female cattle dog, one of four dogs in 
household. 
March 2004, attacked dog and 
companion dogs alive and well. 
ABLV-66  
    and  
ABLV-73 
Oct 2000 ABLV-66 (wild bat) landed on enclosure of 
28 flying foxes. 30 days later ABLV-73 (colony bat) ill 
with ABLV. Remainder of colony potentially exposed. 
March 2004, 26 of remaining colony 
bats alive and well. 1 bat found dead 
July 2002, FAT-negative. 
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2.6 Discussion 
2.6.1 Prevalence and risk factors for ABLV in bats 
The data presented here represents sampling of animals that were submitted for testing because 
they were sick, injured, or orphaned, or had potentially exposed a person or animal to ABLV. As 
such the submissions do not represent the source bat populations as a whole, but rather the sub-
population of bats that  
1. suffer some sort of illness, injury or misadventure, 
2. and come to the attention of human/s 
3. and one or more of the persons involved is aware of the possibility that the bat may have 
a zoonotic disease,  
4. and one or more of the persons involved has or does receive appropriate information 
about the availability of testing,  
5. and one or more persons involved is prepared to submit the bat.  
 
Independent of the proportion of ABLV-positive bats in each population, other factors such as the 
proximity of particular colonies or feeding sites to human activity, the susceptibility of each 
species to other events that bring them to the attention of humans, the attitude of local people to 
bats, the attitude of local carers towards ABLV-testing and the enthusiasm of local carers and 
various agencies (veterinarians, regional DPI offices, etc) for submitting bats for testing may have 
influenced the numbers of bats of each species submitted and the likelihood that ABLV-positive 
rather than ABLV-negative bats be submitted. 
While the interaction of all these factors may mean that the data collected does not reflect risk 
factors for ABLV in the whole bat population, it accurately reflects risk factors for ABLV among the 
population of bats with which humans are in contact, i.e. the sub-population from which humans 
are at risk of exposure to ABLV. 
While data from all the bat submissions could be considered in the crude analysis, more detailed 
statistical analysis was restricted to the four common species of wild flying fox, there being 
insufficient numbers of submissions in other categories. 
Crude analysis showed that 6.5% (95% confidence interval of 5.1 to 8.1%) of all submitted bats 
(n=1,143) were ABLV-positive. However, this overall figure masks significantly different 
proportions for some meaningful groups of bats. ABLV was identified in YBST bats and at least 
one of each of the four common species of flying fox, and one flying fox not identified to species. 
The unidentified wild flying fox was submitted in Rockhampton. Based on species distribution it is 
highly likely to be either a Black or Little Red flying fox and ABLV-positive bats of both species 
have been submitted from this area. 
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2.6.1.1 Health status 
While this study shows no significant difference in the crude proportions of healthy bats (point 
prevalence 0 of 47, 0%) and sick, injured, or orphaned bats (point prevalence 73 of 1075, 6.8%), 
this is principally due to the low numbers of normal healthy bats submitted and the associated 
large standard error. However, in a separate but related structured study of the prevalence of 
ABLV among healthy wild-caught bats by Hume Field (ARI), all of 153 wild-caught flying foxes 
and all of 181 insectivorous bats were ABLV-negative by FAT (McCall et al. 2000). This study 
suggests that the prevalence of ABLV in the general bat population is less than 1% (95% 
confidence interval 0 to 1.1%). In combination, these studies show that sick, injured, and 
orphaned bats have a significantly higher crude prevalence of ABLV infection (p < 0.001) than 
healthy bats.  
Sick injured, and orphaned  > Healthy (clinically normal) 
 
There was a highly significant association between the presence of clinical signs suggesting CNS 
involvement and ABLV infection among all sick, injured, and orphaned bats (n= 1075, p < 0.001). 
This association was shown to be independent of all other tested factors in the generalized linear 
model analysis of data from identified wild flying foxes (n=868, p < 0.001). 
CNS disease  > Non-CNS disease 
 
Obviously, this association is dependent on the criteria by which bats were classified as having 
CNS disease. While involvement of the CNS in many bats was obvious; hind limb paralysis, overt 
aggression, or specific cranial nerve deficits (e.g. nystagmus, seizures), classification of some 
bats was more subjective. In particular some bats had a comparatively subtle generalized 
weakness (not moving about in cage, having voluntary limb movements but difficulty in hanging, 
holding wings in an unusual “loose” position, or failing to groom etc), yet often retained alert and 
responsive facial expressions, giving the bat an uncharacteristically calm appearance. Bats with 
an unexplained weak or calm demeanour (i.e. no obvious wounds or indications of other disease, 
no history of dog attack, and no suggestion of electrical shock) were interpreted as having CNS 
rather than metabolic paresis and included in the CNS classification. Moribund bats were not 
included. As such the criteria for inclusion in the CNS classification was relatively broad. 
Classifications were generally made at the time of post-mortem examination on the basis of the 
submitted history and any phone discussions leading to the bats submission, that is prior to the 
FAT. In some cases (n=13), classification was assisted by the carer submitting the live bat for 
euthanasia permitting direct observation and neurological examination (see Section 3.2.1 Central 
nervous system examination). It is also true that in the case of ABLV-positive bats, and not the 
majority of ABLV-negative bats, follow-up conversations with carers and others allowed for further 
elaboration of the history and clinical signs, which in some cases (5 of 74) revealed unreported 
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evidence of CNS involvement and so an ‘upgrading’ from non-CNS to CNS disease status. At this 
rate of under-reporting of true CNS status (6.7%) it could be extrapolated that approximately 57 
ABLV-negative bats classified as having non-CNS disease may have been classified as having 
CNS disease had further investigations been made. Even after correcting for this level of under-
reporting of CNS disease among ABLV-negative bats, the association of CNS disease status with 
ABLV-positive bats remains highly significant (p< 0.001). Recognition of CNS disease, as defined 
by these broad criteria and based on a thorough history, is a very good indicator of a high risk 
(crude prevalence 21%, model percent prediction 19.3%) of ABLV infection. 
2.6.1.2 Contact status 
Perhaps unexpectedly, there was no significant difference in the proportions of ABLV positive bats 
among the different contact status groups (p > 0.05 in both crude and model analysis). As the 
lyssaviruses are typically thought of as producing aberrant aggressive behaviour, it was expected 
that ABLV infected bats would have been more likely to bite or scratch humans or animals. 
However ABLV-positive bats were statistically no more likely to bite and/or scratch than any other 
submitted bat (p > 0.05).  
Contact None  ≈ Contact Human Yes  ≈  Contact Animal Yes 
In fact the point prevalence of ABLV-positive bats is lower for both Contact Human Yes (11 of 
202, 5.4%) and Contact Animal Yes (9 of 155, 5.8%) than bats with Contact None (56 of 798, 
7.0%) status.  
Reporting a bat as having bitten or scratched a person led to a demand to kill and test the bat by 
the Department of Health. Among bat carers, who are dedicated and very attached to their bat 
patients, such a drastic and uncompromising response to what was very often minor abrasions 
from a recovering bat or clinically well orphan was often unacceptable. Particularly in the case of 
orphan flying foxes, there were considerable feelings of loss associated with the destruction of 
well loved, clinically well, expressive young animals. Virtually all bat carers were vaccinated, and 
did not consider themselves susceptible to ABLV infection. In addition to individual carers not 
wishing to relinquish bats for euthanasia, considerable pressure developed within carer 
communities not to ‘dob in’ a bat. The reluctance to report bites or scratches was exacerbated by 
the response of some pubic health staff who were unsympathetic and unsupportive of carers and 
their “hobby” and resentful of the drain on public funded resources associated with testing and 
vaccination. 
On one occasion (ABLV-60) a carer that had to transfer a very aggressive bat in her care to 
another carer, specifically told the second carer she had not been bitten. They had discussed at 
some length the unusual aggression shown by the bat and the carer’s high suspicion that the bat 
may have had ABLV. Despite their suspicions, the bat was cared for for a further 2 days until it 
died. Only once the positive test results were relayed to the carers did the first ‘admit’ to having 
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received a bite that drew blood on the abdomen, and belatedly receive post-exposure booster 
vaccinations. This example demonstrates the reluctance of carers to report potential exposure not 
only to testing authorities, but to their peers, even when their own suspicions of ABLV-infection 
are high, and their preparedness to persist with caring for even an aggressive and difficult animal 
to the point that this results in a delay in providing potentially life-saving post-exposure treatment. 
While not wise, this near heroic dedication of carers to the welfare of bats in their care is common. 
This is in part due to a ‘selection’ effect. The number of people who cared for bats dropped 
substantially after publication of the first and second cases of fatal ABLV infection in humans (> 
160 carers pre-1996, < 40 carers in 2001, Helen Luckoff pers. comm. ONARR), with only highly 
motivated carers that were comfortable with the risk of infection remaining. 
In cases involving ABLV-positive bats, where there was a real risk of infection and the possibility 
that an exposure may have gone unreported, exhaustive post-testing efforts were made to identify 
all bitten or scratched persons. This was not the case for the majority of ABLV-negative bats. 
Consequently, it is highly likely that the number of bites and scratches in this data are under-
reported only among ABLV-negative bats. The effect of this under-reporting is that the proportion 
of ABLV-positive bats that did not bite or scratch (Contact Status None) is probably higher than 
that indicated (i.e. >7.1%), and the proportions of ABLV-positive bats that did bite or scratch 
(Contact Human Yes and Contact Animal Yes) are probably lower than that indicated (< 5.4% and 
< 5.8%). That ABLV-positive bats are no more or less likely to bite or scratch may be due to most 
ABLV-positive bats being found either dead, moribund or with generalized paresis (46/74) and 
surviving less than 12 hours after rescue (39/64 where the interval was known) and so having a 
reduced capacity and limited opportunity to bite or scratch. 
Of the 14 ABLV-positive bats that did show overt aggression, six (43%) managed to bite or 
scratch one or more humans or animals. The numbers of aggressive and ABLV-positive bats is 
too small to demonstrate statistical significance. It is possible that while the majority of ABLV-
positive bats are less likely to bite or scratch than an ABLV-negative bat, the small proportion of 
ABLV-positive bats that are aggressive are more likely to bite and scratch. If so, it is this small 
proportion of aggressive ABLV-positive bats that poses the greatest risk of ABLV transmission to 
humans. Both known human cases of ABLV infection, and the one naturally infected bat were the 
source of infection was identified (ABLV-73), occurred after exposure to overtly aggressive bats 
(Hanna et al. 2000; Speare et al. 1997). 
 Aggressive ABLV-positive bat  >  ABLV-negative bat  > dead or weak ABLV-positive bat 
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2.6.1.3 YBST bats and other relevant categories of bat submissions 
There were significantly different proportions of ABLV-positive bats between distinct species or 
groups of bats.  
YBST bats  >  wild megachiroptera  >  colony megachiroptera ≈ other microbats  
 (p< 0.001)      (p< 0.05) 
 
A very high 71% of only seven submitted S. flaviventris (YBST bats) were ABLV-positive (95% 
confidence interval of 29.0-96.3%). As it is improbable that such a high proportion of the total 
population of YBST bats become ill with ABLV, it is assumed that some interaction between the 
prevalence of ABLV in this species and other factors such as the distribution, biology, and 
behaviour of this species and/or the effect of ABLV on individuals resulted in the selective 
submission of ABLV-positive YBST bats. Regardless of whatever interactions were involved, the 
fact remains that identification of a sick or injured bat of this species is the strongest risk factor for 
ABLV infection. 
In contrast, none of 151 other microbats was ABLV positive, suggesting ABLV is not present in 
microbats other than YBST bats. However, the usefulness of these data are limited by the large 
number of other microbat species (n=62) compared to the number tested. Individuals of only 12 of 
19 other genera were submitted and the number submitted of most genera was very low (n= 1 or 
2 for seven genera). Consequently the absence of an ABLV-positive bat among such small 
samples is meaningless with respect to the presence or absence ABLV in each microbat species. 
Despite this, it remains true that as a group, other microbats pose a low risk of transmission of 
ABLV to humans due the low prevalence of ABLV in the group and the low frequency with which 
these bats interact with humans (microbats comprise 62 of 76 bat species (82%) yet contributed 
only 151 of 1143 (13.2%) of all bat submissions.) 
The great majority of bat submissions (974/1143, 85.2%) were Megachiroptera and all but eight of 
these were flying foxes. While neither of two Tube nosed bats and none of six Blossom bats were 
ABLV-positive, the numbers of submissions of each species is too small to infer that ABLV is or is 
not present in these species.  
The prevalence of ABLV among wild flying fox submissions (68 of 893, 7.6%) was significantly 
higher (p < 0.05) than among captive flying foxes (1 of 81, 1.2%). The history of the colony from 
which the single ABLV-positive bat was identified (ABLV-73) strongly suggests this infection did 
not arise de novo but as a result of contact with a wild ABLV-infected bat (ABLV-66) that had 
landed on the colony’s cage one month earlier. No other bat in the colony developed clinical signs 
as a result of contact with either bat, suggesting that ABLV is not readily contagious, even among 
closely confined flying foxes. Bat ABLV-73 was a long term dominant resident of the colony. Her 
exposure to ABLV may have been the result of acting defensively to try to drive the wild bat off the 
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cage. Early recognition of clinical signs and removal of ABLV-73 from the cage by staff may have 
precluded transmission of ABLV to other colony residents. 
2.6.1.4 Species associations among wild flying foxes 
Among the four common species of flying fox, there were differences in the number and 
characteristics of wild bats submitted. The model analysis indicated there was a highly significant 
independent association between species (p < 0.001) and the proportion of ABLV-positive flying 
foxes. 
Both the crude and model analysis showed that the prevalence of ABLV was significantly higher 
in Little Red flying foxes (crude prevalence 16.9%, model percent prediction 11.4%) than in Black 
and Grey-headed flying foxes (crude prevalence 7.8% and 4.6% respectively, model percent 
predictions 4.6% and 2.3%) which were not significantly different. The prevalence of ABLV among 
Spectacled flying foxes was significantly lower than the other three species (crude prevalence 
1.0%, model percent prediction 0.2%).  
P. scapulatus  >  P. alecto   ≈  P. poliocephalus  >  P. conspicillatus 
 
Only 9.4% (95 of 893) wild flying foxes submitted were Spectacled flying foxes, which may simply 
reflect the relatively small distribution of these bats in Queensland and the lower human 
population density in coastal far north Queensland relative to southeast Queensland. The 
Spectacled flying fox submissions were heavily biased towards bats with certain characteristics. 
Sixty-eight of the 95 Spectacled submissions (72%) were submitted by a single veterinarian 
during late 1996 and 1997. All were known or clinically suspected of having tick paralysis as a 
result of poisoning with the toxin of Ixodes holocyclus, but had failed to respond to medical 
treatment, including in some cases anti-tick toxin serum. These submissions are biased with 
respect to when they were submitted, the clinical syndrome of paralysis and respiratory difficulty, 
a health status classification of CNS disease, and a high expectation of non-ABLV aetiology. 
While biased, these samples were highly appropriate, as having showed evidence of CNS 
disease and having failed to respond to treatment for tick poisoning meant there was a real 
possibility that the presence of the tick had been incidental or secondary to primary infection with 
ABLV. None of these 68 ‘tick’ submissions were ABLV-positive suggesting that ABLV is not 
contributing to the seasonal incidence of tick paralysis in Spectacled flying foxes. The remaining 
27 Spectacled submissions spanning December 1996 to June 2000 were individual cases from 
individual carers as was typical of the submission pattern of the other flying fox species. One of 
these spectacled flying foxes was ABLV-positive (ABLV-25).  
Due to the apparent bias in the Spectacled flying fox submissions, the low prevalence of ABLV in 
these submissions (1/95) should not be directly interpreted as indicating a low or lower prevalence 
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of ABLV among this species relative to other flying fox populations. While the prevalence of ABLV 
in the Spectacled population as a whole may be significantly higher, similar, or lower than that in 
other species, the combination of this true prevalence, restriction of the spectacled population to a 
relatively small area of the far north coast near Cairns, the low human population density in the 
area, and the high incidence of tick paralysis in this species, combine to result in a very low 
prevalence of ABLV (1/95, 1%) among wild sick, injured, or orphaned Spectacled flying foxes that 
are in contact with humans. Despite the apparent sample bias, these submissions indicate that 
Spectacled flying foxes pose a low, indeed the lowest risk of ABLV infection to humans. 
Wild Black flying foxes were the most commonly submitted bat species (n= 474). This reflects 
their coastal distribution that corresponds to the highest human population densities, and their 
inclination to roost and forage in or near urban development, increasing the likelihood that a sick, 
injured, or orphaned Black flying fox will come in to contact with humans. While the number of wild 
Grey-headed flying foxes in Queensland is comparatively low and their distribution is restricted to 
southeast Queensland only, the high human population density in this region and their use of 
urban sites for roosting and foraging resulted in the second highest number of submissions (n= 
175). In contrast, wild Little Red flying foxes, despite having the widest distribution, including 
southeast Queensland, contributed only 124 submissions. This may be because they disperse 
into inland Queensland, where human population density is low, to give birth and raise their 
young, and fewer of them roost or forage in urban environments. 
2.6.1.5 Age and other factors  
Generalized linear regression models showed that only three factors, species, health status and 
age of were associated with statistically significant differences in the proportions of ABLV positive 
flying foxes.  
The association with age indicated that the proportion of adult bats that were ABLV-positive was 
significantly higher (model percent prediction 4.9%) than that of juvenile bats (<3 years of age 
model percent prediction 1.7%). The basis for this association remains unclear. As up to 5% of 
flying foxes have been shown to have neutralizing antibodies to ABLV, it is possible that 
maternally derived antibodies confer protection to some juvenile bats. Bat colonies are highly 
structured with sections of colonies consisting of juveniles, young adult males, or pregnant or 
lactating females at certain times of the year. Differences in the seasonal and territorial 
aggression among adults and juveniles may influence the transmission of ABLV in certain 
sections of the colony. 
No significant association was identified between any other tested factor (sex, contact status, 
location found, year, and climatic season or bat reproductive season). 
While there was no significant association with year and the proportion of ABLV-positive flying 
foxes, there was certainly a strong downward trend in the total number of ABLV-positive 
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submission (see Table 2-2). In 1996 and 1997, immediately after the recognition of ABLV in bats 
and the first human fatality, the submission rate of bats was very high (average of 34 and 28 bats 
per month respectively), due principally to the valuable support of the bat carer community and 
veterinarians at Currumbin Sanctuary that provided veterinary services to carers in the Gold 
Coast region. However, as testing required euthanasia of bats and the cost and inconvenience of 
submitting bats, once it became clear that the vast majority of bats were ABLV-negative, and as 
carers adapted to minimize or conceal being bitten or scratched, over time fewer bats were being 
submitted. During 2001 only 100 bats (~ 8 per month) were submitted in Queensland (ARI and 
QHSS figures combined). Publicity regarding the risks associated with contact with bats meant 
fewer members of the public became involved with bats. Many carers became selective about the 
bats they submitted. Live bats were generally only submitted if they had bitten or scratched 
someone, and often then only if they had bitten or scratched an unvaccinated person (e.g. a 
member of the public during rescue). Dead bats were often only submitted if the carer suspected 
the bat was ABLV-positive or they had some other interest in determining the cause of death. This 
submission pattern was partly in response to changing research focus over the period. Initially a 
team of three postgraduate students and two research assistants were focused on concurrent 
ABLV and Hendra virus projects. By 2001, ABLV testing was being done simply as a diagnostic 
procedure. As funding and staff dissipated so did the submissions. ABLV is a nationally listed 
notifiable disease, obliging veterinarians or other scientists to notify the nearest veterinary officer 
of the existence or suspected existence of ABLV (Stock Act 1915). As such the Department of 
Primary Industries has an obligation to test any bat suspected of having ABLV. While this 
continues to be the case, without active encouragement and feedback from the research group, 
submissions dwindled and by 2002 the majority of submissions were as a consequence of reports 
of people being bitten or scratched.  
2.6.2 Characterization of ABLV infection in bats 
ABLV infection in bats is not readily recognizable clinically, in part due to an expectation that 
lyssaviruses will produce overt aggression and because it is difficult to appreciate paresis in bats. 
Five ABLV-positive bats were examined by veterinarians that did not recognize the condition to 
the extent that the bats were released back to the carer. A weak, even dead bat is capable of 
hanging due to the anatomy of their hind limbs. A weak bat is therefore quite able to hang, 
apparently normally in a cage, with paresis only evident by their inability to move or groom 
normally. A similarly weak quadruped, such as a cat or dog, would be unable to stand.  
The range of clinical presentations and signs is consistent with that reported previously, (Hooper 
et al. 1997b), however it should be noted that the report refers to some of the same cases 
described here. The ‘classic’ ABLV-positive bat is weak, not aggressive, having been found on the 
ground or hanging inappropriately low in tree or other structure away from camp during the day. 
Presumably these bats were recently well enough to fly from camp, but had deteriorated since 
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and were unable to climb or fly from where they were found. When rescued they often appeared 
calm and alert. Those that could hang may have appeared quite well. In some cases bats that had 
died naturally were submitted with the paradoxical history of “appeared healthy”, others were 
more obviously paralysed and required support. Some showed signs of cranial nerve or cerebral 
involvement. Abnormal use of the mouth, seizures, tremors, or nystagmus, while not common is 
highly suggestive of ABLV infection. Most deteriorate or die unexpectedly within 36 hours.  
Approximately 19% of ABLV positive bats present with overt aggression. Some fly from an 
inappropriate roost to attack humans and other animals. Others behave aggressively when being 
rescued, often vocalizing, and may show intractable aggression towards inanimate objects and 
approaching humans when caged. This behaviour is readily recognized as abnormal by 
experienced carers, and their rapid progression from over-active and aggressive to moribund or 
dead is a strong indicator of ABLV infection. 
Most ABLV-negative bats can be recognized as having a particular problem; trapped in a fence, 
broken limbs, history of dog attack, found near powerlines with electrical burns, or being an 
orphaned juvenile. Any bat that is unwell enough to be caught but has nothing obviously wrong 
with it should be considered likely to have ABLV.  
Surprisingly, very few ABLV-positive bats suffer secondary misadventures. One infected flying fox 
flew into the path of a car, and two others appeared to have received electrical shocks from power 
lines. One had small puncture wounds that may have been the result of a bat attack as no cat or 
dog interaction had been observed. Remarkably, none were seriously injured by dogs or cats, 
despite the fact they invariably ended up vulnerable to such attacks.  
At gross post-mortem examination ABLV infection is a most unremarkable condition. A dead bat 
with no gross indicators of cause of death, with low or moderate fat reserves, with or without 
bruising consistent with a fall, and bladder containing urine, could be considered more likely to be 
ABLV-positive.  
The incubation period of four naturally occurring ABLV infections are believed to be known, those 
of the two human cases, which were 6 weeks (Rockhampton (Speare et al. 1997)) and 27 months 
(Mackay (Hanna et al. 2000)) respectively and those of ABLV-32 and ABLV-73, which were 36 to 
57 days and 30 days respectively. The shorter incubation periods are most consistent with those 
of the majority of rabies cases where 70% occur within one month of exposure, 90% within 6 
months and < 7% after more than 12 months (n=707) (Wilde et al. 1989). 
The clinical duration of naturally-occurring ABLV in most cases is unknown as either there was an 
unknown period of clinical illness prior to the bat being found and/or the duration was shortened 
by euthanasia. Of the two bat cases that became ill while under observation, ABLV-32 died after a 
9-day illness and ABLV-73 was killed on day 2. Minimum clinical durations as indicated by the 
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periods that bats were observed sick before dying naturally varied from 0 (found dead) to 9 days. 
While most died within 36 hours, six survived for 3 (n=2), 5, 6, 8 and 9 days. 
The AAHL rabies-RFFIT detected seroconversion in only six of 16 ABLV-positive bats, indicating 
that a negative rabies-RFFIT titre is meaningless with respect to whether or not a bat is infected 
with ABLV. Titres in ABLV-positive bats were generally low to moderate (0.2 to 1.5 IU/mL). 
Absent, late or poor development of an ABLV titre in these bats may have contributed to their 
becoming clinically ill. 
Both negative and positive titres have been detected in clinically well, wild-caught flying foxes. A 
positive titre of 0.9 IU/mL was detected in 1 of 240 flying foxes (Hume Field, ARI, unpublished 
data), and titres of ~0.2 IU/mL were detected in 3 of 54 (5.5%) Black and Grey-headed flying 
foxes screened prior to experimental use, this thesis. There is a similar prevalence (3%) of 
positive titres in apparently well, wild-caught microbats (8 of 264 with titres of 0.4 to 2.0 IU/mL, 
including 3 positive S. flaviventris sera, Hume Field, ARI, unpublished data). As individual bats 
with ABLV-positive titres have not been serially tested or observed, it remains unclear whether the 
positive titres in healthy bats indicate exposure, subclinical resolution and protection, a carrier 
state, or a pre-clinical response and impending disease. As such, while a positive titre presumably 
indicates prior exposure, it does not indicate whether or not an individual is currently infected or 
whether it presents a risk of infection to others. 
As neither a positive or negative rabies-RFFIT titre in either a clinically ill or healthy bat is 
predicative for the presence or absence of ABLV-disease or a risk of infection, titres are of no 
value in the clinical or risk assessment of bats. 
2.6.3 Estimating the likelihood of being ABLV-positive 
Assessment of likelihood is dependent on taking a detailed and specific history of the 
circumstances and clinical observations of each case. In particular detailed and specific inquires 
should be made regarding the three significant factors, species, health status and age. 
Experienced carers are usually able to identify the species and age. Microbats are comparatively 
difficult to identify. Fortunately, YBST bats, the only microbat associated with a high risk of ABLV, 
are distinctive having pale belly fur and dark fur on the back. Most other microbats are 
brown/black all over.  
Considerable care needs to be made to ensure the history consists of what was seen and heard 
rather than the submitter’s interpretation of the situation. For example, one bat (ABLV-32) was 
submitted with a history that read: 
                     “Hand raised. Hanged itself in cage. 2 cortisone shots and Amoxil 5 days”.  
On getting the ABLV-positive result, further inquires revealed that this orphan, that had been in 
care for 5 weeks, had had a sudden onset of aggression and vocalizing, deteriorated over 7 days 
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until unable to hang, with dysphagia, diarrhoea and weight loss, eventually dying on Day 9. No 
entrapment had been observed but the carer had concluded that the bat must have suffered a 
head injury that must have been the result of getting its head caught in the cage. While the actual 
history readily suggests this bat was likely to be ABLV-positive, the summary assessment 
submitted did not. The care needed to get an indicative history extends particularly to 
observations relating to paresis. It is advisable to ask specifically what the bat can and can’t do 
(can hang, can grip with feet, has moved voluntarily around cage, can groom with wings and feet, 
has inverted to toilet) rather than rely simply on a submitter’s assessment of whether the bat was 
or was not weak.  
As shown in Table 2-6 the combination of species, age and health status can be used to 
differentiate which bats are more likely to be infected. As the table indicates, all Spectacled flying 
foxes have a low (< 2%) likelihood of being ABLV-positive, while all Black, Grey-headed and Little 
Red flying foxes showing signs of CNS disease have a high to very high likelihood of infection (8.2 
to 58%). Within each species, adult bats are more likely to be infected than juveniles.  
Even when a good history is taken and the species, age and health status are known, not all 
ABLV-positive bats are readily recognized. The clinical signs shown by ABLV-positive bats and an 
assessment of how easily those bats would be recognized are shown in Table 2-7. Unfortunately 
none of the circumstances or clinical signs observed in ABLV-positive bats are unique to ABLV, 
and some bats, in particular the dead, moribund or those showing signs suggesting another 
disability are clinically indistinguishable from the majority ABLV-negative bats. Comprehensive 
identification of all ABLV-positive bats would require comprehensive testing of all sick, injured, or 
orphaned bats, as was essentially the case during late 1996 and 1997. As this is no longer 
supported by carers or adequate funding, wildlife carers and associated professionals need to 
make as reasonable an assessment as possible as to which bats are sufficiently likely to be 
ABLV-positive that they should be tested. Invariably this has and will result in many cases not 
being identified.  
2.6.4 Risk factors for ABLV infection in humans and other 
animals 
The risk of infection with ABLV is related to the risk of exposure to an ABLV-positive bat, the type 
and extent of exposure to the bat, and the susceptibility of the person or animal to infection. As 
most humans only come in to contact with sick, injured, or orphaned bats, the risk factors for 
exposure to ABLV are the same as those discussed for the prevalence of ABLV in these bats. It 
should be noted that dogs, and presumably other animals are exposed to ABLV-positive bats and 
there is therefore a theoretical if not real risk of infection in these animals. However, as no case of 
ABLV has been detected in other native or domestic animals, the risk of human exposure to ABLV 
via indirect transmission from other species appears negligible. 
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It is presumed that infection with ABLV in humans will occur as a result of the same sort of 
exposures as those that have led infection with rabies, i.e. principally from bites and scratches, as 
were reported in the two human cases to date, and possibly by contact with urine or saliva and 
broken skin or mucus membranes (NHMRC 1997). Members of the public and professionals with 
no experience of handling bats that attempt to rescue or treat sick, injured, or orphaned flying 
foxes, are very likely to be bitten and scratched. Experienced wildlife carers can usually handle 
bats effectively and avoid being bitten, but are almost universally opposed to wearing gloves. 
They frequently incur minor scratches and abrasions, particularly from the grasping hind limb 
claws, and are invariably exposed to bat blood, urine, and saliva. ABLV RNA was detected in one 
of three urine samples from ABLV positive bats, and not in the single saliva sample tested with 
the pt-ABLV TaqMan assay. Whether ABLV-positive urine is infective has not been established. 
The dedication many carers have for bats in their care results in them continuing to care for bats 
they suspect of having ABLV until they are dead or moribund, increasing the duration of potential 
exposure to up to 9 days. In addition, within the carer community, some expert carers are more 
likely to be allocated bats with ABLV-like symptoms, resulting in some carers dealing with multiple 
ABLV-positive cases a year. 
Three rabies vaccines, Verolab (sic), a human vaccine produced in the vero cell line, IMRAB a 
veterinary vaccine, and V-RG vaccinia, a recombinant expressing rabies glycoprotein, were 
shown to confer cross protection ABLV to intracerebrally inoculated mice challenged 2 months 
after intraperitoneal immunization (Hooper et al. 1997b). The ABLV used in this work was YBST-
variant ABLV (Charles Rupprecht, CDC Atlanta pers comm.). No specific assessment of the cross 
protection conferred against pteropid-variant ABLV has been published. In Australia pre-exposure 
vaccination against rabies and ABLV is done using the human diploid cell rabies vaccine (HDCV, 
CSL/Pasteur Merieux inactivated rabies vaccine) on the presumption it too confers cross 
protection (NHMRC 1997). Post-exposure treatment also includes passive immunization with 
human rabies immunoglobulin (HRIG) (NHMRC 1997). That these vaccines confer protection to 
humans exposed to ABLV has not been specifically demonstrated except that no vaccinated 
person exposed to either ABLV-positive bats or other ABLV-positive material (e.g. during 
diagnosis or research) has yet become ill. Confidence in the effectiveness of pre-exposure 
vaccination with HDCV is generally high in the Australian carer, veterinary and medical 
communities.  
With respect to susceptibility to infection, there are essentially two populations: 
♦ unvaccinated and susceptible, which includes virtually all native and domestic animals, the 
general public, and many veterinarians in general practice 
♦ effectively vaccinated with very low susceptibility, which includes most carers and 
government based professionals that deal with bats, e.g. Department of Environment 
personnel, DPI, AAHL and Department of Health diagnostic and research scientists. 
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Fortunately, virtually all wildlife organizations that arrange for bats to be fostered out to carers 
insist that bat carers receive pre-exposure vaccination with the human diploid cell rabies vaccine. 
Most were vaccinated during a publicly funded campaign in 1996. Some, as has been reported 
(Crome et al. 1998), may be unaware that they had failed to respond to vaccinations received. 
Pre-exposure booster vaccinations for bat carers are no longer free through Medicare, and the 
expense (~$100 /booster) deters carers from requesting regular boosters. Carers that received 
their original vaccinations in 1996, and have not since required free post-exposure booster 
vaccinations, may have waning titres. As such the susceptibility of carers may be increasing. 
The veterinary community may be uniquely at risk of infection with ABLV. Australian veterinary 
schools provide free vaccinations for some diseases but not rabies vaccination. The cost of the 
full course of pre-exposure vaccinations (~$300/ three inoculation course) deters general 
veterinary practitioners from becoming vaccinated, particularly as most wildlife consultations are 
done at no charge, most veterinarians see fewer than 3 bats per year, and it appears no 
veterinarian has been infected. Experienced carers recognize the most common injuries that will 
respond to supportive care and antibiotics to which they often have access. Veterinarians are 
likely to only see bats that are unusually sick or require euthanasia and so are particularly likely to 
be ABLV-positive. In one case a veterinarian was reluctant to get vaccinated because he only saw 
one bat a year, but two of three bats he killed and submitted for the experienced carer in his area 
were ABLV-positive. Some practices manage the risk of exposure to ABLV by refusing to see 
bats, others by directing all bat consultations to particular vaccinated members of staff, but many 
rely on the assistance of experienced carers to avoid getting bitten and scratched and on the 
effectiveness of post-exposure vaccinations. 
Management of unvaccinated persons potentially exposed to ABLV is by post-exposure 
vaccination, i.e. when an person reports that they have been bitten or scratched by an ABLV-
positive bat, or bat that can not be tested (e.g. flies away), post-exposure vaccinations are offered 
free by the Department of Health (NHMRC 1997). This protocol will fail if either the person does 
not appreciate they have been exposed (e.g. unperceived or minor abrasions, or contact with bat 
blood urine or saliva and broken skin or mucosa), or does not report an exposure, as is the case 
in most human rabies cases in the USA (Messenger et al. 2003; Warrell 1995). Fortunately the 
high levels of publicity associated with the two human cases of ABLV infection have resulted in 
many in the general public understanding that bats do pose a risk of infectious disease and that 
they should seek medical advice after contact with bats. 
2.6.5  Non-bat species submissions 
During the period June 1996 and March 2002 only 27 non-bat submissions were tested for ABLV 
with only 1 to 7 submissions of any one species. While all the submissions were ABLV-negative, 
the numbers submitted are far to low for them to indicate an absence of ABLV (or ABLV-like virus) 
among non-bat species in Queensland. Even though most of the submissions (19/27) were of 
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animals with clinical signs suggesting nervous system disease and so had a moderate or high 
index of suspicion for ABLV, the numbers submitted were so small as to clearly indicate that 
neither pet owners, veterinarians, wildlife carers, nor the Department of Natural Resources (who 
through the Queensland Parks and Wildlife Service are responsible for the management of all 
native animals) genuinely consider the possibility of ABLV as a cause of unexplained aggression 
or neurological disease. 
At this point the apparent absence of ABLV in domestic animals (most notably cats and dogs) and 
wildlife species (such as possums, dingoes and native rodents) cannot be attributed to a true 
absence of lyssaviruses in these populations, since the same failure to test appropriate cases 
persists among non-bat species as had existed for bats prior to the Hendra virus-inspired 
research. The dogma that lyssaviruses in Australia exist only among bat populations (with rare 
spill-over to humans), while quite probably true, can simply not yet be justified.  
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2.7 Conclusions 
Prevalence of ABLV in bats and other species 
♦ While ABLV is rare in whole bat populations ( <1%) it is common among sick, injured, or 
orphaned YBST bats (up to 96%) and Black, Grey-headed and Little Red flying foxes (4 to 
17%). 
♦ ABLV has been detected in a single Spectacled flying fox.  
♦ The extent to which ABLV or ABLV-like viruses are present in other native or domestic 
species, either in self-sustaining endemics or in incidental dead end hosts has not yet been 
adequately tested. 
Risk factors for ABLV infection in bats 
♦ There are species (YBST > P. scapulatus > P alecto ≃ P poliocephalus > P conspicillatus > 
other microbats), age (adult > juvenile) and health status (CNS disease > non-CNS disease > 
clinically well) associations with ABLV-positive bats that can be used to asses the likelihood 
that a particular bat is ABLV-positive. 
♦ ABLV is present throughout Queensland throughout the year. There is no regional or 
seasonal association with the proportion of ABLV-positive bats. 
♦ ABLV is rare in captive bats. The single reported case in a captive bat can be attributed to 
contact with a wild ABLV-positive bat. The risk of ABLV in colony bats, and therefore the risk 
colony bats pose to humans could be reduced by preventing contact between wild and 
captive bats, e.g. by housing in ‘double skinned’ enclosures. 
Characterization of ABLV infection 
♦ The incubation periods for ABLV in the two flying fox and two human cases, where it is 
believed to be known, was 36-57 days, 30 days, 6 weeks and 27 months. 
♦ Bats infected by ABLV were usually found on the ground or hanging inappropriately low in 
trees or man-made structures during the day, and do not appear to be prone to secondary 
misadventures, such as entanglement in barb wire, or attacks. 
♦ Most ABLV-positive bats have clinical signs dominated by generalized paresis. A small 
number are overtly aggressive, and others are clinically indistinguishable from ABLV-negative 
bats. 
♦ Most ABLV-positive bats die or clinically deteriorate within 36 hours of being observed, but 
some individuals survive as long as 3 to 9 days in care, during which time human exposure to 
ABLV is likely. All ABLV-positive bats died or became gravely ill or were intractably 
aggressive leading to euthanasia.  
♦ Rabies-RFFIT titres in clinically ill and normal bats are of no diagnostic significance. 
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♦ ABLV-positive bats are statistically no more likely to bite or scratch a human or other animal 
that any other bat, however a high proportion of the small number of aggressive ABLV-
positive bats had bitten or scratched a person or animal. 
♦ Wildlife carers that rehabilitate bats are highly motivated and dedicated to the welfare of bats 
in their care. Failure to consider the impact of protocols requiring mandatory euthanasia of 
bats for ABLV testing has resulted in under-reporting and delayed reporting of potential 
exposure to ABLV through bites and scratches from bats in care. 
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3 Central nervous system disease in 
flying foxes 
Aims 
1. To identify causes of clinical neurological syndromes in flying foxes.  
2. To use a targeted approach to evaluate the sensitivity of the fluorescent antibody test 
performed at the ARI for the detection of Australian bat lyssavirus. 
3.1 Introduction 
During the study presented in Chapter 2, it became obvious that features of the histories and 
clinical signs present in many ABLV-positive bats, were similar to those of a number of ABLV-
negative bats. Recognition that there was a group of bats with histories consistent with being 
ABLV-positive that was ABLV-negative by FAT led to the following conclusions. Either some bats 
infected with ABLV, (or an ABLV like virus) were not being detected in the FAT (false negatives), 
or/and other conditions were producing ABLV-like clinical signs in bats.  
The prospect that the FAT may be failing to recognize all ABLV-positive bats had serious 
implications for both the research data on ABLV and the post-exposure management of people 
bitten and scratched by bats. It seemed likely that at least some ABLV-like clinical signs in bats 
were being produced by other aetiologies that may or may not have been previously reported in 
bats.  
Evidence of lead (Pb) poisoning (plumbism) has been reported as a cause of CNS disease in 
captive (n= 2 (Zook et al. 1970)) and wild (n= 2 (Sutton and Wilson 1983)) flying foxes based on 
the presence of extremely high (> 500 ppm) or high (15 to 60 ppm) liver or kidney lead levels. 
However, in clinical trials flying foxes were shown to be highly resistant to clinical plumbism 
(Hariono 1991), and a Black flying fox with clinical aggression, acid fast eosinophilic inclusion 
bodies in renal tubular epithelium containing lead, and very high kidney lead levels (370 ppm) was 
subsequently shown to be infected with ABLV, suggesting that the lead load might have been 
incidental (Skerratt et al. 1998; Speare et al. 1997 ). The extent to which lead toxicity causes 
clinical disease in ABLV-negative bats remained unclear.  
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3.2 Materials and Methods 
One hundred consecutive diagnostic submissions to the ARI of wild flying foxes from Queensland 
with a health status classification of CNS disease (see 2.2.1. Case submission and classification), 
were examined to determine the aetiological diagnosis. Tests and examinations for each bat were 
done in a sequential manner until a well-supported diagnosis was apparent. Some of the data 
used in this study was compiled retrospectively and in some cases the full range of tests and 
examinations were not done because the necessary material had not been collected. The general 
sequence of tests and examinations is shown in Figure 3-1. 
Figure 3-1 Sequence of tests and examinations to determine the aetiological diagnosis for 
100 wild flying foxes with CNS disease 
 
100 CNS flying foxes  
Histories ± CNS examination 
  Necropsy and FAT 
 
 
ABLV-positive    ABLV Negative 
 
 
  Aetiology evident   No aetiology evident  
at gross necropsy    at gross necropsy 
     Characterization and confirmation               Histological examination  
by radiography, histology, bacteriology etc  of brain ±  other organs 
 
 
 
Aetiology evident   No aetiology evident 
histologically   histologically 
 
Characterization and confirmation  Liver Pb levels 
by bacteriology, parasitology etc    
 
 
          Elevated Pb levels          Normal Pb levels 
           
       TaqMan and PCR 
           assays on brain for ABLV 
       
 
              ABLV-positive  ABLV- negative 
 
No diagnosis 
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3.2.1 Central nervous system examination 
Clinical neurological examination was performed on thirteen live flying foxes submitted to the ARI 
with histories or clinical signs suggesting central nervous system disease. 
The examination included assessment of: 
♦ General demeanour 
♦ Cranial nerve functions examination for evidence of strabismus, nystagmus, head tilt, and 
facial symmetry, and by eliciting menace, corneal, and gag reflexes, and ‘sneeze’ reflex on 
stimulation of nares. 
♦ Forearm and hind limb reflexes by observing for voluntary movement, pain and withdrawal 
responses to ‘pinching’ carpus (forearm) or interdigital tissue (hind limbs) with forceps, and 
‘claw clasping’ reflex in response to touching the palm of the hind limbs. Flying foxes have a 
very strong reflex to grasp with their hind limbs, analogous perhaps to the righting reflex of 
other animals. 
3.2.2 Necropsy 
Necropsies were done in a Class II biosafety cabinet within the PC2/PC3 Diagnostic Virology 
Laboratory as described in Section 2.2.1. Of the 100 flying foxes included in this study, 77 
necropsies were done by the candidate, the remainder were performed by other members of the 
Virology Research Group or ARI diagnostic veterinary pathologists. 
3.2.3 Fluorescent antibody test  
Infection with Australian bat lyssavirus was detected by FAT on fresh brain touch impressions, as 
described in Section 2.2.3 Fluorescent antibody test. 
3.2.4 Radiography 
The spinal columns of nearly half of the flying foxes with known or suspected spinal fractures or 
no known diagnosis were removed and fixed in formalin. Spinal radiographs were taken at the 
University of Queensland School of Veterinary Science under the direction of Morag Wilson 
(radiographer) using exposures of 48KVP, 100 ma, and 63 msecs, with a Toshiba DXB-
0324CS=A X-ray tube and 0.7 aluminium permanent filtration with single screen cassettes on 
FUJI UM-MA-HC 9 (soft tissue) film that was automatically processed by a Fuji FPM 3000 X-ray 
film processor. Interpretation of radiographs was done with the assistance of Annie Rose 
(radiologist) of the University of Queensland Veterinary Teaching Hospital.  
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3.2.5 Histology 
Brains for histological examination were sectioned in three standard planes. 
♦ Transversely through the frontal lobe.  
♦ Transversely through the cerebral cortex and thalamus at the level of the hippocampus 
♦ Longitudinally through the brainstem and cerebrum, including the caudal colliculus pons, 
medulla, and proximal spinal cord.  
Where available, formalin-fixed lungs from bats with neuro-angiostrongylosis were sectioned 
through the hilar region so that the major pulmonary artery branches could be examined for 
nematodes or eggs. 
For all other tissues, representative sections were selected.  
Tissues were routinely processed overnight, paraffin-embedded and 5 µm sections cut and 
routinely stained with haematoxylin and eosin by the histology staff of the ARI. 
Some sections were reviewed in consultation with senior veterinary pathologists Roger Kelly 
(University of Queensland), and Ross McKenzie (ARI), and parasitologists Paul Prociv and Peter 
O’Donahue (University of Queensland). 
3.2.6 Bacteriology 
Bacterial samples taken by the candidate were submitted to the diagnostic ARI Bacteriology 
Laboratory for routine aerobic culture.  
3.2.7 Parasitology 
Nematodes recovered from the brain surface of two flying foxes were fixed in 10% buffered 
neutral formalin. The frozen half brains of other flying foxes in which nematodes had been found 
in histological sections were subsequently fixed in 10% buffered neutral formalin, and then gently 
macerated under stereomicroscopic guidance by Melissa Carlisle (veterinary pathologist, IDEXX, 
Brisbane).  
All worms found were mounted in chorlactophenol on a glass slide under a cover-slip, examined 
by compound microscopy, drawn using a camera lucida attachment and measured by P. Prociv.  
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3.2.7.1 Search of archives for evidence of Angiostrongylus cantonensis in wild 
Queensland flying foxes  
Histological sections of CNS tissue from flying foxes in the archives of the Veterinary Pathology 
Laboratory of The University of Queensland Veterinary School were reviewed.  
AAHL reports on bat brain specimens that had been forwarded to AAHL from ARI for lyssavirus 
testing were reviewed. 
Dave Spratt of the CSIRO was asked for information on the existence and availability of CNS 
material or histological sections from unwell flying foxes pre-1997. 
3.2.7.2 Case control study for Angiostrongylus cantonensis 
Queensland National Parks and Wildlife service permit 
Scientific purposes permit number – E4/000543/98/SAA 
Wild, presumably normal, Black and Grey-headed flying foxes were caught using a mist net at two 
flying fox colonies in urban Brisbane, namely at Indooroopilly Island, Indooroopilly (GPS South 
27.52032, East 152.99458, access courtesy of Indooroopilly Golf Course) and Norman Creek, 
East Brisbane (GPS South 27.481, East 153.053, access courtesy of Anglican Church Grammar 
School, 'Churchie'). These bats had been caught as part of a structured surveillance program for 
ABLV by the ARI Virology Research Group. 
Histological sections of brains from 19 wild-caught flying foxes, matched as far as possible for 
species, sex and age, with bats with A. cantonensis in this study, and trapped during months in 
which cases of neuro-angiostrongylosis in flying foxes were occurring in Southeast Queensland 
(i.e. matched geographically and temporally), were examined for nematode sections. 
Details of the bats examined (species, sex, age, and month, year, and site caught) are given in 
Appendix 7.  
3.2.8 Liver lead (Pb) levels 
Wet formalin-fixed livers were submitted to Brian Burren and Suzanne Noon of the DPI Trace 
Metal Residue Laboratory for Pb determination by inductively-coupled plasma mass spectrometry 
(ICP-MS) using the ELAN 5000 (Perkin-Elmer). Bovine liver Standard Reference Material (SRM 
1577b, National Institute of Standards and Technology) containing 0.129 ± 0.004 µg/g of Pb was 
digested with each run sequence. 
To remove the formalin, livers were washed in ASTM 1193 Type 1 water (18.3 megaohms.cm 
resistivity), and desiccated in evaporation basins in a 100°C oven overnight. 500 mg ± 20 mg of 
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dried liver was prepared by microwave-assisted nitric acid digest (HNO3, analytical grade). The 
acid digest was appropriately diluted and introduced into the ICP-MS system, producing results as 
Pb ppm dry weight.  
Approximations of the equivalent wet weight lead concentration (ppm wet weight) were calculated 
using the average percent dry matter of four clinically normal bats (see Appendix 8), as follows. 
 
Approximate ppm wet weight = ppm dry weight  x 22.8  
          100 
 
 
One sample (CNS-94) was identified for testing after the DPI Trace Metal Residue Laboratory 
was decommissioned in ~ April 2001. Washed and dried liver from this case was submitted to the 
Department of Natural Resources and Mines (DNR) Natural Resource Sciences Laboratories, 
Meiers Rd Indooroopilly for Pb determination by graphite furnace atomic absorption spectrometry 
(GF-AAS) using a Perkin-Elmer 4100ZL graphite furnace using Dog-fish muscle Standard 
Reference Material NRC-CNRC Dorm-2 (National Research Council of Canada) containing 0.064 
± 0.007 µg/g of Pb.  
3.2.8.1 Normal liver Pb levels in urban flying foxes 
As normal Pb levels in clinically well urban flying foxes are not known, formalin-fixed livers from 
50, presumably normal, wild-caught (as described in Section 3.2.7.2), flying foxes from urban 
Brisbane were submitted to the DPI Trace Metal Residue Laboratory for Pb determination. They 
included 25 P. alecto (14 females, 11 males), and 25 P. poliocephalus (11 females, 14 males). 
Further details of bats examined (species, sex, age, and month, year and site caught) are given in 
Appendix 8. 
Five duplicate liver samples representing low (n=1), mid (n=2) and high (n=2) normal range 
samples were also submitted to the DNR Natural Resource Sciences Laboratory to verify that the 
results produced by the different techniques used by the two laboratories were consistent. These 
duplicate results were not used in any further analysis. 
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3.2.9 TaqMan and PCR assays for ABLV 
A targeted approach to assessing the sensitivity of the ARI FAT was used presuming that, if the 
ARI FAT had failed to identify cases of ABLV in fresh brain touch impressions, then of the  
> 1000 FAT-negative flying fox brains tested, those most likely to have produced a false negative 
result would be from bats with lyssavirus-like CNS disease with no alternate diagnosis to account 
for their clinical signs.  
Samples of brains from; 
♦ 23 FAT-negative wild flying foxes with CNS signs, 
♦ 3 FAT-positive bats  
♦ 1 FAT-negative control (wild caught, clinically normal, FAT-negative flying fox)  
♦ and an aliquot of Nobivac® Rabies vaccin(sic) Lot 79050 (Intervet, Boxmeer, Holland), 
containing inactivated Pasteur RIVM stain rabies virus 
were submitted to QHSS for the detection of pteropid-variant-ABLV-RNA by TaqMan assay (see 
Appendix 3) and lyssavirus-RNA by hemi-nested RT-PCR (see Appendix 9). The hemi-nested 
RT-PCR assay uses a combination of primers designed to amplify all other known lyssaviruses, 
detects both pteropid and Yellow-bellied sheathtail variants of ABLV, and potentially other 
unrecognized variants of ABLV. 
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3.3 Results 
The 100 consecutive submissions of wild flying foxes with histories or clinical signs suggesting 
central nervous system disease occurred during the period August 1997 to July 2001.  
A schematic breakdown of the number of flying foxes for each diagnosis, and the level of 
examination at which diagnosis was reached is shown in Table 3-1 and Figure 3-2. Case details, 
the aetiological diagnosis, and the results of examinations are shown in Appendix 6. 
Subsequent reference to individual cases is by CNS Case Number e.g. CNS-1, CNS-2, as 
indicated in Appendix 6, or in the case of ABLV-positive bats by ABLV-case number as indicated 
in Appendix 5 and Appendix 6.  
 
Table 3-1  Aetiology for 100 flying foxes with clinical signs suggesting CNS disease 
Diagnosis Number of cases (equals %) 
Australian bat lyssavirus 32 
Spinal and head injuries 29 
Neuro-angiostrongylosis 18 
Congenital hydrocephalus  2 
Bacterial meningoencephalitis  2 
Vascular hepatopathy  1 
Chronic injury with mydriasis  1 
Plumbism (lead poisoning)  0 
No diagnosis 16 
 
     Note: the total number of diagnoses = 101 as one flying fox had both neuro-angiostrongylosis 
and a spinal injury) 
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Figure 3-2 Aetiology for 100 wild flying foxes with clinical signs suggesting CNS disease 
(Note: the total number of diagnoses = 101 as one flying fox had both neuro-angiostrongylosis 
and a spinal injury) 
 
 
100 CNS flying foxes  
Histories ± CNS examination 
 
Gross necropsy and FAT 
 
 
32 ABLV-positive    ABLV Negative 
 
 
 29 spinal and head injuries   No aetiology evident  
  2 congenital hydrocephalus   at gross necropsy 
  2 neuro-angiostrongylosis  
  1 bacterial meningoencephalitis  
  1 chronic injury with mydriasis    Histological examination  
        of brain ±  other organs 
 
 
 
16 neuro-angiostrongylosis   No aetiology evident    
  1 bacterial meningoencephalitis       histologically 
   1 hepatopathy 
   Liver Pb levels 
    
 
       Normal Pb levels 
           
           TaqMan and RT-PCR assays on 
                   brain for pt-ABLV and other lyssaviruses 
 
         TaqMan and RT-PCR negative 
          
 
  16 no diagnosis 
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3.3.1 ABLV infection 
Thirty-two of the 100 wild flying foxes with clinical signs suggesting central nervous system 
disease in this study were positive for ABLV by FAT. Case numbers and details are provided in 
Appendix 5 and Appendix 6 and have been discussed in detail in Chapter 2. 
An additional 14 ABLV-positive bats were submitted during this period but were not included in 
this study because they were: 
♦ Not a flying fox, n=1 Yellow-bellied sheathtail bat (ABLV-41) 
♦ Not recognized as having central nervous system disease (n=10).  
These bats were either moribund n=5 (ABLV-31, 34, 39, 45, and 48), submitted with 
inadequate or non-specific clinical histories n=4 (ABLV-46, 47, 56, 61), or submitted with a 
clinical signs suggesting another specific diagnosis n=1 (ABLV-57 depressed with electrical 
burns to foot and wing) 
♦ Not submitted to ARI n=3 (ABLV-59, 64, and 66, all submitted to QHSS).  
As other QHSS submissions during this period could not be included as a result of the 
necessary history, clinical signs, and diagnostic test data being unattainable, to have 
selectively included these 3 QHSS ABLV-cases would have biased this study towards ABLV-
positive bats. 
3.3.2 Spinal and head injuries 
Twenty-nine of the 100 flying foxes in this study had evidence of head or spinal injuries. These 
injuries included: 
♦ 19 spinal fractures detected grossly (CNS-2, 13, 18, 29, 31, 33, 34, 35, 40, 41, 42, 44, 45, 
49, 58, 60, 66, 70, and 79). Seven of these bats had concurrent head injuries including 
fractured frontal and nasal bones (CNS-2), a fractured zygomatic arch (CNS-31, 58, and 60), 
haemorrhage over temporal muscles (CNS-41), fractured skull (CNS-44) and subdural 
haemorrhage (CNS-44 and 79).  
♦  2 spinal fractures not detected grossly were detected radiographically (CNS-9 and 68).  
♦ 1 with evidence of spinal trauma, extensive haemorrhage of dorsal and pelvic musculature, 
no fracture identified at post-mortem but radiographs not done (sample not taken, CNS-12). 
♦ 7 with head or neck injuries that were not associated with spinal injuries including; old skull 
injury with focal bony proliferation impinging on cranial space (CNS-38), subdural 
haemorrhage (CNS-61 and 93), fractured zygomatic arch and subdural haemorrhages (CNS-
81), skull fractures (CNS-91 and 92), and bilateral areas of petechial haemorrhages over 
parietal cortex (CNS-96). 
Note: All 7 of these bats were killed by either the candidate or a referring veterinarian and so 
the head injuries are not the result of attempts at euthanasia. 
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Bats with spinal fractures were often clinically distinguished from other bats in this study by the 
severity of hind limb paralysis and loss of deep pain and claw clasping reflexes with sparing of 
forearm (wing) function, and often had a comparatively bright and alert demeanour. Bats with 
other central nervous system diseases were more often generally weak with reduced but not 
absent hind limb and forearm function. Four bats with spinal fractures (CNS-18, 41, 49, and 68) 
were "panicky” or overtly aggressive and to this extent were similar to some flying foxes with 
ABLV.  
Histological sections of brain from one injured bat, CNS-9, showed evidence of neuro-
angiostrongylosis and 11 third stage Angiostrongylus spp. larvae were recovered from half the 
brain (see below). It is presumed that the infection with Angiostrongylus predisposed this bat to an 
accident resulting in the lumbar fracture and that the clinical presentation reflected both the spinal 
fracture and neuro-angiostrongylosis.  
There was no evidence of angiostrongylosis or other predisposing conditions in histological 
sections of brain from other bats with spinal or head injuries.  
Details of the spinal injuries are provided in Table 3-2 and Appendix 6.  
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Table 3-2 Characterization of spinal fractures in flying foxes (n=21) 
   CNS  
case no. 
Detected 
Fracture site 
Gross X-ray 
CNS-2 Luxation of T9-10  ✔  ✔  
CNS-9 ✘  ✔  Fractured caudal endplate of L3 
✔  Not done  CNS-13 Fractured ~T4-T5 
✔  Not done CNS-18 Thoracic spine (site not specifically recorded) 
✔  Not done CNS-29 Lumbar spine (site not specifically recorded) 
✔  ✔  CNS-31 Luxation of L1-L2 
✔  ✔  CNS-33 Corner fracture of T2 
✔  ✔  CNS-34 Collapsed T9 
✔  Not done  CNS-35 Fractured spine (site not specifically recorded) 
✔  Not done CNS-40 Fractured spine (site not specifically recorded) 
✔  Not done  CNS-41 Fractured spine (site not specifically recorded) 
CNS-42 Fractured thoracic spine ~ level of base of heart ✔  Not done 
✔  Not done CNS-44 “broken neck” (site not specifically recorded) 
CNS-45 Fractured mid-body T3 ✔  ✔  
CNS-49 Fractured T8-9 ✔  Not done   
CNS-58 Fractured L2-3 ✔  ✔  
CNS-60 Fractured thoraco-lumbar junction ✔  Not done  
CNS-66 Fractured thoracic spine ~ level of base of heart ✔  Not done  
CNS-68 Subluxation of L2-3 ✘  ✔  
CNS-70 ✔  ✔  
CNS-79 Fractured T7-8 and l3-4 ✔  ✔  
Fractured vertebral body T9 
 
 
3.3.3 Neuro-angiostrongylosis 
Nematodes were recovered at necropsy from the brain of two flying foxes. Sections of brain from 
these and a further 16 of the 100 wild flying foxes in this study showed histological evidence of 
neuro-angiostrongylosis (synonym neuro-angiostrongyliasis). These bats were found in urban 
Brisbane (n= 7), the Gold Coast (n= 8), Sunshine Coast Hinterland (n= 2), or Ipswich (n=1). 
Details of each case are included in Appendix 6 and those of 16 of these 18 cases have been 
published (Barrett et al. 2002). Corresponding case numbers for each case in the paper and this 
thesis are provided in the keys to Table 3-3 and Appendix 6. 
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3.3.3.1 Gross pathological findings 
Twelve of the 18 bats with neuro-angiostrongylosis were well-nourished, with ample fat reserves. 
The conditions of CNS-53 and 64 were poor, while those of CNS-7, 8, 9 and 11 were not 
recorded. CNS-32 and CNS-97, maintained in care for 22 and 28 days respectively, both had 
considerable amounts of abdominal fat, but wasting of the pectoral muscles and brown 
discoloration of the meninges. CNS-9 had a retroperitoneal haemorrhage at the level of the left 
adrenal gland. While no spinal fracture was detected grossly, the spinal column was removed for 
radiological examination, which revealed displacement of the caudal endplate of the third lumbar 
vertebra. Petechial haemorrhages were found on the cerebral cortices of Bats 73, 74, 76 and 97, 
while the meninges of Bat 73 were congested, and the ventral meninges of Bats 76, 87, and 97 
were cloudy. One nematode was recovered from the dorsal surface of the cerebellum and brain 
stem of CNS-87. Three nematodes were recovered from the midline cut surface of CNS-97, near 
the thalamus. 
3.3.3.2 Histopathology 
Eosinophilic and granulomatous meningoencephalitis, and one or more sections of nematodes, as 
shown in Figure 3-3 and Figure 3-4, were found in brain sections from CNS -7, 8, 24, 32, 53, 64, 
65, 67, 73, 74, 76, 87, 88, and 97 (n=14). The meningitis was typically most severe around the 
brain stem and cerebellum, with macrophages predominating in the infiltrate, often with large 
numbers of lymphocytes and eosinophils, some plasma cells, and occasionally, multinucleated 
giant cells. In all but one of these cases there were perivascular cuffs of macrophages, 
lymphocytes and eosinophils. These perivascular cuffs were particularly prominent in CNS-7, 8, 
53, and 64. Foci and tracts of tissue disruption, gliosis, and/or haemorrhage, presumably the 
result of larval migration, were seen in sections from 11 of these cases and were most severe in 
CNS-24, 32, 73, and 76. Nematode sections were seen most frequently in the subarachnoid 
space of the cerebral sulci and/or cerebellar folds, but some were located within the cerebral 
cortex, thalamus, cerebellum, brain stem and lateral ventricles. Bats 9, 11, 77, and 99 (n=4) were 
distinct in that they displayed virtually no inflammation, and their brain parenchyma appeared 
unremarkable except for the occasional presence of very small nematodes, as shown in Figure 
3-5 (insert). 
Sections of lung from all flying foxes with neuro-angiostrongylosis except CNS-53 (sample not 
taken) were examined histologically and neither nematodes nor their eggs were found. 
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Figure 3-3 Female fifth stage larvae of Angiostrongylus cantonensis from CNS-32 
Maximum diameter 102 µm, within a focus of granulomatous meningitis containing 
macrophages, lymphocytes, eosinophils, and multinucleated giant cells 
 
 
 
Figure 3-4 Angiostrongylus cantonensis (L5) migrating through the thalamus of CNS-73 
Maximum diameter 96 µm. Active migration indicated by the absence of an adjacent 
inflammatory reaction. Severe granulomatous meningitis was seen elsewhere in this section in 
association with other worms. 
Figure 3-5 (insert) Angiostrongylus sp. (L3) in the frontal cortex of CNS-77 
Maximum diameter 29 µm. Early stage infection indicated by immaturity of larva and lack of 
inflammatory response in the meninges and brain. 
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3.3.3.3 Identification of worms 
Worms recovered from CNS-8, 24, 32, 65, 67, 73, 74, 76, 87, 88, and 97 (n=11) were identified as 
fifth-stage (L5) larvae (‘immature adults’) of Angiostrongylus cantonensis, as distinct from  
A. mackerrasae, by the relatively long spicules in the males (0.65 to 1.46 mm) and absence of a 
caudal mucron in the females. A fragment of an adult worm consistent with Angiostrongylus sp. 
was recovered from CNS-64. Multiple third-stage larvae (L3) 420 to 565 µm in length were 
recovered from CNS-9 and CNS-11; their identification as Angiostrongylus L3 was based on the 
overall size and shape, internal morphology and dimensions, the buccal details (including a 
‘double spear’) and tail shape (Bhaibulaya 1975; Mackerras and Sandars 1955). No worms were 
recovered from the brains of CNS-7, 53, or 77. Recovery was not attempted from CNS-99 as the 
facilities used previously were no longer available. The number and lengths of worms recovered 
from each bat are shown in Table 3-3. The duration of infection was estimated by comparing the 
size of nematodes with published growth rates in experimental rats (Mackerras and Sandars 
1955). In retrospect, some of these data are known to be derived from A. mackerrasae, although 
the growth of A. cantonensis in comparable stages is almost identical (Bhaibulaya 1968, 1975). It 
was assumed that growth rates in bats, presumably abnormal hosts, equalled the slowest rate 
found in rats, the natural hosts. 
3.3.3.4 Clinical signs of neuro-angiostrongylosis in flying foxes 
Of these 18 cases, nine were found on the ground, six were found hanging inappropriately low in 
a tree and unable to fly away, and three were rescued from a trellis or fence . The clinical picture 
was dominated by paresis, particularly of the hind limbs, and depression. None were aggressive. 
CNS-9, which had severe hind limb paralysis and incontinence, was shown radiographically to 
have a fractured lumbar vertebra and is presumed to have been predisposed to an accident by 
the Angiostrongylus L3 infection, with the clinical presentation reflecting both the spinal fracture 
and neuro-angiostrongylosis. Whereas seven flying foxes died or were killed within 24 hours of 
being found (see Table 3-3), 11 of the 18 cases survived in the care of voluntary wildlife carers for 
variable periods: 3 days (n=3), 7 to 9 days (n=5) and 16, 22, and 28 days.  
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Table 3-3 Numbers and lengths of Angiostrongylus cantonensis recovered from 18 free-
living flying foxes and estimated duration of infection 
Male worms Female worms CNS 
case 
no.1 No. Length (mm) No. Length (mm) 
Total worms 2 
(per ½ brain) 
Time in care 
(days) 
Estimated duration 
of infection 3 (days) 
CNS-7 0 --- 0 --- 0 7 --- 
CNS-8 1 3.5 0 --- 1 3 15 
CNS-9 ? --- ? --- 11 4 1 2 - 3 
CNS-11 ? --- ? --- 7 4 1 2 - 3 
CNS-24 2 4.2 and 6.0 14 4.5 - 15.4 16 7 20 - 30 
CNS-32 9 4.4 - 7.2 11 3.9 - 9.7 20 22 24 
CNS-53 0 --- 0 --- 0 1 --- 
CNS-64 ? --- ? --- 1 (piece) 1 --- 
CNS-65 7 3.9 - 8.9 7 8.6 - 10.1 14 16 25 
CNS-67 3 3.9 - 4.3 5 4.4 5 8 8 9 
CNS-73 8 2.9 - 5.0 12 3.6 - 4 20 1 20 
CNS-74 12 2.6 - 5.1 19 2.6 - 4.7 31 3 19 
CNS-76 26 4.4 - 9.2 14 6.8 - 11.0 43 7 20 
CNS-77 0 --- 0 --- 0 1 --- 
CNS-87 --- --- 16 8.8 16 9 21 - 24 
CNS-88 2 2.9 and 2.3 1 2.2 3 3 12 - 14 
CNS-97 Not done Not done > 5 7 28 Not done 
CNS-99 Not done Not done Not done 8 1 Not done 
1   Details of 16 of the 18 cases of neuro-angiostrongylosis referred to here have been published (Barrett et 
al. 2002). The corresponding published case numbers are: CNS-7=Bat 1, CNS-8=Bat 2, CNS-9=Bat 3, 
CNS-12=Bat 4, CNS-24=Bat 5, CNS-32=Bat 6, CNS-53=Bat 7, CNS-64=Bat 8, CNS-65=Bat 9,  
CNS-67=Bat 10, CNS-73=Bat 11, CNS-74=Bat 12, CNS-76=Bat 13, CNS-77=Bat 14, CNS-86=Bat 15, 
CNS-87=Bat 16.  
CNS- 97 and CNS-99 were not published. Bat 17 of the publication is an archival case from 1992. 
2   Total number derived from intact specimens plus pieces recovered. 
3   Estimated duration of infection at death calculated from recovered worm lengths and published growth 
rates (Mackerras and Sandars 1955). 
4   Immature third stage larvae 420-565 µm long, sex differentiation not possible. 
5   Only one could be measured. 
6   Single female worm recovered from brain surface, worms not extracted from fixed brain. 
7   The half brain of CNS-77 was macerated and a moderate number (estimate 5-10) of worms were 
recovered however, the facilities used to count, sex, and measure these worms ceased to be available 
and so these worms were not characterized further. 
8   The facilities used to recover, count, sex, and measure worms were not available. 
---  Not applicable 
 
Chapter 3 
 129
3.3.3.5 Temporal clustering of onset of clinical neuro-angiostrongylosis 
During the four years of this study (August 1997 to July 2001) flying foxes with neuro-
angiostrongylosis were found sick only during the months of May, June and on July 2nd and during 
October to December.  
This clustering of cases does not appear to reflect the distribution for flying foxes with other 
causes of CNS disease (see Figure 3-6), nor does it appear to be related to the seasons of spring 
(August, September and October), summer, autumn or winter, nor to periods of high or low rainfall 
in Southeast Queensland (data not shown). 
Figure 3-6 Months in which flying foxes presented with CNS disease 
(August 1997 to July 2001) 
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3.3.3.6 Archival evidence of Angiostrongylus cantonensis in wild flying foxes of 
Queensland 
Veterinary Pathology Archives, The University of Queensland 
Histological sections of brain and lung of an adult male P. alecto that died in April 1992 after 15 
days in care with clinical signs that included being unable to hang, tremors, failing to respond to 
antibiotics and treatment for suspected Pb poisoning, depression and terminal respiratory 
distress, showed eosinophilic and granulomatous meningoencephalitis and worm sections in brain 
and neither nematodes nor their eggs in lung (UQ accession number 92-570). At necropsy this 
bat was in good nutritional condition. The location at which this, presumably wild, flying fox was 
found was not recorded. 
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Australian Animal Health Laboratory / ARI 
“Evidence of a nematode in the brain” was reported by Peter Hooper (veterinary pathologist, 
AAHL) in sections of brain examined at AAHL from a male adult P. alecto submitted to the ARI in 
June 1996 and forwarded to AAHL from the ARI for lyssavirus testing (ARI accession 96-141694, 
reference BR149, AAHL SAN 96-1230). This flying fox had been submitted via a veterinary 
surgery in urban Brisbane with a two word history of “CNS signs”. 
 Other institutions 
Dave Spratt (pers. comm.) had records from 709 wild animal necropsies done while a 
postgraduate and post-doctorate fellow of the Department of Parasitology at the University of 
Queensland between 1967 and 1973. The majority of animals were macropods, with a number of 
rats, bandicoots, koalas and possums etc, including three ship rats (Rattus rattus) from Mount 
Glorious with pulmonary A. cantonensis. This collection included only two flying foxes, a P. alecto 
and a P. scapulatus which were shot while free-flying (clinically normal) in Arhnemland in October 
1972. The brains of these flying foxes were grossly normal and not examined further. 
3.3.3.7 Case control study for Angiostrongylus cantonensis 
There was no evidence of neuro-angiostrongylosis (neither eosinophilic or granulomatous 
inflammation nor sections of worms) in sections of brain from 19 wild-caught, presumably normal, 
flying foxes caught in urban Brisbane.  
The difference in the proportion of sick flying foxes with histological evidence of neuro-
angiostrongylosis (18 /100) and the proportion of clinically normal flying foxes without neuro-
angiostrongylosis (0/19) was tested using a Chi-square test, indicating a significant association 
between the presence of Angiostrongylosis spp. and clinical disease (p= 0.045). 
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3.3.4 Congenital hydrocephalus 
Two orphaned P. alecto pups (CNS-16 and 17), both born in late 1997 and submitted in January 
and February 1998 respectively, were found at gross and histological examination to have 
congenital internal hydrocephalus (ventricular dilation). Both were submitted as a result of their 
failure to thrive and physical and social retardation while in the care of experienced bat carers. 
CNS-16 also had a head tremor and a markedly domed skull. 
3.3.5 Bacterial meningoencephalitis 
Only 2 of 100 wild flying foxes with clinical signs of central nervous system disease had evidence 
of bacterial meningoencephalitis. 
A female P. alecto pup (CNS-57, 6-8 months of age) had extensive abscessation of the neck, with 
a subcutaneous pocket of blood and pus extending over the cranium and neck and a thinly 
encapsulated caseous abscess extending from the caudal pharynx ventrally to the epaxial 
muscles and laterally along the trachea, eroding through the ventral aspect of the atlanto-axial 
joint and extending proximally and caudally into the spinal canal and caudal cranial cavity.  
Swabs of the ventral cerebral surface, cervical lymph node, and subcutaneous pocket grew heavy 
pure growths of Pasturella multicida. 
An adult female P. poliocephalus (CNS-80) that was found on the ground and died overnight had 
moderate meningoencephalitis and subarachnoid haemorrhage with infiltrates of predominantly 
lymphocytes, macrophages and some polymorphonuclear cells and prominent bacterial colonies. 
Bacteriological culture was not done. This bat also had puncture wounds and extensive 
subcutaneous haemorrhage to the neck suggestive of a dog or other animal attack. 
3.3.6 Hepatopathy 
One juvenile female P. poliocephalus (CNS-26) that was found on the ground weak and failed to 
improve during 7 days in care, had multiple 0.1-1.0 cm linear to triangular pale green firm liver 
lesions at necropsy. Histologically the liver lesions consisted of multiple areas of coagulative 
necrosis with peripheral zones of fibrosis, with macrophages, and some lymphocytes suggestive 
of a severe multifocal vascular injury. 
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3.3.7 Chronic injury and myiasis 
A male juvenile P. alecto (CNS-59) was rescued as a pup from the ground with wounds on its 
head, near the right eye, and right shoulder. The pup appeared normal as an infant but once able 
to hang appeared uncoordinated and held its head to the right. Whilst his carer always considered 
there was “something amiss with him physically”, it had a healthy appetite, continued to improve 
and “in due course” was able to fly. As the pup “wasn’t quite right” it was not released in February 
with its peers. Over Easter, another carer noted it would occasionally shake, did not wrap its 
wings tightly as was normal, and hung with its head to one side. As the pup was being prepared 
for release, contact with it was minimized but it appeared bright and was eating well. 
Unexpectedly the pup was found dead on the cage floor in late May with a flyblown wound to the 
back of its head. 
At necropsy the pup was a small bat with ~ 50 large (1-1.5 cm long) maggots and 100’s of very 
small maggots in a large open necrotic wound of the back, with sloughing of the skin extending 
proximally and caudally from the right scapula. There was fibrosis of the subcutaneous tissues 
and musculature of the back of the head and back such that the neck could not be extended 
beyond 90 degrees. The right scapula was displaced and fixed medially and caudally. Firm 
adhesions between some liver lobes suggested a low grade chronic peritonitis. Despite the 
presence of this obviously chronic injury, the bat was not emaciated but had some peri-salivary 
and perirenal fat. 
It is presumed that the head and neck injuries with which the pup was found, possibly bite 
wounds, had not resolved but persisted as a chronic subcutaneous abscess of the back, and that 
subsequent myiasis resulted in its apparently sudden death. 
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3.3.8 Lead poisoning 
3.3.8.1 Liver Pb levels in apparently healthy urban flying foxes 
Levels of Pb in the livers of 25 P. alecto and 25 P. poliocephalus wild-caught in urban Brisbane 
between November 1997 and July 1999 were in the range 0.1 to 19.77 ppm dry weight 
(approximately 0.02 to 4.66 ppm wet weight). Details and results for individual flying foxes are 
shown in Appendix 8. For the purposes of comparison with Pb levels from sick flying foxes, levels 
of liver Pb of up to ~20 ppm dry matter (~ 4.35 ppm wet weight) do not appear to be associated 
with clinical disease. The distribution of Pb levels in each species of flying fox is shown in  
Figure 3-7. Summary statistics are as follows (ppm dry weight). 
    Mean =   6.24 
Median =   5.49 
          Minimum =   0.10 
         Maximum = 19.77 
     Lower quartile =   0.88 
  Upper quartile = 10.57 
 
Figure 3-7 Normal liver lead (Pb) levels in clinically normal flying foxes captured in urban 
Brisbane during November 1997 to July 1999 (n=50) 
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As there appeared to be an unexpected association between species and liver Pb levels, further 
statistical analysis was done as described in Appendix 8. Levels of Pb in duplicate liver samples 
(n=5) submitted to the DNR Natural Resource Sciences Laboratory were consistent with those 
reported by the DPI trace metal Laboratory (see Table A8-1, Appendix 8).  
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3.3.8.2 Liver Pb levels in bats with CNS disease 
Livers from 16 of 100 flying foxes with clinical signs suggesting CNS disease were submitted 
including 12 of 16 for which no alternative aetiology was diagnosed.  
The results were in the range 0.1 to 6.56 ppm dry weight (~0.02 to 1.44 ppm wet weight), well 
below the median value in clinically normal flying foxes, and not suggestive of lead poisoning as a 
diagnosis in these cases. Results for specific cases are shown in Table 3-4.  
Table 3-4 Liver Pb levels of 16 wild flying foxes with clinical signs suggesting central 
nervous system disease 
CNS  
case No. 
Species Sex Age Diagnosis Pb ppm dry 
weight 
Approx. Pb ppm 
wet weight 
CNS-9 Black Male Adult Angiostrongylosis 
and spinal fracture 
0.22 0.048 
CNS-10 Little Red Male Juv No diagnosis 0.85 0.19 
CNS-11 Black Male Adult Angiostrongylosis  1.05 0.23 
CNS-19 Black Male Juv No diagnosis 1.62 0.36 
CNS-22 Black Male Juv No diagnosis 6.56 1.44 
CNS-26 Grey Female Juv Hepatopathy 1.69 0.37 
CNS-27 Grey Male Adult No diagnosis  1.6 0.35 
CNS-30 Black Female Juv No diagnosis 0.21 0.05 
CNS-43 Black Male Adult No diagnosis  0.88 0.19 
CNS-47 Black Male Adult No diagnosis 3.09 0.68 
CNS-54 Black Male Juv No diagnosis 0.1 0.02 
CNS-59 Black Male Juv Chronic injury and 
mydriasis 
1.94 0.43 
CNS-72 Grey Female Juv No diagnosis 4.65 1.02 
CNS-75 Spectacled Male Adult No diagnosis 0.28 0.06 
CNS-78 Spectacled Female Juv No diagnosis 0.82 0.18 
CNS-941 Black Male  Juv No diagnosis 0.86  0.201 
 
1  Sample submitted to DNR Natural Resources Sciences Laboratory, Indooroopilly. All other samples 
submitted to DPI Trace Metal Residue Laboratory, Yeerongpilly. 
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3.3.9 No diagnosis 
No definitive diagnosis was reached for 16 flying foxes submitted with clinical histories suggesting 
CNS disease (CNS-10, 19, 22, 27, 30, 43, 47, 54, 55, 63, 72, 75, 78, 85, 89, and 94). The level of 
investigation of these cases varied depending on the availability of relevant samples. In some 
cases histological lesions of unknown significance were found, and as it was unclear the extent to 
which they contributed to the presenting clinical signs, no diagnosis was made. Tests performed 
and comments are provided in Table 3-5, see also Appendix 6. 
Table 3-5 Diagnostic investigation of 16 flying foxes with clinical histories suggesting 
CNS involvement for which no definitive diagnosis was reached 
Histology 
CNS  
case no. 
ABLV 
FAT Brain  Other
1 Spinal 
X-ray 
Liver 
Pb 
ppm 
dry 
Comments 
CNS-10 Neg. NSA2 LiLgKS ---3 0.85 Bacterial colonies in brain and liver suggest 
peracute septicaemia. 
CNS-19 Neg. NSA LiLgKS --- 1.62 Fatty degeneration of liver. 
CNS-22 Neg. NSA LiLgKS and 
eyes 
--- 6.56 Pachymeningitis adjacent one optic nerve, 
bilateral dacryoadenitis. 
CNS-27 Neg. NSA LiLgKS NVL4 1.6 No significant abnormalities detected. 
CNS-30 Neg.  NSA LiLgKS and 
skin 
--- 0.21 Low protein oedema of skin of dorsal 
head/neck with a mild lymphocytic infiltrate. 
Gross hyperaemia of ventral neck and oedema 
of larynx. Suggestive of increased capillary 
permeability due to neck trauma.  
CNS-43 Neg. NSA LiLgKS NVL 0.88 No significant abnormalities detected. 
CNS-47 Neg. NSA LiLgKS NVL 3.09 No significant abnormalities detected. Found 
trapped ‘swimming’ in backyard pool. Clinical 
signs may simply reflect exhaustion. 
CNS-54 Neg. NSA LiLgKS NVL 0.1 No significant abnormalities detected. 
CNS-55 Neg. NSA Not available --- ND No significant abnormalities detected. 
CNS-63 Neg. NSA Not available --- ND No significant abnormalities detected. 
CNS-72  Neg. NSA LiLgKS NVL 4.65 Vacuolar change in obex (brain). 
CNS-75 Neg.  NSA LiLgKS NVL 0.28 No significant abnormalities detected. 
CNS-78 Neg. NSA LiK NVL 0.82 No significant abnormalities detected. 
CNS-85 Neg. NSA Not available --- ND No significant abnormalities detected. 
CNS-89 Neg. NSA Not available --- ND No significant abnormalities detected. 
CNS-94 Neg. NSA LiLgKS and 
skin 
--- ND 4 megaschizonts (synonym merocysts) of 
Hepatocystis pteropi 5 in endothelial cells of 
kidney. Focal dermatophytosis (‘ringworm’). 
1 Other organs examined: Li = liver, Lg = lung, K =kidney, S = spleen  
2 NSA No significant abnormality detected 
3 --- Not done 
4 NVL No visible lesion 
5  Hepatocystis pteropi, malaria-like erythocyte parasite, common in flying foxes (Mackerras 1957). 
No gametocytes visible in erythrocytes included in tissue sections. Blood unavailable for smear 
examination. Infection probably incidental. 
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3.3.10 Targeted evaluation of the sensitivity of the ARI FAT for 
detection of ABLV 
All 23 FAT-negative frozen brain samples from CNS-flying foxes for which either no diagnosis was 
made (n=16), or diagnosed with spinal and head injuries (n= 5, CNS-2, 38, 66, 68, and 96), 
hydrocephalus (n=1, CNS-16), or bacterial meningitis (n=1, CNS-80) were negative for ABLV 
when tested using the TaqMan assay for pteropid-variant-ABLV and hemi-nested PCR 
amplification for lyssavirus RNA (see Table 3-6). 
This test combination detected pteropid-variant-ABLV, Yellow-bellied sheathtail variant-ABLV and 
Genotype 1 rabies (representing other known lyssaviruses) in the positive controls. 
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Table 3-6 Results of TaqMan and PCR assays for 23 ABLV-FAT-negative flying foxes 
with CNS signs, 1 FAT-negative clinically normal flying fox (negative control),  
3 FAT-ABLV-positive bats, and Nobivac rabies vaccine (positive controls) 
Case 
No. 
DPI accession 
No. 
TaqMan  
pt-ABLV 
(CT)1 
Lyssavirus 
PCR 
Interpretn 
re ABLV 
Diagnosis 
CNS-2 97-177844 Neg (> 40)  No band Negative Spinal fracture 
CNS-10 97-203983 Neg (> 40)  No band Negative No diagnosis 
CNS-16 98-106021 Neg (> 40)  No band Negative Hydrocephalus 
CNS-19 98-120342 Neg (> 40)  No band Negative No diagnosis 
CNS-22 98-128821 Neg (> 40)  No band Negative No diagnosis 
CNS-27 98-140095 Neg (> 40)  No band Negative No diagnosis 
CNS-30 98-44761 Neg (> 40)  No band Negative No diagnosis 
CNS-38 98-163314 Neg (> 40)  No band Negative Chronic skull/brain injury 
CNS-43 98-179890 Neg (> 40)  No band Negative No diagnosis 
CNS-47 98-183841 Neg (> 40)  No band Negative No diagnosis (exhaustion) 
CNS-54 99-117491 Neg (> 40)  No band Negative No diagnosis 
CNS-55 99-126934 Neg (> 40)  No band Negative No diagnosis 
CNS-63 99-192936 Neg (> 40)  No band Negative No diagnosis 
CNS-66 99-193425-1 Neg (> 40)  No band Negative Spinal fracture 
CNS-68 99- 201976 Neg (> 40)  No band Negative Spinal fracture 
CNS-72 00-133981 Neg (> 40)  No band Negative No diagnosis 
CNS-75 00-141945 Neg (> 40)  No band Negative No diagnosis 
CNS-78 00-148284 Neg (> 40)  No band Negative No diagnosis 
CNS-80 00-171936 Neg (> 40)  No band Negative Bacterial meningitis and head trauma 
CNS-85 00-180726 Neg (> 40)  No band Negative No diagnosis 
CNS-89 00-195246 Neg (> 40)  No band Negative No diagnosis 
CNS-94 01-154853 Neg (> 40)  No band Negative No diagnosis 
CNS-96 01-158916 Neg (> 40)  No band Negative Head trauma 
--- 98-141060-6 
 
Neg (> 40)  No band Negative Clinically normal (negative control) 
--- Nobivac rabies 
vaccine2 
Neg (> 40)  Appropriate 
band detected 3 
Negative Genotype 1 rabies virus  
(positive ‘other lyssavirus’ control) 
ABLV-17 97-122735 19.31 
Appropriate 
band detected Positive  Pteropid-variant ABLV  
(positive ABLV control) 
ABLV-31 98-102890 19.71 Appropriate 
band detected  
Positive  Pteropid-variant ABLV  
(positive ABLV control) 
ABLV-41 98-144576 Neg (> 40)  Appropriate 
band detected 4 
Positive  YBST-variant ABLV  
(positive ABLV control) 
1  CT > 40 indicates no target RNA detected 
2  Nobivac® Rabies inactivated rabies vaccin (sic) Lot 79050 (Intervet, Boxmeer, Holland) 
3  Positive rabies-TaqMan assay (two extractions CT = 17.7 and 16.3) consistent with genotype 1 rabies virus 
4  Positive YBST-TaqMan assay (two extractions CT =17.4 and15.9) consistent with YBST-variant ABLV 
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3.4 Discussion 
3.4.1 Central nervous system examination 
Flying foxes are reasonably stoic animals and clear assessment of CNS responses required 
minimal restraint. In cases were the subject was not depressed and retained good wing function 
(e.g. bats with lower motor neuron paralysis of the hind limbs as a result of thoracic or lumbar 
spine fractures) minimal restraint allowed flying foxes to attempt to scratch or climb on to the 
candidate. Given the high likelihood of bats with CNS disease being ABLV-positive, and after a 
few ‘close calls’, this examination was considered too hazardous and was subsequently 
abbreviated or discontinued.  
It is strongly recommended that physical and central nervous system examination not be 
attempted on conscious bats with clinical histories or neurological signs suggesting CNS disease.  
3.4.2 Spinal and head trauma 
The presence and extent of head injuries in 7 of 20 bats with spinal fractures, and the absence of 
these injuries in most other bats found on the ground, suggests that in at least some cases the 
primary impact had been ‘head on’. Indeed, in two cases (CNS-60 and CNS-85) the bats were 
heard or seen to fly into (hit) houses. It appears that otherwise healthy flying foxes occasionally 
‘crash’ at speed while in flight. 
3.4.3 Neuro-angiostrongylosis 
The rat lungworm, Angiostrongylus cantonensis, is a metastrongylid nematode that inhabits the 
right ventricle and pulmonary arteries of various rats, being restricted in Australia to the two exotic 
species, Rattus norvegicus and R. rattus. Since its lifecycle was elucidated in Brisbane almost 50 
years ago (Mackerras and Sandars 1955), infection has been reported in humans, captive wildlife 
and domestic animals (Prociv et al. 2000), almost all presenting with disease of the CNS. 
Originally, cases were reported in coastal Queensland and north-eastern New South Wales, 
although, over the last decade, the parasite has been recognized in Sydney in dogs, rats, zoo 
primates and native mammals (Prociv et al. 2000). 
Rats, and abnormal definitive hosts, acquire the infection by eating third stage larvae in the 
tissues of the intermediate hosts, slugs and snails, which have become infected by eating first-
stage larvae expelled in rat faeces. Molluscivorous paratenic hosts (such as land planarians, 
freshwater crustacea) are sometimes infected, although their importance in Australia is unknown. 
Once in the definitive host, infective larvae undergo an obligatory migration through the CNS, 
where they grow and moult twice to attain the immature adult stage. They then invade the venous 
system to return to the right ventricular outflow, where, in suitable hosts, they copulate and 
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produce eggs. Clinical disease arises from mechanical damage and associated inflammation in 
nervous tissue, blood vessels and the subarachnoid space (Mackerras and Sandars 1955). 
In this study, 18 of 100 flying foxes (18%) with clinical CNS signs had gross or histological 
evidence of neuro-angiostrongylosis involving the brain. Histological evidence of infection was 
found in archival material or reports of a further two Black flying foxes from 1992 and 1996. All the 
flying foxes (n=20) with angiostrongylosis presented in south-east Queensland. Nematodes were 
recovered from the brains of 11 of the 18 recent cases, and morphologically confirmed as  
A. cantonensis. The adult worm fragment and third stage larvae recovered from a further three 
cases, and histological sections of nematodes in the remaining four, had features entirely 
consistent with those of Angiostrongylus spp., presumably A. cantonensis. To date, only  
A. cantonensis, not A. mackerrasae, has been identified as a cause of disease in humans and 
animals.  
The number of recent cases involving Black compared to Grey-headed flying foxes (14 and 4, 
respectively) reflects the relative numbers of these species in the study (61 and 26, respectively). 
While the parasite was not identified in the Little Red (P scapulatus) or Spectacled flying fox  
(P conspicillatus), this may simply reflect their small numbers in the study (11 and 2, respectively). 
Histological evidence of Angiostrongylus sp. has been reported in P. scapulatus from Queensland 
(Reddacliff et al. 1999). The presumptive finding of this parasite in histological sections from 1992 
and 1996 suggests that it has been affecting flying foxes for some time. Disease surveillance of 
flying foxes was virtually non-existent prior to them being linked with Hendra virus (previously 
equine morbillivirus), and the discovery of Australian bat lyssavirus. Given the scanty material 
available from flying foxes before 1996, it is not possible to conclude whether or not the 
apparently high number of cases described here reflects a changing prevalence of 
angiostrongylosis. 
Presumably, flying foxes acquire infection by ingesting intermediate or paratenic hosts, such as 
slugs, snails and planarians, or their slime (although slime has not been confirmed to be a vehicle 
of infection)(Prociv et al. 2000). These hosts could readily be concealed among fruit. While it 
might seem unlikely that flying foxes would eat these invertebrates, faecal analysis has shown 
that flying foxes regularly ingest insects, spiders and mites (Jackson 2000). Slugs and snails do 
climb high into trees, especially in wet weather (P. Prociv unpublished observation), and might 
either prove attractive to a hungry flying fox, or be ingested unintentionally.  
Continuing habitat destruction in south-east Queensland has been linked to a reduction in flying 
fox numbers and fragmentation of their colonies, with the establishment of smaller, more 
numerous colonies in urban areas (Hall and Richards 2000). Habitat destruction, with overgrowth 
of introduced plant species, could force hungry flying foxes to eat unusual foods, such as 
molluscs. When food is scarce, flying foxes will retrieve fallen fruit from the ground, thus 
increasing their risk of ingesting molluscs. However, the good nutritional condition of 13 of the 20 
cases suggests these bats had not had difficulty finding food. The circumstances and climatic 
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conditions under which the flying foxes acquired the parasite are unknown, because infection 
might have occurred considerable distances from where they were found. Black flying foxes in 
urban south-east Queensland typically fly up to 7 km per night to feed (Nikki Markus pers. comm.) 
and also migrate considerable distances (>100 km during 10 weeks) to find native fruit and 
flowering trees (Nelson 1965). Grey-headed flying foxes from northern NSW have been shown to 
fly even greater distances each night (up to 50 km) and seasonally (in excess of 600 km) (Eby 
1991). During the 4 years of the study, cases were clustered in the months of May, June, and 
early July or October, November, and December. It is possible that during these months, 
particular trees that are in flower or fruit attract both flying foxes and molluscs, bringing these 
species together. Four captive Grey-headed flying foxes with angiostrongylosis from Sydney also 
presented during May and June (Reddacliff et al. 1999), but this coincidence should be 
interpreted cautiously as the factors leading to infection of captive flying foxes in temperate 
Sydney might differ from those for free-living flying foxes in subtropical Queensland. 
Worm growth rates in flying foxes might differ from those in their normal definitive hosts. 
Nevertheless, assuming growth rates equal to the slowest found in rats, the estimated duration of 
infection in some of the cases allows for interesting conclusions. Four flying foxes (CNS-9, 11, 77 
and 99) had only very small nematodes in histological sections of brain and virtually no 
encephalitis, suggesting early infection. Immature L3 only were recovered from Bats 9 and 11, 
and all four flying foxes were killed within 24 hours of being found. It appears these four flying 
foxes presented with acute, severe disease just 1 to 3 days after infection. CNS-32 also appears 
to have been found only 1 to 2 days after infection, but survived in care for as long as 22 days. 
The remainder from which worms were recovered and measured (n=9) appear to have been 
found, unable to fly, 9 to 23 days after infection, and died or were killed 16 to 30 days after 
infection. CNS-73, the captive-born juvenile, appears to have been infected shortly after release. 
CNS-76 had a particularly intense exposure, with 43 worms recovered from half the brain, yet this 
bat appears to have been infected for 19 days before being found, and survived a further 7 days 
in care before being killed. There seems to be no correlation between the number of worms 
recovered (per half-brain) and either the estimated interval after infection when found, or the 
duration of infection before death. These estimates suggest that most bats become affected and 
cannot fly 1 to 3 weeks after infection. This parallels human infections: in one well-documented 
outbreak in a group of men, several developed neurological symptoms as early as 1 to 2 days 
after exposure, whereas most were hospitalized within 1 to 2 weeks of the onset of symptoms 
(Kliks et al. 1982).  
Ideally, finding worms in the right ventricular outflow would require fresh tissue for careful 
dissection of the heart and pulmonary arterial tree, but all heart and lung samples had been fixed. 
Branches of the major pulmonary arteries were considered most likely to harbour adult worms, yet 
none were found in transverse sections of the pulmonary hilar region, suggesting that  
A. cantonensis had not migrated beyond the CNS. The lungs of infected aberrant hosts are rarely 
examined specifically for the presence of adult worms, but when this parasite has been found in 
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human lungs, it has been in cases with heavy and prolonged infections (Cooke-Yarborough et al. 
1999; Prociv 1999). The ability of Angiostrongylus to reach the lungs and develop further probably 
varies with the host species. 
The circumstances in which flying foxes with neuro-angiostrongylosis are found and initial clinical 
signs closely resemble those of flying foxes with the ‘paretic’ form of Australian bat lyssavirus 
infection (see Chapter 2). However, whereas most bats with ABLV rapidly deteriorate within 24 to 
48 hours of being rescued and die or are killed in extremis, most flying foxes with neuro-
angiostrongylosis have a comparatively prolonged (> 3 days) and stable clinical course, and are 
more often killed as a result of failure to improve and the carer’s assessment that the bat is 
unsuitable for release rather than in extremis. Also, some flying foxes with neuro-
angiostrongylosis had periods of temporary improvement in CNS functions (for example 
appearing stronger or regaining the ability to hang, CNS-32 and CNS-97) which was never the 
case with bats with ABLV (n=74).  
3.4.4 Hydrocephalus 
Two P. alecto pups born in late 1997 were found to have gross congenital internal hydrocephalus. 
In 1990 a similar cluster of pups was investigated by Les Hall and Roger Kelly (pers. comm. and 
review of records) of the School of Veterinary Science at the University of Queensland as 
described below. 
During October and November 1990, carers in Orphan Native Animal Rear and Release 
Association Inc. (ONARR) reported that 6 of 21 orphaned P. alecto pups were found with or 
developed domed heads and showed retardation while hand-reared. Similarly orphaned P. 
poliocephalus pups did not appear affected. Four live affected pups were submitted to the 
Department of Veterinary Pathology; all had “increased cranial volumes due principally to 
expansion of lateral ventricles and compression of cerebral cortex… with some porencephaly 
and/or hydranencephaly of the cerebellum in 3 pups”. Two pups had “irregular asymmetrical 
defects on one side of the cranium, with some brownish pigmentation”, which suggested the pups 
had been bitten on the head. 
There are nutritional and infectious causes of hydrocephalus in other species (DeLahunta 1983) 
and it is likely that nutritional or infectious factors intermittently cause outbreaks of hydrocephalus 
in P. alecto pups. As only two pups during one season (1997-98) of this study were diagnosed 
with hydrocephalus and considering the large number of pups examined during the lyssavirus 
surveillance project in Queensland and the close and supportive relationship between members of 
ONARR, other carer groups, and the research team at ARI, it appears that this event is 
uncommon.  
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3.4.5 Lead poisoning 
Evidence of high tissue lead levels have been reported in Black and Grey-headed flying foxes in 
Queensland (Hariono et al. 1993; Skerratt et al. 1998; Sutton and Wilson 1983; Sutton and 
Hariono 1987). The source of the lead for three captive Grey-headed flying foxes in Washington 
D.C, USA that died with extremely high liver lead levels (> 500 ppm wet tissue), appears to have 
been peeling lead-based paint in the enclosure (Zook et al. 1970). The source of lead for wild bats 
in Australia remains unknown but is presumed to be either lead arsenate in insecticides applied to 
fruit or atmospheric lead pollution, principally from petrol vehicle emissions. Arsenic was absent 
from the liver of one wild bat (Sutton and Wilson 1983), and subsequent research showed that 
wild urban bats rather than non-urban bats accumulate high levels of lead on their fur that could 
be ingested when grooming (Hariono et al. 1993; Sutton and Hariono 1987). This suggests air 
pollution is the main source of lead. Lead on the fur may have been the result of primary 
contamination from the air or secondary to contact while foraging with lead settled on foliage 
(Halliwell et al. 2000; Sutton and Hariono 1987). 
In most other species healthy individuals have lead concentrations of < 5 ppm wet tissue 
(Seawright 1982),(corresponds to < 22 ppm dry flying fox liver). The background level of lead 
exposure in apparently healthy populations of flying foxes had not previously been surveyed. Liver 
lead levels from 25 Black and 25 Grey-headed flying foxes (n=50 total) captured in apparent good 
health from two camp sites in urban Brisbane between November 1997 and July 1999 were low 
(0.1 to 19.77 ppm dry weight, approximately 0.02 to 4.66 ppm wet weight) and consistent with 
levels in healthy individuals of other species.  
The thresholds above which blood or tissue levels of lead in flying foxes are associated with 
clinical toxicity are unknown. Data from domestic species indicates that liver levels > 10 ppm wet 
tissue (extrapolates to 44 ppm dry flying fox liver) are of diagnostic significance (Seawright 1982). 
The finding of exceptionally high concentrations of Pb (> 500 ppm wet liver) in two captive bats 
(Zook et al. 1970) and two bats dosed with lead over a 13 and 9 week period (540 and 556 ppm 
liver) (Hariono 1991) suggests flying foxes are resistant to clinical plumbism. The clinical 
significance of moderate to high tissue lead levels in bats may be over-estimated by extrapolation 
from toxic lead levels of other species. 
In the case reported by Skerratt et al. (1998) and Speare et al. (1997), a wild female Black flying 
fox appeared in a backyard with signs of overt aggression that included chasing and biting other 
bats, including her own pup which sustained fatal skull fractures. A well supported diagnosis of 
lead poisoning was made on the basis of eosinophilic inclusions in renal tubular epithelium shown 
to contain lead, and lead tissue concentrations that were very high in kidney (370 ppm) and 
moderately high in liver (16 ppm). Some 2 years later, a diagnosis of ABLV infection was made 
from stored tissues. The clinical signs shown by this bat, overt aggression then rapid deterioration 
and death, are similar to those described for other ABLV bats. It appears that the clinical condition 
Chapter 3 
 143
of this bat was primarily a consequence of ABLV infection and that the accumulation of tissue lead 
was concurrent and incidental.  
It is unclear to what extent other reports may also have attributed undue clinical significance to 
high tissue lead levels in unwell the bats. Of the two cases reported in Sutton and Wilson (1983), 
Bat B was found in circumstances very like those of ABLV-positive bats (crawling in a yard with no 
obvious injuries, unable to fly, alert, and dying later the same day). It is unclear whether samples 
from this bat were included in a group of archival bat samples sent to the AAHL for ABLV testing, 
all of which were negative. A subsequent survey of lead concentrations in unwell or dead bats 
found tissue lead levels suggestive of toxicity (> 10 ppm wet liver, > 25 ppm wet kidney) in 11 of 
37 urban bats (Hariono et al. 1993)  
The study presented here found no evidence of liver lead levels suggestive of toxicosis in either 
wild caught, apparently normal Black or Grey-headed flying foxes (n=50) or clinically ill bats with 
evidence of ABLV-like CNS disease (n=16). The apparent absence of elevated liver lead in unwell 
urban bats in this study, contrasts with earlier findings (n=10 of 37, (Hariono et al. 1993)) and may 
be the result of reductions in atmospheric lead pollution. Lead free petrol was first used Australia 
in 1975, and in 1987 legislation required all new cars to use lead-free (unleaded) petrol. 
Decreasing numbers of cars manufactured prior to 1988 continued to use leaded petrol (super) 
until 2002, when it was replaced by lead replacement petrol (lead free super). 
3.4.6 Targeted evaluation of the sensitivity of the ARI FAT to 
detect ABLV 
Epidemiological evidence presented here identified bats with clinical signs suggesting CNS 
disease as having a significantly higher prevalence of ABLV than unwell bats without CNS clinical 
signs, and showed that the prevalence of ABLV among bats with CNS signs was high; ~20% (see 
Chapter 2). By examining 100 flying foxes with CNS signs, this study targeted 21 of 825 FAT-
negative wild flying fox samples considered most likely to have given a false-negative FAT result 
on the basis of  
♦ the bats presenting with CNS signs for which there was no well supported alternate diagnosis 
(n=16) or  
♦ the bats having spinal or head injuries that they could have been predisposed to by lyssavirus 
meningoencephalomyelitis (n=5). 
 
The study used the potentially more sensitive TaqMan® and PCR assays to test for the presence 
of lyssavirus RNA, an indicator of lyssavirus infection independent of the detection of lyssavirus 
antigen by the FAT. This independent and targeted approach failed to find evidence of false 
negative FAT results, and did detect pt-ABLV, ybst-ABLV, and non-ABLV lyssavirus (rabies virus) 
in appropriate controls.  
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3.5 Conclusions 
Causes of clinical neurological syndromes in flying foxes 
♦ ABLV is only one of a number of conditions that cause clinical neurological syndromes in 
flying foxes. 
♦ ABLV is the most common cause of paresis, paralysis, or overt aggression in flying foxes 
(32%). 
♦ ABLV, spinal and head injuries (29%), and neuro-angiostrongylosis (18%) combine to 
account for most (79%) neurological syndromes in flying foxes. 
♦ There was no evidence of elevated liver lead levels that would suggest lead toxicity in 50 
apparently healthy urban flying foxes or 16 unwell flying foxes, sugggsting lead poisoning is 
no longer a cause of CNS disease in bats. 
♦ Severe hind-limb paralysis in a bat with good wing function and bright or aggressive 
demeanour strongly suggests a diagnosis of spinal fracture. 
♦ A bat with a comparatively long (> 7 days) and stable history of ABLV-like paresis is highly 
likely to have neuro-angiostrongylosis. 
♦ On initial presentation, bats with the paretic form of ABLV, neuro-angiostrongylosis and head 
trauma are clinically indistinguishable. Given the difficulty of distinguishing these neurological 
syndromes, the risks associated with caring for bats infected with Australian bat lyssavirus, 
and the poor prognosis of all three conditions, wildlife carers should be urged not to care for 
flying foxes with neurological disease, but to submit them for lyssavirus testing. 
Targeted evaluation of the sensitivity of the fluorescent antibody test for ABLV 
detection 
♦ Targeted evaluation of the sensitivity of the ARI-FAT indicates the FAT is highly sensitive, 
with no evidence that the test has failed to detect ABLV in high-risk category flying foxes. 
 
Chapter 3 
 145
4 Molecular diversity of Australian bat 
lyssavirus 
Aims 
1. To examine the molecular diversity of ABLV isolated from pteropid and insectivorous bats. 
2. To determine if there is host species, geographic or temporal variation among ABLV isolates. 
3. To re-examine the phylogenetic evidence for ABLV as a seventh lyssavirus genotype within 
the Lyssavirus genus. 
4.1 Introduction 
At the time this study was done (2001), the sequences of only two ABLV isolates were available, 
one from a Black flying fox that died in Ballina NSW in 1996 ( (Fraser et al. 1996; Gould et al. 
1998), GenBank AF006497, referred to here as ABLBallina), and one from a 1996 YBST bat 
(AF081020, referred to here as AAHLYBST, (Gould et al. 2002)). At that point all published 
sequence and phylogenetic analyses of ABLV, and the proposal of ABLV as a separate genotype 
within the Lyssavirus genus, Genotype 7, related to the single ABLBallina sequence (Badrane et 
al. 2001; Gould et al. 1998 ). There was reference to 16 ABLV N gene sequences being highly 
conserved (Hooper et al. 1997b; McColl et al. 2000), and the phlyographic depiction of the ABLV 
genotype was illustrated with two terminal branches (McColl et al. 2000), however the sequence 
details were not published.  
Unpublished communications between the principal ABLV research groups, notably the AAHL, 
QHSS and ARI, strongly suggested that two major variants of ABLV were present, one in flying 
foxes and the other in YBST bats. However, the extent of sequence diversity among and between 
ABLV isolates from flying foxes and YBST bats remained unclear. There existed the possibility 
that there were multiple species-specific, regional, and temporal ‘sub-variants’ of ABLV. There 
was also the possibility that other ABLV sequences would be more closely related to rabies virus 
isolates and that the genetic distinction between ABLV isolates and rabies isolates would be 
obscured. 
The sequence of the N protein was selected for analysis as the N protein has important structural 
and immunological functions, is involved in the regulation of transcription and replication, and has 
been proposed as a determinant of host range (Kissi et al. 1995). The entire coding sequence 
was used for phylogenetic analysis, as similar analyses performed on shorter sections of the N 
sequence or the intergenic N-P region have shown a parallel evolutionary pattern but were less 
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robust (Kissi et al. 1995). In addition the availability of corresponding sequences from other 
lyssaviruses through GenBank permitted the relationships between the new and available ABLV 
sequences and those of the other lyssaviruses to be evaluated. Sequencing and analysis of the G 
gene from the same material was being done simultaneously by other members of the research 
group (Guyatt et al. 2003). 
4.2 Materials and Methods 
4.2.1 Selection of samples 
At the time of sample selection, material was available from 52 ABLV-positive cases submitted to 
the ARI and stored as frozen tissue (brain and/or salivary glands), as well as inocula prepared 
from these tissues (see Chapters 2 and 5). Some samples submitted in Queensland, particularly 
those submitted within the first year of the recognition of ABLV, were not available as they had be 
forwarded in toto to the AAHL, including samples from two Yellow-bellied sheathtail bats, the only 
Spectacled flying fox sample, and the only sample from a bat submitted from West Queensland 
(Mount Isa). Limited funds precluded examination of material from every available case. Samples 
were selected to reflect the range of bat species, geographic locations and years from which they 
were submitted. The range of available ABLV-positive samples included material from cases with 
the following characteristics. 
♦ Insectivorous bats (n=3, all Yellow-bellied sheathtail bats) or flying fox (n=49) hosts 
♦ Flying foxes found in Southeast Queensland (n=40), Central Queensland (n=4, two from 
Rockhampton and two from Gladstone), or Northeast Queensland (n=5, all from Townsville) 
♦ Black flying foxes (n=23 ), Grey-headed flying foxes (n= 7), or Little Red flying foxes (n=19) 
♦ Samples from 1997 (n=20), 1998 (n=23), 1999 (n=4), or 2000 (n=5). 
As the numbers of available samples from insectivorous bats, and from flying foxes from Central 
and Northeast Queensland were small, all these samples were selected. Inocula 1 to 10, which 
were used in Experiment 1 of Chapter 5 (Detection of live ABLV by intracerebral inoculation of 
suckling mice), were also selected. These inocula had produced clinical disease in suckling mice 
and had been prepared from the tissues of different naturally-infected bats. Other samples were 
selected in order to have minimum group sizes of 5 and to include cases from each year 1997-
2000 for at least one species. Thirty-one samples were selected: samples from three Yellow-
bellied sheathtail bats, 15 Black flying foxes, five Grey-headed flying foxes and eight Little Red 
flying foxes as described in Table 4-1 and Table 4-2. 
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Table 4-1 Selection of samples for molecular analysis 
Six groups permitting comparison of species and geographical diversity. 
Groups of samples Group 
Abbr. 
No. selected/ 
No. avail. 
Comments 
Yellow-bellied sheathtail bats 
(All from Southeast Queensland) 
YBST 3/3 --- 
Central Queensland flying foxes 
(All from Rockhampton or Gladstone) 
Cen 4/4 3 Black flying foxes (Cen-B) 
1 Little Red flying fox (Cen-R) 
North-eastern Queensland flying foxes 
(All from Townsville) 
Tvl 5/5 2 Black flying foxes (Tvl-B) 
3 Little Red flying foxes (Tvl-R) 
Southeast Queensland – Black  
flying foxes 
SEQ-B 9/18 --- 
Southeast Queensland – Grey-headed 
flying foxes 
SEQ-G 5/7 --- 
Southeast Queensland – Little Red 
flying foxes 
SEQ-R 5/15 --- 
 
Genotype 1 rabies virus RNA within the Nobivac Rabies inactivated rabies vaccin (sic) Lot 
79050B (Intervet, Boxmeer, Holland) containing an inactivated culture of rabies virus cloned out of 
strain Pasteur RIVM was also sequenced for comparison with other known rabies virus 
sequences. As the sequence of the Nobivac Pasteur RIVM was expected to very closely 
resemble that of other fixed rabies virus strains (e.g. Pasteur virus, SAD-B19 and CVS), and to be 
clearly distinguishable from the ABLV sequences, it acted as a lyssavirus control sequence during 
amplification and sequencing. 
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Table 4-2 Details of individual samples used for nucleotide sequencing 
Sequence  
name 1 
GenBank 
Accession 
ABLV case 
No. 
ARI 
Accession 
number 
Host Species 
Month & 
year host 
died 
Location host 
found Sample type 
ABL19SEQ-R AY573951 ABLV-11 97-116174 P. scapulatus Feb 97 Woodend Brain 
ABL11YBST2 AY573965 ABLV-12 97-116375 S. flaviventris Feb 97 Kurwongbah Brain 
ABL21SEQ-R2 AY573946 ABLV-14 97-121016 P. scapulatus March 97 Brisbane Brain 
ABL05SEQ-B2 AY573964 ABLV-18 97-125092 P. alecto March 97 Gold Coast Inoculum 2 (brain) 
ABL12YBST2 AY573937 ABLV-22 97-143816 S. flaviventris May 97 Nambour Brain 
ABL22SEQ-B AY573940 ABLV-23 97-152661 P. alecto June 97 Brisbane Brain 
ABL23SEQ-B AY573942 ABLV-24 97-155574 P. alecto June 97 Woodend Inoculum 10 (brain) 
ABL07SEQ-G2 AY573958 ABLV-26 97-176292 P. poliocephalus Aug 97 Brisbane Inoculum 3 (brain) 
ABL02SEQ-G  AY573948 ABLV-27 97-186955 P. poliocephalus Oct 97 Beaudesert Inoculum 1 (brain) 
ABL08SEQ-G AY573941 ABLV-28 97-192894 P. poliocephalus Oct 97 Gold Coast Inoculum 6 (brain) 
ABL24SEQ-R2 AY573955 ABLV-31 98-102890 P. scapulatus Jan 98 Woodend Brain 
ABL13SEQ-G AY573950 ABLV-33 98-105331 P. poliocephalus Jan 98 Brisbane Inoculum 9 (brain) 
ABL29Tvl-R AY573944 ABLV-34 98-40635 P. scapulatus Feb 98 Townsville Brain 
ABL25SEQ-R AY573956 ABLV-36 98-126853 P. scapulatus April 98 Brisbane Brain 
ABL26SEQ-B AY573963 ABLV-38 98-137634 P. alecto May 98 Gold Coast Brain 
ABL14Cen-B AY573943 ABLV-39 98-140331 P. alecto May 98 Rockhampton Brain 
ABL15YBST AY573949 ABLV-41 98-144576 S. flaviventris June 98 Point Arkwright Brain 
ABL17Tvl-B AY573939 ABLV-42 98-189710 P. alecto July 98 Townsville Brain 
ABL09SEQ-G AY573945 ABLV-45 98-167351 P. poliocephalus Aug 98 Gold Coast Inoculum 4 (brain) 
ABL06SEQ-B AY573959 ABLV-46 98-172971 P. alecto Sept 98 Brisbane Inoculum 7  
(salivary glands)  
ABL30Tvl-R AY573953 ABLV-47 98-50290 P. scapulatus Aug 98 Townsville Brain 
ABL31SEQ-R AY573952 ABLV-48 98-182934 P. scapulatus Oct 98 Rockhampton Brain 
ABL16Cen-R AY573960 ABLV-49 98-183454 P. scapulatus Oct 98 Rockhampton Brain 
ABL01SEQ-B AY573935 ABLV-51 98-188455 P. alecto Nov 98 Maryborough Inoculum 5  
(salivary glands) 
ABL03Tvl-R AY573957 ABLV-52 98-189702 P. scapulatus Nov 98 Townsville Inoculum 8  
(salivary glands) 
ABL32Tvl-B AY573947 ABLV-53 98-189756 P. alecto Nov 98 Townsville Brain 
ABL33SEQ-B AY573954 ABLV-54 99-128813 P. alecto April 99 Brisbane Brain 
ABL34Cen-B AY573961 ABLV-55 99-178735 P. alecto Aug 99 Gladstone Brain 
ABL35SEQ-B AY573938 ABLV-58 99-204785 P. alecto Nov 99 Hervey Bay Brain 
ABL36SEQ-B AY573936 ABLV-60 00-132366 P. alecto May 2000 Brisbane Brain 
ABL37Cen-B AY573962 ABLV-63 00-176632 P. alecto Sept 2000 Gladstone Brain 
1 The sequence name contains a number that relates to the essentially random order in which samples were 
processed for RNA extraction. This number does not imply chronological order or any other characteristic 
of the sample or sequence. The name also includes a group abbreviation, as described in Table 4-1, 
indicating the species and regional location of the sample host. Chronology is implied by the corresponding 
ABLV Case No., which was allocated according to the order in which the host died.  
2 Brain from these six cases was forwarded to AAHL for diagnostic confirmation where it was later used for 
virus isolation and partial N sequences were determined (bases 443-892 of the ABLBallina sequence, 
corresponding to bases 513 to 962 of Appendix 10) (Gould et al. 2002). Corresponding sequence names 
and AAHL accession no. are: ABL11YBST = 97-034-6375, ABL21SEQ-R = 97-0388-016,  
ABL05SEQ-B = 97-414-1 and 97-414-2, ABL12YBST = 97-0747, ABL07SEQ-G = 97-1153, ABL24SEQ-R = 98-0126. 
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Figure 4-1 Locations at which selected ABLV isolates (bats) were found 
Flying fox locations are shown in blue. YBST bat locations are shown in orange.  
Also shown (green) are the location of other available ABLV sequences (ABLHumanPt, 
ABLBallina and AAHLYBST) 
Gladstone  • 
Rockhampton  •
Townsville  • 
•    Maryborough   
Hervey Bay  • 
 •  Gold Coast Beaudesert • Woodend • 
•    
  BRISBANE • 
S O U T H E A S T  
 
 
  Kurwongbah 
Nambour • •  Point Arkwright 
 (AAHLYBST)  Murphy’s Creek  • 
•   Mackay (ABLHumanPt) 
•  Ballina  
(ABLBallina, NSW) 
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4.2.2 Primers 
All primers were designed and evaluated with the following programs prior to oligonucleotide 
synthesis. 
♦ Sequencher™ Version 3.1.1 (Gene Codes Corporation, MI, USA) 
Used to align sequences from which primers were to be designed and to identify conserved 
regions as potential primer binding sites. 
♦ Oligo® Version 4.03 (Natural Biosciences, Inc, Plymouth, USA) 
Used to identify primer dimers, hairpins and calculate the melting temperature. 
♦ Amplify version 1.2 (University of Wisconsin, Madison, Wisconsin, USA) 
Used to identify primer dimers and non-specific binding to target cDNA sequences. 
Primers were synthesized commercially by Sigma Genosys (Sigma-Aldrich, Castle Hill, Australia) 
and were purchased deprotected, desalted and dry. Stock solutions of 1 µg/µL were prepared by 
resuspension of the oligonucleotides in nuclease free-water and stored at –20°C. 
Details of the primers used in this study are shown in Table 4-3 and Table 4-4. 
Primers N5’REVERSE, N3’FORWARD and PREVERSE were designed from comparisons of the 
two ABLV sequences available on GenBank at that time, namely the Ballina isolate, GenBank 
accession AF006497 (pteropid-ABLV) (Gould et al. 1998) and an insectivorous isolate, GenBank 
accession AF081020 (ybst-ABLV)(Gould et al. 2002). Both these sequences begin with the N 
gene start codon (ATG) that was inferred from the last three bases of the primer used for cDNA 
sequencing and PCR amplification.  
In the absence of any ABLV-specific 5’ N leader sequence, Kimberley Guyatt (QABC) designed 
the Lys-Leader primer from comparisons of available lyssavirus sequences for this region, namely 
Mokola virus (GenBank S59448), Pasteur rabies virus (X03673), SAD B19 rabies virus (M31046), 
and RCHLVac rabies virus (AB009663), to correspond to the first 22 nucleotides of the 
Mokola/rabies genome. Initial attempts by K Guyatt to use the Lys-Leader primer for both cDNA 
synthesis and as the forward primer for subsequent PCR amplification produced poor results. 
However, downstream sections of the Lys-Leader cDNA were amplified using other primers. 
During the study, the 70 nucleotides of the 5’ N leader sequence of ABLV isolated from the 
second human case of ABLV (pteropid-ABLV) that had been cloned and sequenced at QHSS 
were kindly made available by David Warrilow prior to publication (Warrilow et al. 2002), and used 
to design the primer ABLUTR22. Like the Lys-Leader primer, ABLUTR22 corresponds to the first 
22 nucleotides of this untranslated region, but ‘corrects’ five base mismatches between the 
Mokola and rabies virus derived Lys-Leader sequence, and the pteropid-ABLV sequence 
provided by QHSS.  
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 Table 4-3 Forward Primers 
Primer name Length (mer) Tm °C Position 
a Nucleotide sequence                 5’-3’, + genomic sense Designed by cDNA PCR Seq. 
ABLUTR22 22 64.1  1-22 ACG CTT AAC GAC AAA ACC AGA G Candidate ✔  ✔  ✔  
Lys-Leader 22 61.9  1-22 ACG CTT AAC AAC CAG ATC AAA G K Guyatt ✔  ✔  ✔  
N3’FORWARD 21 53.7 634-654 GAC TAC TCA TAA GAT GTG TGC K Guyatt ✘  ✔  ✔  
YBSTN3’FORW 22 68.4 643-664 CAA AAT GTG TGC GAA TTG GAG C Candidate ✘  ✔  ✔  
N5’SEQ1F 19 52.0 491-509 GTA GGT CTT CTT CTA AGC C K Guyatt & Candidate ✘  ✘  ✔  
N3’SEQ2F 21 61.5 1169-1189 CAA GAT TAT GAG GCA GCA GAG Candidate ✘  ✘  ✔  
NobiVSEQ2F  20 67.2 1093-1112 AGG GGG CTA TTT GGG AGA GG Candidate ✘  ✘  ✔  
 
Table 4-4 Reverse Primers 
Primer Length (mer) Tm °C Position
a Nucleotide sequence                     5’-3’, - genomic sense Designed by PCR Seq. 
N5’REVERSE 22 58.2 932-911 GGA TGA AAT TTG TGT GAG GAA C K Guyatt ✔  ✔  
PREVERSE 
 
 
24 72.7 1584-1561b GTC TCC TCT GCC ATT TCC AGG TCG K Guyatt ✔  ✔  
NobiVPRev 23 64.4 1590-1568b TCA ACA GTT  TCT TCA GCC ATC TC Candidate ✔  ✔  
NobiVSEQ1R 25 67.5 506-482- TCA GGA GAA GACC GAC TAA AGA TGC Candidate ✘  ✔  
N5’SEQ1R 20 54.4 513-494- TAA AGG CTT AGA AGA AGA CC K Guyatt & Candidate ✘  ✔  
N3’SEQ2R 20 52.9 1166-1147- GTT CTT TCT CAT CTC TGA AG Candidate ✘  ✔  
 
a      Numbering corresponds to nucleotide positions within the Pasteur virus + sense genome (GenBank X03673). 
b   The positions of reverse primers PREVERSE and NobiVPREV in Appendix 10 are 1589-1566 and 1595-1573 respectively, due to the renumbering of base 
positions caused by the insertion of 5 additional bases between the N stop codon and intergenic region (CT) of the ABL14CEN-B + sense genome. 
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The YBSTN3’FORWARD, N5’SEQ1F, N5’SEQ1R, N3’SEQ2F, and N3’SEQ2R primers were 
designed from comparisons of the ABLV sequences available on GenBank (AF006497 and 
AF081020) and the preliminary sequence results of this study. As a number of the primers 
designed for amplification and sequencing of ABLV did not work with the Nobivac rabies cDNA, 
some had to be ‘replaced’. The NobiVPRev primer was designed from comparisons of similar 
rabies virus sequences available on GenBank (Pasteur virus, SAD B19, and RC-HL) and 
corresponds closely to the binding site for ABLV primer PREVERSE. Primers NobiVSEQ1R, and 
NobiVSEQ2F were designed from preliminary sequence results of Nobivac vaccine rabies RNA 
and bind to sites close to the binding sites for ABLV primers N5’SEQ1R and N3’SEQF 
respectively. 
4.2.3 RNA extraction and cDNA synthesis 
Extractions from ABLV-positive material were done by K Guyatt in the PC3 facilities of the QHSS 
laboratory. Total RNA was extracted from either naturally infected brain tissues or 20% weight per 
volume suspensions of naturally infected brain or salivary gland tissue in Dulbecco’s Modified 
Eagles Medium that had been prepared for inoculation trials (see Chapter 5). Matchstick-head 
sized tissue samples or 100 µL of inoculum were prepared using the QIAshredder™ 
Homogenizer (QIAGEN) and total RNA extracted from 100 µL of the lysate using the RNeasy Mini 
RNA extraction kit (QIAGEN) in accordance with the manufacturer’s instructions. 
Total RNA was extracted by the candidate from 100µL of the Nobivac Rabies inactivated rabies 
vaccin (sic) Lot 79050B (Intervet, Boxmeer, Holland) using the RNeasy Mini RNA extraction kit at 
the molecular laboratory of the Queensland Agricultural Biotechnology Centre (QABC). 
Initial ABLV cDNA synthesis using the Lys-Leader primer was done by K Guyatt at QHSS. 
Subsequent synthesis of ABLV cDNA using the Lys-Leader and ABLUTR22 primers and of 
Nobivac rabies cDNA using the Lys-Leader primer was done by the candidate at QABC.  
Four (4) µL of extracted RNA and 10 pmol of primer were heated to 95°C for 3 minutes, and then 
chilled on ice. The reverse transcription reaction mixture was made up to 10 µL containing the 
RNA/primer mix, 2.0 µL of 5× First Strand Buffer (GibcoBRL® Life Technologies), 0.5 mM of each 
dNTP, 0.01 mM dithiotreitol (DTT), 0.5 µL (10-20 units) Recombinant RNasin® (Promega, 
Madison, Wisconsin, USA), and 100 units of SUPERSCRIPT™ II Reverse Transcriptase 
(GibcoBRL® Life Technologies). cDNA synthesis was performed using a Gene Amp® System 
2400 PCR thermal cycler (Perkin Elmer) at 42°C for 60 minutes followed by inactivation of the 
SUPERSCRIPT™ Reverse Transcriptase at 95°C for 3 minutes, and the product chilled on ice 
and stored at -20°C. 
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4.2.4 PCR amplification, purification and extraction 
PCR amplification of cDNA primed by either the Lys-Leader or ABLUTR22 primer was performed 
in a volume of 50µL containing 2µL of cDNA, 200 pmol of each forward and reverse primer, 200 
µmol of each dNTP, 2.5 units of Taq DNA polymerase (Roche, Mannheim, Germany) and 5.0 µL 
of 10× Mg+ Buffer (Roche, Mannheim, Germany). The N gene sequences were amplified as two 
overlapping PCR products, N5’HALF and N3’HALF in a Gene Amp® System 2400 PCR thermal 
cycler (Perkin Elmer) programmed for 94°C for 5 minutes, three cycles of 94°C for 30 seconds, 
annealing 50°C for 45 seconds, and extension 72°C for 90 seconds, followed by 30 cycles where 
the annealing temperature was increased to 55°C. The program ended with an elongation period 
of 10 minutes at 72°C, then held the reaction mix at 4°C. 
For reactions using the YBSTN3’FORW (Tm= 68.4) or PREVERSE primers (Tm= 72.7), the 
annealing temperatures were increased to 55°C and 60°C respectively. 
PCR products were separated by gel electrophoresis using 1.0% DNA grade agarose (Progen 
Industries, Darra, Australia) in TAE containing ethidium bromide across 80 V. Bands of product 
were visualized using Ultra◊IIūm electronic UV transilluminator and bands of appropriate length 
were excised with a sterile scalpel. Products were extracted from the gel using the QIAquick® Gel 
Extraction Kit (QIAGEN) according to the manufacturer instructions. The eluted purified PCR 
products were stored at 4°C pending sequencing. The concentrations of the purified PCR 
products were estimated by gel electrophoresis by comparing aliquots of each product with the 
known DNA ladder standard. All PCR amplification reactions, purification, sequence reactions, 
and analyses were done by the candidate. 
4.2.5 Automated sequencing 
Sequencing reactions were performed in a volume of 20 µL containing 3.2 pmol of primer, 5µL of 
BigDye Terminator mix Version 2 (Applied Biosystems, Perkin Elmer) and 1-14 µL of purified PCR 
product as required to provide an estimated 400-800 ng of cDNA template. The sequencing 
reactions were performed using the Gene Amp® System 2400 PCR thermal cycler (Perkin Elmer) 
for 25 or 30 cycles of 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes then held 
at 4 °C. Extraction of unincorporated dye terminators and precipitation of the extension products 
was done by adding 80µL of 75% isopropanol to the sequence reaction mix for 15-40 minutes and 
pelleting the extension products at 13 000 G for 20 minutes. The pellet was washed with 250µL of 
75% isopropanol, dried under vacuum and stored at 4°C until submitted to the Australian Genome 
Research Facility at the University of Queensland for EST/cDNA sequencing using the AB377 
DNA sequencer (Applied Biosystems, Perkin Elmer) and ABI Prism™ DNA Sequencing Analysis 
Software (Applied Biosystems, Perkin Elmer). 
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Table 4-5 Details of 58 GenBank sequences used for sequence comparisons and phylogenetic analysis 
Thesis reference GenBank accession 
Isolate 
reference number 
Isolate Host Year Location host found Virus variant1 Reference 
ABLHumanPt AF418014 Confidential Human 1998 Mackay, Qld, Australia GT-7   Pteropid-ABLV Warrilow et al 2002 
ABLBallina  
 
  
   
   
   
   
 
  
   
   
     
  
  
     
   
   
 
       
      
    
  
     
   
   
     
  
AF006497 96-0591, Ballina Pteropus alecto 1996 Ballina, NSW, Australia GT-7   Pteropid-ABLV Gould et al 1998 
AAHLYBST AF081020 96-12932 
 
Saccolaimus flaviventris 1996 Murphy’s Creek, Qld, Australia GT-7   ybst-ABLV Gould et al 2002 
HoaryBat1Canada AF351845 LC1 Lasiurus cinereus 1992 Alberta, Canada Microbat rabies Group IIa Nadin-Davis et al 2001 
HoaryBat8Canada AF351858 LC8 Lasiurus cinereus 1996 Ontaria, Canada Microbat rabies Group IIa Nadin-Davis et al 2001 
SilverHairBatCanada AF351842 LAN8 Lasionycteris noctivagans 1992 Manitoba, Canada Microbat rabies Group IIb Nadin-Davis et al 2001 
LittleBrown4Canada AF351839 ML4 Myotis lucifugus 1992 British Columbia, Canada Microbat rabies Group 1b Nadin-Davis et al 2001 
LittleBrown6Canada
 
AF351838 ML6 Myotis lucifugus 1994 Nova Scotia, Canada Microbat rabies Group 1a Nadin-Davis et al 2001 
RedBatUSA AF351857 LB7 Lasiurus borealis 1998 Connecticut, USA Microbat rabies Group IIa Nadin-Davis et al 2001 
NorthnYellowUSA AF351843 LI Lasiurus intermedius 1987 Florida, USA Microbat rabies Group IIa Nadin-Davis et al 2001 
BigBrown22Canada AF351830 EF22 Eptesicus fuscus 1988 British Columbia, Canada Microbat rabies Group III Nadin-Davis et al 2001 
BigBrown32Canada AF351828 EF32 Eptesicus fuscus 1993 Ontario, Canada Microbat rabies Group 1d Nadin-Davis et al 2001 
BigBrown57Canada AF351859 EF57 Eptesicus fuscus 1997 Ontario, Canada Microbat rabies Group 1c Nadin-Davis et al 2001 
BigBrown71USA AF351860 EF71 Eptesicus fuscus 1998 Connecticut, USA Microbat rabies Group 1c Nadin-Davis et al 2001 
FreeTailBatUSA AF351849 TB1, V235 Tadarida brasiliensis ? Texus, USA Microbat rabies Group IV Nadin-Davis et al 2001 
FreeTailBatChile AF070450 ? Tadarida brasiliensis 
 
? Chile Microbat rabies Warner et al 1989 
InsectivBatChile AF351850 IB.Ch Microbat 1998 Chile Microbat rabies Group IV Nadin-Davis et al 2001 
VampireBrasil U22479 86118BRE
  
Desmodus rotuntus  1985 Brasil Vampire bat rabies Kissi et al 1995 
VampBrasil AF070449 ? Desmodus rotuntus ? Brazil Vampire bat rabies Warner et al 1989 
VampireHuPeru AF045166 Pehm3230 Human 1996 Peru Vampire bat rabies Warner et al 1989 
MongooseSthAfrica U22628 1500AFS Yellow mongoose 1987 South Africa Rabies Kissi et al 1995 
KuduNamibia U22632 8708NAM Kudu (herbivore)
 
1987 Namibia, Africa Rabies Kissi et al 1995 
DogCentralAfrica
 
U22651 9229CAF Dog 1992 Central African Republic Dog rabies Kissi et al 1995 
DogAfrica U22486 8636HAV Dog 1986 Burkina Fasso, Africa Dog rabies Kissi et al 1995, Bourhy et al 1999 
DogIvoryCoast U22646 9026CI Dog 1990 Ivory Coast, Africa Dog rabies Kissi et al 1995 
DogGuinea U22487 8660GUI Dog 1986 Guinea, Africa Dog rabies Kissi et al 1995, Bourhy et al 1999 
DogAlgeria U22643 9137ALG Dog 1982 Algeria, Africa 
 
Dog rabies Kissi et al 1995, Bourhy et al 1999 
DogIran U22482 89681IRA Dog 1986 Iran Dog rabies Kissi et al 1995, Bourhy et al 1999 
PV X03673 Pasteur Virus (PV) PAS derivative3 1882 France ~ Argentina →Paris 1965 Fixed dog rabies Tordo et al 1986 
SAD-B19 M31046 SAD-B19 (vaccine) 
 
SAD derivative4 1935 Alabama, USA Attenuated dog rabies Conzelmann et al 1990 
CVS D42112 CVS PAS derivative3 1882 France → USA 1940 Fixed dog rabies Mannen et al 1991 
 
 Thesis reference GenBank 
accession 
Isolate 
reference number 
Isolate Host Year Location host found Virus variant1 Reference 
Nishigahara    AB044824 Nishigahara PAS derivative3 1882 France → Japan 1915 Fixed dog rabies  Ito et al 2001 
RCHLVac 
    
     
     
    
   
    
     
  
    
     
    
     
       
        
  
AB009663 RC-HL (vaccine) Nishigahara derivative 1882 France → Japan 1915 
 
Attenuated Nishigahara  Ito et al 2001 
3AGChina AF155039 3AG ? ? China Fixed laboratory rabies Unpublished 
DogMexico U22477 9126MEX Dog  1991 Mexico Dog rabies Kissi et al 1995 
FLARaccoonUSA U27220 FLA 125 Raccoon 1987 Florida, USA Raccoon rabies Nadin-Davis et al 1996 
PARaccoonUSA U27221 PA R89-1811
 
Raccoon 1989 Pennsylvania, USA Raccoon rabies Nadin-Davis et al 1996 
NYRaccoonUSA U27218 NY516 Raccoon
 
1992 New York, USA Raccoon rabies Nadin-Davis et al 1996 
SkunkWestCanada AF344304 WCS2/92RABLV1741 Skunk 1992 Western Canada Arctic fox rabies Nadin-Davis et al 1997 
SKSkunkCanada L20671 SK (clone) Skunk ? Ontario, Canada Arctic fox rabies Nadin-Davis et al 1993 
ONT2SkunkCanada L20674 ONT2/ 91RABN2756 Skunk 1991 Ontario, Canada Arctic fox rabies Nadin-Davis et al 1993 
ONT3RedFoxCanada 
 
L20675 ONT3/ 91RABN0783 
 
Red Fox 1991 Ontario, Canada Arctic fox rabies Nadin-Davis et al 1993 
ArcticFoxRussia U22656 9141Rus Arctic Fox 1988-90 Russia Arctic fox rabies Kissi et al 1995,  Bourhy et al 1999 
ArcticFoxGreenland U22654 8684Gro Arctic Fox 1981 Greenland Arctic fox rabies Kissi et al 1995, Bourhy et al 1999 
RaccoonDogEstonia U42707 9339EST Raccoon dog 1991 Estonia Red fox rabies Bourhy et al 1999 
RaccoonDogPoland U22840 8618POL Raccoon dog 1985 Poland Red fox rabies Kissi et al 1995, Bourhy et al 1999 
RedFoxFrance U43433 9223FRA Red Fox 1974 France Red fox rabies Bourhy et al 1999 
RedFoxYugoslavia U42706 86111YOU Red fox 1986 Bosnia-Herzegovina  (Yugoslavia) Red fox rabies Bourhy et al 1999 
RedFoxGermany U42702 9213ALL Red fox 1991 Germany Red fox rabies Bourhy et al 1999 
HumanThailand U22653 8738THA Human 1983 Thailand Rabies (dog?) Kissi et al 1995 
RabiesIndia AF374721 ? ? ? India Rabies (dog?) Unpublished
EBL-1 Poland U22844 8615POL Eptesicus serotinus 1985 Poland GT-5  EBL-1a Kissi et al 1995, Amengual et al 1997 
EBL-1 France U22845 8918FRA Eptesicus  serotinus 1989 France GT-5  EBL-1b Kissi et al 1995, Amengual et al 1997 
EBL-2 Holland U22847 9018HOL Myotis dasycneme. 1986-87 Holland GT-6  EBL-2a Kissi et al 1995, Amengual et al 1997 
EBL-2 Finland U22846 9007FIN Human 1986 Finland GT-6  EBL-2b Kissi et al 1995, Amengual et al 1997 
Duvenhage U22848 86132AS (AF) Human 1970 South Africa GT-4  Duvenhage Kissi et al 1995, Meredith et al 1971 
LagosBat U22842 8619NGA Eidolon helvum 1958 Nigeria GT-2  Lagos bat Kissi et al 1995, Bourhy et al 1993 
Mokola Y09762 ? Cat 1981 Zimbabwe GT-3  Mokola Le Mercier et al 1997 
1   All viruses are Genotype 1 (GT-1) unless otherwise indicated.  
2  This isolate (AAHL case 96-1293) corresponds to DPI accession 96-33821, described further as ABLV-5 in Chapter 2 of this thesis. The AAHL accession number of this 
sequenced isolate was erroneously published as 96-1256 in Gould et al. (2002)(Allen Gould AAHL pers. comm.). 
3  Divergent laboratory strains of rabies virus (PAS) isolated by Louis Pasteur in 1882 from a rabid cow in urban Paris (i.e. dog-variant ‘urban’ rabies (Sacramento et al. 1992). 
4  SAD-B19 is an attenuated strain, which is non-pathogenic when administered orally or intramuscularly, derived from the street virus SAD isolated from a dog in Alabama. 
? Unknown or unpublished 
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4.2.6 Sequence analysis 
Nucleotide sequence data obtained by automated sequencing were compiled and edited using 
SequencherTM Version 3.1.1 (Gene Codes Corporation, MI, USA). Consensus ABLV sequences, 
the Nobivac sequence, and other lyssavirus sequences available via GenBank 
(http://www.ncbi.nih.gov) that represent the range of other lyssaviruses, were uploaded to the 
Australian National Genomic Information service web site (http://www.angis.org.au) for analysis 
using the Genetics Group Wisconsin Inc (GCG) suite of programs. Details of the selected 
GenBank sequences are shown in Table 4-5.  
 
Nucleoprotein amino acid sequences were deduced using eTRANSLATE (GCG Inc, Madison 
Wisconsin, USA). Multiple sequence alignments of the nucleotide and amino acid sequences 
were constructed using eCLUSTALW (Thompson et al. 1994). Percent amino acid similarities 
were calculated by the HOMOLOGIES program (Jack Leunissen CAOS/CAMM Centre, University 
of Nijmegen, The Netherlands). Alignments and the similarity matrix are presented using Excel 
2000. 
4.2.7 Phylogenetic analysis 
Nucleotide sequences of the new ABLV isolates, the Nobivac sequence, and those of the 
selected lyssavirus sequences available from GenBank were aligned using ClustalX Version 1.83 
(a windows interface version of ClustalW, (Jeanmougin et al. 1998; Thompson et al. 1997) 
available at http://www.biozentrum.unibas.ch/~biophit/clustal/ClustalX_help.html).  
Phylogenetic trees were constructed from the N protein coding sequences using Paup* 4.0b10 
(PPC) (Swofford, D.L. 2002 Phylogenetic Analysis Using Parsimony (*and Other Methods) 
Sinauer Associates, Sunderland, MA) by; (i) neighbour joining using the (Hasegawa et al. 1985) 
distance measure, which estimates a transition/transversion ratio and base frequencies and (ii) 
maximum parsimony using random stepwise-addition. For all analysis a higher weight was 
applied to substitutions occurring at first codon positions relative to second and third codon 
positions (2:1:1) to reflect the higher likelihood of a first codon substitution resulting in an amino 
acid substitution. Bootstrap resampling analysis (Felsenstein 1985) using 1000 replicates was 
done to evaluate the reliability of branch groupings. Consensus trees are presented using 
CorelDRAW Version 7.373. 
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4.3 Results 
An example of the relationship between the N5’HALF and N3’HALF PCR products and the 
sequence data produced using the relevant suite of 8 primers and the resulting consensus 
sequence is shown in Figure 4-2.  
Each of the 31 ABLV isolates produced a nucleotide sequence of 1,542 (n=30) or 1,543 (n=1) 
bases that have been submitted to GenBank (for GenBank numbers see Table 4-2). This 
encoded: 
♦ 35 bases of the leader sequence 
♦ a one base (T) leader to N protein intergenic region 
♦ the complete mRNA N protein sequence, including the complete N protein coding sequence 
♦ a two base (CT) N to P protein intergenic region 
♦ the complete 5’ UTR of the P protein mRNA and the first 47 bases of the P protein coding 
sequence.  
The 1,350 base N coding sequences of two isolates (ABL24SEQ-R and ABL25SEQ-R) were 
identical. The 1,545 bases of the Nobivac vaccine sequence were identical to those of CVS rabies 
(GenBank D42112). One ABLV sequence (ABL14Cen-B) was one base longer than all other 
ABLV sequences due to the insertion of an additional 'A' base in the polyadenylation termination 
signal (AGA8 rather than AGA7). This insertion persisted in both sequencing directions despite 
repeat PCR amplification and sequencing using cDNA synthesized with different primers (Lys-
Leader and ABLUTR22) indicating it to be a sequence anomaly of the source extracted RNA 
population. The aligned nucleotide sequences of this thesis (ABLV n=31 and Nobivac) along with 
those of the other available ABLV sequences (n=3) are given in Appendix 10, Figure A10-1. 
There was an exceptionally high level of nucleotide homology among isolates from pteropid bats 
(flying foxes 98.4 to 99.9%) and from YBST bats (99.4 to 99.9%), while comparisons between 
pteropid and YBST isolates demonstrated relatively high divergence (83.5 to 83.9%). This crude 
analysis suggests that two highly conserved variants of ABLV exist, pteropid-variant ABLV and 
YBST-variant ABLV. 
Many of the base substitutions were synonymous to the extent that the 27 unique pteropid-variant 
N coding sequences encoded only four unique deduced N amino acid sequences. The deduced N 
amino acid sequences of ABL30Tvl-R, ABL35SEQ-B and ABL37Cen-B were unique, each as a 
result of single amino acid substitutions as shown in Table 4-6.  
The deduced N protein of all other pteropid variant-ABLV isolates (n=25) were identical to that of 
ABL01SEQ-B. 
  Molecular diversity of ABLV 
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Table 4-6 Characterization of low N protein amino acid sequence variability among 28 
isolates of Pteropus-variant ABLV  
Number of 
sequences 
Isolate Amino acid 
position 
Amino acid substitution 
n=25 ABL01SEQ-B1 not applicable typical pteropid sequence 
n=1 ABL35SEQ-B 128 (L) Leu → (F) Phe2 
n=1 ABL30Tvl-R 181 (I) Ile → (V) Val3 
n=1 ABL37Cen-B 376 (K) Lys → (R) Arg3 
1     Representative of all other pteropid-variant ABLV sequences. Corresponds to flying fox case  
ABLV-51 and Inoculum 5 as referred to in Chapters 2 and 5 to 7 respectively. 
2   At position 128, Leu, which is typical of pteropid-ABLV is substituted for Phe, typical of ybst-ABLV.  
3   At positions 181 and 376 the amino acids Val and Arg also occur in Lagos bat virus and Mokola 
virus and not ybst-ABLV or any of the other selected rabies or rabies-like sequences. 
 
 
Of the three ybst-ABLV isolates, the deduced N protein sequence of ABL11YBST and 
ABL12YBST were identical. The sequence of ABL15YBST was unique as a result of two amino 
acid substitutions, Lys →Argbase 34 and Arg →Lysbase 290 that did not occur in any other sequence 
used for comparison. 
An alignment of the four unique pteropid-variant ABLV deduced N protein sequences, two unique 
YBST-variant ABLV sequences, other available ABLV sequences (n=3) and 55 other rabies-like 
and rabies virus N protein sequences, is shown in Figure 4-3 
A percent similarity matrix comparing 33 of these N protein sequences, selected to include those 
most and least like ABLV in each group, is shown in Figure 4-4. The ABLV N protein amino acid 
sequences shared the highest similarly with those of rabies virus isolates (88.4 to 93.6%) and 
were least like Lagos bat virus (81.3 to 82.7%). 
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 Figure 4-2 Alignment of forward and reverse sequence reaction data for ABL01SEQ-B generated from two overlapping RT-PCR products  
Numbers correspond to the position on the new sequence. Position 1 corresponds to base 1 of the Pasteur virus + sense genome (GenBank X03673) 
 
 ABLUTR22  (27 to 614) 
            N5’SEQ1F  (526 to 910) 
               N5’REVERSE  (211 to 907) 
       N5’SEQ1R (23 to 449) 
 
 
RT-PCR PRODUCT N5’HALF  (23 to 910)       RT-PCR PRODUCT N5’HALF  (655 to 1564) 
 
          N3’FORWARD  (691 to 1,311) 
                                N3’SEQ2F  (1,205 to 1,564) 
               P-REVERSE  (862 to 1,560) 
                N3’SEQ2R  (655 to 1,132)          
 
 
 
 1            211           450          525            614   654               862   908     1,132     1,204        1,311            1,588 
 
 
 
 
 
 
 
                 Key            
       
      RT-PCR primers (5’-ABLUTR22, 3’-PREVERSE)  Forward sequencing reaction data (labelled with primer and base position range) 
           Single strand of sequencing data only            
           Forward and reverse sequencing data   Reverse sequencing reaction data (labelled with primer and base position range) 
           Multiple forward and/or reverse strands      
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Figure 4-3 N protein amino acid sequence alignment  
of 4 new deduced pteropid-variant ABLV and 2 new YBST-variant ABLV sequences, 
with those of 58 other rabies-like and rabies viruses 
1 10 20 30 40 50 60 70
I I I I I I I I
ABL01SEQ-B MD S D K I V F K V N NQ L V S V K P E V I V DQ Y E Y K Y P A I K DQ K K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
ABL30Tvl-R MD S D K I V F K V N NQ L V S V K P E V I V DQ Y E Y K Y P A I K DQ K K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
ABL35SEQ-B MD S D K I V F K V N NQ L V S V K P E V I V DQ Y E Y K Y P A I K DQ K K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
ABL37Cen-B MD S D K I V F K V N NQ L V S V K P E V I V DQ Y E Y K Y P A I K DQ K K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
ABLHumanPt MD S D K I V F K V N NQ L V S V K P E V I V DQ Y E Y K Y P A I K DQ K K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
ABLBallina ME S D K I V F K V N NQ L V S V K P E V I V DQ Y E Y K Y P A I Q D H T K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
AAHLYBST ME S D K I A F K I N NQ L V S V K P E V I V DQ Y E Y K Y P A I K DQ R K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
ABL12YBST MD S D K I V F K V N NQ L V S V K P E V I V DQ Y E Y K Y P A I K DQ R K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
ABL15YBST MD S D K I V F K V N NQ L V S V K P E V I V DQ Y E Y K Y P A I R DQ R K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
HoaryBat1Canada MD A D K I V F K V K NQ V V S L K P E I I V DQ Y E Y K Y P A I K D S R K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
HoaryBat8Canada MD A D K I V F K V K NQ V V S L K P E I I V DQ Y E Y K Y P A I K D S R K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
SilverHairBatCanada MD A D K I V F K V K NQ V V S L K P E I I V DQ Y E Y K Y P A I K D S R K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
LittleBrown4Canada MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D S K K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
LittleBrown6Canada MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D S K K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
RedBatUSA MD A D K I V F K V K NQ V V S L K P E I I V DQ Y E Y K Y P A I K D S R K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
NorthnYellowUSA MD A D K I V F K V K NQ V V S L K P E I I V DQ Y E Y K Y P A I K D S R K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
BigBrown22Canada MD A D K I V F K V N N R V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
BigBrown32Canada MD A D K I V F K V N N K V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
BigBrown57Canada MD A D K I V F K V N N K V V S L K P E I I I DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
BigBrown71USA MD A D K I V F K V K NQ V V S L K P E I I I DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
FreeTailBatUSA MD A D K I V F K V N DQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
FreeTailBatChile MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S GMN A A K L D P E D V
InsectivBatChile MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S GMN A A K L D P E D V
VampireBrasil MD A D K I V F K V N NQ V V S L K P E I T V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L S K A Y K S I L S GMN A A K L D P D D V
VampBrazil MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L S K A Y K S I L S GMN A A K L D P D D V
VampHuPeru MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
MongooseSthAfrica MD A D K I V F K V N NQ V V S L K P E V I V DQ Y E Y K Y P A I K D S K K P S I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
KuduNamibia MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D S K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
DogCentralAfrica MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
DogAfrica MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
DogIvoryCoast MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L E K A P D L N K A Y K S V L S GMN A A K L D P D D V
DogGuinea MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
DogAlgeria MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
DogIran MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMS A A K L D P D D V
PV MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S CMS A A K L D P D D V
SAD-B19 MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMS A A K L N P D D V
CVS and Nobivac MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
RCHLVac MD A D R I V F R A N NQ V V S L R P E I I A DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
Nishigahara MD A D R I V F R S N NQ V V S L R P E I I A DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
3AGChina MD A D K I V F R A N NQ V V S L R P E I I A DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
DogMexico MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
RaccoonUSA MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I S L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
RaccoonUSA MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I S L G K A P D L N K A Y K S I L S GMN A A K L D P D D V
RaccoonUSA MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I S L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
SkunkWestCanada MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
SkunkCanada MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S G L N A A K L D P D D V
ONT2SkunkCanada MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S G L N A A K L D P D D V
ONT3RedFoxCanada MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S G L N A A K L D P D D V
ArcticFoxRussia MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S G L N A A K L D P D D V
ArcticFoxGreenland MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L S G L N A A K L D P D D V
RaccoonDogEstonia MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
RaccoonDogPoland MD A D K I V F K V H NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
RedFoxFrance MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
RedFoxYugoslavia MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
RedFoxGermany MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P C I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
HumanThailand MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y K Y P A I K D L K K P S I T L G K A P D L N K A Y K S V L Y GMN A A K L D P D D V
RabiesIndia MD A D K I V F K V N NQ V V S L K P E I I V DQ Y E Y R Y P R I K D L K E P S I T L G K A P D L N K A Y K S V L S GMN A A K L D P D D V
EBL-2 Holland MD A D R I V F K V H NQ L V S V K P E V I V DQ Y E Y K Y P A I K D R K K P S I T L E K A P D L N R A Y K S I L S G I N A A R L D P D D V
EBL-2 Finland MD A D K I V F K V H NQ L V S V K P E V I V DQ Y E Y K Y P A I K D R K K P S I T L G K A P D L N R A Y K S I L S G I N A A R L D P D D V
EBL-1 France MD V N R V V F K V H NQ L V S V K P E V I S DQ Y E Y K Y P A I K D K K K P S I T L G K D P D L K T A Y K S I L S GMN A A K L D P D D V
EBL-1 Poland MD V N K V V F K V H NQ L V S V R P E V I S DQ D E Y K Y P A I K D K K K P S I T L G K D P D L K T A Y K S I L S GMN A A K L D P D D V
Duvenhage MD A E R I V F K V R NQ L V S V K P E V I S DQ Y E Y K Y P A I T D K K K P S I T L G R A P D L K T A Y K S I L S GMN A A K L D P D D V
Lagos Bat MD S E R I V F R V H NQ V V S L K P E I I S DQ Y E Y K Y P A I T DG K K P G I T L G R A P D L S T A Y K S I L S GMN A A K L D S D D V
Mokola ME S D K I V F K V N NQ V V S L K P E V I S DQ Y E Y K Y P A I L DG K K P G I T L G K A P D L N T A Y K S I L S GMK A A K L D P D D V
* . . . * . . . * * . . * * . * * * * . * * * * * * . * . * * * * * * * . * . * * . * . *
 I-
---
---
---
---
---
---
---
-- 
Th
e A
me
ric
as
 --
---
---
---
---
---
---
---
---
--I
 I-
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
-T
er
re
str
ial
 ra
bie
s--
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
-I
 I-
---
---
---
---
---
---
---
---
---
--B
at 
ra
bie
s--
---
---
---
---
---
---
---
---
---
I
 I-
---
- P
ter
op
id-
---
-I
 Y
BS
T
I--
---
---
Af
ric
a-
---
---
-I
 I-
---
---
ra
bie
s -
---
---
I
Ea
st
 I-
---
---
Th
e A
me
ric
as
 --
---
-I 
As
ia
I--
- E
BL
 --
-I
Mi
d.
La
bo
ra
tor
*
y
 I-
---
---
--E
ur
op
e-
---
---
--I
 I-
---
---
---
---
-  
AB
L  
---
---
---
---
--I
Ot
he
r r
ab
ies
-lik
e
 
KEY 
ABLV amino acids that differ from the predominant lyssavirus amino acid at each site, and similarly substituted amino acids of 
other (non-ABLV) lyssaviruses are highlighted in yellow (first substitution e.g. E) or green (second substitution e.g. Q).  
Other (non-ABLV) lyssavirus amino acids that differ from the predominant lyssavirus amino acid at each site are highlighted in 
blue (e.g. V). GenBank accession numbers for each sequence are given in Table 4-2 and Table 4-5. Conserved sites are 
indicated by an asterisk (*), sites at which substitutions with similar amino acids occur are indicated by a stop (.).
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Figure 4-3 –continued  N protein alignment (page 2 of 7) 
 
 
 
71 80 90 100 110 120 130 140
I I I I I I I I
ABL01SEQ-B C S Y L A A A ME L F E G V C P E DWT S Y G I L I A R K G D K I T P A T L V D I K R T D I E G NWA L T GGQ D L T R D P T V A E H A S L
ABL30Tvl-R C S Y L A A A ME L F E G V C P E DWT S Y G I L I A R K G D K I T P A T L V D I K R T D I E G NWA L T GGQ D L T R D P T V A E H A S L
ABL35SEQ-B C S Y L A A A ME L F E G V C P E DWT S Y G I L I A R K G D K I T P A T L V D I K R T D I E G NWA L T GGQ D F T R D P T V A E H A S L
ABL37Cen-B C S Y L A A A ME L F E G V C P E DWT S Y G I L I A R K G D K I T P A T L V D I K R T D I E G NWA L T GGQ D L T R D P T V A E H A S L
ABLHumanPt C S Y L A A A ME L F E G V C P E DWT S Y G I L I A R K G D K I T P A T L V D I K R T D I E G NWA L T GGQ D L T R D P T V A E H A S L
ABLBallina C S Y L A A A ME L F E G V C P E DWT S Y G I M I A R K G D K I T P A T L V D I K R T D I E G NWA L T GGQ D L T R D P T V A E H A S L
AAHLYBST C S Y L A A A ME L F E G I C P E DWT S Y G I L I A R K G D K I T P A T L V D I R R T D I QG SWA L AGGQ D F T R D P T I A E H A S L
ABL12YBST C S Y L A A A ME L F E G I C P E DWT S Y G I L I A R K G D K I T P A T L V D I R R T D I E G SWA L AGGQ D F T R D P T I A E H A S L
ABL15YBST C S Y L A A A ME L F E G I C P E DWT S Y G I L I A R K G D K I T P A T L V D I R R T D I E G SWA L AGGQ D F T R D P T I A E H A S L
HoaryBat1Canada C S Y L A A A MQ F F E G A C P D DWV S Y G I L I A R K G D K I T P G T L V D I R R T N V E G SWA L T GGME L T R D P T V P E H A S L
HoaryBat8Canada C S Y L A A A MQ F F E S A C P D DWV S Y G V L I A R K G D K I T P G T L V G L R R T N V E G SWA L T GGME L T R D P T V P E H A S L
SilverHairBatCanada C S Y L A A A MQ F F E G A C P D DWV S Y G I L I A R RG D K I T P N S L V D I R R T N V E G NWA L T GGME L T R D P T V P E H A S L
LittleBrown4Canada C S Y L A A A MQ F F E G A C P D DWT S Y G I L I A R K G D K I T P N S L V E I K R T H V E G NWA L T GGME L T R D P T V S E H A S L
LittleBrown6Canada C S Y L A A A MQ F F DG A C P D DWT S Y G I L I A R K G D K I T P D S L V D I K R T H V E G NWA L T GGME L T R D P T V S E H A S L
RedBatUSA C S Y L A A A MQ F F E G A C P D DW I S Y G I L I A R K G D K I T P G S L V D I R R T N V E G SWA L T GGME L T R D P T V P E H A S L
NorthnYellowUSA C S Y L A A A MQ F F E G A C P D DW I S Y G I L I A R K G D K I T P D F V A Y I R R T N V E G SWA L T GGME L T R D P T V P E H A S L
BigBrown22Canada C S Y L A A A MQ F F E G A C P D DWT S Y G I L I A R K G D K I T P N S L V D I R R T N V E G NWA L T GGME L T R D P T V S E H A S L
BigBrown32Canada C S Y L A A A MQ F F E G T C P D DWA S Y G I L I A R K G D K I T P N S L V D I K R T N V E G NWA L T GGME L T R D P T V P E H A S L
BigBrown57Canada C S Y L A A A MQ F F E G T C P D DWT S Y G I L I A R RG D K I T P N S L V D I K R T N V E G NWA L T GGME L T R D P T V S E H A S L
BigBrown71USA C S Y L A A A MQ F F E G T C P D DWT S Y G I L I A R K G D K I T P N S L V D I K R T N V E G NWA L T GGME L T R D P T V S E H A S L
FreeTailBatUSA C S Y L A A A MQ F F E G S C P E DWT S Y G I L I A R K G D K I T P D S L V D I R R T D V E G NWA L T GGME L T R D P T V S E H A S L
FreeTailBatChile C S Y L A A A MQ F F E G A C P D DWT S Y G I L I A R K G D K I T P D S L V D I R R T N V E G NWA L T GGME L T R D P T V S E H A S L
InsectivBatChile C S Y L A A A MQ F F E G A C P D DWT S Y G I L I A R K G D K I T P D S L V D I R R T N V E G NWA L T GGME L T R D P T V S E H A S L
VampireBrasil C S Y L A A A MQ F F E G S C P A DWT S Y G I L I A R K G D K I T P H S L V E I K R T D V E G NWA L T GG I E V T R D P T V C E H A S L
VampBrazil C S Y L A A A MQ F F E G S C P E DWT S Y G I L I A R K G D K I T P D S L V D I R R T D V E G NWA L T GGME L T R D P T V S E H A S L
VampHuPeru C S Y L A A A MQ F F E G S C P E DWT S Y G I L I A R K G D K I T P D S L V D I R R T D V E G NWA L T GGME L T R D P T V S E H A S L
MongooseSthAfrica C S Y L A A A MQ F F E G I C P E NWT S Y G I L I A R K G D K I T P D S I V D I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
KuduNamibia C S Y L A A A MQ F F E G T C P E DWT S Y G T L I A R K G D K I T P D S L V E I K R T D V E G T G A L AGGME L T R D P T V S E H A S L
DogCentralAfrica C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
DogAfrica C S Y L A A A MQ L F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T D V KG NWA L T GGME L T R D P T V S E H A S F
DogIvoryCoast C S Y L A A A MQ L F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
DogGuinea C S Y L A A A MQ L F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
DogAlgeria C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
DogIran C S Y L A A A MQ F F E G TWP E DWT S Y G I L I A R K G D K I T P D S L V E I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
PV C S Y L A A A MQ F F E G T C P E DWT S Y G I V I A R K G D K I T P G S L V E I K R T D V E G NWA L T GGME L T R D P T V P E H A S L
SAD-B19 C S Y L A A A MQ F F E G T C P E DWT S Y G I V I A R K G D K I T P G S L V E I K R T D V E G NWA L T GGME L T R D P T V P E H A S L
CVS and Nobivac C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D R I T P N S L V E I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
RCHLVac C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P N S L V E I K R N D V E G NWA L T GGME L T R D P T V S E H A S L
Nishigahara C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P N S L V E I K R N D V E G NWA L T GGME M T R D P T V S E H A S L
3AGChina C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K R D K I T P N S R V E I K R N D V E G NWA L T GGME M T R D P T V S E H S S L
DogMexico C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
RaccoonUSA C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P N S L V D I K R T D V E G NWA L T GGME L T R D P T I P E H A S L
RaccoonUSA C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P N S L V D I K R T D V E G NWA L T GGME L T R D P T I P E H A S L
RaccoonUSA C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P N S L V D I K R T D V E G NWA L T GGME L T R D P T I P E H A S L
SkunkWestCanada C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A P K G D K I T P D S L V E I K R T D V E G NWA L T GG V E L T R D P T V S E H A S L
SkunkCanada C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T G V E G NWA L T GGME L T R D P T V P E H A S L
ONT2SkunkCanada C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T G V E G NWA L T GGME L T R D P T V P E H A S L
ONT3RedFoxCanada C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T G V E G NWA L T GGME L T R D P T V P E H A S L
ArcticFoxRussia C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T G V E G NWA L T GGME L T R Y P T V P E H A S L
ArcticFoxGreenland C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T G V E G NWA L T GGME L T R D P T V P E H A S L
RaccoonDogEstonia C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T G V E G NWA L T GGME L T R D P T V S E H A S L
RaccoonDogPoland C S Y L A A A MQ F F E G T C P E DW I S Y G I L I A Q K G A K I T P D S L V E I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
RedFoxFrance C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G A K I T P D S L V E I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
RedFoxYugoslavia C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G A K I T P D S L V E I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
RedFoxGermany C S Y L A A A MQ F F E G T C P E DWT S Y G I L I A R K G A K I T P D S L V E I K R T D V E G NWA L T GGME L T R D P T V S E H A S L
HumanThailand C S Y L A A A MQ F F E G T S P E DWT S Y G I L I A R K G D K I T P D S L V E I K R T D I E G NWA Q T GGME V T R D P T V A E H A S L
RabiesIndia C S Y L A A A MQ F F E G S C P E DWT S Y G I L I A R K G D K I T P D S L V D I K R T D V E G SWA L T GGME L T R D P T V S E H A S L
EBL-2 Holland C S Y L A A A MA L F E G I C P D DWE S Y G I L I A R K G D K I T P A N L V N I Q R T D V E G NWA L AGGQ D V I K D P T T A E H A S L
EBL-2 Finland C S Y L A A A MA L F E G I C P D DWE S Y G I L I A R K G D R I T P A S L V N I Q R T D I E G NWA L AGGQ D V T K D P T T A E H A S L
EBL-1 France C S Y L A G A MV L F E G I C P E DWT S Y G I N I A K K G D K I T P A T L V D I N R T N T E G NWA Q T GGQ D L T R D P T T P E H A S L
EBL-1 Poland C S Y L A G A MV L F E G I C P E DWT S Y G I N I A K K G D K I T P A T L V D I H R T N T E G NWA Q T GGQ D L T R D P T T P E H A S L
Duvenhage C S Y L A G A M I L F E G V C P E DWV S Y G I H I A R K G D K I T P A T L V D I V R T N T E G NWA Q T GGQ D L T R D P T I S E H A S L
Lagos Bat C S Y L A A A MQ L F E G V C P E DW I S Y G I H I A T K G E T I T P D V L I D V T R T N V E G NWA Q AGG T DM T R D P T I A E H A S L
Mokola C S Y L A A A MH L F E G V C P E DWV S Y G I V I A K K G E K I N P S V I V D I V R T N V E G NWA Q AGG T D V I R D P T MA E H A S L
* * * * * * * * . * * * * * * * . * . * . * . * * . * * . . * * * * . *
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Figure 4-3 –continued  N protein alignment (page 3 of 7) 
 
*  
ABLV amino acids that differ from the predominant lyssavirus amino acid at each site, and similarly substituted amino acids of 
other (non-ABLV) lyssaviruses are highlighted in yellow (first substitution e.g. E) or green (second substitution e.g. Q).  
Other (non-ABLV) lyssavirus amino acids that differ from the predominant lyssavirus amino acid at each site are highlighted in 
blue (e.g. V). GenBank accession numbers for each sequence are given in Table 4-2 and Table 4-5. Conserved sites are 
indicated by an asterisk (*), sites at which substitutions with similar amino acids occur are indicated by a stop (.). 
141 150 160 170 180 190 220 210
I I I I I I I I
ABL01SEQ-B V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F A K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
ABL30Tvl-R V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F A K V V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
ABL35SEQ-B V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F A K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
ABL37Cen-B V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F A K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
ABLHumanPt V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F A K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
ABLBallina V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F A K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
AAHLYBST V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F A K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
ABL12YBST V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F A K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
ABL15YBST V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F A K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
HoaryBat1Canada V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
HoaryBat8Canada V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
SilverHairBatCanada V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H TWM T T H K MC A NWS T I P N F R F L A G T Y
LittleBrown4Canada V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
LittleBrown6Canada V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
RedBatUSA V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
NorthnYellowUSA V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
BigBrown22Canada V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
BigBrown32Canada V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
BigBrown57Canada V G L L L S L Y R L S K I S GQ N T G I Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
BigBrown71USA V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
FreeTailBatUSA V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F A K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
FreeTailBatChile V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
InsectivBatChile V G L L L S L Y R L S K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F V K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
VampireBrasil V G L L L S V Y RMS K I S GQ N T G N Y K T N I A D R I E Q I F E T A P F A K I V E H H T L M T T H K MC A NWS T I P N F R F L A G T Y
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Figure 4-3 -continued   N protein alignment (page 5 of 7) 
 
281 290 300 310 320 330 340 350
I I I I I I I I
ABL01SEQ-B V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I S T C A P H E MS V L GG Y L G E E F F
ABL30Tvl-R V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I S T C A P H E MS V L GG Y L G E E F F
ABL35SEQ-B V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I S T C A P H E MS V L GG Y L G E E F F
ABL37Cen-B V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I S T C A P H E MS V L GG Y L G E E F F
ABLHumanPt V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I S T C A P H E MS V L GG Y L G E E F F
ABLBallina V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I S T C A P H E MS V L GG Y L G E E F F
AAHLYBST V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I S T C A P H E MS V L GG Y L G E E F F
ABL12YBST V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I S T C A P H E MS V L GG Y L G E E F F
ABL15YBST V P H S Y F I H F K S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I S T C A P H E MS V L GG Y L G E E F F
HoaryBat1Canada I P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
HoaryBat8Canada I P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
SilverHairBatCanada V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
LittleBrown4Canada V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
LittleBrown6Canada V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I T T C A P H E MS V L GG Y L G E E F F
RedBatUSA V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
NorthnYellowUSA V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
BigBrown22Canada V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
BigBrown32Canada V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
BigBrown57Canada V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
BigBrown71USA V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
FreeTailBatUSA V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MG H V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
FreeTailBatChile V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
InsectivBatChile V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
VampireBrasil V P H S Y L I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
VampBrazil V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
VampHuPeru V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
MongooseSthAfrica V L H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
KuduNamibia V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L S H C CG C Y MGQ V R S L N A T V I G A C A P Q E MS V L G A Y L G E E I F
DogCentralAfrica V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F I G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
DogAfrica V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A R A P H E MS V L GG Y L G E E F F
DogIvoryCoast V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
DogGuinea G P H S Y F I H F R S L G L S G K S P Y S K N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
DogAlgeria V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V C N L I H F V G C Y MGQ V R S L N A T V I A A C V P H E MS V L GG Y L G E E F F
DogIran V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
PV V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
SAD-B19 V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
CVS and Nobivac V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
RCHLVac V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
Nishigahara V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
3AGChina V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N S T V I A A C A P H E MS V L GG Y L G E E F F
DogMexico V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
RaccoonUSA V P H S Y F I H F R S L G L S G K S P Y S S S A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
RaccoonUSA V P H S Y F I H F R S L G L S G K S P Y S S S A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
RaccoonUSA V P H S Y F I H F R S L G L S G K S P Y S S S A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
SkunkWestCanada V P H S Y F I H F R S L G F S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A T C A P H E MS V L GG Y L G E E F F
SkunkCanada V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
ONT2SkunkCanada V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
ONT3RedFoxCanada V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
ArcticFoxRussia V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
ArcticFoxGreenland V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
RaccoonDogEstonia V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
RaccoonDogPoland V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
RedFoxFrance V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
RedFoxYugoslavia V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
RedFoxGermany V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
HumanThailand V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
RabiesIndia V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ V R S L N A T V I A A C A P H E MS V L GG Y L G E E F F
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Duvenhage V P H S Y F I H F R S L G L S G K S P Y S S N A V G H V F N L I H F V G C Y MGQ I R S L N A T V I Q S C A P H E MS V L GG Y L G E E F F
Lagos Bat V P H P Y F I H F R A L G V S G K S P Y S S T A V G H H F N L I H F I G C Y MGQ V K S L N A T V I Q T C A P H E MS V L GG Y L G E E F F
Mokola V P H S Y F I H F R A L G L S G K S P Y S S N A V G H T F N L I H F V G C Y MGQ I R S L N A T V I Q T C A P H E MS V L GG Y L G E E F F
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*  
KEY 
ABLV amino acids that differ from the predominant lyssavirus amino acid at each site, and similarly substituted amino acids of 
other (non-ABLV) lyssaviruses are highlighted in yellow (first substitution e.g. E) or green (second substitution e.g. Q).  
Other (non-ABLV) lyssavirus amino acids that differ from the predominant lyssavirus amino acid at each site are highlighted in 
blue (e.g. V). GenBank accession numbers for each sequence are given in Table 4-2 and Table 4-5. Conserved sites are 
indicated by an asterisk (*), sites at which substitutions with similar amino acids occur are indicated by a stop (.). 
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Figure 4-3 –continued  N protein alignment (page 6 of 7) 
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I I I I I I I I
ABL01SEQ-B G K G T F E R R F F R D E K E L Q D Y E A A E S MK T D I A L A D D A T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
ABL30Tvl-R G K G T F E R R F F R D E K E L Q D Y E A A E S MK T D I A L A D D A T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
ABL35SEQ-B G K G T F E R R F F R D E K E L Q D Y E A A E S MK T D I A L A D D A T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
ABL37Cen-B G K G T F E R R F F R D E K E L Q D Y E A A E S MR T D I A L A D D A T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
ABLHumanPt G K G T F E R R F F R N E K E L Q D Y E A A E S MK T D I A L A D D A T V N S D D E D Y F S G E T RG P E A V Y T R I MMNGGR L K R S H
ABLBallina G K G T F E R R F F R D E K E L Q D Y E A A E S MK T D I A L A D D A T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
AAHLYBST G K G T F E R R F F R D E K E L Q D Y E A A E AMK I D L A L A D DG T V N S Y D E D Y L S G E T R S P E A V Y T R I MMNGGR L K K S H
ABL12YBST G K G T F E R R F F R D E K E L Q D Y E A A E AMK I D L A L A D DG T V N S D D E D Y L S G E T R S P E A V Y T R I MMNGGR L K K S H
ABL15YBST G K G T F E R R F F R D E K E L Q D Y E A A E AMK I D L A L A D DG T V N S D D E D Y L S G E T R S P E A V Y T R I MMNGGR L K K S H
HoaryBat1Canada G K G T F E R R F F R D E K E L Q E Y E A A E L T K T E V A L A D DG T V N S D D E D Y F S S E T R S P E A V Y T R I MMNG S R L K R S H
HoaryBat8Canada G K G T F E R R F F R D E K E L Q E Y E A A E L T K T E V A L A D DG T V N S D D E D Y F S S E T R S P E A V Y T R I MMNG S R L K R S H
SilverHairBatCanada G K G T F E R R F F R D E K E L Q E Y E A A E L T K T E V A F A D DG T V N S D D E D Y F S S E T R S P E A V Y T R I MMNGGR L K R S H
LittleBrown4Canada G K G T F E R R F F R D E K E L Q E Y E A A E L T K T E V A L A D DG T V N S D D E D Y F S S E T R S P E A V Y T R I MMNGGR L K R S H
LittleBrown6Canada G K G T F E R R F F R D E K E L Q E Y E A A E L T K T E V A L A D DG T V N S D D E D Y F S G E T R S P E S V Y T R I MMNGGR L K R S H
RedBatUSA G K G T F E R R F F R D E K E L Q E Y E A A E L T K T E V A L A D DG T V N S D D E D Y F S S E T R S P E A V Y T R I MMNGGR L K R S H
NorthnYellowUSA G K G T F E R R F F R D E K E L Q E Y E A A E L T K T E V A L A D DG T F N S D D E D Y F S S E T R S P E A V Y T R I MMNGGR L K R S H
BigBrown22Canada G K G T F E R R F F R D E K E L Q E Y E A A E L T K T E V A L A D DG T V N S D D E D Y F S S E T R S P E A V Y T R I MMNGGR L K R S H
BigBrown32Canada G K G T F E R R F F R D E K E L Q E Y E A A E S T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
BigBrown57Canada G K G T F E R R F F R D E K E L Q E Y E A A E S T K T E I A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
BigBrown71USA G K G T F E R R F F R D E K E L Q E Y E A A E S T K T E I A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
FreeTailBatUSA G K G T F E R R F F R D E K E L Q E Y E A A E L T K A D T A L A D DG T V N S D D E D Y F S S E T R S P E S V Y T R I MMNGGR L K R S H
FreeTailBatChile G K G T F E R R F F R D E K E L Q E Y E A A E L T K T E T A L A D DG T V N S D D E D Y F S S E T R S P E A V Y T R I MMNGGR L K R S H
InsectivBatChile G K G T F E R R F F R D E K E L Q E Y E A A E L T K T E T A L A D DG T V N S D D E D Y F S S E T R S P E A V Y T R I MMNGGR L K R S H
VampireBrasil G K G T F E R R F F R D E K E L Q E Y E A A E L T K A E T A L A D DG T V N S D D E D Y F S S E T R S P E A V Y T R I MMNGGR L K R S H
VampBrazil G K G T F E R R F F R D E K E L Q E Y E A A E L T K A E T A L A D DG T V N S D D E D Y F S S E T R S P E A V Y T R I MMNGGR L K R S H
VampHuPeru G K G T F E R R F F R D E K E L Q E Y E A A E L T K A E T A L A D DG T V N S D D E D Y F S S E T R S P E A V Y T R I MMNGGR L K R S H
MongooseSthAfrica G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D T N T A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
KuduNamibia G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T Q I MMNGGR L K R S H
DogCentralAfrica G K G T F E R R F F R D E K E L Q E Y E A A E L T K T DMA L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
DogAfrica G K A T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
DogIvoryCoast G K G T F E R R F F R D E K E L Q E Y Q A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
DogGuinea G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
DogAlgeria G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
DogIran G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D S F S G E T R S P E A V Y T R I MMNGGR L K R S H
PV G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I I MNGGR L K R S H
SAD-B19 G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
CVS and Nobivac G K G T F E R R F F R D E K E L Q E Y E A A E L T K S D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
RCHLVac GRG T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V D S D D E D H F P G E A RG P E A V Y A R I MMNGGR L K R S H
Nishigahara GRG T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V D S D D E D Y F S G E A RG P E A V Y A R I MMNGGR L K R S H
3AGChina GRG T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T RG P E A V Y A R I MMNGGR L K R S H
DogMexico G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
RaccoonUSA G K G T F E R R F F R D E K E L Q D Y E A A E L T K T E V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I M I NGGR L K R S H
RaccoonUSA G K G T F E R R F F R N E K E L Q D Y E A A E L T K T E V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I M I NGGR L K R S H
RaccoonUSA G K G T F E R R F F R N E K E L Q D Y E A A E L T K T E V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I M I NGGR L K R S H
SkunkWestCanada G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
SkunkCanada G K G T F E R R F F R D E K E L Q E Y E T A E L T K T D A A L A D DG T V N S D D E D Y F S G E T R S P E A V Y A R I MMNGGR L K R S H
ONT2SkunkCanada G K G T F E R R F F R D E K E L Q E Y E T A E L T K T D A A L A D DG T V N S D D E D Y F S G E T R S P E A V Y A R I MMNGGR L K R S H
ONT3RedFoxCanada G K G T F E R R F F R D E K E L Q E Y E T A E L T K T D A A L A D DG T V N S D D E D Y F S G E T R S P E A V Y A R I MMNGGR L K R S H
ArcticFoxRussia GRG T F E R R F F R D E K E L Q E Y E T A E L T K T D T A L A D DG T V N S D D E D Y F S G E T R S P E A V Y A R I MMNGGR L K R S H
ArcticFoxGreenland G K G T F E R R F F R D E K E L Q E Y E T A E L T K T D T A L A D DG T V N S D D E D Y F S G E T R S P E A V Y A R I MMNGGR L K R S H
RaccoonDogEstonia G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
RaccoonDogPoland G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T RG P E A V Y T R I MMNGGR L K R S H
RedFoxFrance G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
RedFoxYugoslavia G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
RedFoxGermany G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E E Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
HumanThailand G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D V A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
RabiesIndia G K G T F E R R F F R D E K E L Q E Y E A A E L T K T D I A L A D DG T V N S D D E D Y F S G E T R S P E A V Y T R I MMNGGR L K R S H
EBL-2 Holland G K G T F E R R F F R D E R E L A E H E A I E S T K T D V A L A D DG T V N S D D E E L Y S GG T R T P E A V Y T R I MV NGGK L Q K S H
EBL-2 Finland G K G T F E R R F F R D E R E L A E H E A I E S T K T D V A L A D DG T V N S D D E E L Y S GG T R T P E S V Y T R I MV NGGK L K K S H
EBL-1 France G K G T F E R R F F R D E K E L Q D Y E A A E S T K V D V A L A D DG T V N S D D E D F F S GD T R S P E A V Y T R I MMNGGR L K R S H
EBL-1 Poland G K G T F E R R F F R D E K E L Q D Y E A A E S T K V D V A L A D DG T V N S D D E D F F S GD T R S P E A V Y T R I MMNGGR L K R S H
Duvenhage G K G T F E R R F F R D E K E L Q D Y E E A E A T K I E A A L A D DG T V N S D D E D F F S GD T R S P E A V Y T R I MMNGGR L K G A H
Lagos Bat G K G T F E R R F F R D E K E MQ D Y A D L E G A R V E A S L A D DG T V D S D D E D F F S G E T R S P E A V Y S R I MMN NGR L K K S H
Mokola G K G T F E R R F F R D E K E MQ D Y T E L E E A R V E A S L A D DG T V D S D E E D F F S G E T R S P E A V Y S R I MMN NGK L K K V H
* . * * * * * * * * * . * . . * . . * * * * * . * . . * * * . * * . . * . . * . . * .
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Figure 4-3 –continued  N protein alignment (page 7 of 7) 
 
 
 
421 430 440 450
I I I
ABL01SEQ-B I
I
R R Y I S V S S N HQ S R P N S F A E F L N K T Y S S D S -
ABL30Tvl-R I R R Y I S V S S N HQ S R P N S F A E F L N K T Y S S D S -
ABL35SEQ-B I R R Y I S V S S N HQ S R P N S F A E F L N K T Y S S D S -
ABL37Cen-B I R R Y I S V S S N HQ S R P N S F A E F L N K T Y S S D S -
ABLHumanPt I R R Y I S V S S N HQ S R P N S F A E F L N K T Y S S D S -
ABLBallina I R R Y I S V S S N HQ S R P N S F A E F L N K T Y S S D S -
AAHLYBST I R R Y I S V S S N HQ S R P N S F A E F L N K T Y S S D S -
ABL12YBST I R R Y I S V S S N HQ S R P N S F A E F L N K T Y S S D S -
ABL15YBST I R R Y I S V S S N HQ S R P N S F A E F L N K T Y S S D S -
HoaryBat1Canada I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
HoaryBat8Canada I R R Y V S V S S N HQ A R P N S F A E F L N K A Y S S D S -
SilverHairBatCanada I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
LittleBrown4Canada I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
LittleBrown6Canada I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
RedBatUSA I R R Y V S V S S N HQ A R P N S F A E F L N K A Y S S D S -
NorthnYellowUSA I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
BigBrown22Canada I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S N D S -
BigBrown32Canada I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
BigBrown57Canada I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
BigBrown71USA I R R Y V S V S S N HQ A R P N S F A E F L S K T Y S S D S -
FreeTailBatUSA I R R Y V S V S S N HQ T R P N S F A E F L N K T Y S S D S -
FreeTailBatChile I R R Y V S V S S N HQ A R P N S S A E F L N K T Y S S D S -
InsectivBatChile I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
VampireBrasil I R R Y V S V S S N HQ T R P N S F A E F L N K T Y S S D S -
VampBrazil I R R Y V S V S S N HQ T R P N S F A E F L N K T Y S S D S -
VampHuPeru I R R Y V S V S S N HQ T R P N S F A E F L N K T Y S S D S -
MongooseSthAfrica I R R F V S V S S N HQ A R P N T F A E F L N K T Y S S D S -
KuduNamibia I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
DogCentralAfrica I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
DogAfrica I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
DogIvoryCoast I R R Y V S V S S N HQ A R P N S F A E F L K K T Y S S D S -
DogGuinea I R R Y V A V S S N HQ A R P N S F A E F L N K T Y S S D S -
DogAlgeria I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
DogIran I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S N D S -
PV I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
SAD-B19 I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
CVS and Nobivac I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S N D S -
RCHLVac I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
Nishigahara I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
3AGChina I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
DogMexico I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
RaccoonUSA I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S N D P -
RaccoonUSA I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S N D P -
RaccoonUSA I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S N D P -
SkunkWestCanada I R R Y V S V S S N HQ T R P N S F A E F L N K T Y S S D S -
SkunkCanada I R R Y V S V S S N HQ A R P N S F A E F L N K T Y T S D S -
ONT2SkunkCanada I R R Y V S V S S N HQ A R P N S F A E F L N N T Y S S D P -
ONT3RedFoxCanada I R R Y V S V S S N HQ A R P N S F A E F L N N T Y S S D P -
ArcticFoxRussia I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
ArcticFoxGreenland I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D S -
RaccoonDogEstonia I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S N D S -
RaccoonDogPoland I R R Y V S V S S N HQ A R P N S F A E F L N K T Y S N D S -
RedFoxFrance I R R Y V S V S S N HQ A R P N S F A D F L N K T Y S N D S -
RedFoxYugoslavia I R R Y V S V S S N HQ A R P N S F A D F L N K T Y S N D S -
RedFoxGermany I R R Y V S V S S N HQ A R P N S F A D F L N K T Y S N D S -
HumanThailand I R R Y V E V S S N HQ A R P N S F A E F L N K T Y S S D P -
RabiesIndia I R R Y V S V S S N HQ A R P N S S P E F L N K T Y S S D S -
EBL-2 Holland I K R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D P R
EBL-2 Finland I K R Y V S V S S N HQ A R P N S F A E F L N K T Y S S D P R
EBL-1 France I K R Y V S V S A N HQ A R P N S F A E F L N K T Y S S D P R
EBL-1 Poland I K R Y V S V S A N HQ A R P N S F A E F L N K T N S S D S R
Duvenhage I R R Y V S V S S S HQ A R P N S F A E F L N K T Y S S D S R
Lagos Bat I R R Y V S V S S N HQ A R P N S F A E F L N K V Y S E S S -
Mokola I R R Y I A V S S N HQ A R P N S F A E F L N K V Y A DG S -
* . * . . * * . * * . * * * . . * * .
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Chapter 4 
 Figure 4-4 Percent similarity matrix comparing the unique N protein amino acid sequences of pteropid-variant ABLV (n=5) and YBST-variant ABLV 
(n=3) with those of 24 other rabies-like and rabies viruses 
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ABL30Tvl-R 99.8 100
ABL35SEQ-B 99.8 99.6 100
ABL37Cen-B 99.8 99.6 99.6 100
ABLHumanPt 99.6 99.3 99.3 99.3 100 Key
ABLBallina 98.9 98.7 98.7 98.7 98.4 100
ABL12YBST 97.1 96.9 97.3 96.9 96.7 96.2 100
ABL15YBST 96.7 96.4 96.9 96.4 96.2 96.0 99.6 100
AAHLYBST 96.0 95.8 96.2 95.8 95.6 95.6 98.9 98.4 100
BigBrown71USA 93.6 93.3 93.3 93.3 93.1 92.7 91.3 90.9 90.2 100
VampHuPeru 93.6 93.3 93.3 93.3 93.1 92.7 92.4 92.0 91.3 96.2 100
HoaryBat8Canada 90.7 90.4 90.4 90.4 90.2 90.0 90.2 89.8 89.1 94.4 94.9 100
DogAfrica 92.2 92.0 92.0 92.0 91.8 91.3 90.4 90.0 89.6 94.9 95.3 92.4 100
MongooseSthAfrica 92.4 92.2 92.2 92.2 92.0 91.6 90.9 90.4 89.8 95.1 95.6 92.4 95.1 100
KuduNamibia 90.9 90.7 90.7 90.7 90.4 90.0 89.8 89.3 88.7 93.8 94.0 91.8 94.4 94.4 100
DogIran 92.4 92.2 92.2 92.2 92.0 91.6 90.7 90.2 89.6 95.6 96.0 93.1 96.7 95.8 95.6 100  
CVS and Nobivac 92.9 92.7 92.7 92.7 92.4 92.0 91.3 90.9 90.2 96.2 96.4 93.6 96.9 96.0 95.8 98.4 100
PV 92.4 92.2 92.2 92.2 92.0 91.8 90.7 90.2 89.6 95.3 95.6 93.6 96.2 95.3 95.1 97.8 97.8 100
3AGChina 90.4 90.2 90.4 90.2 90.4 89.6 88.9 88.4 88.0 93.6 93.3 90.7 94.0 93.3 92.9 95.1 95.8 94.9 100
DogMexico 93.6 93.3 93.3 93.3 93.1 92.7 91.8 91.3 90.7 96.7 97.1 94.2 97.8 96.9 96.7 98.9 99.1 98.4 96.2 100
SkunkWestCanada 93.1 92.9 92.9 92.9 92.7 92.2 91.3 90.9 90.2 96.0 96.7 93.3 96.4 95.8 95.6 97.6 97.8 97.1 94.9 98.7 100
NYRaccoonUSA 92.0 91.8 91.8 91.8 92.0 91.1 90.7 90.2 89.6 95.6 95.1 92.7 94.4 94.4 93.3 95.6 96.2 95.3 92.9 96.2 95.6 100
ArcticFoxGreenland 92.9 92.7 92.7 92.7 92.4 92.0 91.1 90.7 90.0 95.8 96.4 93.6 96.4 96.0 95.3 97.1 97.3 97.1 94.9 98.2 96.9 95.3 100
RaccoonDogEstonia 92.9 92.7 92.7 92.7 92.4 92.0 91.1 90.7 90.0 96.2 96.4 93.8 97.1 96.2 96.0 98.7 98.9 97.8 95.6 99.3 98.0 96.0 98.0 100
RedFoxFrance 92.9 92.7 92.7 92.7 92.4 92.0 91.1 90.7 90.0 96.0 96.4 93.6 97.1 96.2 96.0 98.7 98.9 97.8 95.6 99.3 98.0 96.0 97.6 99.1 100
RabiesIndia 92.9 92.7 92.7 92.7 92.4 92.0 91.3 90.9 90.2 95.8 96.4 93.3 96.0 96.0 94.7 96.7 96.9 96.2 94.0 97.8 96.4 94.9 96.7 97.1 97.1 100
Duvenhage 90.2 90.0 90.0 90.0 89.8 89.8 89.8 89.6 88.7 89.1 88.5 86.9 87.1 87.4 85.6 87.6 88.0 87.4 85.6 88.5 87.6 87.4 87.8 88.0 87.8 87.6 100
EBL-1 France 90.2 90.0 90.0 90.0 89.8 89.6 89.1 88.7 88.0 88.5 88.0 86.7 87.4 87.6 85.8 87.8 88.2 88.0 85.8 88.7 88.0 87.8 88.0 88.2 88.0 87.6 93.3 100
EBL-1 Poland 90.0 89.8 89.8 89.8 89.6 89.4 88.9 88.5 87.8 88.2 87.8 86.5 87.1 87.4 85.6 87.6 88.0 87.8 86.0 88.5 87.8 87.1 87.8 88.0 87.8 87.4 92.7 98.7 100
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  Other rabies-like lyssaviruses
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4.3.1 Phylogenetic trees 
Phylogenetic trees generated from the N protein coding sequences of ABLV and other lyssavirus 
isolates using either neighbour joining or maximum parsimony show very similar overall 
topologies that are shown in Figure 4-5 to Figure 4-11.  
The ABLV sequences form a discrete clade with strong bootstrap support (100% using neighbour 
joining and 97% using maximum parsimony) that is separate, but most closely related to, the 
clade comprised of the rabies virus isolates. Furthermore, the ABLV clade consists of two 
monophyletic sister groups, each with 100% bootstrap support, one comprised of all 30 ABLV 
isolates from pteropid bats (pteropid-variant ABLV), and one comprised of all 4 ABLV isolates 
from YBST bats (YBST-variant ABLV).  
Branch lengths differentiating the Lyssavirus lineages are in virology taxonomy terms 
comparatively short, but this is particularly so within the pteropid-variant and YBST-variant ABLV 
sister groups. The relationships within the ABLV clade were more closely examined using these 
sequences alone as shown in Figures 4-8 to 4-11. The topology among the YBST-variant isolates 
was identical using both methods, and the relationships within the pteropid-variant sister group 
using both methods are more similar than might immediately be apparent. Within the pteropid-
variant isolates there is no suggestion of any species specific (i.e. Black, Grey-headed or Little 
Red flying fox), regional (SEQ, Cen, or Tvl), or temporal (1997 to 2000) sub-variants. Rather the 
relatively long branch length between the two ABLV variants, their strong bootstrap support, and 
the very short branch lengths between isolates within each variant suggest that each variant is 
comparatively stable with only very low levels of genetic divergence between isolates of each 
variant. 
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Figure 4-5 Lyssavirus phylogeny: unrooted neighbour joining phylogram generated from 
the complete N protein coding sequences of 30 pteropid-variant ABLV, 4 YBST-
variant ABLV, and 55 other rabies-like and rabies virus isolates 
Branch lengths are proportional to evolutionary distances as indicated by the distance bar. Virus 
isolate and GenBank accession details are shown in Table 4-2 and Table 4-5. Relationships 
within each shaded group are shown in Figure 4-6 and Figure 4-7. 
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Figure 4-6 Lyssavirus phylogeny: rooted neighbour joining phylogram  
Generated from the same complete N protein coding sequences as Figure 4-5. Numbers at 
major nodes indicate percent bootstrap support (1000 replicates). Horizontal branch lengths are 
proportional to evolutionary distances as indicated by the distance bar. Mokola virus defined as 
outgroup. Virus isolate and GenBank accession details are shown in Table 4-2 and Table 4-5.  
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Figure 4-7 Lyssavirus phylogeny: rooted maximum parsimony phylogram  
Generated by fast stepwise addition search from the same complete N protein coding 
sequences as Figure 4-5 and Figure 4-6. Numbers at major nodes indicate percent bootstrap 
support (1000 replicates). Horizontal branch lengths are proportional to the number of changes 
as indicated by the distance bar. Branches are collapsed (creating polytomies) if maximum 
branch length is zero. Mokola virus defined as outgroup. Virus isolate and GenBank accession 
details are shown in Table 4-2 and Table 4-5.  
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Figure 4-8 ABLV phylogeny: midpoint rooted neighbour joining phylogram generated from 
the complete N protein coding sequences of 28 new pteropid-variant ABLV, 3 
new YBST-variant ABLV, and 3 other ABLV isolates 
Horizontal branch lengths are proportional to evolutionary distances as indicated by the 
distance bar. The evolutionary distance of the major branch is shown. Virus isolate and 
GenBank accession details are shown in Table 4-2 and Table 4-5. Due to the short branch 
lengths, a cladogram showing bootstrap support for this tree is shown separately in Figure 4-9. 
ABLHumanPt
ABL05SEQ-B
ABL22SEQ-B
ABL13SEQ-G
ABL30Tvl-R
ABL03Tvl-R
ABLBallina
ABL08SEQ-G
ABL32Tvl-B
ABL14Cen-B
ABL09SEQ-G
ABL35SEQ-B
ABL01SEQ-B
ABL26SEQ-B
ABL36SEQ-B
ABL17Tvl-B
ABL23SEQ-B
ABL29Tvl-R
ABL21SEQ-R
ABL24 &25SEQ-R
ABL07SEQ-G
ABL06SEQ-B
ABL16Cen-R
ABL34Cen-B
ABL37Cen-B
ABL02SEQ-G
ABL31SEQ-R
ABL33SEQ-B
ABL19SEQ-R
AAHLYBST
ABL12YBST
ABL11YBST
ABL15YBST
0.005 substitutions/site
Pteropid-variant  ABL 
YBST-variant  ABL 
0.134
 
 
 
   Molecular diversity of ABLV  
173
Figure 4-9 ABLV phylogeny: neighbour joining cladogram  
Generated by bootstrap resampling (1000 replicates) of 34 complete ABLV N protein coding 
sequences. Shows groups compatible with 50% majority-rule consensus and bootstrap 
proportions >5%. Virus isolate and GenBank accession details are shown in Table 4-2 and 
Table 4-5. 
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Figure 4-10 ABLV Phylogeny: rooted maximum parsimony phylogram generated from 34 
complete ABLV N protein sequences 
Horizontal branch lengths are proportional to evolutionary distances as indicated by the 
distance bar. The evolutionary distance of the major branch is shown. Branches are 
collapsed (creating polytomies) if maximum branch length equals zero. YBST-variant ABLVs 
defined as monophyletic sister outgroup. Sequence details are in Table 4-2 and Table 4-5. 
Due to the short branch lengths, a cladogram showing bootstrap support for this tree is 
shown separately in Figure 4-11. 
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Figure 4-11 ABLV phylogeny: maximum parsimony cladogram  
Generated by bootstrap resampling (1000 replicates) of 34 complete N protein coding 
sequences. Shows groups compatible with 50% majority-rule consensus and bootstrap 
values >5%. Branches are collapsed (creating polytomies) if maximum branch length is zero. 
Sequence details are in Table 4-2 and Table 4-5.  
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4.4 Discussion 
In this study direct cDNA synthesis, amplification, and sequencing from naturally infected, primary 
(bat) host tissues was done to preclude the possibility of selection mutations occurring during 
passage in humans, mice, or in vitro cell culture. The sequences were consistent with those of 
three other ABLV isolates that were (ABLBallina, GenBank AF006497, and AAHLYBST 
AF081020) or became (ABLHumanPt AF418014) available during this study (Gould et al. 1998; 
Gould et al. 2002; Warrilow et al. 2002). These other isolates had been passaged in a non-bat 
species (a human or mice) and amplified in non-bat cell cultures ( BHK-21 or mouse 
neuroblastoma cells) prior to RNA extraction (Gould et al. 1998; Gould et al. 2002; Warrilow et al. 
2002). 
4.4.1 Functional features of the ABLV and other lyssavirus 
sequences  
The complete ABLV genome is 11,918 nucleotides long (Warrilow et al. 2002), with the first ORF 
encoding the N protein. The functional features of the 5’ end of available lyssavirus sequences 
are shown in Table 4-7. The N gene is preceded by a leader sequence of unknown function 
which, in the few isolates where it has been completely determined (ABLHumanPt, several rabies 
isolates, and Mokola virus (Bourhy et al. 1993a; Le Mercier et al. 1997)), is 57 nucleotides long. 
The first nucleotide determined in the 31 ABLV and Nobivac RIVM sequences reported here 
corresponds to position 23 in the leader sequence, and the last corresponds to the 47  (ABLV) or 
54  (Nobivac) nucleotides of the phosphoprotein (P) coding sequence.  
th
th
The leader sequence has an AAGCA TG termination signal which is common to all 31 ABLV 
sequences determined here, the ABLHumanPt sequence, and several isolates of laboratory strain 
rabies virus (PV, CVS, Nobivac (RIVM), Nishigahara, RCHLVac, and SAD-B19, see Table 4-7). 
The leader termination signal for PV differs slightly (GAGCA TG), and is substantially different for 
Mokola virus (TA CA TG). For all these lyssaviruses, the leader to N gene intergenic region is a 
single nucleotide (T). The ABLV N gene transcription initiation signal (A CAC T) is perfectly 
conserved among the 31 new ABLV sequences, ABLHumanPt, and three laboratory rabies virus 
strains (Nobivac RIVM, CVS and SAD-B19), but differs at a single site for some other rabies virus 
stains (A CAC TCT, PV Nishigahara and RC-HVL) and for Mokola virus (A CACTC T). The N 
protein start codon for all these sequences is ATG, at positions 71 to 73.  
5
5
3 4
2 4
2 2 2 2
The leader sequence, intergenic region, N gene transcription initiation signal, and N protein start 
codon for Lagos bat virus, Duvenhage virus, EBL-1, EBL-2, ABLBallina and AAHLYBST, have not 
been determined as all have been sequenced from cDNA synthesized using the PVN7 primer that 
corresponds to positions 55 to 73 and includes what is presumed to be the ATG start codon. 
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Table 4-7 Comparison of functional features of the 5’ end (leader to P protein) of the lyssavirus sequences 
(Differences are highlighted with red font) 
Leader sequence  N gene    P gene 
Leader to N 
intergenic 
region 
N to P 
intergenic 
region 
Virus  1  mRNA 
transcription 
initiation 
Start 
codon 
Coding 
length 
(bases) 
Stop 
codon 
3’ UTR 
length 
(bases) 
Polyadenylatio
n termination 
signal 
 mRNA 
transcription 
initiation 
Start 
codon 
Length 
(bases) 
Termination 
signal 
1350  2ABLBallina   --- --- --- --- --- TAA    AGA  66 A CACCCCT ATG  CT 6 2
2AAHLYBST 1350  --- --- --- --- ---      
         
       
    
     
    
  
  
    
TAA 65 AGA    CT A CACCCCT2 ATG7
ABLHumanPt   57   AAGCA TG T A CACCCCT ATG 1350 TAA 66 AGA    CT A CACCCCT ATG5 2 7 2
 66 or 67  3 AGA or AGA  31 new ABLV   AAGCA TG  T A CACCCCT ATG 1350 TAA A CACCCCT ATG  CT >35 87 5 2 2
ARabies virus / AGCA TG TAG    57 5 T ATG 1350 TAA 62   CT ATG G A CACC / CT 2 TC A CAC / / CT C C7 T T2
Mokola   57   TA CA TG 3 4 T A CACTCCT 2 ATG 1350 TAA AGA  7 A CACCACT 2
Lagos bat --- --- --- 1350 TAA 68 7   CTC 2 ATG 
Duvenhage   --- 
  CTT71 ATG 
2 A CATCTCT AGA    --- --- 
1353  2 TAG  A CACCACT TAA 62   CT ATG --- --- --- --- 7 2
1353  2EBL1  TAA 63 or 68 AGA    CT A CACCCCT ATG  --- --- --- --- --- 7 2
--- 1353  2EBL2 TAA 73 AGA    CT A CACCCCT ATG  --- --- --- --- 7 2
 
--- Not determined, sequence unknown. 
1 Virus isolate and GenBank accession details are shown in Table 4-2 and Table 4-5. The rabies isolates referred to are PV, CVS, Nobivac (RIVM), Nishigahara, RCHLVac, and 
SAD-B19. The N gene 3’UTR and start of the P gene sequence for Lagos bat, Duvenhage, EBL-1 and EBL-2 are from Bourhy et al. (1993a). 
2 Sequence length based on the presumption that the N protein start codon corresponds with the terminal ATP of the PVN7 primer used for cDNA synthesis and PCR amplification. 
3 One of 31 new ABLV sequences (ABL14Cen-B) had a 67 base 5’UTR due to an extra A base in the polyadenylation termination signal (AGA ). 8
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For all available ABLV, rabies and Mokola virus sequences, the N protein coding sequence is the 
same length, 1350 nucleotides, encodes a 450 amino acid protein, and terminates with a perfectly 
conserved TAA stop codon at position 1421 to 1423. The coding sequence for Duvenhage, EBL1 
and EBL2 is apparently three bases longer, encoding an extra terminal Arginine (R) before the 
TAA stop codon (Bourhy et al. 1993a). As in all previously published lyssavirus sequences, the 
putative phosphorylation site at amino acid Ser  (Minamoto et al. 1994), is conserved in the 
pteropid and YBST-variant ABLV sequences reported here.  
389
Regions of rabies virus amino acid sequences have been identified as important linear (RCHLVac 
antigenic sites I and IV, residues 358-367 and 375-383, (Goto et al. 2000), ERA antigenic sites at 
residues 313-337 and 374-383 (Dietzschold et al. 1987a)), or conformational epitopes (RCHLVac 
antigenic sites II and III). The amino acid sequence at antigenic site I (amino acids 358-367) is 
perfectly conserved and would be expected to form common epitopes among YBST and pteropid-
variant ABLV (except ABLHumanPt, Asp  to Asn ), most rabies viruses (not RaccoonUSA, 
also Asp  to Asn ), Duvenhage, and EBL-1. This common lyssavirus reactivity has been 
demonstrated for RCHLVac, HEP-Flury, CVS and ERA rabies virus, Duvenhage, Mokola and 
Lagos bat viruses using three antigenic site I antibodies (Goto et al. 2000). In contrast the YBST-
variant and pteropid-variant ABLV sequences at antigenic site IV (amino acids 375-383), while 
perfectly conserved among sequences of each variant, are very different, not only from those of 
all other lyssaviruses, but also from each other, so that it is likely that linear site IV epitopes are 
probably ABLV and variant specific. Within the other linear antigenic site (residues 313-317), all 
the ABLV sequences are perfectly conserved with a unique combination of I  and S  
substitutions that may form epitopes that differentiate them from all other lyssaviruses. There is a 
very high amino acid homology among isolates of each variant of ABLV over the entire N protein, 
suggesting that ABLV N protein sequence variation is tightly constrained while circulating in the 
respective natural pteropid or YBST bat host populations. 
362
321 331
The 3’UTR of the N protein mRNA for all ABLV isolates is 66 bases long, and the lyssaviruses 
end with a transcription termination polyadenylation signal of either TAG (Duvenhage and rabies 
viruses) or AGA , with the following exceptions. While 30 of the 31 ABLV sequences reported 
here and that of AAHLYBST and ABLHumanPt end with the AGA  signal, in one ABLV sequence 
(ABLBallina) the polyadenylation signal is one A base short (AGA ) and in one of the sequences 
reported here (ABL14Cen-B) the signal is one A base long (AGA ). Whether the 
uncharacteristically short signal was present in the host animal virus population or is secondary to 
in vivo or in vitro passage prior to cDNA synthesis or an artefact of cDNA synthesis or PCR 
7 
7
7
8
362
362 362
In contrast, the sequence and length of the 3’ untranslated region (UTR) of the N gene are highly 
variable between the lyssavirus genotypes, the length varying between 62 bases for rabies and 
Duvenhage isolates and 73 bases for EBL2 (n=2) (Bourhy et al. 1993a). This variability in length 
and sequence makes alignment and subsequent analysis of this region quite subjective, and 
contributes to phylogenetic analysis of this region being less robust.  
6
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amplification is unclear. The long signal reported here occurred in both directions using cDNAs 
synthesized from RNA extracted directly from the natural host (P. alecto) brain and peristed 
despite use of two separate cDNA primers, and multiple PCR and sequencing reactions. This 
suggests this anomaly was present in the natural host virus population and that variations in the 
ABLV polyadenylation signal do occur naturally. 
4.4.2 Similarity analysis of ABLV 
The large scale of sequence variability between early laboratory rabies virus sequences and 
those of the other related lyssaviruses, Mokola, Duvenhage, and Lagos bat virus was readily 
described by percent similarity matrixes, with amino acid sequences within genotypes sharing  
> 97.1% similarity and sequences from different genotypes having < 93.3% amino acid similarity 
(Bourhy et al. 1993a). As more divergent genotype 1 rabies virus isolates were sequenced and 
compared with the most closely related EBL-1 and EBL-2 sequences, the greater intragenotype 
variability and low intergenotype variability meant that clear limits of percentage nucleotide or 
amino acid similarity enabling classification in or between genotypes was no longer apparent, with 
some overlap in intra- and inter-group similarity occurring (Kissi et al. 1995).  
Similarly, percent similarity analysis is unable to differentiate ABLV sequences from those of 
rabies virus isolates. As shown in Figure 4-4, the similarity between ABLV and the rabies virus 
sequences (88.0 - 93.6%), was no less than that amongst rabies isolates themselves (90.7- 
99.3%). At this level of analysis, while the ABLV isolates are clearly unique, they are not 
sufficiently different to be clearly distinguished from the rabies virus genotype.  
4.4.3 Phylogenetic analysis of ABLV 
Phylogenetic analysis of all the available ABLV N coding sequences (n=34) alone, and in 
combination with other sequences representing the range of other lyssaviruses clearly indicate 
that all the ABLV isolates cluster together as a discrete sister group, with ≥ 97% bootstrap 
However, this analysis is comparatively crude as it only counts the number of differences between 
pairs of sequences and does not consider the characteristics of and relationships between those 
changes. For example the greater functional significance of non-synonymous rather than 
synonymous nucleotide changes is not reflected in nucleotide sequence similarity matrixes. While 
doing amino acid rather than nucleotide similarity matrixes restricts the analysis to only non-
synonymous nucleotide changes, it results in the loss of other potentially significant information. 
The crude similarities between some lyssavirus sequences exceeds the capacity of similarity 
matrixes to differentiate related virus groups. Proper consideration of the similarities and 
differences between ABLV and the other lyssaviruses should include not only the number, but the 
position, type, and the relationships between, the sequence differences. Such consideration is 
provided by phylogenetic sequence analysis.  
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support, within the genus Lyssavirus. The ABLV lineage is most closely related to that of the 
rabies viruses and then EBL-2. The ABLV lineage consists of two clads, one isolated only from 
YBST bats (YBST-variant ABLV), and one isolated from the three common species of flying fox 
(Black, Grey-headed and Little Red flying fox (pteropid-variant ABLV). The distinction between the 
variants is strongly supported by 100% bootstrap support and a relatively long branch length. 
Within each variant, the four YBST-variant isolates and 30 pteropid-variant isolates are separated 
by very short branch lengths, notably shorter than the branch lengths between rabies isolates, 
indicating that genetic variability within each variant is very low. This analysis supports and 
strengthens previous analyses using the original pteropid and YBST sequences (ABLBallina, and 
AAHLYBST) and later pteropid sequence (ABLHumanPt) that proposed that the ABLV isolates 
consisted a new genotype, Genotype 7, within the Lyssavirus genus (Gould et al. 1998; Gould et 
al. 2002; Hooper et al. 1997b ; McColl et al. 2000 ; Warrilow et al. 2002).  
Among the isolates recovered from pteropid bats, there was no geographical association among 
the sequences, despite sequences from flying foxes having been collected over a range of more 
than 700 km (Townsville to the Gold Coast). In particular neither the four isolates from Central 
Queensland nor the five isolates from Far North Queensland showed unique sequence 
characteristics compared to those from Southeast Queensland.  
This contrasts with what has been demonstrated among terrestrial rabies virus isolates where 
both global (Arai et al. 2001; Kissi et al. 1995 ; Nel et al. 1993) and local (Bourhy et al. 1999 ; Ito 
et al. 1999; Nadin-Davis et al. 1993 ; Sacramento et al. 1992) associations have been found 
between sequences and the geographical area in which they occurred. Regional associations 
within a single rabies reservoir species have been attributed to slow evolution of the virus 
population in parallel with spatial and temporal progression of an epizootic (Bourhy et al. 1999 ; 
Nadin-Davis et al. 1993; Sacramento et al. 1992 ), or to local geographical features such as 
mountains and rivers producing functional isolation of sub-populations of the host species and 
independent evolution of the virus within these sub-populations (Bourhy et al. 1999; Ito et al. 
1999; Nadin-Davis et al. 1999 ). 
More surprisingly, no species-specific associations were found among the pteropid isolates, i.e. 
no Black, Grey-headed, or Little Red flying fox specific sub-variants. This is not unexpected 
among the isolates from Black, Grey-headed and Spectacled flying foxes, as these bats are very 
similar in terms of their reproductive biology and feeding behaviour and frequently camp in mixed 
colonies of Black and Grey-headed flying foxes in Southeast Queensland, and Black and 
The absence of regional ‘sub-variants’ of pteropid-ABLV can probably be attributed to the fact 
bats fly and live together in large colonies, with individuals flying considerable distances and 
interacting with other colonies (Eby 1991; Nelson 1965). As a result, there are probably 
comparably few degrees of separation between individuals separated by great distance. It 
appears that with respect to ABLV, the flying foxes of Queensland function as a single population 
rather than as regionally distinct sub-populations.  
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Spectacled flying foxes in Far North Queensland. However, Little Red flying foxes differ most from 
the other species physically, have a reproductive cycle that is offset from other flying foxes by 
approximately 6 months, disperse to inland Queensland during the winter, and feed principally on 
blossom and nectar rather that fruit. It was thought possible that these social and biological 
differences may have been associated with species-specific adaptations of ABLV; however no 
sequence specificity was found among any of the flying fox species. Little Red flying foxes do 
camp in mixed colonies with the other flying foxes. It would appear that they, together with the 
other species, act as a single host population for pteropid-variant ABLV. 
The attempt to demonstrate the presence or absence of temporal variation in the ABLV 
sequences was limited by the relatively brief collection period of 3 ½ years. No temporal 
associations were found. 
All these findings are consistent with those of a closely related study published while this work 
was underway (Gould et al. 2002) that was based on only partial sequencing of the N gene 
(nucleotides 443 to 892 of the ABLBallina isolate, corresponding to bases 513 to 962 of Appendix 
10, Figure A10-1) of ABLV isolates that had been passaged in mice and/or one or more cell 
culture lines. At least seven of the partial sequences used in that study are derived from material 
from the same bat ABLV cases as those of this study (see Table 4-2), having been forwarded to 
the AAHL from the ARI for diagnostic confirmation. Unfortunately the partial sequences 
themselves have not been published nor provided to GenBank and so direct comparison of the 
sequence results from the same cases by the two laboratories has not been possible.  
The phylogeny of the 31 ABLV N protein coding sequences shown here is also strikingly similar to 
that of the corresponding G gene sequences determined from 22 of the same RNA extractions by 
other members of the research group (Guyatt et al. 2003). The numbers in the sequence names 
of these 22 G gene sequences, e.g. G gene ABLPA01MB, (Guyatt et al. 2003), correspond with 
the similarly numbered N gene sequence reported here, e.g. ABL01SEQ-B. The G gene has been 
used to examine the phylogeny of ABLV and other lyssaviruses as the glycoprotein is the major 
antigen involved in eliciting humoral immunity and vaccine efficacy, is important in pathogenesis 
through its role in binding to host cell receptors and in host cell penetration, and may also play a 
role in host specificity. As in studies of other lyssaviruses (Nadin-Davis et al. 1993; Nadin-Davis et 
al. 1999), the phylogeny of the N and G genes of ABLV are in agreement, with respect to the 
relationships between individual ABLV isolates, between the YBST and pteropid variants, and the 
relationship of the ABLV lineages to the other lyssaviruses.  
With respect to the absence of temporal variants of ABLV, the capacity to detect variants among 
the sequences used by Gould et al. (2002) and this study is limited by the short period (< 4 years 
per report) during which sequences were collected. A truer reflection of the temporal stability of 
ABLV will require isolates from the distant past (none of which have been found), or the future. 
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With respect to the absence of regional or pteropid species-specific variants of ABLV, the capacity 
of the partial sequences in Gould et al. (2002) to detect potential variants was limited by the well-
conserved nature of the section of N gene used. However it is strongly supported by the use in 
this report of the complete N gene coding sequence, including the more variable 5’ and 3’ end 
regions, and the even more variable G gene (Guyatt et al. 2003). 
The clear phylogenetic evidence for two genus-specific (Pteropus and Saccolaimus) ABLV 
variants, the exceptionally high sequence homogeneity within each variant, and the lack of 
regional ‘sub-variants’ suggests each has been present in their host populations for sufficient time 
for optimal ‘end-point’ host specific adaptations to have occurred. This would indicate that ABLV 
has been present in Australia since long before European colonization (pre 1788) and the 
apparently fortuitous and incidental recognition of ABLV in 1996. 
4.4.4 Two land masses, two lineages of rabies virus 
A further finding from the selection of rabies virus (genotype 1) sequences used here in both the 
neighbour joining and maximum parsimony analyses, was that the rabies virus clade consisted of 
two monophyletic sister groups, separated by a relatively long branch length, albeit with only 
modest bootstrap support (75 and 49% using neighbour joining and 62 and 44% using maximum 
parsimony). While this dichotomy had been noted by Nadin-Davis et al. (2001) using fewer 
complete N sequences, and by Smith et al. (1995) using partial N protein sequences from the 
USA and Mexico only, no interpretation with respect to the evolutionary origins of lineages of 
rabies virus (rather than variants) was made.  
There are no pre-colonial references to rabies in the Americas (Smith and Seidel 1993), which 
may suggest that the multiple species-specific and/or regional variants of rabies in the Americas 
were all introduced following European colonization. Instead this phyogenetic analysis suggests 
that there are two ancient lineages of genotype 1 rabies virus, both of which are now present in 
the Americas. One consists of rabies variants that were initially recognized in Africa, Europe, and 
Asia during the time that these land mass were made confluent by human activity but remained 
discrete from the Americas. It is well recognised that some of these ‘Old World’ rabies variants 
have since been introduced to the Americas and have established themselves in introduced host 
populations (e.g. dog rabies in dogs in Mexico) or related native hosts e.g. Arctic fox rabies in 
Arctic foxes and red foxes in Alaska, in Canadian red foxes and striped skunks (Nadin-Davis et al. 
1994), and red foxes in north-eastern USA (Smith 1989; Smith et al. 1995). The other lineage 
consists of rabies variants specific to indigenous host populations of the Americas (multiple 
American bat rabies variants and raccoon-variant rabies). It is proposed here that it represents a 
separate indigenous lineage of multiple ‘New World’ variants that were present and evolved in 
America prior to European colonization and had minimal (unrecorded) impact on indigenous 
human populations. 
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Complete N protein sequences for every variant / endemic of rabies within the United States were 
not found for use in this analysis, however the broad phylogenetic relationships seen using the 
terminal 320 nucleotides of the N gene (Smith et al. 1995), can reasonably be inferred and 
transposed onto this analysis. Only the rabies variant of striped skunks in Texas would be 
expected to associate with the bat and raccoon variants in the ‘New World’ group. Such a 
clustering was evident in a phylogeneteic study of lyssavirus P gene sequences, in which four 
Texan skunk isolates clustered with raccoon and American bat isolates (Nadin-Davis et al. 2002). 
The N gene sequences of isolates from the other US endemics not included in this analysis, 
skunks in California and Iowa-Minnesota-South Dakota, gray foxes in Texas and Arizona, and 
coyotes in Texas and Mexico would be expected to associate with the ‘Old World’ group. This was 
the case for one Texan coyote in the P gene analysis (Nadin-Davis et al. 2002). The outbreak in 
coyotes is known to be a spill-over from domestic dogs in Texas and Mexico (Smith et al. 1995).  
If the origins of rabies variants along ‘New World’/’Old World’ lineages is true, then the position of 
the sequence from the West Canadian skunk in this analysis is interesting. It associates most 
strongly with two laboratory strains of dog-variant rabies (PV and SAD-B19), then with other dog-
variant isolates from Central Africa, Algeria and Iran, other laboratory strains of dog-variant rabies 
(3AGChina, Nishigahara and RCHLVac) and the red fox and raccoon dog-variants of rabies from 
Europe that are believed to be dog-variant derivatives (Bourhy et al. 1999; Holmes et al. 2002). It 
occurs in the ‘Old World’ group of rabies viruses that includes the Arctic fox variant rabies virus 
present in red foxes and skunks in eastern Canada that is believed to have originated in Europe. 
It is not in the ‘New World’ group of isolates that affect the other indigenous American host 
species, the microbats and raccoon. This association with ‘Old World’ dog-variant rabies suggests 
that the rabies virus circulating in skunks in West Canada is also a derivative of dog-variant 
rabies, presumably introduced by European settlers, that has established itself in the endemic 
skunk population.  
Given the phylogenetic relationships shown here and inferred from Smith et al. (1995) and Nadin-
Davis et al. (2002), and what has been previously published about the origins of some of the 
American endemics, it appears that there were rabies viruses in the Americas that evolved in the 
Americas, prior to European contact. These ‘New World’ indigenous rabies variants are those of 
the microbats, raccoons, and skunks in Texas. All the other variants presently in the Americas are 
either known (Mexican dogs, Arctic foxes, red foxes, coyotes, Ontario skunks, and Caribbean 
mongooses) or proposed here (West Canadian skunks, skunks of California and Iowa-Minnesota-
South Dakota, and grey foxes) to involve exotic dog-derived rabies variants introduced after 1700 
(Smith and Seidel 1993) that subsequently adapted to resident host species.  
It has been shown that there is no evidence of recombination in lyssavirus evolution, and that 
point mutation and purifying selection are the major forces in lyssavirus evolution (Badrane and 
Tordo 2001). In the absence of recombination and presuming evolution at similar rates, Badrane 
and Tordo (2001) proposed that the phylogeny of the genotype 1 rabies sequences indicates two 
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successful host switching events from American microbats to carnivores, both estimated to have 
occurred 888 to 1,459 years ago. They further proposed that one (or more) spillover event 
produced the native American raccoon and Texan skunk variants, while the other gave rise to the 
now worldwide ‘Old World’ terrestrial/carnivore variants. This however is not consistent with 
historical accounts of rabies.  
‘Old World’ carnivore (dog) rabies is believed to have been present in Mesopotamia at least since 
2300 BC and was known to Aristotle in fourth century B.C. Greece (Wilkinson 2002). These 
accounts indicate carnivore rabies virus evolved far earlier than just 1,459 years ago. No 
connection between carnivores in Europe and the Middle East, and microbats in the Americas is 
known for that time. Had ‘Old World’ rabies in carnivores in Europe and the Middle East arisen 
from bats, it would surely have been as a result of contact with European, African or Asian bat 
species; however the relatively distant relationships between carnivore rabies and EBL-1, EBL-2, 
Duvenhage, Lagos bat and Mokola viruses do not suggest this.  
Rather than ‘Old World’ carnivore rabies having evolved from a spillover from bats, the 
evolutionary origin of genotype 1 rabies virus that is proposed here is that ‘Old World’ and ‘New 
World’ lineages of rabies virus are each derived from an ancient progenitor virus. Furthermore 
that these lineages were separated at the time of continental shift. A theory of continental isolation 
of progenitor lyssaviruses with independent evolution also suggests an explanation for the origins 
of ABLV: that the ancient progenitor virus was also isolated on the Australian continent and 
evolved along a third lineage into two variants, pteropid- and ybst-ABLV. The phylogeny of the 
‘New World’ microbat, raccoon and Texan skunk isolates certainly suggests spillover between bat 
and carnivore hosts, but the direction of the spillover, to or from bats is not indicated. 
It is highly relevant to Australia to note that while the establishment of ‘new’ endemics in ‘new’ 
host populations has occurred in Europe and North America on multiple occasions in the past 
1000 years, all have involved dog-variant or dog-derived variants of ‘Old World’ genotype 1 rabies 
virus (Bourhy et al. 1999; Smith et al. 1992). Australia has susceptible populations of domestic 
dogs, red foxes, presumably dingoes, and possibly carnivorous marsupials such as quolls 
(Dasyurus spp.) that would be expected to support the establishment of self sustaining cycles of 
dog-type rabies infection if adequately introduced. The presence of ABLV in Australia in no way 
reduces the very real threat genotype 1 dog-type rabies variants pose to these and other potential 
host populations. This is particularly so given the demonstrated propensity of dog-type rabies to 
establish itself in new canine and non-canine (e.g. skunk, mongoose, raccoon dog) populations, in 
contrast to the apparently ‘inert’ epidemiology of ABLV and other non-rabies bat lyssaviruses. If 
Australia is to avoid the establishment of multiple dog-type variant endemics, as has occurred in 
America, it is important our rabies-prevention quarantine measures be upheld, despite the 
presence of ABLV. 
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4.5 Conclusions 
Examination of molecular diversity of ABLV isolates 
♦ Sequences for 35 bases of the leader sequence, the entire N gene, and start of the P gene 
were determined and examined for 28 isolates of ABLV from Black, Grey-headed, and Little 
Red flying foxes and 3 isolates from YBST bats. 
Host species, geographic, and temporal variation among ABL isolates 
♦ The strong bootstrap support (>97%), low inter-variant variability, and the relatively long 
branch separating all ABLV sequences from all those of rabies virus and EBL-1, provide good 
phylogenetic evidence for ABLV as a discrete, seventh lyssavirus genotype.  
♦ Suitable material was not available for determination the ABLV sequence from the only known 
ABL-positive Spectacled flying fox.  
♦ All the ABLV isolates cluster together as a discrete sister group within the Lyssavirus genus. 
♦ The ABLV lineage consists of two variants separated by a relatively long branch length, one 
isolated only from YBST bats (YBST-variant ABLV), and one common to three common 
species of flying fox; Black, Grey-headed, and Little Red flying fox (pteropid-variant ABLV). 
♦ Within each variant the level of sequence variability is extremely low, indicating sequence 
stability and suggesting end-point adaptation to the relevant host genus. 
♦ There are no geographical or temporal sub-variants, nor did variants associate with individual 
flying fox species. 
♦ A discrete variant of ABLV appears to be associated with one species of insectivorous bat 
(Saccolaimus flaviventris, YBST bat), however as the number of submissions from microbats 
is small, it is possible this variant is also associated with other microbat species, and/or other 
variants are also circulating in other microbats.  
ABLV as the seventh genotype 
♦ The ABLV lineage is most closely related to that of the rabies viruses and then EBL-2. 
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5 Selection and characterization of an 
inoculum containing ABLV 
Aims  
2. 
5.1 Introduction 
1. To evaluate in vivo the virulence of a number of inocula prepared from the tissues of naturally 
ABLV-infected flying foxes. 
To select and characterize the most virulent inoculum for subsequent use in flying foxes. 
3. To evaluate by quantitative-PCR (TaqMan ) the relative amount of viral RNA in each 
inoculum, relate that to the effects of those inocula in mice, and evaluate the potential role of 
quantitative PCR in the selection of inocula. 

On two previous occasions Grey-headed flying foxes had been inoculated with preparations 
containing ABLV that had been isolated from a naturally infected bat and had undergone limited 
passage in mice and cell culture (McColl 1999; McColl et al. 2002). Using inocula containing 10  
TCID  and 10  TCID50 respectively, one of seven and three of 10 flying foxes developed clinical 
disease and were subsequently shown to be infected with ABLV. While the small number of 
affected bats provided preliminary observations of the disease in flying foxes, further studies of 
ABLV in bats were indicated. The small proportion of affected animals (23%, n=17) suggested 
that inducing disease in flying foxes by experimental inoculation would be difficult. 
3.7
50
5.0
For this study is was decided that inocula would be prepared directly from ABLV-positive tissues 
recovered from naturally infected bats in order to avoid any alteration in the virulence or 
pathogenesis of ABLV in experimental animals that might occur due to virus passage and 
amplification in aberrant species such as mice or cell culture. However, there had been 
considerable variation in the handling and storage of tissues collected from naturally affected 
bats, and it was presumed this would affect the viability and virulence of the ABLV in the stored 
tissues and the inocula prepared from them. Clearly, successful inoculation of flying foxes would 
require identification and characterization of an inoculum that was highly virulent. Ideally this 
would be done in the principal host species, however Australian native bats are protected species, 
some species are declining in numbers, and they are difficult and expensive to keep, making them 
poor candidates as experimental animals. In order to minimize the number of experimental bats 
required, and maximize the likelihood that inoculated bats would be affected, aliquots of candidate 
inocula were first evaluated in mice for their ability to induce disease.  
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5.2 Experimental Design 
Two models of mouse inoculation were used for the evaluation of inocula. Intracerebral 
inoculation of suckling mice was used as a sensitive method to detect and quantify the presence 
of live virus in inocula. To ensure selection of an inoculum most likely to induce disease in 
peripherally inoculated bats, a second model involving peripheral inoculation of weanling mice 
(~21 days old) was used to compare and quantify the peripheral virulence of inocula.  
Animal ethics requirements precluded death as an endpoint. Mice showing clear clinical signs of 
disease were killed. To reduce the numbers of mice required to identify and characterize an 
inoculum of high virulence, the following approach was taken. 
Figure 5-1 Experimental design to identify an inoculum of high virulence in mice 
to detect those containing viable ABLV 
 
 
 
Experiment 1 
Identification of inocula containing live virus 
Initial screening of 15 inocula by intracerebral inoculation  
 
Experiment 2 
Comparison of the ability of inocula to induce disease by peripheral inoculation 
8 inocula selected for assessment of virulence by peripheral inoculation  
Characterization of the most virulent inoculum 
     
 
 
         Experiment 3             Experiment 4 
Titration by intracerebral inoculation     Titration by peripheral inoculation 
   of suckling mice           of weanling mice  
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5.3 Materials and methods 
Biosafety Committee 
 
5.3.1 Permits 
Animal Ethics Committees 
♦ University of Queensland – approval number SVASP/263/99/QDPI/PHD 
♦ Animal Research Institute – approval number ARI/015/RES/JUN1999-1  
♦ Animal Research Institute – approval number DPI / IBC / PC3 / 99 / 00 
5.3.2 Inocula 
Inocula were prepared using tissue stored at –70°C that had been collected from naturally 
infected flying foxes submitted to the ARI as part of a surveillance program for the detection of 
Australian bat lyssavirus (see Chapter 2). A systematic evaluation of all available tissue samples 
was not possible as animal ethics considerations limited the number of mice and hence the 
number of inocula that could be evaluated. Of 96 available samples from approximately 40 ABLV-
positive cases, eight brains and seven salivary gland samples were selected because they 
satisfied one or more of the following criteria: 
♦ Samples from bats where there had been a short interval between the death of the bat and 
likely storage of the sample at –70 0C, such that the tissue sample was likely to be in good 
condition with presumably less post-mortem degradation of the virus.  
♦ Samples from Grey-headed flying foxes in preference to other species as this was the 
intended experimental bat species. 
♦ Samples from salivary glands that had fluoresced strongly in the fluorescent antibody test. 
Each sample was ground into a 20% weight per volume suspension in a Class II biosafety cabinet 
within the Diagnostic Virology Laboratory with a sterile mortar and pestle using Dulbecco's 
Modified Eagles Medium (Gibco BRL®, Life Industries) containing 20% bovine serum albumin 
(CSL) and an antibiotic/antimycotic preparation containing Penicillin G, streptomycin sulphate and 
amphotericin B as fungizone (Gibco BRL®, Life Industries). Sterile sand was used to assist in the 
grinding of the salivary gland tissues. Suspensions were clarified at ~200 G for 5 minutes and the 
supernatant removed, divided into aliquots, and stored at –70 0C. All subsequent uses of these 
inocula, in mice and bats, were done using separate aliquots of the original preparations at the 
same freeze/thaw generation. Aliquots containing 200 µL of each inoculum were submitted to 
QHSS for quantitative real-time PCR amplification (TaqMan®, see Appendix 3). 
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5.3.3 Mice 
Specific pathogen-free Quackenbush (outbred) mice were purchased from the barrier-maintained 
colony at the Central Animal Breeding House of the University of Queensland. Experimental mice 
were kept in commercial cages with ad lib food and water dispensers within the PC3 Animal 
House at the ARI.  
5.3.4 Confirmation of lyssavirus infection 
Infection with Australian bat lyssavirus was confirmed by FAT on fresh mouse brain touch 
impressions, as described in Section 2.2.3 Fluorescent antibody test. The tests were performed 
and read by the candidate and the results confirmed by Barry Rodwell of the Diagnostic Virology 
Laboratory of the ARI. 
5.3.5 Experiment 1: Detection of viable ABLV by IC inoculation 
of suckling mice 
One to three-day-old suckling mice were inoculated by intracerebral injection by Peter Young 
(ARI) with 10 to 20 µL of inoculum with a tuberculin syringe and 27 gauge needle. Each of the 15 
original inocula were inoculated into litters containing 9 to 11 mice (n=141) on post-inoculation 
day 0 (PI-day 0). Mice that died or disappeared (presumed eaten by dam) within three days of 
inoculation were considered to have died of non-specific causes related to their transport to the 
PC3 Animal House or the trauma of the inoculation. These losses were discounted when 
evaluating the results, reducing the number of experimental suckling mice to 124. Details of the 
source of each inoculum (bat accession number, bat species and source tissue) and the number 
of experimental mice per inoculum are shown in Table 5-1. 
Mice were considered to be affected if they died, required euthanasia or disappeared between 3 
and 24 days post-inoculation. Affected mice were killed by CO2 inhalation. All surviving mice were 
killed on PI-day 24 by intraperitoneal injection of an anaesthetic overdose containing 0.1-0.3 mL 
of a 1:1 mix of ketamine (100 mg/mL) and xylazine (20 mg/mL).  
5.3.6 Experiment 2: Comparison of virulence by peripheral 
inoculation of weanling mice (3-mouse footpad assay) 
Eight inocula from Experiment 1 were selected for further evaluation by peripheral inoculation, for 
details refer to Table 5-2 . Each inoculum was inoculated into the footpads of three 3-week old 
weanling mice anaesthetized by intraperitoneal injection of 0.01 mL of a 1:1 mix of ketamine (100 
mg/mL) and xylazine (Rompun SA 20 mg/mL). Each mouse was inoculated by the candidate, as 
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previously demonstrated by Charles Rupprecht, CDC Atlanta Georgia, USA, with 60µL of 
inoculum divided into the right and left hind footpads, approximately 30µL per foot, using a 
tuberculin syringe and 27 gauge needle.  
Each group of three mice was housed separately. Within each group, mice were individually 
identified with silver nitrate, creating brown markings on white fur. Mice were killed when clinically 
ill or at the conclusion of the experiment on PI-day 162 by intraperitoneal injection of an 
anaesthetic overdose of 0.1-0.3 mL of a 1:1 mix of ketamine (100 mg/mL) and xylazine (20 
mg/mL). Blood samples were collected with heparinized syringes peri-mortem by severing the 
vessels of one axilla. Blood was centrifuged at ~800 G for 10 minutes and the plasma stored at  
–20 °C and submitted to the AAHL for detection of anti-lyssavirus antibodies using the  
rabies-RFFIT. 
5.3.7 
5.3.8 
Experiment 3: Titration of selected inoculum by IC 
inoculation of suckling mice 
Based on the results of Experiment 2, one inoculum was selected as the most virulent, for 
determination of the ABLV-titre by intracerebral inoculation of 2 to 3-day-old suckling mice. Ten 
fold serial dilutions (10–1 to 10-8) were prepared from the neat inoculum (20% w/v suspension) in a 
Class II biosafety cabinet within the PC3 Diagnostic Virology Laboratory using Dulbecco's 
Modified Eagles Medium and an antibiotic/antimycotic preparation. One litter containing 6 or 10 
mice (see Table 5-2) was inoculated with each dilution of inoculum as described for Experiment 1. 
Mice showing clear signs of being clinically ill were killed by CO2 inhalation. All surviving mice 
were killed on PI-day 25 by intraperitoneal injection of a ketamine/xylazine overdose as in 
Experiment 2. Mice were considered positive if they died or required euthanasia and were 
subsequently shown to be ABLV-positive by FAT on fresh brain touch impressions. All mice that 
were clinically well on PI-day 25 were considered negative. As clinical disease and a positive FAT 
result, rather than death, was used as the endpoint, the 50% endpoint dilution, calculated using 
the Spearman-Kärber Method (Lorenz and Bogel 1973), was determined as the 50% effective 
dose (ED50) rather than 50% lethal dose (LD50). The titre determined in this assay is expressed as 
mouse intracerebral 50% effective dose per mL (MICED50/mL).  
Experiment 4: Titration of selected inoculum by 
peripheral (footpad) inoculation of weanling mice 
The inoculum selected based on the results of Experiment 2 was further characterized for 
virulence by determination of the ABLV-titre by peripheral inoculation of 21-day-old mice weighing 
13-18 g. Ten fold serial dilutions (10–1 to 10-7) of the inoculum were prepared from the neat 
inoculum in a Class II biosafety cabinet within the PC3 Virology Laboratory using Optimax 
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Modified Eagles Medium (Gibco BRL®, Life Technologies) and an antibiotic/antimycotic 
preparation. Six unanaesthetised mice were inoculated with 60 µL of each dilution of inoculum as 
described for Experiment 2. Mice were weighed using digital laboratory scales (UWE SC-1500, 
increments 0.5 g, Taiwan) when inoculated, when killed, and every second day between PI-days 
4 and 40, then every 2nd to 4th day until PI-day 60. Clinically ill mice and all surviving mice on PI-
day 91 were killed by ketamine/ xylazine overdose, as in Experiment 2. Mice were considered 
positive if they died or required euthanasia and were subsequently shown to be ABLV-positive by 
FAT on fresh brain touch impressions. All mice that were clinically well on PI-day 91 were 
considered negative. The 90 day mouse footpad 50% effective dose (MFP90ED50 /mL) was 
calculated using the Spearman-Kärber Method (Lorenz and Bogel 1973).  
Aliquots of the serial dilutions were submitted to Queensland Health Scientific Services for 
quantitative real-time PCR assay (TaqMan®). 
5.4 Results 
5.4.1 
5
Experiment 1: Detection of viable ABLV by IC inoculation 
of suckling mice  
One or more suckling mice were affected in 14 of the 15 inoculated litters; and one to three 
suckling mice per affected litter were confirmed as ABLV-positive by FAT on fresh brain touch 
impressions. Details of the bat species and tissue source of the inoculum, the range of days post-
inoculation that suckling mice were affected, the number of mice affected of the total alive 3 days 
post-inoculation, the percent of affected mice per litter, and the number of cycles required for 
TaqMan amplification of viral RNA to reach the positive detection threshold, are shown in Table 
-1. 
Australian bat lyssavirus was isolated from the three tissue sources used to prepare the inocula: 
brain, parotid salivary gland, and the submandibular and sublingual salivary glands. Fifty-seven of 
67 mice (85%) inoculated with material prepared from the brains of naturally infected flying foxes 
were affected with 100% of mice affected in six of eight litters. Thirty of 38 mice (79%) inoculated 
with submandibular and sublingual salivary gland inocula were affected, with 100% of mice 
affected in three litters and 50% of mice affected in two litters. Only five of 19 mice (26%) 
inoculated with parotid salivary gland derived inocula were affected. One of these mice 
disappeared on PI-day 7, midway between the last of the non-specific deaths prior to PI-day 3 
and the first of the confirmed ABLV-affected mice on PI-day 11 (see Figure 5-2). The loss of this 
mouse may have been incidental. The remaining four affected parotid-inoculated mice were 
among the last mice to be affected. 
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Table 5-1  Experiment 1: Detection of live ABLV by intracerebral inoculation of 15 inocula 
into litters of suckling mice 
Details of inoculum 
Bat No. and  
ARI accession No. 
Bat species and 
tissue 
-70°C 
delay 1
(days)
Period of 
clinical 
effect2      
(PI-days) 
Number 
affected/total 
Percent 
affected 
TaqMan 
threshold3 
(cycles) 
ABLV-27   97-186955  1 Grey4 brain 2 11-13 6/6 100 16.9 
ABLV-18   97-125092 2 Black5 brain 2 12-13 9/9 100 17 
ABLV-26   97-176292 3 Grey brain 2 12-13 8/8 100 17.5 
ABLV-45   98-167351 4 Grey brain 16 12-15 10/10 100 18 
ABLV-51   98-188455 5 Black submandib. 
and sublingual SG6 
13 12 3/3 100 18.6 
ABLV-28   97-192894 6 Grey brain 2 13-14 8/8 100 19 
ABLV-46   98-172971 7 Black submandib. 
and sublingual SG 
7 11-13 9/9 100 20 
ABLV-52   98-189702 8 Red7 submandib. 
and sublingual SG 
6 12-13 10/10 100 21.2 
ABLV-33   98-105331 9 Grey brain 11 14-24 8/8 100 17.8 
ABLV-24   97-155574 10 Black brain 1 12-13 8/9 89 18.6 
ABLV-45   98-167351 11 Grey submandib.    
and sublingual SG 
16 13-15 5/10 50 26.5 
ABLV-33   98-105331 12 Grey submandib. 
And sublingual SG 
11 15-24 3/6 50 26.7 
ABLV-18   97-125092 13 Black parotid SG8 2 16-20 3/10 33 25 
ABLV-27   97-186955 14 Grey parotid SG 2 7 and 15 2/9 22 32.5 
ABLV-40   98-140882 15 Red brain 3 Not applicable 0/9 0 26.8 
Bold font  Inocula selected for further evaluation in Experiment 2. 
 1  estimated minimum delay between the death of the flying fox and storage of the source tissue at –70 °C 
based on diagnostic recording indicating time of death, receipt of bat and testing of sample assuming the 
sample was transferred to the –70 freezer the day after testing. 
 2  period post-inoculation when mice were clinically ill, onset of disease in first affected mouse to death or 
euthanasia of last affected mouse. 
 3  number of cycles required for TaqMan amplification of viral-RNA  from each inoculum to reach the 
positive detection threshold. 
 4  Grey-headed flying fox (P. poliocephalus). 
 5  Black flying fox (P. alecto). 
 6  submandibular and sublingual salivary glands. 
 7  Little Red flying fox (P. scapulatus). 
 8  parotid salivary gland. 
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Figure 5-2 Cumulative results of Experiment 1: detection of viable ABLV by intracerebral 
inoculation of suckling mice (n=141) with 15 inocula 
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Inocula 1 through 8 were selected for further evaluation by peripheral (footpad) inoculation as they 
contained sufficient live ABLV to affect 100% of mice. Inoculum 9 was not selected for further 
evaluation, despite 100% of mice being affected and a low qualitative TaqMan threshold 
indicating relatively high amounts of viral-RNA, because only sufficient mice for the evaluation of 
eight inocula had been approved by the animal ethics committees, and the comparatively long 
incubation periods for the Inoculum 9 mice (PI-days 14 (n=2), 15 (n=3), 16, 21, and 24) suggested 
this preparation contained a lower titre of live ABLV than Inocula 1-8. 
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5.4.2 Experiment 2: Comparison of virulence by peripheral 
(footpad) inoculation of weanling mice 
Ten of 24 footpad-inoculated mice developed clinical signs of lyssavirus infection and were 
subsequently shown to be ABLV-positive by FAT on fresh brain touch impressions. The 
incubation period of the affected mice ranged from 10 to 39 days as shown in Table 5-2. One 
clinically normal mouse inoculated with Inoculum 2 was inadvertently killed and discarded on PI-
day 61. All other surviving mice remained well until killed on PI-day 162, and were negative for 
ABLV by FAT on fresh brain touch impressions. 
Table 5-2 Experiment 2: Comparison of virulence by 3-mouse footpad assay 
Details of Inoculum 
ABLV case No. and 
ARI Bat accession No. 
Bat species and 
tissue 
Number 
affected 
(n=3) 
Period of 
clinical effect1   
(PI-days) 
Percent 
affected 
(%) 
TaqMan 
threshold 
(CT)2 
Virulence 
ranking 
ABLV-27   97-186955
 
1 
  
Grey3 Brain 
 
3 
18-19 
21-24 
35-39 
 
100 
 
16.9 2nd 
ABLV-18   97-125092 2 Black4 Brain 0 --- 0 17.0 Equal last 
ABLV-26   97-176292 3 Grey Brain 2 25 
39-42 
66 17.5 
 
 
3rd 
ABLV-45   98-167351 4 Grey Brain 0 --- 0 18.0 Equal last 
ABLV-51   98-188455
 
5 
 
Black submandib. 
and sublingual SG 
 
3 
10-12 
10-12 
10-12 
 
100 
 
18.6 1st  
ABLV-28   97-192894 6 Grey Brain 0 --- 0 19.0 Equal last 
ABLV-46   98-172971 7 Black submandib. 
and sublingual SG 
1 15-17 33 20.0 4th 
ABLV-52   98-189702 8 Red5 submandib. 
and sublingual SG 
1 27-28 33 21.2 5th 
 1  period post-inoculation when each mouse was clinically ill, onset of disease to death or euthanasia of 
mouse 
 2  number of cycles until amplification of viral-RNA reached the positive detection threshold 
 3  Grey-headed flying fox (P. poliocephalus) 
 4  Black flying fox (P. alecto) 
 5  Little Red flying fox (P. scapulatus) 
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5.4.2.1 Clinical signs  
Clinical signs included: 
♦ weight loss 
♦ dehydration 
♦ shaking, tremors and hyperaesthesia (jumped when touched) 
♦ reluctance to move 
♦ proprioceptive deficits (knuckling), ataxia, and paresis, particularly of the hind limbs 
♦ conjunctivitis 
Typically, the first indication of disease was the affected mouse appearing smaller than group-
mates. Proprioceptive deficits, ataxia and paresis would then become evident in one or both hind 
limbs, and while use of the forelimbs was initially preserved, peripheral nerve deficits would 
progress, and unless killed, lead to recumbency. Some mice developed generalized tremors and 
hyperaesthesia. A number developed conjunctivitis. A clinically ill mouse showing typical signs of 
ABLV infection is shown in Figure 5-3.  
The proportion of weanling mice that became affected following footpad inoculation was more 
variable than had been observed following intracerebral inoculation of suckling mice with the 
same inocula (Experiment 1). Whereas 100% of suckling mice given these inocula were affected 
within 11 to 15 days (n=8 inocula), none (n=3), one (n=2), two (n=1), or three (n=2) mice were 
affected per footpad-inoculated group within 162 days.  
5.4.2.2 Selection of Inoculum 5 
Of the two inocula that affected all three mice, one (Inoculum 5) produced disease much more 
quickly and more consistently than the other (Inoculum 1). All three mice treated with Inoculum 5 
were clinically ill by PI-day 10 compared to PI-days 18, 21, and 35 for mice treated with Inoculum 
1. The incubation period for Inoculum 5 by footpad inoculation (10 days, n=3) was actually shorter 
than that observed following intracerebral inoculation (12 days, n=3). Inoculum 5 was considered 
the most virulent by peripheral inoculation in mice and was selected for further characterization in 
mice and subsequent use in flying foxes. 
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Figure 5-3 Clinically ill ABLV-positive mouse showing typical signs of ABLV infection 
Three inoculated mice, each identified by brown silver nitrate markings on white fur. One mouse 
(top left) shows typical signs of ABLV infection including weight loss, dehydration, paresis, 
ataxia, and proprioceptive deficits, as indicated by its smaller size, gaunt appearance, and 
abnormal position of the hind limbs. The two companion mice are clinically well, as indicated by 
their round body condition and normal posture. 
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5.4.2.3 Prevalence of anti-lyssavirus titres in inoculated mice 
Experiment 2 presented the opportunity to compare the prevalence and titres of neutralizing 
lyssavirus antibodies in mice that were affected or survived experimental inoculation with ABLV. 
Titres were measured as cross-neutralising titres against rabies virus in a rabies-RFFITAAHL. No 
quantitative in vitro test for titres to ABLV is available in Australia (i.e. no standardized ABLV-
RFFIT or ABLV-ELISA).The use of mice for ABLV-serum neutralization tests was not considered 
justified. The rabies antibody titre for each mouse from Experiment 2 is shown in Table 5-3. 
Table 5-3 Experiment 2: rabies-RFFIT titres of peripherally inoculated mice 
Accession Inoculum.mouse1 Status of mouse Died  (PI-day) 
Rabies-RFFIT titre 
(IU/mL) 
98-188455 5.1 Affected 12 <0.52 
98-188455 5.2 Affected 12 0.6 
98-188455 5.3 Affected 12 0.7 
98-172971 7.1 Affected 17 <0.5 
97-186955 1.1 Affected 19 0.8 
97-186955 1.2 Affected 23 1.1 
97-176292 3.1 Affected 25 <0.5 
98-189702 8.1 Affected 28 2.8 
97-186955 1.3 Affected 38 <0.5 
97-176292 3.2 Affected 42 Not done 
97-125092 2.1 Survived 61 Not done 
97-125092 2.2 Survived 162 <0.5 
97-125092 2.3 Survived 162 <0.5 
None 3.uninoc. control Survived 162 <0.5 
97-176292 3.3 Survived 162 <0.5 
98-167351 4.1 Survived 162 <0.5 
98-167351 4.2 Survived 162 <0.5 
98-167351 4.3 Survived 162 <0.5 
97-192894 6.1 Survived 162 <0.5 
97-192894 6.2 Survived 162 <0.5 
97-192894 6.3 Survived 162 <0.5 
98-172971 7.2 Survived 162 <0.5 
98-172971 7.3 Survived 162 <0.5 
98-189702 8.2 Survived 162 2.83 
98-189702 8.3 Survived 162 <0.5 
  1  inoculum number. Mouse number e.g. 5.1 = mouse number 1 inoculated with Inoculum 5. 
  2  titres of < 0.5 IU/mL indicate an absence of quantitative serum neutralisation at a serum dilution of 
1:20. These results are considered negative. 
  3  Aliquots of plasma from mice 8.1, 8.2 and 8.3 were resubmitted to AAHL for repeat testing with 
consistent results of 2.2, 2.5 and < 0.5 IU/mL respectively. 
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Plasma samples from nine ABLV-affected mice were tested for rabies antibodies, of which five 
were positive for rabies antibodies, and four were negative (titres less than < 0.5 IU/mL). There 
are two instances where plasma was tested from more than one affected mouse per inoculum. Of 
the three mice inoculated with Inoculum 1, one mouse was negative, and two had low to 
moderate titres (0.8 and 1.1 IU/mL). Of three mice inoculated with Inoculum 5, again one mouse 
was negative and two had low titres (0.6 and 0.7 IU/mL). There was no apparent association 
between the absence of a titre in affected mice and the incubation period, negative titres occurring 
in affected mice that were killed 12, 17, 25, and 38 days post-inoculation. In affected mice that did 
seroconvert, there was a slight trend for titres to be higher in mice affected after a longer 
incubation period.  
Twelve of 13 plasma samples collected from mice with no evidence of clinical disease by PI-day 
162 were negative (< 0.5 IU/mL, no antibody detected). One inoculated mouse (mouse 8.2) that 
survived until PI-day 162 had a relatively high antibody titre (2.2-2.8 IU/mL). 
 
5.4.3 Experiment 3: Titration of Inoculum 5 by IC inoculation of 
suckling mice 
There were no non-specific deaths during the first 3 days post-inoculation and no mice 
disappeared. One mouse inoculated with a 10-6 dilution of inoculum was found dead, without 
preceding clinical signs on PI-day 14 and was negative for ABLV by FAT on three occasions. The 
death of this mouse was considered incidental. All other mice (n=45) that died or were clinically ill 
were subsequently confirmed as ABLV-positive by fluorescent antibody test. Mice were attributed 
as either positive (died or killed and FAT-positive) or negative (clinically well when killed on PI-day 
24). The outcome for each dilution is shown in Table 5-4. 
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Table 5-4 Experiment 3: Titration by intracerebral inoculation with 10-fold dilutions of 
Inoculum 5 
Dilution Positive Negative Total 
Neat 10 0 10 
10-1 6 0 6 
10-2 10 0 10 
10-3 10 0 10 
10-4 7 3 10 
10-5 2 8 10 
10-6 0 10 10 
10-7 0 10 10 
10-8 0 10 10 
 
Spearman-Käber formulae 
Log10 50% endpoint dilution /0.01-0.02 mL= − (χ0 – d/2 + d ∑ ri / ni ) 
Where: 
χ0 = log10 of the reciprocal of the highest dilution at which all animals are positive 
d = log10 of the dilution factor 
r i = number of positive animals at the highest dilution at which all animals are positive and at 
each higher dilution. 
ni = total number of animals (after discounting accidental deaths) at the highest dilution at which 
all animals are positive and at each higher dilution. 
 
 
Such that: 
 
Log10 endpoint dilution = − (3 – ½ + 1(10/10 + 7/10 + 2/10 + 0/10)  
       = − 4.4 
The 50% endpoint dilution / 0.01 to 0.02 mL = 10-4.4 
That is there are 104.4 mean effective doses per 0.01 to 0.02 mL of neat inoculum  
The titre of the neat inoculum = 106. 1 to 10 6.4 MICED50 /mL  
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5.4.4 Experiment 4: Titration of Inoculum 5 by peripheral 
(footpad) inoculation of weanling mice 
One mouse inoculated with neat inoculum became acutely recumbent, with a right head tilt and 
persistent rolling to the right-hand side on PI-day 6, was killed, and was subsequently negative for 
ABLV by FAT on three fresh brain touch impressions, the loss of this mouse was considered 
incidental. All other clinically ill mice (n=31) were ABLV-positive. The outcome for each dilution is 
shown in Table 5-5. 
Table 5-5 Experiment 4:Titration by footpad inoculation with serial dilutions of Inoculum 5 
TaqMan 
threshold Dilution Positive Negative Total 
17.5 Neat 5 0 5 
21. 10-1 6 0 6 
24 10-2 6 0 6 
28 10-3 6 
6 
0 6 
30.5 10-4 0 6 
34 10-5 2 4 6 
50 10-6 0 6 6 
50 10-7 0 6 6 
     
MFP90ED50 = 90 day mouse footpad 50% effective dose 
Spearman-Käber formulae 
Log10 endpoint dilution /0.06 mL= − (χ0 – d/2 + d ∑ ri / ni ) 
 
Such that: 
Log10 endpoint dilution = − (4 – ½ + 1( 6/6 + 2/6 + 0/6 )  
     = − 4.8 
Using Spearman-Käber tables or formulae the endpoint dilution /0.06mL = 10 -4.8. 
That is there are 10 4.8 mean effective doses per 0.06 mL of neat inoculum  
The titre of the neat Inoculum 5 = 10 6.0 MFP90ED50 /mL. 
  Selection of an inoculum 
 202
5.4.4.1 Effect of dose on incubation period  
Groups of mice inoculated with lower dilutions of Inoculum 5 became clinically ill after shorter and 
less variable incubation periods than mice inoculated with higher dilutions. The onset of disease 
was defined as the first day sustained weight loss was detected or the day of onset of more 
specific clinical signs suggesting ABLV-infection, such as hind limb paresis. In all mice weight loss 
was the first clinical sign of disease. The relationship between the dose and incubation period is 
shown in Table 5-6 and illustrated in Figure 5-4. 
Table 5-6 Experiment 4: Effect of dose on incubation period 
Dilution 
TaqMan  
(CT) 
Number 
Positive 
Onset of disease            
(PI-days) 
Mean incubation 
period (days) 
Neat 17.4 5 8, 8, 8,  9, and 9 8.4 
10-1 21.1 6 8, 8, 8, 8, 8, and  9 8.2 
10-2 24.1 6 12, 12, 12, 14, 14, and 14 13.0 
10-3 28.0 6 16, 18, 22, 22, 24, and 28 21.7 
10-4 30.4 6 18, 24, 26, 28, 30 and 37 27.2 
10-5 34.2 2 37 and 50 43.5 
 
Figure 5-4 Effect of dilution of Inoculum 5 on the mean incubation period in peripherally 
inoculated mice  
(vertical bars indicate ± 1 standard deviation) 
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5.4.5 Consistency of the effect of Inoculum 5 
Aa a result of being chosen for further work, aliquots of neat Inoculum 5 were used on four 
occasions. The results of all footpad inoculations of weanling mice using Inoculum 5 are 
presented together here to demonstrate the consistency of the effect in the footpad assay. 
Table 5-7 Consistency of the in vivo effect of Inoculum 5 
Reference  Date No. affected No. inoculated 
Onset of 
weight loss  Onset of paresis  
This Chapter, Experiment 2 (Screening) Aug 1999 3/3 not measured 10, 10, and 10 
This Chapter, Experiment 4 (Titration) Sept 1999   5/6* 8, 8, 8, 9, and 9 10, 10, 11, 12, and 12 
Chapter 6, Bat inoculation (mouse controls) Nov 1999 2/2 not measured 9 and 9 
Chapter 7, Experiment B (inoculatn controls) July 2000 3/3 9, 9, and 9 10, 11, and 11 
* One mouse became ill on PI-day 6, was later shown to be ABLV negative, and is considered to have died 
of incidental causes.  
 
5.4.6 Case history of Inoculum 5 
Inoculum 5 was derived from the salivary glands of a young adult female Black flying fox 
submitted for lyssavirus testing in November 1998 (ARI accession 98-188455, ABLV-51). 
The bat had been noticed in a tree in the morning approximately 3 km from the nearest flying fox 
colony by a groundsman of an aged persons/ retirement complex in a country town in central 
Queensland. During the afternoon, as the groundsman was raking leaves, the bat flew at him and 
was hit to the ground by the groundsman. The bat attempted to fly up at the groundsman again 
and was again hit to the ground. A box was put over the bat and it was collected by the 
Queensland National Parks and Wildlife Service and transferred to the care of a registered 
vaccinated wildlife carer. The bat was placed in a cage and as food was put in the cage, it came 
forward within the cage rather than retreating normally. The bat appeared ravenous, dropping to 
the floor of the cage to gulp food placed in a dish on the cage floor. Three hours later the bat was 
found dead, hanging normally within the cage. The dead bat was refrigerated until sample 
collection 8 days post-mortem. At necropsy small haemorrhages were detected over the right eye 
and left neck, consistent with the history of minor trauma. The brain and salivary glands were 
refrigerated until tested by FAT 6 days later and then transferred to the –70°C freezer, a minimum 
of 13 days post-mortem. The date of transfer to –70°C and the dates of any subsequent thawing 
and use of the brain or salivary glands (as FAT test controls by ARI staff) prior to preparation as 
inocula are not recorded. 
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5.5 Discussion 
The principle objective of this study was to identify and characterize an inoculum that was likely to 
be the most virulent when inoculated peripherally into Grey-headed flying foxes. Mice were 
selected as the models for disease in bats as they have been used extensively in similar rabies 
virus studies. So that the mice would as closely as possible represent wild bats, out bred 
‘ordinary’ (Quackenbush) mice were used rather than any of the inbred breeds available. 
Only assays that require virus in the sample to replicate detect relative amounts of viable virus. 
Both cell culture assays and intracerebral inoculation of suckling mice do this. However neither 
differentiates between highly pathogenic, low pathogen, and apathogenic virus under natural 
conditions, i.e. peripheral infection of immune competent animals. A number of laboratory rabies 
virus strains, such as SAD-B19 and RV194-2 variants of CVS and ERA, grow in cell culture and 
cause mortalities in intracerebrally inoculated mice but fail to induce disease in adult mice 
(Conzelmann et al. 1990; Dietzschold et al. 1983). Intracerebral inoculation in mice is however the 
most sensitive method for detecting viable virus and for that purpose it was used to screen 
samples in Experiment 1. Concurrent attempts to assess the samples by cell culture were 
unsuccessful (data not shown). 
Viable ABLV was detected in samples prepared from all tissue sources used; brain, the combined 
submandibular and sublingual salivary glands, and the parotid salivary glands. While the numbers 
of litters and inocula tested are small, the numbers of mice affected per litter, and the periods of 
clinical effect suggest that the samples derived from brain or submandibular and sublingual 
salivary glands have similar pathogenicity in mice by intracerebral inoculation, and that 
preparations derived from the parotid salivary gland are less virulent. Eight of 15 samples 
screened produced similar results, with 100 percent of suckling mice dying during a brief period 
(2-4 days) 11 to 14 days post-inoculation. Unexpectedly the better performing samples included 
Inocula 4 and 5, that had been prepared from material where the minimum post-mortem interval 
prior to storage at –70 °C was very long (16 and 13 days respectively). It had been presumed that 
prolonged post-mortem delay prior to –70 °C storage would have led to substantial reduction in 
virus titre. Clearly samples stored at 5 °C for up to 16 days may continue to contain relatively high 
quantities of viable virus. 
To determine which of the eight best inocula was likely to be most pathogenic in peripherally 
inoculated bats, a peripheral inoculation model in mice was used in Experiment 2. In this 
experiment much greater differences in the proportion of mice affected and incubation periods 
were detected among the inocula. One, Inoculum 5, clearly produced disease in more mice, more 
quickly, and more consistently than all other inocula, with all three inoculated mice developing 
clinical signs only 10 days post-inoculation. It was presumed that the incubation periods seen in 
the intracerebrally inoculated mice would be the minimum possible for each inoculum, because 
direct inoculation in the brain would bypass the requirement to migrate via spinal axons and avoid 
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any delays due to immune recognition. That Inoculum 5 produced clinical disease only 10 days 
after peripheral inoculation, where intracerebrally inoculated mice had not died until PI-day-12, 
suggested the peripheral virulence of Inoculum 5 was particularly high.  
Determination of the rabies-RFFIT titres enabled comparisons to be made between the titres in 
mice that were ABLV-positive or survived and those of ABLV-positive bats (Chapter 2). As in bats, 
ABLV-positive mice had both negative (4 of 9) and positive (5 of 9) titres, with the strength of the 
positive titres in mice (0.6-2.8 IU/mL) being comparable to those of ABLV-positive bats (4 of 15, 
0.2-1.5 IU/mL). Surprisingly, only one of 14 inoculated mice that remained clinically well until killed 
on PI-day 162 had a positive rabies-RFFIT titre. The titre in this mouse (2.5-2.8 IU/mL) equalled 
the highest seen in any ABLV-positive mouse or bat suggesting that either: 
♦ the mouse had been infected but induction of early and adequate humoral and /or cell-
mediated immunity had led to subclinical resolution of the infection,  
♦ this mouse was an asymptomatic carrier,  
♦ or that it was killed during an uncharacteristically long incubation period. If this were the case, 
the incubation period would have been more than 5 times that of the only other mouse in that 
group to be affected (mouse 8.1, died PI-day 28) and nearly 4 times longer than the longest 
incubation period observed (mouse 3.2, died PI-day 42). 
The absence of a rabies-RFFIT titre in the vast majority of surviving mice suggests either they had 
simply not been infected or that subclinical resolution had occurred either without development of 
a detectable antibody response or that an early antibody response had dropped below the 
detectable threshold by PI-day 162. As in bats, this study indicates that neither positive nor 
negative rabies-RFFIT titres in either clinical ill or normal mice can be used to determine whether 
a mouse is infected or poses a risk of infection to others.  
Titration of Inoculum 5 by intracerebral inoculation of mice to determine the 50% effective dose 
(MICED50 ) was done so that direct comparisons could be made between the virulence of this 
inoculum and those used in rabies virus studies. Australian codes of practice for the ethical use of 
experimental animals preclude death as an endpoint. The MICED50 assay is the same as that for 
determining the traditional rabies virus LD50, except that clinically ill mice were killed rather than 
left to die. Assuming all ABLV-positive clinically ill mice would have died, the MICED50 value 
equals that that would have been determined in a traditional (lethal) LD50 assay.  
The virus titre of Inoculum 5 (10 4.4 MICED50 / 0.01 to 0.02 mL) was sufficiently high that doses of 
Inoculum 5 could be prepared that were comparable to those of street rabies virus used to 
successfully infect more that 30% of peripherally inoculated animals of a relevant host species (for 
example 102.2 to 105.2 MICLD50 of arctic fox rabies virus in skunks and foxes (Charlton et al. 
1987b), 101.7 to 5.8 MICED50 of Ethiopian or Mexican origin dog rabies virus in beagles (Fekadu et 
al. 1982a), 102.3 and 10 3.6 MICED50 of bat rabies virus in Mexican free-tail bats (Baer and Bales 
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1967; Constantine 1966b)). Consequently Inoculum 5 was considered suitable for further use in 
bats. 
Titration of Inoculum 5 by footpad inoculation was done to determine the mean effective dose in a 
model that more closely represents natural, peripheral infection (MFP90ED50). Just as the 
incubation periods for Inoculum 5 after intracerebral and footpad suggested the virulence of 
Inoculum 5 was very similar in both methods, the titre of 106.1 to 6.4 MICED50 / mL is essentially 
equal to the titre of 106.0 MFP90ED50/mL, again suggesting this inoculum was as virulent 
peripherally as by intracerebral inoculation. 
The footpad titration assay also demonstrated the effect of dose on incubation period. Mice in 
groups inoculated with lower doses of Inoculum 5 became ill after longer and more variable 
periods. At dilutions of 10-1 and below (neat) the onset of clinical signs in all mice occurred 8-9 
days post-inoculation. At higher dilutions the incubation period increased to 12 to 50 days with the 
average incubation period increasing with each 10-fold dilution 
A secondary objective was to examine the potential use of the in vitro TaqMan assay as a 
preliminary screening tool to identify inocula suitable for further examination, increasing the 
numbers of inocula that could be considered and reducing the numbers of animals required for in 
vivo evaluations. The TaqMan assay detects the relative amounts of viral RNA in a sample, with 
samples containing higher quantities of target RNA requiring fewer cycles to reach the detection 
threshold, i.e. having lower CT values. However, the target RNA can have been in the form of 
RNA fragments, unincorporated genomic material, within non-viable (non-infective) or non-
pathogenic (but infective) viral particles, as well as in the viable virulent virus particles that 
produce disease. As the proportions of RNA in each of these forms can be affected by post-
mortem degradation and the storage history (e.g. variable freeze/thaw durations), RNA assays do 
not intrinsically indicate the relative viability or virulence of the sample.  
There was a crude correlation between lower CT values and those inocula that killed more 
intracerebral- or footpad-inoculated mice. In intracerebrally inoculated mice, only inocula with CT 
values less than 22 cycles killed 100% of mice, while only 50% or less per litter were killed using 
inocula with CT values greater than 25. In footpad-inoculated mice there was no simple correlation 
between the CT values and virulence ranking. The three salivary gland inocula, which had 
relatively high CT   values (18.6, 20 and 21.2), did comparatively well, being three of the five 
samples that killed at least one mouse. Three brain inocula with lower CT values (17, 18, and 19) 
failed to produce disease. The results suggested that the inocula derived from salivary gland 
material were more virulent than the inocula prepared from brains containing similar or higher 
quantities of viral RNA. To what extent this could be a property of the distribution of virulent virus 
in flying foxes, or simply an artefact of variable post-mortem degradation and storage conditions 
for the source materials remained unclear.  
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There was however, a clear relationship between the CT value and number and speed with which 
mice were affected in the footpad titration assay. Each 10-fold dilution of Inoculum 5 correlated to 
an approximately 3 cycle increase in the CT value. This is consistent with the theory of PCR 
amplification where there is a doubling of RNA in each PCR cycle. Theoretically a 10 fold increase 
in amplified product occurs approximately every 3.32 cycles. This suggests that, where the 
variable effects of post-mortem degradation and storage conditions are constant, as in this dilution 
series of a single inoculum, there is a very strong correlation between CT values and virulence. A 
similar strong linear correlation between virus titre (MICLD50 ) and TaqMan CT value was shown 
for homogenates of salivary glands (n=5) from experimentally infected skunks (Hughes et al. 
2004). However, it should be noted that this strong linear relationship was demonstrated on 
homogenates from a single tissue source (salivary gland) using samples that were presumably 
collected, stored, and used under controlled and optimised conditions. 
5.6 Conclusions 
In vivo evaluation of the virulence of inocula prepared from the tissues of naturally 
infected bats 
♦ Inocula prepared from the brains or submandibular and sublingual salivary glands appear to 
have similar pathogenicity in mice, while preparations derived from the parotid salivary gland 
appear to be less virulent. However given the limited number of samples examined, the 
variation in the tissue handling and storage histories, and the fact that brain and salivary 
gland preparations from the same animal were not always used, this relationship requires 
further evaluation. 
♦ Footpad inoculation trials are more sensitive for differentiation of the virulence of inocula than 
intracerebral inoculation, and require the use of fewer mice to differentiate inocula of interest. 
♦ Prolonged (up to 16 days) post-mortem storage of tissue at 5°C does not preclude the 
presence of high concentrations of virulent virus in tissues.  
Selection and characterisation of the most virulent inoculum for subsequent use 
♦ A combination of intracerebral and footpad inoculation assays in mice identified and 
characterised the most virulent inoculum (Inoculum 5).  
♦ 
♦ 
The titre of Inoculum 5 by intracerebral inoculation of mice (106.1 to 106.4 MICED50 /mL) was 
similar to that of rabies virus inocula used to experimentally infect other host species. 
Consequently Inoculum 5 was considered suitable for use in flying foxes.  
♦ The titre of Inoculum 5 by intracerebral inoculation of mice (106.1 to 106.4 MICED50 /mL) and by 
footpad inoculation of mice (106.0 MFP90ED50 /mL) were similar, further suggesting Inoculum 5 
would be virulent by peripheral inoculation in bats.  
The virulence of the selected inoculum was consistent (number of mice affected and onset of 
weight loss/paresis) using four aliquots of the neat preparation.  
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Use of TaqMan® CT values to determine relative quantities of viral RNA and the 
potential use of quantitative PCR in the selection of inocula  
♦ There is an association between TaqMan CT  values and virulence in that inocula with lower 
CT  values (< 22 cycles) are more virulent than inocula with higher CT   values when the 
variable effects of post-mortem degradation and storage conditions are controlled. 
♦ When inocula are to be compared and factors affecting post-mortem degradation such as 
storage conditions are unknown or variable, there is a crude association between inocula with 
low CT values (< 22 cycles) being more likely to be virulent and inocula with high CT, values      
(> 25 cycles) being more likely to be less virulent. This crude relationship could be used for 
preliminary assessment of large numbers of inocula to identify or prioritize those most suitable 
for further in vivo assessment, leading to a reduction in the number of animals required.  
Other conclusions 
♦ As in bats, rabies-RFFIT titres in mice are of no diagnostic value. 
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6 Experimental infection of Grey-headed flying 
foxes with ABLV 
Aims 
1. To develop an experimental model for infection with Australian bat lyssavirus in Australian 
flying foxes. 
2. To characterize the incubation period, clinical disease, histopathology, and distribution of viral 
antigen as a result of experimental infection. 
4. To examine plasma from inoculated bats for evidence of seroconversion. 
5. To examine saliva from inoculated bats for evidence of viral excretion. 
6.1 Introduction 
Characterization of the clinical disease caused by Australian bat lyssavirus in naturally infected 
Australian bats is limited because; 
♦ the time and route of infection of naturally infected bats are unknown 
♦ naturally infected bats only come to the attention of humans when either they are sufficiently 
unwell to be found on or near the ground or once their behaviour is grossly altered, and 
♦ Ill bats are generally cared for by lay wildlife carers, with the involvement of veterinary or 
medical professionals occurring either very late in the progression of the disease or after 
death.  
Consequently the incubation period is unknown, the early stages of the clinical disease are not 
observed, and most observations are made by persons not trained in clinical evaluation. 
In order to characterize the incubation period and the onset and progression of clinical disease, 
an experimental model of ABLV infection is required. Classically, experimental models of 
lyssavirus (namely rabies virus) infection involved mice and rats as the experimental hosts. The 
comparatively recent recognition of relationships between virus variants and their principal host 
species implies that the pathogenesis and natural history of lyssaviruses is variant-host specific, 
and that the most appropriate experimental model would involve Australian bat lyssavirus in the 
principal host, namely pt-ABLV in flying foxes and/or ybst-ABLV in Yellow-bellied sheathtail bats. 
A model of pteropid-ABLV infection is more pressing as the social, zoonotic, and financial impact 
of ABLV in flying foxes is considerably greater than that of ABLV in Yellow-bellied sheathtail bats. 
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Two trials of experimental inoculation of ABLV in Grey headed flying foxes had been already been 
carried out at the AAHL. In the first, only one of seven flying foxes inoculated intramuscularly with 
ABLV developed clinical disease on PI-day 27 and in the second, only three of 10 flying foxes 
were clinically affected on PI-days 15, 23 , and 24 (McColl 1999; McColl et al. 2002). The small 
number of affected animals limits the data from these trials, and further trials were indicated.  
It is also possible that research will be directed towards the development of an ABLV vaccine for 
the wild bat population, much as rabies vaccines have been developed for use in wildlife in 
Europe and North America (Barrat and Aubert 1993; Charlton et al. 1992; Rupprecht et al. 1986; 
Setien et al. 1998). Evaluation of a vaccine for use in bats will require an effective experimental 
model of ABLV infection in bats to demonstrate vaccine efficacy. 
6.2 Materials and methods 
6.2.1 Permits 
Queensland National Parks and Wildlife service 
Scientific purposes permit number – E4/001046/99/SAA 
Animal Ethics Committees 
University of Queensland – approval VET/FAC/111/98/PHD,  VPA/411/99/PHD 
Animal Research Institute – approval number ARI/032/RES/OCT1998-1 
Institutional Biosafety Committee 
Animal Research Institute – approval number DPI/IBC/PC3/99/00 
6.2.2 Flying foxes 
Wild Grey-headed flying foxes (Pteropus poliocephalus) were caught with a mist net at two flying 
fox colonies in urban Brisbane, namely at Indooroopilly Island, Indooroopilly and Norman Creek, 
East Brisbane. Grey-headed flying foxes were chosen because anecdotal evidence suggested 
that this species adapted best to captivity. Bats were identified with subcutaneous microchips, 
their weight, forearm lengths, and general condition noted, and an estimate of age made based 
on tooth wear, evidence of sexual maturity, forearm length, weight and pectoral, and temporal 
muscle mass. Plasma was submitted to the AAHL to be tested for naturally occurring anti-
lyssavirus antibodies in the modified rabies-RFFIT (see Appendix 2). Captured bats were held as 
a single colony for an observation period of 19 to 27 days at the University Farm, Pinjarra Hills.  
Ten pre-breeding or young adult, seronegative bats in good nutritional condition (four females and 
six males) were selected for experimental infection and transferred to individual cages within the 
PC3 Animal House at the ARI, 3 days prior to inoculation. All surplus seronegative bats were 
released at their site of capture, one seropositive bat was killed. 
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6.2.3 Cage design and layout 
Bats were housed in separate cages so that the incubation period for clinically ill bats could be 
calculated from the day of inoculation and to prevent infection occurring as a result of bites, 
scratches or direct contact with infected companions. As inoculated bats posed a risk to health 
and safety, cages were designed so that bats could be isolated within the cage using a removable 
sliding panel during routine management procedures such as changing food and waste removal 
(see Figure 6-1 and Figure 6-2). The sliding panel was made of steel sheeting and could show a 
reflection. Water and fruit juice were supplied via commercial rabbit drip watering bottles hung on 
the outside of the cages. 
As far as possible, cages were designed to minimize the impact on normal bat behaviour and 
reduce stress. Factors considered important for their welfare included: 
♦ Being able to extend both wings to groom and flap. Wing dimensions were estimated as 
approximately 80 cm across. 
♦ Being as high as possible from the ground. Bats usually roost and feed >20 m from the 
ground. It was assumed that being close to the ground and in particular being lower than a 
perceived predator would be stressful. 
♦ The cage being tall enough that, when hanging, the bats head was well clear of the bottom of 
the cage, but not so tall that there was risk of significant injury if an ill bat should fall. 
♦ Being in close proximity to the other bats. Bats usually roost in large colonies, often within  
<1 m of each other. 
Cage design was also limited by the necessity of ensuring that the entire area of the cage was 
accessible by the candidate while standing on the floor, limiting cage height to 1690 mm. These 
considerations were met by constructing 900 mm high, 900 mm wide and 600 mm deep cages 
mounted on stands. The dimensions and features of the cages are shown in Figure 6-1 and 
Figure 6-2. The cages could be partitioned into two sections by a dividing board, isolating the bat 
in one or other side, permitting safe access to the other side for cage management. When bats 
were isolated within the smaller section, the narrow confines prevented bats from opening their 
wings defensively/aggressively and allowed bats to be given intramuscular anaesthesia. Cages 
were constructed by the farm staff of the ARI. 
Cages containing inoculated bats were arranged in two rows of five cages, such that there was a 
10 cm gap between cages, sufficient to prevent direct contact between bats. The arrangement of 
the cages within the PC3 Animal house is illustrated in Figure 6-3. 
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Figure 6-1 Cages used to house experimentally inoculated flying foxes 
Two cages on stands approximately 10 cm apart. The cage on the left has the dividing board 
inserted, partitioning the cage as if to isolate a bat in one or other side.  
 
Figure 6-2 Dimensions and features of cages used to house experimentally inoculated 
flying foxes 
Re-enforcement
around front of cage
Slot through which dividing board
is inserted ~ 20 mm
Guide rails for board
Hinged flap in door
for access to food
(325 x 150 mm)
Sides and doors of cage
made of galvanised
20 x 20 mm mesh
Fixed top-front panels to prevent bats
climbing directly out (125 mm deep)
Large front door
(600 x 760 mm)
Small front door
(280 x 760 mm)
  900 mm
  600 mm
  280 mm   600mm
  900 mm
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Figure 6-3 Floor plan of cages within the PC3 Animal House 
The individuals occupying each cage are identified by their Bat number, which was allocated in 
the order in which clinical signs were observed. ABLV-positive bats are indicated in red font. 
Cages are separated in both directions by approximately 10 cm. 
 
 Bat 7     Bat 1         Bat 5  Bat 10      Bat 9 
   ♀       ♀         ♂     ♂       ♂   
 
 Bat 3     Bat 4         Bat 2  Bat 8      Bat 6 
   ♀     ♀         ♂    ♂       ♂  
 
 
6.2.4 Daily care and observations 
Bats were fed a range of fresh fruit late each afternoon to encourage natural nocturnal feeding 
patterns, water was available ad lib and fruit juice provided intermittently. Their diet included 
mangos, bananas, papaw (papaya), apples, stone fruit (peaches, plums etc), rockmelon, grapes 
and other seasonal fruits as were available, the majority of which was kindly donated by the Fresh 
Foods section of Woolworths at Westfield Shopping Centre, Indooroopilly. Food was provided 
diced in a dish on the cage wall, and hung to swing freely within the cage. A range of at least 
three fruits was provided each evening ad libitum. The provision of food and removal of waste 
took approximately 1 to 1.5 hours during which time the condition and behaviour of the bats was 
observed in detail. Their condition also was monitored by intermittent observation during the day. 
6.2.5 Inoculations 
6.2.5.1 Mice controls 
Two 3-week-old female Quackenbush mice were inoculated into the footpads with 60 µL of 
Inoculum 5 as described in Chapter 4, Experiment 2. One mouse was inoculated prior to 
inoculation of the 10 bats, the other after inoculation of the bats. The prepared doses of inoculum 
were kept at 4°C during the period that the inoculations were taking place. 
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6.2.5.2 Bat inoculations 
Bats were anaesthetized with an intravenous injection of 2.0 to 2.5 mL of a 1:5 dilution of Propofol 
(10 mg/mL, Rapinovet Schering-Plough Animal Health) in sterile water via the uropatagial vein. 
Nine bats were inoculated with 0.12 mL of neat Inoculum 5, a 20% weight per volume suspension 
of the submandibular and sublingual salivary gland of a naturally infected Black flying fox (ABLV-
51 for details of inoculum preparation, selection and characterization see Chapter 5.).  
The 0.12 mL volume, containing 10 5.2 to 10 5.5  MICED50 =  10 5.1  MFP90ED50, was divided into 
four inoculation sites (approximately 0.03 mL per site) administered via a single tuberculin syringe 
and 27 gauge needle. These sites, illustrated in Figure 6-4, were: 
♦ Left ‘footpad’  (thick dermis over the plantar surface of the metatarsals) 
♦ Left pectoral muscle 
♦ Left temporal muscle 
♦ Left muzzle, under the whiskers 
 
6.2.6 
                                                          
A further bat (Bat 7) was inoculated with only 0.06 mL of Inoculum 5 containing  
10 4.9 to 10 5.2 MICED50 =  10 4.8 MFP90ED50, divided into only two inoculation sites, the left footpad 
and pectoral muscle. 
 
Sample collection 
Bats were anaesthetized with an intramuscular injection of  0.1-0.2 mL of a 2:1 mix of Ketamine 
(100 mg/kg) : Xylazine (20mg/kg), usually in the pectoral muscles, on PI-days 7, 141, 21, 28, 35, 
42, 49, 56, 63, and PI-day 70. This produced anaesthesia within 1-2 minutes lasting 10-20 
minutes during which time the following were recorded/collected.  
♦ general condition  
♦ 1.5 to 2.5 mL plasma samples taken via the uropatagial vein using a heparinized 3 mL 
syringe and 25 gauge needle. 
♦ a swab of the oral cavity taken using a sterile cotton swab which was then stirred vigorously 
in SPGA viral transport medium. The virus transport medium sample was stored at -70°C 
pending submission for quantitative PCR assay. 
 
1 On PI-day 14, two bats (Bat 3 and Bat 4) were given Reversine (2mg/mL 4-aminopyridine and 1.25 mg/mL 
yohimbine hydrochloride, Parnell Laboratories) in an attempt to speed recovery. However Bats 3 and 4 had 
seizures 1 hour 15 minutes and 2 hours 30 minutes later and so the use of Reversine was discontinued. 
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Figure 6-4 Sites of inoculation with ABLV of Grey-headed flying foxes  
 
              Left footpad 
 
  
 
 
 
 
 
Left pectoral muscle           Left muzzle 
             Left temporal muscle 
 
6.2.7 Euthanasia and post-mortem sample collection 
Animal welfare requirements precluded death of infected bats as an endpoint. When clinically ill, 
or at the termination of the experiment, bats were killed by intraperitoneal injection of 0.3 mL 
Lethobarb® (Virbac) diluted to 2.5 to 5 mL in water. This produced a period of anaesthesia (~3 to 
10 minutes), during which 10 to 20 mL of whole blood was collected by cardiac puncture using a 
heparinized 10 mL syringe and 21 gauge needle, followed by death by barbiturate overdose. 
Weight, general condition and, where appropriate, an oral swab were recorded/collected as 
described above. 
Post-mortem examination was performed in a Class II biosafety cabinet within the PC3 Virology 
Laboratory, ARI. A range of fresh tissue samples including brain, the parotid salivary glands and 
the submandibular / sublingual salivary glands were collected using separate sterile instruments. 
A range of tissues including the brain, trigeminal and coeliaco-mesenteric ganglia, spinal column, 
salivary glands, adrenal glands, eyes, and skin were collected in 10% buffered neutral formalin. 
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6.2.8 Confirmation of lyssavirus infection 
Infection with Australian bat lyssavirus was confirmed by FAT on fresh brain touch impressions, 
as described in Section 2.2.3 Fluorescent antibody test. The tests were performed and read by 
the candidate and the results confirmed by Barry Rodwell of the Diagnostic Virology Laboratory of 
the ARI. 
The presence of ABLV was also confirmed by mouse inoculation and TaqMan PCR. Details of 
methods used and results are provided in Chapter 7. 
6.2.9 TaqMan assay for ABLV-RNA in saliva 
Virus transport medium containing saliva, cells and other material released from swabs of the oral 
cavity were submitted to QHSS for the detection of ABLV-RNA in the pteropid-ABLV-TaqMan 
assay (see Appendix 3).  
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6.2.10 Histology and Immunohistochemistry 
Brains for histological examination were sectioned in three standard planes. 
♦ Transversely through the frontal lobe.  
♦ Transversely through the cerebral cortex and thalamus at the level of the hippocampus 
♦ Longitudinal section of the brainstem and cerebellum, which included the caudal colliculus, 
pons, medulla, and cranial end of the spinal cord.  
For all other tissues, representative blocks were selected. Tissues were routinely processed, 
paraffin-embedded and 5 µm sections cut and routinely stained with haematoxylin and eosin by 
the histology staff of the ARI and examined by light microscopy. 
Sections for immunohistological staining were cut at The University of Queensland veterinary 
histology laboratory to 5 µm onto sialinized slides and dried in a 37°C oven overnight, then 
dehydrated and cleared. Endogenous peroxidase activity was quenched in 3% H2O2  in water for 
20 minutes, prior to loading the slides into the Cadenza® (programmable automatic 
immunostainer). Staining was done with a 1:100 dilution of the HAM monoclonal anti-rabies 
nucleoprotein antibody (Feiden et al. 1988) in Tris buffer containing 8.5 g/l NaCL and 0.1% Triton 
X-100  for 30 minutes, followed by a Tris-NaCL-Triton X-100 buffer rinse, 30 minute incubation 
with link (secondary) antibody (DAKO LSAB +/HRP detection system, DAKO, Australia), buffer 
rinse, 30 minute incubation with streptavidin peroxidase complex (DAKO +), buffer rinse, a 30 
minute incubation with AEC chromogen reagent (Immumon, Edward Keller, Australia) followed by 
two final buffer rinses. Stained slides were then removed from the Cadenza and counterstained 
with Mayer’s haematoxylin for 1-2 minutes, blued in running tap water, dried, and mounted with 
aqueous mounting media (Faramount, DAKO, Australia) and a clover-slip. Stained sections were 
examined by light microscopy, with positive immunostaining appearing red (AEC). Duplicate 
sections stained with a 1:50 dilution of monoclonal mouse IgG1 (anti-Aspergillus niger glucose 
oxidase, DAKO, Australia) were stained and examined as negative antibody controls. Included in 
each run were sections of rabies-positive brain stained with the HAM and negative control 
antibodies as positive tissue controls. All immunohistological staining was done by the candidate.  
6.2.11 Serology 
Plasma was taken by the candidate to the AAHL for the detection of rabies and ABLV antibodies 
using the modified rabies CVS-RFFIT and a partially developed ABLV-RFFITs using pteropid- and 
ybst-ABLV (see Appendix 2). The tests were performed by Ross Lunt and Kim Newberry. 
Duplicate samples were submitted to the Rabies Laboratory of the Centers for Disease Control 
and Prevention, Atlanta, USA for confirmation by rabies CVS-RFFIT and an independently 
developed pteropid-ABLV-RFFIT, see also Appendix 2, (Arguin et al. 2002). 
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6.3 Results 
Seven of the 10 inoculated bats developed clinical disease and either died or required euthanasia, 
including 6 of 9 bats (Bats 1-6) which received 0.12 mL of inoculum divided into four inoculation 
sites and 1 of 1 bat (Bat 7) that received only 0.06 mL of inoculum divided into the footpad and 
pectoral muscle only. Infection with Australian bat lyssavirus was confirmed in each case by FAT 
on fresh brain touch impressions, positive detection of lyssavirus antigen in formalin fixed tissues, 
virus isolation in mice and detection of pt-ABLV RNA by TaqMan assay (see also Chapter 7). 
Three bats, Bats 8, 9, and 10, remained clinically well until killed on either PI-day 80 (Bat 8) or PI-
day 82 (Bats 9 and 10). Bats 8, 9, and 10 were negative for ABLV by FAT, immunohistochemical 
staining, and mouse inoculation.  
Both inoculated control mice showed weight loss and a reluctance to move on PI-day 9. Both 
were recumbent on PI-day 10 at which time they were killed and confirmed ABLV-positive by FAT.  
6.3.1 Normal behaviour  
6.3.1.1 Pre-clinical period: 3 days pre-inoculation to PI-day 19 
Normal behaviour for these bats was to hang quietly from the cage roof in a back corner, typically 
near an adjacent bat, with wings folded. They would watch attentively as people moved about the 
room, but would not move themselves unless approached. When the front of the cage was 
approached bats would move to the furthermost corner, and if the cage were approached closely, 
for example to remove waste, the bat would attempt to retreat further by crouching up and turning 
away. They moved across the roof of the cage, not the sidewalls. Bats would rarely approach 
fresh food when people were in the room or even when observed through glass windows. Bats 
would evert (hang by the thumbs rather than the feet) to pass faeces and urinate, but rarely while 
the candidate was in the room. Their coats were normally clean and dry. 
6.3.1.2 Long term survivors: 3 days pre-inoculation to PI-day 82 
The normal behaviour observed in the first three weeks persisted in the three bats that survived 
(Bats 8, 9, and 10) until PI-days 80 and 82, except that they appeared to adapt to the presence of 
the candidate, no-longer crouching up or turning away, and would occasionally groom or start to 
eat fresh food as the candidate moved around the room. However at no point did they come 
forward or vocalize at the candidate, rather they would simply hang in the corners that maximized 
their proximity to each other and distance from the candidate, and watch. 
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6.3.2 Clinical disease 
Seven experimentally inoculated Grey-headed flying foxes (Bats 1-7) developed clinical signs due 
to ABLV infection. The onset of disease occurred 10 to 19 days post-inoculation, with clinical 
disease lasting 1 to 4 days. The clinical signs for each bat are described below and are 
summarized in Table 6-1. 
 
Bat 1  Pre-breeding female, 0.12 mL Inoculum 5 
P1-day 10 Vocalizing and scrambling around the cage, appeared to be vocalizing at other 
bats and the candidate as food was being allocated. Eating well. 
PI-day 11-13 Increasing degrees of agitation, loud vocalizing generally and apparently directed 
at other bats, scrambling up and down the cage wall as if trying to reach food and bats in 
neighbouring cages yet ignoring fresh food within the cage while the candidate was present. Ate 
well each evening. 
PI-day 14 Had eaten overnight, found hanging over food bowl looking gaunt and depressed 
with rapid respiration with forced expiration. The coat was unkempt, with food and faeces on the 
fur suggesting failure to groom/ evert to toilet. Both cheeks were stuffed with food, suggesting 
dysphagia. On returning four hours later, Bat 1 had died, remained hanging. 
 
Bat 2  Young sexually mature adult male, 0.12 mL Inoculum 5 
PI-day 13 Vocalizing, in particular vocalizing at Bat 1 in diagonally opposite cage who was 
also ill and vocalizing. Moved towards people as they approached the front of the cage rather than 
moving away and lunging forward rather than retreating as waste was removed, licking penis. 
Eating well. 
PI-day 14 Continuing to vocalize and constantly moving. Repeatedly approaching the front 
of the cage when approached and climbing up and down the cage front with some clumsiness 
and knuckling of the feet suggesting ataxia and/or proprioceptive deficits. Appeared to attack his 
reflection in the cage divider, attempting to bite divider while vocalizing and opening the wings 
aggressively, attacked inanimate objects such as probes placed in the cage. Licking penis. 
Unremarkable ketamine/xylazine anaesthesia for data/sample collection, not offered food 
overnight.  
PI-day 15 Appeared calmer but shaky, tongue protruding, suggesting cranial nerve deficits. 
Ate banana and mango provided in the morning while candidate present. Later voice croaky, 
mouth contained unswallowed food, coat unkempt with food over face and body and faeces 
around anus, depressed, killed. 
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Bat 3  Pre-breeding female, 0.12 mL Inoculum 5 
PI-day 12-14 Appeared normal, but eating noticeably less than during preceding week. 
PI-day14  16:43 Anaesthetized with ketamine/xylazine for routine data / sample collection. 
17:15 given Reversine (2mg/mL 4-aminopyridine and 1.25 mg/mL yohimbine 
hydrochloride, Parnell Laboratories) to assist recovery.  
17:21 Hanging from roof of cage, during next hour moving around cage, 
apparently normal anaesthetic recovery. 
18:30 Dropped to floor of cage, convulsing, copious froth at mouth. 
18:35 Dead. 
 
Bat 4  Pre-breeding female, 0.12 mL Inoculum 5 
PI-day 12-14 Appeared normal, eating particularly well. 
PI-day 14   17:15 Anaesthetized with ketamine/xylazine for routine data / sample collection. 
17:35 given Reversine to assist recovery. 
17:45 Hanging from roof of cage. 
20:05 Convulsing while hanging, copious froth from mouth, remained hanging, 
seizure lasted approximately 3 minutes. 
20:10 Appeared recovered from seizure. 
20:45 Continuing to hang from cage roof, not offered food overnight. 
PI-day 15 Initially appeared normal, but in the morning ate pear provided while candidate 
present. Afternoon, scratching body and licking body and wings, responded aggressively towards 
cage divider/reflection 
PI-day 16 Appeared shaky, slight tremors, attacking divider/reflection and newspaper, 
licking genitals, everted to urinate. Later, observed from adjacent room via window to be hanging 
half way down cage, and moving around cage walls and heading to the cage floor, appeared 
ataxic in the hind limbs. On the candidate entering the room, Bat 4 scrambled to cage roof and 
hung, came to the front of the cage when approached, repeatedly attacked divider/reflection, later 
moving and hanging low on cage wall again, appeared to be looking for something yet ignoring 
fresh food in cage. 
PI-day 17 Vocalizing, active, coming to front of cage when approached and climbing down 
cage walls, some faeces on coat, licking genitals, grabbing at food repeatedly but not eating. 
Later in the day, appeared weaker, less vigorous efforts to attack cage divider/reflection, still vocal 
and coming to front of cage. 
PI-day 18 Found dead, still hanging, food had been knocked / dropped to the floor. 
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Bat 5  Young sexually mature adult male, 0.12 mL Inoculum 5 
PI-day 14 Appeared normal, unremarkable ketamine/xylazine (no Reversine) anaesthesia 
for sampling, but appeared to be gesticulating at Bat 2 after recovery, not offered food overnight. 
PI-day 15 Vocalizing and gesticulating at Bat 2 in opposite cage who was also ill, licking 
genitals, attacking divider/reflection. Ate mango provided in the morning while candidate present. 
When at rest, tongue protruding slightly suggesting cranial nerve deficits. 
PI-day 16-17 Incessant licking of genitals producing hair loss and excoriation of scrotum, 
repeatedly attacking divider/reflection, coming forwards when approached and vocalizing and 
gesticulating aggressively towards candidate. 
PI-day 18 Found dead, still hanging, had eaten a large amount of food overnight, mouth 
packed with food. 
 
Bat 6  Mature adult male, 0.12 mL Inoculum 5 
PI-day 14 Appeared normal, uneventful ketamine/xylazine anaesthetic for data /sample 
collection. 
PI-day 15 Stretching wings out, aggressive towards divider/reflection and Bat 8 in adjacent 
cage. Ate nectarine provided in the morning while candidate present. 
PI-day 16 Continuing aggression towards reflection, uncharacteristic hypermetric/violent 
‘grabbing’ movement to grasp grapes hanging from the cage roof, biting forcefully at mango.  
PI-day 17 Less active, appears shaky, slight tremors, vocalizing and coming to the front of 
cage aggressively when approached. Tongue protruding at rest, but withdrawn when approached, 
and both cheeks distended with food, suggesting cranial nerve deficits and mild dysphagia. Coat 
unkempt with fur wet, presumably by urine and some faeces around anus. There appeared to be 
paresis and proprioceptive deficits with hypermetric grasping with the right hind foot and right wing 
with repeated attempts to grasp at each point. Mild excoriation of the penis consistent with 
incessant licking. 
PI-day 18 Very depressed, cheeks distended with food, tongue protruding, less inclined to 
move to front of cage when approached, very weak attempt to attack divider/reflection, able to 
evert to urinate, killed. 
 
Bat 7  Pre-breeding female, only 0.06 mL Inoculum 5 
PI-day 15-18 Most timid bat of the group, slightly more so during days 15-17, however, this 
may have been in response to the vocalization and aggressive behaviour of other clinically ill bats.  
PI-Day 16 noticed to hang with head slightly more extended than other bats, PI-day 18 appeared 
normal. 
PI-day 19 Dramatic incessant movement and licking of genitals, tremors, ataxia, 
hypermetria and proprioceptive deficits all four limbs, unkempt coat, excoriation around anus due 
to licking. Had eaten overnight and while being observed, attempted to eat some peach, but not 
sufficiently coordinated to hold fruit, and dropped it. Not aggressive, not vocalizing. Killed later that 
day. 
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Table -  Clinical observations of 10 Grey-headed flying foxes inoculated with pt-ABLV (Inoculum 5) 6 1
     Name 
Incubation 
period 
(days) 
Clinical 
duration 
(days) 
Outcome Diagnosis Vocalizing Aggression Licking
Paresis, ataxia 
proprioceptive 
deficits 
Protruding 
tongue Dysphagia 
Seizures 
assoc. with 
Reversine 
 Bat 1 10    3.5-4 Died ABLV ✔  ✔  ✘  ✘  ✘  ✔  n/a 
 Bat 2 13    
   
    
    
    
   
2-3 Killed ABLV ✔  ✔  ✔  ✔  ✔  ✔  n/a 
 Bat 3 14 <1 Died ABLV ✘  ✘  ✘  ✘  ✘  ✘  ✔  
 Bat 4 14 3-3.5 Died ABLV ✔  ✔  ✔  ✔  ✘  ✘  ✔  
 Bat 5 14 3-3.5 Died ABLV ✔  ✔  ✔  ✘  ✔  ✔  n/a 
 Bat 6 15 2-2.5 Killed ABLV ✔  ✔  ✔  ✔  ✔  ✔  n/a 
 Bat 7 19 1 Killed ABLV ✘  ✘  ✔  ✔  ✘  ✘  n/a 
 Bat 8 > 80 0 Survived Negative ✘  ✘  ✘  ✘  ✘  ✘  n/a 
 Bat 9 > 82 0 Survived Negative ✘  ✘  ✘  ✘  ✘  ✘  n/a 
 Bat 10 > 82 0 Survived Negative ✘  ✘  ✘  ✘  ✘  ✘  n/a 
Outcome: Died – found dead in cage, Killed - required euthanasia due to clinical disease, Survived – remained clinically well until killed at end of experiment on PI-day 80 or 82 
✔   observed 
✘   not observed 
n/a  not applicable 
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6.3.3 Gross necropsy 
The pectoral muscles of all bats were moderately wasted. 
Of the seven ABLV-positive flying foxes, Bat 1 was in poor nutritional condition with very low peri-
salivary gland and perirenal fat reserves, Bats 2, 4, 5, and 6 were in moderate nutritional condition 
with some fat reserves and Bats 3, and 7 were in good condition with ample fat reserves. The 
meninges of Bats 2 and 4 were slightly congested. The pharynx and trachea of Bat 3, which had 
died during a post-anaesthetic seizure, contained considerable froth suggesting this bat may have 
asphyxiated. The skin of the right scrotum of Bat 5 was ulcerated with dehydration and necrosis of 
exposed underlying fat, the penis of Bat 6 was excoriated, and the perianal skin of Bat 7 was 
excoriated and hyperaemic, consistent with observed incessant licking by these bats. No other 
gross abnormalities were detected. 
Bats 8, 9, and 10, which had remained clinically normal until killed on days 80 or 82, were in fat to 
very fat condition with considerable peri-salivary, intra-abdominal and subcutaneous fat reserves. 
They had similar pectoral muscle wasting, but no other abnormalities were detected.  
6.3.4 Histopathology and immunohistochemistry 
6.3.4.1 Clinically ill ABLV-positive bats (n=7) 
All seven affected flying foxes had very mild to moderate non-suppurative 
meningoencephalomyelitis, with focal gliosis, peri-vascular cuffs of lymphocytes, and meningeal 
infiltrates of mononuclear cells, predominantly lymphocytes, in the meninges. In some bats there 
were occasional cytoplasmic eosinophilic inclusion bodies in neurons of the brain stem (see 
Figure 6-5A to C). Inflammation of the central nervous system was most obvious in the brain 
stem. There was also a severe ganglioneuritis in all seven bats involving the dorsal root ganglia, 
trigeminal (Gasserian, 5th cranial nerve) and coeliaco-mesenteric ganglia with marked gliosis and 
neuronal necrosis (see Figure 6-5D and E). 
Several bats had a very mild to moderate interstitial mononuclear, predominantly lymphocytic, 
sialoadenitis involving the parotid (Bats 3 and 7) and/or submandibular (Bats 1, 2, 3, 4, 6, and 7, 
not Bat 5) salivary glands (see Figure 6-5F).  
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Lyssavirus nucleocapsid antigen, as detected by the HAM monoclonal antibody, was found 
throughout the central and peripheral nervous systems and in retinal ganglion cells in all seven 
clinically affected flying foxes (see Figure 6-6 A to D). Antigen was detected in neuronal cell 
bodies and the neuropil of the:  
♦ cerebral cortex 
♦ brain stem 
♦ cerebellum 
♦ spinal cord 
♦ sensory dorsal root ganglia 
♦ trigeminal and coeliaco-mesenteric ganglia 
♦ parasympathetic ganglia and nerve roots within multiple organs including the salivary 
glands, lung, heart, stomach, small and large intestine, and kidney 
♦ retinal ganglion cells (of eye) 
♦ and in large nerves such as the brachial and sciatic nerves.  
Antigen was also detected in salivary gland epithelial cells of four affected flying foxes (Bats-2, 4, 
5, and 6), in each case involving only rare individual or small groups of epithelial cells in the 
submandibular salivary gland (see Figure 6-6E). While antigen was obvious in the 
parasympathetic ganglia associated with all three salivary glands (see Figure 6-6C), no antigen 
was detected in the epithelium of the parotid or sublingual salivary glands. 
Small foci of reactivity were detected in rare epithelial cells within the pancreas of two affected 
bats (Bats-4 and 5, see Figure 6-6F). 
Antigen was not detected in the adrenal glands, testes or ovaries of any experimentally infected 
bats but had been detected in the adrenal glands of at least one naturally infected bat (data not 
shown). 
6.3.4.2 Survivor ABLV-negative bats (n=3) 
Neither histological lesions nor lyssavirus antigen was detected in sections of the central or 
peripheral nervous systems of the three surviving experimentally inoculated bats killed on PI-day 
80 or 82. Focal mononuclear sialoadenitis that was indistinguishable from that seen in some 
clinically ill bats was detected in the parotid (Bats 8, 9, and 10) and submandibular (Bats 8 and 
10) salivary glands. No lyssavirus antigen was detected in the salivary glands or other organs.  
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Figure 6-5 Histology associated with experimental infection of flying foxes with ABLV 
Routine haematoxylin and eosin stained sections of formalin fixed, paraffin embedded tissue. 
 
 
 
Figure 6-5
Figure 6-5B  Eosinophilic inclusion 
bodies Bat 1 
Small group of brain stem neurons 
containing multiple cytoplasmic 
eosinophilic inclusion bodies. 
924 x magnification (oil emersion). 
Figure 6-5
A  Encephalitis Bat 1  
Brain grey matter with perivascular 
cuffs of mononuclear cells, 
predominantly lymphocytes. 
370 x magnification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C  Myelitis Bat 2  
Focal gliosis in spinal cord grey matter.  
185 x magnification. 
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Figure 6-5
 
Figure 6-5
 
Figure 6-5E Ganglionitis Bat 3 
Large perivascular cuff of 
mononuclear cells, predominantly 
lymphocytes, and neuronal necrosis 
in the parasympathetic coeliaco-
mesenteric ganglion.  
370 x magnification. 
Figure 6-5
  (continued)    Histology associated with experimental infection with ABLV 
 
 
D Ganglionitis Bat 2 
Neuronal necrosis (          ) and 
gliosis in a lumbar dorsal root 
ganglion.  
370 x magnification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
F Sialoadenitis Bat 2 
Focal mononuclear inflammatory 
infiltrate in the submandibular 
salivary gland. 
370 x magnification.  
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Figure 6-6 Immunohistological detection of ABLV nucleocapsid antigen in experimentally 
infected flying foxes 
Stained using HAM anti-rabies nucleocapsid monoclonal antibody with AEC chromogen (red) 
and counterstained with Mayer’s haematoxylin (blue). 
 
 
Figure 6-6
Figure 6-6
Figure 6-6
A  ABLV antigen in brain 
stem neuron Bat 1  
924 x magnification (oil emersion). 
 
 
 
 
 
 
 
 
 
B ABLV antigen in 
neurons of a lumbar dorsal root 
ganglion Bat 2 
370 x magnification. 
 
 
 
 
 
 
 
C Salivary gland Bat 1 
Positive (red) staining of ABLV antigen 
in neurons within a parasympathetic 
ganglion adjacent to negatively stained 
(blue) sublingual salivary gland acini.  
370 x magnification. 
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Figure 6-6
Figure 6-6
Figure 6-6
 
Figure 6-5
  (continued)    Immunohistological detection of ABLV nucleocapsid antigen 
 
 
 
D  ABLV antigen (red) in 
myenteric plexus of the stomach 
Bat 1 
370 x magnification. 
 
 
 
 
 
 
 
 
E  Salivary gland Bat 5 
ABLV antigen (red) in epithelial cells 
of the submandibular salivary gland.  
924 x magnification (oil emersion). 
 
 
 
 
 
 
 
F  Pancreas Bat 5 
ABLV antigen (red) in pancreatic 
epithelial cells.  
924 x magnification (oil emersion). 
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6.3.5 
Using the pteropid-ABLV TaqMan say, ABLV RNA was detected in the saliva of four affected 
flying foxes on PI-day 14, and the saliva of a fifth bat on PI-day 19. The results are shown in  
Table 6-2.  
Detection of pt-ABLV RNA in oral swabs 
 as
Table 6-2 Detection by TaqMan assay of pt-ABLV RNA in saliva samples collected from 
seven ABLV-positive experimentally infected flying foxes 
PI-day 7 PI-day 14 PI-day 19  
CT Result CT Result CT Result 
Bat-1 50.0 Neg No sample No result Dead No result 
Bat-2 50.0 Neg 33.6 Positive Dead No result 
Bat-3 50.0 Neg 35.7 Positive Dead No result 
Bat-4 50.0 Neg 50.0     Neg Dead No result 
Bat-5 45.7 Neg 33.1 Positive Dead No result 
Bat-6 49.1 Neg 31.4 Positive Dead No result 
Bat-7 50.0 Neg 50.0     Neg 35.02 Positive 
 
Saliva samples from Bats-8, 9, and 10 (ABLV-negative survivors) collected on PV-days 7, 14, 21, 
28, 35, 42, 49, 56, 63, and 70, were all negative (CT= 50 for all samples, except Bat 8 PV-day 42 
Ct=42 and Bat-9 PV-day 49 CT=38.9) 
6.3.6 Serology 
6.3.6.1 Clinically ill ABLV-positive bats (n=7) 
None of the seven clinically ill ABLV-infected flying foxes showed clear evidence of 
seroconversion when tested at the AAHL and CDC, Atlanta, using either CVS-11 rabies or ABLV-
RFFITs. Two plasma samples showed very weak / equivocal reactivity near the limit of detection 
of the AAHL modified CVS-11 and ABLV-RFFITs as indicated in Table 6-3.  
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Table 6-3 Rabies and ABLV serology of seven ABLV-positive experimentally infected bats 
Positive results are shown in bold. --- not done 
AAHL modified RFFIT CDC RFFIT (titre) 
Bat  PI-day CVS-11 
(IU/mL) 
pt-ABLV ybst-ABLV CVS-11  pt-ABLV Interpretation 
Bat 1 -22 capture 0 --- --- --- <11 Negative 
 -3 0 --- --- --- --- Negative 
   7 Toxic  --- --- 0     0 Negative 
 14 died < 0.2 + 0 0     0 Equivocal 
Bat 2 -22 capture 0 --- --- 0 <11 Negative 
 -3 0 --- --- 0     0 Negative 
   7 0 --- 
--- 
--- 
--- 
    0 Negative 
7 
--- 0 <  9 Negative 
 14  0 --- --- 0 <13 Negative 
 15 killed 0 --- --- --- <13 Negative 
Bat 3 -23 capture 0 --- --- 0     0 Negative 
 -3 0 --- --- 0     0 Negative 
   7 0 --- --- 0 <11 Negative 
 14 died < 0.2 + 0 0     0 Equivocal 
Bat 4 -22 capture 0 --- 0     0 Negative 
 -3 0 --- --- ---     0 Negative 
 7 0 --- 0  <11 Negative 
 14  0 --- --- 0 <11 Negative 
 18 died 0 0 0 --- <  9 Negative 
Bat 5 -22 capture 0 --- --- 0 <11 Negative 
 -3 0 --- --- ---     0 Negative 
 7 0 --- --- 0     0 Negative 
 14  0 --- --- 0 <11 Negative 
 18 died 0 --- --- <  9 Negative 
Bat 6 -23 capture 0 --- --- 0 <11 Negative 
 -3 0 --- --- --- 
 7 0 --- --- 0 <11 Negative 
 14  0 --- --- 0 <11 Negative 
 18 killed 0 --- --- --- <10 Negative 
Bat 7 -30 capture 0 --- --- 0 <11 Negative 
 -3 0 --- --- ---     0 Negative 
 0 --- --- 0 <11 Negative 
 14  0 --- --- 0 <11 Negative 
 19 killed 0 --- --- 0 <  9 Negative 
AAHL results: ‘0’ indicates 20 of 20 positive fields contained fluorescent foci at a 1:20 dilution.  
Results < 0.2 IU/mL correspond to counts of 14 and 15 of 20 fields.  
+  there was subjective evidence of inhibition at a dilution of 1:20 but not 1:50. This test is 
not standardized. See Appendix 2 for details of the RFFIT procedure and assessment.  
CDC results: ‘0’ indicates 20 of 20 positive fields contained fluorescent foci at a 1:5 dilution.  
   Positive results expressed as calculated 50% endpoint dilutions. 
   Results expressed as < 9 to <11 had cytotoxicity at the 1:5 dilution and a count of 20 of 20 
  positive fields at a plasma dilution of 1:25. These results are considered negative. 
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6.3.6.2 Clinically well, survivor bats (n=3) 
Plasma from one of the three survivor flying foxes (Bat-8) showed strong anti-rabies and anti-
ABLV activity that peaked around PI-day 7. Results for Bat 8 are shown in Table 6-4.  
Plasma from one other survivor (Bat 9) showed weak intermittent responses near the limits of 
detection for these assays on PI-day 21 and PI-day 70 in the AAHL modified rabies-RFFIT (< 0.2 
IU/mL), but no evidence of CVS-rabies or pt-ABLV activity in the CDC RFFITs as shown in Table 
-4. Plasma from all other days was either negative or not done.  6
Plasma from the other survivor (Bat 10) showed no evidence of anti-rabies or anti-ABLV activity. 
Table 6-4 Strong anti-rabies and anti-ABLV response in one of three unaffected 
experimentally-inoculated flying foxes (Bat 8) 
AAHL modified RFFIT CDC RFFIT 
Bat  8  
PV-day CVS (IU/mL) 
pt-
ABLV 
 
ybst-
ABLV  
CVS 
(titre) 
pt-ABLV 
(titre) 
Interpretation 
-30 capture 0 --- --- 0 50 Positive  
-3 0 --- --- --- 13 Weak positive 
7 >> 2 ++++ ++++ --- 480 Strong Positive 
14 0.54 ++++ ++++ --- 170 Strong Positive 
 7 
<8 
21 0.17 ++++ ++++ 11 180 Strong Positive 
28      0.1 --- ---  0 50 Positive 
35   < 0.1 --- ---  9 125 Positive 
42 0 --- --- --- 54 Positive 
49 0 --- --- 0 60 Positive 
56 0 --- --- --- 54 Positive 
63 0 --- --- 70 Positive 
70 0 --- ---  7 70 Positive 
80 0 --- --- --- 25 Positive 
       
Bat 9 (plasma from all other days either negative or not done)  
21 <0.2 --- --- 0 <11 Equivocal 
70 <0.2 --- --- 0 Equivocal 
       
---    Not done 
AAHL results: ‘0’ indicates 20 of 20 positive fields contained fluorescent foci at a 1:20 dilution.  
++++ indicates 0 of 20 low power fields contained fluorescent foci at a dilution of 1:50. 
CDC results: ‘0’ indicates 20 of 20 positive fields contained fluorescent foci at a 1:5 dilution.  
   Results expressed as < 8  and <11 had cytotoxicity at the 1:5 dilution and a count of 20 of  
  20 positive fields at a plasma dilution of 1:25. These results are considered negative. 
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6.4 Discussion 
An important consideration in the development of this model of ABLV infection was to simulate 
natural infection as closely as possible. To this end pteropid-variant-ABLV recovered directly from 
the tissues of a naturally infected bat (ABLV-51), and not passaged in either cell culture or an 
aberrant species such as mice, was inoculated peripherally, into Grey-headed flying foxes, a 
natural host. As earlier pathogenesis studies with ABLV in flying foxes had produced clinical 
disease in only 1 of 7 and 3 of 10 inoculated bats (23.5%) (McColl 1999; McColl et al. 2002), two 
strategies were used to increase the proportion affected. First, candidate inocula were evaluated 
in a mouse model for peripheral virulence, and the most virulent inoculum (Inoculum 5) selected 
for use in bats (see Chapter 5). Secondly, multiple inoculation sites, rather than just one, were 
used in order to reduce the possibility of inadvertent placement of the inoculum into a tissue or 
site that was not conducive to the establishment of infection. 
The use of multiple sites was considered consistent with the presumptive natural route of ABLV 
transmission by biting. Flying foxes are quarrelsome and do bite and scratch each other while 
defending territory. One naturally infected rescued bat (ABLV-52, see Chapter 2) was observed 
attacking and biting another bat in a cage, and was found with multiple small punctures 
suggesting it had been in prior fights with other bats. An ABLV-positive female Black flying fox 
was found near a release cage, chasing and biting other flying foxes, including her own pup, 
which sustained fatal head injuries (Skerratt et al. 1998). These observations support biting as a 
route of natural transmission. Inoculation of the temporal and pectoral muscle was done as these 
were large, easy to identify and inoculate muscle masses, and were considered to be likely sites 
of natural bat bite wounds. The muzzle was selected as the face is highly innervated and was 
considered likely to have a high density of nerve endings that would take up ABLV, and because 
wounds to the face have been associated with a higher prevalence of clinical rabies and shorter 
incubation periods in humans (Hattwick 1974; Warrell 1995). The ‘footpad’ was selected because 
successful footpad models of infection are well established in rodents and it was thought possible 
that this success may involve suitability of the connective tissue structure for establishing 
infection. 
While the numbers of bats used are small, this appears to be highly successful model for ABLV 
infection of flying foxes, inducing clinical disease and/or death in 7 of 10 bats (70%). This 
compares favourably with mortalities of 0 to 31% in six reports of experimental peripheral 
inoculation of insectivorous bats with bat-variant rabies virus (Baer and Bales 1967; Constantine 
1966b; Constantine and Woodall 1966; Kuzmin and Botvinkin 1996; Stamm et al. 1956; Sulkin et 
al. 1960), and with the previous ABLV trials in which 4 of 17 were affected (23.5%) (McColl 1999; 
McColl et al. 2000; McColl et al. 2002), and is comparable to the 89% mortality of vampire bats 
given vampire-variant rabies virus (Setien et al. 1998). In only one insectivorous-rabies virus study 
(Baer and Bales 1967) and the vampire bat study were the bats shown to be free of detectable 
Chapter 6 
 233
rabies antibody prior to inoculation. The low mortalities in the other insectivorous bat rabies 
studies may be secondary to natural immunity resulting from prior exposure.  
The incubation period for the seven affected bats was unexpectedly short; only 10 to 15 days 
(n=6) and 19 days, when compared to the four known incubation periods of naturally occurring 
ABLV in bats (ABLV-32: 36 to 57 days and ABLV-73: 30 days see Chapter 5), and in humans (6 
weeks and 27 months (Allworth et al. 1996; Hanna et al. 2000)). They were generally shorter but 
consistent with those of the previous ABLV trials in flying foxes (27 days (McColl 1999) and 15, 
23, and 24 days (McColl et al. 2002)). The short incubation periods are consistent with those seen 
using this inoculum in mice (see Chapter 5). The unique inoculation protocol for Bat 7, using only 
half the dose in only two sites, the footpad and pectoral muscle, was an artefact of there being 
insufficient inoculum. This bat was the last to become ill, however no significance is attributed to 
this association. 
One bat (Bat 3) died during a seizure that occurred during an otherwise uneventful recovery from 
ketamine/xylazine/Reversine anaesthesia, without any other clinical signs being detected. The 
brain of this bat was ABLV-positive by FAT, immunoperoxidase staining, virus isolation in mice 
and TaqMan PCR. Bat 4 had a very similar seizure during recovery from the same anaesthetic 
but recovered and showed other signs of ABLV infection the next day. Bat 2, which was showing 
clinical signs of aggression and vocalizing at the time, recovered uneventfully from a similar 
ketamine/xylazine anaesthetic (no Reversine). This suggests there was an interaction with 
Reversine component of the anaesthetic and pre-clinical CNS ABLV disease, however 
‘spontaneous’ seizures have been recorded in naturally infected bats. No other seizures were 
seen during the limited time the bats were under direct observation. 
Unexpectedly, the clinical manifestation in the six other affected bats was dominated by agitation 
and/or aggression rather than the depression and paresis seen in most naturally infected bats 
(see Chapter 2) and the four affected bats of the previous trials (McColl 1999; McColl et al. 2002). 
Why these six inoculated bats should develop a similar but apparently less common ‘furious’ 
clinical form is unclear. Clinical signs lasted 3 to 4 days in those that died (n= 3), and three others 
became very ill and were killed within 1 to 3 days. Clinical signs included vocalizing, ‘rushing at’ 
and apparently trying to attack neighbouring bats and the candidate, and incessant licking, 
particularly of the genitals similar to that noted in at least one naturally occurring case of ABLV 
infection in a bat (ABLV-73). Involvement of the genitals may involve the same mechanisms that 
induce increased libido, nymphomania, and spontaneous ejaculation in rabid humans (Warrell 
1976). Four bats developed proprioceptive deficits and paresis, most readily seen as knuckling 
and unsteadiness while scrambling around the cage but none became so weak that they were 
unable to hang or fell from the cage roof, and the aggression persisted until moribund.  
In one naturally infected bat (ABLV-32) the clinical course had progressed from initial signs of 
aggression (vocalizing, aggressive to cage mate, biting objects) to a prolonged period (2 to 6 
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days) of typical depression, paresis, and an inability to hang (Field et al. 1999). This had 
suggested that an aggressive phase may have occurred prior to rescue in cases of naturally 
occurring ABLV that presented alert and calm with unexplained paresis, and led to an expectation 
that a similar period of calm paresis would develop in the inoculated bats. That three bats died in 
this trial, rather than being killed, was a consequence of the unexpectedly rapid terminal 
deterioration of these bats. As was seen in some cases of naturally infected flying foxes (e.g. 
ABLV-25, ABLV-52, and ABLV-53) ABLV-infected bats showing overt aggression can rapidly 
change from hyperactive and aggressive to moribund or dead in a matter of hours. This is 
consistent with observations that humans with ‘furious’ rabies die after a shorter illness than those 
with ‘paralytic’ rabies (Warrell 1995). In general the clinical signs observed fell within the range of 
clinical signs reported in humans and animals infected with street rabies virus.  
The diagnosis of ABLV infection in the seven affected bats was well supported by FAT, 
immunoperoxidase staining, virus isolation in mice, and TaqMan PCR (see also Chapter 7). 
Unlike previous trials (McColl et al. 2002), in all cases there was strong and unequivocal staining 
in the FAT on fresh brain touch impressions, as seen in the vast majority of naturally occurring 
cases of ABLV infection. In the previous trials, attempts at virus isolation were prohibited by 
biosecurity concerns in the first trial (n=1) (McColl 1999), and ABLV was isolated from only two of 
three affected bats in the second trial in mouse neuroblastoma cells (MNA) (McColl et al. 2002). 
Attempts to isolate ABLV in MNA at the time candidate inocula for this study were prepared also 
failed (data not shown) and isolation of ABLV in cell culture from the second human case required 
two blind passages (14 day incubation) before detection by fluorescent antibody (Hanna et al. 
2000). It would appear that wild-type ABLV is more difficult to isolate in cell culture than in mice, 
however use of the more sensitive in vivo models is limited by animal ethics requirements.  
The only abnormalities at gross post-mortem examination were wastage of the pectoral muscles, 
self inflicted skin lesions, and the presence of froth in the trachea of Bat 3 that died during a 
seizure. The pectoral muscle wastage, seen in both the ABLV-positive and ABLV-negative bats, 
was considered secondary to confinement, initially in a reasonably large outdoor cage for 19 to 27 
days that permitted limited flight, and later in the smaller experimental cages.  
Histological lesions were confined to the central and peripheral nervous systems of clinically 
affected ABLV-positive bats with the exception of a multifocal non-suppurative sialoadenitis 
involving the parotid and/or submandibular salivary glands of Bats 1, 2, 3, 4, 6, 7, 8, 9 and 10 (not 
Bat 5). Similar sialoadenitis was observed by the candidate in diagnostic submissions of ABLV-
negative flying foxes (data not shown). Sialoadenitis in ABL-negative flying foxes has also been 
observed by others (Deborah Middleton, AAHL pers. comm.) and is considered incidental.  
In contrast to the frequently high number of large and easily observed eosinophilic cytoplasmic 
neuronal inclusions pathognomic for street rabies virus infection, inclusions were absent or small, 
rare, and very difficult to detect in these bats. This is consistent with the previously reported low 
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incidence of eosinophilic inclusions in naturally infected ABL-positive flying foxes (Hooper et al. 
1999b). There was no reference to the presence of eosinophilic neuronal inclusions in reports of 
the previous ABLV trials, suggesting inclusions were absent (McColl 1999; McColl et al. 2002), 
and inclusions were often absent and in the few reports of natural or experimental infection with 
Mokola virus or Lagos bat virus (Kemp et al. 1973; Percy et al. 1973; Shope et al. 1970). In 
general the histological lesions were entirely consistent with those previously reported in naturally 
infected ABL-positive bats (Hooper et al. 1999a), and fall within the range of lesions reported in 
humans and animals infected with street rabies virus. 
The distribution of antigen in the brain, as demonstrated by immunoperoxidase staining with the 
HAM monoclonal anti-nucleocapsid antibody, did differ from that seen in some naturally infected 
bats (data not shown) in that antigen occurred in multiple small/fine granules within neurons that 
were only readily seen at high power. In some naturally affected bats the aggregates of antigen 
were larger and easily seen at low power. The small size of the aggregates may be a reflection of 
the short incubation period.  
Viral antigen was found throughout the central and peripheral nervous system, including within 
parasympathetic ganglia in virtually all tissues examined including the heart and gastrointestinal 
tract as had been reported previously (Hooper et al. 1997b). As was noted in the previous ABLV 
trials (McColl et al. 2002), within the nervous system there often appeared to be an inverse 
correlation between the severity of histological lesions and the quantity of antigen detected by the 
HAM monoclonal antibody. Antigen was also found in retinal cells and ganglia in the salivary 
gland, lungs and kidney, and in nerve fibres. Due to the limits of resolution using light microscopy, 
it remains unclear whether antigen in nerve fibres is within axons and/or dendrites, or in 
supporting Schwann cells. Detection of antigen in ganglion neurons in the kidney support the 
speculation that the original isolation of ABLV from kidney samples of the index ‘Ballina’ case was 
due to the presence of ABLV in parasympathetic neurons within the sample (Fraser et al. 1996; 
Hooper et al. 1997b).  
The near ubiquitous nature of the virus in organs secondary to parasympathetic innervation 
means that the presence of antigen and isolation of virus from the salivary glands does not 
intrinsically indicate saliva plays a significant role in transmission. The presence of antigen in 
serous epithelial cells of the salivary glands of a YBST bat has been reported previously (Hooper 
et al. 1997b), and small quantities of antigen in rare submandibular (mixed serous and mucous) 
salivary gland epithelial cells were detected in four flying foxes in this study. This is more 
suggestive of the salivary glands playing a role in transmission, as is the detection of small 
quantities of ABLV RNA in the saliva samples of four bats on PI-day 14 and a fifth bat on  
PI-day 19. However, the quantities of RNA detected were very small (CT= 30 to 36), and near the 
positive-negative detection threshold. In retrospect it would have been better to have tested the 
oral swabs directly rather than transport media in which the swabs had been agitated. A clearer 
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indication of the potential role of saliva for transmission requires demonstration that the saliva 
contains infectious ABLV rather than simply genomic material. 
Interpretation of the serological results of this trial is complicated by a number of factors. Bat 
plasma is toxic to BHK and neuroblastoma cells at low dilutions. This limits the sensitivity of the 
RFFIT by limiting the lowest dilution at which plasma that can be tested without interpretation 
being compromised by poor cell growth. At AAHL, using BHK cells, this is managed by using 1:20 
as the lowest plasma dilution, and by reducing the time that plasma is in contact with the cell 
sheet to 90 minutes (see Appendix 2). The thresholds at which naturally occurring titres are of 
biological significance, i.e. indicating prior exposure and/or protective immunity to ABLV are 
unknown. It is possible that low but biologically significant titres below the sensitivity limits of the 
RFFIT format are not detected. 
In Australia there is no standardized RFFIT using ABLV rather than rabies virus, and virtually all 
Australian research into the seroprevalence of ABLV is based on cross-reactivity to CVS-rabies 
and expressed as international units (IU/mL) of anti-rabies activity. Prototype pteropid-variant and 
YBST-variant ABLV RFFITs developed at AHHL suffer from poor growth of the virus isolates in 
cell culture. Pteropid and YBST-variant RFFITs have been developed at CDC Atlanta, however, 
the growth characteristics of the virus isolates used in these assays has not been reported. A 
serological survey of insectivorous and fruit bats of the Philippines using the CDC ybst-ABLV 
RFFIT showed that there was poor correlation between positive neutralization in the ABLV and 
CVS-11 RFFITs. Of 231 samples tested, 17 of 22 samples that were positive in the ABLV-RFFIT 
were negative in the CVS-RFFIT, and one sample was positive in the CVS-RFFIT but negative in 
the ABLV-RFFIT (Arguin et al. 2002). While the lyssavirus responsible for induction of these 
antibodies was not specifically identified, it is likely to be ABLV or closely related to ABLV, and the 
results suggest that a negative result in the CVS-RFFIT does not necessarily indicate an absence 
of neutralizing antibodies for ABLV. 
Given these considerations, comparison of the CVS-11 rabies and ABLV RFFIT results from 
AAHL and CDC points to some interesting conclusions.  
None of the clinically affected, ABLV-positive bats developed an early or high antibody response 
to either CVS-11 or ABLV. Clearly the development of clinical signs in these bats was associated 
with an absent or insufficient (weak and/or late) antibody response to ABLV infection. The very 
low or negative CVS-11 RFFIT titres of these experimentally infected bats are consistent with 
those seen in naturally infected bats (see Chapter 2) and experimentally infected mice (see 
Chapter 5). 
Of the three bats that did not develop clinical disease and were ABLV-negative, Bat 10 showed no 
evidence of a serological response. Bat 9 showed very weak and intermittent anti-CVS activity on 
PI-days 21 and 70 in the AAHL RFFIT, which were near or below the tests detection thresholds, 
and are of questionable significance. Certainly neither bat developed an early or high antibody 
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response to which their not developing clinical signs could be attributed. It appears that either 
these bats were not infected with ABLV or they were killed before showing clinical signs that 
would have developed after an incubation period > 80 or 82 days.  
The serological response of Bat 8 is most interesting. The CVS-RFFITs at both AAHL and CDC 
indicate a brief but strong antibody response that peaked around PI-day 7 and was below the 
formal test parameters by PI-day 28. This brief spike of cross-reactive anti-rabies activity is similar 
to that previously reported for three of five survivors of experimental inoculation with ABLV 
(McColl et al. 2002). However, the ABLV-RFFITs at AAHL and CDC indicated a higher and more 
sustained anti-ABLV response that also peaked around PI-day 7. The time of this peak 
corresponds to the subclinical development of infection in the seven clinically affected bats, and 
strongly suggests that failure of this bat to develop clinical signs was not due failure to be infected 
but was related to an early and adequate immune response.  
Of perhaps more significance is the observation that while both the CDC and AAHL CVS-11 
RFFITs for Bat 10 were negative prior to ABLV-inoculation, the CDC ABLV-RFFIT detected 
moderate or low anti-ABLV activity both 30 and 3 days prior to inoculation. These ABLV results 
suggest this bat had naturally-occurring ABLV antibodies, presumably indicating prior exposure to 
ABLV, that were not evident in the pre-trial AAHL CVS-11 RFFIT used to screen for susceptible 
experimental animals. The post-inoculation antibody response and resistance to clinical infection 
appear to be the result of stimulation of pre-existing ABLV immunity. Similar undetected pre-
existing immunity may account for the low number of clinically affected animals and serological 
responses of survivors in previous ABLV trials (McColl 1999; McColl et al. 2002).  
The serological results of Bat 8 suggest that: 
♦ While high levels of anti ABLV antibodies may be reflected in CVS-11 cross-reactivity, low 
levels of ABLV immunity are not detected in CVS-11 RFFITs. 
♦ Levels of ABLV immunity below the detection threshold of the cross-reactive CVS-11 RFFIT 
may confer protective immunity to ABLV challenge. 
♦ Screening with the CVS-11 RFFIT will not always identify individuals with natural immunity to 
ABLV infection and resistance to infection in inoculation trials. 
♦ Serological surveys for ABLV done using CVS-RFFITs may underestimate the proportion and 
level of naturally occurring ABLV immunity in bat populations. 
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6.5 Conclusions 
Development of a successful model of experimental infection of flying foxes with 
ABLV 
♦ This experimental model successfully induced clinical disease in 7 of 10 inoculated bats that 
was consistent with that of naturally occurring ABLV in flying foxes. 
♦ Diagnosis of ABLV infection in all seven clinically affected bats was unequivocal. 
♦ No ABLV was detected in any of three bats that remained clinically well until killed at the 
conclusion of the trial. 
Characterization of the clinical disease, pathology, and viral distribution following 
experimental infection 
♦ Bats became ill after a comparably short and consistent incubation period of 10 to 19 days, 
and were ill for 1 to 4 days before dying or requiring euthanasia. 
♦ One bat (Bat 3) died during a seizure apparently induced by an interaction between pre-
clinical ABLV encephalitis and one or more components of the ketamine/xylazine/Reversine 
anaesthetic.  
♦ Five Bats (Bats 1,2, 4, 5. and 6) showed clinical signs of overt aggression towards other bats, 
inanimate objects and/or the candidate, consistent with those described in ~ 14 of 74 (19%) of 
bats with naturally occurring ABLV infection. 
♦ One bat (Bat 7) showed intractable agitation, pacing, tremors and ataxia. 
♦ While 4 of 7 affected bats showed evidence of paresis, ataxia, and proprioceptive deficits, in 
none were these the dominant clinical signs, and none lost the ability to hang or became 
recumbent. 
♦ No significant gross lesion was detected. 
♦ The histopathology associated with experimental infection was entirely consistent with that 
reported in naturally infected ABL-positive bats, and within the range of lesions described for 
rabies virus and other lyssavirus infections. 
♦ ABLV is only weakly negrigenic (forms few eosinophilic intracytoplasmic neuronal inclusions) 
compared to terrestrial variants of street rabies virus. 
♦ The predominant histological lesions were mild to moderate non-suppurative 
meningoencephalomyelitis and severe ganglioneuritis. 
♦ ABLV nucleocapsid antigen was detected throughout the central and peripheral nervous 
systems, including parasympathetic ganglia and nerve fibres within most tissues examined. 
♦ Antigen was detected in a very small number of submandibular salivary gland epithelial cells 
from four bats.  
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Examination of plasma for evidence of seroconversion 
♦ None of seven affected bats showed clear evidence of seroconversion to ABLV in RFFITs 
using rabies virus or ABLV. 
♦ Two of three unaffected bats showed no or equivocal antibody responses as detected in the 
CVS and ABLV-RFFITs, suggesting these bats were not infected.  
♦ One of three unaffected bats showed evidence of pre-existing (natural) ABLV immunity in the 
CDC pt-ABLV RFFIT, and a strong but brief antibody response on PI-days 7, 14 and 21 that 
waned to pre-inoculation levels by PI-day 28. 
♦ Serological surveys for ABLV and selection of susceptible individuals for experimental 
infection should be done using ABLV-RFFITs rather than the relying on the cross-reactivity 
detected in rabies-RFFITs.  
Examination of saliva for evidence of viral excretion 
♦ Low levels of ABLV RNA were detected in samples of saliva from four bats that were clinically 
ill, and the saliva of one bat (Bat 6) that was behaving abnormally within 12 hours. Together 
with the presence of viral antigen in the parasympathetic ganglia of all three salivary glands 
and the epithelial cells of the submandibular salivary glands, this suggests that saliva does 
play a role in the natural transmission of ABLV. 
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7 Relative virulence in mice of inocula 
prepared from the brain and salivary gland of 
experimentally infected flying foxes 
Aims 
1. To confirm by virus isolation the presence or absence of ABLV in the brains and salivary 
glands of 10 experimentally inoculated flying foxes.  
2. To compare the virulence of inocula prepared from the brain, parotid salivary gland or 
submandibular and sublingual salivary glands from 10 experimentally inoculated flying foxes. 
3. To compare the effects of these inocula in mice with the relative amount of viral-RNA 
detected by quantitative-PCR (TaqMan) to evaluate the potential role of quantitative-PCR in 
the selection of inocula. 
7.1 Introduction 
The results of Chapter 5, where the virulence of 15 inocula were compared to select one for 
further use, suggested that inocula derived from the submandibular and sublingual salivary glands 
had higher virulence than either the relative amount of viral RNA in the inocula, or the relative 
amount of viral antigen detected in some naturally infected bat salivary glands (data not shown) 
would have implied. However, the source tissues used to prepare the inocula had been collected 
from naturally affected bats, after variable post-mortem intervals during which they had been 
stored in a range of different conditions, and the source tissues had subsequently been subjected 
to variable storage conditions for variable periods and had undergone variable numbers of freeze 
/thaw cycles prior to inoculum preparation. The extent to which the differences in virulence 
indicated some specific property of salivary gland-derived inocula or was simply an artefact of the 
storage and handling histories of the source tissues was unclear.  
The experimental infection of bats in Chapter 6, presented the opportunity to re-evaluate the 
relative virulence of brain and salivary gland inocula using tissues that had been collected after 
brief post-mortem intervals and stored in similar conditions. It also allowed further evaluation of 
the potential use of TaqMan PCR assays in the selection of inocula. 
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7.2 Materials and methods 
7.2.1 Permits 
Animal Ethics Committees 
University of Queensland – approval number VP/231/00/PHD 
Animal Research Institute – approval number   ARI/025/2000-1 
Biosafety Committee 
Animal Research Institute – approval number DPI/IBC/PC3/99/00 
7.2.2 Source and preparation of inocula 
Ten Grey-headed flying foxes were experimentally inoculated with an inoculum prepared from the 
submandibular and sublingual salivary glands of a naturally infected ABLV-positive Black flying 
fox (Inoculum 5, for details see Chapters 5 and 6). Seven of the 10 bats became clinically ill and 
subsequently died or were killed 14 to 19 days post-inoculation, three remained clinically well until 
killed on PI-day 80 or 82. Three tissue samples, the brain, the parotid salivary gland and the 
submandibular and sublingual salivary glands from each bat were removed separately with sterile 
instruments and stored at –70°C.  
Each sample was ground into a 20% w/v suspension with a sterile mortar and pestle in 
Dulbecco’s modified Eagles medium, 20% bovine plasma albumin and an antibiotic/antimycotic 
preparation as described in Section 5.3.2 Inocula. Suspensions were clarified at ~200 G for 10 
minutes and the supernatant removed, divided into aliquots, and stored at –70 0C. All inoculations 
were done using separate aliquots of the original preparations at the same freeze/thaw 
generation.  
7.2.3 Experimental design 
Animal ethics requirements required that the number of mice used be minimized, precluding 
evaluation by systematic in vivo titration of inocula. To reduce the numbers of mice required to 
evaluate inocula, the following approach was taken. 
Inocula prepared from ABLV-positive bats, which were expected to contain viable ABLV, were 
tested by footpad inoculation of 21-day old weanling mice. Inocula prepared from ABLV-negative 
bats, which were expected to not contain viable ABLV, were tested using the more sensitive 
method intracerebral inoculation of two to three-day old mice. 
Animal ethics requirements precluded death as an endpoint. Mice showing clear clinical signs of 
disease were killed. All inoculations were performed by the candidate. 
The experimental design is illustrated in Figure 7-1. 
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 Figure -  Experimental design for the evaluation of brain, parotid and submandibular/sublingual salivary glands from 10 ABLV-inoculated bats  7 1
 
30 Inocula for evaluation = 10 inoculated bats × 3 tissues per bat 
brain, parotid salivary gland and submandibular/sublingual salivary glands 
 
 
     (Experiment A)                (Experiment B) 
        Intracerebral inoculation of suckling mice     Footpad inoculation of 21-day old mice 
    Samples from 3 clinically well ABLV-negative bats            Samples from 7 clinically ill ABLV-positive bats 
    Bats 8, 9, and 10          Bats 1 to 7  
        9 inocula = 3 bats × 3 tissues              21 inocula = 7 bats × 3 tissues 
     
 
No clinical disease         Clinical disease/FAT positive   No clinical disease   Clinical disease/FAT-positive  
Negative for ABLV             Inocula to be evaluated by                comparison of virulence 
     footpad inoculation                       
       (Experiment C) 
     Test for ABLV by more sensitive         (Experiment D) 
intracerebral inoculation   Footpad titration of selected inocula 
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7.2.3.1 Experiment A and Experiment C: Intracerebral inoculation of suckling 
mice  
Each of the nine inocula prepared from the surviving ABLV-negative bats (3 bats x 3 inocula, 
Experiment A), and inocula that failed to produce clinical disease in Experiment B by footpad 
inoculation (Experiment C) were inoculated intracerebrally into litters of two to three-day-old 
Quackenbush (outbred) mice on PI-day 0. Losses within the first 3 days post-inoculation were 
considered incidental and not considered in the results.  
Inocula were considered positive for ABLV if one or more mice per litter died or required 
euthanasia 4 to 30 days post-inoculation and were confirmed ABLV-positive by FAT.  
Inocula were considered negative for ABLV if all inoculated mice survived with no clinical disease 
until PI-day 30.  
7.2.3.2 Experiment B: Comparison of virulence by footpad inoculation of 
weanling mice 
Each of 21 inocula prepared from the tissues of ABLV-positive bats (7 bats x 3 tissues) were 
inoculated into the footpads of three 21-day old female Quackenbush mice which were 
anaesthetized with 0.01 mL of 1:1 mix of ketamine (100 mg/mL) and xylazine (Rompun SA, 20 
mg/mL). Anaesthetic deaths reduced the number of mice in four groups to only two mice (see 
Table 7-2). Each group of two or three mice was housed separately. Within each group, 
individuals were identified with silver nitrate markings. Mice were weighed with digital laboratory 
scales every 2 to 3 days until PI-day 30, then once or twice a week until PI-day 90, then 
intermittently as required. When clinically ill or at the conclusion of the experiment on PI-day 287 
(~ 9.5 months) mice were killed and blood collected, as described in Chapter 5, Experiment 2. 
Plasma was submitted to the AAHL for detection of anti-lyssavirus antibodies using the rabies-
RFFIT. 
7.2.3.3 Experiment D: Footpad titration of selected inocula 
Three inocula were selected from those used in Experiment B for titration by footpad inoculation 
for quantitative comparison of peripheral virulence. Unanaesthetized mice were inoculated with 
ten-fold dilutions of the neat inoculum as described in Chapter 5, Experiment 4. Unaffected mice 
were killed at the conclusion of the experiment on PI-Day 92. 
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7.2.4 Confirmation of lyssavirus infection by FAT 
Infection with Australian bat lyssavirus in clinically ill mice was confirmed by FAT on fresh brain 
touch impressions, as described in Section 2.2.3 Fluorescent antibody test. The tests were 
performed and read by the candidate and results confirmed by Barry Rodwell of the Diagnostic 
Virology Laboratory of the ARI. 
7.3 Results 
7.3.1 Experiment A: Intracerebral inoculation of suckling mice 
with inocula from ABLV-negative bats  
All inoculated suckling mice survived until killed on PI-day 30 or 31 following inoculation with 
inocula prepared from the tissues of bats that had themselves survived experimental inoculation 
(Bats 8, 9, and 10, see Chapter 5) as shown in Table -1. These inocula were considered 
negative for ABLV.  
7
Table 7-1 Experiment A: Intracerebral inoculation of mice with inocula prepared from 
three clinically well, ABLV-negative bats that survived experimental inoculation 
Inoculum source 
Bat      Tissue  
No. 
inoculated   
(PI-day 3) 
No. clinically ill 
& FAT positive 
Day killed 
(PI-day) Result 
Bat 8 Brain 9 0 31 Negative 
Bat 8 Parotid SG 11 0 31 Negative 
Bat 8 
30 
 
Submandib./sublingual SG 10 0 31 Negative 
Bat 9 Brain 9 0 30 Negative 
Bat 9 Parotid SG 9 0 30 Negative 
Bat 9 
 
Submandib./sublingual SG 8 0 30 Negative 
Bat 10  Brain 9 0 30 Negative 
Bat 10 Parotid SG 10 0 30 Negative 
Bat 10 Submandib./sublingual SG 10 0 Negative 
 
As none of the inocula was positive for ABLV, none required further evaluation by footpad 
inoculation. 
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7.3.2 Experiment B: Comparison of inocula from ABLV-
positive experimentally-inoculated bats by footpad 
inoculation of weanling mice 
All clinically ill mice were confirmed ABLV-positive by FAT. ABLV was detected in mice inoculated 
with material from each of the seven clinically ill/FAT-positive bats, and was detected in at least 
four of the seven inocula from each of the three source tissues; brain, parotid salivary gland and 
submandibular/sublingual salivary glands. The numbers of ABLV-positive mice per inoculum are 
shown in Table 7-2, and corresponding TaqMan PCR values are shown in Table 7-3.  
Table 7-2 Experiment B: Footpad inoculation of mice with inocula prepared from seven 
clinically ill, ABLV-positive, experimentally infected bats 
Number of ABLV-positive mice / number inoculated, duration 287 days 
Inoculum source  
Inoculum source tissue Bat 1 Bat 2 Bat 3 Bat 4 Bat 5 Bat 6 Bat 7 
Total 
positive % positive 
Brain 3/3 3/3 2/2 3/3 3/3 3/3 2/2 19/19a 100 
Submandib./sublingual SG 1/3 2/3 1/2 0/3 2/2 3/3 0/3 9/19b 47 
Parotid SG 1/3 0/3 0/3 3/3 3/3 2/3 0/3 9/21b 43 
Values with the same superscripts are not significantly different (p< 0.05) on chi-square test. 
 
Table 7-3 Quantitative PCR (TaqMan®) values for inocula prepared from three different 
tissues from seven clinically ill, ABLV-positive, experimentally infected bats 
TaqMan CT value  
Inoculum source tissue Bat 1 Bat 2 Bat 3 Bat 4 Bat 5 Bat 6 Bat 7 
Mean CT 
Brain 16.4 15.3 15.5 15.6 15.2 15.4 15.0 15.5 
Submandib./sublingual SG 30.5 26.8 27.0 29.0 29.2 23.6 29.0 27.9 
Parotid SG 23.0 24.8 25.7 26.0 25.2 27.5 28.6 25.8 
 
The amounts of ABLV RNA detected in the TaqMan assay and the proportions of mice affected 
as shown in Table 7-2, suggest that the relative virulence of the 20% w/v inocula produced from 
these three tissues is 
brain > submandibular/sublingual salivary gland ≈ parotid salivary gland.  
However, evaluation of the duration of infection (interval from inoculation to day died or killed; that 
is the incubation and clinical period) as shown in Table 7-4 allows further discrimination. 
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Table -  Experiment B: Durations of infection in footpad inoculated mice 7 4
Tissue Bat 1 Bat 2 Bat 3 Bat 4 Bat 5 Bat 6 Bat 7 Range 
(days) 
Average 
(days) 
Standard 
deviation 
Brain 10, 17, 26 13, 14, 22 16,17 13, 14, 14 15, 20, 21 14, 17, 21 14, 16 10-26 16.5 3.7 
Submandib./sublingual SG 52 • • 14, 30 • 39 • • • • 14, 34 16, 24, 27 • • • 14-52 27.8 12 
Parotid SG 253 • • • • • • • • 25, 29, 33 40, 55, 156 67, 79 • • • • 25-253 81.8 71 
• Mouse that remained clinically well until killed at conclusion of experiment PI-day 287 
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Inocula derived from brain tissue produced clinical disease requiring euthanasia in 100% of mice 
within a relatively narrow period of 10 to 26 days (n=19).  
Inoculation with submandibular/sublingual salivary gland inocula resulted in the deaths of only 
47% of mice after a more variable period of 14 to 52 days (mean 28 days). A similar proportion of 
mice inoculated with parotid salivary gland inocula was affected (43%), however the period of 
infection was generally longer and far more variable at 25-253 days (mean 82 days). Four parotid 
inocula produced disease in mice. Mice inoculated with the parotid salivary glands of Bats 1, 5 
and 6 had long and highly variable incubation times, deaths occurring 40 to 253 days post-
inoculation including six of the seven longest incubation periods. The inoculum produced from the 
parotid salivary gland of Bat 4 produced disease comparatively quickly with low variability, 
resulting in the deaths of three mice on PI-days 25, 29, and 33. For all inocula produced from bats 
other than Bat 4, the proportion of mice affected and the duration of infection for the first and last 
mice affected followed the trend of 
 brain  ≥  submandibular/sublingual salivary gland >  parotid salivary gland 
As the virulence of the Bat 4 parotid inoculum was uncharacteristically high compared to other 
parotid inocula and the Bat 4 submandibular/sublingual inoculum, inoculation with these and three 
other inocula were repeated and mice observed for 60 or 90 days post-inoculation as indicated in 
Table 7-5 
Table 7-5 Experiment B Repeat: Footpad inoculation using five inocula 
ABLV-positive/ number inoculated, duration 60 or 90 days 
Tissue 
Bat 1 
60days 
Bat 3 
60days 
Bat 4 
90days 
Bat 7 
60days 
Submandib./sublingual SG 0/3 0/3 0/3 0/3 
not done not done  1/31 not done Parotid SG 
1 one clinically affected/FAT-positive mouse, killed 32 days post-inoculation 
 
7.3.2.1 Prevalence of anti-lyssavirus titres in inoculated mice 
All mice that survived until PI-day 287, Experiment B (n=22) or survived until PI-day 60 or PI-day 
90 following repeat inoculations, Experiment B Repeat (n=14) were negative for anti-rabies 
antibodies at a plasma dilution of 1:20 (< 0.5 IU/mL). The rabies antibody titre for each affected 
mouse from Experiment B is shown in Table 7-6. Both positive and negative anti-rabies titres 
occurred in ABLV-positive mice inoculated with material from each of the seven bats, from mice 
inoculated with each of the three tissue sources of inoculum, and from mice which died after short 
and long durations of infection. 
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 Table -  Titres of cross-reacting anti-rabies antibodies in clinically ill mice infected with ABLV by footpad inoculation 7 6
Rabies-RFFIT titre (IU/mL) 
(PI-day died) 
 
Tissue 
Bat 1 Bat 2 Bat 3 Bat 4 Bat 5 Bat 6 Bat 7 
Brain Neg., Neg., Neg. 
(10, 17, 26) 
0.8, NS , 0.6 
(13, 14, 22) 
0.1, Neg. 
(16, 17) 
0.9, 0.7, 0.5 
(13, 15, 15) 
Neg., Neg., Neg. 
(15, 20, 21) 
Neg., 0.1,  0.3 
(14, 17, 21) 
0.5, 0.3 
(14, 16) 
Submandib./sublingual SG 0.2 
(52 • •) 
0.4, 1.6 
(14, 30 •) 
Neg. 
(39 •) 
 
(• • •) 
1.2, 1.1 
(14, 34) 
7.8, Neg.,  2.2 
(16, 24, 27) 
 
(• • •) 
Parotid SG Neg. 
(253 • •) 
 
(• • •) 
 
(• • •) 
<0.1, Neg., Neg., 0.3* 
(25, 29, 33, 32*) 
0.7, 1.1, Neg. 
(40, 55, 156) 
0.5, 0.2 
(67, 79 •) 
 
(• • •) 
Neg.  no evidence of neutralizing antibodies at a dilution of 1:20 (< 0.5 IU/mL) 
NS    no sample 
•       Mouse that remained clinically well until killed at conclusion of experiment PI-day 287 with negative rabies-RIFFT titre 
*       Clinically ill mouse from Experiment B repeat 
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7.3.3 Experiment C: Intracerebral inoculation of suckling mice 
with inocula negative by footpad inoculation 
Five inocula failed to produce clinical disease following footpad inoculation of 21 day old mice and 
required more sensitive testing for ABLV. Four of the five inocula produced clinically ill/ FAT-
positive mice following intracerebral inoculation of litters of two to three day old mice. 
Table 7-7 Experiment C: Intracerebral inoculation of mice with five inocula that failed to 
produce disease in footpad-inoculated mice 
    Inoculum source 
Bat Tissue 
Number 
positive / total 
Died               
(PI-day) Result 
Bat 2 Parotid SG  6/8  11, 11, 13, 14, 19, 24 Positive 
Bat 3 Parotid SG 1/8  
Submandib./sublingual SG 
Bat 7 
Negative 
14 Positive 
Bat 4 5/10  14, 14, 18, 19, 19 Positive 
Submandib./sublingual SG  1/8  24 Positive 
Bat 7 Parotid SG 0/8  Not applicable 
 
7.3.4 Experiment D: Comparison of inocula by footpad titration 
Limitations by Animal Ethics Committees on the numbers of mice used precluded systematic 
titration of all inocula. Three inocula used in Experiment B were selected for comparison of 
peripheral virulence by footpad titration.  
♦ Bat 4 Brain, selected as it had produced disease in 3/3 inoculated mice with the shortest 
average period between inoculation and death. 
 
♦ Bat 6 submandibular/sublingual SG, selected as it was one of two 
submandibular/sublingual SG inocula that had affected 100% of inoculated mice (3/3) and 
had the shorter average period between inoculation and death. 
♦ Bat 6 Brain, selected for comparison as it was from the same bat as the selected salivary 
gland inoculum. 
All clinically ill mice were FAT-positive. The number of affected mice for each dilution and the 
calculated endpoint dilutions and titre (90 day mouse footpad 50% effective dose, MFP90ED50) are 
shown in Table 7-8 . Also shown are other indicators of virulence for these inocula such as the 
durations of infection for mice inoculated with neat inocula in Experiment B (n= 3 mice) and 
Experiment D (titration, n= 6 mice) and the neat quantitative TaqMan CT value. 
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Table 7-8 Experiment D: Footpad titration of three inocula derived from the tissues of 
flying foxes infected with Inoculum 5 
Number positive / total inoculated  
Dilution Bat 4 
Brain  
Bat 6 
Brain 
Bat 6 
Submandibular/sublingual SG 
6/6 5/6    6/6 
-1 6/6 5/6    6/6 
10-2 4/6 3/6 
10-3 2/6    2/6 
10-4 0/6    1/6 
10-5    0/6 
10-6 Not done 0/6 Not done 
   
50% endpoint dilution /0.06mL1  10− 2.5 10− 1.8 10− 2.7 
Titre MFP90ED50 /mL 10 3.7 10 3.0 10 3.9 
Neat inocula (days, n=6) 
Duration of infection            Mean 
                                            Median 
                                           (Range) 
 
17 
16 
(12 to 23) 
 
21 
21 
(15 to 26) 
 
   23 
   23.5 
(13 to 34) 
Experiment B (days, n=3) 
Duration of infection            Mean 
                                            Median 
                                           (Range) 
 
   14.3 
14 
(13 to 15) 
 
    17.3 
17 
(14-21) 
 
   22.3 
   24 
(16 to 27) 
TaqMan CT (neat inocula)  15.6 15.4    27.6 
Neat 
10
   4/6 
1/6 
0/6 
0/6 0/6 
 
1 Calculated using the Spearman-Käber formulae (Lorenz and Bogel 1973), see Section 5.4.3 
 
     Relative virulence of tissues in mice 
 252
7.3.4.1 Effect of dose on incubation period 
During the 92 days of Experiment D, fewer mice developed clinical disease when inoculated with 
higher dilutions of each inoculum. There was also a tendency for mice inoculated with lower 
dilutions to develop clinical disease and require euthanasia after shorter durations compared to 
those of mice inoculated with higher dilutions of inoculum, as shown in Table 7-9 and Figure 7-2. 
Table 7-9 Experiment D: Effect of dose on the duration between inoculation and death 
following peripheral inoculation of 21-day old mice 
Bat 4 
Brain 
Bat 6 
Brain 
Bat 6 
submandib./sublingual SG 
 
Dilution 
Died (PI-day) Mean  Died (PI-day) Mean Died (PI-day) Mean 
Neat 12, 14, 14, 18, 23, 23 17.3 15, 20, 21, 23, 26  • 21 13, 21, 22, 25, 25, 34 23.3 
10-1 18, 21, 23, 27, 34, 58 30.2 20, 22, 23, 36, 50  • 30.2 15, 20, 21, 24, 28, 30 23.0 
10-2 31, 52,  57,  64   •    • 51.0 22, 48, 37    •    •    • 35.7 28, 31, 60, 75    •   • 48.5 
10-3 22, 31    •     •     •    • 26.5 56    •     •    •    •    • 56 26, 43   •   •   •   •   • 34.5 
10-4 none n/a none n/a 56    •    •   •   •   •   • 56 
• inoculated mouse that remained clinically well until the conclusion of the experiment on PI-day 90 
 
Figure 7-2 Effect of dose on the mean interval between inoculation and death following 
peripheral inoculation of 21-day old mice  
(error bars  ± 1 standard error calculated separately for each plotted data point) 
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7.4 Discussion 
These mouse inoculations confirmed the presence of ABLV in the brains and both salivary glands 
preparations of all seven clinically affected experimentally inoculated bats, with the exception that 
ABLV was not isolated from the parotid salivary gland of Bat 7. Intracerebral inoculation of 
suckling mice detected ABLV in four of five inocula that did not produce clinical disease in any of 
three footpad-inoculated mice, consistent with intracerebral inoculation being a more sensitive 
method for the detection of ABLV. Using this more sensitive intracerebral assay, no ABLV was 
detected in the brains or salivary glands of the three inoculated bats that survived. These in vivo 
findings are entirely consistent with the clinical presentations, FAT, and immunoperoxidase 
staining results of all 10 experimental bats.  
The 3-mouse footpad assay (Experiment B) was used to crudely determine the relative virulence 
of inocula as reflected in the proportion of mice affected and rate at which they were affected. The 
low number of mice used per inoculum was a result of animal ethics considerations and obviously 
limits the capacity of the assay to accurately reflect virulence and to differentiate between inocula 
with similar virulence. Despite these limitations, the considerable variation in numbers of mice 
affected and durations of infection observed allow for some interesting conclusions.  
Comparison of the number of mice affected following footpad inoculation clearly indicated that 
inocula prepared from the brains were most virulent, affecting 100% of mice, while inocula from 
the submandibular and sublingual or parotid salivary glands affected similar proportions of only 
47% and 43% respectively. Further comparison of how quickly mice were affected, also indicated 
that brain derived inocula were most virulent, with all mice being affected within 10 to 26 days, 
whereas mice inoculation with the salivary glands were generally affected after a longer and more 
variable period of 14 to 253 days. It also shows that, when considered together, mice inoculated 
with submandibular and sublingual salivary gland inocula were affected more quickly, (average 28 
days, n=9/19, range 14 to 52 days) than mice inoculated with parotid derived inocula (average 82 
days, n=9/21, range 25 to 253 days). 
Broadly, these in vivo results are consistent with the quantitative TaqMan assay results for viral 
RNA, where lower CT values indicate greater amounts of RNA and an increase in CT value of 3 
points indicates an approximately 10 fold decrease in RNA amount. The TaqMan assays 
indicated that the brain inocula all contained very similar amounts of RNA (mean CT  = 15.5, range 
15.2 to 16.4) and substantially more than either type of salivary gland inocula (submandibular and 
sublingual mean CT  = 27.9, range 23.6 to 30.5; parotid mean CT  = 25.8, range 23.0 to 28.6). The 
substantially lower and less variable CT  values of the brain inocula were associated with high and 
less variable virulence compared to salivary gland inocula. However, among the salivary gland 
inocula, lower CT  values were not necessarily associated with higher virulence when comparing 
the two groups of salivary gland inocula, when comparing within groups of salivary gland inocula 
or when comparing the two salivary glands of individuals.  
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As a group, compared to the parotid derived inocula, submandibular and sublingual salivary 
glands had modestly higher CT  values, yet affected a slightly higher proportion of mice after 
generally shorter and less variable periods. 
Among the submandibular and sublingual inocula, that of Bat 6 had the lowest CT value (23.6) 
and highest virulence (3/3 mice), and that of Bats 1, 4 and 7 had higher CT values (30.5, 29.0 and 
29.0) and the lowest virulence (0/3 or 1/3 mice), yet that of Bat 5 with a similarly high CT value 
(29.2) managed to kill 2 of 2 mice after reasonablly short periods (14 and 34 days). Similarly the 
most virulent of the parotid salivary gland inocula (Bat 4 CT = 26.0 and Bat 5 CT = 25.2) had CT 
values that were higher than those of other less effective inocula, and parotid inocula with CT 
values as low as 23.0 and 24.8 (Bats 1 and 2) either failed to induce disease or did so after an 
exceptionally long incubation period (Bat 1, 1/3 mice, 253 days). 
While for some individual bats the salivary gland with the lower CT value had the highest virulence 
(e.g. Bats 4 and 6), in others (e.g. Bat 2) the relationship was reversed.  
Clearly the TaqMan assay can be used to identify inocula of high virulence by identifying those 
that contain high amounts of ABLV RNA (CT < 16.5). However, there was a very poor association 
between the CT value and virulence among salivary gland inocula with CT values of 23 to 31. In 
part this may be due the limited scope of the 3-mouse footpad assay to accurately reflect 
virulence, and it is also presumed to reflect the indirect relationship between the quantity of RNA 
and the quantity and characteristics of viable ABLV. 
Experiment B and Experiment B Repeat also gave the opportunity to re-examine the prevalence 
and titres of lyssavirus antibodies in plasma with the AAHL rabies-RFFIT. That none of 36 mice 
that remained clinically well until the conclusion the experiments had detectable cross-reacting 
antibodies is consistent with Experiment 2 of Chapter 5 and the results of the bat inoculation 
study. In Experiment 2, only one of 13 survivor mouse sera was positive, and in the bat study two 
of three survivor bats had no clear evidence of seroconversion. Apparently survival in mice is 
usually not the consequence of an adequate humoral response, or at least not of one of sufficient 
strength or duration to be detected in the rabies-RFFIT 60 to 287 post-inoculation. It suggests that 
either these mice were not infected by the inoculum, or some other mechanism enabled the mice 
to remain well. Serial serological tests, preferably using an appropriate ABLV-variant RFFIT would 
more clearly demonstrate the absence of a humoral response in survivors.  
Among clinically affected mice there was no apparent correlation between the presence, absence, 
or titre of anti-rabies antibodies and either the inoculum source bat or source tissue or duration of 
infection. The slight trend in Experiment 2 towards affected mice that did seroconvert having 
higher titres after longer incubation periods was not observed here and is probably coincidental.  
To further investigate the results of the 3-mouse footpad assay, in particular to evaluate more 
precisely the relative virulence of inocula prepared from the brains of Bats 4 and 6 and the 
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submandibular and sublingual salivary glands of Bat 6, a 90 day mouse footpad titration assay 
was used (Experiment D) to calculate the clinical titre (MFP90ED50). As shown in Table 7-8, while 
CT  values of brain inocula from Bats 4 and 6 are very similar (CT  = 15.6 and 15.4 respectively) 
the relative virulence indicated by the number of mice affected and duration of infection in the 3-
mouse assay and in the 6 mice inoculated with the neat inoculum as part of the titration, together 
with the calculated MFP90ED50 , indicate that the inoculum of Bat 4 brain was moderately more 
virulent than that of Bat 6 brain (MFP90ED50 /mL = 103.7 and 103.0 respectively). In comparison the 
CT  value of the Bat 6 salivary inoculum (CT  = 27.6) was up to 12 points lower than that of either 
brain sample indicating there was ~104 times less RNA in the sample, yet the 3-mouse and 6-
mouse virulence assays suggested it had similar virulence to the brain inocula and the more 
precise clinical titre indicated it had a similar or higher virulence (MFP90ED50 /mL = 103.9 ).  
Clearly this submandibular and sublingual gland-derived inoculum had a much higher virulence 
than suggested by the relative amount of viral RNA in the gland inoculum compared to that in 
brain inocula. The same was true for Inoculum 5 prepared from the salivary glands of ABLV-51 
and used to inoculate the flying foxes (see Chapter 5, CT value 18.6, MFP90ED50 /mL =106.0 ). 
Immunoperoxidase staining had also indicated that the source salivary glands had contained 
noticeably less visible viral antigen than the brains. It appears that the virulence : viral RNA and 
virulence : viral antigen ratios for inocula derived from the submandibular and sublingual salivary 
glands can be very high compared to those of the brain.  
Why this should be the case remains unclear. It may be the result of the presence or absence of 
some ‘contaminating’ factor from the source tissue affecting either the viability of ABLV in the 
tissues prior to or after preparation of the inoculum, or assisting in the establishment of infection 
once inoculated. It may be due to differences in the replication strategy in the salivary gland 
resulting in a higher proportion of replicated RNA and viral proteins being incorporated into viable 
and virulent virus particles rather than accumulating in non-viable but detectable forms. Or it may 
be due to some as yet uncharacterized specific and functional difference in the actual virus 
particles themselves when formed or accumulated in salivary glands. For example there may be 
subtle differences in the lipoprotein component of the virus capsule that is derived from the host 
cell in the salivary gland cell that confers greater viability or virulence, such as the capacity to 
support more or less glycoproteins. It may also be due to differences in the pressures for clonal 
selection of the virus population within the salivary gland resulting in the salivary gland ABLV 
population containing quasi-species with higher virulence characteristics. Unfortunately, further 
investigation of this apparent paradox was beyond the scope of this project.  
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As the relationship between the CT value and virulence of inocula prepared from brains and 
salivary glands appear to differ, it is proposed that different TaqMan CT criteria be used to select 
inocula derived from each tissue source.  
In order to select inocula likely to have a MFP90ED50 /mL ≥ 103.0, priority should be given to 
brain inocula with a CT value ≤ 16, and  ♦ 
♦ salivary gland inocula with a CT value ≤ 24.  
Had such a combination of thresholds been used on the candidate inocula prepared in Chapters 5 
and 7, it would have led to selection of 12 of the 45 candidates for further characterization, and 
substantially reduced the amount/number of mice and other resources required. It should be 
noted that, while all inocula with high virulence would have been selected (notably Inoculum 5, 
brain inocula of Bats 1 to 7, and Bat 6 submandibular/sublingual gland inoculum), and all the 
inocula that would have been excluded had low virulence, not all the inocula that would have been 
selected had high virulence. In vivo characterization of TaqMan-selected candidates is still 
required to establish which of the selected inocula have high or the highest virulence when 
inoculated peripherally. 
The footpad titration assay also offered the opportunity to observe the effect of dose on incubation 
period. As seen in the titration of Inoculum 5, higher dilutions were generally associated with 
either longer incubations times and/or fewer mice being affected. This was particularly true where 
data for three or more affected mice were available (dilutions Neat, 10 –1, and 10-2). At higher 
dilutions a few mice died after relatively short periods. Had the experiment run longer than 90 
days and data from mice that may have gone on to become ill after longer periods been included, 
continuation of the linear effect of dose on average incubation period at higher dilutions may have 
been apparent. In general it suggests that hosts dying of ABLV after very long incubation periods, 
such as in the second human patient who died 27 months after her only reported exposure to a 
bat (Hanna et al. 2000), had been infected with very low doses of virus.  
It is of particular interest that two footpad-inoculated mice became sick after very long incubation 
periods and were killed 156 and 253 days post-inoculation. The mouse that was killed after 253 
days was the only mouse in that cage to become ill, precluding the possibility that the long 
incubation period was the result of re-exposure to an affected cage mate. The data from these 
mice suggests a model of long-incubation ABLV could be developed. Together with the 
apparently long incubation period of the second human patient, they indicate it is possible that low 
dose long-incubation infections with ABLV may play a significant role in the maintenance of ABLV 
in populations.  
It should be noted that, while ABLV can be readily transmitted via salivary gland-derived inocula, 
and such inocula may have relatively high virulence : viral RNA and virulence : viral antigen ratios, 
this does not of itself indicate any special role of the submandibular and/or sublingual salivary 
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glands in natural transmission. Immunoperoxidase staining of the salivary glands detected ABLV 
in two sites; submandibular salivary gland epithelial cells and the ganglia and nerve fibres of the 
associated parasympathetic innervation of all three salivary glands. It is unclear what the 
characteristics and relationships of virus present in these two sites are. It is unclear to what extent 
virus from either or both locations may contribute to virus excretion in saliva and the role either or 
both may play in transmission. It is unclear what effect the method of extraction of virus from the 
salivary glands into the inoculum (post-mortem freezing of glands, defrosting, maceration and 
clarification in media) has on the quantities of virus from each site in the inocula. It is possible that 
the high virulence of salivary gland inocula is simply a useful artefact of inoculum preparation and 
that it is no more an indicator of a role in transmission than the ability to infect others with brain 
derived inocula indicates ABLV is transmitted via brain tissue. This does not; however detract 
from the usefulness of using high virulence inocula prepared from the salivary glands in 
experimental studies.  
It is reasonable to assume ABLV is transmitted via saliva contamination of bites and scratches, 
based on the histories of bat bites in the two human cases and the data available for rabies 
viruses. However, confirmation that this is the only or most important method of transmission 
responsible for the maintenance of ABLV in bat populations will require studies on the infectivity of 
saliva, urine, and other potential modes of transmission and controlled transmission studies 
between individuals. Given the possible role of low dose, long incubation infections in the 
population, recognition of important but subtle modes of transmission may be difficult. 
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7.5 Conclusions 
Confirmation by virus isolation of the presence or absence of ABLV in 10 
experimentally inoculated flying foxes 
♦ Infection with ABLV in seven experimentally infected, clinically ill flying foxes was confirmed 
by virus isolation in mice. 
♦ ABLV was not isolated from the brains or salivary glands of three experimentally inoculated 
flying foxes that remained clinically well until the end of the experiment on PI-day 80 or 82. 
♦ Intracerebral inoculation of suckling mice is a more sensitive method of virus isolation of wild-
type ABLV than the 3 mouse footpad assay.  
♦ There is some evidence that intracerebral inoculation of suckling mice is a more sensitive 
method of virus isolation of wild type ABLV than in vitro isolation in neuroblastoma cells. 
Comparison of virulence of inocula prepared from the brain, parotid, or combined 
submandibular and sublingual salivary glands 
♦ The 3-mouse footpad assay appears to be a reasonable method of assessing peripheral 
virulence using minimal numbers of animals and other resources. 
♦ In the 3-mouse footpad assay, both the number of mice affected and the speed in which they 
are affected reflect the virulence of the inocula.  
♦ Evaluation of the number and speed at which mice were affected indicates that the relative 
virulence of inocula prepared from the brain and salivary glands are as follows. 
Brain  ≥  submandibular/sublingual salivary gland  >  parotid salivary gland 
There is a more or less linear relationship between dose and incubation period in footpad-
inoculated mice, with lower doses associated with longer incubation periods. 
♦ 
♦ 
Relationship of the relative amount of viral RNA detected by quantitative PCR 
(TaqMan®) assay, to the virulence of inocula in mice, and the potential for use of 
quantitative PCR in the selection of inocula 
♦ Using tissues that had been collected and stored in near optimal and very similar conditions, 
inocula prepared from the brains of seven ABL-positive bats contained substantially more 
viral RNA (102 to 105 times) than the salivary glands of the corresponding individual. 
Despite inocula prepared from the submandibular and sublingual salivary glands containing 
substantially less viral RNA, they may be highly virulent in mice, and more virulent that inocula 
prepared from the corresponding brain. 
♦ The TaqMan quantitative PCR assay can be used to select inocula that are more likely to be 
highly virulent using different selection criteria for inocula prepared from different sources.  
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♦  Proposed selection criteria are: 
Brain derived inocula TaqMan CT ≤ 16 
Submandibular and sublingual salivary gland inocula TaqMan CT ≤ 24 
♦ Not all inocula selected using these criteria will be highly virulent and virulence should be 
evaluated in appropriate in vivo models. 
Other conclusions 
♦ Despite salivary glands containing much less visible viral antigen by immunoperoxidase 
staining, inocula prepared from these glands, in particular inocula prepared from the 
submandibular and sublingual salivary glands may be highly virulent in mice. 
♦ The anti-lyssavirus titre, as detected in the CVS-RFFIT, is of no predictive value in the 
assessment of potentially exposed individuals, with both positive and negative titres being 
detected in both clinically ill and clinically well exposed mice and bats. 
♦ There is no apparent relationship between the incubation period and the presence, or 
absence, or titre of antibodies detected in the CVS-RFFIT.  
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8 Vaccination of Black and Grey-headed flying 
foxes with Nobivac rabies vaccine 
Aims 
1. To demonstrate that flying foxes vaccinated with commercial rabies vaccines would 
seroconvert and develop titres against rabies virus. 
2. To demonstrate that rabies-vaccinated flying foxes developed cross-neutralising  titres 
against ABLV. 
3. To co-vaccinate flying foxes with a marker protein that would induce seroconversion that 
could be used to differentiate rabies-vaccinated flying foxes from unvaccinated flying foxes 
with naturally acquired ABLV-antibodies. 
4. To develop an enzyme linked immunoabsorbant assay to detect seroconversion to the marker 
protein.  
8.1 Introduction 
Human exposure to ABLV has occurred through contact with unwell wild bats (see Chapter 2), an 
orphan in temporary care (ABLV-32), and a long term resident of a wildlife park (ABLV-73). To 
date management of the risk of ABLV from bats has relied on pre- and post-exposure vaccination 
of potentially exposed humans and increasing public awareness of the need to avoid contact with 
bats. The high incidence of urban rabies in humans in developing countries, and the very low but 
persistent incidence of sylvatic rabies in developed countries such as the USA, demonstrate the 
limitations of this approach. Vaccination and animal control programs in the United Kingdom, 
Europe and USA have, by reducing the susceptibility and prevalence of rabies in dogs and foxes 
further reduced the incidence of rabies in humans. Unfortunately neither control nor vaccination of 
the general bat population is feasible and no mode of vaccine delivery to wild bats is available. 
This is not the case for captive bats.  
Effective vaccination of captive bats, particularly those in medium term or permanent captivity 
would have two benefits. It would prevent the development of clinical ABLV in captive bats, such 
as ABLV-32 and ABLV-73, and so prevent potential human exposure to ABLV from such cases. It 
would also allow the bat’s welfare to be considered in the event of a person being bitten or 
scratched by a vaccinated captive bat. Current Queensland Health Department policies require 
any captive bat that bites or scratches a person be killed and submitted for ABLV testing. As a 
result, at least eight clinically well, ABLV-negative, captive flying foxes have been killed following 
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reports of them having bitten or scratched humans, causing considerable distress to the staff and 
keepers (data not shown). Other potential exposures have gone unreported. At some facilities 
entire colonies of healthy bats were killed as a result of concerns about potential exposure of staff 
or the public to ABLV. Effective vaccination of captive flying foxes would allow bites or scratches 
from captive bats to be considered not to be potential exposures to ABLV and not requiring 
surrender of the bat. Staff and the public could again enjoy ‘safe’ contact with captive bats. 
Vaccination trials at CDC demonstrated cross-protection against ABLV in mice challenged after 
vaccination with commercial rabies vaccine (Hooper et al. 1997b). It seemed highly likely that 
commercial rabies vaccines could provide similar protection to vaccinated bats. A further 
consideration was that vaccinated bat plasma be distinguishable from unvaccinated bat plasma 
as the prevalence of naturally occurring lyssavirus antibodies was being studied and had 
implications for current and ongoing research into the prevalence and distribution of ABLV in 
Australia. This study evaluated the serological responses of Black and Grey-headed flying foxes 
to the commercial animal rabies vaccine available in Australia (Nobivac) and the effectiveness of 
a serological marker (keyhole limpet hemocyanin) in distinguishing vaccinated from unvaccinated 
bats. 
8.2 Materials and Methods 
8.2.1 Permits  
Australian Quarantine Inspection Service (AQIS) 
♦ Approval for in vivo use of Restricted Imported Biological Material (Nobivac inactivated rabies 
vaccine) in Non-laboratory Animals Permit # 00/066 
♦ Quarantine approved premises Q1056, Bat Holding Facility at the University of Queensland 
Farm, Pinjarra Hills. 
Queensland National Parks and Wildlife service 
♦ Scientific purposes permit number W4/002537/00/SAA 
Animal Ethics Committees 
♦ University of Queensland – approval number VP/232/00/PHD 
♦ Animal Research Institute – approval number ARI/030/2000-1 
Chapter 8 
 263
8.2.2 Flying foxes 
Thirteen (13) Black flying foxes (Pteropus alecto) and 24 Grey-headed flying foxes (Pteropus 
poliocephalus) were caught from the Indooroopilly Island colony, Brisbane and transferred to the 
University of Queensland bat facility at Pinjarra Hills, where they were held as a single colony for 
the trial (see Figure 8-1). Bats were held for observation within the facility for 52 to 60 days prior 
to vaccination on PV-day 0 (31 July 2000). 
8.2.3 Microchips 
8.2.4 
8.2.5 
Bats were individually identified on the day of capture with LIFECHIPTM NDL assembly or 
TROVAN Passive Transponder microchips, implanted subcutaneously between the scapulae, at 
the base of the neck. The identifying microchip number was read using a Pocket•Reader EXTM 
(Destron Fearing Corporation). The microchip number for each bat is listed in Appendix 11. 
Rabies vaccine 
The Nobivac Rabies inactivated rabies vaccin (sic) Lot 79050B (Intervet, Boxmeer, Holland) 
contains a beta-propriolactone inactivated culture of Pasteur RIVM strain rabies virus, grown on 
the BHK-21 clone cell line, in an aqueous aluminium phosphate suspension. The vaccine is 
widely used in rabies-endemic countries for vaccination of dogs, cats and other domestic animals. 
Its use in Australia is restricted to pre-export vaccination of domestic animals. The vaccine was 
purchased as individual (1 mL) doses per vial. 
Keyhole Limpet Hemocyanin (KLH) 
Keyhole limpet hemocyanin (Sigma, Saint Louis, Missouri USA) is a highly immunogenic protein 
prepared from the hemolymph of the mollusc Metathura crenulata (“keyhole limpets”). Two mL of 
deionised water (dH2O) was added to each 20 mg vial to prepare a stock solution of 10 mg/mL. 
8.2.6 Alhydrogel 
Alhydrogel (Superfos a/s, Vedbaek, Denmark) is a stable gel containing 6 mg/mL of aluminium 
hydroxide with a pH of the order of 6 to 6.5. It is a well-established adjuvant used for vaccine 
production. The alhydrogel used in this study was kindly provided by Ian Wilkie (The University of 
Queensland). 
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Figure 8-1 Flying foxes within the bat holding facility  
Black and Grey-headed flying foxes held as a single mixed colony. Each afternoon fresh fruit 
and water were provided in multiple buckets throughout the cage to reduce the likelihood that 
dominant or territorial individuals would prevent others from feeding. Hessian bags were hung to 
provide soft, mobile landing points. Natural tree-limb ‘perches’ were installed to provide 
alternate ‘footing’ to the cage wire. This was almost universally ignored, bats preferring to hang 
from the highest possible (wire) position.  
 
Chapter 8 
 265
8.2.7 Experimental design 
This project was done in two phases. 
 
♦ Phase 1  
Thirty-six bats were allocated in a random block design into one of four treatment groups 
balanced as far as possible for sex and age (see Table A11-1 in Appendix 11). Bat species 
were allocated to groups as indicated in Table 8-1. Each bat was vaccinated with one of two 
rabies vaccine protocols and one of four KLH ± Alhydrogel protocols as described below. One 
control bat was vaccinated with KLH + Alhydrogel only (no Nobivac). 
 
♦ Phase 2 
Because the response to KLH during Phase 1 was inadequate, all bats received a higher 
dose KLH + Alhydrogel booster on PV-day 85.  
 
An overview of the experimental design is illustrated in Figure 8-2. 
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 Figure 8-2 Experimental design for the vaccination of Black and Grey-headed flying foxes with Nobivac rabies vaccine and KLH  
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8.2.8 
1. 
Rabies vaccination 
Thirty-six of the 37 flying foxes were vaccinated intramuscularly in the right pectoral muscle with 
Nobivac Rabies inactivated rabies vaccine either; 
♦ on PV-day 0 only (n=18, Groups 1 and 2) or 
♦ on PV-day 0 and a booster on PV-day 28 (n=18, Groups 3 and 4). 
One control bat was not vaccinated with rabies vaccine. 
The rabies vaccine was administered either mixed with KLH or given separately as described 
below. 
8.2.9 KLH ± Alhydrogel vaccination 
8.2.9.1 Phase 1: Rabies and KLH 
During Phase 1, four protocols for KLH vaccination, using a dose of 100 µg, were used (see Table 
8-1 and previous overview of experimental design in Figure 8-2). 
KLH in Nobivac – PV-day 0 only (n = 6, Group 1)  100 µg KLH in 0.1 mL dH20 added to the 
vial of Nobivac, administered together as a single intramuscular injection 
2. KLH + Alhydrogel – PV-day 0 only (n = 13, Group 2 and control bat)  
100 µg KLH in 0.1 mL dH20 combined with 0.1 mL Alhydrogel, total 0.2 mL vaccine 
administered as a single intramuscular injection to the left pectoral muscle. Nobivac rabies 
vaccine administered separately into the right pectoral muscle of 12 bats (Group 2). 
3. KLH in Nobivac – PV-day 0 + booster PV-day 28 (n = 6, Group 3)  
4. KLH + Alhydrogel – PV-day 0 + booster PV-day 28 (n = 12, Group 4)  
Table 8-1 Phase 1 Experimental design: Nobivac rabies vaccine and KLH ± Alhydrogel 
                 PV-day 0 to PV-day 85 (n=37) 
KLH in Nobivac Nobivac and KLH + Alhydrogel 
KLH + Alhydrogel only  
(no Nobivac) 
 
 
Bat species Day 0  
only 
Day 0 + 28 Day 0 
only 
Day 0 + 28     Day 0  
     only 
Black flying fox 
 
   Nil Nil 6 6     1 (control) 
Grey-headed flying fox   6 6 6 6       Nil 
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8.2.9.2 
8.2.10 
Figure 8-3
Phase 2: High-dose KLH with Alhydrogel  
On PV-day 85 all bats (n = 37) received 1 mg KLH in 0.1 mL dH20 combined with 0.2 mL 
Alhydrogel, total 0.3 mL vaccine administered intramuscularly i.e. a 10 fold increase in antigen 
and double the adjuvant compared to the Phase 1 KLH protocols. No additional rabies vaccine 
was administered. 
Sample collection 
Bats were captured for blood collection on PV-days 0, 7, 14, 21, 28, 42, 56, 85, 99, 127 and either 
PV-day 171 or 172. Bats within the enclosure were captured by Craig Smith, wrapped in a towel 
and held hands-free on the ‘bat-board’ (flat wooden board, ~34 x 17 cm with thick flexible rubber 
puncture-proof flap that could be secured over the bat on both sides of board, see Figure 8-3, 
developed by Hume Field, ARI). They were positioned so that their hind limbs were free, with the 
body, wings, and head secured, allowing ‘hands free’ access to the hind limbs while preventing 
injury to the bat or candidate. Blood (1 to 2.5 mL/ adult, up to 0.5 mL/ pup (baby flying fox)) was 
collected from the uropatagial vein into heparinised syringes, centrifuged at ~800 G for 10 
minutes, and the plasma removed and aliquoted.  
 
Figure 8-3 Restraint of conscious bat with ‘bat-board’ for venipuncture 
A Bat caught using protective gloves and clothing and restrained so as to control the 
head, both wings, and both hind feet. 
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Figure 8-3B Bat wrapped snugly in a small towel, with the hind feet protruding, being placed in dorsal 
recumbency on the ‘bat board’. The rubber cover of the ‘bat board’ (black, at right) was then secured over 
the bat and towel. Without use of the bat board the bat would rapidly escape the towel. 
 
Figure 8-3
Figure 8-3
C (left) Bat secured within the ‘bat board’, hind limbs protruding. 
D (right) Venipuncture of the uropatagial vein. 
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8.2.11 Lyssavirus serology 
Rabies serology 
Plasma stored at 4 °C was submitted to the AAHL for detection of rabies virus titres in the  
modified rabies (CVS)-RFFITAAHL (see Appendix 2).  
To determine the variability of individual test results, 82 sera with titres in the range of 0.3 to 31.5 
IU/mL were submitted and tested on two occasions and the variance between the paired results 
calculated by Tony Swain (ARI) using GenStat (GenStat 2000). Values were log transformed prior 
to calculating the variance in order to be consistent with the statistical analysis of the study data.  
The back-transformed standard deviation of an individual rabies-RFFIT result was 0.19 IU/mL. 
ABLV serology 
Twenty-two plasma samples with low (0.2 to 0.7 IU/mL, n=7), moderate (2 to 5 IU/mL, n=8) or 
high (> 5 IU/mL, n=7) CVS-rabies-RFFITAAHL titres, were stored at –20°C and later submitted to 
the Rabies Laboratory, CDC Atlanta, Georgia, USA for CVS-rabies-RFFITCDC and pt-ABLV-
RFFITCDC (see Appendix 2 for test details). 
8.2.12 KLH Serology 
Plasma was stored at –20 °C prior to use in the KLH ELISA. 
Seroconversion to KLH was detected using an indirect enzyme linked immunoabsorbant assay 
(ELISA) developed under the direction of John Molloy (ARI). Nunc 96-well microtitre plates (Nunc 
Maxisorb, Nunc Roskilde, Denmark) were coated with 100 µl/well of KLH antigen (Sigma, Saint 
Louis, Missouri USA) diluted 1/2,500 in carbonate buffer pH=9.6 at 4 °C overnight. All subsequent 
incubations were at room temperature. Excess antigen was discarded and the plate blocked with 
200 µl/well of 2% casein in carbonate buffer pH = 9.6 for a minimum of 1 hour. After a brief rinse 
(3 × 200 µl/well) with phosphate buffered saline containing 0.1% Tween 20 (PBST20), plates 
where incubated with 100µl/well of plasma diluted 1/200 in PBST20 containing 2% skim milk 
powder for 30 minutes with continuous gentle shaking. Plates were washed with PBST20 (3 × 
rinse, 1×5-min soak with shaking, 3 × rinse) then incubated with 100 µl/well of peroxidase-
conjugated recombinant Protein G (Zymed, San Francisco, California USA) diluted 1/ 500,000 in 
PBST20 containing 2% skim milk powder for 30 minutes with continuous gentle shaking. After 
washing, 100 µl of TMB peroxidase substrate (KPL, Gaithersburg, Maryland USA) was added to 
each well and the plates incubated for 8 minutes, at which point the absorbance of the positive 
control standard wells approximated an optical density of ≥1. The reaction was stopped by the 
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addition of 50 µl of 2M phosphoric acid and the absorbance read at 450 nm. Positive and negative 
control plasma and blanks (nil plasma) were included on each test plate and all samples were 
tested in duplicate/plate. The percent absorbance (PA) for test samples was calculated relative to 
the positive control standard plasma where: 
        Test PA  =  mean test absorbance – mean blank absorbance         x 100 
                           mean positive control absorbance – mean blank absorbance 
8.2.12.1 Variability of the KLH-ELISA 
Sixteen plasma samples with low (PA <20 n=4), intermediate (20 < PA >60, n=8) or high  
(PA >80, n=4) KLH-titres were tested on four separate occasions. The variability of each result 
was determined as the sum of the estimated between-plate and within-plate components of 
variance. The components were estimated by analysis of variance using a residual maximal 
likelihood model with GenStat 2000.  
The standard deviation of an individual test result was: 
♦ Low titre (PA < 20) standard deviation = 1.6 
♦ Intermediate titre (PA= 20 to 60) standard deviation = 4.3 
♦ High titre (PA > 80) standard deviation = 4.8 
8.2.12.2 KLH-ELISA positive / negative result threshold 
To determine the positive/negative result threshold for KLH titres in the ELISA, 200 sera from wild, 
presumed unvaccinated and KLH-negative, Black and Grey-headed flying foxes were tested. 
They included pre-vaccination sera (PV-day 0) from the bats used in this vaccination experiment 
(n=37) and 163 other stored (-20°C) wild-caught bat sera collected in Southeast Queensland by 
Hume Field (ARI) and Craig Smith (ARI) for other serological studies, see Table 8-2. 
Table 8-2 Wild-caught unvaccinated-bat sera used to determine the positive/negative 
result threshold for KLH-ELISA titres 
Source of Sera Grey-headed flying foxes Black flying foxes 
Expt. bats PV-day 0   24  13 
Other bats (stored sera)   76   87 
               Total     100 100 
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8.2.13 Statistical analysis 
The statistical package GenStat 2000 was used for all analyses under the direction of Tony Swain 
(ARI). 
Response to rabies (Nobivac) and KLH vaccination 
The effects of vaccination method (KLH in Nobivac versus Nobivac and KLH + Alhydrogel), 
booster vaccination on PV-day 28, age (juvenile versus adult) and their interactions on the rabies-
RFFIT or KLH-ELISA titres at each sample day were tested by analysis of variance using a 
general linear model. Species differences (within the KLH + Alhydrogel, adult bat category), the 
interaction with booster vaccination and the main effect of sex (female versus male), were also 
included in the model.  
Values for rabies-RFFIT titres were log transformed prior to analysis after examination of the 
residuals from analysis of the original test values showed increasing variation with increasing 
means.  
Values for KLH titres were analysed untransformed. 
Estimated duration of positive KLH titres 
The length of time that KLH-titres in individual flying foxes could be expected to remain positive 
(KLH ELISA titre >20 PA) following either Phase 1 vaccinations alone or following the subsequent 
PV-day 85 high-dose KLH + Alhydrogel booster was estimated by Tony Swain (ARI) by 
mathematical extrapolation (Tukey 1977) from the known titres using GenStat 2000. 
The duration of positive titres following Phase 1 vaccination alone was estimated by fitting an 
exponential regression line to the declining titres from PV-days 21, 28, 42, 56 and 85 for bats in 
Groups 1 and 3, which had received a single primary vaccination, and by linear extrapolation of 
the declining titres following the PV-day 28 booster (titres from PV-days 42, 56, and 85) for 
Groups 2 and 4. These calculations estimated how long titres could have been expected to have 
remained positive had the Phase 2 high dose KLH + Alhydrogel booster not been given on PV-
day 85. 
The estimated duration of positive titres following the high-dose KLH + Alhydrogel booster on PV-
day 85 was estimated by linear extrapolation of titres from PV-days 99, 127 and 171. 
Chapter 8 
 273
8.3 Results 
All bats responded to the Nobivac rabies vaccine and the KLH immunogen, however the extent 
and duration of seroconversion varied between individuals and with the vaccination protocol. 
8.3.1 Response to vaccination with Nobivac  
Details of each bat (microchip number, species, sex, age, capture weight, treatment group, n=37) 
and the rabies-RFFIT titres are shown in Appendix 11. Plots of the individual responses within 
each group are also shown in Appendix 11. 
8.3.1.1 Nobivac response: Crude summary 
The mean responses of treatment groups 1, 2, 3 and 4, for each species are summarized in 
Figure 8-4 and Figure 8-5. There were no treatment differences between Groups 1 and 3 (KLH in 
Nobivac) or Groups 2 and 4 (Nobivac and KLH + Alhydrogel) until PV-day 28, at which time 
Groups 3 and 4 received their respective booster vaccinations, so data for these pairs of groups 
have been combined for PV-days 0 to 28. 
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Figure 8-4 Mean response to Nobivac vaccination in Grey-headed flying foxes 
(vertical bars ± 1 standard error of mean calculated separately for each plotted data point)  
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Figure 8-5 Mean response to Nobivac vaccination in Black flying foxes  
(vertical bars ± 1 standard error of mean calculated separately for each plotted data point) 
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8.3.1.2 Nobivac response: Analysis of variance 
Analysis of variance indicated that five factors; age, sex, species, booster vaccination, and 
method had statistically significant effects on rabies-RFFIT titres (conditional probability < 0.05). 
♦ Age: Juveniles > Adults 
Titres were higher in juveniles compared to adult flying foxes on PV-days 14, 21 and 171. 
♦ Sex: Females > Males 
Titres were higher in females compared to male flying foxes on PV-days 14, 85 and 171 
♦ Species: Blacks > Grey-headed flying foxes 
Species comparisons could only be made among adult flying foxes vaccinated with Nobivac 
and KLH + Alhydrogel, as no juvenile Blacks or Blacks vaccinated with KLH in Nobivac were 
included in the study. Within this class, titres were higher in Black flying foxes compared to 
Grey-headed flying foxes on PV-days 14 and 85. 
♦ Booster on PV-day 28 > No booster 
Booster vaccination produced higher rabies titres on PV-days 42 and 56 only. 
♦ Method: Nobivac and KLH + Alhydrogel > KLH in Nobivac 
Concurrent vaccination with KLH + Alhydrogel as a separate injection produced a higher 
rabies-RFFIT titre on PV-days 7 and 42 compared with vaccination with KLH in Nobivac. 
 
Estimated mean titres for statistically significant factors (conditional probability < 0.5), adjusted 
with respect to other factors, are shown in Table 8-3. 
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Table 8-3 Nobivac response: significant factors 
Back-transformed1 fitted mean rabies-RFFITAAHL titres (IU/mL) for statistically significant factors as predicted by the regression model  
(conditional probability < 0.5) 
 
Significant factors PV-day 7 PV-day 14 PV-day 21 PV-day 42 PV-day 56 PV-day 85 PV-day 171 
Age  Adult ---   0.8** 1.8 --- --- --- 1.3 
Juvenile ---   3.0** 6.5 --- --- --- 2.9 
Sex Male ---   0.6** --- --- --- 1.1 1.4 
Female ---   1.7** --- --- --- 1.8 1.8 
Species2 Grey-headed --- 0.5 --- --- ---   0.7** --- 
Black --- 1.4 --- --- ---   3.6** --- 
Booster None n/a n/a n/a   1.2** 1.3 --- --- 
PV-day 28 n/a n/a n/a 11.2** 4.7 --- ---
Method KLH in Nobivac 0.2 --- --- 1.5 --- --- ---
KLH + Alhydrogel 0.4 --- --- 3.6 --- --- ---
  
  
  
  
  
          
        
         
 
 1    anti-log 10
2   species comparisons only available among adult bats vaccinated with Nobivac and KLH + Alhydrogel (Groups 2 and 4) 
--- not statistically significant 
n/a not applicable as booster factor not applied until PV-day 28 
** conditional probability < 0.01 
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In general, the interactions between these factors were not statistically significant (p > 0.5). 
However on PV-days 56, 85 and 171 there was a significant interaction between vaccination 
method and age, with the response associated with the two methods (KLH in Nobivac compared 
with Nobivac and KLH + Alhydrogel) being dependant on age. In juveniles the response was 
statistically higher using the KLH in Nobivac method and the response in adults was statistically 
higher using the Nobivac and KLH + Alhydrogel method (see Table 8-4).  
Table 8-4 Nobivac response: significant interactions 
Back-transformed1 fitted mean rabies-RFFIT titres (IU/mL) for statistically significant interactions 
of factors as predicted by the regression model (conditional probability  < 0.5) 
PV-day Method Juvenile Adult 
56 KLH in Nobivac 9.4 0.6 
 Nobivac and KLH + Alhydrogel 3.6 2.4 
85 KLH in Nobivac 4.9 0.8 
 Nobivac and KLH + Alhydrogel 1.6 1.4 
171 KLH in Nobivac 4.6 0.9 
 Nobivac and KLH + Alhydrogel 2.0 1.8 
 
             1  anti-log 10 
 
8.3.1.3 Comparison of titres against rabies and ABLV in rabies vaccinated bats 
There was a good correlation between the CVS-RFFIT results for the same sera when done at 
AAHL and CDC, Atlanta.  
There was good evidence for cross-reactive neutralisation of ABL in the pt-ABL-RFFITCDC. In fact, 
for all sera with moderate (> 2 to < 5 IU/mL) or high (> 5 IU/mL) CVS-RFFIT titres, the 50% 
endpoint dilution against pt-ABLCDC was higher than that for CVS-11CDC rabies virus. However, 
this may simply reflect poorer cell-adaptation and growth characteristics of the pt-ABL strain used. 
In the absence of a pt-ABL plasma standard, and without the results being expressed relative to 
the 50% endpoint dilution of the rabies 2 IU/mL standard (control) plasma (results not provided by 
CDC), it is difficult to assess the relative neutralising cross reactivity neutralization of this rabies–
vaccinated plasma against pt-ABL. The CVS-RFFIT results from both AAHL and CDC, Atlanta, as 
well as the pt-ABL-RFFIT results from CDC are shown in Table 8-5.  
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Table 8-5 Comparison of titres against rabies and ABLV in response to Nobivac 
Bat No. PV-Day Species. Sex. Age Booster PI-day 28 
 CVS rabies 
RFFITAAHL  
(IU/mL) 
CVS rabies 
RFFITCDC   
(titre) 
pt-ABLV 
RFFITCDC 
(titre) 
CIB.D56 Black.Male.Adult No 0.2 7 NR 
CIB.D85 Black.Male.Adult No 0.5 11 
0.5 
Yes 
NR 
361.D85 Grey.Male.Juvenile No 11 <11 
A24.D85 Grey.Female.Adult Yes 0.5 9 NR 
11A.D85 Grey.Female.Adult No 0.6 11 <11 
51D.D85 Grey.Female.Adult Yes 0.6 9 <11 
E64.D85 Grey.Female.Adult Yes 
Lo
w
 A
A
H
L 
tit
re
 
 (<
1 
IU
/m
L)
  
0.7 9 NR 
256.D85 Grey.Male.Adult No 2.5 25 NR 
E64.D56 Grey.Female.Adult Yes 2.8 13 NR 
565.D85 Black.Female.Adult Yes 2.9 56 280 
10B.D85 Black.Male.Adult  Yes 2.9 16 NR 
F43.D56 Black.Male.Adult 3.0 42 NR 
B32.D85 Black.Male.Adult No 3.1 33 NR 
84D.D85 Grey.Female.Adult No 3.1 60 224 
179.D85 Grey.Female.Juvenile No 
M
od
er
at
e 
A
A
H
L 
tit
re
  
(>
2.
0 
to
 <
5 
IU
/m
L)
 
3.1 70 353 
E4B.D56 Black.Female.Adult  No 5.5 56 214 
778.D56 Grey.Male.Juvenile No 5.7 40 154 
179.D56 Grey.Female.Juvenile No 5.9 50 665 
D03.D56 Grey.Male.Juvenile Yes 5.9 50 418 
B43.D56 Grey.Female.Adult Yes 6.1 125 771 
565.D56 Black.Female.Adult Yes 7.3 70 270 
119.D56 Grey.Female.Juvenile Yes H
ig
h 
A
A
H
L 
tit
re
 (>
5.
0 
IU
/m
L)
 
12.5 >390 1100 
 
Bat No.PV-Day samples of plasma are identified by the unique last three digits of the bat’s microchip 
number and the day post-primary vaccination on PV-day 0 that the sample was taken e.g. 
CIB.D56 is the sample from the bat with the microchip having the last three digits of CIB 
taken on PV-day 56. 
AAHL results: expressed as international units, i.e. relative to 2 IU/mL standard (control) plasma.  
  In the CVS rabies RFFITAAHL  a result of 0.5 IU/mL ≃ 50% endpoint dilution of 10.  
CDC results:   expressed as calculated 50% endpoint titres. See Appendix 2.  
NR   No result  Cytotoxicity at the 1:5 and 1:25 dilutions precluded test evaluation. The higher incidence of 
cytotoxicity in the ABL-RFFITCDC compared to the CVS-RFFITCDC is probably due to the 
cell sheet remaining in contact with the bat serum for a longer test incubation time (48 
hours rather than 24 hours). 
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8.3.2 Result threshold for KLH-ELISA titres 
KLH-ELISA titres for 200 wild-caught (negative) bats are represented in Figure 8-6. 
Only five stored sera from Grey-headed flying foxes had titres > 20 PA. Four of these ‘high-
negative’ sera were tested on four occasions, giving consistent results. A moderate number of 
both Black (n=4) and Grey-headed (n=8) flying foxes had titres between 10 and 20 PA, the 
remainder (n=183) had titres <10 PA. 
Figure 8-6 KLH-ELISA titres of 200 wild-caught (KLH-negative) flying foxes 
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These titres suggest that > 95% of unvaccinated Black and Grey-headed flying foxes have KLH 
titres < 20 PA. Accordingly, titres < 20 PA were considered negative for KLH, and titres > 20 PA 
were considered positive, indicating previous exposure (vaccination) to KLH. The possible result 
outcomes and types of errors made when interpreting titres with a result threshold of 20 PA are 
shown in Table 8-6. 
Table 8-6 Interpreting KLH titres: Results and types of errors  
 Unvaccinated bat Vaccinated bat  
Titre < 20 PA True negative (>95%) False negative  
Titre > 20 PA False positive (<5%) True positive 
 
  Vaccination trial 
 280
8.3.3 Response to the KLH immunogen 
Details of each bat (microchip number, species, sex, age, capture weight, treatment group, n=37) 
and their KLH titres are shown in Appendix 11. Plots of the individual responses within each group 
are also shown in Appendix 11. 
8.3.3.1 KLH Phase 1 (PV-day 0 to 85): Crude summary 
The mean responses of treatment groups 1, 2, 3 and 4, for each species ars summarized in 
Figure 8-7 and Figure 8-8. There were no treatment differences between Groups 1 and 3 (KLH in 
Nobivac) or Groups 2 and 4 (Nobivac and KLH + Alhydrogel) until PV-day 28, at which time 
Groups 3 and 4 received their respective booster vaccinations, so data for these pairs of groups 
have been combined for PV-days 0 to 28. 
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Figure 8-7 Mean response to Phase 1 KLH vaccination in Grey-headed flying foxes 
(vertical bars indicate ± 1 standard error of mean) 
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Figure 8-8 Mean response to Phase 1 KLH vaccination in Black flying foxes  
(vertical bars indicate ± 1 standard error of mean) 
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8.3.3.2 KLH Phase 1 (PV-days 0 to 85): Analysis of variance 
Analysis of variance indicated that three factors; vaccination method, booster vaccination and 
age, had statistically significant effects on KLH titres (conditional probability < 0.05). 
♦ Method: KLH + Alhydrogel > KLH in Nobivac 
Vaccination using KLH + Alhydrogel as a separate injection produced higher KLH titres 
between PV-day 14 to 85 compared to those following vaccination with KLH in the Nobivac 
vaccine.  
♦ Booster PV-day 28 > No booster 
Booster vaccination using either method produced higher KLH titres between PV-day 42 to 85 
♦ Age: Juveniles > Adults 
There was a higher KLH response in juveniles compared to adult flying foxes on PV-day 21, 
and again between PV-day 42 and 85. 
 
Two of these factors, method and age, had similarly significant effects on the concurrent rabies-
RFFIT titres during this period. 
Estimated mean values of statistically significant factors (conditional probability < 0.05), adjusted 
with respect to other factors, and appropriate standard errors are shown in Table 8-7. 
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Table 8-7  Phase 1 KLH response: significant factors.  
Fitted mean values and standard errors for statistically significant factors predicted from regression model (conditional probability < 0.05) 
PV-day 14 PV-day 21 PV-day 28 PV-day 42 PV-day 56 PV-day 85  
Significant factors 
fM%            s.e fM% s.e fM% s.e fM% s.e fM% s.e fM% s.e
Method KLH in Nobivac 47.6**            4.7 52.6** 4.9 34.7** 5.8 37.9** 4.1 27.2** 4.5 17.0** 4.2
 KLH + Alhydrogel 73.6**            
            
            
Age           
          
3.6 78.4** 3.7 65.7** 4.5 62.0** 3.1 48.4** 3.4 28.3** 3.2
Booster None n/a n/a n/a n/a n/a n/a 40.6** 3.6 34.2** 4.0 20.6 3.7
 PV-day 28 n/a n/a n/a n/a n/a n/a 79.2** 3.4 56.6** 3.8 32.7 3.5
Adult --- --- 69.1 3.8 --- --- 41.5** 2.9 39.5** 3.2 22.1 3.0
 Juvenile --- --- 79.7 5.6 --- --- 72.8** 5.0 56.6** 5.5 38.0 5.1
 
fM% fitted mean percent absorbence 
s.e standard error of fM% 
--- not statistically significant 
n/a not applicable as booster factor not applied until PV-day 28 
** conditional probability < 0.01 
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In general, the interactions between these factors were not statistically significant (conditional 
probability > 0.05). However, during the period of peak response to the primary vaccination, i.e. 
PV-days 14 and 21, there was a significant interaction between vaccination method and age, with 
a stronger effect of method for the juveniles than the adults (see Table 8-8) 
 
Table 8-8 Phase 1 KLH response: significant interactions. 
Fitted mean values and standard errors for statistically significant interactions of factors 
predicted from regression model (conditional probability < 0.05) 
Juvenile Adult 
  Method 
fM% s.e fM% s.e 
PV-day 14 KHL in Nobivac 37.0 7.1 51.7 6.2 
 KLH + Alhydrogel 84.5 7.1 70.8 4.3 
PV-day 21 KLH in Nobivac 50.3 7.3 53.5 6.4 
 KLH + Alhydrogel 94.3 7.3 74.3 4.4 
 
      fM% fitted mean percent absorbence 
      s.e standard error of fM% 
 
8.3.3.3 Estimated duration of positive KLH-titres following Phase 1 vaccination 
on PV-days 0 and 28 
The estimated duration of positive KLH-titre resulting from vaccination on PV-day 0 ± PV-day 28 
(i.e. Phase 1 only) for each flying fox is shown in Table A12-2 in Appendix 11 and summarized in 
Figure 8-9 , Table 8-9, and Figure 8-1 . They indicate how long titres could have been expected 
to have remained positive (KLH ELISA PA > 20) had the Phase 2 high-dose KLH + Alhydrogel 
booster not been given on PV-day 85. 
0
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Figure 8-9 Estimated median duration of positive KLH titres after Phase 1 vaccinations  
on PV-day 0 and 28 
Unbroken lines indicate means of actual titres, dashed lines indicate median duration until  
KLH titre= 20 PA. Error bars omitted for clarity. 
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Table 8-9 Summary statistics of estimated duration of positive KLH titres after 
Phase 1 vaccinations 
Estimated duration of positive KLH response (days) 
Group 
Median Minimum Maximum 
Group 1 47 21 75 
Group 2 86 56 282 
Group 3 87 72 102 
Group 4 100 75 178 
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Figure 8-10  Schematic plots of estimated duration of positive KLH titres after Phase 1  
vaccinations  
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As the median duration of positive KLH response is only 45 to 100 days and the maximum 
estimated duration is only 282 days, i.e. considerably less than one year, all four of the original 
Phase 1 KLH vaccination protocols failed to produce positive KLH titres for sufficient duration to 
be a used to indicate a history of rabies vaccination. 
In an attempt to increase the strength and duration of KLH titres, bats in all four groups and the 
control bat (n=37) were vaccinated with the 10 times the quantity of antigen (1 mg KLH) and twice 
the Alhydrogel adjuvant (0.2 mL) on PV-day 85 (i.e. Phase 2 KLH trial). 
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8.3.3.4 KLH Phase 2 high-dose KLH booster: Crude summary 
On PV-day 85 all flying foxes (n=37), having previously been vaccinated according to one four 
different KLH protocols, received the same high-dose KLH+ Alhydrogel booster.  
The mean response of bats in Group 1, 2, 3 and 4, for each species is summarized in  
Figure 8-1 . 1
1
 
Figure 8-1  Mean response to Phase 2 PV-day 85 High-dose KLH + Alhydrogel booster 
 (n=37, vertical bars indicate ± 1 standard error of mean) 
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8.3.3.5 KLH Phase 2 (PV-days 85 to 171): Analysis of variance 
Analysis of variance indicated that four factors, previous vaccination method (during Phase 1), 
age, species, and sex had statistically significant effects on the response to the high-dose KLH + 
Alhydrogel booster given on PV-day 85 (conditional probability < 0.05). 
♦ Previous vaccination method: KLH +Alhydrogel > KLH in Nobivac 
Flying foxes that had previously been vaccinated using KLH + Alhydrogel had higher titres in 
response to the high-dose KLH between PV-days 99 and 171 than flying foxes previously 
vaccinated with KLH in the Nobivac vaccine. 
♦ Age: Juveniles > Adults 
Juveniles had higher titres in response to the high-dose KLH than adult flying foxes on PV-days 
127 and 171. 
♦ Species: Black flying foxes > Grey-headed flying foxes 
Species comparisons could only be made between adults that had previously been vaccinated 
with KLH + Alhydrogel (no juvenile Blacks or Blacks vaccinated with KLH in Nobivac were 
included in the study). Within this class, Black flying foxes had significantly higher titres in 
response to the high-dose KLH than Grey-headed flying foxes on PV-day 171 only. 
♦ Sex: Females > Males 
Females had significantly higher titres than males on PV-day 171 only. 
 
Two of these factors, prior vaccination method and age had had similarly significant effects on 
rabies-RFFIT and KLH –ELISA titres during Phase 1.  
Prior Phase 1 booster vaccination on PV-day 28 did not have a significant effect on the response 
to the subsequent PV-day 85 high-dose booster. 
Estimated mean values of statistically significant factors (conditional probability < 0.05), adjusted 
with respect to other factors, and appropriate standard errors are shown in Table 8-1 . 0
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Table 8-1  Phase 2 High-dose KLH response: Significant factors  0
Fitted mean values and standard errors for statistically significant factors 
(conditional probability < 0.05)  
PV-day 99 PV-day 127 PV-day 171 Significant factor 
fM% s.e fM% s.e fM% s.e 
Method KLH in Nobivac 91.8** 3.0 76.5** 3.5 46.4** 5.0 
 KLH + Alhydrogel 101.4** 2.2 86.0** 2.7 56.4** 3.8 
Age Adult --- --- 80.8** 2.6 46.5** 3.6 
 Juvenile --- --- 93.9** 4.3 81.4** 6.0 
Species† Grey --- --- --- --- 37.5** 6.1 
 Black --- --- --- --- 61.5** 4.8 
Sex Male --- --- --- ---  52.8 4.7 
 Female --- --- --- ---  54.7 4.0 
 
fM% fitted mean percent absorbence 
s.e standard error of fM% 
**  conditional probability < 0.01 
---  not statistically significant 
† species comparisons only available among adult bats vaccinated with Nobivac and KLH + 
Alhydrogel (Groups 2 and 4) 
 
 
In general, the interactions between these factors were statistically not significant (p > 0.05). 
However, during the period of peak response to the high-dose KLH, i.e. PV-day 99, there was a 
significant negative interaction between previous vaccination method and previous booster on PV-
day 28 (conditional probability = 0.045), with bats that had previously received two doses of KLH 
in Nobivac having lower titres in response to the high-dose KLH (see Table 8-11). 
 
Table 8-1  Phase 2 High-dose KLH response: Significant interactions 1
Fitted means and standard errors for statistically significant interactions of factors (conditional 
probability < 0.05) predicted from regression model 
No PV-day 28 Booster Booster PV-day 28  
PV-day Method 
fM% s.e fM% s.e 
99 KLH in Nobivac 96.6 4.3 85.2 4.0 
99 KLH + Alhydrogel 100.9 3.1 102.1 3.0 
 
           fM% fitted mean percent absorbence 
      s.e standard error of fM% 
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8.3.3.6 Estimated duration of positive KLH titres following Phase 2 vaccination  
The estimated duration of positive KLH titres following the high-dose KLH + Alhydrogel booster for 
each flying fox is shown in Table A1 -2 in Appendix 11. Titres from two juvenile Grey-headed 
flying foxes (Bats 179 and 402, Groups 2 and 4 respectively) which failed to cross the KLH titre = 
20 PA threshold (i.e. infinity positive) were nominally extrapolated to 1000 days.  
The results are summarized in Figure 8-1 , Table 8-1  and Figure 8-1 .  
2
2 2 3
Figure 8-12 Estimated median duration of positive KLH titres following Phase 2  
As the median estimated duration of KLH positive titres is only 217 to 264 days, i.e. less than one 
year, even the high-dose KLH booster failed to produce positive titres of sufficient duration for the 
intended purpose.  
 
Bold lines indicate mean titres, dashed lines indicate extrapolation to estimated median 
duration until KLH titre = 20 PA. Error bars omitted for clarity 
Vaccinations:  
PV-day 0   KLH in Nobivac (Groups 1 and 3) or Nobivac and KLH + Alhydrogel (Groups 2 and 4) 
PV-day 28 booster KLH in Nobivac (Group 3) or Nobivac and KLH + Alhydrogel (Group 4) 
PV-day 85 high-dose KLH + Alhydrogel (Groups 1, 2, 3, and 4) 
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Table 8-1  Summary statistics for the estimated duration of positive KLH titres following 
Phase 2 vaccination 
2
Estimated duration of positive KLH-response (days)  
Method 
Median Minimum Maximum 
KLH in Nobivac / High dose (n=12) 218 181   592 
KLH + Alhydrogel / High dose (n=24) 255 166 1000+ 
Group    
                 Group 1   (n=6) 218 182   592 
                 Group 2   (n=12) 264 187 1000+ 
                 Group 3   (n=6) 217 181   445 
                 Group 4   (n=12) 224 166 1000+ 
 
Figure 8-1  Schematic plot summaries of the estimated durations of positive KLH titres 3
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8.3.4 Relationship between Nobivac and KLH responses 
The relationship between responses to the Nobivac and KLH vaccinations within individuals was 
examined using the transformed rabies-RFFIT titres and the untransformed KLH titres. The time 
points examined were: 
♦ PV-days 14, 21, and 28, the points of maximum response to the primary vaccination on PV-
day 0 
♦ PV-day 42, the point of maximum response to the Phase 1 booster vaccination of PV-day 28 
and  
♦ PV-day 85, the point of maximum duration following the Phase 1 vaccinations 
Titres from PV-day 171 were not considered as these titres reflect a response to the high-dose 
KLH + Alhydrogel booster without a concurrent Nobivac booster.  
The correlation co-efficients and corresponding F probabilities indicating the level of significance 
of these relationships are shown in Table 8-13. The relationship between the Nobivac and KLH 
responses are illustrated in Figure 8-1 , Figure 8-1 , and Figure 8-1 .  4 5 6
3Table 8-1  Summary statistics of the relationship between the responses to Nobivac and 
KLH vaccination. 
 Correlation co-efficient F probability Interpretation 
PV-day 14                         0.20    0.23 No correlation 
PV-day 21                         0.25    0.14 No correlation 
Pv-day-28                         0.31    0.06 No correlation 
PV-day 42                         0.83 < 0.001 Highly significant correlation 
PV-day 85                         0.40    0.02 Significant correlation 
 
Figure 8-1  PV-day 21: Relationship of responses to Nobivac and KLH vaccination 4
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Figure 8-1  PV-day 42: Relationship of responses to Nobivac and KLH vaccination 5
6
x = Groups 1 and 2, no boosters    o = Groups 3 and 4, boosters on PV-day 28 
 
Figure 8-1  PV-day 85: Relationship of responses to Nobivac and KLH vaccination 
x = Groups 1 and 2, no boosters    o = Groups 3 and 4, boosters on PV-day 28 
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8.3.5 Effect on pups of pre- and post-natal vaccination of 
dams  
Of the 18 female flying foxes captured for the trial, two were pre-breeding juveniles, one adult 
showed no evidence of being pregnant (no weight gain or abdominal distension) and 15 
developed clear evidence of pregnancies that were the result of matings prior to capture. 
Eleven healthy pups, three abortions and one stillborn pup were born to flying foxes during the 
trial. The cause of the stillbirth remains unclear. 
The three abortions and the death of one of the apparently healthy pups occurred within 24 hours 
of the colony being disturbed by: 
♦ capturing flying foxes for blood sampling (n=2) 
♦ the installation of ‘tree limb’ perches in the cage in an attempt to provide environmental 
enrichment and more natural ‘footing’ than cage wire (n=1) 
♦ and by feeding bats uncharacteristically late (after dark), at which time they were flying 
around the cage where the food was stationed rather than hanging calmly as a ‘colony’ at the 
far end (n=1). 
 
The loss of these pups was attributed to the stress of these procedures rather than as a specific 
interaction with any components of the vaccine/s. Extreme susceptibility to stress-induced 
abortion (20 to 100%) has been demonstrated among Little Red flying foxes (Dukelow et al. 
1990). 
Details of these losses are shown in Table 8-1 . 4
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Table 8-1  Details of pup losses during the vaccination trial 4
Details of dam  
  Species 
 (Bat no.)1 
Group, vaccination protocol 
 
Circumstances 
PV-day 30 
 
Black 
(E64) 
Group 4 
Nobivac and KLH + Alhydrogel 
PV-day 0 + 28  
 
Pre-term foetus found 48 hours after 
sampling and vaccination on PV-day 28, 
which was also 24 hours after the colony 
was disturbed by feeding after dark on 
PV-day 29 
PV-day 38 Grey  
(B7A) 
Group 4  
Nobivac and KLH + Alhydrogel  
PV-day 0 + 28 
Pre-term foetus found next day following 
disturbance of colony on PV-day 37 to 
install tree-limb ‘perches’ in cage  
PV-day 43 Grey 
(B43) 
Group 3 
KLH in Nobivac  
PV-day 0 + 28  
Pre-term foetus found next day following 
sampling on PV-day 42 
PV-day 64 Grey 
(11A) 
Group 2  
Nobivac and KLH + Alhydrogel 
PV-day 0  
Stillborn full term pup 
PV-day 128 Grey 
(326) 
Group 1 
KLH in Nobivac  
PV-day 0   
Pup 610. Apparently healthy 65-day old 
pup found hanging dead in cage next day 
following sampling on  PV-day 127 
 
7 8
1 Bat no. = the unique last three digits of the female flying fox’s microchip number  
 
8.3.5.1 Rabies-RFFIT and KLH ELISA titres in pups 
Bat details, rabies-RFFIT, and KLH ELISA titres for the 11 healthy pups and their dams are shown 
in Appendix 12. Pups were born between PV-days 48 and 82, 28 days (Bat 51D) to 82 days (Bat 
95B) after the dams last Phase 1 vaccination, and 2 to 37 days prior to the High-dose KLH 
booster on PV-day 85. 
Sampling of the colony was minimized during late pregnancy and while pups were maternally 
dependant and samples were not taken from pups < 4 weeks of age, to reduce the likelihood of 
pup losses/abortions. Consequently, the number of samples from pups is small and no statistical 
analysis was attempted. Pup titres are summarized in Figure 8-1  and Figure 8-1 . The age of 
pups when sampled was calculated using their known or nominal birth dates, which were 
determined as described in Appendix 14. 
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Figure 8-1  Positive rabies-RFFIT titres detected in six of 11 pups born to female flying 
foxes vaccinated with Nobivac rabies vaccine 28 to 82 days before birth 
7
8
Horizontal error bars indicate possible error in age for pups with positive titres. 
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Figure 8-1  KLH ELISA titres in 11 pups born to females vaccinated with KLH during  
(Phase 1) and after pregnancy (Phase 2) 
Positive threshold = 20 PA. Horizontal error bars indicate possible error in age for pups with 
positive titres. 
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8.4 Discussion 
No vaccination trials or protocols exist for Pteropus species (flying foxes) in Australia or elsewhere 
using either rabies virus or other vaccines. This trial demonstrated induction and quantification of 
neutralizing serological responses to rabies virus and ABLV in Black and Grey-headed flying 
foxes using a commercial animal rabies virus vaccine (Nobivac). This discussion includes 
consideration of the use of vaccination in the pre- and/or post-exposure management of captive 
flying foxes. 
8.4.1 Response to vaccination with Nobivac 
The prime objective of vaccinating captive flying foxes with the animal rabies vaccine 
commercially available in Australia (Nobivac®, Intervet) is to confer protective immunity against 
ABLV infection and so reduce the incidence of ABLV in captive flying foxes and the risk infected 
captive flying foxes pose to humans. To have demonstrated that vaccination was cross-protective 
would have required post-vaccination ABLV challenge experiments that were unfortunately 
beyond the available resources. In lieu of experimental challenge, modified rabies-RFFITs were 
done at AAHL to asses the serological response to the rabies antigen.  
All the Black and Grey-headed flying foxes developed peak neutralising antibody titres of  
0.8 to 29 IU/mL (mean = 6.0, median = 3.8, n= 36) typically 21 or 28 days (n=31 of 36) days  
after vaccination with a single dose of Nobivac vaccine, and those given a booster vaccination on 
PI-day 28 developed peak neutralizing titres of 4.7 to 53.6 IU/mL (mean = 17.6, median = 14.0,  
n= 18) on PI-days 42 or 56.  
A nominal rabies-RRFIT titre of ≥ 0.5 IU/mL is considered indicative of protective immunity for 
rabies virus in humans (QHSS) and a titre ≥ 0.5 IU/mL is considered indicative of protective 
immunity for domestic animals being assessed for export/import by Australian authorities (AQIS). 
While the minimum rabies titre associated with protective immunity for flying foxes is not known, 
extrapolation from other species suggests that vaccination with the Nobivac vaccine using either 
the single or booster vaccination protocol conferred protective immunity to rabies virus challenge, 
as all the flying foxes developed titres ≥ 0.5 IU/mL.  
Analysis of variance indicated that age, sex, species, and method (Nobivac and KLH + Alhydrogel 
versus KLH in Nobivac) had statistically significant effects on the rabies-RFFIT titres at various 
time points post-vaccination. However, these effects were typically transient or intermittent, and 
did not involve large or functionally relevant differences in mean titre values (e.g. titres 
substantially more or less than the nominal 0.5 IU/mL). These effects are not considered to be 
sufficiently important to be considered in the development of Nobivac vaccination protocols for 
flying foxes, except that the trial demonstrated that juvenile flying foxes (estimated age 6 months 
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to <3 years of age) are suitable vaccination candidates, producing titres as high or higher than 
those in adults. Interestingly while booster vaccination on PI-day 28 had highly significant effect 
on rabies titres 14 and 28 days after the booster (PI-days 42 and 56), this strong effect was only 
transient, with titres rapidly returning to levels that were no longer significantly higher than those 
of bats that received only a single vaccination by PI-day 85. This would suggest that booster 
vaccination, while potentially useful in inducing rapid and high titres, as would be desirable for 
post-exposure management of situations such as occurred with a captive colony in Rockhampton 
(case nos. ABLV-66 and ABLV-73, see Appendix 5), may not provide better long-term immunity.  
There was an intriguing significant interaction between vaccination method and age on longer 
term rabies titres (PI-days 56, 85 and 171), with juveniles having a higher response when 
vaccinated with KLH in Nobivac, while adults had higher responses to Nobivac and KLH + 
Alhydrogel. Again the differences in titres were not consistent, nor large, nor likely to be 
functionally relevant, and so are not considered sufficiently important to recommend different 
vaccination methods for different age classes of flying foxes. 
Because the purpose of the vaccination was to provide immunity to ABLV, not rabies virus, 
duplicate sera were sent to CDC Atlanta for determination of the cross-neutralisation response to 
ABLV as assessed in a pt-ABLV-RFFIT. Twenty two sera were selected from PI-days 56 and 85, 
(being the longest PI-days for which rabies-RFFITAAHL results were known at the time) to 
represent low (~0.5 IU/mL, n=7), moderate (>2 to <5 IU/mL n=8), and high (> 5 IU/mL, n=7) 
persistent titres from flying foxes that either had (n=11) or had not (n=11) received a booster on 
PI-day 28. Unfortunately all sera with low (~0.5 IU/mL) rabies-RFFITAAHL and rabies RFFITCDC 
titres (n= 7) demonstrated cytotoxicity at the 1:5 plasma dilution, precluding detection of positive 
neutralizing ABLV endpoint titres < 1:11. Four of these sera were also toxic at the 1:25 dilution, 
precluding demonstration of positive ABLV titres <1:25. Consequently it remains unclear to what 
extent sera with low rabies titres in response to Nobivac rabies vaccination, have low, potentially 
protective cross-neutralising activity against ABLV. 
All sera with rabies-RFFITAAHL titres of ≥ 2 IU/mL for which results were obtained (n=10) 
demonstrated neutralising titres against ABLV of 1:154 to 1:1100. While the minimum  
pt-ABLV RFFITCDC titre associated with protective immunity for flying foxes is not known, the 
results for Bat-8 in the experimental inoculation trial (see Chapter 6) suggest that naturally 
occurring pt-ABLV RFFITCDC titres as low as 1:13 to 1:50 may be associated with immunity to 
ABLV challenge, and that challenge can stimulate a rapid increase in pt-ABLV-titre to 1:480 within 
7 days. In combination, these results suggest that flying foxes that develop rabies titres ≥ 2 IU/mL 
in response to vaccination with Nobivac, do develop cross-protective ABL immunity and that flying 
foxes with rabies titres as low as 0.5 IU/mL may also be ABLV immune. 
In the absence of post-vaccination challenge experiments, the duration for which Nobivac rabies 
vaccination confers immunity to rabies virus or ABL remains unclear. Individual flying foxes with 
titres that had waned below 0.5 to 2.0 IU/mL may still have protective immunity to naturally 
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occurring ABLV exposure, depending on the exposure dose, given the potential for a strong and 
rapid anamnestic response such as that seen in Bat-8. Rabies virus challenge experiments after a 
single dose of Nobivac in domestic animals indicate that the duration of protection is at least; dogs 
and cats 3 years, cattle and horses 2 years, foxes, ferrets, sheep and goats 1 year (Intervet 
1996). By PI-day 171, flying foxes that had or had not received a Nobivac booster on PI-day 28 
had rabies-RFFITAAHL titres of 0.2 to 11.7 IU/mL (n= 18) and 0.7 to 10.2 IU/mL (n= 18) 
respectively. Mean rabies-RFFITAAHL for each group of Black or Grey-headed flying foxes on  
PI-day 171 ranged from 1.6 to 4.6 IU/mL, which is comparable to the mean rabies-RFFIT titres of 
3.0 to 3.5 IU/mL in groups of dogs and cats 6 months after single primary vaccination that 
persisted as mean titres of 2.0 to 3.0 IU/mL after 36 months (Intervet 1996). Pending the results of 
challenge experiments with flying foxes more than 6 months post-vaccination, it appears that 
Nobivac/ABLV vaccination protocols for flying foxes should include an ongoing, at least yearly, 
booster vaccination schedule. 
8.4.2 Use of KLH as an immunological marker 
KLH is frequently used in medical research as a strongly immunogenic carrier protein to which 
haptens such as short peptides are conjugated to elicit specific antibodies to the hapten of 
interest. It is also used as a non-specific immune stimulant to investigate the role of the immune 
system in disease. No reports of the strength or duration of antibody responses to KLH itself, in 
bats or other species, were found.  
As the objective of the KLH vaccination was to induce positive antibody titres that could be used 
to differentiate rabies-vaccinated from unvaccinated flying foxes, the purpose of the KLH 
vaccination was not to produce high KLH titres per se but rather to produce positive titres (KLH 
ELISA >20 percent absorbance, PA) for as long a period as possible, a persistent moderate 
response of 30 or 40 PA being more desirable than an initially high response that rapidly falls to  
< 20 PA. For KLH to be an effective serological marker, a KLH vaccination protocol would need to 
reliably produce positive KLH titres that lasted either: 
♦ for a minimum of one year, such that annual boosters would sustain a positive KLH titre 
♦ or preferably substantially longer than the concurrent positive rabies-RFFIT response, so that 
any positive rabies-RFFIT titres could be recognized as due to vaccination 
♦ or ideally for the lifespan of the flying fox (~10 years), ‘permanently’ indicating a history of 
vaccination. 
Most flying foxes (n= 35 of 37) responded to the primary KLH vaccination with titres of > 40 to 96 
PA which were clearly distinguishable from >95% of unvaccinated flying foxes using the 20 PA 
positive threshold. Two bats (B66 and F19, both juvenile Grey-headed flying foxes) failed to 
develop positive titres in response to primary vaccination (maximum titres of 14 and 21 PA 
respectively), however Bat F19 subsequently responded well (75 PA) to booster vaccination on 
PI-day 28. There was a consistent (PV-day 14 to PV-day 85) and highly significant association 
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between the KLH + Alhydrogel method and higher KLH titres, and both booster vaccination on  
PI-day 28 and age (juveniles) were associated with significantly higher KLH titres on days 42, 56 
and 85, i.e. in the medium term, towards the end of Phase 1. 
Unfortunately, the KLH titres declined sharply and by PI-day 85, 19 of 37 flying foxes (52%) had 
titres near or below the positive threshold (<23 PA), including 3 of 12 (25%) that had benefited 
from the optimal method and protocol combination of KLH + Alhydrogel and PV-day 28 booster. 
As such it was clear that none of the trialled KLH vaccination strategies would induce KLH titres 
>20 PA for the minimum duration requirement of 1 year. Indeed mathematical extrapolations of 
the declining titres predicted that the median duration for which the KLH response was expected 
to remain positive was as short as ≤ 100 days, and the maximum expected duration was only 282 
days. 
At this point, the KLH component of the vaccination trial was deemed to have failed. A second 
attempt to induce sustained positive KLH responses was made using a higher dose of KLH 
antigen (10 X) and the most effective method (KLH + Alhydrogel), using twice the adjuvant, on 
PV-day 85 (Phase 2). All bats (n= 37) responded very well to the high dose, Phase 2 booster, with 
titres of 82 to 111 PA 14 days later. Again however, titres fell rapidly. By the termination of the 
experiment on PV-day 171 (86 days after Phase 2 booster), the response of one bat (F43) had 
fallen from 102 to 16 PA (negative), and the titres of three others were less than 30 PA. 
Mathematical extrapolations of the titres indicated that median date to which KLH titres could 
have been expected to have remained positive was between PV-days 217 to 264 days, i.e. only 
132 to 179 days after the Phase 2 booster. While it is likely that the titres of at least some flying 
foxes would plateau and remained positive for longer than that calculated by linear extrapolation, 
it is clear that in some or most cases, the positive KLH response would not persist for the 
minimum I year required, and certainly not for the potential lifespan (~10 years) of the bat.  
When vaccinated with the rabies virus and/or KLH antigen, a substantial proportion of bats 
responded with a transiently high serological titre, with a tendency towards low or nominally 
negative titres in the mid to long term. Given the apparent failure of KLH as a serological marker 
and the often strong but transient nature of the serological response to antigens in flying foxes, 
differentiation of vaccinated from unvaccinated bats might more reliably be done with the use of 
traditional identification methods, such as thumb bands and microchips.  
8.4.3 Effect on pups of vaccination of pregnant and/or 
lactating dams 
A secondary objective of the trial was to evaluate the serological response in pups born to flying 
foxes that were vaccinated when pregnant. Black and Grey-headed flying foxes were caught 
during May, i.e. shortly after the principal mating season for these species in southeast 
Queensland, when most breeding age females were expected to be in early pregnancy. Selection 
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of females for the trial was biased towards those of breeding age, and 14 of 15 subsequently 
showed evidence of pregnancy. Three females aborted in late pregnancy; in each case this 
followed stressful interactions with the colony. While these losses were attributed to stress rather 
than to the vaccinations per se, the stage of possible pregnancies should be considered when 
instituting a vaccination program for ‘untamed’ captive bats in order to avoid stress-induced 
abortions. 
Six of 11 pups born to vaccinated dams had rabies-RFFITAAHL titres of 0.3 to 22.5 IU/mL at ~ 30 to 
60 days of age, which dropped to 0 to 3.0 IU/mL by ~100 days of age. Similarly all 11 pups had 
KLH titres of 5.2 to 44.6 PA at ~30 to 70 days of age, which dropped to 0.4 to 15.8 PA at 80 to 
120 days of age. This antibody profile is highly suggestive of maternally-derived antibody, and it 
appears that the maternal antibodies in most pups would be very low or absent by 3 to 4 months 
of age.  
The extent to which maternally derived antibodies could have been acquired via milk is unclear as 
no studies have been done to determine whether or not flying foxes produce colostrum, or the 
capacity of pups to absorb antibody sized macromolecules. In a detailed study of the placenta of 
the Indian flying fox (Pteropus giganteus) using both light and electron microscopy, the placenta 
was shown to be endotheliodichorial at late limb bud stage and by advanced pregnancy showed a 
tendency to be haemochorial (Karim and Bhatnagar 1996). The placentation of Black and Grey 
headed flying foxes has not been so thoroughly examined. The aborted terminal placentas of 
Grey-headed and Little Red flying foxes were shown to be discoidal labyrinthine endotheliochorial 
(Hughes 1989), however the use of aborted placentas rather than ‘fresh’ placentae in utero, may 
have precluded detection of a tendency towards a haemochorial placenta in these species. Trans-
placental transfer of maternal antibodies would be expected to occur across a haemochorial 
placenta and is also likely, at least to some extent, across an endotheliochorial placenta. It is likely 
that the positive rabies and KLH titres detected in the pups of this trial are the result of maternal 
antibody transfer in utero, and possibly also via milk. The extent to which maternally-derived 
rabies antibodies could be protective in pups is unknown. By 3 to 4 months of age titres had 
dropped to levels that would not be expected to interfere with subsequent vaccination. While the 
capacity of pups of this age to respond to vaccination has not been demonstrated, flying fox pups 
are comparatively precocious when born (fully furred, eyes open, able to cling to dam during 
flight), and are capable of flight and living independently by 3 to 4 months of age. Given this and 
the excellent response of young bats in this trial that were possibly only 6 months of age when 
vaccinated, it is presumed that the immune system of 3 to 6 month old pups would be sufficiently 
mature to respond adequately. This should however be established by determining the post-
vaccination rabies-RFFIT titre of pups of known age. 
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8.4.4 Consideration of an ABLV vaccination protocol for 
captive flying foxes 
Both pre-and post-exposure rabies vaccination protocols are regularly used to manage human 
exposure to rabies worldwide. Pre-exposure management of domestic animals in the USA 
consists of vaccination with an approved veterinary rabies vaccine and appropriate regular 
booster vaccinations, with immediate re-vaccination following any potential exposure to rabies. It 
is recommended that post-exposure management of unvaccinated animals consist of euthanasia 
to preclude subsequent transmission or placing the animal in isolation for 6 months with 
vaccination 1 month before release should no clinical rabies develop (Jenkins et al. 2003). 
Protocols for the post-exposure vaccination of unvaccinated domestic animals have not been 
validated and are controversial. However, successful post-exposure vaccination of naturally 
exposed pigs and experimentally infected sheep with commercial animal vaccine ± equine rabies 
immunoglobulin, suggests that post-exposure vaccination can be used safely and effectively to 
manage exposure to rabies in valuable farm (captive) animals (Blancou et al. 1991; Mitmoonpitak 
et al. 2002). In Australia, use of animal rabies vaccines is strictly controlled by the Chief 
Veterinary Officer of each state and the Australian Quarantine Inspection Service (AQIS). Its use 
is currently limited to pre-export vaccination and management of rabies outbreaks. 
Captive flying foxes generally fall into one of two categories: those in permanent or long term 
captivity, such as those in zoological parks and sanctuaries, and those in temporary care, typically 
bats that are sick, injured, or orphaned, and being cared for pending re-release. Captive flying 
foxes may be considered ‘valuable’ animals, if not in terms of monetary value, then because they 
are protected native species, often induce strong feelings of attachment in those that care for 
them, and in some cases because they are trained and used for educational display.  
Management of potential exposure of captive flying foxes to ABLV could take two forms: 
♦ Maintenance of colonies in enclosures that preclude direct contact with wild flying foxes 
♦ Pre-exposure vaccination 
Currently very few captive colonies are kept in ‘contact-proof’ facilities and use of vaccines in 
wildlife, including captive bats is not authorized. Use of a pre-exposure vaccination program in 
permanent captive residents could act as a primary strategy to reduce the risk of ABLV infection 
in bats kept in single layer facilities, and as a secondary level of protection in bats in double layer 
facilities. Zoos and research institutions may establish rabies vaccination programs for wildlife in 
the USA (Jenkins et al. 2003). While the incidence of ABLV in permanent captive residents is 
particularly low (a single case, ABLV-73), the close and on ongoing nature of their contact with 
staff, and in some cases the use or display of these animals with the unvaccinated public warrants 
consideration of this approach. The need to differentiate vaccinated from non-vaccinated bats by 
serological means would be essentially eliminated because these bats would not be released into 
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the wild population and veterinary records and individual identification (thumb bands, microchips) 
would indicate their vaccination status.  
The two ABLV cases involving the Rockhampton colony also raise the prospect of post-exposure 
vaccination of captive flying foxes. The colony was known to have been exposed to ABL on two 
occasions: 1. when wild ABLV-66 landed on the enclosure and 2. as a consequence of contact 
with colony resident ABLV-73. In response to the ABLV-positive diagnosis of ABL-66, there was a 
reluctance to slaughter the entire colony to preclude further transmission and bats were retained 
on public display (albeit separated from the public by a pre-existing double fence) and normal 
management practices continued. Following the development of ABLV disease within the colony 
(ABLV-73), the remaining bats were removed to an outdoor facility at the home of a volunteer 
where they were observed for 3 months (Warrilow et al. 2003). In the absence of any clinical or 
serological evidence of infection they were then returned to public display, and the cage upgraded 
to double layer mesh (contact proof). Post-exposure vaccination of the colony following the 
diagnosis of either case would potentially have reduced the risk of ABLV infection for both the 
colony bats and staff. While post-exposure treatment of humans ideally uses both vaccines and 
immune serum, the cost of immune serum is high and it is not known if commercial equine or 
human immune serum would be tolerated in flying foxes. Given the good immune response 
demonstrated in this trial to the Nobivac vaccine alone in comparison to those of pigs receiving a 
similar vaccine ± immune serum (Mitmoonpitak et al. 2002), the strong booster effect, and known 
incubation periods of naturally occurring ABLV infection being ≥ 30 days (n=4, see Chapter 2), a 
vaccine only protocol for flying foxes may be effective. However, post-exposure prophylaxis with 
rabies vaccine only was universally unsuccessful in dogs experimentally infected with a high dose 
of street rabies virus. All vaccinated dogs died earlier (days 9 and 10, n=4) than unvaccinated 
controls (days 11 to 13, n=5), suggesting an ‘early death’ effect (Hanlon et al. 2002). Because the 
high rabies dose used may not represent natural ABLV exposures, these results in dogs do not 
preclude a protective effect for post-exposure vaccination in naturally infected bats. Should post-
exposure vaccination of bats fail, it may well be associated with an also advantageous effect of 
early death.  
8.4.4.1 Proposals for pre-exposure vaccination protocol for flying foxes in 
captivity 
♦ Vaccination of long-term permanent residents only. Eligible bats to have been held in captivity 
for at least 6 months (or since birth to long term resident), to demonstrate probable ABLV 
negative status.  
Vaccination only of bats with (or given) suitable permanent identification, preferably a 
combination of a microchip (permanent, but requiring scanner to read and not externally 
visible) and a thumb band (externally visible and so readily identifying the bat as one of 
interest, but can be lost). 
♦ 
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♦ Vaccination schedule to consist of one initial vaccination with Nobivac® rabies vaccin (sic), 
followed by yearly boosters. 
Consideration to be given to not vaccinating bats susceptible to the stress of handling during 
late pregnancy, and to vaccinating captive born pups at 3 to 6 months of age, e.g. yearly 
vaccination of Black and Grey-headed colonies during March to May. 
♦ 
♦ Formal records of bat identification and vaccination history to be kept at the colony, and 
potentially on a centralised register (such as the Australian Bird and Bat Banding Scheme 
register kept by the federal environment department, http://www.enviroment.gov.au/bg/abbs ). 
♦ Vaccinated bats would be exempt from a demand for surrender for FAT in the event of a bite 
or scratch of a human. 
While the optimum protocol to induce rapid and high titres is not known some suggestions are 
offered. 
8.4.4.2 Proposals for post-exposure vaccination protocol for flying foxes in 
captivity 
♦ Vaccination to be given as soon after confirmation of an ABLV-positive result in bat (or other 
animal) to which flying foxes were exposed. Use of vaccine in post-exposure management to 
be authorized by the Chief Veterinary Officer on a case by case basis.  
♦ Exposed flying foxes to be isolated from other animals and contact strictly restricted to 
vaccinated staff. 
♦ Vaccination with two (or three) Nobivac inoculations, e.g. PV-Day 0 and 14, or PV-Day 0, 10, 
and 20. 
♦ Identification and record requirements should apply as for pre-exposure vaccination.  
♦ Response validated by determination of plasma titres in rabies-RFFIT on PV-day 28. 
♦ Flying foxes that respond with rabies-RFFIT titres ≥ 2 IU/mL and remain clinically well for 3 
months to be returned to normal status.  
♦ Bats that respond with titres < 2 IU/mL to be housed separately and given a further booster, 
and observed for a further 4 months before reverting to normal status. 
 
Sick, injured, and orphaned bats temporarily in captivity are typically in the care of volunteer 
wildlife carers and the facilities in which they are kept vary. Often unwell bats are kept within the 
carer’s home in small ‘cat basket/carrier’ type cages. Some carers also have larger walk-in style 
cages in their yards, which are invariably single barrier type and permit contact with wild bats. 
Most bats require care for only days or weeks. While bats in this category have the highest 
incidence of clinical ABLV disease, or are most likely to have had recent exposure to ABLV, pre- 
and/or post-exposure vaccination of this group is precluded by the expense of vaccination and 
permanent identification, the unfunded volunteer nature of wildlife care, the high number bats 
treated each year (>1,000, Helen Luckoff ONARR, pers. comm.), and the undesirability of 
releasing vaccinated animals into the wild population where the outcome and impact of the 
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animals would be unknown. Consideration could be given to providing pre-exposure vaccination 
to the few bats that are retained by carers permanently due to injuries that preclude their release.  
8.5 Conclusions 
Demonstration that flying foxes vaccinated with a commercial rabies vaccine will 
seroconvert and develop detectable titres against rabies virus. 
♦ 
♦ Young bats (possibly as young as 6 months of age) responded to Nobivac vaccination as well 
or better than adults. 
All flying foxes vaccinated with the commercial Nobivac rabies vaccine did seroconvert to the 
rabies virus antigen and developed detectable rabies titres. 
♦ All vaccinated Black and Grey-headed flying foxes responded to a single inoculation of 
Nobivac® rabies vaccine developed titres greater than or equal to 0.5 IU/mL, which is 
nominally indicative if protective immunity, within 28 days. 
♦ Booster vaccination on PV-day 28 induced a rapid and very strong serological response in 
most flying foxes that waned in the medium (< 6 months) term to levels comparable to those 
that did not receive a booster.  
Demonstration that rabies-vaccinated flying foxes developed cross-neutralising  
titres against ABLV 
♦ Demonstration that rabies-vaccinated flying foxes were cross protected against ABLV 
required post-vaccination challenge experiments that were beyond the resources of this trial. 
♦ Bats with rabies-RFFIT titres of ≥ 2 IU/mL were shown to have cross-reactive neutralising 
ABL-titres ≥ 1:154. The cross reactive titres of seven samples with rabies-RFFIT titres of ~ 0.5 
IU/mL could not be determined due to the cytotoxic effect of the plasma at low dilutions. 
♦ Extrapolation from Bat 8 (Chapter 6) suggests residual ABLV-titres as low as 1:13 and 1:50 
can protect against subsequent challenge. 
Differentiation of rabies-vaccinated from unvaccinated flying foxes by inducing 
concurrent seroconversion to a marker (KLH) protein 
♦ Attempts to reliably differentiate Nobivac-vaccinated bats from naturally immune bats by 
inducing a concurrent serological response to a marker protein (KLH) failed. While there was 
a strong immune response that was readily detectable in a specifically developed ELISA, 
titres had a tendency to fall to levels (≤ 20 PA) similar to those seen in up to 5% of 
unvaccinated bats, after an unacceptably short (<<1 year) duration. 
♦ Permanent recognition of the vaccination status of captive bats can most reliably be done by 
suitable individual identification (banding and microchipping) and the maintenance of 
adequate records. 
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Development of an enzyme linked immunoabsorbant assay for the detection of 
seroconversion to the marker (KLH) protein. 
♦ An enzyme linked immunoabsorbant assay was successfully developed to detect 
seroconversion to the KLH marker protein, with fewer than 5% of wild-caught presumably 
unvaccinated flying foxes having titres > 20 PA. 
Other conclusions are: 
♦ There was evidence of passive maternal antibody transfer to pups born to vaccinated dams; 
however the level of protection provided is unknown. 
♦ Use of commercial rabies vaccines such as Nobivac for pre-or post-exposure management of 
captive flying foxes is likely to reduce risk of ABLV infection in captive bats and the people 
with whom they have contact. 
♦ Use of the vaccine for this purpose requires approval by State Veterinary Officers and AQIS, 
which would be subject to other considerations such as the impact of such use on Australia’s 
rabies-free status. 
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General Discussion 
9 General Discussion 
The overriding objectives of this project were to characterise ABLV and ABLV infection, to 
compare those characteristics with those of other lyssaviruses, in particular rabies virus, and to 
identify risk factors for consideration in the management of potential exposure to ABLV.  
As described in this study and in reports from Australia’s WHO Rabies Laboratory, AAHL (Fraser 
et al. 1996; Gould et al. 1998; Gould et al. 2002; Hanna et al. 2000; Hooper et al. 1997b; Hooper 
et al. 1999a; Speare et al. 1997), Australian bat lyssavirus has only been identified in each of the 
four common species of Australian flying fox (Black, Grey-headed, Little Red and Spectacled), 
Yellow-bellied sheathtail (YBST) bats, and two humans.  
The complete coding sequence of the nucleoprotein of 31 isolates of ABLV were determined in 
this study and provided to GenBank (accession numbers AY573935 to AY573665). They include 
sequences of ABLV isolated from all affected bat species except for the single isolate from a 
Spectacled flying fox. Phylogenetic analysis presented here of these sequences together with 
other ABLV, rabies, and rabies-like virus sequences indicated that ABLV occurs as two variants. 
One was only isolated from YBST bats and the first human case, the other was isolated from 
flying foxes and the second human case. The results of this study confirm those of a similar 
analysis done using only partial coding sequences of a conserved region of the N gene from 
fewer samples (Gould et al. 2002), and complements analysis of the complete G protein coding 
sequence done on a subset of the isolates used here that was done by other members of our 
research group (Guyatt et al. 2003). This molecular epidemiological pattern, where infection with a 
particular virus-variant is found primarily in one host with occasional spill-over to dead end hosts, 
is very similar to that of the other lyssaviruses, including rabies virus. In the Americas, there are 
many rabies virus variants, each of which is most frequently recognised in a single (primary) host 
species in a region (e.g. dogs, foxes, raccoons). The primary host is believed to be responsible for 
enzootic maintenance, with sporadic disease occurring in many mammalian species (Smith et al. 
1990; Smith et al. 1995). The basis of maintenance host-virus specificity is unknown. Unlike dog- 
and fox-variant rabies virus (Holmes et al. 2002; Nadin-Davis et al. 1993), ABLV does not appear 
to have regional sub-variants. This is presumably because bats fly, thus precluding regional 
isolation of hosts and virus that could give rise to genetic drift. In general a similar lack of regional 
sub-variants is seen for rabies virus isolates from insectivorous bats in the USA and Canada 
(Nadin-Davis et al. 2001; Nadin-Davis et al. 2002; Smith 1988; Smith et al. 1995).  
In the case of ABLV it appears YBST-variant ABLV is maintained among YBST bats. 
Phylogenetic analysis of isolates from flying foxes (pteropid-variant ABL) indicated that only a 
single ABLV variant occurs among Black, Grey-headed, and Little Red flying foxes. The level of 
sequence homology among isolates from the three flying fox species throughout Queensland was 
very low, and there was no evidence of species specific-sub-variants. That pteropid-ABLV 
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infection is common in three, albeit closely related, bat host species is similar to the situation in 
Canada where Arctic foxes (in the north) and Red foxes and skunks (in the south) are vectors for 
Arctic fox-variant rabies (Nadin-Davis et al. 1993). For ABLV it is not clear whether one or all three 
flying fox species function as maintenance hosts. The populations of these bat species are in 
close proximity, with Black, Little Red and Spectacled flying foxes sharing camps in Queensland’s 
north; Black, Grey-headed, and Little Red flying foxes sharing camps in Queensland’s south, and 
considerable migration of Black and Little Red flying foxes occurring throughout Queensland (Eby 
1991; Hall and Richards 1979; Hall and Richards 2000). It is possible that ABLV is maintained in 
only one or two flying fox species with frequent ‘incidental’ dead-end spill-over affecting the other 
species as a consequence of their close proximity and social interactions. A similar situation 
affects thousands of cattle each year in South America. There a variant of rabies maintained in 
vampire bats kills humans and cattle as dead-end hosts because infected vampire bats transmit 
rabies when feeding on the blood of living animals (Martinez-Burnes et al. 1997; Warner et al. 
1999; World Health Organization 1992). The extent to which other Australian native or domestic 
animal species are infected with ABLV remains unclear as adequate numbers of non-bat species 
with ABLV-like clinical signs have not been submitted for ABLV exclusion.  
This study is the first to describe and analyse the epidemiology of ABLV in the population of 
unwell bats with which most humans have contact and from whom the there is a risk of human 
infection with ABLV that is of public health significance. The results reported here identify risk 
factors for ABLV infection and characterise the clinical histories and progression of ABLV in wild 
bats. These data provide a basis on which assessment of the likelihood of ABLV infection in 
individual bats can be made by carers and veterinarians.  
Statistical analysis of 1,143 bat submissions indicated there was a highly significant association 
with species and prevalence of ABLV among sick, injured, and orphaned bats. The rate of ABLV 
infection in the few YBST bat submissions (5 of 7, 71%) was exceptionally high, and ABLV was 
significantly more prevalent among Little Red flying foxes (16.9%) than Black and Grey-headed 
flying foxes (7.8 and 4.6%), and significantly less prevalent in Spectacled flying foxes (1%). These 
data are based on bats submitted as a consequence of them having come in to contact with 
humans, and indicates that species is a highly significant risk factor for human exposure to ABLV. 
This data does not, however, necessarily indicate that the same species-specific differences in 
the prevalence of ABLV occur in the whole bat population as species-specific factors other than 
the true population prevalence may be reflected in this data. Factors such as proximity of camps 
to human activity, feeding, migration and behavioural patterns, prevalence of other diseases or 
injuries, and the enthusiasm and experience of local wildlife carers, may have contributed to the 
proportion of each species submitted that was ABLV-positive. Similarly this data does not indicate 
which flying fox species is/are important in the maintenance of pteropid-ABLV. Differentiation of 
maintenance as against incidental hosts will be important should a method or ABLV-control in wild 
bats become available. 
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Both age and health status were also associated with the prevalence of ABLV. Infection was 
higher in adult rather than juvenile bats. However even orphan pups, hundreds of which are 
raised by volunteers each year, pose a risk of ABLV infection to humans (Field et al. 1999). 
Infection with ABLV was very common (21%) in bats showing clinical signs suggesting CNS 
disease, significantly less common (3%) among unwell bats not showing signs of CNS disease, 
and virtually absent (0%) among apparently healthy bats. In the absence of any reported bite or 
scratch of a human by a bat, veterinarians presented with bats need to make assessments as to 
whether or not to treat an individual and whether or not to submit individuals for testing. Criteria 
for making this assessment have not been published elsewhere. Knowledge about the species, 
age, and health status of a presented bat, based on careful inquires in to the clinical history, 
should allow veterinarians to make rational choices using the information presented in Table 2-6 
and Table 2-7. For example, the very high predicted prevalence of ABLV among unwell adult Little 
Red flying foxes with CNS signs (>55%) suggests all carers presenting with these bats should be 
strongly advised to kill the bat and submit it for testing.  
The incubation periods, clinical signs, clinical duration and outcome, serological responses, gross 
and histological lesions, and distribution of viral antigen of bats naturally and experimentally 
infected with ABLV are described in this report. They are indistinguishable from those of humans 
and animals infected with other lyssaviruses, notably rabies (Allworth et al. 1996; Fraser et al. 
1996; Hanna et al. 2000; Hooper et al. 1999a; Hooper et al. 1999b; McColl et al. 2002; 
Samaratunga et al. 1998). The few known incubation periods for natural ABLV infection in bats 
(36 to 57 days and 30 days), humans ( 4.5-6 weeks, and 27 months), and experimentally infected 
bats (10 to 19 days, this study, and up to 27 days McColl (1999) and McColl et al. (2002)), fall 
within the wide range of incubation periods for rabies of 7 days to 6 years. As described here, the 
clinical picture of natural ABLV infection, like rabies, occurs as two forms; furious, characterised 
by uncharacteristic aggression including flying out of trees to bite humans and dogs, and the more 
common paralytic form characterised by progressive hind limb or generalised paresis. As in 
rabies, bats with furious ABLV infection often die after a short clinical period (within 1 day of 
rescue) with rapid terminal deterioration. Those with paralytic ABLV infection can linger for up to 9 
days in care. As in rabies, bats infected with ABLV have absent or low antibody titres at death and 
lyssavirus titres in clinically ill or normal potentially exposed bats are of no diagnostic significance 
and should not be used to determine post-exposure management procedures. Street (wild-type) 
ABLV has a tendency to form less obvious and less numerous eosinophilic neuronal inclusions 
(poorly negrigenic) than street rabies virus, however this characteristic is not distinctive as the 
presence of inclusions is highly variable in rabies.  
The mode of transmission of ABLV among bats is not known, but anecdotal evidence from the 
two human cases suggests that like rabies it is transmitted by biting, presumably via saliva. A role 
for saliva in the transmission of ABLV is supported by detection in this study of ABLV RNA in the 
saliva of experimentally infected bats, and by the detection of ABLV antigen in the salivary gland 
parasympathetic ganglia and rare epithelial cells of some submandibular glands. The extent to 
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which other modes of transmission play a role in the maintenance of ABLV is unknown but is 
suggested by the detection during this study of ABLV RNA in the urine of one of three naturally 
infected bats. A potential role for urine and other body fluids in the transmission of rabies virus via 
atmospheric contamination has been suggested for cave dwelling insectivorous bats. However as 
flying foxes roost in open tree canopies, there is substantially less potential for ABLV to 
accumulate in the atmosphere. 
The question of how long ABLV has been present in Australia remains unclear due a lack of 
suitable archival material. ABLV was first recognised in 1996 as a consequence of bats becoming 
the focus of research for the natural reservoir of Hendra virus (Fraser et al. 1996). ABLV had not 
been recognised in bats or humans prior to that, despite Australia having good standards of 
veterinary care, suggesting ABLV may have been recently introduced. However, the presence of 
ABLV in all flying fox populations from which sufficient numbers of appropriate samples have 
been taken, and the presence of two discrete, genetically stable variants in two host genera 
(YBST bats and flying foxes), suggest ABLV has been present for sufficient time to allow evolution 
and distribution into these two ecological niches. The diagnostic investigations of 100 consecutive 
flying fox submissions with signs suggesting CNS disease indicated that (1) CNS disease was 
common among flying foxes (100 cases in a 4 year period), (2) ABLV infection in bats was not 
unique in its clinical presentation, and (3) ABLV was not the only cause of infectious CNS disease 
in wild flying foxes that had not be previously reported e.g. neuro-angiostrongylosis. It is proposed 
here that our apparent failure to have recognised the presence of ABLV prior to 1996 is not an 
indication that ABLV is new in Australia. It more probably reflects (1) that flying foxes had not 
previously been viewed as being of veterinary or economic importance and so appropriate 
material had not previously been examined (2) that most Australians, including veterinarians, 
expected ‘rabies’ to present with overt aggression, (3) that most flying foxes present with paralytic 
(dumb) clinical signs and (4) spill-over into domestic animals or humans is apparently rare.  
Recognition of lyssaviruses in bats was first made in vampire bats as a consequence of relating 
human rabies virus infection to a history of vampire bite. Similarly recognition of Duvenhage virus 
was a consequence of human infection following a bat bite (Meredith et al. 1971). The discovery 
of all other bat lyssaviruses occurred only as a result of surveillance of bat populations prompted 
by recognition of rabies in vampires and the resulting recognition of other lyssaviruses in bats. It 
was not as a consequence other bat lyssavirus infections having caused economic losses, human 
deaths, or bat health concern (Amengual et al. 1997; Boulger and Porterfield 1958; King and Crick 
1988; Lumio et al. 1986; Shope et al. 1970). In the case of ABLV, its recognition in flying foxes 
was ‘incidental’ to a separate investigation for the natural host of Hendra virus (Fraser et al. 
1996). With the notable exceptions of rabies in vampire bats and the cost of post-exposure 
treatment, the presence of lyssaviruses in bats is of comparatively little consequence to humans, 
causing only rare human fatalities and having virtually no impact on domestic or commercially 
significant animals. As this also appears to be the case for ABLV, and given the previous lack of 
professional interest in Australian bat diseases, it is not surprising ABLV was not detected earlier.  
Chapter 9 
 311
In this study a targeted approach and TaqMan® PCR assay were used to demonstrate that 
detection of ABLV by FAT on fresh brain touch impressions at ARI was highly sensitive. The 
results reported here showed that ABLV is relatively easy to find if sufficient numbers of 
appropriate tissues are examined, being the brains of unwell adult bats, particularly those showing 
signs of CNS disease. With the exception of samples from Spectacled flying foxes, the predicted 
ABLV prevalence in such samples is > 20%, forecasting a 99% detection rate from targeted 
surveillance of as few as 21 samples. Targeted surveillance of unwell/CNS bats in southeast Asia 
is likely to reveal that the geographical and host ranges of ABLV extend north of Australia and 
may also detect other related lyssaviruses. Attempts to detect ABLV (and presumably other 
lyssaviruses) through surveillance of apparently normal animals is comparatively wasteful, but has 
been successful (Botvinkin et al. 2003; Boulger and Porterfield 1958). In Australia 
collection/submission of appropriate samples was relatively easy due to the extensive network of 
volunteer carers that rescue and treat unwell wildlife. This resource has the potential to reveal any 
number of other pathogens of Australian wildlife. The establishment and development of 
relationships with local wildlife carers and members of the public interested in animal welfare is 
likely to allow this targeted approach to be used for more effective surveillance of other bat 
populations in Australia and elsewhere.  
Isolation of ABLV in mice (Fraser et al. 1996), demonstration of cross-protection of rabies 
vaccines by mouse neutralisation tests (Hooper et al. 1997b), and the experimental mice 
infections described here demonstrate that the mouse is a suitable, convenient, and affordable 
model for ABLV research. As for other lyssaviruses there is evidence that isolation of ABLV in 
mice is more sensitive than by cell culture, however the use of mice, very common in rabies virus 
research, is limited in Australia by animal welfare concerns. 
A core objective of this study was to successfully demonstrate experimental infection of flying 
foxes, the primary host species, with pt-ABLV in a manner that would as closely as possible 
simulate natural infection in the wild. It was considered important to maximise the likelihood that 
inoculated bats would develop clinical disease while minimising the extent to which the 
experimental model differed from what was presumed to be the typical exposure to ABLV in wild 
bats; transfer of ABLV via saliva through the bite of an infected bat. To do this the following 
strategies were used. 
♦ Preparation of the inoculum directly from tissue of a naturally infected bat in order to inoculate 
a virus population with the same characteristics as occurs naturally. There was no prior virus 
isolation in cell culture or by mouse inoculation to avoid selection effects that may have 
altered the virulence and pathogenesis of the inoculum in the experimental host. 
♦ Matching the experimental host species (pteropid bat) with ABLV variant (pteropid-ABLV). 
Phylogenetic analysis of the sequence from an aliquot of the inoculum used (Inoculum 5, 
ABL01SEQ-B, GenBank AY573935) indicated that while the inoculum was derived from a 
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Black flying fox, the inoculum was of the same ABLV-variant present in Grey-headed flying 
foxes, the species used as the experimental host. 
♦ Storing the initial preparation of all candidate inocula in multiple aliquots in the -70 freezer so 
that all uses of the inoculum would be of the same freeze/thaw generation, and the virus titre, 
virulence, and pathogenesis resulting from multiple use would be consistent. 
Selection of an inoculum not only based on a demonstrated ability to affect IC inoculated mice 
or cell culture, but by characterizing and titrating the virulence of multiple (n=15) candidate 
inocula in IC and footpad inoculated mice. In particular the selection procedure used a model 
of peripheral inoculation of weanling, immune competent, outbred (ordinary) mice in a new  
3-mouse footpad assay. This assay considered both the number and rate at which inoculated 
mice were affected to rank the relative peripheral virulence of candidate inocula and select 
the most virulent. This 3-mouse footpad assay used fewer mice than classic titration methods 
(Reed and Muench 1938) and successfully identified a consistent and highly virulent inoculum 
(Inoculum 5) from 15 candidate inocula. 
♦ 
♦ Selection of bats without demonstrable anti-lyssavirus titres for experimental inoculation using 
the modified rabies-RFFITAAHL. Subsequent testing in a pt-ABLV-RFFIT at CDC suggests the 
rabies-RFFITS at both AAHL and CDC are not sufficiently sensitive to identify all flying foxes 
with naturally occurring immunity to pt-ABLV and that such a selection process should be 
based on serology specifically to ABLV.  
♦ Use of a moderate dose of virus (compared to other lyssavirus infection studies) to maximise 
the likelihood of clinical disease without excessively influencing the pathogenesis by using a 
very high virus dose. 
♦ Peripheral inoculation of the inoculum in multiple sites on the body (2 or 4) that were 
considered likely to be places a bat might be bitten and/or were likely to support 
establishment and progression of infection. It was expected that this would avoid inadvertent 
inoculation into an inappropriate site.  
 
Many experimental rabies virus studies use either well characterised, stable ‘fixed’ laboratory 
strains, or isolates of street (wild type) virus that have been amplified by limited mouse brain or 
cell culture passage. The only previous trials of ABLV infection in flying foxes used ABLV isolated 
from the brain of a naturally infected Grey-headed flying fox (AAHL 96-1432-1) passaged four 
times in mice and four times in cell culture (McColl et al. 2002). Inoculation of primary host 
species with rabies virus inocula prepared directly from the salivary glands of the same naturally 
infected host species was done for a large body of work with Canadian skunks by Charlton and 
co-workers (Balachandran and Charlton 1994; Charlton and Casey 1979a, 1981; Charlton et al. 
1983, 1984a, 1987a; Charlton et al. 1987b; Charlton 1994; Charlton et al. 1996; Charlton et al. 
1997; Smart and Charlton 1992). A similar approach was used here. Fortunately the intrinsic 
virulence of Inoculum 5 was sufficiently high that further amplification was not required.  
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The use of a selection procedure to identify virulent lyssavirus inocula for subsequent 
experimental use is rarely described in the literature. The titres of inocula are usually simply 
described as the LD50 of intracerebrally infected mice (MICLD50) or TCID’s. Neither of these 
intrinsically reflect peripheral virulence as the titres of some rabies virus strains that have low 
pathogenicity or are apathogenic in peripherally inoculated adult mice (e.g. HEP-flury, SAD-B19) 
can be high when expressed with these assays. The use of the 3-mouse footpad assay to select, 
characterise and/or quantify the virulence of inocula is proposed here as a more appropriate 
means of expressing the dose of virus used in experimental research.  
Use of these strategies resulted in the demonstration of a highly successful model for ABLV 
infection of experimentally inoculated bats, with clinical disease occurring within 10 to 19 days in 
seven of 10 bats. The clinical, gross, histological and immunological findings of this study 
(Chapter 6) were consistent with those of naturally infected bats (Chapter 1), allowed further 
observations to be made regarding the incubation period, early clinical signs and clinical 
progression, and provided relatively controlled/standardized tissue samples for subsequent 
comparative studies in mice. Use of this model may contribute to further successful investigation 
into the characterisation of ABLV and ABLV infection.  
Comparison of virulence of inocula from the brain and salivary glands of the experimentally 
infected flying foxes indicated that while the relative virulence of inocula from the brain was 
always high, inocula from the combined submandibular and sublingual salivary glands was often 
as high or higher. This was despite substantially less ABLV RNA being present in salivary gland 
inoculum and substantially less ABLV antigen being detected in salivary gland tissue. The relative 
virulence of inocula prepared from the brains and salivary glands of naturally infected flying foxes 
is likely to be variably impacted by post-mortem degradation, storage, and transport conditions, 
and so the virulence of a particular inoculum requires in vivo assessment. This study 
demonstrated a crude correlation between the quantitative detection of ABLV-RNA using the 
TaqMan assay and the peripheral virulence of multiple inocula determined in the 3-mouse footpad 
assay. It is proposed that the TaqMan assay could be useful screening tool to identify inocula of 
interest reducing the number of mice, time, and other resources required to assess large numbers 
of inocula. 
As expected from the close serological and antigenic relationship between ABLV and rabies virus, 
commercial rabies vaccines conferred protection to mice challenged with YBST-variant ABLV 
(Hooper et al. 1997b)(Charles Rupprecht CDC pers. comm.). No person known or suspected to 
have been exposed to ABLV that has received pre- or post-exposure rabies vaccination with the 
human diploid cell vaccine ± human rabies immune immunoglobulin has developed clinical ABLV 
infection. It is presumed that rabies vaccination confers cross-protection against both pteropid-
variant and YBST-variant ABLV because of their high antigenic and G gene sequence similarities 
to rabies virus. Rabies vaccination is not cross-protective for the more divergent Lagos bat or 
Mokola viruses and is protective at higher titres for Duvenhage, EBL-1 and EBL-2.  
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This study reports for the first time use of an animal rabies vaccine in pteropid bats. Black and 
Grey-headed flying foxes were vaccinated with the only commercial animal rabies vaccine 
available for use in Australia (Nobivac® Rabies inactivated vaccin (sic)). Vaccination resulted in 
the development of neutralizing antibody titres to rabies virus (CVS-11) and ABLV that were 
detected in RFFITs done at AAHL and CDC, Atlanta. All bats developed rabies titres > 0.5 IU/mL, 
which are indicative of protective immunity in other species, as calibrated against international 
standard control serum. In the absence of post-vaccination challenge experiments or an 
international reference standard for protection against ABLV, it is unclear to what extent the 
detected cross-reactive neutralizing titres to ABLV indicate protection to subsequent ABLV 
challenge. However, one of three experimentally infected bats to survive ABLV inoculation had a 
fluctuating low (1:13 and 1:50) neutralizing ABLV titre prior to inoculation and developed a strong 
(up to 1:480) but transient ABLV titre that coincided with the onset and progression of clinical 
disease in seven other bats. The protective ABLV immunity apparently present in this bat was not 
detected in pre-inoculation samples tested in the rabies-RFFIT at either AAHL or CDC. These 
results suggest that while the serological relationship between ABLV and rabies virus in bats is 
close, low but biologically significant ABLV titres occur below the cross-reactive rabies-RFFITs 
detection threshold. Clearly meaningful surveys of the prevalence and titres of naturally occurring 
ABLV immunity will require development of a reliable and sensitive ABLV-RFFIT in Australia.  
9.1 ABLV: a rose by any other name  
The recognition and classification of a lyssavirus in Australia is not just an academic exercise as it 
has substantial cultural, trade, financial, legal, and veterinary/medical implications with respect to 
Australia’s WHO rabies-free status. The same is true of the presence of EBL-1 and EBL-2 in parts 
of Europe, which are also otherwise lyssavirus free. There are essentially two schools of thought 
regarding the classification of the EBLs, Duvenhage, and ABLV. One, that these rabies-like 
viruses are sufficiently different from the comparatively diverse rabies-virus variants that in 
addition to being unique and distinguishable variants/species/genotypes of the Lyssavirus genus 
that they warrant classification completely distinct from the multiple variants of rabies virus. The 
other, that these differences, while discernable and useful as a basis for nomenclature, do not 
justify classification of these viruses as other than simply the most divergent variants/genotypes 
within a broader functional rabies virus group. The classification of ABLV has been the subject of 
considerable private if not published international debate.  
The morphology, chemical composition, and replication strategies of ABLV are indistinguishable 
from those of rabies virus or the other lyssaviruses (Hooper et al. 1997b). As discussed, all 
aspects of clinical ABLV disease are indistinguishable from rabies virus and the other 
lyssaviruses. Both rabies virus and ABLV are serotype 1 lyssaviruses and consequently 
diagnostic reagents for rabies (Centocor, HAM) and rabies vaccines are effective in the diagnosis 
and management of ABLV. The ecological niche in which ABLV is maintained (Australian bats) is 
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unique among lyssaviruses. However, it is identical in its characteristics; maintenance in primary 
bat species with occasional ‘dead-end’ spill-over into humans and potentially other mammalian 
species, to other unique ecological niches occupied by other bat lyssaviruses including rabies 
virus. In the absence of monoclonal antibody typing, molecular sequence and phylogenetic 
analysis, ABLV is simply indistinguishable from rabies virus, and would presumably have been 
called such had it been recognised prior to 1970. Indeed this may already have been the case for 
two isolates of ‘bat rabies’ in fruit bats from India and Thailand (Pal et al. 1980; Smith et al. 1967). 
Antigenic typing of multiple ABLV isolates indicates ABLV has a unique antigenic profile that 
differentiates it from all other known lyssaviruses, including multiple variants of rabies virus in bats 
and terrestrial animals (Gould et al. 1998; Hooper et al. 1997b). However this uniqueness is 
dependant on a negative reaction to only one of a panel of monoclonal antibodies (62-15-2) of the 
ERA series (Smith et al. 1984a), having 18 other reactions in common with raccoon variant rabies 
virus (Smith 1989). When compared to those of rabies virus variants and the clearly more 
distantly related Lagos bat and Mokola viruses, the antigenic profile of ABLV, while unique, is 
simply not unique enough for ABLV to be considered other than another unique variant of rabies 
virus.  
The most distinctive feature of ABLV is its molecular sequence. Based on sequence similarity of 
either the N or G genes, even this is not sufficiently different (maximum ABLV N protein amino 
acid similarity to rabies virus 93.6%, Figure 4-4) from all other rabies virus variants to be 
recognised as a new type of virus rather than a new rabies virus variant (minimum intra-rabies 
genotype N protein similarity 92.2% (Kissi et al. 1995)). Phylogenetic analysis alone, a powerful 
and very sensitive tool, suggests ABLV warrants classification as its own ‘type’ of virus. Both 
maximum parsimony and neighbour joining methods when used to analyse the N, P or G genes 
or amino acid sequences place both ybst-variant and pteropid-variant ABLV together, with very 
strong (>97%) bootstrap support. ABLV lies between EBL-2 and all rabies virus isolates, 
separated from each by a relatively long branch length (Gould et al. 2002; Guyatt et al. 2003; 
Nadin-Davis et al. 2002; Warrilow et al. 2002). There are however no objective criteria for defining 
a lyssavirus genotype based on phylogenetic trees, and this is problematic for Duvenhage and 
EBL-1, ABLV and rabies virus, and the new Asian bat isolates; Aravan, Khujand, Irkut and West 
Caucasian bat viruses (Botvinkin et al. 2003; Kuzmin et al. 2003). A high bootstrap value is 
supportive of a genotype, indicating the level of confidence that all sequences on that branch 
belong on that branch and not elsewhere on the tree. However, it in no way indicates that the 
level of similarity within the branch and the level of divergence between that and the adjacent 
branch are sufficiently high that the branch defines a genotype. Controversy surrounding virus 
taxonomy, both in terms of how it is expressed and what criteria should be used to group and 
differentiate related isolates is ongoing (Eberhard 2004; van Regenmortel and Mahy 2004). 
Of greater practical significance is the distinction between ABLV and rabies virus, notably 
terrestrial rabies variants and vampire bat rabies, in terms of the threat posed to human and 
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domestic/economically important animal health. Unlike rabies in vampire bats and carnivores, 
especially dogs, ABLV, like the other bat lyssaviruses, is an insignificant cause of rabies or rabies-
like disease in humans. The standard of medical care in Australia is sufficiently high that were 
ABLV a frequent cause of disease in Australians, even without prior recognition of the virus in 
bats, it would have been recognised and isolated from humans. The same is also true, to a lesser 
extent, of the level of veterinary surveillance for rabies-like disease in domestic animals. That 
ABLV has not been detected in other animals, particularly dogs and cats since the deaths of two 
women received widespread media attention, suggests that ABLV is not a frequent cause of non-
bat disease. However, it is certainly possible, even likely, that occasional cases of ABLV infection 
in humans and other animals have gone undetected given the often unspectacular clinical signs 
associated with the paralytic form, the indistinct or absent gross and histological lesions, and the 
low level of specific surveillance testing for lyssaviruses by FAT in non-bat species. The presence 
of ABLV in Australia in no way decreases the threat to human and domestic animal health posed 
by the introduction of dog-variant or dog-derived variants of ABLV present in rabies endemic 
countries. These variants have a history of establishing new enzootic cycles in dogs and related 
carnivore species (Bourhy et al. 1999; Holmes et al. 2002). Domestic dogs, the Australian dingo, 
red foxes, and carnivorous marsupials such as quolls are expected to be suitable maintenance 
hosts into which sylvatic cycles of dog- or dog-derived rabies variants could adapt and become 
established. Presuming ABLV has been present for the past 200 years, the risk to our export 
markets has not increased and the threat to Australia from imported animals and virus remains 
high. Consequently there is no justification for changing Australia’s rabies-free status. 
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♦ The prevalence of ABLV in healthy bats is <1%, is 5 to 8% among unwell bats, and is as high 
as 20 to 30% in bats with clinical signs suggesting central nervous system disease, 
particularly paresis or uncharacteristic aggression.  
9.2 General conclusions and future directions 
General conclusions 
♦ ABLV is a unique virus of the genus Lyssavirus.  
♦ Two variants of ABLV have been recognised; YBST-variant ABLV apparently prevalent in 
YBST bats and pteropid-variant ABLV prevalent in four species of Australian flying fox 
(Pteropus alecto, P. poliocephalus, P. scapulatus, and P. conspicillatus). 
♦ ABLV infection is associated with a rabies like-disease in bats and humans that like rabies 
occurs in two clinical forms, furious and paralytic. 
♦ Species, age and health status are risk factors associated with the prevalence of ABLV in 
bats. 
♦ Members of the public, wildlife carers, and veterinarians that have contact with unwell bats 
are at moderate to high risk of exposure to ABLV.  
♦ Histories of bites from uncharacteristically aggressive bats in both human cases of ABLV 
infection, a history of direct contact with an ABLV-positive bat in a bat case of ABLV (ABLV-
73), the high virulence of inocula prepared from the salivary glands in bats, and 
demonstration of ABLV RNA in the saliva of experimentally infected bats support transfer of 
saliva in a bite site/other lesion by infected bats as a mode of transmission for ABLV. 
♦ The cross-reactive rabies-RFFIT is not sufficiently sensitive for the detection of natural ABLV 
immunity in bats. 
♦ The serological response in captive flying foxes to vaccination with a commercial rabies 
vaccine (Nobivac) is likely to confer cross-protection against ABLV challenge. 
Future directions 
♦ While transmission by bites is probably a mode of ABLV transmission, it is unclear to what 
extent this and/or other modes of transmission are important in the maintenance of ABLV in 
bats. Further research into modes of natural ABL transmission is indicated.  
♦ While it is clear that ABLV infection is common in Black, Grey-headed, and Little Red flying 
foxes, and significantly less common in Spectacled flying foxes, it unclear whether one or all 
of these species is responsible for maintenance of ABLV infection. Further research into the 
epidemiological role of each species is indicated. 
♦ Development and standardisation of ABLV-RFFITs in Australia, particularly for pteropid 
variant ABLV, but also YBST-variant ABLV, is required if meaningful interpretations of bat 
immune responses to natural and experimental exposure to ABLV are to be made. This 
should preferably involve development of the test in a cell line not subject to the cytotoxic 
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effects of bat serum, or identification and ‘treatment’ of the cause of this toxic effect on BHK 
and neuroblastoma cells. 
♦ The cross-protective effect of rabies vaccination in bats against ABLV challenge needs to be 
established by post-vaccination challenge experiments. The duration of this effect and the 
effectiveness of immunity in different age classes of bats should be established if vaccination 
of captive bats is to be used to reduce the risk of infection in captive bats and the risk of 
exposure to ABLV in the humans that care for them. 
♦ Detection of ‘rabies virus’ in fruit bats in India and Thailand, extension of the range of Black 
flying foxes into islands north of Australia (Craig Smith and Hume Field, unpublished data by 
satellite tracking), and the detection of serum with neutralising activity for rabies virus and 
ABLV (Arguin et al. 2002) suggest ABLV and/or another lyssavirus is present in Asia. 
Targeted surveillance of sick bats in Asia, particularly those with signs of paresis or 
aggression is indicated.  
♦ Development of a suitable means of vaccine delivery is necessary if control programs for bat 
lyssavirus such as ABLV are to be implemented. 
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Appendix 1 Map: DPI regions and centres of Queensland 
Figure A1-1 Map of Queensland: Department of Primary Industries Regions and Centres 
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Appendix 2 Rapid fluorescent focus inhibition test  
The rapid fluorescent focus inhibition test (RFFIT) is an in vitro assay for neutralizing antibodies to 
rabies virus. The test is essentially a 24 or 48 hour serum neutralization test that uses 
immunofluorescent staining to detect viral growth. In Australia all lyssaviruses other than ABLV, 
which includes all Genotype 1 rabies variants, are classified as PC3 Exotic animal viruses 
(AS/NZS 2243.3:1995) and so can only be used at the AAHL, precluding the performance of this 
test at the ARI. Unless otherwise specified, all RFFITs referred to in this thesis were performed by 
Ross Lunt and Kim Newberry of the AAHL Rabies Laboratory. The RFFIT can be adapted for use 
with any of the lyssaviruses. For the purposes of this thesis the various RFFITs referred to are: 
♦ 
♦ 
♦ 
♦ 
rabies-RFFIT  RFFIT using genotype 1 rabies virus (CVS-11), synonym CVS-RFFIT  
modified rabies-RFFITAAHL rabies-RFFIT modified for bat plasma to reduce toxic effects of 
bat plasma on BHK cells at AHHL 
pt-ABLV-RFFIT  RFFIT using pteropid-variant ABLV 
ybst-ABLV-RFFIT RFFIT using Yellow-bellied sheathtail bat-variant ABLV 
 
Rabies-RFFIT at AAHL 
Within the AHHL all lyssaviruses are classified as Biosafety Level 3Z (PC3 Zoonotic).  
The test 
♦ The challenge virus is rabies challenge virus standard (CVS–11). 
♦ BHK 21 BVT vaccine strain cells were used to propagate and grow stock quantities of virus, 
and in the rabies-RFFIT assays.  
♦ The tests were conducted in Lab-Tek 8-Well Chamber Slides (Permanox). 
♦ Plasma samples heat inactivated at 56 °C for 30 minutes to inactivate complement. 
♦ Each test sample is normally screened at final dilutions (after the addition of virus) of 1:20 and 
1:200, and the 2 IU/mL WHO international standard serum is used at dilutions of 1:8, 1:16, 
1:32, and 1:64. For endpoint titration of test sera, further test sera dilutions may be required. 
CVS–11 and plasma samples are diluted in Basal Medium Eagle (BME, Gibco) with 5% TPB, 
hepes, glutamine, pen/strep and Fungizone. 
100µL of diluted plasma and 100µL of diluted CVS–11 containing 50 50% Fluorescing Focus 
Doses (i.e. 50 FFD50/0.1mL) are added to each well and incubated at 35°C in 3.5% CO2 for 
90 minutes. 
Healthy BHK vaccine cells that had been passed 2 days earlier are prepared as a suspension 
containing 0.5 × 106 cells/mL in BME - 5% TPB with 10% heat inactivated foetal calf serum, 
and treated with 1µL/mL of cells of 1% DEAE dextran (final concentration 10µg/mL). 
200µL of treated cells (100,000 cells) are added to each well and incubated at 35°C in 3.5% 
CO2 for 24 hours.  
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♦ After incubation, culture medium is removed and discarded and wells washed with 200-400µL 
of PBS with Mg and Ca, fixed with acetone, air dried, and stained for rabies virus with a 1:100 
dilution of Centocor anti-rabies monoclonal FITC conjugate containing Evans Blue 
(counterstain) at 35°C in 3.5% CO2 for 30 minutes. Slides are cover-slipped with glycerol 
immersion fluid and read under low power (20×) magnification lens by epifluorescence.  
♦ Twenty low-power microscopic fields are examined per well and the number of fields 
containing fluorescent cells recorded. Wells that show poor cell coverage are noted, poor cell 
growth being attributed to toxic effects of the test plasma. Sera were considered negative if 20 
of 20 low power fields contained fluorescent foci at a dilution of 1:20.  
♦ Endpoint titres were calculated in international units per mL (IU/mL) by using the calculated 
50% endpoint dilutions (titres) of the test plasma with that of the 2 IU/mL WHO international 
standard as follows:  
 Test plasma (IU/mL) = 2 x test plasma 50% endpoint titre 
        2 IU/mL International standard 50% endpoint titre 
Cell and virus controls 
A control virus back-titration is run for each test that comprises two wells each with 50, 5 and 0.5 
FFD of CVS-11 and diluent (no plasma), and two wells containing diluent only (no virus and no 
plasma) during the initial serum neutralization phase. The wells containing CVS-11 indicate the 
ability of the virus to grow in the absence of plasma. The diluent only wells indicate the capacity 
for growth of the BKH cells in the absence of virus and plasma. Only when the virus growth and 
cell growth in these controls are sufficient, are the results from test wells recorded.  
 
Quality assurance 
The quality of the rabies-RFFIT at AAHL is monitored by  
♦ Progressive monitoring Assay performance is monitored by progressive monitoring of the 
cell and virus control titres and by plotting the titre of the international standard control serum. 
♦ External proficiency testing AAHL participates in a program of external proficiency testing of 
the RFFIT by the UK Pet Travel Scheme. 
 
Additional notes on the rabies-RFFIT at AAHL 
The 2 IU/mL WHO international standard was the operating standard for the AAHL rabies RFFIT 
until May 2001, at which time it was replaced with the 0.5 IU/mL OIE international standard. The 
WHO standard remains a valid and recognized standard. The vast majority of tests performed by 
AAHL for this research were done before May 2001, using the WHO standard. The CVS rabies 
virus was obtained in 1986 from the Commonwealth Serum Laboratories (Melbourne, Australia) 
and has been determined to be antigenically indistinguishable from CVS-31. The designation of 
this virus as CVS-11 in prior records does not appear to have any recorded basis. The virus has 
been passaged once in mice and five times in BHK cells at AAHL. 
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Bat plasma modification of rabies-RFFIT at AAHL (modified rabies-RFFITAAHL) 
Samples from bats were collected as plasma, through the use of heparinized syringes, because 
the small size of bat peripheral blood vessels meant that sample collection was frequently slow 
enough to cause blood to clot in plain syringes before acquiring adequate volumes. It became 
obvious early in the use of the rabies-RFFIT at AAHL, that flying fox plasma often had a strong 
toxic effect on the BHK cells. The basis of this toxicity remains unclear. It may be related to the 
variable quantities of heparin in the samples, although heparinized samples are usually 
considered suitable for other neutralization based tests (Ross Lunt, AAHL pers comm.). It is 
therefore presumed that the toxic effect is due to a specific interaction between the cells used and 
some unknown component of the bat plasma. Using the standard RFFIT protocol cell growth was 
often so poor the test could not be read at low plasma dilutions (e.g. 1:20) reducing the sensitivity 
and reliability of the test. The toxic effect appeared to be random within batches of plasma 
submitted and there was no obvious correlation with method of sample collection, preparation, or 
storage. To reduce these toxic effects, the standard rabies-RFFIT protocol was modified to reduce 
exposure of the BHK cells to flying fox plasma by discarding the virus/plasma/culture medium 
supernatant 90 minutes after addition of the treated cells and completing the 24 hour cell 
incubation with replacement supernatant. The relatively short virus/plasma/cell incubation was 
sufficient to allow adequate adherence of the BHK cells to the wells and for un-neutralized virus to 
infect the cells. The modified cell, virus and international standard controls continued to perform 
within acceptable parameters, and the incidence and severity of cell toxicity was reduced. 
Occasional individual bat sera still had persistent toxic effects on cells.  
pt-ABLV-RFFIT and ybst-ABLV-RFFIT at AAHL 
Variations on the rabies-RFFIT using two isolates of ABLV were used for research purposes only. 
The pt-ABLV-RFFIT at AAHL uses an isolate of ABLV from a pteropid bat, (AAHL SAN 96-0648), 
a juvenile female Black flying fox found under a tree at Ballina (Fraser et al. 1996). The virus 
growth of the pt-ABLV isolate is comparatively poor despite extending the cell incubation time 
from 24 to 48 hours and back titration controls of this isolate indicate 48 hour viral growth is below 
that which would be acceptable for the rabies-RFFIT. Nevertheless, virus growth is sufficient to 
differentiate sera that inhibit/ neutralize virus. Results for each well were recorded as either none 
(0), some (+), moderate (++) or high (+++) numbers of fluorescent cells per well rather than by 
counting the number of low-power microscopic fields containing fluorescent cells.  
The ybst-ABLV-RFFIT uses an isolate of from the first human case of ABLV (SAN 96-1256) that 
was characterised as being YBST-variant ABLV (Gould et al. 2002). This ABLV isolate is more 
vigorous and performs better in the assay, but still does not meet the virus back titration 
standards.  
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Rabies-RFFIT and pt-ABLV-RFFIT at CDC  
Sera were sent to Charles Rupprecht of the Rabies Laboratory at the Centers for Disease Control 
and Prevention in Atlanta, Georgia, USA for testing in their rabies-RFFIT and independently 
developed pteropid-variant ABLV-RFFIT. 
The CDC rabies-RFFIT is very similar to that used at the AAHL, also using CVS-11 as the 
challenge virus as described in (Arguin et al. 2002). Differences include: 
♦ Use of 75,000 murine neuroblastoma (MNA) cells/well rather than BHK cells 
♦ Growth of MNA cells, and dilution of viruses and bat plasma in Eagle minimum essential 
medium containing 10% foetal calf serum and antibiotics (Smith et al. 1996) 
Use of Lab-Tek 8-well glass slides with covers (Nalgen Nunc International, Naperville, IL) 
rather than plastic chamber slides. 
♦ 
♦ 100 infectious units of CVS-11 per well, rather than 50 FFD50. 
♦ Incubation of the MNA cells with the virus/ plasma/ culture medium for 20 hours (CVS) or 40 
hours (pt-ABLV). 
♦ Sera were considered negative if 20 of 20 microscope fields contained fluorescent foci at a 
dilution of 1:5. For positive sera, the 50% endpoint titre was calculated using Reed-Muench 
values (Reed and Muench 1938).  
Sera were screened at dilutions of 1:5 and 1:25, and when necessary retested at higher dilutions 
to calculate the endpoint dilution titres. Standard immune globulin (HRIG) diluted to contain 2 
IU/mL anti-rabies antibodies was used as a positive control. The standard reference serum 
dilution of 1:90 ≈ 1.0 IU/mL.  
The CDC pt-ABLV-RFFIT uses isolate sm4476, first isolated from the second human case 
(Mackay 1998), subsequently characterised as pteropid-variant ABLV (Warrilow et al. 2002), and 
forwarded to CDC by QHSS (Charles Rupprecht, CDC, and Ina Smith, QHSS, pers. comm.).   
The CDC also has a ybst-ABLV-RFFIT that uses isolate sm4068, first isolated from the first 
human case (Rockhampton 1996, AAHL SAN 95-1256), subsequently characterised as YBST-
variant ABLV (Gould et al. 2002), and forwarded to CDC by AAHL (Charles Rupprecht , CDC pers 
comm.). This test was not used due to insufficient plasma volumes.   
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Quantitative real-time PCR: TaqMan Appendix 3 
 
The TaqMan assay (Perkin Elmer Applied Biosystems) is a PCR-based molecular genetic assay 
that amplifies target regions of DNA that is detected as a fluorescent signal produced as a result 
of simultaneous cleavage of a fluorogenic probe.  
The probe, a 25 to 35 mer oligonucleotide that is labelled with a fluorescent reporter (6-carboxy-
fluorescein, FAM) and quencher dye (6-carboxy-tetramethyl-rhodamine, TAMRA), is added to the 
PCR cocktail containing forward and reverse primers, and anneals between these primers. The 
quencher dye reduces emission intensity of the reporter dye when the probe is intact and 
phosphorylation of the ‘3 end of the probe prevents probe extension during amplification. The 
assay utilises the 5’-3’ endonuclease activity of AmplTaqGold DNA polymerase to cleave the 
probe, during primer extension. Cleavage of the probe releases the reporter dye from the activity 
of the quencher. With successive PCR cycles there is both exponential amplification of PCR 
product and cleavage of the probe, resulting in increased fluorescence intensity that is detected 
and displayed in real time on the ABI Prism 7700 sequence detection system (PE, Applied 
Biosystems, USA).  
Figure A3-1 Principles of the TaqMan Assay 
Adapted from TaqMan One-Step RT-PCR Master Mix Reagents Kit Protocol, Applied 
Biosystems. 
 
Polymerization      R = reporter 
       Forward primer         Probe           Q = quencher 
       3’P 
  3’        5’ 
  5’        3’  
        
        
  3
  5
  Reverse Primer 
R Q
 
Strand Displacement 
 
        3’P 
’        5
’        3
’ 
’ 
R
Q
           
 
 
Cleavage 
   
        3’P 
  3’        5’ 
  5’        3’ 
R
Q
 
Appendix 3 
 325
The increase in fluorescence signal is detected only if the target sequence is complementary to 
the probe and is amplified during PCR. Because of these requirements, non-specific amplification 
is not detected. 
The change in fluorescence that occurs during PCR amplification is plotted by the sequence 
detection software while the PCR reaction is under way, hence the term “real-time PCR”. The 
threshold cycle value (CT) is the PCR cycle number at which a statistically significant increase in 
the normalized reporter emission ( ∆Rn) is first detected (see Figure A3-2). The CT value is 
predictive of the quantity of target genome initially present, hence the term “quantitative PCR”.  
Figure A3-2 Example of plotted output of TaqMan assay fluorescence detection 
The output below shows the results for five samples (see designations D4 to E8 in 
‘Samples’ window), three of which are positive (D4, E7 and E8). The fluorescent signals of 
the three positive samples cross the significant (positive) threshold after 32.0, 17.4, and 
15.9 amplification cycles; as illustrated in the graph and indicated in the ‘Threshold Cycle 
Calculation’ window. Other samples that failed to cross the threshold have a CT value of 40 
and are negative. The threshold cycle value (CT) reflects the amount of template RNA or 
DNA in the original sample, with samples initially containing higher quantities of RNA/DNA 
crossing the threshold after fewer cycles. In this example, sample E8 had a low CT  value 
(15.9) indicating a large amount of target template in the original sample, whereas sample 
D4 had a high CT  value (32.0) indicating only a small amount of template in the sample.  
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As lyssaviruses are -ssRNA viruses, a One-Step RT-PCR version of the TaqMan assay (Applied 
Biosystems) allows for reverse transcription as well as PCR in a single buffer system using total 
RNA. The TaqMan assays referred to in this thesis were developed and performed by Ina Smith, 
Greg Smith and staff of the QHSS (Smith et al. 2002). The ABLV specific primers and probes 
used are shown in Table A3-1. 
Table A3-1 Primers and probes for pt-ABLV and ybst-ABLV TaqMan assays 
Primer/Probe Sequence 
pt-ABLV forward primer  
(LYSF-FF) 
5’ 175GGA ATG AAT GCT GCA AAG CTG195 3’ 
ybst-ABLV forward primer  
(LYSF-YB) 
5’ 180 GAA CGC CGC GAA GTT GG195 3’ 
common reverse primer for 
pt-ABLV and ybst ABLV (LYSR) 
5’ 256GGC AGA YCC CCT CAA ATA ACT C235 3’ 
pt-ABLV probe       (FF-FAM) 5’ 6FAM-197ACC CCG ATG ATG TAT GTT CTT ACT TAG CTG CAG229-TAMRA 3’ 
ybst-ABLV probe   (YB-FAM) 5’ 6FAM-200CGG ACG ATG TTT GCT CCT ACC TAG CTG C227-TAMRA 3’ 
Sequence numbers indicate corresponding nucleotide base position in the lyssavirus N protein coding 
sequence, where 1 = A of ATG start codon. 
 
Advantages of the TaqMan PCR assay over other detection methods include: 
♦ Simple and quick allowing rapid diagnosis (3-4 hours, similar to fluorescent antibody test, 
same day results). 
♦ Highly sensitive as relatively low levels of dye fluorescence can be detected compared to 
those required for gel electrophoresis. Sensitivity comparable to nested RT-PCR assays. 
♦ Highly specific as a result of requiring adequate annealing of not only the two primers (43 mer 
pt-ABLV or 39 mer ybst-ABLV) but also the probe between them (33 mer pt-ABLV or 28 mer 
ybst-ABLV). This high specificity has been utilized to develop pt-ABLV and ybst-ABLV specific 
assays, but limits its use where the sequence of the target genome is unknown or has 
changed. 
♦ Greatly reduced risk of contamination as a result of the one-step, closed tube, single buffer 
system, particularly when compared to nested or hemi-nested PCR and gel electrophoresis.  
♦ Large numbers of samples (up to 96) can be done simultaneously. 
 
Appendix 3 
 Appendix 4 Non-bat submissions for ABLV testing 
Table A -  Non-bat animal submissions for ABLV-testing June 1996 to April 2002 (n=27) 4 1
All ABLV-Negative by FAT 
NR not recorded 
Rx treatment 
Dx  diagnosis 
PME post-mortem examination 
Accession 
number Month/Year Status 
Genus. species 
(common name) Sex/Age 
Health 
status 
Contact 
status Comments 
97-138340 April 1997 Domestic Canis familiaris 
(Labrador dog) Male/NR CNS None  Sudden change in behaviour, previously friendly/good with children, became highly aggressive, “manic’” foaming at mouth. 
97-150074 June 1997 Domestic Canis familiaris 
(Rottweiler dog) Male/Adult CNS None  Dog missing several days and found on island in middle of creek. 2 days later sudden onset of, twitching, constricted pupils, died overnight. Cerebral 
vasculitis, suggested Toxoplasma or Neospora sp. 
98-157960 July 1998 Domestic Canis familiaris 
(Australian Terrier dog) Male/Adult CNS Human Abnormal aggression, bit 2 people. Wandering aimlessly, ataxic, disoriented, going to water but not drinking, killed. As and Pb negative. Mild vacuolation of 
cerebral white matter, congenital status spongiosis. 
98-174714-1 Sept 1998 Domestic Canis familiaris 
(Miniature Poodle dog) Male/Adult Normal None  
98-174714-2 Sept 1998 Domestic Canis familiaris 
(Miniature Poodle dog) Male/Adult Normal None  
2 companion miniature poodles in a back yard in which an ABLV-positive flying 
fox was found stuck in fence (Case no. ABLV-46). Dogs had access to and 
‘sniffed’ bat, 1 dog thought to have bitten bat about head. Owner requested 
euthanasia of both dogs. 
96-204224 Dec 1996 Domestic Felis catus 
(domestic cat) Male/Adult CNS None  Change in behaviour, violent seizures, biting body and cage, and abnormal posture, for  2 ½ days, killed. 
97-151174 June 1997 Domestic Felis catus 
(Burman cat) Male/Adult CNS Human Dribbling saliva, frothing at mouth, eating, Rx antibiotics. 2 days later aggressive, growling, barking, circling, hydrophobic, then paralysis, incontinent, 
spasms, killed. Malacia and encephalitis of both grey and white matter with 
intralesional organisms consistent with Cryptococcus neoformans. 
97-186746 Oct 1997 Domestic Felis catus 
(domestic shorthair cat) Male/NR CNS Human 1-2 week illness, hind and forelimb paresis/paralysis, erratic behaviour.  PME: 2 cm fungal granuloma in right rostral cerebrum with coning of the 
cerebellum. Dx phaeohyphomycosis due to Xylohypa bantianum. 
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Accession 
number Month/Year Status 
Genus. species 
(common name) Sex/Age 
Health 
status 
Contact 
status Comments 
97-50290 Oct 1997 Domestic Felis catus 
(domestic cat) Male/Juv  CNS Human  3 day history of progressive neurological signs. Initially protruding nictitating membranes, slight depression, went “berserk” when restrained, “exhausted” 
with froth in mouth when released. Next day, less mobile, “jumpy” and hyper-
responsive to movements and noise, protruding tongue and dilated pupils. 
Third day, paralysis of tongue, recumbent, able to move head in response to 
stimuli, killed. No diagnosis following haematology, biochemistry, 
bacteriological and mycology cultures of brain and histological examination of 
brain and other tissues. 
99-100175 Jan 1999 Domestic Felis catus 
(Persian cat) F/Adult CNS Human 4 week history of ataxia and bumping into things, though apparently not blind. 1 week history of reluctance to eat, difficulty swallowing. Became unable to stand 
and constantly growling, killed. Some months earlier cat had been found in yard 
next to a bat that crawled across the ground and up a tree, bat gone next day 
(bat not tested). 
97-43846 June 1997 Domestic Equine caballus 
(Thoroughbred horse) Male/Adult 
99-101936 
98-179723-3
97-147033 
CNS None Grinding teeth, generalized ataxia, bright, alert, eating. PME: unilateral focal 
haemorrhages in lumbosacral, posterior and mid-thoracic spinal cord grey 
matter, non-suppurative encephalomyelitis, possibly an arbovirus. 
Jan 1999 Domestic Equine caballus  
(Stockhorse) F/Adult CNS Human Acute onset apparent blindness, circling, head pressing, muscle tremors, frothing at mouth, and photosensitisation (no jaundice) worsening to mania and 
biting of legs when sedated with xylazine and acepromazine, killed. History of 
chronic lantana/weed ingestion, suspect hepatoencephalopathy. 
98-179723-1 Oct 1998 Domestic Mustela putorius furo (ferret) Male/NR Normal None  
98-179723-2 
 
Oct 1998 Domestic Mustela putorius furo (ferret) Male/NR Normal None  
Oct 1998 Domestic Mustela putorius furo (ferret) F/NR Normal None  
3 ferrets seized and destroyed as illegal pets (Qld) by Department of Natural 
Resources. Vet inspection found no clinical abnormalities, killed. Origin of 
ferrets in doubt, possible illegal import from rabies-endemic country, hence 
lyssa-FAT. 
97-116464 Feb 1997 Wild Pseudocheirus peregrinus 
(Ringtail possum) F/Juv CNS None Rescued from power lines, unable to balance, fit-like episodes of waving paws and jumping about, died overnight. 
May 1997 Wild Pseudocheirus peregrinus 
(Ringtail possum) Male/NR CNS None Fell from tree, unable to use hind limbs, positive withdrawal reflex, no voluntary movement, deteriorated overnight, cold, disoriented, killed. PME revealed 
spinal fracture T7-T8. 
97-46655 July 1997 Wild  Possum NR CNS None Salivating, vague neurological signs, two in-contact possums died in past week. 
PME: one lung partly collapsed, focal interstitial pneumonia and non-
suppurative epicarditis. 
 
 Accession 
number Month/Year Status 
Genus. species 
(common name) Sex/Age 
Health 
status 
Contact 
status Comments 
98-199790 Dec 1998 Wild Pseudocheirus peregrinus 
(Ringtail possum) F/Adult CNS None  Fell out of tree. Hind limb paralysis, head arched back, nystagmus. 
99-187301 Oct 1999 Wild Pseudocheirus peregrinus  
(Ringtail possum) F/Adult CNS None  
   
Wild 
 
Found recumbent in yard with dead joey in pouch. No external injuries, RX 
antibiotics and fluids. Next day cyanotic, frothy salivation, twitching of face and 
ears, RX atropine and dexamethasone, died 2 hours later. DX Neuro-
angiostrongylosis due to Angiostrongylus cantonensis (Rat lung worms 
recovered from fresh brain). 
2000-132656 April 2000 Wild Trichosurus vulpecula 
(Brushtail possum) F/Juv CNS None  Acute onset CNS signs in previously healthy hand-reared possum. Died within 48 hours. 
2001-198515 Oct 2001 Wild Pseudocheirus peregrinus 
(Ringtail possum) F/Adult CNS None  Found on ground, salivating, in lateral recumbency with periods of frantic behaviour, biting cage bars and towel. 
97-183992 Aug 1997 Wild Vulpes vulpes 
(Red fox) 
Male/Juv Non-CNS None 3-4 wk old orphan with scarcoptic mange and seborrheic dermatitis, depressed, 
killed. 
97-191481 Oct 1997 Wild Vulpes vulpes 
(Red fox) NR Non-CNS None  Found in extremis with respiratory distress near railway, suspected poisoning. Mild heartworm disease (Dirofilaria immitis) and mild segmental nephropathy 
considered incidental. Stomach contents negative for 1080.  
97-201616 Nov 1997 Vulpes vulpes 
(Red fox) Male/Juv Non-CNS None  Found near road with fractured hind leg. 
 
97-117595 Feb 1997 Captive 
colony Sarcophilus harrissi (Tasmanian devil) F/Adult CNS None  Captive > 6 yrs. Sudden onset ‘rabid’ behaviour, furious and fixative biting inanimate objects, hind limb paresis, progressed to coma, died.  
98-108116 Feb 1998 Captive 
colony Macaca sp. (Macaque monkey) Male/Adult CNS None Tethered on grassy area. Became drowsy and almost drunk/’high’. Rx fluids for 2 days, still not himself, died during transport to 2nd vet. PME Acute necrotising 
enteritis and acute suppurative (possibly aspiration) pneumonia with peracute 
septicaemia. 
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Appendix 5 Case details of 74 ABLV-postive bat submissions 
Table A -  Case details of 74 ABLV-positive bat submissions, Queensland June 1996 to March 2002 5 1
Key 
Case No.  Positive cases listed in the order in which bats died, not the order in which they were submitted, as some bats were not submitted until 4 or 6 months later. 
DPI regions   SEQ = South East Queensland, Central = Central Queensland, North = North Queensland, West = West Queensland, see map, Appendix 1. 
Health status  CNS = unwell with signs suggesting CNS involvement, Non-CNS = unwell without signs suggesting CNS involvement, as defined in Materials and methods, Chapter 2. 
Contact status  None = no reported contact with animals or humans, Animal = reported to have had contact with another animal, Human = reported to have bitten or scratched human/s, 
Dual = reported contact with humans and animals, as defined in Materials and methods, Chapter 2 
NR = not recorded, F = Female, M = Male, A = Adult, Juv = Juvenile, PME = Post-mortem examination, NVL = No visible lesions, NC = nutritional condition 
 
Case No. 
Laboratory 
accession 
number 
Month/ Year 
died 
DPI region/ Location 
found Species/ Sex/Age
Health / Contact 
status 
Days in 
care Summary of history, post-mortem examination and other comments 
ABLV-1 96-198384 Aug 1996 SEQ / Mt Coolum YBST / NR Non-CNS / None 8 Found sick on ground, would not eat or drink, died 8 days later Note: frozen until 
submitted 4 months later. 
ABLV-2 North / Townsville 
 
 
ABLV-5 
 
 
 
 
 SEQ / Pialba
96-48186 Sept 1996 Little Red / NR NR / None NR Records held at regional DPI lab. could not be found. 
ABLV-3 96-168934 Sept 1996 SEQ / Robina Black / F/A Non-CNS / None < 1 Found on ground “sick”, put back in tree, fell down, put in box and hung briefly, very 
weak, drank a lot, then choking, became unable to hang with laboured breathing. Dead 
on arrival to vet. PME: Pregnant (foetus not tested). 
ABLV-4 96-185461 Nov 1996 SEQ / Tally Valley Black / M/A CNS / Animal < 1 Hanging low in tree all day, tooth through right lip, killed. May have bitten or scratched a 
dog, as dog had blood on nose. 
96-33821 Nov 1996 South / Murphy's Creek YBST / F/A Non-CNS / None < 1 Found alive on ground in cleared bushland. Aborted still born full term foetus in box 
during transport, killed. 
ABLV-6 96-199751 Dec 1996 SEQ / Bald Hills Black / F/A CNS / None < 1 Seen hanging low in tree (~1m from ground), had fallen to ground when rescued, 
gravely ill, tremors and hind limb paralysis, died within an hour, appeared to have bump 
on head, suspected head injury. PME: NVL. 
ABLV-7 97-109143 Jan 1997 SEQ / Woodend Black / M/NR CNS / None < 1 Found on ground, “nervous signs”. 
ABLV-8 97-109700 Jan 1997 SEQ / Woodend Black / F/A CNS / None < 1 Found on ground debilitated, uncoordinated, hypersalivation. Rabies-RFFIT< 0.5 IU/mL. 
ABLV-9 97-40585 Feb 1997 West / Mt. Isa 
 
Black / NR CNS / None NR Had difficulty (paresis) using legs, killed. 
ABLV-10 97-114442 Feb 1997 Little Red / F/A CNS / None 3 Found on ropes of children school play area, “fitting” shaking, tremors, docile, not 
eating, killed. Brain FAT only weakly positive at ARI and AAHL, positive by 
immunoperoxidase test on paraffin tissues and virus isolation at AAHL. PME: pregnant 
(foetus not tested). 
 
 Case No. 
Laboratory 
accession 
number 
Month/ Year 
died 
DPI region/ Location 
found Species/ Sex/Age
Health / Contact 
status 
Days in 
care Summary of history, post-mortem examination and other comments 
ABLV-11 97-116174 Feb 1997 SEQ / Woodend Little Red / M/A Non-CNS / None NR Suspected electric shock or electrocution? 
 
ABLV-12 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
97-116375 Feb 1997 SEQ / Kurwongbah YBST / NR Non-CNS / None NR Ill bat found, taken to vet, died 2 to 3 days later. 
ABLV-13 97-117003 Feb 1997 SEQ / Hervey Bay Little Red / F/NR CNS / None 1 Hanging in tree on wire, seen to fly into path of oncoming car, rescued from verge. Able 
to hang, vocalizing, tremors, aggressive, would not calm down when placed in covered 
cage, persistently agitated/distressed, killed next morning PME: well nourished, 
haemothorax with bruising of head, thorax, lung, and olfactory lobe of brain. 
ABLV-14 97-121016 Mar 1997 SEQ / Sandgate Little Red / M/A CNS / None NR Paralysed legs. 
ABLV-15 97-121024 Mar 1997 SEQ / Ipswich Little Red / F/A NR / None NR No history supplied, no submitter identified. 
ABLV-16 97-122333 Mar 1997 SEQ / Toan Toan Ck Little Red / M/NR Non-CNS / None < 1 Ill, died. PME: lean, NVL. 
ABLV-17 97-122735 Mar 1997 SEQ / Hervey Bay Little Red / M/A Non-CNS / None < 1 Found in canal, weak, died soon after. PME: Fat, moderate haemoperitoneum. 
ABLV-18 97-125092 Mar 1997 SEQ / Nth Tamburine Black / F/A CNS / None < 1 Found under tree bright and alert but weak and unable to move, paralysed, killed. PME: 
distended haemorrhagic urinary bladder. Rabies-RFFIT< 0.5 IU/mL. 
ABLV-19 97-127470 Mar 1997 SEQ / Ipswich Little Red / M/A Non-CNS / None 0 Found dead under fig tree. 
ABLV-20 97-130104 April 1997 SEQ / Hervey Bay Little Red / F/A Non-CNS / None < 1 Found in weak state, died overnight. PME: poor body condition. 
ABLV-21 97-72873 April 1997 Central / Rockhampton Black / NR Non-CNS / None NR Original records at regional laboratory could not be found. 
ABLV-22 97-143816 May 1997 SEQ / Nambour YBST / F/A CNS / None 1 Presented to vet cold and depressed with graze to chin, initially ate well and appeared 
to improve, later biting towel aimlessly. Left hanging overnight. When touched, fell and 
was unable to right, depressed, unable to feed, didn’t swallow food put in mouth, 
became less responsive, purposeless movement, killed. 
ABLV-23 97-152661 June 1997 SEQ / Yeronga Black / M/A Non-CNS /Animal < 1 Found moribund in backyard, dog ‘sniffing around’ but no observed contact. Killed. 
Rabies-RFFIT1.5 IU/mL. 
ABLV-24 97-155574 June 1997 SEQ / Woodend Black / M/A CNS / None NR Found on ground, apparently behaving abnormally, depressed with head tremor, killed. 
Rabies-RFFIT< 0.5 IU/mL. 
ABLV-25 97-45315 July 1997 North / Kuranda Spectacled / NR CNS / Human 1 Bat bit initial rescuer, transferred to carer in cage. Bat very aggressive, vocalising, 
trying to bite if approached, able to hang, ravenous, next morning still “angry”, clearly 
‘ill” by the afternoon when transported to third person. On arrival hanging but not 
moving about, wings held loosely, ungroomed, glazed eyes, respiratory difficulty, died 
within half an hour.  
ABLV-26 97-176292 Aug 1997 SEQ / Indooroopilly Grey / F/A CNS / None < 1 Found on ground beside road, paralysis of legs and wings, killed. Pregnant, pup 
delivered by C-section but died. Pup brain weakly FAT-positive. 
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Case No. 
Laboratory 
accession 
number 
Month/ Year 
died 
DPI region/ Location 
found Species/ Sex/Age
Health / Contact 
status 
Days in 
care Summary of history, post-mortem examination and other comments 
ABLV-27 97-186955 Oct 1997 SEQ / Beaudesert Grey / F/A CNS /None < 1 Found on ground unable to hang, thin, refusing food, killed. Rabies-RFFIT 
< 0.5 IU/mL. 
ABLV-28 
 
 
 
 
 On back in garden “last couple of days”, taken to vet, paralysed wings and feet, killed. 
PME: good NC, food in mouth (dysphagic). Rabies-RFFIT 0.9 IU/mL. 
 
 
 
 
 
 
97-192894 SEQ / Coolamon Grey / M/A CNS / None < 1 Hanging low in tree, depressed, ‘walked’ on to a stick to be transferred to a shed, thin, 
didn’t fly, no external injuries, killed. PME: bruising to right temporal muscle and 
periosteum of cranium. Rabies-RFFIT< 0.5 IU/mL. 
ABLV-29 97-193673 Oct 1997 SEQ / Strathpine Black / M/A 
Oct 1997 
CNS / Animal < 1 Found on ground convulsing, dog with bat, died. 
97-196033 Nov 1997 SEQ / Laidley Little Red / F/A ABLV-30 CNS / Human 3 Found under tree, ascending paralysis. PME: minimal body fat. Rabies-RFFIT toxic, no 
result. 
ABLV-31 Jan 1998 SEQ / Woodend Little Red / M/A Non-CNS / None < 1 
ABLV-32 98-104881 Jan 1998 SEQ / Brisbane Black / M/Juv 
98-102890 Found moribund near colony, killed. PME: contracted patagium suggested electric 
shock. 
CNS / Human 50 Apparently normal 2-3 week old orphan rescued from low in tree, in care for 5 weeks 
then sudden aggression to cage mate, vocalizing, had spasms and was biting objects. 
By Day-3 of illness, only able to eat pulped food, appeared to improve with antibiotics 
and dexamethasone. Day-7, unable to hang, dysphagic, diaorrhea, weight loss, Day-9 
died. PME: emaciated. Note: original history provided was only that the bat was 
suspected of hurting its neck in the cage. 
98-105331 Jan 1998 ABLV-33 SEQ / Moorooka Grey / M/A CNS / None 
ABLV-34  98-40635 Feb 1998 North / Townsville Little Red / NR Non-CNS / None No visible lesions, semiconscious. 
ABLV-35 98-120582 Mar 1998 SEQ / Gumdale Little Red / F/A CNS / None 1 Found on back on ground, flaccid paralysis hind limbs, some bleeding from mouth, 
noisy respiration, unable to spit out pulp when hand fed fruit puree (dysphagic), died 
next day. PME: pregnant, food in proximal trachea (poss. asphyxiation), urinary bladder 
distended. Foetal brain FAT-negative. 
ABLV-36 98-126853 April 1998 SEQ / Sandgate CNS / None 1 Found with hind limb paralysis, killed. PME: good NC, NVL. 
ABLV-37 98-130425 April 1998 SEQ / Coorparoo Black / M/Juv CNS / None 6 Found by public, taken to RSPCA, collected by carer 36 hours later. Initially appeared 
healthy, progressive weakness, reduced consciousness, unable to swallow, reduced 
blink reflex, twitching of head and ears, ‘clamped’ teeth, died overnight 6 days after 
found. PME: moderate NC, distended urinary bladder. 
ABLV-38 98-137634 SEQ / Surfers Paradise Black / M/A CNS / None < 1 Found in carpark on ground, quiet with paresis of all limbs, withdrawal reflexes absent 
in all four limbs, killed. PME: NVL. 
ABLV-39 98-140331 May 1998 Central / Rockhampton Black / F/A Non-CNS / None 0 Found face-down under tree in backyard. Initially ears twitching, soon died. Not 
handled until dead. PME: advance autolysis. 
ABLV-40
< 1 
NR 
Little Red / M/A 
May 1998 
98-140822 May 1998 SEQ / Ipswich CNS / None Little Red / M/Juv < 1 Found in school grounds, and covered by box. Hind limb paralysis, killed. PME: lean 
NC, well muscled. 
 
 Case No. 
Laboratory 
accession 
number 
Month/ Year 
died 
DPI region/ Location 
found Species/ Sex/Age
Health / Contact 
status 
Days in 
care Summary of history, post-mortem examination and other comments 
ABLV-41 98-144576 June 1998 SEQ / Pt Arkwright YBST / M/A 6 Found on ground, able to lap a milk/egg mix and flap a bit. Submitted live after carer 
bitten when bat ‘slipped’ (not aggressive), killed. PME: encrusted material (food?) on 
face, multiple Argasid (soft) ticks. 
North / Townsville Black / F/A CNS / None Found on ground, very weak, gripping weakly with toes, drank fluids, chewed towel, 
sticks in mouth, eyes glazed, tremors, laboured respiration, died. Submitted for testing 
4 months later. PME: poor NC, pregnant. Foetal brain FAT-negative.  
ABLV-43 98-158731 SEQ / Woody Point Black / M/A 3
X
ABLV-44 SEQ / Clayfield Black / F/A CNS / None < 1 
ABLV-45 98-167351 Aug 1998 
Non-CNS / Human
ABLV-42 < 1 
 July 1998  Found on ground, no withdrawal right hind, withdrawal and grasping with left hind, 
excessive yawning, difficulty eating, R  fluids, vitamins, amino acids. Progressive 
deterioration, became recumbent, died. PME: dehydrated, poor NC, pale and poor 
pectoral muscle mass. 
 Aug 1998 Found on ground, generalized paresis, unable to hang or right itself, intermittent head 
tremor, unusually docile, killed. No external injuries, aged, 536 g (light). PME: poor NC, 
early pregnant. 
 SEQ / Helensvale 
 Black / M/A 
ABLV-47 Non-CNS / None
 98-182934 < 1 
 Oct 1998 Solitary bat had earlier been observed in Torrelinana tree (in blossom) near house 
during day (abnormal). Elderly woman with rockmelon went to front door, bat flew from 
behind her to land on an ornament attached to house, then flew on to woman’s head 
and bit her, then flew back to tree and ate blossom, occasionally vocalising with 
abnormally harsh voice, and remained in tree while many people arrived (abnormal) 
including wildlife carers, police, and onlookers. Experienced carer shot bat from tree. 
Woman had sustained substantial injuries to head, back and hands requiring 
hospitalization. PME: gun shot injuries.  
98-189710 July 1998 
CNS / Human 
98-165882 
Grey / F/Juv Non-CNS / None < 1 Found on ground, weak, moribund, dehydrated, no external injuries, killed. PME: poor 
NC, haemorrhage right side neck. 
98-172971 Sept 1998 SEQ / West End Non-CNS / Animal < 1 Bat found in backyard ~ noon on ground with dogs that were approaching it and may 
have bitten bat, scrambled over fence and into bush during capture ~ 7 pm. Collected 
by carer, able to hang, and lap fruit juice but weak, deteriorated overnight, killed. PME: 
very poor NC, no head or bite injuries. 
ABLV-46
98-50290 Oct 1998 North / Townsville < 1 Found unwell on grounds of native wildlife sanctuary, killed.  
Oct 1998 SEQ / Hervey Bay Little Red / M/A Seen in tree, next day in another tree, fell down, lethargic when rescued and died ~1 hr 
later. PME: poor NC, punctures and soft tissue damage right wing, other puncture 
wounds and haemorrhage of pectorals (poss cat, small dog, or other bat wounds hence 
contact status Animal). 
ABLV-49 98-183454 Central / Rockhampton Little Red / F/A CNS / Human < 1 
Little Red / NR 
ABLV-48 Non-CNS / Animal
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Case No. 
Laboratory 
accession 
number 
Month/ Year 
died Species/ Sex/Age
Health / Contact 
status 
Days in 
care Summary of history, post-mortem examination and other comments 
DPI region/ Location 
found 
ABLV-50 SEQ / Tennyson 98-184361 Oct 1998 Little Red / F/A 4 Found on ground in garden, marked weakness of one hind limb, unable to hang, 
fidgety. Day 3, some voluntary movement of both hind limbs but weak, abnormal 
positioning of wings, Day 4, moribund, CNS exam: conscious, depressed, grinding 
teeth, poor/ absent corneal, ‘sneeze’, and gag reflexes, reduced pain reflexes, 
markedly reduced or absent withdrawal reflexes and voluntary movement of all limbs. 
Killed. PME: very lean, NVL. Rabies-RFFIT< 0.5 IU/mL. 
ABLV-51 Black / F/A CNS / None < 1 
  
 
ABLV-54 
  
 
98-188455 Nov 1998 SEQ / Maryborough Bat noticed in tree at aged persons complex in morning (abnormal, ~ 3 km from nearest 
camp), flew at groundsman, who hit it to ground with broom/rake, attempted to fly at 
man again, hit again, nudged into box. Collected by carer, ravenous, kept coming 
forward in cage (abnormal), not vocalising, found hanging dead ~ 3 hours later. PME: 
bruising over right eye and left neck. 
ABLV-52 98-189702 Nov 1998 North / Townsville Little Red / M/A CNS / Animal 1 Rescued from tree, during which it descended tree towards carer (abnormal), very alert 
and vocal, vigorous attempts to bite when handled, prone to erections and ejaculated 
on self during transport. Bruising, swelling, and tooth marks on right arm (self or other 
bat bites). Wounds RX with Otoderm and bat placed with other injured bat in aviary 
~1830. 2 hours later, heard bats, had cornered and was attacking other bat, biting 
vigorously. Could not distract bat, had to separate bats manually. Bat then passive, 
almost torpid, more ejaculate noted, hung in cage corner, occasionally losing grip with 
one leg and swinging without obvious volition. Within an hour of being found fighting, 
appeared to be dying. 0530, comatose, 0700 found dead on cage floor. PME: good NC, 
punctures and cuts to head and bruising of right arm. Note: attacked companion bat 
held for observation, recovered uneventfully from original injuries, released 56 days 
later.  
ABLV-53 98-189756 Nov 1998 North / Townsville Black / F/Juv CNS / None 1 In banana tree all day, agitated and repeatedly ran forward and then away during 
rescue, hypersalivating. Remained agitated and vocal in small cage, initially no 
evidence of paralysis. Next morning, lying twitching on cage floor, died. PME: poor NC. 
99-128813 April 1999 SEQ / Bay View Black / F/Juv CNS / None < 1 Found on ground at down at caravan park, lifted with rake to hang off tow-bar. Rescued 
by carer, very lethargic, unable to hang in cage, paresis of hind limbs and wings, killed. 
PME: poor NC, dehydrated. Rabies-RFFIT< 0.2 IU/mL. 
ABLV-55 99-178735 Aug 1999 Central / Gladstone Black / F/Juv CNS / Human 1 Rescued moribund from bamboo, unable to swallow RX s/c fluids, improved. 
Responsive but uncoordinated, weak voluntary movement of limbs, very docile, dazed, 
would bite and hold cloth in mouth, saliva accumulated in throat. Died early next 
morning. PME: poor NC, dehydrated, large s/c bruise over frontal bone, fractured distal 
10th rib, multiple small punctures to back, pectorals and abdomen with s/c haemorrhage 
and minor muscle damage (small animal bites or s/c fluid administration sites). 
ABLV-56 QHSS6067 Oct 1999 Central / Rockhampton Unidentified 
Pteropus sp. / NR
Non-CNS / Human NR Neither QHSS nor referring public health unit could locate records or submitter details. 
CNS / None 
 
 Case No. 
Laboratory 
accession 
number 
Month/ Year 
died 
DPI region/ Location 
found Species/ Sex/Age
Health / Contact 
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Days in 
care Summary of history, post-mortem examination and other comments 
ABLV-57 99-204611 Dec 1999 SEQ / Dutton Park Black / F/Juv Non-CNS / None 1 Found on ground in backyard eating peaches with electrical burns to right foot and left 
wing. Initially alert with weak hind limbs but able to hang, within 4-6 hours depressed 
and unable to hang. Next morning, depressed and vocalising, killed. PME: poor NC, 
deep linear burns to ‘palm’ of right foot, and necrosis of left thumb. Rabies-RFFIT 0.2 
IU/mL. 
ABLV-58 
  
 
 
 
 
99-204785 Nov 1999 SEQ / Hervey Bay Black / F/Juv CNS / None < 1 Found ~ 1 m up tree, generalised paresis, would not eat, “fitted”, killed next morning. 
PME: good NC, NVL. Rabies-RFFIT 1.9 IU/mL. 
ABLV-59 QHSS
16992373 April 2000 SEQ / Coombabah Black / F/A CNS / None < 1 Found hanging very docile low in bush beneath Cocos palm. Could hang but not using thumbs, hanging with head extended, limp, ‘snuffly’ respiration, dull eyes, reduced 
responsiveness to surroundings, poss. unable to swallow, died o’night. PME at QHSS. 
ABLV-60 00-132366 April 2000 SEQ / Redland Bay Black / M/Juv CNS / Human 3 Seen in Cocos palm tree for 2 days, had fallen out, was put back, later rescued from 
position part way up tree. When in cage uncharacteristically aggressive, lunging at any 
movement, bit rescuer through cage wire and towel when carrying cage, ‘attacked’ 
water bowel, gabbing, chewing, and pushing it around cage. Next day, still lunging 
towards passers by, fell in cage and appeared stunned, eyes ‘wavering’ (nystagmus), 
recovered and could hang again. Transferred to second carer. Attacked water container 
again, attempted to bite carer, wings held loosely, thumbs extended (paresis), ‘nodding’ 
head, sedated with acepromazine. Day-3, depressed, not eating, when held just lay 
there. Day-4, hanging but reduced consciousness, flaccid, died ~0800. PME: moderate 
to good NC, NVL. 
ABLV-61 00-177442 June 2000 SEQ / Woodridge Grey / F/A Non-CNS / None < 1 Found on ground, taken to vet, could hang when put in cage, voluntary movement of 
wings, lethargic, died overnight. Submitted 4 months later. 
ABLV-62 00-175973 Sept 2000 SEQ / Labrador Grey / M/A CNS / None < 1 Found thin, weak and dehydrated on ground in garden nursery with corneal ulcer and 
cataract of right eye, soil in mouth, dehydrated, unable to hang, killed. Rabies-RFFIT< 
0.5 IU/mL. 
ABLV-63 00-176632 Sept 2000 Central / Gladstone Black / M/A CNS / None 1 Woman alerted to bat on ground next door by her dogs, rescued attempting to climb 
low bush using thumbs, flaccid hind limbs, appeared unafraid and very hungry, 
swallowed juice and ate fruit, licking objects, appeared alert. During night, found 
semiconscious, laboured noisy breathing, froth at mouth. Next morning, ‘not coherent’, 
respiration. improved, poking tongue in and out. Voluntary movement of wings when 
handled, killed. PME: poor to moderate NC, NVL. 
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Case No. 
Laboratory 
accession 
number 
Month/ Year 
died 
DPI region/ Location 
found Species/ Sex/Age
Health / Contact 
status 
Days in 
care Summary of history, post-mortem examination and other comments 
ABLV-64  QHSS
42178795 Oct 2000 Central / Calliope Black / F/A CNS / Dual 1 Bat noticed in tree, dead pup found below tree and discarded. Bat flew onto back of lady, husband assisted to remove with shovel, flew back to tree, then on to dog, 
scratching dog’s eye, then on to empty bird cage, also attempted to enter rear door of 
house. Next day, experienced carer climbed tree to capture, bat climbing towards him 
in ‘pugnacious’ manner, bit carer while being carried. That evening, very thirsty, eating, 
appeared disoriented, biting at things, transferred to larger cage, wandering about 
aimlessly, very responsive to surroundings, vocalising and attempting to bite at people 
through wire, appeared distressed, settled when wrapped in towel and returned to 
smaller cage. Next morning, vocalising, aggressive when approached, still biting 
objects and cage, appeared confused, killed. No episodes of paresis or dysphagia. 
PME at QHSS.  
ABLV-65 
  
 
 
 
 
00-179793 Oct 2000 SEQ / Kelvin Grove Black / M/A CNS / None 3 Rescued by 2 children who found bat on ground with older children throwing stick and 
rocks at bat. Nudged bat into school bag and took home, collected by carer. Appeared 
exhausted, initially unable to hang, hind limb paresis right worse than left. Accepted 
juice by syringe, later responded to food and ate well, moved to hang. Next day. 
Partially hanging from side of cage, yawning, accepted juice, later flaccid paresis hind 
limbs, no grip reflex, Day 3 deteriorating, Died early morning Day 4. PME: poor NC, 
urinary bladder distended. Rabies-RFFIT 0.91 IU/mL. 
ABLV-66 QHSS
42140461 Oct 2000 Central / Rockhampton Black / M/A CNS / Dual < 1 Wild bat behaving abnormally on top of captive bat colony cage, scrambling on cage, would not fly away, behaved aggressively when approached, caught in net and bit 
person. Transferred to separate large cage, hanging on side of cage, wings out, lunging 
a people, vocal and baring teeth, jumped towards carer during recapture. No obvious 
paresis, killed. PME at QHSS. See also ABLV-73. 
ABLV-67 00-189691 Oct 2000 SEQ / Logan Village Grey / M/A CNS / None < 1 Found on roof, rescued and transferred to another carer. Hind limb paresis, unable to 
hang without support, then hanging by thumbs. Later biting cage, other objects and 
himself. Would open wings and lash out with thumbs if approached. Eventually on 
bottom of cage, killed. PME: moderate NC, small amount of urine in bladder.  
ABLV-68 01-103951 Jan 2001 SEQ / Holland Park Black / M/A CNS / None < 1 Rescued hanging by thumbs and head-butting ~50 cm up base of tree with blood from 
mouth and hind limb paresis. Vocalising and banging itself on cage, appeared to be 
attacking towels and cage, unable to hang. Would not settle when left alone with cage 
covered, could be heard thrashing about violently from other room, chewing cage wires 
abnormal tongue movements, killed. PME: moderate to good NC, fractured incisor teeth 
and lacerated gums. Rabies-RFFIT< 0.5 IU/mL. 
ABLV-69 01-157670 May 2001 SEQ / Burleigh Heads Black / M/A CNS / None < 1 Found beneath fruiting fig tree at wildlife park. Calm, absent hind limb grip reflexes, 
unable to hang, no injuries, while drinking fluids from syringe bit its own tongue, rapid 
respiration, died later that morning. PME: lean NC, NVL. 
ABLV-70 01-162141 May 2001 SEQ / Hervey Bay Black / M/A CNS / None < 1 Found at base of fig tree unable to climb, listless. Later biting rungs of cage and own 
wing, aggressive when approached, not eating, drinking, hind limb paresis, purposeless 
movement of wings, during night recumbent and biting cage, dead next morning.  
 
 Case No. 
Laboratory 
accession 
number 
Month/ Year 
died 
DPI region/ Location 
found Species/ Sex/Age
Health / Contact 
status 
Days in 
care Summary of history, post-mortem examination and other comments 
ABLV-71 01-178364 July 2001 SEQ / Hervey Bay Black / M/A CNS / None 1 Found on ground covered with ants, depressed, quiet and placid, hind limb paresis, 
unable to hang, toileting on self, accepted some fluid next morning, later gasping, died. 
PME: moderate NC, blood around spinal cord at foramen magnum, congested 
meninges. 
ABLV-72  
   
 
01-190415 Sept 2001 SEQ / Noosa Black / M/A CNS / None 2 Fell from tree, unable to climb, rescued from ground outside Court House. Initially able 
to invert to urinate, next day unable to hang unaided, taken to vet, altered respiration / 
auscultation suggested pneumonia RX antibiotics and finadyne, deteriorated. Day 3 
generalised paresis, semi-conscious, killed. PME: lean NC, NVL.  
Rabies-RFFIT< 0.5 IU/mL. 
ABLV-73 QHSS
42145588 
Nov 2001 Central / Rockhampton 
              Captive colony
Grey / F/A CNS / Animal > 30 Captive colony exposed 30 days earlier to wild ABLV-positive bat on cage (ABLV-66). 
Dominant female colony bat developed abnormal behaviour, hunched and vocalising in 
cage, licking vulva, vet exam RX antibiotics and metacam (NSAID) for suspected 
urinary tract infection, during transport home, ravenous and aggressive while eating, 
‘snatching’ food, became more aggressive during afternoon, biting cage, 
hypersalivating, vocalising, had seizures followed by periods of being placid, glassy 
eyes. Could be heard during the night. Next day very ill, still hanging but semi-
comatose, weak voluntary movement, killed. PME at QHSS. 
ABLV-74 02-102994 Jan 2002 SEQ / Brisbane CBD Black / F/A CNS / None 1 Found on ground in city, paresis of 4 limbs, deteriorated and became unable to hang, 
killed. PME: poor NC, fractured frontal process of zygomatic arch. 
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Appendix 6 Case details of 100 CNS flying foxes 
Table A6-1 Case details of 100 consecutive submissions of wild Queensland flying foxes with clinical signs suggesting central nervous system disease 
  (August 1997 to July 2002) 
Key 
Case No.  Positive cases listed in the order in which bats died, not the order in which they were submitted, as some bats were not submitted until 4 or 6 months later. 
Diagnosis Where the diagnosis was ABLV, the ABLV case number is given as per Appendix 5. 
A. cantonensis Sixteen of the 18 cases of neuro-angiostrongylosis referred to here were published in (Barrett et al. 2002). The corresponding published case numbers are: CNS-7= Bat 
1, CNS-8= Bat 2, CNS-9= Bat 3, CNS-12= Bat 4, CNS-24= Bat 5, CNS-32= Bat 6, CNS-53= Bat 7, CNS-64= Bat 8, CNS-65= Bat 9, CNS-67= Bat 10, CNS-73= Bat 11, 
CNS-74= Bat 12, CNS-76= Bat 13, CNS-77= Bat 14, CNS-86= Bat 15, CNS-87= Bat 16. CNS- 97 and CNS-99 were not published. Bat 17 of the publication is an 
archival case from 1992 
DPI regions   SEQ = South East Queensland, Central = Central Queensland, North = North Queensland, West = West Queensland, see map, Appendix 1. 
Contact status  None = no reported contact with animals or humans, Animal = reported to have had contact with another animal, Human = reported to have bitten or scratched human/s, 
as defined in Materials and methods, Chapter 2 
NR = not recorded, ND = not done, F = Female, M = Male, A = Adult, Juv = Juvenile, PME = Post-mortem examination, NVL = No visible lesions, NC = nutritional condition 
H&E = Haematoxylin and eosin stained histological sections of brain +/- other organs as listed 
Recovered = Number of worms recovered by maceration of half (not whole) brain, X-ray = results of radiographs of formalin fixed spinal columns removed at post-mortem examination 
  
Pb = Liver lead levels as parts per million dry weight (ppm DW), RNA-Neg = brain negative for ABLV and other lyssavirus RNA by TaqMan and RT-PCR assay  
 
CNS 
case no. 
Diagnosis Accession
Number 
 Month 
died 
DPI 
Region
Species Sex/Age Contact 
status 
Comments 
CNS-1        ABLV-26 97-176292 8/97 SEQ Grey F/A None (see Appendix 5) 
CNS-2        
        
        
        
      
      
      
Spinal fracture 97-177844 9/97 SEQ Black F/A None Found on ground, vet exam depressed, no deep pain in hind limbs laceration of forehead. PME: pregnant, 
dislocated thoracic vertebrae fractured frontal and nasal bones with associated haemorrhage. H&E: NVL. X-
ray: (by submitting vet) luxation of 9th and 10th thoracic vertebrae. 
CNS-3 ABLV-27 97-186955 10/97 SEQ Grey F/A None (see Appendix 5) 
CNS-4 ABLV-28 97-192894 10/97 SEQ Grey M/A None (see Appendix 5) 
CNS-5 ABLV-29 97-193673 10/97 SEQ Black M/A Animal (see Appendix 5) 
CNS-6 ABLV-30 97-196033 11/97 SEQ Little Red F/A Human (see Appendix 5) 
CNS-7 A. cantonensis 97-201373 11/97 SEQ Black M/A None Found on back under mango tree, persistent hind limb paresis, passive disposition, killed 7 days later. PME: 
NVL. H&E: severe granulomatous meningoencephalitis with a worm section. No worms recovered. 
CNS-8 A. cantonensis 97-201984 11/97 SEQ Black M/A None Rescued from wire fence, paresis, poor hind limb reflexes, killed 3 days later. PME: very distended bladder, 
multiple pale foci in both kidneys. H&E: Severe granulomatous and eosinophilic meningoencephalitis with a 
worm section. 1 worm recovered. 
 
 CNS 
case no. 
Diagnosis Accession 
Number 
Month 
died 
DPI 
Region
Species Sex/Age Contact 
status 
Comments 
CNS-9 A. cantonensis  
and  
spinal fracture 
97-202152      11/97 SEQ Black M/A None Found under palm tree. Flaccid paralysis all limbs, unable to right, voluntary movement of head, pupils equal 
and constricted, no grip or placing reflexes  or pain response in feet, urinary and faecal incontinence, killed. 
PME: distended bladder and colon, retroperitoneal haemorrhage around left adrenal gland. H&E: occasional 
very small worm sections, virtually no inflammation. 11 3rd stage worm larvae recovered. X-ray: fractured 
caudal endplate of the 3rd lumbar vertebra. Pb = 0.22 ppm DW. 
CNS-10       
     
        
       
       
        
       
      
       None Hanging low in tree by thumbs, “very panicky”, hind limb paralysis, killed. PME: fractured thoracic spine, 
distended bladder. H&E: NVL. X-ray: ND. 
        
        
        
        
        
No diagnosis 97-203983 11/97 North Little Red M/Juv None Found on ground with suspected tick poisoning and two areas on head that could have been tick sites, Rx tick 
serum, died 3 days later. PME: no significant abnormalities. H&E: Bacterial colonies in brain and liver suggest 
parachute septicaemia. X-ray ND. Pb = 0.85 ppm DW. RNA-Neg. 
CNS-11 A. cantonensis 97-207876 11/97 SEQ Black M/A Human Rescued from tree on footpath, deteriorated overnight, “frothing”, head tilt, one fixed and one dilated pupil, 
killed. PME: distended urinary bladder. H&E: Occasional very small worm sections, virtually no inflammation. 7 
3rdstage worm larvae recovered. Pb = 1.05 ppm DW. 
CNS-12 Spinal trauma 97-204696 12/97 SEQ Black F/Juv None ~3 week old pup found on ground under tree with hind limb paralysis, killed. PME: extensive s/c and muscle 
haemorrhage of abdomen, dorsum, and pelvis, no fracture palpated. H&E: ND. X-ray: ND. 
CNS-13 Spinal fracture 98-100690 1/98 SEQ Grey F/A Human Found with hind limb paralysis, killed. PME: fractured ~T4-T5 thoracic spine. H&E: NVL X-ray: ND. 
CNS-14 ABLV-32 98-104881 1/98 SEQ Black M/Juv Human (see Appendix 5) 
CNS-15 ABLV-33 98-105331 1/98 SEQ Grey M/A None (see Appendix 5) 
CNS-16 Hydrocephalus 98-106021 1/98 SEQ Black M/Juv None ~ 15 week old pup found on ground, poorly developed, head tremor, unresponsive killed 8 days later. PME: 
domed skull with hydrocephalus. RNA-Neg. 
CNS-17 Hydrocephalus 98-107032 2/98 SEQ Black M/Juv Human Rescued at ~10 weeks of age, raised as orphan for 47 days, “strange” behaviour including poor feeder, 
uncoordinated, not flapping wings, biting own wing and thumbs, wide-based hanging stance, initially quite, 
then “vocal nashing or fearful screams”, bit carer, killed. PME: pronounced hydrocephalus. 
CNS-18 Spinal fracture 98-110042 2/98 SEQ Black M/A
CNS-19 No diagnosis 98-120342 3/98 North Black M/Juv None Pup found hanging low on branch with nail polish on feet claws (ex-orphan). Moribund, somnolent, then series 
of convulsions / seizures, killed. PME: pale friable liver: H&E: Fatty degeneration of liver. X-ray: ND Pb = 1.62 
ppm DW. RNA-Neg. 
CNS-20 ABLV-35 98-120582 3/98 SEQ Little Red F/A None (see Appendix 5) 
CNS-21 ABLV-36 98-126853 4/98 SEQ Little Red M/A None (see Appendix 5) 
CNS-22 No diagnosis 98-128821 4/98 SEQ Black M/Juv None Found on ground being harassed by birds with dilated pupils, killed. PME: fat, NVL. H&E: Pachymeningitis 
adjacent one optic nerve, bilateral dacryoadenitis. X-ray: ND Pb = 6.56 ppm DW. RNA-Neg. 
CNS-23 ABLV-37 98-130425 4/98 SEQ Black M/Juv None (see Appendix 5) 
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CNS 
case no. 
Diagnosis Accession 
Number 
Month 
died 
DPI 
Region
Species Sex/Age Contact 
status 
Comments 
CNS-24 A. cantonensis 98-136012      5/98 SEQ Grey M/A None Found on ground surrounded by cats, put up into tree, still there next day, rescued and kept in care for 6 days, 
no improvement, killed. PME: NVL. H&E: Severe granulomatous and eosinophilic meningitis with large worm 
sections. 16 worms recovered. 
CNS-25        
        
        
        
        
        
        
      
        
        
        
        
       
ABLV-38 98-137634 5/98 SEQ Black M/A None (see Appendix 5) 
CNS-26 Hepatopathy 98-138510 5/98 SEQ Grey F/Juv None Found on ground, weak, no improvement over 7 days, killed. PME: Multiple 0.1-1.0 cm linear to triangular pale 
green firm areas of discolouration in liver. H&E: brain-NVL, liver-coagulative necrosis indicating severe 
vascular injury. X-ray: oblique fracture of vertebral body of L5 with dorsal and left lateral displacement. Pb = 
1.69 ppm DW. RNA-Neg. 
CNS-27 No diagnosis 98-140095 5/98 SEQ Grey M/A None Hind limb paralysis and respiratory distress, killed 2 days later. PME: no spinal fracture detected. H&E: NVL. 
X-rays: NVL Pb = 1.6 ppm DW. RNA-Neg. 
CNS-28 ABLV-40 98-140822 5/98 SEQ Little Red M/Juv None (see Appendix 5) 
CNS-29 Spinal fracture 98-189861 5/98 North Black F/A None Found on ground with damaged wings and hind limb paralysis, died few hours later. PME: fractured lumbar 
spine. H&E: NVL. X-ray: ND. 
CNS-30 No diagnosis 98-44761 6/98 North Black F/Juv Animal Presented to vet moribund, ataxic with swollen head. PME: hyperaemic skin ventral neck, serosanguineous 
oedema dorsal head and around neck, larynx, face and shoulders. Lethobarb artefact crystal in lungs and 
heart, liver unremarkable, no thoracic or abdominal fluid. H&E: Low protein oedema of skin of dorsal 
head/neck with a mild lymphocytic infiltrate. X-ray: ND. Pb = 0.21 ppm DW. RNA-Neg. 
CNS-31 Spinal fracture 98-146896 6/98 SEQ Black F/A None Found trying to cling to base of tree while attacked by Indian Mynas. Hind limb reflexes absent, left wing 
reflexes depressed, killed. PME: early pregnant, fractured lumbar spine and right zygomatic arch, 
haemorrhage of right abdominal fat and wall. H&E: NVL. X-ray: fracture of intervertebral disc between 1st and 
2nd lumbar vertebra, gross displacement.  
CNS-32 A. cantonensis 98-150283 6/98 SEQ Black M/Juv None Hanging low in tree, docile, paresis, initially able to hang. Day 8 “legs much stronger, alert and eating well”, 
Day 13 eating little, “eyes half-mast, seems weak”. Day 20 no longer able to hang. Day 22, recumbent, cranial 
nerves normal, poor hind limb reflexes, killed. PME: fat with pectoral muscle wasting, brown meninges. H&E: 
Very severe granulomatous and eosinophilic meningoencephalitis with multiple worm sections. 20 worms 
recovered. 
CNS-33 Spinal fracture 98-150380 6/98 SEQ Grey M/A None Found on ground hind limb paralysis with absent reflexes, poor wing reflexes, swollen right wrist, vocal and 
stressed, killed. PME: fractured frontal bone under skin wound, deep haemorrhage of thoracic spinal muscles, 
fractured cranial thoracic spine. H&E: NVL. X-ray: corner fracture of 2nd thoracic vertebral body.  
CNS-34 Spinal fracture 98-155261 7/98 SEQ Grey M/Juv None Flaccid paralysis hind limbs, killed. PME: fractured thoracic spine and head of one rib. H&E: NVL. X-ray: 
collapsed 9th thoracic vertebra. 
CNS-35 Spinal fracture 98-158271 7/98 SEQ Grey M/A None Found ‘tangled’ on fence, hind limb paralysis, absent hind limb reflexes, killed. PME: fractured spine, 
distended bladder, free blood in chest cavity. H&E: multiple small perivascular haemorrhages. X-ray: ND. 
CNS-36 ABLV-42 98-189710 7/98 North Black F/A None (see Appendix 5) 
CNS-37 ABLV-43 98-158731 7/98 SEQ Black M/A Human (see Appendix 5) 
 
 CNS 
case no. 
Diagnosis Accession 
Number 
Month 
died 
DPI 
Region
Species Sex/Age Contact 
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Comments 
CNS-38       Chronic
skull/brain 
injury 
98-163314 8/98 SEQ Black F/NR Human Juvenile hanging from guttering with injury to back of head, docile, poor ‘doer’, moderate left head tilt, used 
thumbs but didn’t flap wings, “nervy” bat in care 4 months then 30 second seizure and bit carer, killed. PME: 
abnormal skull shape over left temporal and occipital lobes with corresponding cerebral deficits and adhesion 
of dura to bony proliferation. Bacto: No culture from skull swab.  
CNS-39        
        
        
        
      M/A  
 
      
       
        
        
     Black   
        
ABLV-44 98-165882 8/98 SEQ Black F/A None (see Appendix 5) 
CNS-40 Spinal fracture 98-189772 8/98 North Black F/A None Paralysis hind limbs, bright, feeding well, 2 days later delivered live near–term pup. Dam Rx corticosteroids, no 
improvement, killed. PME: fractured spine. H&E: NVL. X-ray: ND. 
CNS-41 Spinal fracture 98-170411 9/98 SEQ Black F/A None Paralysis hind limbs, vocal and aggressive. Absent hind limb reflexes, voluntary movement wings, attempting 
to bite during examination despite acepromazine sedation. PME: pregnant. Fractured spine, fur loss and 
subcutaneous haemorrhage over temporal muscle. H&E: NVL. X-rays: ND. 
CNS-42 Spinal fracture 98-173935 9/98 SEQ Grey F/Juv None Found on ground, next day had climbed up bush to hang by thumbs, hind limb paralysis, in care 9 days, 
docile, no improvement, hind limb reflexes absent, visible bump in low thoracic spine, killed. PME: fractured 
thoracic spine at level of base of heart. H&E: haemorrhages in brain stem. X-ray: ND. 
CNS-43 No diagnosis 98-179890 9/98 SEQ Black None Bat found on ground and put into tree, next day, on ground again, in to care, third day killed. PME: good NC, 
no spinal fracture detected. H&E: NVL. X-rays: NVL Pb =  0.88 ppm DW. RNA-Neg. 
CNS-44 Spinal fracture 98-181970 10/98 SEQ Little Red M/A None Found in school yard, moribund, hind limb paresis, killed. PME: fractured skull with subdural haemorrhage and 
“broken neck”, deep laceration of pectoral muscle with subcutaneous haemorrhage but no perforation of skin. 
H&E: haemorrhages in cerebellum and subarachnoid space. X-rays: ND. 
CNS-45 Spinal fracture 98-181985 10/98 Central Little Red M/A None Hind limb paralysis and blood in mouth, killed. PME: fractured thoracic spine, haemorrhage and atelectasis left 
lung, malenic gut contents (swallowed blood). H&E: NVL.  X-ray: fractured mid-body 3rd thoracic vertebra with 
ventral and right lateral displacement. 
CNS-46 ABLV-49 98-183454 10/98 Central Little Red F/A Human (see Appendix 5) 
CNS-47 Exhaustion 98-183841 10/98 SEQ Black M/A Human Bat rescued from swimming pool in morning, bit man, therefore killed. Wide-based stance, depressed, panting 
respiration, ‘sleepy’, very good cranial nerve and wing reflexes, poorer hind limb reflexes, generally depressed 
but no deficits. Closed eyes as if needing to sleep immediately after strong stimulation and response. PME: 
lean NC, dehydrated. H&E: NVL. X-ray: NVL. Pb = 3.09 ppm DW. RNA-Neg. 
CNS-48 ABLV-50 98-184361 10/98 SEQ Little Red F/A None (see Appendix 5) 
CNS-49 Spinal fracture 98-186762 11/98 SEQ Grey F/A None Found on ground, unable to hang, hind limb weakness, initially vocal, thought to be agitated/frightened so 
sedated with acepromazine, then ‘screaming’ beating wings, thrashing in cage, biting at own feet, chewing 
cage bars. Poor or absent hind limb reflexes except deep pain response, poor wing responses, killed. PME: 
Fractured thoracic spine between ribs 8 and 9, ~10 mL free blood in thorax, urine in bladder, colon full, pale 
friable liver. H&E: NVL. X-ray: ND. 
CNS-50 ABLV-51 98-188455 11/98 SEQ F/A None (see Appendix 5) 
CNS-51 ABLV-52 98-189702 11/98 North Little Red M/A None (see Appendix 5) 
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CNS-52        ABLV-53 98-189756 11/98 North Black F/Juv None (see Appendix 5) 
CNS-53 A. cantonensis 98-199503      
       
        
        
       
        
        
      M/A  
        
      
       
12/98 SEQ Grey F/Juv Animal Owner alerted to weak and uncoordinated bat by dogs. Owner killed bat by drowning! PME: very poor NC. 
H&E: severe eosinophilic and granulomatous meningoencephalitis with one worm section. No worms 
recovered. 
CNS-54 No diagnosis 99-117491 3/99 Central Black M/Juv None Bat acting strangely, chewing himself, aggressive, erratic behaviour. PME: NVL H&E: NVL. X-ray: NVL.  
Pb =  0.1 ppm DW. RNA-Neg. 
CNS-55 No diagnosis 99-126934 3/99 SEQ Black F/A None Found on lawn, hind limb paralysis, vocal, killed. PME: full bladder, no fracture apparent. H&E: NVL. X-ray: ND 
Pb: ND. RNA-Neg. 
CNS-56 ABLV-54 99-128813 4/99 SEQ Black F/Juv None (see Appendix 5) 
CNS-57 Bacterial
encephalitis 
(P. multocida) 
99-136960 4/99 SEQ Black F/Juv Human Found with laceration on nose, had seizure, appeared “in pain”, hanging with all limbs, uncoordinated, 
maggots under wing. PME: poor NC, subcutaneous pocket of blood and pus over cranium and neck.  Mass of 
thinly encapsulated caseous pus extending from the caudal pharynx ventral to epaxial muscles of neck and 
laterally along trachea, eroding through ventral aspect of atlanto-axis joint capsule and extending proximally 
and distally within the spinal canal and caudal cranial cavity. Also 2 irregular areas of fibrosis with pus on the 
dorsal thorax near scapula margins and puncture wounds through skin of head, neck, and back. Bacto: P. 
multicida from brain, cervical lymph node and subcutis. 
CNS-58 Spinal fracture 99-141686 5/99 SEQ Black M/A None Found 3-4 metres in tree hanging by thumbs, hind limb paralysis, wings strong. PME: fractured left zygomatic 
arch with haemorrhage in adjacent temporal muscle, fractured lumbar spine. H&E: NVL. X-ray: fracture at 
intervertebral space of 2nd and 3rd lumbar, gross displacement. 
CNS-59 Chronic injury
and mydriasis 
99-147385 5/99 SEQ Black M/Juv None Pup found on ground with wounds on head and right shoulder. Appeared normal as infant, once hanging was 
uncoordinated, head held to right, learned to fly. During preparation for release 6 months later seen to ‘shake’, 
held wings ‘loosely’, head tilt persisted. Thought to be improving, found dead 1 month later with wound to back 
of head. PME: large open necrotic wound with maggots on back extending from right scapulae with fibrosis, 
scapula fixed and displaced medially and caudally, fibrosis back of neck and greatly reduced range of head 
movement, hepatomegaly, low grade chronic peritonitis. H&E: NVL. X-rays: ND. Bacto: ND Pb = 1.94 ppm 
DW. RNA-Neg. 
CNS-60 Spinal fracture 99-155102 6/99 SEQ Black None Heard thump on roof, bat seen flopping on ground attempting to climb tree and falling down. Rescued hanging 
low in tree by thumbs with hind limb paralysis, visible bump in back, hind limb reflexes absent. PME: fractured 
right zygomatic arch and spine at thoraco-lumbar junction with associated s/c haemorrhage. Also subdural 
haematoma. H&E: some small haemorrhages. X-ray: ND. 
CNS-61 Head trauma 99-174173 7/99 SEQ Black M/A None Found moribund, responded to fluids and Amoxil. 2 days later developed neurological signs of weakness and 
contorted body, killed. PME: subdural haemorrhage over occipital lobes. H&E: NVL. 
CNS-62 ABLV-55 99-178735 8/99 Central Black F/Juv Human (see Appendix 5) 
CNS-63 No diagnosis 99-192936 10/99 SEQ Grey F/Juv Human Dam and pup found on ground, pup in unusual position on dam. Dam killed humanely (reason unknown) 
during next 5 days later pup had reduced appetite, diarrhoea, distress calls, lethargy, and seizures, killed. 
PME: petechiation both lungs. H&E: NVL Bacto: lung-no aerobic growth. X-ray: ND. Pb: ND. RNA-Neg. 
 
 CNS 
case no. 
Diagnosis Accession 
Number 
Month 
died 
DPI 
Region
Species Sex/Age Contact 
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CNS-64 A. cantonensis 99-192944    F/Juv  10/99 SEQ Black None Found in tree, crashed when attempted to fly, dehydrated, generalized weakness, died same day. PME: poor 
NC, NVL. H&E: eosinophilic and granulomatous meningoencephalitis with multiple worm sections. 1 worm 
fragment recovered. 
CNS-65 A. cantonensis 99-192952      
      
  
        
        
        
       
  00-133981      
      
      
       
      
10/99 SEQ Grey F/A None Seen in tree, next day on ground, ascending hind limb paresis. Day 3 delivered stillborn pup. Persistent 
paresis, then day-16 head tilt, head tremor, nystagmus, pallor, killed. PME: fat, NVL. H&E: severe 
granulomatous meningitis and multiple worm sections. 14 worms recovered.  
CNS-66 Spinal fracture 99-193425-1 10/99 SEQ Grey F/A Human Found on ground with hind limb paralysis and dystocia, vet caesarean (pup died). Demeanour improved after 
a few days, paralysis persisted, killed. PME: gross displacement of fractured thoracic vertebrae at level of base 
of heart some post-op ascites. H&E: NVL. X-ray: fractured vertebral body and caudal endplate of 7th thoracic 
vertebra, severe ventral displacement.  
CNS-67 A. cantonensis 99-193425-2 10/99 SEQ Grey M/A None Found on ground, hind limb paresis, depressed, intermittent shivering, no improvement over 8 days, killed. 
PME: NVL. H&E: moderate nonsuppurative meningitis with sections of worms. 8 worms recovered. 
CNS-68 Spinal fracture 99-201976 11/99 SEQ Black M/A None Bat found in backyard with hind limb paralysis, aggressive, not calmed by acepromazine sedation. Vocalising 
and attempting to bite during CNS exam, hind limb reflexes absent or very depressed. PME: No spinal fracture 
seen. H&E: NVL. X-ray: subluxation of 2nd and 3rd lumbar vertebra. RNA-Neg. 
CNS-69 ABLV-58 99-204785 12/99 SEQ Black F/Juv None (see Appendix 5) 
CNS-70 Spinal fracture 00-125390 3/00 SEQ Black M/A None Found caught in trees, paralysis, unable to fly, killed 2 days later. PME: good NC, fractured mid-thoracic spine, 
distended bladder. H&E: ND. X-ray: fractured vertebral body of 9th thoracic vertebra, ventral displacement. 
CNS-71 ABLV-60 00-132366 4/00 SEQ Black M/Juv Human (see Appendix 5) 
CNS-72 No diagnosis 5/00 SEQ Grey F/Juv None Found under palm tree eating fruit, hanging weakly with wings held loosely, could invert to toilet. During next 4 
days deteriorated, lying in bottom of cage, killed. PME: NVL H&E: Vacuolar change in obex. X-rays: NVL  
Pb = 4.65 ppm DW. RNA-Neg. 
CNS-73 A. cantonensis 00-137464 5/00 SEQ Black F/Juv None Captive born, released. 2-3 weeks later found depressed in tree near cage containing dam, easily captured, 
movements ‘stiff’ and slow. Deteriorated over 24 hrs, nystagmus, died. PME: good NC, congested meninges 
and petechial cerebral haemorrhages. H&E: very severe granulomatous and eosinophilic meningoencephalitis 
with large worm sections. 20 worms recovered. 
CNS-74 A. cantonensis 00-138193 5/00 SEQ Black F/Juv None Found on ground, depressed, wide based stance, drooped wings, ate well, day-3 recumbent, killed. PME: 
Good NC, petechial haemorrhages in cerebral cortices. H&E: very severe granulomatous and eosinophilic 
meningoencephalitis with large worms sections. 31 worms recovered. 
CNS-75 No diagnosis 00-141945 6/00 North Spectacled M/A None Found in garden, thin dehydrated, hungry but difficulty chewing and unable to spit out pulp, tongue sticking our 
one side, difficulty hanging with wide-based stance, wings hanging to side, eyes dull and unfocused. Next day 
seizures, head nodding, died. PME: marked autolysis, NVL. H&E: NVL. X-rays: NVL. Bacto: brain-mixed 
aerobic culture, no significant isolates. Pb = 0.28 ppm DW. RNA-Neg. 
CNS-76 A. cantonensis 00-145676 6/00 SEQ Black M/Juv None Found on ground depressed, deteriorated over 7 days, profoundly depressed, generalized paresis, 
nystagmus, killed. PME: petechiae on cerebrum, cloudy ventral meninges. H&E: Very severe granulomatous 
and eosinophilic meningoencephalitis with large nematodes. 43 worms recovered. 
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CNS 
case no. 
Diagnosis Accession 
Number 
Month 
died 
DPI 
Region
Species Sex/Age Contact 
status 
Comments 
CNS-77 A. cantonensis 00-147973      6/00 SEQ Black F/A None Seen on ground under palm tree, rescued next day, depressed, unable to hang, hind limb paresis, killed. PME: 
good NC, NVL. H&E: two sections of small worms, no inflammation. No worms recovered. 
CNS-78       
        
        
        
        
       
        
        
        
      
      
        
        
No diagnosis 00-148284 6/00 North Spectacled F/Juv None Unable to climb, hung low in tree and low in cage. Bit hard on to towel and “shook it like a dog”. PME: 
(incomplete examination) moderate NC, ants over body. H&E: NVL.  X-rays: NVL. Pb = 0.82 ppm DW.  
RNA-Neg. 
CNS-79 Spinal fracture 00-169326 8/00 SEQ Grey F/A None Blood on nose, breathing heavily, hind limb paralysis, wings held weakly, depressed, tremors, hind limb 
reflexes absent, died. PME: pregnant, good NC, fractured mid-thoracic spine, free blood in thorax and 
abdomen, fractured ribs on right. Large subdural haemorrhage over caudoventral and caudo-dorsal aspects of 
both cerebral hemispheres and cerebellum (contrecoup), dirt impacted nostrils. H&E: subarachnoid 
haemorrhage. X-ray: two spinal fractures: at intervertebral disc of 7th and 8th thoracic vertebra with right 
displacement and at intervertebral disc of 3rd and 4th lumbar vertebra, also right displacement. 
CNS-80 Bacterial
encephalitis & 
neck trauma 
00-171936 9/00 SEQ Grey F/A Animal Found on ground with wing paralysis, died overnight. PME: puncture wounds and extensive subcutaneous 
haemorrhage to neck suggestive of dog or other animal attack. H&E: moderate meningoencephalitis and 
subarachnoid haemorrhage with infiltrates of predominantly lymphocytes and macrophages and some 
polymorphonuclear cells and prominent bacterial colonies. Bacto: ND. 
CNS-81 Head trauma 00-171944 9/00 SEQ Grey M/Juv None Found on ground lethargic, unable to hang, killed. PME: fat, fractured left zygomatic arch, haemorrhage of left 
temporal muscles and large subdural haemorrhages of right and left cerebral hemispheres. No spinal fractures 
detected. H&E: haemorrhage in brain stem, frontal cortex and subarachnoid space. X-ray: NVL. 
CNS-82 ABLV-62 00-175973 9/00 SEQ Grey M/A None (see Appendix 5) 
CNS-83 ABLV-63 00-176632 9/00 Central Black M/A None (see Appendix 5) 
CNS-84 ABLV-65 00-179793 10/00 SEQ Black M/A None (see Appendix 5) 
CNS-85 No diagnosis 00-180726 10/00 SEQ Grey F/A Animal Flew into (hit) deck of house, rescued. Initially weak down one side, over next 14 days, eating but no 
improvement, rarely moving within cage, killed. PME: fat, no evidence of head trauma, limbs appeared normal, 
chronic thumb and foot injuries on left. H&E: NVL X-ray: ND. Pb: ND. RNA-Neg. 
CNS-86 ABLV-67 00-189691 10/00 SEQ Grey M/A None (see Appendix 5) 
CNS-87 A. cantonensis 00-186762 11/00 SEQ Grey F/A None Found low in bush, would not fly, docile. Hung with wide-based stance, wings held loosely. By day-9 
inappetant, depressed, killed. PME: good NC, cloudy ventral meninges, 1 worm recovered from surface of 
caudal cerebellum/brain stem.  
CNS-88 A. cantonensis 00-189346 11/00 SEQ Black M/A None Found low on fence, rescued 3 days later, moribund, recumbent, no voluntary limb movement, killed. PME: 
moderate NC, NVL. H&E: mild non-suppurative meningoencephalitis with sections of worms. Bacto: mixed 
aerobic culture, no significant isolates. 3 worms recovered. 
CNS-89 No diagnosis 00-195246 12/00 SEQ Black F/Juv None Pup found on driveway, good growth but slow feeder, not flapping, placid, not active or social,” no sparkle”, 
carer suspect brain damage, killed 43 after rescue. PME: head shape brain grossly unremarkable. H&E: NVL 
Pb: ND. RNA-Neg. 
CNS-90 ABLV-68 01-103951 1/01 SEQ Black M/A None (see Appendix 5) 
 
 CNS 
case no. 
Diagnosis Accession 
Number 
Month 
died 
DPI 
Region
Species Sex/Age Contact 
status 
Comments 
CNS-91 Fractured skull 01-108921 2/01 SEQ Little Red M/A None Found in parking lot salivating and fitting, killed. PME:  multiple skull fractures with cerebral haemorrhages and 
large s/c haemorrhage over temporal muscles extending down neck. H&E: extensive haemorrhage and 
disruption of cerebellum and parietal cortex with subarachnoid haemorrhage. 
CNS-92        
        
       
        
        
      
        
      
  
Fractured skull 01-119571 3/01 SEQ Black M/A None Left on vet doorstop in box. Recumbent, “semi-paralysed” no external injuries detected, killed. PME: good NC 
with fractured skull associated s/c haemorrhage and fractured right elbow. H&E: haemorrhage and disruption 
of frontal and parietal cortex with malacia associated with mild lymphocytic meningitis. 
CNS-93 Head trauma 01-134141 3/01 SEQ Black F/Juv None Found on driveway, lethargic and not wanting to move, killed. PME:  large subdural haemorrhage over left 
cerebral cortex, ecchymosis of right cerebral cortex and s/c haemorrhage extending from neck, over right 
temporal muscle to right eye. H&E: focal haemorrhages in frontal cortex. X-ray: ND. 
CNS-94 No diagnosis 01-154853 5/01 SEQ Black M/Juv Human Found crawling along lawn, no visible injuries, very lethargic, hung in cage, died 12 hours later. PME: poor NC, 
bruising to left shoulder, bladder partly distended, 1 cm crusty alopecia over left pectoral muscle, moderately 
congested meninges. H&E: NVL, Kidney-Megaschizonts (merocysts) of Hepatocystis pteropi in endothelial 
cells. Focal dermatophytosis ‘ringworm’. X-ray: ND. Pb = 0.86 ppm DW. RNA-Neg. 
CNS-95 ABLV-69 01-157670 5/01 SEQ Black M/A None (see Appendix 5) 
CNS-96 Head trauma 01-158916 5/01 SEQ Black M/A None Seen hanging in tree for 2 days then on ground 1 day. Able to hang, alert but “not able to move limbs well” 
(paresis?), deteriorated over 6 days, killed. PME: congestion of meninges and bilateral patches of petechial 
haemorrhages and ‘bruising’ over parietal lobes.  H&E: focus of multiple haemorrhages in parietal cerebrum 
with hyperplastic endothelium and gitter cells.  
CNS-97 A. cantonensis 01-161772 5/01 SEQ Black M/Juv None Found on ground, unable to hang, poor grip reflexes, urinary incontinence Rx Antirobe. Day-3 able to grip but 
weak. Day-6 climbs slowly about cage with urinary incontinence Day-10, voluntary movement legs and wings 
not dribbling urine (improved), remains weak. Day-17 “flicker in eyes” (nystagmus), slight head tilt. Day-20 
flicker left eye only, right eye no palpebral reflex. Day-23 Rx corticosteroids. Day-25 some improvement after 
steroids, hanging, weak, no right palpebral reflex and corneal ulcer, eating very slowly horizontal nystagmus , 
Day-27 has deteriorated, very depressed, not hanging, poor or absent grip reflex, killed. PME: good NC, poor 
pectoral muscle mass (wastage), cloudy ventral meninges with patchy discolouration of the cerebral cortexes 
and ~10 petechial haemorrhages. Very distended bladder. 3 worms recovered from cut surface near 3rd 
ventricle. H&E: severe non-suppurative meningoencephalitis with sections of worms.  
CNS-98 ABLV-70 01-162141 5/01 SEQ Black M/A None (see Appendix 5) 
CNS-99 A. cantonensis 01-169415 7/01 SEQ Black F/Juv None Found on trellis in garden, weak, depressed, paresis, wings held loosely, aggressive, distressed, and fearful, 
deteriorated over 24 hours, killed. PME: moderate NC, full bladder and colon. H&E: 2 sections of small worms, 
minimal inflammation.  
CNS-100 ABLV-71 01-178364 7/01 SEQ Black M/A None (see Appendix 5) 
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Appendix 7 Case controls for neuro-angiostrongylosis 
Nineteen normal, wild flying foxes were caught in urban Brisbane within 2 weeks of one or more 
sick flying foxes with neuro-angiostrongylosis being found, as follows; 
Table A7-1 Temporal and geographical matching of case control samples for 
neuro-angiostrongylosis 
Month/s wild normal flying foxes 
caught in urban Brisbane 
Corresponding cases of neuro-angiostrongylosis 
November, December 1997 CNS-7, 8 and 9 found sick at Cleveland, Brisbane and 
Nambour respectively 
May 1998   CNS-24 found sick at Ashgrove 
June 1998   CNS-32 found sick at Bundamba 
 
Table A7-2 Species, age, and sex matching of case control samples for 
neuro-angiostrongylosis 
Class of flying fox 
Number with 
angiostrongylosis 
n=18 
Number  
clinically normal 
n=19 
Black adult female 3 8 
5 1 
Black juvenile female 3 2 
Black juvenile male 
 
Grey adult female  1 1 
Grey adult male  2 2 
1 1 
Grey juvenile male  0 4 
Black adult male 
3 0 
Grey juvenile female  
 
Fewer Black flying foxes had been caught during months in which cases of neuro-
angiostrongylosis were occurring, resulting in an inability to match each class exactly.  All 
available Black flying foxes were examined. Substitutions were made in an effort to preserve 
species, then age, then sex matches 
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Table A7-3 Details of 19 wild-caught, presumably normal flying foxes examined 
histologically for evidence of subclinical neuro-angiostrongylosis 
(All negative) 
Accession 
number 
Species Age Sex Month, Year and Site of Capture 
97-195560 Black Adult Female Nov 97    Norman Creek,   East Brisbane 
97-195575 Black Adult Female Nov 97    Norman Creek,   East Brisbane 
97-195583 Black Adult Female Nov 97    Norman Creek,   East Brisbane 
97-195591 Black Adult Female Nov 97    Norman Creek,   East Brisbane 
97-203012 Black Adult Female Nov 97    Norman Creek,   East Brisbane 
97-203020 Black 
Dec 97    Norman Creek,   East Brisbane 
Adult Female Nov 97    Norman Creek,   East Brisbane 
97-203056 Black Adult Female 
98-143194-19 Black Adult Female June 98   Norman Creek,   East Brisbane 
98-143194-21 Black Adult Male June 98   Norman Creek,   East Brisbane 
98-143194-17 Black Juvenile Female June 98   Norman Creek,   East Brisbane 
98-143194-18 Black Juvenile Female June 98   Norman Creek,   East Brisbane 
98-141060-9 Grey Adult Female May 98    Indooroopilly Is. 
98-141060-3 Grey Adult Male May 98    Indooroopilly Is. 
98-143186-13 Grey Adult Male June 98   Norman Creek,   East Brisbane 
98-141060-12 Grey Juvenile Female May 98    Indooroopilly Is. 
98-141060-1 Grey Juvenile Male May 98    Indooroopilly Is. 
98-141060-4 Grey Juvenile Male May 98    Indooroopilly Is. 
98-141060-6 Grey Juvenile Male May 98    Indooroopilly Is. 
98-141060-8 Grey Juvenile Male May 98    Indooroopilly Is. 
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Appendix 8 Liver lead determination in normal flying foxes 
Determination of average percent dry matter of normal, formalin-fixed flying fox 
livers 
   
Bat 99-165731-53 Wet liver weight = 1.1312 
Dry liver weight = 0.2613 
 
% Dry matter = 23.1 
Bat 99-165731-54 Wet liver weight = 1.7084 
Dry liver weight = 0.3885 
 
% Dry matter = 22.7 
Bat 99-165731-58 Wet liver weight = 1.3767 
Dry liver weight = 0.3344 
  
% Dry matter = 24.3 
Bat 99-165731-51 
  
Wet liver weight = 1.2852 
Dry liver weight = 0.2752 
% Dry matter = 21.4 
 
Average % Dry matter = 22.8 
Relationship between fresh wet weights, formalin-fixed wet weights, and dry 
weights  
Accurate liver Pb results were determined as ppm dry weight, using desiccated formalin fixed 
liver. 
Approximations of the equivalent formalin-fixed wet weight lead concentration (ppm wet weight) 
were calculated using the average percent dry matter (see above) as follows. 
ppm wet weight = ppm dry weight  x  22.8  
              100 
The approximate ppm wet weight results are generally comparable to published fresh wet weight 
values for flying foxes and other species. However, as the relationship between the fresh wet liver 
weights and formalin-fixed wet liver weights is unknown, it is preferable to compare and analyse 
these results as dry weight concentrations (ppm dry weight) where possible.  
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Table A8-1 Liver lead levels in 50 clinically normal flying foxes captured at two sites in 
urban Brisbane during November 1997 to July 1999 
Note: table continues over page 
DPI accession 
number 
Species  Capture site Sex Age Year Month Pb ppm dry 
weight1 
98-143193/17 Black Norman creek F Juv 98 6 5.35 
98-143193/18 Black Norman creek F Juv 98 6 5.65 
98-143193/20 Black Norman creek F Adult 98 6 8.05 
98-143193/19 Black Norman creek F Adult 98 6 
99 
99 
8 
98-162624/32 
M 
16.05 
98-143193/21 Black Norman creek M Adult 98 6 17.36 (21.1)   
99-165746/56 Black Norman creek F Adult 99 7 5.63 
99-165746/54 Black Norman creek F Juv 99 7 5.99 
99-164766/47 Black Norman creek F Adult 99 7 6.9 (6.15) 
99-165746/53 Black Norman creek M Adult 99 7 7.02 
99-165746/57 Black Norman creek F Adult 99 7 7.16 
99-165746/58 Black Norman creek F Adult 7 10.04 
99-165746/55 Black Norman creek F Adult 99 7 10.47 
99-165746/52 Black Norman creek F Adult 7 10.67 
98-162624/28 Black Norman creek M Adult 98 8 3.06 
98-162624/22 Black Norman creek M Adult 98 8 10.46 
98-162624/29 Black Norman creek M Adult 98 8 10.57 
98-162624/25 Black Norman creek M Adult 98 8 10.74 
98-162624/27 Black Norman creek M Adult 98 8 11.67 
98-162624/24 Black Norman creek M Adult 98 8 12.56 
98-162624/23 Black Norman creek M Adult 98 13.06 
98-162624/31 Black Norman creek M Adult 98 8 16.68 
98-162624/26 Black Norman creek M Adult 98 8 18.29 
Black Norman creek F Adult 98 8 19.77 (16.0) 
97-203004 Black Indooroopilly Is. F Adult 97 11 3.52 
97-195591 Black Norman creek F Adult 97 11 13.22 
98-143186/13 Grey Norman creek M Adult 98 6 0.27 
98-143186/14 Grey Norman creek M Adult 98 6 0.8 
98-141186/16 Grey Norman creek Juv 98 6 0.81 
98-143186/15 Grey Norman creek M Juv 98 6 1.76 
99-157162/43 Grey Norman creek F Adult 99 6 6.95 (6.07) 
99-165731/50 Grey Norman creek F Adult 99 7 1.5 
99-165731/51 Grey Norman creek F Adult 99 7 4.04 
99-164774/49 Grey Norman creek F Juv 99 7 4.34 
98-162744/34 Grey Norman creek F Adult 98 8 5.92 
97-195575 Grey Norman creek F Adult 97 11 13.24 
98-141060/2 Grey Indooroopilly Is. M Adult 98 5 0.10 (0.08)  
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DPI accession 
number 
Species  Capture site Sex Age Year Month Pb ppm dry 
weight1 
98-141060/6 Grey Indooroopilly Is. M Juv 98 5 0.13 
98-141060/4 Grey Indooroopilly Is. M Juv 98 5 0.26 
98-141060/12 Grey Indooroopilly Is. F Juv 98 5 0.26 
98-141060/10 Grey Indooroopilly Is. F Juv 98 5 0.44 
98-141060/9 Grey Indooroopilly Is. F Adult 98 5 0.45 
98-141060/5 Grey Indooroopilly Is. M Adult 98 5 0.47 
98-141060/3 Grey Indooroopilly Is. 
Indooroopilly Is. 
Indooroopilly Is. 
M Adult 98 5 0.83 
98-141060/1 Grey Indooroopilly Is. M Juv 98 5 0.88 
98-141060/11 Grey Indooroopilly Is. F Adult 98 5 0.96 
98-141060/7 Grey M Juv 98 5 1.28 
98-141060/8 Grey Indooroopilly Is. M Juv 98 5 1.35 
98-180974/38 Grey F Juv 98 10 0.74 
98-196145/40 Grey Indooroopilly Is. M Adult 98 12 1.68 
98-196145/39 Grey Indooroopilly Is. M Adult 98 12 2.41 
 
     1 Values in brackets (n=5) are for duplicate samples submitted to the DNR Natural Resources Sciences 
Laboratories. All other values are results of testing at the DPI Trace Metal Laboratory. The results from 
the two laboratories were considered consistent. The duplicate results were not used in any further 
analysis. 
Statistical analysis of the relationships between flying fox characteristics and Pb 
levels 
Known characteristics that could have been associated with Pb levels included species, capture 
site and date, age, and sex. However there is a very close association between some of these 
terms in the data collected. In particular relationships between species, capture site, and capture 
date show three main groups. 
♦ Greys-IIs-May Grey-headed flying foxes caught at Indooroopilly Island during  
May 1998 (n=12) 
♦ Greys-NC-JJA Grey-headed flying foxes caught at Norman Creek Island during  
June, July or August 1998 or 1999 (n=9) 
♦ Blacks-NC-JJA  Black flying foxes caught at Norman Creek during June, July or August 
1998 or 1999 (n=23) 
The remaining six flying foxes were caught in October, November or December 1997 or 1998 and 
include: 1 Black from Norman Creek (Pb = 13.22 ppm DW), 1 Black from Indooroopilly Is. (Pb = 
3.52 ppm DW), 1 Grey from Norman Creek (Pb = 13.34 ppm DW), and 3 Greys from Indooroopilly 
Is (Pb = 0.74, 1.68, and 2.41 ppm DW).  
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There are clear differences in the levels of liver Pb between the three main groups (see Figure 
A8-1 and Figure A8-2). The differences were tested by analysis of variance with the log (x + 1) 
transformation before analysis to stabilize variance. All analysis was done by Tony Swain (ARI) 
using the statistical package GenStat 2000. 
 
Figure A8-1 Liver Pb levels of 50 wild flying foxes from urban Brisbane 
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Figure A8-2 Box plot summary: liver Pb in 50 wild urban Brisbane flying foxes  
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The predicted liver Pb levels for each group from the regression model are:  
 
♦ Blacks-NC-JJA   Predicted Pb = 9.68  ppm dry weight 
♦ Greys-NC-JJA   Predicted Pb = 2.27  ppm dry weight 
♦ Greys-IIs-May   Predicted Pb = 0.57 ppm dry weight 
 
In terms of statistically different liver Pb levels (p = 0.01) 
 
Blacks-NC-JJA   >   Greys-NC-JJA  >   Greys-IIs-May  
 
The effects of year, age and sex when added to a general linear model containing the three main 
groups were not statistically significant (p = 0.63, 0.19 and 0.43 respectively) 
 
In addition, the low levels and tight distribution of values for the Grey-headed flying foxes caught 
at Indooroopilly Is. in May 1998 suggests that this group has had minimal exposure to sources of 
lead. All values for this group are less than 1.5 ppm dry weight and there is a gap in the values at 
this point, further suggesting that this is an indicator level.   
Conclusion 
Why there should be statistically different liver Pb levels among two species of flying fox (P. alecto 
and P. poliocephalus) camped at two apparently similar camp sites only 7.2 km apart in urban 
Brisbane, is not known. Further investigation of this unexpected result was beyond the scope of 
this project.  
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Appendix 9 Heminested RT-PCR for lyssavirus RNA 
A hemi-nested reverse transcriptase (RT) PCR assay, as described in Heaton et al. (1997), is 
used at QHSS for the detection of known and potentially unknown variants of ABLV. The assay 
uses a combination of primers capable of amplifying the RNA of all seven lyssavirus genotypes, 
including both the pteropid and Yellow-bellied sheathtail-variants of ABLV (Smith et al. 2002). 
Primers were designed to amplify regions with high homology on the nucleocapsid (N) protein 
genes (see Table A9-1 and Table A9-2). This combination of primers is presumed to be likely to 
amplify the RNA of any further, as yet unrecognised variants of ABLV, such as may be identified 
among other species of Australian microchiroptera. 
Table A9-1 Oligonucleotide primers for primary amplification of lyssavirus RNA in 
hemi-nested RT-PCR at QHSS 
Primer name1 Direction Position on genome2 Nucleotide sequence 
5’-3’, + genomic sense 
JW12 Forward  55-73 ATG TAA CAC C(C/T)C TAC AAT TG 
JW6 (DPL) Reverse 660-641 CAA TTC GCA CAC ATT TTG TG 
JW6 (E1E2) Reverse 660-641 CAG TTG GCA CAC ATC TTG TG 
JW6 (M) Reverse 660-641 CAG TTA GCG CAC ATC TTA TG 
 
Table A9-2 Oligonucleotide primers for second-round amplification of lyssavirus RNA 
in hemi-nested RT-PCR at QHSS 
Primer name1 Direction Position on genome2 Nucleotide sequence 
5’-3’, + genomic sense 
JW12 Forward  55-73 ATG TAA CAC C(C/T)C TAC AAT TG 
JW10 (DLE2) Reverse 636-617 GTC ATC AAA GTG TG(A/G) TGC TC 
JW10 (ME1) Reverse 636-617 GTC ATC AAT GTG TG(A/G) TGT TC 
JW10 (P) Reverse 636-617 GTC ATT AGA GTA TGG TGT TC 
1   Letters in parentheses refer to the genotype on which the primer designs were based. D-Duvenhage 
    virus, P-Pasteur virus (GenBank PV-X03673), L-Lagos bat virus, E1-European bat lyssavirus 1,  
    E2-European bat lyssavirus 2, M-Mokola virus (GenBank S59448). 
2   Numbering corresponds to nucleotide positions within the Pasteur virus + sense genome,  
    (GenBank X03673) 
Adapted from Heaton et al. (1997). 
 
The hemi-nested RT-PCR assay was demonstrated to be more sensitive than the FAT for the 
detection of rabies virus in brain samples that had undergone extensive deterioration (to the point 
of liquefaction and incubated at 37°C for 360 hrs) (Heaton et al. 1997). Because of this higher 
sensitivity in sub-optimal samples, and the potential to amplify sequences from the RNA of 
unrecognised variants of ABLV, the hemi-nested RT-PCR is indicated whenever poor sample 
quality or the possibility of a new ABLV variant is suspected. The hemi-nested RT-PCR is 
currently performed at QHSS on all brain samples from non-Yellow-bellied sheathtail 
microchiroptera, due to the possibility of other ABLV-variants being present in these bat species.
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Appendix 10 Nucleotide sequences 
1
 
 
Figure A 0-1 Nucleotide alignment of ABLV (n=34) and Nobivac (n=1) sequences  
Multiple sequence alignment of the + sense 5’ nucleotide sequences of 28 new pteropid-variant ABLV isolates (green), 3 new YBST-variant ABLV 
isolates (orange), other available ABLV sequences (ABLHumanPt and ABLBallina (lime), and AHHLYBST (gold) and the Nobivac rabies vaccine 
strain (Pasteur virus RIVM, blue).  
Base position 1 corresponds to position 1 of the Pasteur virus + sense genome (GenBank X03673).  
Primer binding sites are indicated in pale font, over and underlined, and labelled with the primer name and an arrow indicating the direction of primer extension.  
The start and stop of the N protein mRNA sequence are indicated by vertical arrows (positions 59 and 1486). 
The start and stop codons of the N protein coding sequence (positions 71-73 and 1,421-1,423), N-P intergenic sequence (CT1489), and start codon for the P protein 
(positions 1519-1521) are boxed and labelled.  
Bases that differ from the predominant base at each position and are like that of one or more ybst-ABLV sequence are shown in yellow (e.g. A).  
Bases that differ from the predominant base at each position and are like that of the Nobivac rabies sequence are shown in blue (e.g. A).  
Bases that differ from the predominant base at each position and are unlike either the predominant base of the ybst-ABLV or the Nobivac sequences are highlighted in 
green (e.g. T).
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                Appendix 10 
start N mRNA
1 10 20 30 40 50 60 70 80 90 100
I I ABLUTR22 I I I I I I N start codon I I I
A C G C T T A A C G A C A A A A C C A G A G A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A AG T C
A A GG A G T A G A C A T G A T C A T T T G C A A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
ABLHumanPt A C G C T T A A C G A C A A A A C C A G A G A A GG A G T A G A C A T G A T C A T T T G C G A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T T C T G A T A A G A T T G T C T T T A A GG T C
ABLBallina G A G T C T G A T A A G A T T G T C T T T A A GG T C
A A G A A G T A G A C A T G A T C A T C T G C G A A G A A A A A A T G T A A C A C C C C T A CA A TG G A T T C C G A T A A G A T T G T T T T C A A GG T A
A A G A A G T A G A C A T G A T C A T C T G C G A A G A A A A A A T G T A A C A C C C C T A CA A TG G A T T C C G A T A A G A T T G T T T T C A A GG T A
A A G A A G T A G A C A T G A T C A T C T G C G A A G A A A A A A T G T A A C A C C C C T A CA A TG G A T T C C G A T A A G A T T G T T T T C A A GG T A
G A G T C T G A T A A G A T T G C C T T T A A G A T C
Lys-Leader
Nobivac A C T C T T A A C A A C C A G A T C A A A G A A G A A A A A G A C A G C G T C A A T T G C A A A G C A A A A A T G T A A C A C C C C T A CA A TG G A T G C C G A C A A G A T T G T G T T C A A AG T C
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
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Figure A10-1 (continued)  Nucleotide alignment of ABLV (n=34) and Nobivac (n=1) sequences (page 1 of 16) 
ABL01SEQ-B
ABL02SEQ-G
ABL03Tvl-R
ABL05SEQ-B
ABL06SEQ-B
ABL07SEQ-G
ABL08SEQ-G
ABL09SEQ-G
ABL13SEQ-G
ABL14Cen-B
ABL16Cen-R
ABL17Tvl-B
ABL19SEQ-R
ABL21SEQ-R
ABL22SEQ-B
ABL23SEQ-B
ABL24SEQ-R
ABL25SEQ-R
ABL26SEQ-B
ABL29Tvl-R
ABL30Tvl-R
ABL31SEQ-R
ABL32Tvl-B
ABL33SEQ-B
ABL34Cen-B
ABL35SEQ-B
ABL36SEQ-B
ABL37Cen-B
ABL11YBST
ABL12YBST
ABL15YBST
AAHLYBST
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Figure A10-1 (continued)  Nucleotide alignment of ABLV (n=34) and Nobivac (n=1) sequences (page 2 of 16)  
ABL01SEQ-B
ABL02SEQ-G
ABL03Tvl-R
ABL05SEQ-B
ABL06SEQ-B
ABL07SEQ-G
ABL08SEQ-G
ABL09SEQ-G
ABL13SEQ-G
ABL14Cen-B
ABL16Cen-R
ABL17Tvl-B
ABL19SEQ-R
ABL21SEQ-R
ABL22SEQ-B
ABL23SEQ-B
ABL24SEQ-R
ABL25SEQ-R
ABL26SEQ-B
ABL29Tvl-R
ABL30Tvl-R
ABL31SEQ-R
ABL32Tvl-B
ABL33SEQ-B
ABL34Cen-B
ABL35SEQ-B
ABL36SEQ-B
ABL37Cen-B
101 110 120 130 140 150 160 170 180 190 200
I I I I I I I I I I I
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T C A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C T GC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T T T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A GC A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A G T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A G T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T T A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
ABLHumanPt A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T C A A A G A C C A A A A G A A GC C T A G T A T A A C T C T T G
ABLBallina A A C A A T C A G T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A A T A T G A G T A C A A A T A T C C CGC T A T A C A A G A C C A T A CG A A GC C T A G T A T A A C T C T T G
A A C A A T C A A T T GG T G T C T G T T A A GC C T G A GG T G A T A G T A G A T C A G T A T G A A T A T A A G T A C C C T GC A A T C A A A G A T C A G A GG A A GC C T A GC A T T A C T C T T G
A A C A A T C A A T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A G T A T G A A T A T A A G T A C C C T GC A A T C A A A G A T C A G A GG A A GC C T A GC A T T A C T C T T G
A A C A A T C A A T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A G T A T G A A T A T A A G T A C C C T GC A A T C A G A G A T C A G A GG A A GC C T A GC A T T A C T C T T G
A A C A A T C A A T T GG T G T C T G T T A A GC CGG A GG T G A T A G T A G A T C A G T A T G A A T A T A A G T A C C C T GC A A T C A A A G A T C A G A GG A A GC C T A GC A T T A C T C T T G
Nobivac A A T A A T C A GG T GG T C T C T T T G A A GC C T G A G A T T A T CG T GG A T C A A T A T G A G T A C A A G T A C C C T GC C A T C A A GG A T T T G A A A A A GC C T T G T A T C A C C C T AG
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
ABL11YBST
ABL12YBST
ABL15YBST
AAHLYBST
        
 Figure A10-1 (continued)   Nucleotide alignment of ABLV (n=34) and Nobivac (n=1) sequences (page 3 of 16) 
ABL01SEQ-B
ABL02SEQ-G
ABL03Tvl-R
ABL05SEQ-B
ABL06SEQ-B
ABL07SEQ-G
ABL08SEQ-G
ABL09SEQ-G
ABL13SEQ-G
ABL14Cen-B
ABL16Cen-R
ABL17Tvl-B
ABL19SEQ-R
ABL21SEQ-R
ABL22SEQ-B
ABL23SEQ-B
ABL24SEQ-R
ABL25SEQ-R
ABL26SEQ-B
ABL29Tvl-R
ABL30Tvl-R
ABL31SEQ-R
ABL32Tvl-B
ABL33SEQ-B
ABL34Cen-B
ABL35SEQ-B
ABL36SEQ-B
ABL37Cen-B
201 210 220 230 240 250 260 270 280 290 300
I I I I I I I I I I I
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A T T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
ABLHumanPt GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T A T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
ABLBallina GG A A GGC T C C A G A T T T A A A T A A GGC A T A T A A G T C C A T A T T G T CGGG A A T G A A T GC T GC A A A GC T GG A C C C CG A T G A T G T A T G T T C T T A C T T A G C T GC A GC
G A A A GGC C C C A G A T T T A A A T A A AGCG T A C A A G T C T A T A T T A T C T GG C A T G A A CGC CGCG A A G T T GG A C C CGG A CG A T G T T T GC T C C T A C C T A G C T GC A GC
G A A A GGC C C C A G A T T T A A A T A A AGCG T A C A A G T C T A T A T T A T C T GG C A T G A A CGC CGCG A A G T T GG A C C CGG A CG A T G T T T GC T C C T A C C T A G C T GC A GC
G A A A GGC C C CGG A T T T A A A T A A AGCG T A C A A G T C T A T A T T A T C T GG C A T G A A CGC CGCG A A G T T GG A C C CGG A CG A T G T T T GC T C C T A C C T A G C T GC A GC
G A A A GGC C C C A G A T T T A A A T A A AGCG T A C A A G T C T A T A T T A T C T GG C A T G A A CGC CGCG A A G T T GG A C C CGG A CG A T G T T T GC T C C T A C C T A G C T GC A GC
Nobivac GG A A AGC C C C CG A C T T G A A C A A AGC A T A C A A A T C AG T T T T A T C AGG C A T G A A T GC CGC C A A AC T T G A T C CGG A T G A T G T A T GC T C C T A C T T GG C AGC A GC
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T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T C A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T T T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C T G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
ABLHumanPt T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T T T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
ABLBallina T A T GG A G T T A T T T G A GGGGG T C T GC C C A G A A G A T T GG A CG A G T T A T GGG A T T A T G A T T GC C A G A A A A GG A G A T A A A A T T A C A C C A GC C A C C C T T G T T G A C
T A T GG A G T T A T T T G A GGGG A T C T GC C C A G A GG A C T GG A C A A G T T A CGGG A T T T T A A T T GC C A G A A A A GG A G A C A A A A T C A C A C CGGC T A C T T T AG T T G A C
T A T GG A G T T A T T T G A GGGG A T C T GC C C A G A GG A C T GG A C A A G T T A CGGG A T T T T A A T T GC C A G A A A A GG A G A C A A A A T C A C A C CGGC T A C T T T AG T T G A C
T A T GG A G T T A T T T G A GGGG A T C T GC C C A G A GG A C T GG A C A A G T T A CGGG A T T T T G A T T GC C A G A A A A GG A G A C A A A A T C A C A C CGGC T A C T T T AG T T G A C
T A T GG A G T T A T T T G A GGGG A T C T GC C C A G A GG A C T GG A C A A G T T A CGGG A T T T T G A T T GC C A G A A A A GG A G A C A A A A T C A C A C CGGC T A C T T T AG T T G A C
Nobivac A A T GC A G T T C T T T G A GGGG AC A T G T C CGG A A G A C T GG A C C A GC T A T GG A A T C C T G A T T GC ACG A A A A GG A G A T A GG A T C A C C C C A A AC T C T C T AG T GG A G
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ABL22SEQ-B
ABL23SEQ-B
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ABL25SEQ-R
ABL26SEQ-B
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A T A A A G A G A A C A G A T A T T G A GGG T A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C N5'Seq
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A T G C T T C T T T A G T A GG T C T T C N5'Seq
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A T G C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A T G C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A T G C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A C A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
A T A A A G A G A A C A G A T A T T G A GGGC A A C T GGG C A T T G A CGGG A GG A C A A G A C T T G A C C A GGG A T C C C A C A G T A G C A G A A C A CG C T T C T T T A G T A GG T C T T C
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T T T T G C A A A G A T T G T GG A A C A T C A C A CG T T A A T G A C T A C T C A T A A G A T G T G T GC A A A C T GG A G T A CG A T C C C A A A T T T T A G A T T T T T GGC T GG A A C T T A T
T T T T G C A A A G A T T G T GG A A C A T C A C A CG T T A A T G A C T A C T C A T A A G A T G T G T GC A A A C T GG A G T A CG A T C C C A A A T T T T A G A T T T T T GGC T GG A A C T T A T
ABLHumanPt T T T T G C A A A G A T T G T GG A A C A T C A C A CG T T A A T G A C T A C T C A T A A G A T G T G T GC A A A C T GG A G T A CG A T C C C A A A T T T T A G A T T T T T GGC CGG A A C T T A T
ABLBallina T T T T G C A A A G A T T G T GG A A C A T C A C A CG T T A A T G A C T A C T C A T A A G A T G T G T GC A A A C T GG A G T A CG A T C C C A A A T T T T A G A T T T T T GGC T GG A A C T T A T
C T T T G C A A A G A T CG T AG A A C A T C A C A C A T T A A T G A C C A C C C A C A A A A T G T G T GC A A A T T GG A G C A C A A T T C C A A A C T T T A G A T T T C T GGC T GGG A C T T A T
C T T T G C A A A G A T CG T AG A A C A T C A C A C A T T A A T G A C C A C C C A C A A A A T G T G T GC A A A T T GG A G C A C A A T T C C A A A C T T T A G A T T T C T GGC T GGG A C T T A T
C T T T G C A A A G A T CG T AG A A C A T C A C A C A T T A A T G A C C A C C C A C A A A A T G T G T GC A A A T T GG A G C A C A A T T C C A A A C T T T A G A T T T C T GGC T GGG A C T T A T
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G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T A T A C T C T GC A A T T C G A G T A GGG A CGG T GG T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T A T A C T C T GC A A T T C G A G T A GGG A CGG T GG T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T A T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T A T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
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G A C A T G T T C T T T T C T CG A G T T G A GC A C T T A T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
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G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CGGG T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T A T A C T C C GC A A T C C G A G T A GGG A CGG T GG T A A C T GC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T A T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T A T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CGGG T T G A GC A C T T G T A C T C T GC A A T T C GGG T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A C A T G T T C T T T T C T CG A G T T G A GC A C T T G T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
ABLHumanPt G A C A T G T T C T T T T C T CG A G T T G A GC A C T T A T A C T C T GC A A T T C G A G T A GGG A CGG T GG T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
ABLBallina G A C A T G T T C T T T T C T CG A G T T G A GC A C T T A T A C T C T GC A A T T C G A G T A GGG A CGG T A G T A A C CGC T T A T G A A G A T T G T T C T GG A C T T G T C T CG T T T A C A G
G A T A T G T T C T T T T C T CG A G T T G A AC A T T T A T A C T C C GC A A T T C GGG T A GG T A CGG T GG T A A CGGC T T A T G A A G A C T G T T C CGG A C T T G T C T CG T T C A C A G
G A T A T G T T C T T T T C T CG A G T T G A AC A T T T A T A C T C C GC A A T T C GGG T A GG T A CGG T GG T A A CGGC T T A T G A A G A C T G T T C CGG A C T T G T C T CG T T C A C A G
G A T A T G T T C T T T T C T CG A G T T G A AC A T T T A T A C T C C GC A A T T C GGG T A GG T A CGG T GG T A A CGGC T T A T G A A G A C T G T T C CGG A C T T G T C T CG T T C A C A G
G A T A T G T T C T T T T C T CG A G T T G A AC A T T T A T A C T C C GC A A T T C GGG T A GGC A CGG T A G T A A CGGC T T A T G A A G A C T G T T C CGG A C T T G T C T CG T T C A C A G
Nobivac G A C A T G T T T T T C T C A CGG A T T G A GC A T C T G T A T T CGGC A A T C AG A G T GGGC A C AG T CG T C A C CGC T T A T G A A G A C T GC T C AGG A C T GG T A T CG T T T A C A G
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GG T T T A T C A A A C A A A T C A A C C T C A C T GC T A GGG A A GC A A T A C T G T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C C GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A GG A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T C G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC G A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC G A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A A A T C A A C C T C A C T GC T A GGG A A GC A A T A C T G T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
ABLHumanPt GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
ABLBallina GG T T T A T C A A A C A G A T C A A C C T C A C T GC T A GGG A A GC A A T A C T A T A T T T C T T C C A T A A G A A C T T C G A A G A A G A A A T T A G A A G A A T G T T T G A A C C C GG A C A
G A T T C A T C A A G C A A A T A A A C C T C A C T GC T A GGG A A GC G A T A C T T T A C T T C T T C C A T A A G A A C T T T G A GG A GG A A A T C A GG A G A A T G T T T G A GC C C GG A C A
G A T T C A T C A A G C A A A T A A A C C T C A C T GC T A GGG A A GC G A T A C T T T A C T T C T T C C A T A A G A A C T T T G A GG A GG A A A T C A GG A G A A T G T T T G A GC C C GG A C A
G A T T C A T C A A G C A A A T A A A C C T C A C T GC T A GGG A A GC G A T A C T T T A C T T C T T C C A T A A G A A C T T T G A GG A GG A A A T C A GG A G A A T G T T T G A GC C C GG A C A
G A T T C A T C A A G C A A A T A A A C C T C A C T GC T A GGG A A GC G A T A C T T T A C T T C T T C C A T A A G A A C T T T G A GG A GG A A A T C A GG A G A A T G T T T G A GC C C GG A C A
Nobivac GG T T C A T A A A G C A G A T C A A T C T C A C C GC A A GGG A A GC A A T A C T A T A T T T C T T C C A C A A G A A C T T T G A GG A A G A G A T A A G A A G A A T G T T C G A GC C AGGGC A
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Figure A10-1 (continued)  Nucleotide alignment of ABLV (n=34) and Nobivac (n=1) sequences (page 10 of 16)  
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ABL21SEQ-R
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ABL37Cen-B
901 910 920 930 940 950 960 970 980 990 1000
I I N5Reverse I I I I I I I I I
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C T C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C C C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC T G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A G T GG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C C T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GCGG T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GCGG T T GG C C A T G T G T T C A A T
A G A A A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T CGG C C A T G T A T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A A A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T CGG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T GGG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C T C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A A A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T CGG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A G A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
ABLHumanPt A G A G A C T GC T G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
ABLBallina A G A A A C T GC A G T T C C T C A C T C T T A T T T C A T C C A T T T C A G A T C T C T A GG A C T T A GCGG A A A G T C C C C T T A C T C C T C C A A T GC A G T T GG C C A T G T G T T C A A T
A G A A A C T GC CG T T C C T C A C T C T T A T T T C A T C C A C T T C A G A T C C C T T GGGC T C A G T GG A A A G T C T C C A T A C T C C T C C A A T GC A G T CGG C C A T G T G T T T A A T
A G A A A C T GC CG T T C C T C A C T C T T A T T T C A T C C A C T T C A G A T C C C T T GGGC T C A G T GG A A A G T C T C C A T A C T C C T C C A A T GC A G T CGG C C A T G T G T T T A A T
A G A A A C T GC CG T T C C T C A C T C T T A T T T C A T T C A C T T C A A A T C C C T T GGGC T C A G T GG A A A G T C T C C A T A C T C C T C C A A T GC A G T CGG C C A T G T G T T T A A T
A G A A A C T GC CG T T C C T C A C T C T T A T T T C A T C C A C T T C A G A T C C C T T GGGC T C A G T GG A A A G T C T C C A T A C T C C T C C A A T GC A G T CGG C C A T G T G T T T A A T
Nobivac A G A G A C AGC T G T T C C T C A C T C T T A T T T C A T C C A C T T C CG T T C AC T A GGC T T G A G T GGG A A G T C T C C T T A T T C A T CG A A T GC T G T CGG T C A T G T G T T C A A T
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 Figure A10-1 (continued)  Nucleotide alignment of ABLV (n=34) and Nobivac (n=1) sequences (page 11 of 16)  
1001 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100
I I I I I I I I I I I
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T T G T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G C A A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T CGG T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A C T T T G T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T T C A T T T T G T GGG A T G T T A C A T GGGC C A G A T A A GG T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T CGG T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T A A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T CGG T T T T GGG A GGC T
ABLHumanPt C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
ABLBallina C T C A T C C A T T T CG T GGG A T G T T A C A T GGGC C A G A T A A G A T C T T T G A A T G CG A C T G T C A T A T C C A C C T G T GC T C C T C A T G A G A T G T C T G T T T T GGG A GGC T
C T C A T T C A T T T T G T GGGC T G T T A C A T GGGGC A G A T A A G A T C T T T A A A T G C C A C T G T T A T A T C T A C T T GCGC AC C T C A CG A G A T G T C AG T C T T GGGGGG T T
C T C A T T C A T T T T G T GGGC T G T T A C A T GGGGC A G A T A A G A T C T T T A A A T G C C A C T G T T A T A T C T A C T T GCGC AC C T C A CG A G A T G T C AG T C T T GGGGGG T T
C T C A T T C A T T T T G T GGGC T G T T A C A T GGGGC A G A T A A G A T C T T T A A A T G C C A C T G T C A T A T C T A C T T GCGC AC C T C A CG A G A T G T C AG T C T T GGGGGG T T
C T C A T T C A T T T T G T GGG A T G T T A C A T GGGGC A G A T A A G A T C T T T A A A T G C C A C T G T T A T A T C T A C T T GCGC AC C T C A CG A G A T G T C AG T C T T GGGGGG T T
NobiVSeq2F
Nobivac C T C A T T C A C T T T G T T GG A T GC T A C A T GGG T C A AG T C A G A T C T C T A A A T G CG A CGG T T A T T GC T GC A T G T GC C C C T C A T G A G A T G T C T G T T C T AGGGGGC T
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A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A CGGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A CGGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GG T GG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GC AG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C A A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A T A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A T A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A CGGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GG T GG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GG T GG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
ABLHumanPt A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
ABLBallina A T G A A T GGGGG T CG A C T T A A A A GG T C A C A C A T T A GG A G A T A C A T C T C A G T C A GC T C C A A C C A T C A G T C C CG A C CG A A C T C A T T T GCGG A G T T T C T C A A C A
A T G A A T GG AGG C CG A C T C A A G A AG T C A C A C A T C A GG A GG T A C A T C T C A G T G A G T T C T A A C C A T C A G T C T CG A C CG A A C T CG T T T GC T G A A T T C C T A A A C A
A T G A A T GG AGG C CG A C T C A A G A AG T C A C A C A T C A GG A GG T A C A T C T C A G T G A G T T C T A A C C A T C A G T C T CG A C CG A A C T CG T T T GC T G A A T T C C T A A A C A
A T G A A T GG AGG C CG A C T C A A G A AG T C A C A C A T C A GG A GG T A C A T C T C A G T G A G T T C T A A C C A T C A G T C T CG A C CG A A C T CG T T T GC T G A A T T C C T A A A C A
A T G A A T GG AGG C CG A C T C A A G A AG T C A C A C A T C A GG A GG T A C A T C T C A G T G A G T T C T A A C C A T C A G T C T CGGC CG A A C T CG T T T GC T G A A T T C C T A A A C A
Nobivac A T G A A T GG AGG T CG A C T G A A G A G A T C T C A T A T ACGG A G A T A T G T C T C A G T C A G T T C C A A T C A T C A AGC C CG T C C A A A C T C A T T CGC CG A A T T T T T A A A C A
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 Figure A10-1 (continued)  Nucleotide alignment of ABLV (n=34) and Nobivac (n=1) sequences (page 15 of 16)  
ABL01SEQ-B
ABL02SEQ-G
ABL03Tvl-R
ABL05SEQ-B
ABL06SEQ-B
ABL07SEQ-G
ABL08SEQ-G
ABL09SEQ-G
ABL13SEQ-G
ABL14Cen-B
ABL16Cen-R
ABL17Tvl-B
ABL19SEQ-R
ABL21SEQ-R
ABL22SEQ-B
ABL23SEQ-B
ABL24SEQ-R
ABL25SEQ-R
ABL26SEQ-B
ABL29Tvl-R
ABL30Tvl-R
ABL31SEQ-R
ABL32Tvl-B
ABL33SEQ-B
ABL34Cen-B
ABL35SEQ-B
ABL36SEQ-B
ABL37Cen-B
end N mRNA
1401 1410 1420 1430 1440 1450 1460 1470 1480 1490 1500
I I I N stop codon I I I I I I intergenic CT I
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A G A T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A A A CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T C A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CA T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C T T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A G T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A GG A C A T C A C C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A T C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
ABLHumanPt A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A G A T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A A - CT A A C A C C C C T C C
ABLBallina A G A C A T A T T C A A G T G A C T CG T AA T C A G A T G T G T C A GG T C T T G C C C C T A A A T T A T T G A G A A C A T C A C C T C A T C T T A C A A G A A A A A A - - CT A A C A C C C C T C C
A G A C A T A C T CG A G T G A T T CT T AA C T A G A C GC T AC A AGC C T G A T T C A T A A A C T A T C AGG A A GG T T GC T T C T T C T T C C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A C T CG A G T G A T T CT T AA C T GG A C GC T AC A AGC C T G A T T C A T A A A C T A T C AGG A A GG T T GC T T C T T C T T C C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A C T CG A G T G A T T CT T AA C T A G A C GC T AC A AGC C T G A T T A A T A A A C T A T C AGG A A GG T T GC T T C T T C T T C C A A G A A A A A A A - CT A A C A C C C C T C C
A G A C A T A C T CG A G T G A T T CT T AA C T A G A C GC T - C A AGC C T G A T T C A T A A A C T A T C AGG A A GG T T GC T T C T T C T T C C A A G A A A A A A A - CT A A C A C C C C T C C
Nobivac A G A CG T A T T CG A A T G A C T CA T AA GG A G T T G A T T G A T AGGG T G C C AG A A A T C T A T - - - - A G A T T G T A T A T A T C C A T C A T G A A A A A A A - CT A A C A C T C C T C C
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Figure A10-1 (continued)  Nucleotide alignment of ABLV (n=34) and Nobivac (n=1) sequences (page 16 of 16)  
ABL01SEQ-B
ABL02SEQ-G
ABL03Tvl-R
ABL05SEQ-B
ABL06SEQ-B
ABL07SEQ-G
ABL08SEQ-G
ABL09SEQ-G
ABL13SEQ-G
ABL14Cen-B
ABL16Cen-R
ABL17Tvl-B
ABL19SEQ-R
ABL21SEQ-R
ABL22SEQ-B
ABL23SEQ-B
ABL24SEQ-R
ABL25SEQ-R
ABL26SEQ-B
ABL29Tvl-R
ABL30Tvl-R
ABL31SEQ-R
ABL32Tvl-B
ABL33SEQ-B
ABL34Cen-B
ABL35SEQ-B
ABL36SEQ-B
ABL37Cen-B
1501 1510 1520 1530 1540 1550 1560 1570 1580 1590
I I I P start codon I I I I I PReverse I I
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC CG A C C T GG A A A T GGC A G A GG A G A C
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A G AGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A C C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T C A A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
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T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
T T T CG A T C C A T C T T CGCT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC G A T C A GGGC A GGC A T GGC
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T T T T G A T C C A T C T T C A AT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC A A T C A G AGC A GGC A T GGC
T T T T G A T C C A T C T T C A AT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC A A T C A G AGC A GGC A T GGC
T T T T G T A C C A T C T T C A AT A TG AG C A A G A T C T T T G T C A A T C C G A G T GC A A T C A G AGC A GGC A T GGC CG A T C T GG A A A T GGC A G A GG A G A C T G T T G A
NobiVPRev
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Appendix 11 Response to Nobivac rabies vaccine 
Individual rabies-RFFIT titres for 36 flying foxes vaccinated with the Nobivac rabies vaccine and 
one control flying fox (no Nobivac) are shown in Table A11-1. Rabies-RFFITs were kindly 
performed by Ross Lunt and Kim Newberry at the AAHL (see Appendix 2). 
Key to Table A11-1 
Bat no.  Unique last three digits of bat microchip number 
Species Black = Black flying fox (Pteropus alecto) (n=13) 
  Grey = Grey-headed flying fox (Pteropus poliocephalus) (n=24) 
  F lact = female that gave birth to and lactated for a pup (n=11) 
F abort = female that aborted a pre-term foetus (n=4) 
F np = female that was not pregnant (n=3) 
Age class Juv = juvenile, pre-pubescent flying fox 1-3 years of age (n=10) 
  A = adult flying fox > 3 years of age (n=27)  
Capt. weight Weight of flying fox on the day of capture on PV-day –52 to –60  
Method Nobivac = flying fox vaccinated with KLH in Nobivac vaccine on PV-day 0 ± PV-
day 28 (Phase 1), and subsequently vaccinated with High-dose KLH + Alhydrogel 
on PV-day 85 (Phase 2) 
Alhydrogel = flying fox vaccinated with Nobivac vaccine and a separate injection 
of KLH + Alhydrogel on PV-day 0 ± PV-day 28 (Phase 1), and subsequently 
vaccinated with High-dose KLH + Alhydrogel on PV-day 85 (Phase 2) 
Boost day 28 Flying fox that did (Yes) or did not (No) receive a booster vaccination on  
PV-day 28. 
 
The data for individuals shown in Table A11-1 are illustrated in Figure A11-1 to Figure A11-6. The 
graphs have been truncated at a rabies-RFFIT titre of 25 IU/mL for clarity, values for titres in 
excess of 25 IU/mL can be read from Table A11-1.  
 
Sex  M = male (n=19) 
 No Nobivac Alhydrogel = single control flying fox vaccinated with KLH + 
Alhydrogel only on PV-day 0 (no separate Nobivac vaccination) during Phase 1, 
and subsequently vaccinated with high dose KLH + Alhydrogel on PV-day 85 
(Phase 2) 
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Table A 1-1 Response to vaccination with Nobivac (rabies) vaccine in Black and Grey-headed flying foxes (n=37) 1
Bat details 
PV-day Microchip 
number 
Bat 
No Sex Age Method 
Boost 
day-28
7 14 21 42 56 85 171
5034144778 1 Grey Male 405 Nobivac No 0 0.1
rabies-RFFIT titres (IU/mL) 
Group Species 
          
Capt. 
weight
0 28 127
                   778 Juv 1.6 3.1 2.8 2.6 5.7 5 7.3 7.2
41066E1B66                   
                   
                   
                   
                   
                  
                
       Alhydrogel            
    Male              
                  
                 
                  
    F np   0     5.2     
    Male    0     2.    
    F lact    0 0.3 2      
    F lact   0        
    F abort A 692           10 
B66 1 Grey Male Juv 373 Nobivac No 0 0.1 0.9 0.7 0.9 1 2.6 0.7 1 0.8
40366C4256 256 1 Grey Male A 673 Nobivac No 0 0.1 1 3.3 3.5 2.3 2.2 2.5 3 1
400F2E2332 332 1 Grey F lact A 666 Nobivac No 0 0.2 1.2 2.3 0.8 0 0.1 0.6 0.2 0.7
4105485215 215 1 Grey F lact A 710 Nobivac No 0 0.1 1.1 2.9 3.5 0.8 1.3 1.2 1.8 2.2
A 630 Nobivac No 0 0.3 0.6 1.7 0.9 0 0 0.4 0.9 0.940374E6362 362 1 Grey F lact
4105523A75 A75 2 Black Male A 846 Alhydrogel No 0 0.3 1.5 3.1 6.2 5.2 3.6 1.2 0.4 0.8
0001BB1B30 B30 2 Black Male A 774 Alhydrogel No 0 1.4 3.1 17.1 10.5 10.3 4.6 1.5 2.6 1.9
4036384B32 B32 2 Black Male A 800 No 0 0.8 1 4.4 14.3 11 10.3 3.1 1.3 1.2
50340F2CIB CIB 2 Black A 884 Alhydrogel No 0 0.7 0.6 2.1 1.5 0.5 0.2 0.5 1.6 0.9
50341B5E4B E4B 2 Black F np A 552 Alhydrogel No 0 3.6 7.2 7.6 4.6 5.2 5.5 7.3 11.8 10.2
A 855 Alhydrogel No 0 0.1 1.1 2.5 1.5 1.1 1.9 5 2 DIED41055B595B 95B 2 Black F lact
50066A1361 361 2 Grey Male Juv 410 Alhydrogel No 0 0.6 1 3.5 4.6 1 0.8 0.5 0.4 0.8
 Juv 401 Alhydrogel No 0.3 2.6 8.5 8.7 5.9 3.1 7.8 4.541054F2179 179 2 Grey
4035220813 813 2 Grey A 626 Alhydrogel No 0.5 0.1 1.4 3.1 6 0.9 0.5 1.8 1.1
410556384D 84D 2 Grey A 634 Alhydrogel No 3.3 4.1 2.3 2.9 3.1 5 10
41066D3A35 A35 2 Grey  A 604 Alhydrogel No 0.8 1.8 2 1 0.2 0.8 0.9 1.1
0001BBA11A 11A 2 Grey Alhydrogel No 0 0.1 0.8 0.8 1 1 1.1 0.6 1
0.7
        
  
Table A11-1 (continued): rabies-RFFIT titres (IU/mL) page 2 of 2 
PV-day Microchip 
number 
Bat 
No Group Species Sex Age           
Capt. 
weight Method 
Boost 
day-28 0 7 14 21 28 42 56 85 127 171
50325D1655                   655 3 Grey Male Juv 427 Nobivac Yes 0 0.7 0.5 3.6 4.6 16.3 21.5 10 13.3 8.4
41050E1F19                   
                   
                   
                   
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                 
                 
             0   
F19 3 Grey Male Juv 385 Nobivac Yes 0 0.2 2 3.3 4.1 11.3 11.8 2.9 8.9 5.1
41055B2119 119 3 Grey F np Juv 440 Nobivac Yes 0 0.1 7.2 29 9.7 53.6 12.5 11.3 9.8 11.7
400F3F6551D 51D 3 Grey F lact A 651 Nobivac Yes 0 0.1 1 1 0.9 4.7 0.7 0.6 0.3 0.7
4105391A24 A24 3 Grey F lact A 760 Nobivac Yes 0 0.1 0.9 1.7 2.1 5 0.7 0.5 0 0.2
5006683B43 B43 3 Grey F abort A 460 Nobivac Yes 0 1.5 4.9 7.5 1.4 10 6.1 2.9 4.8 1.5
41054D0424 424 4 Black Male A 845 Alhydrogel Yes 0 0.1 0.5 1.2 2.1 13.4 11.8 3.3 6.5 3.6
41064A610B 10B 4 Black Male A 848 Alhydrogel Yes 0 1.4 1.4 2.9 4.3 18.5 11.1 2.9 2.5 0.9
0001DC383F 83F 4 Black Male A 975 Alhydrogel Yes 0 0.1 0.6 0.7 1.1 19.2 12.5 9.1 19.1 10.2
4017293F43 F43 4 Black Male A 851 Alhydrogel Yes 0 0.8 0.2 0.5 0.8 17.5 3 1.1 1 0.2
4036732565 565 4 Black F lact A 655 Alhydrogel Yes 0.2 1.8 2.5 3.3 1 20.1 7.3 2.9 1 1
405C0E6D58 D58 4 Black F lact A 777 Alhydrogel Yes 0 0.3 1.2 3.5 5 14.6 11.8 31.5 28.1 9
400F1D4174 174 4 Grey Male Juv 356 Alhydrogel Yes 0.2 1.3 4.6 22.4 4.1 63 13.4 5.4 7.2 4.8
5034150402 402 4 Grey Male Juv 402 Alhydrogel Yes 0 1.1 4 6.3 1.5 15.2 11.8 2.9 7.8 2.2
4010276D03 D03 4 Grey Male Juv 464 Alhydrogel Yes 0 1.5 2 2.9 4.1 7.6 5.9 1.4 1 1.2
4056740707 707 4 Grey F lact A 611 Alhydrogel Yes 0 0.1 0.7 2.9 1.1 10 3.7 1.8 0.5 0.9
40366D2E64 E64 4 Grey F abort A 642 Alhydrogel Yes 0 0.1 1.3 2.5 1.8 6.6 2.8 0.7 0.9 0.4
50341F2B7A B7A 4 Grey F abort A 696 Alhydrogel Yes 0 0.3 0.7 0.5 0.8 5 1.2 0.9 1.6 0.2
50335F1775 775 Control Black Male A 834 No Nobivac
Alhydrogel
No 0 0 0 0 0 0 0 0 0
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Figure A11-1 Response to Nobivac rabies vaccine: Group 1 Grey headed flying foxes (n=6) 
Vaccinations: PV-day 0   KLH in Nobivac 
                                 PV-day 85  High dose KLH + Alhydrogel (no Nobivac) 
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Figure A11-2 Response to Nobivac rabies vaccine: Group 3 Grey headed flying foxes (n=6) 
Vaccinations: PV-day 0   KLH in Nobivac 
                   PV-day 28  KLH in Nobivac 
                                 PV-day 85  High dose KLH + Alhydrogel (no Nobivac) 
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Figure A11-3 Response to Nobivac rabies vaccine: Group 2 Grey-headed flying foxes (n=6) 
Vaccinations: PV-day 0   Nobivac and KLH + Alhydrogel 
                                 PV-day 85  High dose KLH + Alhydrogel (no Nobivac) 
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Figure A11-4 Response to Nobivac rabies vaccine: Group 4 Grey headed flying foxes (n=6) 
Vaccinations: PV-day 0   Nobivac and KLH + Alhydrogel 
                        PV-day 28  Nobivac and KLH + Alhydrogel 
                        PV-day 85  High dose KLH + Alhydrogel (no Nobivac) 
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Figure A11-5 Response to Nobivac rabies vaccine: Group 2 Black flying foxes (n=6) 
 Vaccinations: PV-day 0   Nobivac and KLH + Alhydrogel 
                                 PV-day 85  High dose KLH + Alhydrogel (no Nobivac) 
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Figure A11-6 Response to Nobivac rabies vaccine: Group 4 Black flying foxes (n=6) 
 Vaccinations: PV-day 0   Nobivac and KLH + Alhydrogel 
                                 PV-day 28  Nobivac and KLH + Alhydrogel 
                                 PV-day 85  High dose KLH + Alhydrogel (no Nobivac) 
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Appendix 12 Response to vaccination with KLH 
Individual KLH ELISA titres for 37 flying foxes vaccinated with KLH either combined with the 
Nobivac rabies vaccine or as a separate injection with the adjuvant Alhydrogel are shown in Table 
A12-1. Titres were determined relative to a positive control standard (percent absorbance) in a KLH 
ELISA developed by the candidate (see Chapter 8).  
 
Key to Table A12-1 
Bat no.  Unique last three digits of bat microchip number 
Species Black = Black flying fox (Pteropus alecto) (n=13) 
  Grey = Grey-headed flying fox (Pteropus poliocephalus) (n=24) 
Sex  Male = male (n=19) 
  F lact = female that gave birth to and lactated for a pup (n=11) 
F abort = female that aborted a pre-term foetus (n=4) 
F np = female that was not pregnant (n=3) 
Age class Juv = juvenile, pre-pubescent flying fox 1-3 years of age (n=10) 
  A = adult flying fox > 3 years of age (n=27)  
Capt. weight Weight of flying fox on the day of capture on PV-day –52 to –60  
Method Nobivac = flying fox vaccinated with KLH in Nobivac vaccine on PV-day 0 ± PV-
day 28 (Phase 1), and subsequently vaccinated with High-dose KLH + Alhydrogel 
on PV-day 85 (Phase 2) 
Alhydrogel = flying fox vaccinated with Nobivac vaccine and a separate injection 
of KLH + Alhydrogel on PV-day 0 ± PV-day 28 (Phase 1), and subsequently 
vaccinated with High-dose KLH + Alhydrogel on PV-day 85 (Phase 2) 
 No Nobivac Alhydrogel = single control flying fox vaccinated with KLH + 
Alhydrogel only on PV-day 0 (no separate Nobivac vaccination) during Phase 1, 
and subsequently vaccinated with high dose KLH + Alhydrogel on PV-day 85 
(Phase 2) 
Boost day 28 Flying fox that did (Yes) or did not (No) receive a booster vaccination on  
PV-day 28. 
 
Actual KLH responses for individuals in each group and species are illustrated in Figure A12-1 to 
Figure A12-6. 
  Appendix 12 
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Table A12-1 Response to vaccination with KLH immunogen in Black and Grey-headed flying foxes (n=37) 
Bat details   Phase 1 KLH-ELISA titres (percent absorbance) Phase 2 titres 
PV-day Microchip 
number 
Bat 
No. 
Group Species Sex Age 
class
Capt. 
weight 
Method  
         
Boost
Day 28 0 7 14 21 28 42 56 85 99 127 171
5034144778         778 1 Grey Male Juv 405 Nobivac No 1.5 33.7 60.5 66.0 52.8 37.8 30.3 19.3 94.9 87.6 83.7 
41066E1B66         
         
         
         
         
         
     A    74.4
         
         
         72.3 
         
         
         
         
         97.0
         
       36.9
B66 1 Grey Male Juv 373 Nobivac No 0.6 1.8 10.6 14.6 11.4 10.3 8.7 6.9 101.5 85.6 38.7 
40366C4256 256 1 Grey Male A 673 Nobivac No 1.1 16.4 41.4 42.8 32.4 20.0 16.4 21.3 97.7 90.6 53.7 
400F2E2332 332 1 Grey F lact A 666 Nobivac No 2.1 15.9 53.5 53.8 38.6 23.3 20.7 9.5 89.3 59.8 30.2 
4105485215 215 1 Grey F lact A 710 Nobivac No 5.2 45.4 46.3 45.1 27.2 19.2 15.1 7.1 100.9 86.9 47.1 
40374E6362 362 1 Grey F lact A 630 Nobivac No 0.6 18.6 53.3 47.6 26.5 9.3 5.2 6.0 96.6 79.4 53.4 
4105523A75 A75 2 Black Male A 846 Alhydrogel No 0.4 5.2 67.6 34.4 84.4 56.7 39.5 21.0 100.3 86.7 62.3 
0001BB1B30 B30 2 Black Male 774 Alhydrogel No 0.5 12.7 70.9 77.4 65.9 57.2 53.0 101.1 94.0 79.6 
4036384B32 B32 2 Black Male A 800 Alhydrogel No 5.3 47.7 94.8 82.6 82.1 79.5 67.4 59.2 104.3 95.0 72.1 
50340F2CIB CIB 2 Black Male A 884 Alhydrogel No 0.5 59.6 61.6 48.8 35.8 25.2 19.1 14.4 101.1 75.5 53.2 
50341B5E4B E4B 2 Black F np A 552 Alhydrogel No 0.5 38.1 73.8 75.8 67.2 54.4 45.5 31.2 111.3 96.3
41055B595B 95B 2 Black F lact A 855 Alhydrogel No 3.9 23.5 78.9 74.0 67.7 31.1 18.7 16.1 101.2 83.5 70.9 
50066A1361 361 2 Grey Male Juv 410 Alhydrogel No 3.4 34.5 79.7 91.0 80.1 50.4 35.1 22.8 102.6 94.5 69.9 
41054F2179 179 2 Grey F np Juv 401 Alhydrogel No 0.6 43.2 78.3 92.9 92.2 83.3 64.7 46.9 99.6 97.1 100.5 
4035220813 813 2 Grey Male A 626 Alhydrogel No 2.6 4.2 50.3 84.6 78.5 39.0 23.0 7.7 103.8 85.5 35.6 
410556384D 84D 2 Grey F lact A 634 Alhydrogel No 10.3 36.8 92.3 96.0 90.9 42.8 64.5 12.8 75.9 35.5 
41066D3A35 A35 2 Grey F lact A 604 Alhydrogel No 0.9 9.2 70.4 75.8 53.2 28.3 24.6 11.2 100.1 79.8 33.7 
0001BBA11A 11A 2 Grey F abort A 692 Alhydrogel No 3.3 23.7 79.8 80.8 77.3 43.5 28.7 97.2 94.1 62.5 
 
  
Table A12-1 (continued): KLH-ELISA titres (PA) page 2 of 2 
PV-day Microchip 
umber 
Bat 
No. 
Group Species Sex Age 
class
Capt. 
weight 
Method  
          
Boost
Day 28 0 7 14 21 28 42 56 85 99 127 171
50325D1655         655 3 Grey Male Juv 427 Nobivac Yes 2.4 48.2 60.0 66.1 46.7 78.0 59.7 31.3 92.5 80.1 54.0 
41050E1F19         81.2
         
         
       
       
         
         
         
         
         
         
         
         
         
         
  4     
 B7A       74.3
50335F1775 775       
F19 3 Grey Male Juv 385 Nobivac Yes 0.0 1.1 9.4 21.0 17.9 75.9 49.7 20.8 108.2 59.6 
41055B2119 119 3 Grey F np Juv 440 Nobivac Yes 0.8 6.4 29.7 68.0 22.1 85.1 57.6 39.9 94.8 94.7 79.6 
400F3F6551D 51D 3 Grey F lact A 651 Nobivac Yes 4.5 25.5 58.9 82.9 44.3 51.8 37.8 19.4 82.7 63.3 26.9 
4105391A24 A24 3 Grey F lact  A 760 Nobivac Yes 15.4 37.3 56.6 54.3 33.4 34.4 22.0 16.6 45.1 44.3 26.2 
5006683B43 B43 3 Grey F abort A 460 Nobivac Yes 2.0 48.1 76.8 74.1 55.3 69.6 47.7 25.6 97.3 77.9 45.5 
41054D0424 424 4 Black Male A 845 Alhydrogel Yes 0.9 14.7 56.4 78.2 58.7 73.5 64.3 50.5 86.7 77.7 56.6 
41064A610B 10B 4 Black Male A 848 Alhydrogel Yes 0.3 9.7 54.4 59.0 47.4 83.8 57.3 37.2 100.2 55.1 29.2 
0001DC383F 83F 4 Black Male A 975 Alhydrogel Yes 0.2 22.8 58.3 70.6 50.1 75.7 36.2 13.4 106.8 85.4 50.8 
4017293F43 F43 4 Black Male A 851 Alhydrogel Yes 0.0 2.9 35.9 32.7 32.7 68.7 27.7 12.3 102.6 60.6 16.6 
4036732565 565 4 Black F lact A 655 Alhydrogel Yes 0.5 5.3 53.8 55.6 55.8 91.4 59.7 28.6 92.0 69.9 45.4 
405C0E6D58 D58 4 Black F lact A 777 Alhydrogel Yes 2.3 37.3 85.4 76.6 61.9 79.8 54.5 37.5 107.1 101.1 98.5 
400F1D4174 174 4 Grey Male Juv 356 Alhydrogel Yes 1.0 8.9 90.6 81.3 37.0 104.3 96.3 73.4 106.1 105.9 95.4 
5034150402 402 4 Grey Male Juv 402 Alhydrogel Yes 1.9 7.3 69.0 102.0 88.1 103.8 84.8 45.8 100.9 94.7 103.1 
4010276D03 D03 4 Grey Male Juv 464 Alhydrogel Yes 3.7 18.4 89.9 88.8 91.2 97.0 85.6 72.4 111.2 104.2 96.8 
4056740707 707 4 Grey F lact A 611 Alhydrogel Yes 1.2 19.6 75.7 73.4 55.1 94.8 63.0 33.9 97.2 78.4 41.8 
40366D2E64 E64 Grey F abort A 642 Alhydrogel Yes 2.4 35.3 88.4 80.3 18.3 77.3 50.6 19.1 111.6 86.7 32.6 
50341F2B7A 4 Grey F abort A 696 Alhydrogel Yes 1.2 27.1 86.3 74.8 79.4 67.8 37.3 102.1 92.7 59.2 
 Control Black Male A 834 Alhydrogel
No Nobivac
No 4.1 18.5 79.8 91.0 90.7 64.2 48.7 30.0 99.8 95.6 86.1 
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Extrapolated duration of positive KLH-titre  
The length of time that KLH-ELISA titres in individual flying foxes could have been expected to 
remain positive (titre >20 PA) following either Phase 1 vaccinations alone or following both Phase 
1 and the PV-day 85 high-dose KLH + Alhydrogel booster (Phase 2) was estimated by 
mathematical extrapolation of the known titres. 
The estimated duration for each flying fox is shown in Table A1 -2.  2
2-2Table A1  Extrapolated duration of positive KLH titres following Phase 1 and Phase 2 
vaccinations 
Extrapolated duration of positive 
titre >20 PA  (days) Bat  
No Group Species Sex Age  Method 
Boost Day 
28 
Phase 1  Phase 2  
778 1 Grey Male Juv Nobivac No 76 592 
B66 1 Grey Male Juv 
Male 
292 
Grey 
Nobivac
Nobivac No 21 194 
256 1 Grey Male A Nobivac No 52 228 
332 1 Grey F lact A Nobivac No 58 182 
215 1 Grey F lact A Nobivac No 43 209 
362 1 Grey F lact A Nobivac No 32 227 
A75 2 Black A Alhydrogel No 83 251 
B30 2 Black Male A Alhydrogel No 232 370 
B32 2 Black Male A Alhydrogel No 282 288 
CIB 2 Black Male A Alhydrogel No 56 219 
E4B 2 Black F n p A Alhydrogel No 114 268 
95B 2 Black F lact A Alhydrogel No 59 
361 2 Grey Male Juv Alhydrogel No 81 281 
179 2 Grey F np Juv Alhydrogel No 168 1000+ 
813 2 Grey Male A Alhydrogel No 62 189 
84D 2 Grey F lact A Alhydrogel No 90 190 
A35 2 Grey F lact A Alhydrogel No 56 187 
11A 2 F abort A Alhydrogel No 88 261 
655 3 Grey Male Juv Nobivac Yes 95 235 
F19 3 Grey Male Juv Nobivac Yes 84 228 
119 3 Grey F np Juv Nobivac Yes 103 445 
51D 3 Grey F lact A Nobivac Yes 83 181 
A24 3 Grey F lact   A Nobivac Yes 72 199 
B43 3 Grey F abort A Yes 89 207 
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Table A12-2 (continued): Extrapolated KLH positive titre durations 
Extrapolated duration of positive 
titre >20 PA  (days) Bat  
No Group Species Sex Age Method 
Boost Day 
28 
Phase 1  Phase 2  
424 4 Black Male A Alhydrogel Yes 142 259 
10B 4 Black Male A Alhydrogel Yes 99 176 
83F 4 Black Male A Alhydrogel Yes 77 211 
F43 4 Black Male A Alhydrogel Yes 75 166 
565 4 Black F lact A Alhydrogel Yes 89 209 
D58 4 Black F lact A Alhydrogel Yes 
Yes 104 
No Nobivac 
Alhydrogel
101 853 
174 4 Grey Male Juv Alhydrogel Yes 159 659 
402 4 Grey Male Juv Alhydrogel 1000+ 
D03 4 Grey Male Juv Alhydrogel Yes 178 559 
707 4 Grey F lact A Alhydrogel Yes 93 200 
E64 4 Grey F abort A Alhydrogel Yes 83 184 
B7A 4 Grey F abort A Alhydrogel Yes 103 238 
775 Control Black Male A No 
  
 
The data for individuals shown in Table A12-1 and Table A12-2 are illustrated in Figure A12-1 to 
Figure A12-6. Actual titres in Table A1 -1 are represented by solid lines. The calculated 
extrapolations to the day at which the titre would no longer be positive (KLH positive threshold = 
20 PA, Table A1 -2) are shown in broken lines. The graphs have been truncated to 400 days for 
clarity. Values for the extrapolated duration of positive KLH titres in excess of 400 days can be 
read from Table A12-2. 
2
2
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Figure A  Response to KLH: Group 1 Grey-headed flying foxes (n=6) 12-1
2-2
 Actual (solid lines) and extrapolated (broken lines) KLH titres 
 Vaccinations: PV-day  0  KLH in Nobivac 
                                 PV-day 85 High-dose KLH + Alhydrogel 
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Figure A1  Response to KLH: Group 3 Grey-headed flying foxes (n=6) 
 Actual (solid lines) and extrapolated (broken lines) KLH titres 
 Vaccinations: PV-day  0   KLH in Nobivac 
                                PV-day 28  KLH in Nobivac 
                                PV-day 85  High-dose KLH + Alhydrogel 
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Figure A1  Response to KLH: Group 2 Grey-headed flying foxes (n=6) 2-3
2-4
 Actual (solid lines) and extrapolated (broken lines) KLH titres 
 Vaccinations: PV-day  0  Nobivac and KLH + Alhydrogel 
                                PV-day 85 High-dose KLH + Alhydrogel 
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Figure A1  Response to KLH: Group 4 Grey-headed flying foxes (n=6) 
 Actual (solid lines) and extrapolated (broken lines) KLH titres 
 Vaccinations: PV-day  0  Nobivac and KLH + Alhydrogel 
                                 PV-day 28 Nobivac and KLH + Alhydrogel 
                                 PV-day 85 High-dose KLH + Alhydrogel 
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Figure A  Response to KLH: Group 2 Black flying foxes (n=6) 12-5
2-6
 Actual (solid lines) and extrapolated (broken lines) KLH titres 
 Vaccinations: PV-day  0  Nobivac and KLH + Alhydrogel  
                                 PV-day 85 High-dose KLH + Alhydrogel 
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Figure A1  Response to KLH: Group 4 Black flying foxes (n=6) 
 Actual (solid lines) and extrapolated (broken lines) KLH titres 
 Vaccinations: PV-day  0  Nobivac and KLH + Alhydrogel 
                                 PV-day 28 Nobivac and KLH + Alhydrogel 
                                 PV-day 85 High-dose KLH + Alhydrogel 
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Appendix 13 Response in pups to vaccination of dam during 
(Phase 1) and after pregnancy (Phase 2)  
The rabies-RFFIT and KLH ELISA titres for 11 pups born to flying foxes born between PV-day 48 
and 83 of the vaccination trial, the corresponding titres of their dams and other relevant details are 
shown in Table A13-1. 
All pups were born towards the end of Phase 1, i.e. a minimum of 28 days (Bat 51D) and a 
maximum of 82 days (Bat 95B) after the dams last Phase 1 vaccination on PV-day 28, and 2 to 37 
days prior to the high-dose KLH booster on PV-day 85. 
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Table A 3-1 Response in pups to vaccination of adult female flying foxes during (Phase 1) and after (Phase 2) pregnancy 1
---  not done 
*    In addition to the Phase 1 vaccination protocols described in this table, all adult bats (not pups) were vaccinated with a high-dose KLH + Alhydrogel booster on PV-day 85. 
†   Where the exact date of birth for individual pups was not known (see Appendix 14 Determination of pup age), the possible range of dates for the birth is shown, followed by 
a nominal birth-PV-day in parentheses. 
Red font Nominally positive pup rabies-RFFIT titres (> 0.5 IU/mL) and positive pup KLH ELISA titres (>20 PA) are shown in red font. 
Rabies-RFFIT titres (IU/mL) KLH  ELISA titres (PA) Details of dam 
 
Details of pup 
  PV-days        PV-days 
Bat 
No. 
Species             Vaccination* Pup
No. 
Date of birth† Sex  85 99 127 171 85 99 127 172
332    0 Grey Group 1
KLH in Nobivac 
PV-day 0  
745 17 Sept  
PV-day 48 
F Pup 
Dam 
--- 
0.6 
0 
--- 
0 
0.2 0.7 
--- 
9.5 
5.6 
89.3 
2.4 
59.8 
0.4 
30.2 
215    
    --- 
 6.4 
 
0.9 
Grey Group 1
KLH in Nobivac 
PV-day 0  
512 19 or 20 Sept 
PV-day 50 or 51 
(PV-day 50) 
Male Pup 
Dam 
0.3 
1.2 
0 
--- 
0 
1.8 
0 
2.2 
7.8 
7.1 
3.6 
100.9 
3.3 
86.9 
7.9 
47.1 
362 Grey Group 1
KLH in Nobivac 
PV-day 0  
610 30 Sept - 22 Oct 
PV-days 61-83 
(PV-day 62) 
Male Pup 
Dam 
--- 
0.4 
--- 
--- 
0 
0.9 
--- 
0.9 
--- 
6.0 96.6 
1.3 
79.4 
--- 
53.4 
95B Black Group 2  
Nobivac, KLH +Alhydrogel  
PV-day 0 
760 17 or 20 Oct 
PV-days 78-82 
(PV-day 78) 
Male Pup 
Dam 
--- 
5.0 
--- 
--- 
1.2 
2.0 
3.0 
--- 
--- 
16.1 
--- 
101.2 83.5 
0.9 
70.9 
A35 Grey Group 2  
Nobivac, KLH +Alhydrogel  
PV-day 0 
F2C 19 or 20 Sept 
PV-day 50 or 51 
(PV-day 50) 
F Pup 
Dam 
0 
0.7 
--- 
--- 
0 0 
1.1 
18.4 
11.2 
--- 
100.1 
3.3 
79.8 
0.7 
33.7 
 
  
Table A13-1 (continued): Pup and dam rabies-RFFIT and KLH-ELISA titres 
Rabies-RFFIT titres (IU/mL) KLH  ELISA Titres (PA) Bat 
No. 
Species     
        
     
Vaccination* Pup
No. 
Date of birth† Sex  
85 99 127 172 85 99 127 172
84D Grey Group 2
Nobivac, KLH +Alhydrogel  
PV-day 0 
251 19 or 20 Sept 
PV-day 50 or 51 
(PV-day 50) 
Male Pup
Dam 
--- 
3.1 
0.5 
--- 
0 
5.0 
0 
10.0 
--- 
12.8 
16.9 
97.0 
5.5 
75.9 
0.5 
35.5 
51D       
--- 
     
  --- 
  
107.1 
  
Grey Group 3
KLH in Nobivac 
PV-day 0 + 28 
056 25 Sept
PV-day 56 
Male Pup
Dam 
--- 
0.6 
--- 0 
0.3 
0 
0.7 
--- 
19.4 
--- 
82.7 
5.2 
63.3 
1.6 
26.9 
A24 Grey Group 3
KLH in Nobivac 
PV-day 0 + 28 
423 30 Sept - 22 Oct 
PV-days 61-83 
(PV-day 62) 
F Pup
Dam 
--- 
0.5 
1.4 
--- 
--- 
0 
0 
0.2 
--- 
16.6 
11.9 
45.1 
--- 
44.3 
10 
26.2 
565 Black Group 4  
Nobivac, KLH +Alhydrogel  
PV-day 0 + 28 
227 17 or 20 Oct 
PV-days 78-82 
(PV-day 78) 
F Pup
Dam 
--- 
2.9 
--- 
--- 
9.5 
1.0 
1.6 
1.0 28.6 
--- 
92.0 69.9 
11.9 
45.4 
D58 Black Group 4  
Nobivac, KLH +Alhydrogel  
PV-day 0 + 28 
926 17 or 20 Oct 
PV-days 78-82 
(PV-day 78) 
Male Pup
Dam 
--- 
31.5 
--- 
--- 
22.8 
28.1 
2.2 
9.0 
--- 
37.5 
--- 42.8 
101.1 
15.8 
98.5 
707 Grey Group 4  
Nobivac, KLH +Alhydrogel  
PV-day 0 + 28 
411 30 Sept - 22 Oct 
PV-days 61-83 
(PV-day 62) 
F Pup
Dam 
--- 
1.8 
--- 
--- 
0 
0.5 
0 
0.9 
--- 
33.9 
--- 
97.2 
7.8 
78.4 
1.2 
41.8 
44.6 
 
.
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Appendix 14 Determination of pup age 
Disturbance of the colony was kept to a minimum in order to reduce the incidence of pup losses/ 
abortion. Consequently, new mothers were not identified until captured for sampling on PV-days 
56 and 85. The arrival of pups was detected by daily observation of the colony for increased pup 
numbers. While the correct date of birth for every pup is not known, known or nominal birth dates 
were determined by cross-referencing the increasing pup numbers and species with captured 
mother/pup pairs on PV-days 56 and 85 as shown in Table A1 -1. 4
4-1Table A1  Pup detection and determination of known or nominal birth dates 
Date Species Comments 
17 Sept 1 Grey First pup observed, possibly 1-3 days old. Dam identified as Bat No 332 on  
18 Sept 
19 Sept 2 Greys Second and third Grey pups observed 
20 Sept 1 Grey Fourth Grey pup observed with wet umbilical cord 
25 Sept 1 Grey Fifth Grey with a new born pup with a long umbilical cord 
25 Sept  Capture and sampling PV-day 56 
5 Grey mother/pup pairs captured and identified  
     Bat 332 from 17 Sept 
     Bat 51D with a newborn pup = 25 Sept 
     Bats 215, A35, and 84D from 19 and 20 Sept 
As it is unclear which dam gave birth on each day, the nominal birth date for 
Bats 215, A35 and 84D is 19 Sept 
30 Sept 1 Grey Sixth Grey pup observed with wet umbilical cord 
2 Oct 1 Grey Seventh Grey pup observed with wet fur. 
17 Oct 2 Blacks First and second Black pups observed with wet umbilical cords 
20 Oct 1 Black Third Black pup observed, no wet cord seen, poss. 0-2 days old 
22 Oct  1 Grey Eight Grey pups counted, no wet cord seen*  
24 Oct  Capture and sampling PV-day 85 
3 new Grey mother/pup pairs captured and identified as Bats A24, 707 and 362 
that gave birth between 30 Sept, 2 Oct and ~ 22 Oct.  
As it is unclear which dam gave birth on each day, the nominal birth date for 
Bats A24, 707 and 362 is 1 Oct, being ± 1 day from the correct birth date for two 
pups, and up to 21 days early for the third 
3 Black mother/pup pairs captured and identified as Bats 565, 95B, and D58 
from 17 or 20 Sept.  
As it is unclear which dam gave birth on each day, the nominal birth date for 
Bats 565, 95B, and D58 is 17 Oct, being correct for two pups and up to 3 days 
early for the third. 
 
* By this time, the presence of 11 pups made counting difficult. As none of the pups on 22 Oct appeared to 
have a wet or long umbilical cord, indicating a recent birth, the ‘eighth’ pup may have been born any time 
between 2 Oct and 22 Oct, but probably much closer to 22 Oct. 
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